JP2019065018A - Harmful arthropod controlling method using heterocyclic compound - Google Patents

Abstract

To provide a harmful arthropod controlling method.SOLUTION: A harmful arthropod controlling method includes applying effective amounts of a compound represented by formula (I) or an N oxide thereof to harmful arthropods, a habitat of harmful arthropods, plants or the soil. [Het is an oxodihydropyridyl group having a substituent such as a fluoroalkoxy group, or the like; Ais N or CH, or the like; n is an integer of 0-2; q is an integer of 0-3; Ris a C1-C6 alkyl group, a cyclopropyl group or the like, optionally substituted with one or more halogen atoms; Ris a C1-C6 chain hydrocarbon group or the like].SELECTED DRAWING: None

Description

  The present invention relates to a method for controlling harmful arthropods using a heterocyclic compound.

So far, various compounds have been studied and put to practical use for the purpose of controlling harmful arthropods.
In addition, it is known that certain compounds have pest control effects (see, for example, Patent Document 1).

International Publication No. 2013/018928

  An object of the present invention is to provide a method for controlling harmful arthropods.

［式中、
Ｒ²は、１以上のハロゲン原子で置換されていてもよいＣ１−Ｃ６アルキル基、シクロプロピル基、又はシクロプロピルメチル基を表し、
ｎは、０、１又は２を表し、
Ｒ³は、群Ｂより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６鎖式炭化水素基、群Ｅより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ７シクロアルキル基、群Ｊより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ７シクロアルケニル基、群Ｈより選ばれる１以上の置換基を有していてもよいフェニル基、群Ｈより選ばれる１以上の置換基を有していてもよい５もしくは６員芳香族複素環基、ＯＲ¹²、ＮＲ¹¹Ｒ¹²、ＮＲ^11aＲ^12a、ＮＲ²⁴ＮＲ¹¹Ｒ¹²、ＮＲ²⁴ＯＲ¹¹、ＮＲ¹¹Ｃ（Ｏ）Ｒ¹³、ＮＲ²⁴ＮＲ¹¹Ｃ（Ｏ）Ｒ¹³、ＮＲ¹¹Ｃ（Ｏ）ＯＲ¹⁴、ＮＲ²⁴ＮＲ¹¹Ｃ（Ｏ）ＯＲ¹⁴、ＮＲ¹¹Ｃ（Ｏ）ＮＲ¹⁵Ｒ¹⁶、ＮＲ²⁴ＮＲ¹¹Ｃ（Ｏ）ＮＲ¹⁵Ｒ¹⁶、Ｎ＝ＣＨＮＲ¹⁵Ｒ¹⁶、Ｎ＝Ｓ（Ｏ）_xＲ¹⁵Ｒ¹⁶、Ｃ（Ｏ）Ｒ¹⁷、Ｃ（Ｏ）ＯＲ¹⁷、Ｃ（Ｏ）ＮＲ¹⁵Ｒ¹⁶、ＣＲ²⁴＝ＮＯＲ¹⁷、ＮＲ¹¹ＣＲ²⁴＝ＮＯＲ¹⁷、シアノ基、ニトロ基、又はハロゲン原子を表し、
ｑは、０、１、２、又は３を表し、ｑが２又は３である場合、複数のＲ³は同一でも異なっていてもよく、
２つのＲ³が隣接している場合、２つのＲ³はそれらが結合する炭素原子と一緒になってベンゼン環、ピロール環、フラン環、チオフェン環、ピラゾール環、イミダゾール環、トリアゾール環、オキサゾール環、イソオキサゾール環、チアゾール環、オキサジアゾール環、チアジアゾール環、ピリジン環、ピリダジン環、ピリミジン環、又はピラジン環｛該ベンゼン環、該ピロール環、該フラン環、該チオフェン環、該ピラゾール環、該イミダゾール環、該トリアゾール環、該オキサゾール環、該イソオキサゾール環、該チアゾール環、該ピリジン環、該ピリダジン環、該ピリミジン環、及び該ピラジン環は、各々独立して、群Ｈより選ばれる１以上の置換基を有していてもよい｝を形成していてもよく、
Ｈｅｔは、下式Ｈｅｔ１で示される基又は下式Ｈｅｔ２で示される基を表し、

Ａ¹は、窒素原子又はＣＲ⁶を表し、
Ａ²は、窒素原子又はＣＲ^4aを表し、
Ａ³は、窒素原子又はＣＲ^4bを表し、
Ａ⁴は、窒素原子又はＣＲ^4cを表し、
Ｑ¹は、酸素原子又は硫黄原子を表し、
Ｑ²は、酸素原子、Ｎ−ＣＮ、Ｎ−ＮＯ₂、ＮＲ²⁰、Ｎ−Ｃ（Ｏ）Ｒ²⁰又はＮ−Ｃ（Ｏ）ＯＲ¹⁵を表し、ｎが２である場合、２つのＱ²は同一でも異なっていてもよく、
Ｒ²⁰は、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキル基又は水素原子を表し、
Ｒ⁵は、群Ｆより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６鎖式炭化水素基、群Ｊより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ６シクロアルキル基、群Ｈより選ばれる１以上の置換基を有していてもよいフェニル基、又は群Ｈより選ばれる１以上の置換基を有していてもよい５もしくは６員芳香族複素環基を表し、
Ｒ^4a、Ｒ^4b、及びＲ^4cは、同一又は相異なり、各々独立して、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６鎖式炭化水素基、ニトロ基、ＯＲ¹⁸、ＮＲ¹⁸Ｒ¹⁹、シアノ基、アミノ基、ハロゲン原子、又は水素原子を表し、
Ｒ⁶は、水素原子、又はハロゲン原子を表し、
Ｔは、Ｃ１−Ｃ１０鎖式炭化水素基、（Ｃ１−Ｃ５アルコキシ）Ｃ２−Ｃ５アルキル基、（Ｃ１−Ｃ５アルキルスルファニル）Ｃ２−Ｃ５アルキル基、（Ｃ１−Ｃ５アルキルスルフィニル）Ｃ２−Ｃ５アルキル基、（Ｃ１−Ｃ５アルキルスルホニル）Ｃ２−Ｃ５アルキル基｛該Ｃ１−Ｃ１０鎖式炭化水素基、該（Ｃ１−Ｃ５アルコキシ）Ｃ２−Ｃ５アルキル基、該（Ｃ１−Ｃ５アルキルスルファニル）Ｃ２−Ｃ５アルキル基、該（Ｃ１−Ｃ５アルキルスルフィニル）Ｃ２−Ｃ５アルキル基、及び該（Ｃ１−Ｃ５アルキルスルホニル）Ｃ２−Ｃ５アルキル基は、各々独立して、シアノ基及びハロゲン原子からなる群より選ばれる１以上の置換基を有する｝、（Ｃ３−Ｃ７シクロアルキル）Ｃ１−Ｃ３アルキル基、Ｃ３−Ｃ７シクロアルキル基｛該（Ｃ３−Ｃ７シクロアルキル）Ｃ１−Ｃ３アルキル基及び該Ｃ３−Ｃ７シクロアルキル基は、各々独立して、シアノ基、ハロゲン原子及びＣ１−Ｃ６ハロアルキル基からなる群より選ばれる１以上の置換基を有する｝、ＯＲ¹、Ｓ（Ｏ）_vＲ¹、ＯＳ（Ｏ）₂Ｒ¹、ＣＨ₂ＯＲ¹、ＮＲ¹Ｒ²⁹、Ｃ（Ｏ）Ｒ¹、Ｃ（Ｏ）ＮＲ¹Ｒ²⁹、ＮＲ²⁹Ｃ（Ｏ）Ｒ¹、Ｎ＝ＣＲ¹Ｒ³⁰、下式Ｔ−１で示される基、下式Ｔ−２で示される基、下式Ｔ−３で示される基、下式Ｔ−４で示される基、下式Ｔ−５で示される基、下式Ｔ−６で示される基、下式Ｔ−７で示される基、下式Ｔ−８で示される基、下式Ｔ−９で示される基、下式Ｔ−１０で示される基、下式Ｔ−１１で示される基、又は下式Ｔ−１２で示される基を表し、

Ｘ¹は、窒素原子又はＣＲ^1aを表し、
Ｘ²は、窒素原子又はＣＲ^1bを表し、
Ｘ³は、窒素原子又はＣＲ^1cを表し、
Ｘ⁴は、窒素原子又はＣＲ^1dを表し、
Ｘ⁵は、窒素原子又はＣＲ^1eを表し、
Ｒ^1xは、１以上のハロゲン原子を有するＣ１−Ｃ５鎖式炭化水素基、ＯＲ⁷、ＯＳ（Ｏ）₂Ｒ⁷、Ｓ（Ｏ）_mＲ⁷、ＮＲ⁸Ｓ（Ｏ）₂Ｒ⁷、又はハロゲン原子を表し、
Ｒ^1a、Ｒ^1b、Ｒ^1c、Ｒ^1d、及びＲ^1eは、同一又は相異なり、各々独立して、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６鎖式炭化水素基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基、ハロゲン原子、又は水素原子を表し、
Ｙ¹は、ＮＲ²⁵、酸素原子又は硫黄原子を表し、
Ｙ²は、窒素原子又はＣＲ²⁶を表し、
Ｙ³は、窒素原子又はＣＲ²⁷を表し、
Ｙ⁴は、窒素原子又はＣＲ²⁸を表し、
Ｒ²⁵、Ｒ²⁶、Ｒ²⁷、及びＲ²⁸は、同一又は相異なり、各々独立して、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６鎖式炭化水素基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基、ハロゲン原子、又は水素原子を表し、
Ｒ^1yは、１以上のハロゲン原子を有するＣ１−Ｃ５鎖式炭化水素基、ＯＲ⁷、ＯＳ（Ｏ）₂Ｒ⁷、Ｓ（Ｏ）_mＲ⁷、ＮＲ⁸Ｓ（Ｏ）₂Ｒ⁷、シアノ基、又はハロゲン原子を表し、
Ｒ^1ay及びＲ⁷は、同一又は相異なり、各々独立して、１以上のハロゲン原子を有するＣ１−Ｃ６鎖式炭化水素基を表し、
ｍ及びｖは、同一又は相異なり、各々独立して、０、１、又は２を表し、
Ｒ¹は、Ｃ１−Ｃ１０鎖式炭化水素基、（Ｃ１−Ｃ５アルコキシ）Ｃ２−Ｃ５アルキル基、（Ｃ１−Ｃ５アルキルスルファニル）Ｃ２−Ｃ５アルキル基、（Ｃ１−Ｃ５アルキルスルフィニル）Ｃ２−Ｃ５アルキル基、（Ｃ１−Ｃ５アルキルスルホニル）Ｃ２−Ｃ５アルキル基｛該Ｃ１−Ｃ１０鎖式炭化水素基、該（Ｃ１−Ｃ５アルコキシ）Ｃ２−Ｃ５アルキル基、該（Ｃ１−Ｃ５アルキルスルファニル）Ｃ２−Ｃ５アルキル基、該（Ｃ１−Ｃ５アルキルスルフィニル）Ｃ２−Ｃ５アルキル基、及び該（Ｃ１−Ｃ５アルキルスルホニル）Ｃ２−Ｃ５アルキル基は、各々独立して、シアノ基及びハロゲン原子からなる群より選ばれる１以上の置換基を有する｝、（Ｃ３−Ｃ７シクロアルキル）Ｃ１−Ｃ３アルキル基、又はＣ３−Ｃ７シクロアルキル基｛該（Ｃ３−Ｃ７シクロアルキル）Ｃ１−Ｃ３アルキル基及び該Ｃ３−Ｃ７シクロアルキル基は、各々独立して、シアノ基、ハロゲン原子及びＣ１−Ｃ６ハロアルキル基からなる群より選ばれる１以上の置換基を有する｝を表し、
Ｒ³⁰は、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６鎖式炭化水素基、ハロゲン原子、ＯＲ³⁵、ＮＲ³⁶Ｒ³⁷、又は水素原子を表し、
Ｒ¹⁸及びＲ³⁵は、同一又は相異なり、各々独立して、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６鎖式炭化水素基を表し、
Ｒ¹⁷は、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６鎖式炭化水素基、群Ｄより選ばれる１以上の置換基を有していてもよいフェニル基、又は水素原子を表し、
Ｒ⁸、Ｒ¹¹、Ｒ¹⁹、Ｒ²⁴、Ｒ²⁹、Ｒ³⁶、及びＲ³⁷は、同一又は相異なり、各々独立して、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６鎖式炭化水素基、又は水素原子を表し、
Ｒ¹²は、群Ｆより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６鎖式炭化水素基、群Ｊより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ７シクロアルキル基、群Ｊより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ７シクロアルケニル基、フェニル基、６員芳香族複素環基｛該フェニル基、及び該６員芳香族複素環基は、各々独立して、群Ｄより選ばれる１以上の置換基を有していてもよい｝、水素原子、又はＳ（Ｏ）₂Ｒ²³を表し、
Ｒ²³は、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６鎖式炭化水素基、又は群Ｄより選ばれる１以上の置換基を有していてもよいフェニル基を表し、
Ｒ^11a及びＲ^12aは、それらが結合する窒素原子と一緒になって、群Ｅより選ばれる１以上の置換基を有していてもよい３−７員非芳香族複素環基を表し、
Ｒ¹³は、水素原子、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６鎖式炭化水素基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ７シクロアルキル基、１以上のハロゲン原子を有していていてもよい（Ｃ３−Ｃ６シクロアルキル）Ｃ１−Ｃ３アルキル基、群Ｄより選ばれる１以上の置換基を有していてもよいフェニル基、又は群Ｄより選ばれる１以上の置換基を有していてもよい５もしくは６員芳香族複素環基を表し、
Ｒ¹⁴は、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６鎖式炭化水素基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ７シクロアルキル基、１以上のハロゲン原子を有していていてもよい（Ｃ３−Ｃ６シクロアルキル）Ｃ１−Ｃ３アルキル基、又はフェニルＣ１−Ｃ３アルキル基｛該フェニルＣ１−Ｃ３アルキル基におけるフェニル部分は、群Ｄより選ばれる１以上の置換基を有していてもよい。｝を表し、
Ｒ¹⁵は、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキル基、又は水素原子を表し、
Ｒ¹⁶は、群Ｆより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６鎖式炭化水素基、群Ｊより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ７シクロアルキル基、Ｓ（Ｏ）₂Ｒ²³、又は水素原子を表し、
ｘは、０又は１を表す。
群Ｂ：１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルコキシ基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルケニルオキシ基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニルオキシ基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルスルファニル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルスルフィニル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルスルホニル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基、シアノ基、ヒドロキシ基、及びハロゲン原子からなる群。
群Ｄ：１以上のハロゲン原子を有していてもよいＣ１−Ｃ６鎖式炭化水素基、ヒドロキシ基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルコキシ基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルケニルオキシ基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニルオキシ基、スルファニル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルスルファニル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルスルフィニル基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキルスルホニル基、アミノ基、ＮＲ⁹Ｒ¹⁰、Ｃ（Ｏ）Ｒ¹⁰、ＯＣ（Ｏ）Ｒ⁹、Ｃ（Ｏ）ＯＲ⁹、シアノ基、ニトロ基、及びハロゲン原子からなる群。
Ｒ⁹は、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキル基、又は１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基を表し、
Ｒ¹⁰は、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基、又は水素原子を表す。
群Ｅ：１以上のハロゲン原子を有していてもよいＣ１−Ｃ６鎖式炭化水素基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルコキシ基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルケニルオキシ基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６アルキニルオキシ基、ハロゲン原子、オキソ基、ヒドロキシ基、シアノ基、及びニトロ基からなる群。
群Ｆ：１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基、フェニル基、６員芳香族複素環基｛該フェニル基及び該６員芳香族複素環基は、各々独立して、群Ｄより選ばれる１以上の置換基を有していてもよい｝、ＯＲ¹⁰、アミノ基、ＮＲ⁹Ｒ¹⁰、ハロゲン原子、ニトロ基、及びシアノ基からなる群。
群Ｈ：５もしくは６員芳香族複素環基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基、ＯＲ¹⁰、アミノ基、ＮＲ⁹Ｒ¹⁰、Ｃ（Ｏ）Ｒ¹⁰、Ｃ（Ｏ）ＮＲ⁹Ｒ¹⁰、ＯＣ（Ｏ）Ｒ⁹、ＯＣ（Ｏ）ＯＲ⁹、ＮＲ¹⁰Ｃ（Ｏ）Ｒ⁹、ＮＲ¹⁰Ｃ（Ｏ）ＯＲ⁹、Ｃ（Ｏ）ＯＲ¹⁰、ハロゲン原子、ニトロ基、及びシアノ基からなる群。
群Ｊ：１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキル基、ハロゲン原子、シアノ基、トリアゾリル基、及びＮＲ¹⁰Ｃ（Ｏ）Ｒ⁹からなる群。］
で表される化合物又はそのＮオキシド（以下、式（Ｉ）で示される化合物又はそのＮオキシドを本化合物と記す）の有効量を有害節足動物、有害節足動物の生息場所、植物又は土壌に施用する有害節足動物の防除方法。
［２］［１］において、式（Ｉ）で示される化合物と、群（ａ）、群（ｂ）、群（ｃ）、群（ｄ）、群（ｅ）、群（ｆ）、群（ｇ）、群（ｈ）、群（ｉ）及び群（ｊ）からなる群より選ばれる１以上の成分とを含む組成物：
群（ａ）：殺虫活性成分、殺ダニ活性成分及び殺線虫活性成分からなる群；
群（ｂ）：殺菌活性成分；
群（ｃ）：植物成長調整成分；
群（ｄ）：薬害軽減成分；
群（ｅ）：共力剤；
群（ｆ）：忌避成分；
群（ｇ）：殺軟体動物成分；
群（ｈ）：昆虫フェロモン；
群（ｉ）：除草活性成分；
群（ｊ）：微生物資材。
［３］ ［２］に記載の組成物の有効量を有害節足動物、有害節足動物の生息場所、植物又は土壌に施用する有害節足動物の防除方法。
［４］ ［１］に記載の化合物又は［２］に記載の組成物の有効量を保持している種子又は栄養生殖器官。 The present invention is as follows.
[1] Formula (I)

[In the formula,
R ² represents a C 1 -C 6 alkyl group, a cyclopropyl group, or a cyclopropylmethyl group which may be substituted by one or more halogen atoms,
n represents 0, 1 or 2;
R ³ is a C 1 -C 6 chain hydrocarbon group optionally having one or more substituents selected from group B, and C ³ -C 7 optionally having one or more substituents selected from group E A cycloalkyl group, a C3-C7 cycloalkenyl group optionally having one or more substituents selected from group J, a phenyl group optionally having one or more substituents selected from group H, group H 5 or 6-membered aromatic heterocyclic group optionally having one or more substituents selected from OR ¹² , NR ¹¹ R ¹² , NR ^11a R ^12a , NR ²⁴ NR ¹¹ R ¹² , NR ²⁴ OR ¹¹ , NR ¹¹ C (O) R ¹³ , NR ²⁴ NR ¹¹ C (O) R ¹³ , NR ¹¹ C (O) OR ¹⁴ , NR ²⁴ NR ¹¹ C (O) OR ¹⁴ , NR ¹¹ C (O) NR ¹⁵ R ^{16 , NR 24 NR 11 C (O} ) NR 15 R 16, N = CHNR 15 R 16, N = S (O) x R 15 R 16, C (O) ^{17, C (O) OR 17} , C (O) NR 15 R 16, CR 24 = NOR 17, NR 11 CR 24 = NOR 17, represents a cyano group, a nitro group, or a halogen atom,
q represents 0, 1, 2, or 3, and when q is 2 or 3, plural R ^{3 s} may be the same or different,
When two R ^{3 s} are adjacent, two R ^{3 s} together with the carbon atom to which they are attached form a benzene ring, a pyrrole ring, a furan ring, a thiophene ring, a pyrazole ring, an imidazole ring, a triazole ring, an oxazole ring , Isoxazole ring, thiazole ring, oxadiazole ring, thiadiazole ring, pyridine ring, pyridazine ring, pyrimidine ring, or pyrazine ring {the benzene ring, the pyrrole ring, the furan ring, the thiophene ring, the pyrazole ring, The imidazole ring, the triazole ring, the oxazole ring, the isoxazole ring, the thiazole ring, the pyridine ring, the pyridazine ring, the pyrimidine ring, and the pyrazine ring are each independently one or more selected from group H Which may have a substituent of
Het represents a group represented by the following formula Het1 or a group represented by the following formula Het2,

A ¹ represents a nitrogen atom or CR ⁶ ,
A ² represents a nitrogen atom or CR ^4a ,
A ³ represents a nitrogen atom or CR ^{4 b} ,
A ⁴ represents a nitrogen atom or CR ^4c ,
Q ¹ represents an oxygen atom or a sulfur atom,
Q ² represents an oxygen atom, N—CN, N—NO ₂ , NR ²⁰ , N—C (O) R ²⁰ or N—C (O) OR ^15, and when n is 2, two Q ² May be the same or different,
R ²⁰ represents a C1-C6 alkyl group optionally having one or more halogen atoms or a hydrogen atom,
R ⁵ is a C 1 -C 6 chain hydrocarbon group which may have one or more substituents selected from group F, and C 3 -C 6 which may have one or more substituents selected from group J 5- or 6-membered aromatic heterocycle optionally having a cycloalkyl group, a phenyl group optionally having one or more substituents selected from group H, or one or more substituents selected from group H Represents a group,
R ^4a , R ^4b , and R ^4c are the same or different, and each independently represent a C1-C6 chain hydrocarbon group optionally having one or more halogen atoms, a nitro group, OR ¹⁸ , NR ¹⁸ R ^{19 represents} a cyano group, an amino group, a halogen atom or a hydrogen atom,
R ⁶ represents a hydrogen atom or a halogen atom,
T is a C1-C10 chain hydrocarbon group, (C1-C5 alkoxy) C2-C5 alkyl group, (C1-C5 alkylsulfanyl) C2-C5 alkyl group, (C1-C5 alkylsulfinyl) C2-C5 alkyl group, (C1-C5 alkylsulfonyl) C2-C5 alkyl group {C1-C10 chain hydrocarbon group, (C1-C5 alkoxy) C2-C5 alkyl group, (C1-C5 alkyl sulfanyl) C2-C5 alkyl group, The (C1-C5 alkylsulfinyl) C2-C5 alkyl group and the (C1-C5 alkylsulfonyl) C2-C5 alkyl group are each independently at least one selected from the group consisting of a cyano group and a halogen atom Having a group}, (C3-C7 cycloalkyl) C1-C3 alkyl group, C3-C7 cycloalkyl group { The (C 3 -C 7 cycloalkyl) C 1 -C 3 alkyl group and the C 3 -C 7 cycloalkyl group are each independently at least one substituent selected from the group consisting of a cyano group, a halogen atom and a C 1 -C 6 haloalkyl group. ^{a}, OR 1, S (O} ) v R 1, OS (O) 2 R 1, CH 2 OR 1, NR 1 R 29, C (O) R 1, C (O) NR 1 R 29, NR 29 C (O) R ¹ , N = CR ¹ R ³⁰ , a group represented by the following formula T-1, a group represented by the following formula T-2, a group represented by the following formula T-3, a group represented by the following formula T-4 A group represented by the group represented by the formula T-5, a group represented by the formula T-6, a group represented by the formula T-7, a group represented by the formula T-8, a group represented by the formula T-9 Or a group represented by the following formula T-10, a group represented by the following formula T-11, or a group represented by the following formula T-12,

X ¹ represents a nitrogen atom or CR ^1a ,
X ² represents a nitrogen atom or CR ^1b ,
X ³ represents a nitrogen atom or CR ^1c ,
X ⁴ represents a nitrogen atom or CR ^{1 d} ,
X ⁵ represents a nitrogen atom or CR ^1e ,
R ^1x is a C1-C5 chain hydrocarbon group having one or more halogen atoms, OR ⁷ , OS (O) ₂ R ⁷ , S (O) _m R ⁷ , NR ⁸ S (O) ₂ R ⁷ , or Represents a halogen atom,
R ^1a , R ^1b , R ^1c , R ^1d , and R ^1e are the same or different and each independently a C1-C6 chain hydrocarbon group which may have one or more halogen atoms, one or more A C3-C6 cycloalkyl group optionally having one or more halogen atoms, a halogen atom, or a hydrogen atom,
Y ¹ represents NR ²⁵ , an oxygen atom or a sulfur atom,
Y ² represents a nitrogen atom or CR ²⁶ ,
Y ³ represents a nitrogen atom or CR ²⁷ ;
Y ⁴ represents a nitrogen atom or CR ²⁸ ,
R ²⁵ , R ²⁶ , R ²⁷ and R ²⁸ are the same or different and each independently represents a C1-C6 chain hydrocarbon group optionally having one or more halogen atoms, one or more halogen atoms Represents a C3-C6 cycloalkyl group which may have a halogen atom or a hydrogen atom,
R ^1y is a C1-C5 chain hydrocarbon group having one or more halogen atoms, OR ⁷ , OS (O) ₂ R ⁷ , S (O) _m R ⁷ , NR ⁸ S (O) ₂ R ⁷ , cyano Represents a group or a halogen atom,
R ^1ay and R ⁷ are the same or different and each independently represents a C1-C6 chain hydrocarbon group having one or more halogen atoms,
m and v are the same or different and each independently represents 0, 1 or 2;
R ¹ represents a C1-C10 chain hydrocarbon group, a (C1-C5 alkoxy) C2-C5 alkyl group, a (C1-C5 alkylsulfanyl) C2-C5 alkyl group, a (C1-C5 alkylsulfinyl) C2-C5 alkyl group , (C1-C5 alkylsulfonyl) C2-C5 alkyl group {C1-C10 chain hydrocarbon group, (C1-C5 alkoxy) C2-C5 alkyl group, (C1-C5 alkyl sulfanyl) C2-C5 alkyl group And the (C1-C5 alkylsulfinyl) C2-C5 alkyl group and the (C1-C5 alkylsulfonyl) C2-C5 alkyl group are each independently one or more selected from the group consisting of a cyano group and a halogen atom. With a substituent}, (C3-C7 cycloalkyl) C1-C3 alkyl group, or C3-C7 cycloalkyl Group {wherein the (C 3 -C 7 cycloalkyl) C 1 -C 3 alkyl group and the C 3 -C 7 cycloalkyl group are each independently at least one selected from the group consisting of a cyano group, a halogen atom and a C 1 -C 6 haloalkyl group Represents a substituted group},
R ³⁰ represents a C1-C6 chain hydrocarbon group which may have one or more halogen atoms, a halogen atom, OR ³⁵ , NR ³⁶ R ³⁷ , or a hydrogen atom,
R ¹⁸ and R ³⁵ are the same or different and each independently represents a C1-C6 chain hydrocarbon group which may have one or more halogen atoms,
R ¹⁷ represents a C1-C6 chain hydrocarbon group optionally having one or more halogen atoms, a phenyl group optionally having one or more substituents selected from Group D, or a hydrogen atom ,
R ⁸ , R ¹¹ , R ¹⁹ , R ²⁴ , R ²⁹ , R ³⁶ , and R ³⁷ are the same or different, and each independently C1 to C6 chain formula optionally having one or more halogen atoms Represents a hydrocarbon group or a hydrogen atom,
R ¹² is a C 1 -C 6 chain hydrocarbon group optionally having one or more substituents selected from group F, and C 3 -C 7 optionally having one or more substituents selected from group J A cycloalkyl group, a C3-C7 cycloalkenyl group optionally having one or more substituents selected from group J, a phenyl group, a six-membered aromatic heterocyclic group {the phenyl group, and the six-membered aromatic complex Each of the ring groups may independently have one or more substituents selected from Group D}, a hydrogen atom, or S (O) ₂ R ²³ ,
R ²³ represents a C1-C6 chain hydrocarbon group which may have one or more halogen atoms, or a phenyl group which may have one or more substituents selected from Group D,
R ^11a and R ^12a together with the nitrogen atom to which they are attached represent a 3-7 membered non-aromatic heterocyclic group which may have one or more substituents selected from group E,
R ¹³ is a hydrogen atom, a C 1 -C 6 chain hydrocarbon group which may have one or more halogen atoms, a C 3 -C 7 cycloalkyl group which may have one or more halogen atoms, one or more (C3-C6 cycloalkyl) C1-C3 alkyl group optionally having a halogen atom, phenyl group optionally having one or more substituents selected from group D, or 1 selected from group D Represents a 5- or 6-membered aromatic heterocyclic group which may have the above substituents,
R ¹⁴ is a C1-C6 chain hydrocarbon group which may have one or more halogen atoms, a C3-C7 cycloalkyl group which may have one or more halogen atoms, one or more halogen atoms (C3-C6 cycloalkyl) C1-C3 alkyl group which may have, or phenyl C1-C3 alkyl group {phenyl moiety in the phenyl C1-C3 alkyl group is one or more substituents selected from group D May be included. Represents},
R ¹⁵ is 1 or more halogen atoms optionally may C1-C6 alkyl group optionally having, or represents a hydrogen atom,
R ¹⁶ is a C 1 -C 6 chain hydrocarbon group optionally having one or more substituents selected from group F, and C 3 -C 7 optionally having one or more substituents selected from group J Represents a cycloalkyl group, S (O) ₂ R ²³ or a hydrogen atom,
x represents 0 or 1;
Group B: C1-C6 alkoxy group optionally having one or more halogen atoms, C3-C6 alkenyloxy group optionally having one or more halogen atoms, one or more halogen atoms A C3-C6 alkynyloxy group, a C1-C6 alkylsulfanyl group optionally having one or more halogen atoms, a C1-C6 alkylsulfinyl group optionally having one or more halogen atoms, one or more A group consisting of a C1 to C6 alkylsulfonyl group which may have a halogen atom, a C3 to C6 cycloalkyl group which may have one or more halogen atoms, a cyano group, a hydroxy group, and a halogen atom.
Group D: C1-C6 chain hydrocarbon group optionally having one or more halogen atoms, hydroxy group, C1-C6 alkoxy group optionally having one or more halogen atoms, one or more halogen atoms A C3-C6 alkenyloxy group which may have one or more groups, a C3-C6 alkynyloxy group which may have one or more halogen atoms, a sulfanyl group, C1-which may have one or more halogen atoms C6 alkylsulfanyl group, C1 to C6 alkylsulfinyl group optionally having one or more halogen atoms, C1 to C6 alkylsulfonyl group optionally having one or more halogen atoms, amino group, NR ⁹ R ¹⁰ , C (O) R ¹⁰ , OC (O) R ⁹ , C (O) OR ⁹ , a cyano group, a nitro group, and a halogen atom.
R ⁹ represents a C 1 -C 6 alkyl group which may have one or more halogen atoms, or a C 3 -C 6 cycloalkyl group which may have one or more halogen atoms,
R ¹⁰ represents a C 1 -C 6 alkyl group which may have one or more halogen atoms, a C 3 -C 6 cycloalkyl group which may have one or more halogen atoms, or a hydrogen atom.
Group E: C1-C6 chain hydrocarbon group optionally having one or more halogen atoms, C1-C6 alkoxy group optionally having one or more halogen atoms, one or more halogen atoms A group consisting of an optionally substituted C3-C6 alkenyloxy group, an optionally substituted C3-C6 alkynyloxy group, a halogen atom, an oxo group, a hydroxy group, a cyano group, and a nitro group.
Group F: C3-C6 cycloalkyl group optionally having halogen atom or more, phenyl group, 6-membered aromatic heterocyclic group {The phenyl group and the 6-membered aromatic heterocyclic group are each independently Group which may have one or more substituents selected from group D}, OR ¹⁰ , amino group, NR ⁹ R ¹⁰ , a halogen atom, a nitro group, and a cyano group.
Group H: 5- or 6-membered aromatic heterocyclic group, C1-C6 alkyl group optionally having one or more halogen atoms, C3-C6 cycloalkyl group optionally having one or more halogen atoms, OR ¹⁰ , amino group, NR ⁹ R ¹⁰ , C (O) R ¹⁰ , C (O) NR ⁹ R ¹⁰ , OC (O) R ⁹ , OC (O) OR ⁹ , NR ¹⁰ C (O) R ⁹ , A group consisting of NR ¹⁰ C (O) OR ⁹ , C (O) OR ¹⁰ , a halogen atom, a nitro group, and a cyano group.
Group J: 1 or more halogen atoms optionally may C1-C6 alkyl group optionally having a halogen atom, a cyano group, triazolyl group, and NR ¹⁰ C (O) group consisting of R ^9. ]
An effective amount of a compound represented by the formula: or its N-oxide (hereinafter referred to as the compound represented by the formula (I) or its N-oxide as the present compound) Method of controlling harmful arthropods to be applied to
[2] [1], a compound represented by the formula (I), and a group (a), a group (b), a group (c), a group (d), a group (e), a group (f), a group ( g) a composition comprising one or more components selected from the group consisting of group (h), group (i) and group (j):
Group (a): a group consisting of an insecticidal active ingredient, an acaricidal active ingredient and a nematode active ingredient;
Group (b): bactericidal active ingredient;
Group (c): plant growth regulating component;
Group (d): drug damage reducing component;
Group (e): synergist;
Group (f): repellent component;
Group (g): mollusc component;
Group (h): Insect pheromone;
Group (i): herbicidal active ingredient;
Group (j): Microbial material.
[3] A method for controlling a harmful arthropod, which comprises applying an effective amount of the composition according to [2] to a harmful arthropod, a habitat of the harmful arthropod, a plant or a soil.
[4] A seed or vegetative organ which retains an effective amount of the compound of [1] or the composition of [2].

  According to the present invention, harmful arthropods can be controlled.

The substituents in the present invention will be described.
The "halogen atom" represents a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
When a substituent has 2 or more halogen atoms, it means that those halogen atoms may be the same or different.
The notation "CX-CY" in the present specification means that the number of carbon atoms is X to Y. For example, the notation "C1-C6" means that the number of carbon atoms is 1 to 6.
The "chain hydrocarbon group" represents an alkyl group, an alkenyl group or an alkynyl group.
As the "alkyl group", for example, methyl group, ethyl group, propyl group, isopropyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, 1-ethylpropyl group, butyl group, sec-butyl group, A tert- butyl group, a pentyl group, a hexyl group, an octyl group, a nonyl group, and a decyl group are mentioned.
As the “alkenyl group”, for example, a vinyl group, 1-propenyl group, 2-propenyl group, 1-methyl-1-propenyl group, 1-methyl-2-propenyl group, 1,2-dimethyl-1-propenyl group, Examples include 1-ethyl-2-propenyl group, 3-butenyl group, 4-pentenyl group, 5-hexenyl group, 7-octenyl group, 8-nonenyl group, and 9-decenyl group.
As the “alkynyl group”, for example, ethynyl group, 1-propynyl group, 2-propynyl group, 1-methyl-2-propynyl group, 1,1-dimethyl-2-propynyl group, 1-ethyl-2-propynyl group, Examples include 2-butynyl group, 4-pentynyl group, 5-hexynyl group, 7-octynyl group, 8-nonynyl group, and 9-decynyl group.
Examples of “C1-C6 alkyl group having one or more halogen atoms” and “C1-C6 haloalkyl group” include, for example, trifluoromethyl group, 2,2,2-trifluoroethyl group, 2-bromo-1,1,1 2,2- tetrafluoroethyl group, 2,2,3,3- tetrafluoropropyl group, 1-methyl-2,2,3,3- tetrafluoropropyl group and perfluorohexyl group are mentioned.

Examples of the "cycloalkyl group" include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group and cycloheptyl group.
Examples of the "cycloalkenyl group" include cyclopropenyl group, cyclobutenyl group, cyclopentenyl group, cyclohexenyl group and cycloheptenyl group.
As a C3-C6 cycloalkyl group which may have one or more halogen atoms, for example, 2,2-difluorocyclopropyl group, 1- (2,2,2-trifluoroethyl) cyclopropyl group, and 4- (trifluoromethyl) cyclohexyl group is mentioned.
Examples of the "alkoxy group" include a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group and a hexyloxy group.
The “C1-C6 alkoxy group optionally having one or more halogen atoms” represents a group in which one or more hydrogen atoms of the C1-C6 alkoxy group are substituted with a halogen atom, for example, trifluoromethoxy And difluoromethoxy, 2,2,2-trichloroethoxy, and 2,2,2-trifluoroethoxy.
The alkylsulfanyl group, the alkylsulfinyl group, and the alkylsulfonyl group represent, for example, an alkyl group having a portion represented by S (O) n.
For example, examples of the alkylsulfanyl group in which n is 0 include, for example, a methylsulfanyl group, an ethylsulfanyl group, a propylsulfanyl group, and an isopropylsulfanyl group.
For example, examples of the alkylsulfinyl group where n is 1 include, for example, methylsulfinyl group, ethylsulfinyl group, propylsulfinyl group, isopropylsulfinyl group and the like.
For example, examples of the alkylsulfonyl group in which n is 2 include, for example, a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, and an isopropylsulfonyl group.

"3-7 membered non-aromatic heterocyclic group" means aziridine ring, azetidine ring, pyrrolidine ring, imidazoline ring, imidazolidine ring, piperidine ring, tetrahydropyrimidine ring, hexahydropyrimidine ring, piperazine ring, azepane ring, oxazolidine Ring, isoxazolidine ring, 1,3-oxazinane ring, morpholine ring, 1,4-oxazepane ring, thiazolidine ring, isothiazolidine ring, 1,3-thiadinane ring, thiomorpholine ring, or 1,4-thiazepane ring . As a 3-7 membered non-aromatic heterocyclic group which may have one or more substituents selected from the group E, the group shown below is mentioned, for example.

"(C1-C5 alkoxy) C2-C5 alkyl group having one or more halogen atoms" represents a group in which (C1-C5 alkoxy) and / or (C2-C5 alkyl) have one or more halogen atoms, For example, 2- (trifluoromethoxy) ethyl group, 2,2-difluoro-3-methoxypropyl group, 2,2-difluoro-3- (2,2,2-trifluoroethoxy) propyl group, and 3- ( And 2-chloroethoxy) propyl.
The "(C1-C5 alkylsulfanyl) C2-C5 alkyl group having one or more halogen atoms" means a group having (C1-C5 alkylsulfanyl) and / or (C2-C5 alkyl) having one or more halogen atoms. For example, a 2,2-difluoro-2- (trifluoromethylthio) ethyl group is mentioned.
The "(C1-C5 alkylsulfinyl) C2-C5 alkyl group having one or more halogen atoms" means a group having (C1-C5 alkylsulfinyl) and / or (C2-C5 alkyl) having one or more halogen atoms. For example, a 2,2-difluoro-2- (trifluoromethanesulfinyl) ethyl group is mentioned.
The "(C1-C5 alkylsulfonyl) C2-C5 alkyl group having one or more halogen atoms" means a group having (C1-C5 alkylsulfonyl) and / or (C2-C5 alkyl) having one or more halogen atoms. For example, a 2,2-difluoro-2- (trifluoromethanesulfonyl) ethyl group is mentioned.
The “(C3-C7 cycloalkyl) C1-C3 alkyl group optionally having one or more halogen atoms” means (C3-C7 cycloalkyl) and / or (C1-C3 alkyl) at least one halogen Represents a group which may have an atom, and examples thereof include (2,2-difluorocyclopropyl) methyl group, 2-cyclopropyl-1,1,2,2-tetrafluoroethyl group, and 2- (2, 2-difluorocyclopropyl) -1,1,2,2-tetrafluoroethyl group is mentioned.
“C3-C7 cycloalkyl) and / or (C1-C3 alkyl) is selected from group G as“ (C3-C7 cycloalkyl) C1-C3 alkyl group having one or more substituents selected from group G ” Group having one or more substituents, for example, (2,2-difluorocyclopropyl) methyl group, [1- (trifluoromethyl) cyclopropyl] methyl group, [2- (trifluoromethyl) cyclopropyl] Methyl group, 2-cyclopropyl-1,1,2,2-tetrafluoroethyl group, 2-cyclopropyl-3,3,3-trifluoropropyl group, and 1,1,2,2-tetrafluoro- And 2- [2- (trifluoromethyl) cyclopropyl] ethyl group.
The “phenyl C1-C3 alkyl group {the phenyl moiety in the phenyl C1-C3 alkyl group may have one or more substituents selected from group D}” is, for example, a benzyl group, 2-fluoro group Examples include benzyl group, 4-chlorobenzyl group, 4- (trifluoromethyl) benzyl group, and 2- [4- (trifluoromethyl) phenyl] ethyl group.
The “5- or 6-membered aromatic heterocyclic group” represents a 5-membered aromatic heterocyclic group or a 6-membered aromatic heterocyclic group, and the 5-membered aromatic heterocyclic group represents a pyrrolyl group, a furyl group, a thienyl group, It represents a pyrazolyl group, an imidazolyl group, a triazolyl group, a tetrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, an oxadiazolyl group, or a thiadiazolyl group. As a 5-membered aromatic heterocyclic group, 5-membered aromatic heterocyclic group having 1 to 4 nitrogen atoms, that is, pyrrolyl group, pyrazolyl group, imidazolyl group, 1,2,4-triazolyl group, 1, 2, 3 -A triazolyl group or a tetrazolyl group is preferable. The 6-membered aromatic heterocyclic group represents a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazinyl group or a triazinyl group.

［式中、Ｒ^Ha、Ｒ^Hb、及びＲ^Hcは、同一又は相異なり、各々独立して、５もしくは６員芳香族複素環基、１以上のハロゲン原子を有していてもよいＣ１−Ｃ６アルキル基、１以上のハロゲン原子を有していてもよいＣ３−Ｃ６シクロアルキル基、ＯＲ¹⁰、アミノ基、ＮＲ⁹Ｒ¹⁰、Ｃ（Ｏ）Ｒ¹⁰、Ｃ（Ｏ）ＮＲ⁹Ｒ¹⁰、ＯＣ（Ｏ）Ｒ⁹、ＯＣ（Ｏ）ＯＲ⁹、ＮＲ¹⁰Ｃ（Ｏ）Ｒ⁹、ＮＲ¹⁰Ｃ（Ｏ）ＯＲ⁹、Ｃ（Ｏ）ＯＲ¹⁰、ハロゲン原子、ニトロ基、又はシアノ基を表し、その他の記号は前記と同じ意味を表す。］ “When two R ³ are adjacent, two R ³ together with the carbon atom to which they are attached form a benzene ring, a pyrrole ring, a furan ring, a thiophene ring, a pyrazole ring, an imidazole ring, a triazole ring, an oxazole Examples of “form a ring, isoxazole ring, thiazole ring, oxadiazole ring, thiadiazole ring, pyridine ring, pyridazine ring, pyrimidine ring or pyrazine ring” include, for example, the compounds shown below when forming a pyrrole ring: Be

[Wherein, R ^Ha , R ^Hb , and R ^Hc are the same or different, and each independently C 1 -C 6 optionally having a 5- or 6-membered aromatic heterocyclic group and one or more halogen atoms Alkyl group, C3-C6 cycloalkyl group optionally having one or more halogen atoms, OR ¹⁰ , amino group, NR ⁹ R ¹⁰ , C (O) R ¹⁰ , C (O) NR ⁹ R ¹⁰ , OC (O) R ⁹ , OC (O) OR ⁹ , NR ¹⁰ C (O) R ⁹ , NR ¹⁰ C (O) OR ⁹ , C (O) OR ¹⁰ , a halogen atom, a nitro group or a cyano group, Other symbols have the same meanings as described above. ]

  The compounds may have one or more stereoisomers. Stereoisomers include enantiomers, diastereomers, geometric isomers and the like. The present compounds include each stereoisomer and a mixture of stereoisomers in any ratio.

  The compounds may form acid addition salts. Examples of the acid which forms an acid addition salt include inorganic acids such as hydrogen chloride, phosphoric acid and sulfuric acid, and organic acids such as acetic acid, trifluoroacetic acid, benzoic acid and p-toluenesulfonic acid. Such an acid addition salt can be obtained by mixing the present compound with an acid.

  Next, the process for producing the present compound will be described.

［式中、記号は前記と同じ意味を表す。］ Manufacturing method 1
The compound represented by the formula (Ib) (hereinafter referred to as compound (Ib)) or the compound represented by the formula (Ic) (hereinafter referred to as compound (Ic)) is a compound represented by the formula (Ia) (hereinafter referred to as It can manufacture by oxidizing a compound (it is described as (Ia)).

[Wherein, the symbols have the same meanings as described above. ]

First, the method for producing compound (Ib) from compound (Ia) will be described.
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include halogenated hydrocarbons such as dichloromethane and chloroform (hereinafter referred to as halogenated hydrocarbons); nitriles such as acetonitrile (hereinafter referred to as nitriles); alcohols such as methanol and ethanol Hereinafter, it is described as alcohols); acetic acid; water and mixtures thereof.
Examples of the oxidizing agent used for the reaction include sodium periodate, m-chloroperbenzoic acid (hereinafter referred to as mCPBA), and hydrogen peroxide. When using hydrogen peroxide as an oxidizing agent, a base (for example, sodium carbonate) or a catalyst may be added as needed.
As a catalyst used for reaction, tungstic acid and sodium tungstate are mentioned, for example.
In the reaction, the oxidizing agent is usually at a ratio of 1 to 1.2 moles, the base is usually at a ratio of 0.01 to 1 moles, and the catalyst is usually 0.01 to 0.5 moles relative to 1 mole of the compound (Ia) Used in proportions of
The reaction temperature is usually in the range of -20 to 80 ° C. The reaction time is usually in the range of 0.1 to 12 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is carried out with an organic solvent, and the organic layer is optionally treated with an aqueous solution of a reducing agent (eg sodium sulfite, sodium thiosulfate) and an aqueous solution of a base (eg sodium hydrogencarbonate) Wash. The organic layer is dried and concentrated to give compound (Ib).

Next, a method for producing compound (Ic) from compound (Ib) is described.
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include halogenated hydrocarbons, nitriles, alcohols, acetic acid, water and mixtures thereof.
Examples of the oxidizing agent used for the reaction include mCPBA and hydrogen peroxide.
When using hydrogen peroxide as an oxidizing agent, you may add a base or a catalyst as needed.
Sodium carbonate is mentioned as a base used for reaction.
As a catalyst used for reaction, sodium tungstate is mentioned, for example.
In the reaction, the oxidizing agent is usually at a ratio of 1 to 2 moles, the base is usually at a ratio of 0.01 to 1 moles, and the catalyst is usually at a ratio of 0.01 to 0.5 moles relative to 1 mole of the compound (Ib) Used in
The reaction temperature is usually in the range of -20 to 120 ° C. The reaction time is usually in the range of 0.1 to 12 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is carried out with an organic solvent, and the organic layer is optionally treated with an aqueous solution of a reducing agent (eg sodium sulfite, sodium thiosulfate) and an aqueous solution of a base (eg sodium hydrogencarbonate) Wash. The organic layer is dried and concentrated to give compound (Ic).

Further, compound (Ic) can be produced by a one-step reaction (one pot) by reacting compound (Ia) with an oxidizing agent.
The reaction can be carried out according to the method of producing a compound (Ic) from a compound (Ib), using an oxidizing agent in a proportion of usually 2 to 5 mol per 1 mol of the compound (Ia).

［式中、Ｘ^bは塩素原子又は臭素原子を表し、Ｔ¹はＯＲ¹、ＮＲ¹Ｒ²⁹、式Ｔ−５で示される基、式Ｔ−６で示される基、式Ｔ−７で示される基、又は式Ｔ−８で示される基を表し、その他の記号は前記と同じ意味を表す。］
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばテトラヒドロフラン（以下、ＴＨＦと記す）、メチルｔｅｒｔ−ブチルエーテル（以下、ＭＴＢＥと記す）等のエーテル（以下、エーテル類と記す）；トルエン、キシレン等の芳香族炭化水素（以下、芳香族炭化水素類と記す）；ニトリル類；Ｎ−メチルピロリドン（以下、ＮＭＰと記す）; Ｎ，Ｎ−ジメチルホルムアミド（以下、ＤＭＦと記す）、ジメチルスルホキシド（以下、ＤＭＳＯと記す）等の非プロトン性極性溶媒（以下、非プロトン性極性溶媒と記す）及びこれらの混合物が挙げられる。
反応に用いられる塩基としては、例えば炭酸カリウム等のアルカリ金属炭酸塩類（以下、アルカリ金属炭酸塩類と記す）、又は水素化ナトリウム等のアルカリ金属水素化物類（以下、アルカリ金属水素化物類と記す）が挙げられる。
反応には、化合物（Ｍ−２）１モルに対して、化合物（Ｒ−１）が通常１〜２モルの割合、塩基が通常１〜１０モルの割合で用いられる。
反応温度は、通常−２０℃〜１５０℃の範囲である。反応時間は通常０．５〜２４時間の範囲である。
反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより、化合物（Ｉｄ−２）を得ることができる。 Manufacturing method 2
The compound represented by the formula (Id-2) (hereinafter referred to as a compound (Id-2)) is a compound represented by the formula (M-2) (hereinafter referred to as a compound (M-2)), It can be produced by reacting a compound represented by R-1) (hereinafter referred to as compound (R-1)) in the presence of a base.

[Wherein, X ^b represents a chlorine atom or a bromine atom, T ¹ represents a group represented by OR ¹ , NR ¹ R ²⁹ , the formula T-5, a group represented by the formula T-6, a group represented by the formula T-7 Or a group represented by Formula T-8, and the other symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include ethers such as tetrahydrofuran (hereinafter referred to as THF) and methyl tert-butyl ether (hereinafter referred to as MTBE) (hereinafter referred to as ethers); and aromatic hydrocarbons such as toluene and xylene (Hereinafter referred to as aromatic hydrocarbons); nitriles; N-methylpyrrolidone (hereinafter referred to as NMP); N, N-dimethylformamide (hereinafter referred to as DMF), dimethyl sulfoxide (hereinafter referred to as DMSO) And aprotic polar solvents (hereinafter referred to as aprotic polar solvents) and mixtures thereof.
Examples of the base used for the reaction include alkali metal carbonates such as potassium carbonate (hereinafter referred to as alkali metal carbonates), or alkali metal hydrides such as sodium hydride (hereinafter referred to as alkali metal hydrides) Can be mentioned.
In the reaction, 1 to 2 moles of Compound (R-1) and 1 to 10 moles of base are usually used per 1 mole of Compound (M-2).
The reaction temperature is usually in the range of -20 ° C to 150 ° C. The reaction time is usually in the range of 0.5 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give a compound (Id-2).

［式中、記号は前記と同じ意味を表す。］
反応は、製造法２に記載の方法に準じて実施することができる。 Manufacturing method 3
A compound represented by the formula (Id-4) (hereinafter referred to as a compound (Id-4)) is a compound represented by the formula (M-3) (hereinafter referred to as a compound (M-3)), a compound (hereinafter referred to as a compound (M-3)) It can be produced by reacting R-1) in the presence of a base.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production method 2.

［式中、Ｔ²は式Ｔ−１で示される基、式Ｔ−２で示される基、式Ｔ−３で示される基、式Ｔ−４で示される基、式Ｔ−９で示される基、式Ｔ−１０で示される基、式Ｔ−１１で示される基、又は式Ｔ−１２で示される基を表し、Ｍは９−ボラビシクロ［３．３．１］ノナン−９−イル基、ボロノ基、４，４，５，５−テトラメチル−１，３，２−ジオキサボロラン−２−イル基、トリブチルスタンニル基、ＺｎＣｌ、ＭｇＣｌ、又はＭｇＢｒを表し、その他の記号は前記と同じ意味を表す。］
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、芳香族炭化水素類、非プロトン性極性溶媒、水及びこれらの混合物が挙げられる。
反応に用いられる金属触媒としては、テトラキス（トリフェニルホスフィン）パラジウム（０）、１，１’−ビス（ジフェニルホスフィノ）フェロセンパラジウム（ＩＩ）ジクロリド、トリス（ジベンジリデンアセトン）ジパラジウム（０）、酢酸パラジウム（ＩＩ）等のパラジウム触媒；ビス（シクロオクタジエン）ニッケル（０）、塩化ニッケル（ＩＩ）等のニッケル触媒；塩化鉄（III）、アセチルアセトン鉄（III）等の鉄触媒；及びヨウ化銅（Ｉ）、塩化銅（Ｉ）等の銅触媒等が挙げられる。
反応は必要に応じて、配位子、塩基、及び／又は無機ハロゲン化物を加えてもよい。
反応に用いられる配位子としては、トリフェニルホスフィン、キサントホス、２，２’−ビス（ジフェニルホスフィノ）−１，１’−ビナフチル、１，１’−ビス（ジフェニルホスフィノ）フェロセン、２−ジシクロヘキシルホスフィノ−２’，４’，６’−トリイソプロピルビフェニル、２−ジシクロヘキシルホスフィノ−２’，６’−ジメトキシビフェニル、１，２−ビス（ジフェニルホスフィノ）エタン、２，２’−ビピリジン、２−アミノエタノール、８−ヒドロキシキノリン、及び１，１０−フェナントロリン等が挙げられる。
反応に用いられる塩基としては、例えばアルカリ金属水素化物類、アルカリ金属炭酸塩類、及びトリエチルアミン、ジイソプロピルエチルアミン、ピリジン、４−（ジメチルアミノ）ピリジン等の有機塩基類が挙げられる。
反応に用いられる無機ハロゲン化物としては、フッ化カリウム、フッ化ナトリウム等のアルカリ金属フッ化物；及び塩化リチウム、塩化ナトリウム等のアルカリ金属塩化物が挙げられる。
反応には、化合物（Ｍ−２）１モルに対して、化合物（Ｒ−２）が通常１〜１０モルの割合、金属触媒が通常０．０１〜０．５モルの割合、配位子が通常０．０１〜１モルの割合、塩基が通常０．１〜５モルの割合、無機ハロゲン化物が通常０．１〜５モルの割合で用いられる。
反応温度は、通常−２０℃〜２００℃の範囲である。反応時間は通常０．１〜２４時間の範囲である。
反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｉｅ−２）を得ることができる。
化合物（Ｒ−２）は、市販の化合物であるか、又は既知の方法を用いて製造することができる。 Manufacturing method 4
The compound represented by the formula (Ie-2) (hereinafter referred to as the compound (Ie-2)) is a compound (M-2), and the compound represented by the formula (R-2) (hereinafter the compound (R-2) Can be produced by reacting in the presence of a metal catalyst.

[Wherein, T ² represents a group represented by the formula T-1, a group represented by the formula T-2, a group represented by the formula T-3, a group represented by the formula T-4, represented by the formula T-9 Group, a group represented by the formula T-10, a group represented by the formula T-11, or a group represented by the formula T-12, and M is a 9-borabicyclo [3.3.1] nonan-9-yl group Represents a borono group, 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl group, tributylstannyl group, ZnCl, MgCl, or MgBr, and the other symbols have the same meanings as described above Represents ]
The reaction is usually carried out in a solvent. As a solvent used for reaction, ether, aromatic hydrocarbons, aprotic polar solvent, water, and these mixtures are mentioned, for example.
As a metal catalyst used for the reaction, tetrakis (triphenylphosphine) palladium (0), 1,1′-bis (diphenylphosphino) ferrocenepalladium (II) dichloride, tris (dibenzylideneacetone) dipalladium (0), Palladium catalysts such as palladium (II) acetate; nickel catalysts such as bis (cyclooctadiene) nickel (0), nickel (II) chloride etc; iron catalysts such as iron (III) chloride, iron (III) acetylacetonate; Copper catalysts such as copper (I), copper (I) chloride and the like can be mentioned.
The reaction may optionally add a ligand, a base and / or an inorganic halide.
As a ligand used for the reaction, triphenylphosphine, xanthophos, 2,2′-bis (diphenylphosphino) -1,1′-binaphthyl, 1,1′-bis (diphenylphosphino) ferrocene, 2- Dicyclohexylphosphino-2 ', 4', 6'-triisopropylbiphenyl, 2-dicyclohexylphosphino-2 ', 6'-dimethoxybiphenyl, 1,2-bis (diphenylphosphino) ethane, 2,2'-bipyridine 2-aminoethanol, 8-hydroxyquinoline, 1,10-phenanthroline and the like.
Examples of the base used for the reaction include alkali metal hydrides, alkali metal carbonates, and organic bases such as triethylamine, diisopropylethylamine, pyridine, 4- (dimethylamino) pyridine and the like.
Examples of inorganic halides used for the reaction include alkali metal fluorides such as potassium fluoride and sodium fluoride; and alkali metal chlorides such as lithium chloride and sodium chloride.
In the reaction, the compound (R-2) is usually at a ratio of 1 to 10 moles, the metal catalyst is usually at a ratio of 0.01 to 0.5 moles, and the ligand is usually 1 to 1 mole of the compound (M-2). Usually, a proportion of 0.01 to 1 mol, a proportion of 0.1 to 5 mol of a base, and a proportion of 0.1 to 5 mol of an inorganic halide are generally used.
The reaction temperature is usually in the range of -20 ° C to 200 ° C. The reaction time is usually in the range of 0.1 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give compound (Ie-2).
Compound (R-2) is a commercially available compound or can be produced using a known method.

［式中、記号は前記と同じ意味を表す。］
反応は、製造法４に記載の方法に準じて実施することができる。 Manufacturing method 5
The compound represented by the formula (Ie-4) can be produced by reacting the compound (M-3) with the compound (R-2) in the presence of a metal catalyst.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production Method 4.

［式中、Ｘ^cは塩素原子、臭素原子又はヨウ素原子を表し、Ｔ³は１以上のハロゲン原子を有するＣ１−Ｃ１０鎖式炭化水素基、１以上のハロゲン原子を有する（Ｃ１−Ｃ５アルコキシ）Ｃ２−Ｃ５アルキル基、１以上のハロゲン原子を有する（Ｃ１−Ｃ５アルキルスルファニル）Ｃ２−Ｃ５アルキル基、１以上のハロゲン原子を有する（Ｃ１−Ｃ５アルキルスルフィニル）Ｃ２−Ｃ５アルキル基、１以上のハロゲン原子を有する（Ｃ１−Ｃ５アルキルスルホニル）Ｃ２−Ｃ５アルキル基、群Ｇより選ばれる１以上の置換基を有する（Ｃ３−Ｃ７シクロアルキル）Ｃ１−Ｃ３アルキル基、群Ｇより選ばれる１以上の置換基を有するＣ３−Ｃ７シクロアルキル基又はＳ（Ｏ）₂Ｒ¹を表し、その他の記号は前記と同じ意味を表す。］
反応は、化合物（Ｒ−１）に代えて化合物（Ｍ−４）、化合物（Ｍ−２）に代えて化合物（Ｒ−３）を用い、製造法２に記載の方法に準じて実施することができる。
化合物（Ｒ−３）は、市販の化合物であるか、又は既知の方法を用いて製造することができる。 Manufacturing method 6
The compound represented by the formula (If-2) is a compound represented by the formula (M-4) (hereinafter referred to as a compound (M-4)) and the compound represented by the formula (R-3) (hereinafter referred to as a compound (R-3) can be produced by reacting in the presence of a base.

[Wherein, X ^c represents a chlorine atom, a bromine atom or an iodine atom, and T ³ represents a C 1 -C 10 chain hydrocarbon group having one or more halogen atoms, and one or more halogen atoms (C 1 -C 5 alkoxy)] C2-C5 alkyl group, (C1-C5 alkylsulfanyl) having one or more halogen atoms, C2-C5 alkyl group, (C1-C5 alkylsulfinyl) C2-C5 alkyl group having one or more halogen atoms, one or more halogens (C1-C5 alkylsulfonyl) C2-C5 alkyl group having an atom, (C3-C7 cycloalkyl) C1-C3 alkyl group having one or more substituents selected from Group G, one or more substituents selected from Group G represents C3-C7 cycloalkyl group or S (O) ₂ R ¹ with a group, the other symbols have the same meanings as described above. ]
The reaction is carried out according to the method described in Production Method 2 using compound (M-4) in place of compound (R-1) and compound (R-3) in place of compound (M-2). Can.
Compound (R-3) is a commercially available compound or can be produced using a known method.

［式中、記号は前記と同じ意味を表す。］
反応は、製造法６に記載の方法に準じて実施することができる。 Manufacturing method 7
The compound represented by the formula (If-4) is a compound represented by the formula (M-5) (hereinafter referred to as a compound (M-5)) and a compound (R-3) in the presence of a base It can be manufactured by

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production Method 6.

［式中、Ｔ⁴は１以上のハロゲン原子を有するＣ１−Ｃ１０鎖式炭化水素基、１以上のハロゲン原子を有する（Ｃ１−Ｃ５アルコキシ）Ｃ２−Ｃ５アルキル基、１以上のハロゲン原子を有する（Ｃ１−Ｃ５アルキルスルファニル）Ｃ２−Ｃ５アルキル基、１以上のハロゲン原子を有する（Ｃ１−Ｃ５アルキルスルフィニル）Ｃ２−Ｃ５アルキル基、１以上のハロゲン原子を有する（Ｃ１−Ｃ５アルキルスルホニル）Ｃ２−Ｃ５アルキル基、群Ｇより選ばれる１以上の置換基を有する（Ｃ３−Ｃ７シクロアルキル）Ｃ１−Ｃ３アルキル基、又は群Ｇより選ばれる１以上の置換基を有するＣ３−Ｃ７シクロアルキル基を表し、その他の記号は前記と同じ意味を表す。］
化合物（Ｒ−４）は、市販の化合物であるか、又は既知の方法に準じて製造することができる。
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えば芳香族炭化水素類、非プロトン性極性溶媒、及びこれらの混合物が挙げられる。
反応には、化合物（Ｍ−２）１モルに対して、化合物（Ｒ−４）が通常１〜１０モルの割合、銅が通常１〜１０モルの割合で用いられる。
反応温度は、通常４０℃〜２００℃の範囲である。反応時間は通常０．１〜２４時間の範囲である。
反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより、化合物（Ｉｇ−２）を得ることができる。 Manufacturing method 8
The compound represented by the formula (Ig-2) (hereinafter referred to as a compound (Ig-2)) is a compound represented by the compound (M-2) and the formula (R-4) (hereinafter referred to as a compound (R-4) ) Can be produced by reacting in the presence of copper.

[Wherein, T ⁴ is a C 1 -C 10 chain hydrocarbon group having one or more halogen atoms, (C 1 -C 5 alkoxy) C 2 -C 5 alkyl group having one or more halogen atoms, one or more halogen atoms ( (C1-C5 alkylsulfanyl) C2-C5 alkyl group, (C1-C5 alkylsulfinyl) C2-C5 alkyl group having one or more halogen atoms, (C1-C5 alkylsulfonyl) C2-C5 alkyl having one or more halogen atoms A group, a (C 3 -C 7 cycloalkyl) C 1 -C 3 alkyl group having one or more substituents selected from Group G, or a C 3-C 7 cycloalkyl group having one or more substituents selected from Group G; The symbol of has the same meaning as described above. ]
Compound (R-4) is a commercially available compound or can be produced according to a known method.
The reaction is usually carried out in a solvent. As a solvent used for reaction, aromatic hydrocarbons, aprotic polar solvent, and these mixtures are mentioned, for example.
In the reaction, the compound (R-4) is usually used in a proportion of 1 to 10 moles, and copper is usually used in a proportion of 1 to 10 moles relative to 1 mole of the compound (M-2).
The reaction temperature is usually in the range of 40 ° C to 200 ° C. The reaction time is usually in the range of 0.1 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give a compound (Ig-2).

［式中、記号は前記と同じ意味を表す。］
反応は、製造法８に記載の方法に準じて実施することができる。 Manufacturing method 9
The compound represented by the formula (Ig-4) can be produced by reacting the compound (M-3) with the compound (R-4) in the presence of copper.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production method 8.

［式中、Ｒ⁴⁰は、メトキシ基、エトキシ基、フェノキシ基、又はＮ（ＣＨ₃）ＯＣＨ₃を表し、その他の記号は前記と同じ意味を表す。］
化合物（Ｒ−５）は、市販の化合物であるか、又は既知の方法に準じて製造することができる。
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、芳香族炭化水素類が挙げられる。
反応に用いられる塩基としては、ブチルリチウム、リチウムジイソプロピルアミド、リチウムテトラメチルピペリジド、リチウムビス（トリメチルシリル）アミド等が挙げられる。
反応には、化合物（Ｍ−２）１モルに対して、化合物（Ｒ−５）が通常１〜１０モルの割合、塩基が通常１．０〜２．０モルの割合で用いられる。
反応温度は、通常−１００℃〜６０℃の範囲である。反応時間は通常０．１〜２４時間の範囲である。
反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより、化合物（Ｉｈ−２）を得ることができる。 Manufacturing method 10
The compound represented by the formula (Ih-2) (hereinafter referred to as a compound (Ih-2)) is a compound represented by the compound ((M-2) and the formula (R-5) (hereinafter referred to as a compound (R- And 5) can be reacted in the presence of a base.

[Wherein, R ⁴⁰ represents a methoxy group, an ethoxy group, a phenoxy group, or N (CH ₃ ) OCH ₃ , and the other symbols have the same meanings as described above. ]
Compound (R-5) is a commercially available compound or can be produced according to a known method.
The reaction is usually carried out in a solvent. As a solvent used for reaction, ethers and aromatic hydrocarbons are mentioned, for example.
Examples of the base used for the reaction include butyllithium, lithium diisopropylamide, lithium tetramethylpiperidide, lithium bis (trimethylsilyl) amide and the like.
In the reaction, the compound (R-5) is usually used in a proportion of 1 to 10 moles, and the base is usually used in a proportion of 1.0 to 2.0 moles relative to 1 mole of the compound (M-2).
The reaction temperature is usually in the range of -100 ° C to 60 ° C. The reaction time is usually in the range of 0.1 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give compound (Ih-2).

［式中、記号は前記と同じ意味を表す。］
反応は、製造法１０に記載の方法に準じて実施することができる。 Manufacturing method 11
The compound represented by the formula (Ih-4) can be produced by reacting the compound (M-3) with the compound (R-5) in the presence of a base.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production method 10.

［式中、記号は前記と同じ意味を表す。］
化合物（Ｒ−６）は、市販の化合物であるか、又は既知の方法に準じて製造することができる。
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、ハロゲン化炭化水素類、芳香族炭化水素類、非プロトン性極性溶媒、及びこれらの混合物が挙げられる。
反応に用いられる縮合剤としては、１−エチル−３−（３−ジメチルアミノプロピル）カルボジイミド塩酸塩等が挙げられる。
反応には必要に応じて塩基を加えてもよく、塩基としては有機塩基類が挙げられる。
反応には、化合物（Ｍ−６）１モルに対して、化合物（Ｒ−６）が通常１〜１０モルの割合、縮合剤が通常１〜５モルの割合、塩基が通常０．１〜１０モルの割合で用いられる。
反応温度は、通常−２０℃〜１２０℃の範囲である。反応時間は通常０．１〜２４時間の範囲である。
反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより、化合物（Ｉｉ−２）を得ることができる。 Manufacturing method 12
The compound represented by the formula (Ii-2) (hereinafter referred to as a compound (Ii-2)) is a compound represented by the formula (M-6) (hereinafter referred to as a compound (M-6)) and the formula The compound represented by (R-6) (hereinafter referred to as compound (R-6)) can be produced by reacting in the presence of a condensing agent.

[Wherein, the symbols have the same meanings as described above. ]
Compound (R-6) is a commercially available compound or can be produced according to a known method.
The reaction is usually carried out in a solvent. The solvent used for the reaction includes, for example, ethers, halogenated hydrocarbons, aromatic hydrocarbons, aprotic polar solvents, and mixtures thereof.
As a condensing agent used for reaction, 1-ethyl 3- (3-dimethylaminopropyl) carbodiimide hydrochloride etc. are mentioned.
If necessary, a base may be added to the reaction, and examples of the base include organic bases.
In the reaction, the compound (R-6) is usually at a ratio of 1 to 10 moles, the condensing agent is usually at a ratio of 1 to 5 moles, and the base is usually 0.1 to 10 based on 1 mole of the compound (M-6) Used in molar proportions.
The reaction temperature is usually in the range of -20 ° C to 120 ° C. The reaction time is usually in the range of 0.1 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give compound (Ii-2).

［式中、記号は前記と同じ意味を表す。］
反応は、製造法１２に記載の方法に準じて実施することができる。 Manufacturing method 13
The compound represented by the formula (Ii-4) is a compound represented by the formula (M-7) (hereinafter referred to as a compound (M-7)) and a compound (R-6) in the presence of a condensing agent It can manufacture by making it react.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production method 12.

［式中、記号は前記と同じ意味を表す。］
化合物（Ｒ−７）は、市販の化合物であるか、又は既知の方法に準じて製造することができる。
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、芳香族炭化水素類、非プロトン性極性溶媒、及びこれらの混合物が挙げられる。
反応に用いられる塩基としては、有機塩基類、アルカリ金属水素化物類、及びアルカリ金属炭酸塩類が挙げられる。
反応には、化合物（Ｍ−８）１モルに対して、化合物（Ｒ−７）が通常１〜１０モルの割合、塩基が通常０．１〜５モルの割合で用いられる。
反応温度は、通常−２０℃〜１２０℃の範囲である。反応時間は通常０．１〜２４時間の範囲である。
反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより、化合物（Ｉｊ−２）を得ることができる。 Manufacturing method 14
The compound represented by the formula (Ij-2) (hereinafter referred to as the compound (Ij-2)) is a compound represented by the formula (M-8) (hereinafter referred to as the compound (M-8)) and the formula The compound represented by (R-7) (hereinafter referred to as compound (R-7)) can be produced by reacting in the presence of a base.

[Wherein, the symbols have the same meanings as described above. ]
Compound (R-7) is a commercially available compound or can be produced according to a known method.
The reaction is usually carried out in a solvent. As a solvent used for reaction, ether, aromatic hydrocarbons, aprotic polar solvent, and these mixtures are mentioned, for example.
As a base used for reaction, organic bases, alkali metal hydrides, and alkali metal carbonates are mentioned.
In the reaction, the compound (R-7) is usually used in a proportion of 1 to 10 moles, and the base is usually used in a proportion of 0.1 to 5 moles, relative to 1 mole of the compound (M-8).
The reaction temperature is usually in the range of -20 ° C to 120 ° C. The reaction time is usually in the range of 0.1 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give compound (Ij-2).

［式中、記号は前記と同じ意味を表す。］
反応は、製造法１４に記載の方法に準じて実施することができる。 Manufacturing method 15
The compound represented by the formula (Ij-4) is a compound represented by the formula (M-9) (hereinafter referred to as a compound (M-9)) and a compound (R-7) in the presence of a base It can be produced by reaction.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production Method 14.

［式中、記号は前記と同じ意味を表す。］
化合物（Ｒ−８）は、市販の化合物であるか、又は既知の方法に準じて製造することができる。
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、ハロゲン化炭化水素類、芳香族炭化水素類、非プロトン性極性溶媒、及びこれらの混合物が挙げられる。
反応には必要に応じて酸を加えてもよく、酸としてはｐ−トルエンスルホン酸、１０−カンファースルホン酸等が挙げられる。
反応には、化合物（Ｍ−１０）１モルに対して、化合物（Ｒ−８）が通常１〜１０モルの割合、酸が通常０．１〜１０モルの割合で用いられる。
反応温度は、通常−２０℃〜１８０℃の範囲である。反応時間は通常０．１〜２４時間の範囲である。
反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより、化合物（Ｉｋ−２）を得ることができる。 Manufacturing method 16
The compound represented by the formula (Ik-2) (hereinafter referred to as the compound (Ik-2)) is a compound represented by the formula (M-10) (hereinafter referred to as the compound (M-10)) and the formula It can manufacture by making it react with the compound (Hereafter, it is described as a compound (R-8).) Shown by (R-8).

[Wherein, the symbols have the same meanings as described above. ]
Compound (R-8) is a commercially available compound or can be produced according to a known method.
The reaction is usually carried out in a solvent. The solvent used for the reaction includes, for example, ethers, halogenated hydrocarbons, aromatic hydrocarbons, aprotic polar solvents, and mixtures thereof.
If necessary, an acid may be added to the reaction, and examples of the acid include p-toluenesulfonic acid and 10-camphorsulfonic acid.
In the reaction, the compound (R-8) is usually used in a proportion of 1 to 10 moles, and the acid is usually used in a proportion of 0.1 to 10 moles relative to 1 mole of the compound (M-10).
The reaction temperature is usually in the range of -20 ° C to 180 ° C. The reaction time is usually in the range of 0.1 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give compound (Ik-2).

［式中、記号は前記と同じ意味を表す。］
反応は、製造法１６に記載の方法に準じて実施することができる。 Manufacturing method 17
The compound represented by the formula (Ik-4) is produced by reacting a compound represented by the formula (M-11) (hereinafter referred to as a compound (M-11)) with a compound (R-8) can do.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production method 16.

［式中、記号は前記と同じ意味を表す。］
化合物（Ｒ−９）は、市販の化合物であるか、又は既知の方法に準じて製造することができる。
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、ハロゲン化炭化水素類、芳香族炭化水素類、非プロトン性極性溶媒、及びこれらの混合物が挙げられる。
反応には必要に応じて塩基を加えてもよく、塩基としては有機塩基類が挙げられる。
反応には、化合物（Ｍ−１２）１モルに対して、化合物（Ｒ−９）が通常１〜１０モルの割合、塩基が通常０．１〜１０モルの割合で用いられる。
反応温度は、通常−２０℃〜１２０℃の範囲である。反応時間は通常０．１〜２４時間の範囲である。
反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより、化合物（Ｉｍ−２）を得ることができる。 Manufacturing method 18
The compound represented by the formula (Im-2) (hereinafter referred to as a compound (Im-2)) is a compound represented by the formula (M-12) (hereinafter referred to as a compound (M-12)) and the formula It can manufacture by making it react with the compound (Hereafter, it is described as a compound (R-9).) Shown by (R-9).

[Wherein, the symbols have the same meanings as described above. ]
Compound (R-9) is a commercially available compound or can be produced according to a known method.
The reaction is usually carried out in a solvent. The solvent used for the reaction includes, for example, ethers, halogenated hydrocarbons, aromatic hydrocarbons, aprotic polar solvents, and mixtures thereof.
If necessary, a base may be added to the reaction, and examples of the base include organic bases.
In the reaction, the compound (R-9) is usually used in a proportion of 1 to 10 moles, and the base is usually used in a proportion of 0.1 to 10 moles relative to 1 mole of the compound (M-12).
The reaction temperature is usually in the range of -20 ° C to 120 ° C. The reaction time is usually in the range of 0.1 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give a compound (Im-2).

［式中、記号は前記と同じ意味を表す。］
反応は、製造法１８に記載の方法に準じて実施することができる。 Manufacturing method 19
The compound represented by the formula (Im-4) is produced by reacting a compound represented by the formula (M-13) (hereinafter referred to as a compound (M-13)) with a compound (R-9) can do.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production method 18.

［式中、記号は前記と同じ意味を表す。］
はじめに、化合物（Ｉｎ−２）の製造法について記す。
化合物（Ｉｎ−２）は、化合物（Ｍ−８）に代えて式（Ｍ−１４）で示される化合物（以下、化合物（Ｍ−１４）と記す。）を用い、製造法１４に記載の方法に準じて製造することができる。 Manufacturing method 20
The compound represented by the formula (In-2) (hereinafter referred to as the compound (In-2)), the compound represented by the formula (Io-2) (hereinafter referred to as the compound (Io-2)), and the formula The compound represented by (Ip-2) (hereinafter referred to as compound (Ip-2)) can be produced according to the following method.

[Wherein, the symbols have the same meanings as described above. ]
First, the method for producing the compound (In-2) will be described.
Compound (In-2) is a method described in Production method 14 using a compound represented by formula (M-14) (hereinafter referred to as compound (M-14)) in place of compound (M-8) It can manufacture according to.

Then, it describes about the manufacturing method of a compound (Io-2).
Compound (Io-2) can be produced according to the method described in Production Method 1 using compound (In-2) in place of compound (Ia).

Then, it describes about the manufacturing method of a compound (Ip-2).
Compound (Ip-2) can be produced according to the method described in Production Method 1, using Compound (Io-2) in place of Compound (Ib).

［式中、記号は前記と同じ意味を表す。］
反応は、製造法２０に記載の方法に準じて実施することができる。 Manufacturing method 21
A compound represented by the formula (In-4) (hereinafter referred to as a compound (In-4)), a compound represented by the formula (Io-4) (hereinafter referred to as a compound (Io-4)), and a formula The compound represented by (Ip-4) (hereinafter referred to as compound (Ip-4)) can be produced according to the following method.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production method 20.

［式中、Ｑ³は、Ｎ−ＣＮ、Ｎ−ＮＯ₂、ＮＲ⁵、Ｎ−Ｃ（Ｏ）Ｒ⁵又はＮ−Ｃ（Ｏ）ＯＲ¹⁵を表し、その他の記号は前記と同じ意味を表す。］
化合物（Ｉｑ）は、化合物（Ｉａ）を用い、Organic Letters, 9(19), 3809, 2007.に記載の方法に準じて製造することができる。
化合物（Ｉｒ）は、化合物（Ｉｑ）を用い、製造法１に記載の化合物（Ｉａ）から化合物（Ｉｂ）を製造する方法に準じて製造することができる。 Manufacturing method 22
The compound represented by the formula (Iq) (hereinafter referred to as compound (Iq)) and the compound represented by the formula (Ir) (hereinafter referred to as compound (Ir)) can be produced according to the following scheme.

[Wherein, Q ³ represents N-CN, N-NO ₂ , NR ⁵ , N—C (O) R ⁵ or N—C (O) OR ¹⁵ , and the other symbols have the same meanings as described above] . ]
Compound (Iq) can be produced from compound (Ia) according to the method described in Organic Letters, 9 (19), 3809, 2007.
Compound (Ir) can be produced according to the method for producing compound (Ib) from compound (Ia) described in production method 1 using compound (Iq).

［式中、記号は前記と同じ意味を表す。］
化合物（Ｉｓ）は、化合物（Ｉａ）を用い、また化合物（Ｉｔ）は、化合物（Ｉｓ）を用い、Russian Journal of Organic Chemistry, Vol, No. 5, 778-779, 2013.に記載の方法に準じて製造することができる。 Manufacturing method 23
The compound represented by the formula (Is) (hereinafter referred to as a compound (Is)) and the compound represented by the formula (It) (hereinafter referred to as a compound (It)) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
The compound (Is) uses the compound (Ia), and the compound (It) uses the compound (Is), and the method described in Russian Journal of Organic Chemistry, Vol, No. 5, 778-779, 2013. It can manufacture according to the same.

［式中、Ｒ⁵³は、水素原子、群Ｂより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６アルキル基、群Ｅより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ７シクロアルキル基、群Ｈより選ばれる１以上の置換基を有していてもよいフェニル基、又は群Ｈより選ばれる１以上の置換基を有していてもよい５もしくは６員芳香族複素環基を表し、その他の記号は前記と同じ意味を表す。］
反応は、国際公開第2009/076387号に記載の方法に準じて実施することができる。 Manufacturing method 24
The compound represented by the formula (Iu-2) (hereinafter referred to as the compound (Iu-2)) is a compound represented by the formula (M-25) (hereinafter referred to as the compound (M-25)) and trifluoroacetic acid Anhydrides can be prepared by reacting in the presence of organic bases. In addition, compound (Iu-2) can also be produced by reacting compound (M-25) with acetic anhydride and then reacting with methanol.

[Wherein, R ⁵³ has a hydrogen atom, a C1-C6 alkyl group optionally having one or more substituents selected from group B, and one or more substituents selected from group E] A good C3-C7 cycloalkyl group, a phenyl group optionally having one or more substituents selected from group H, or a 5 or 6 member optionally having one or more substituents selected from group H It represents an aromatic heterocyclic group, and the other symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in WO 2009/076387.

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｍ−４）に代えて化合物（Ｉｕ−２）を用い、化合物（Ｒ−３）に代えて化合物（Ｒ−２０）を用い、製造法６に記載の方法に準じて実施することができる。
化合物（Ｒ−２０）は、市販の化合物であるか、又は既知の方法を用いて製造することができる。 Manufacturing method 25
The compound represented by the formula (Iv-2) is a compound (Iu-2) and a compound represented by the formula (R-20) (hereinafter referred to as a compound (R-20)) in the presence of a base It can be manufactured by

[Wherein, the symbols have the same meanings as described above. ]
The reaction is carried out according to the method described in Production Method 6, using Compound (Iu-2) in place of Compound (M-4) and using Compound (R-20) in place of Compound (R-3). can do.
Compound (R-20) is a commercially available compound or can be produced using a known method.

［式中、Ｒ⁵⁵は、群Ｂより選ばれる１以上の置換基を有していてもよいＣ１−Ｃ６鎖式炭化水素基、群Ｅより選ばれる１以上の置換基を有していてもよいＣ３−Ｃ７シクロアルキル基、群Ｈより選ばれる１以上の置換基を有していてもよいフェニル基、又は群Ｈより選ばれる１以上の置換基を有していてもよい５もしくは６員芳香族複素環基を表し、その他の記号は前記と同じ意味を表す。］
反応は、化合物（Ｍ−２）に代えて化合物（Ｉｖ−２−１）を用い、化合物（Ｒ−２）に代えて化合物（Ｒ−２１）を用い、製造法４に記載の方法に準じて実施することができる。
化合物（Ｒ−２１）は、市販の化合物であるか、又は既知の方法を用いて製造することができる。 Manufacturing method 26
The compound represented by the formula (Iw-2) is a compound represented by the formula (Iv-2-1) (hereinafter referred to as a compound (Iv-2-1)) and the compound represented by the formula (R-21) Hereinafter, it can manufacture by making a compound (R-21) be made to react in presence of a metal catalyst.

[Wherein, R ⁵⁵ is a C1-C6 chain hydrocarbon group optionally having one or more substituents selected from group B, and one or more substituents selected from group E; A good C3-C7 cycloalkyl group, a phenyl group optionally having one or more substituents selected from group H, or a 5 or 6 member optionally having one or more substituents selected from group H It represents an aromatic heterocyclic group, and the other symbols have the same meanings as described above. ]
The reaction is performed according to the method described in Production Method 4 using Compound (Iv-2-1) in place of Compound (M-2) and using Compound (R-21) in place of Compound (R-2). Can be implemented.
Compound (R-21) is a commercially available compound or can be produced using a known method.

［式中、記号は前記と同じ意味を表す。］
反応は、国際公開第2009/076387号に記載の方法に準じて実施することができる。 Manufacturing method 27
The compound represented by the formula (Iu-4) (hereinafter referred to as compound (Iu-4)) is a compound represented by the formula (M-29) (hereinafter referred to as compound (M-29)) and trifluoroacetic acid It can be produced by reacting an anhydride with an organic base in the presence of an organic base. Compound (Iu-4) can also be produced by reacting compound (M-29) with acetic anhydride and then reacting with methanol.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in WO 2009/076387.

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｍ−４）に代えて化合物（Ｉｕ−４）を用い、化合物（Ｒ−３）に代えて化合物（Ｒ−２０）を用い、製造法６に記載の方法に準じて実施することができる。 Manufacturing method 28
The compound represented by formula (Iv-4) can be produced by reacting compound (Iu-4) with compound (R-20) in the presence of a base.

[Wherein, the symbols have the same meanings as described above. ]
The reaction is carried out according to the method described in Production Method 6, using Compound (Iu-4) in place of Compound (M-4) and using Compound (R-20) in place of Compound (R-3). can do.

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｍ−２）に代えて化合物（Ｉｖ−４−１）を用い、化合物（Ｒ−２）に代えて化合物（Ｒ−２１）を用い、製造法４に記載の方法に準じて実施することができる。 Manufacturing method 29
The compound represented by the formula (Iw-4) comprises a compound represented by the formula (Iv-4-1) (hereinafter referred to as a compound (Iv-4-1)) and a compound (R-21) as a metal catalyst It can be produced by reacting in the presence of

[Wherein, the symbols have the same meanings as described above. ]
The reaction is performed according to the method described in Production Method 4 using Compound (Iv-4-1) in place of Compound (M-2) and using Compound (R-21) in place of Compound (R-2). Can be implemented.

［式中、Ｘ^aはフッ素原子又は塩素原子を表し、その他の記号は前記と同じ意味を表す。］
反応は、化合物（Ｍ−２）に代えて化合物（Ｍ−３０）を用い、化合物（Ｒ−１）に代えて化合物（Ｒ−１６）を用い、製造法２に記載の方法に準じて実施することができる。
化合物（Ｒ−１６）は市販の化合物であるか、又は既知の方法を用いて製造することができる。 Manufacturing method 30
The compound (Ia) is a compound represented by the formula (M-30) (hereinafter referred to as a compound (M-30)) and a compound represented by the formula (R-16) (hereinafter referred to as a compound (R-16) ) In the presence of a base.

[Wherein, X ^a represents a fluorine atom or a chlorine atom, and the other symbols have the same meanings as described above. ]
The reaction is carried out according to the method described in Production Method 2, using Compound (M-30) in place of Compound (M-2) and using Compound (R-16) in place of Compound (R-1). can do.
Compound (R-16) is a commercially available compound or can be produced using known methods.

［式中、記号は前記と同じ意味を表す。］
化合物（Ｒ−２）に代えて化合物（Ｍ−３１）を用い、化合物（Ｍ−２）に代えて化合物（Ｍ−１）を用い、製造法４に記載の方法に準じて実施することができる。
化合物（Ｍ−３１）は、参考製造法３１に記載の方法、又は既知の方法を用いて製造することができる。 Manufacturing method 31
The compound represented by the formula (Ix-2) (hereinafter referred to as the compound (Ix-2)) is a compound represented by the formula (M-31) (hereinafter referred to as the compound (M-31)) and the compound represented by the formula (M-31) It can manufacture by making the compound (it is hereafter described as a compound (M-1)) shown by -1) react in presence of a metal catalyst.

[Wherein, the symbols have the same meanings as described above. ]
The method may be carried out according to the method described in Production Method 4, using Compound (M-31) in place of Compound (R-2) and using Compound (M-1) in place of Compound (M-2) it can.
Compound (M-31) can be produced using the method described in Reference Production Method 31, or a known method.

［式中、記号は前記と同じ意味を表す。］
化合物（Ｒ−２）に代えて化合物（Ｍ−３２）を用い、化合物（Ｍ−２）に代えて化合物（Ｍ−１）を用い、製造法４に記載の方法に準じて実施することができる。
化合物（Ｍ−３２）は、参考製造法３２に記載の方法、又は既知の方法を用いて製造することができる。 Manufacturing method 32
The compound represented by the formula (Ix-4) (hereinafter referred to as compound (Ix-4)) is a compound represented by the formula (M-32) (hereinafter referred to as compound (M-32)) and the compound (M-32) It can manufacture by making -1) react in presence of a metal catalyst.

[Wherein, the symbols have the same meanings as described above. ]
The compound (M-32) may be used instead of the compound (R-2), and the compound (M-1) may be used instead of the compound (M-2) according to the method described in Production Method 4. it can.
Compound (M-32) can be produced using the method described in Reference Production Method 32, or a known method.

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｍ−２）に代えて化合物（Ｍ−４３）を用い、製造法２に記載の方法に準じて実施することができる。 Manufacturing method 33
The compound (Id-2) is produced by reacting a compound represented by the formula (M-43) (hereinafter referred to as compound (M-43)) with a compound (R-1) in the presence of a base be able to.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production Method 2, using Compound (M-43) in place of Compound (M-2).

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｍ−２）に代えて化合物（Ｍ−４６）を用い、製造法２に記載の方法に準じて実施することができる。 Manufacturing method 34
The compound (Id-4) is produced by reacting the compound represented by the formula (M-46) (hereinafter referred to as compound (M-46)) with the compound (R-1) in the presence of a base be able to.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production Method 2, using Compound (M-46) in place of Compound (M-2).

［式中、記号は前記と同じ意味を表す。］
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばハロゲン化炭化水素類；ニトリル類；酢酸エチル等のエステル（以下、エステル類と記す）；アルコール類；酢酸；水及びこれらの混合物が挙げられる。
反応に用いられる酸化剤としては、例えばｍＣＰＢＡ及び過酸化水素が挙げられる。
酸化剤として過酸化水素を用いる場合は、必要に応じて塩基又は触媒を加えてもよい。
反応に用いられる塩基としては、炭酸ナトリウムが挙げられる。
反応に用いられる触媒としては、例えばタングステン酸及びタングステン酸ナトリウムが挙げられる。
反応には、化合物（Ｉ−Ｎ）１モルに対して、酸化剤が通常１〜１０モルの割合、塩基が通常０．０１〜１モルの割合、触媒が通常０．０１〜０．５モルの割合で用いられる。
反応温度は、通常−２０〜８０℃の範囲である。反応時間は通常０．１時間〜７日間の範囲である。
反応終了後は、反応混合物を有機溶媒で抽出し、有機層を必要に応じて還元剤（例えば亜硫酸ナトリウム、チオ硫酸ナトリウム）の水溶液、及び塩基（例えば炭酸水素ナトリウム）の水溶液で洗浄する。得られた有機層を乾燥、濃縮することにより、化合物（Ｉ−ＮＯ）を得ることができる。 Manufacturing method 35
A compound represented by the formula (I-NO) (hereinafter referred to as a compound (I-NO)) is a compound represented by the formula (I-N) (hereinafter referred to as a compound (IN)) and an oxidant Can be produced by reacting

[Wherein, the symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include halogenated hydrocarbons; nitriles; esters such as ethyl acetate (hereinafter referred to as esters); alcohols; acetic acid; water and mixtures thereof.
Examples of the oxidizing agent used for the reaction include mCPBA and hydrogen peroxide.
When using hydrogen peroxide as an oxidizing agent, you may add a base or a catalyst as needed.
Sodium carbonate is mentioned as a base used for reaction.
As a catalyst used for reaction, tungstic acid and sodium tungstate are mentioned, for example.
In the reaction, the oxidizing agent is usually at a ratio of 1 to 10 moles, the base is usually at a ratio of 0.01 to 1 mole, and the catalyst is usually 0.01 to 0.5 moles, relative to 1 mole of the compound (IN) Used in proportions of
The reaction temperature is usually in the range of -20 to 80 ° C. The reaction time is usually in the range of 0.1 hour to 7 days.
After completion of the reaction, the reaction mixture is extracted with an organic solvent, and the organic layer is washed with an aqueous solution of a reducing agent (eg, sodium sulfite, sodium thiosulfate) and an aqueous solution of a base (eg, sodium hydrogencarbonate) as necessary. The compound (I-NO) can be obtained by drying and concentrating the obtained organic layer.

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｍ−２）に代えて化合物（Ｒ−１０）、化合物（Ｒ−１）に代えて化合物（Ｍ−２ｃ）を用い、製造法２に記載の方法に準じて実施することができる。
化合物（Ｒ−１０）は、市販の化合物であるか、又は既知の方法を用いて製造することができる。 Reference manufacturing method 1
The compound (M-2) is a compound represented by the formula (M-2c) (hereinafter referred to as the compound (M-2c)) and a compound represented by the formula (R-10) (hereinafter the compound (R-10) Can be produced by reacting in the presence of a base).

[Wherein, the symbols have the same meanings as described above. ]
The reaction is carried out according to the method described in Production Method 2, using Compound (R-10) in place of Compound (M-2) and Compound (M-2c) in place of Compound (R-1). Can.
Compound (R-10) is a commercially available compound or can be produced using a known method.

［式中、Ｒ⁵¹は、メチル基、エチル基又はベンジル基を表し、その他の記号は前記と同じ意味を表す。］
式（Ｍ−２ｂ）で示される化合物（以下、化合物（Ｍ−２ｂ）と記す）は、式（Ｍ−２ａ）で示される化合物（以下、化合物（Ｍ−２ａ）と記す）と式（Ｒ−１１）で示される化合物（以下、化合物（Ｒ−１１）と記す）とを塩基の存在下で反応させることにより製造することができる。反応は、製造法２に記載の方法に準じて実施することができる。
化合物（Ｍ−２ｃ）は、化合物（Ｍ−２ｂ）と酸とを反応させることにより製造することがでる。反応は、例えば国際公開第2016/052455号に記載の方法に準じて実施することができる。
化合物（Ｒ−１１）は、市販の化合物であるか、又は既知の方法を用いて製造することができる。 Reference manufacturing method 2
Compound (M-2c) can be produced according to the following scheme.

[Wherein, R ⁵¹ represents a methyl group, an ethyl group or a benzyl group, and the other symbols have the same meanings as described above. ]
The compound represented by the formula (M-2b) (hereinafter referred to as the compound (M-2b)) is a compound represented by the formula (M-2a) (hereinafter referred to as the compound (M-2a)) and the compound represented by the formula (R-2) It can be produced by reacting the compound represented by -11) (hereinafter referred to as compound (R-11)) in the presence of a base. The reaction can be carried out according to the method described in Production method 2.
Compound (M-2c) can be produced by reacting compound (M-2b) with an acid. The reaction can be carried out, for example, according to the method described in WO 2016/052455.
Compound (R-11) is a commercially available compound or can be produced using a known method.

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｍ−２）に代えて化合物（Ｍ−１）、化合物（Ｒ−２）に代えて化合物（Ｒ−１２）を用い、製造法４に記載の方法に準じて実施することができる。
化合物（Ｒ−１２）は、市販の化合物であるか、又は既知の方法を用いて製造することができる。 Reference manufacturing method 3
The compound (M-2a) can be produced by reacting a compound represented by the formula (R-12) (hereinafter referred to as a compound (R-12)) with a compound (M-1) in the presence of a metal catalyst It can be manufactured.

[Wherein, the symbols have the same meanings as described above. ]
The reaction is carried out according to the method described in Production Method 4 using compound (M-1) in place of compound (M-2) and compound (R-12) in place of compound (R-2). Can.
Compound (R-12) is a commercially available compound or can be produced using a known method.

［式中、記号は前記と同じ意味を表す。］
反応は、参考製造法１に記載の方法に準じて実施することができる。 Reference manufacturing method 4
The compound (M-3) is obtained by reacting the compound represented by the formula (M-3c) (hereinafter referred to as the compound (M-3c)) with the compound (R-10) in the presence of a base It can be manufactured.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Reference Production Method 1.

［式中、記号は前記と同じ意味を表す。］
これらの反応は、参考製造法２に記載の方法に準じて実施することができる。 Reference manufacturing method 5
Compound (M-3c) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
These reactions can be carried out according to the method described in Reference Production Method 2.

［式中、記号は前記と同じ意味を表す。］
反応は、参考製造法３に記載の方法に準じて実施することができる。
化合物（Ｒ−１３）は、市販の化合物であるか、又は既知の方法を用いて製造することができる。 Reference manufacturing method 6
The compound represented by the formula (M-3a) is a compound represented by the formula (R-13) (hereinafter referred to as a compound (R-13)) and the compound (M-1) in the presence of a metal catalyst It can be manufactured by

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Reference Production Method 3.
Compound (R-13) is a commercially available compound or can be produced using a known method.

［式中、記号は前記と同じ意味を表す。］
これらの反応は、参考製造法２に記載の方法に準じて実施することができる。 Reference manufacturing method 7
Compound (M-4) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
These reactions can be carried out according to the method described in Reference Production Method 2.

［式中、記号は前記と同じ意味を表す。］
これらの反応は、参考製造法２に記載の方法に準じて実施することができる。 Reference manufacturing method 8
Compound (M-5) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
These reactions can be carried out according to the method described in Reference Production Method 2.

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｒ−５）に代えてドライアイスを用い、製造法１０に記載の方法に準じて実施することができる。 Reference manufacturing method 9
Compound (M-6) can be produced by reacting compound (M-2) with dry ice in the presence of a base.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production Method 10 using dry ice in place of compound (R-5).

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｒ−５）に代えてドライアイスを用い、製造法１０に記載の方法に準じて実施することができる。 Reference manufacturing method 10
Compound (M-7) can be produced by reacting compound (M-3) with dry ice in the presence of a base.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production Method 10 using dry ice in place of compound (R-5).

［式中、記号は前記と同じ意味を表す。］
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、脂肪族炭化水素類、芳香族炭化水素類、アルコール類、及びこれらの混合物が挙げられる。
反応に用いられる還元剤として、水素化ホウ素ナトリウム、水素化ホウ素リチウム、、水素化アルミニウムリチウム、水素化ジイソブチルアルミニウム等が挙げられる。
反応には、化合物（Ｍ−６）１モルに対して、還元剤が通常１〜５モルの割合で用いられる。
反応の反応温度は、通常−２０〜１２０℃の範囲である。反応の反応時間は通常０．１〜２４時間の範囲である。
反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより、化合物（Ｍ−８）を得ることができる。 Reference manufacturing method 11
Compound (M-8) can be produced by reacting compound (M-6) with a reducing agent.

[Wherein, the symbols have the same meanings as described above. ]
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include ethers, aliphatic hydrocarbons, aromatic hydrocarbons, alcohols, and mixtures thereof.
As a reducing agent used for the reaction, sodium borohydride, lithium borohydride, lithium aluminum hydride, diisobutylaluminum hydride and the like can be mentioned.
In the reaction, a reducing agent is usually used in a proportion of 1 to 5 moles relative to 1 mole of the compound (M-6).
The reaction temperature of the reaction is usually in the range of -20 to 120 ° C. The reaction time of the reaction is usually in the range of 0.1 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give a compound (M-8).

［式中、記号は前記と同じ意味を表す。］
これらの反応は、参考製造法１１に記載の方法に準じて実施することができる。 Reference manufacturing method 12
Compound (M-9) can be produced by reacting compound (M-7) with a reducing agent.

[Wherein, the symbols have the same meanings as described above. ]
These reactions can be carried out according to the method described in Reference Production Method 11.

［式中、記号は前記と同じ意味を表す。］
式（Ｍ−１０ａ）で示される化合物（以下、化合物（Ｍ−１０ａ）と記す。）は、化合物（Ｍ−２ａ）に代えて化合物（Ｍ−２）、化合物（Ｒ−１１）に代えてｐ−メトキシベンジルアミンを用い、参考製造法２に記載の方法に準じて製造することができる。
化合物（Ｍ−１０）は、化合物（Ｍ−２ｂ）に代えて化合物（Ｍ−１０ａ）を用い、参考製造法２に記載の方法に準じて製造することができる。 Reference manufacturing method 13
Compound (M-10) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
The compound represented by the formula (M-10a) (hereinafter referred to as the compound (M-10a)) is substituted for the compound (M-2a) and is substituted for the compound (M-2) and the compound (R-11) It can manufacture according to the method as described in the reference manufacturing method 2 using p-methoxy benzylamine.
Compound (M-10) can be produced according to the method described in Reference Production Method 2 using compound (M-10a) in place of compound (M-2b).

［式中、記号は前記と同じ意味を表す。］
これらの反応は、参考製造法１３に記載の方法に準じて実施することができる。 Reference manufacturing method 14
Compound (M-11) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
These reactions can be carried out according to the method described in Reference Production Method 13.

［式中、記号は前記と同じ意味を表す。］
化合物（Ｒ−１４）は、市販の化合物であるか、又は公知の方法に準じて製造することができる。
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、芳香族炭化水素類、非プロトン性極性溶媒、及びこれらの混合物が挙げられる。
パラジウム触媒としては、アリルパラジウム（ＩＩ）クロリド等が挙げられる。
反応には、添加剤としてフェノール、塩基としてカリウムｔｅｒｔ−ブトキシドが用いられる。
反応には、化合物（Ｍ−２）１モルに対して、化合物（Ｒ−１４）が通常１〜１０モルの割合、パラジウム触媒が、通常０．０１〜１モルの割合、フェノールが１〜５モルの割合、カリウムｔｅｒｔ−ブトキシドが０．１〜１０モルの割合で用いられる。
反応温度は、通常４０℃〜１８０℃の範囲である。反応時間は通常０．１〜２４時間の範囲である。
反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより、化合物（Ｍ−１２）を得ることができる。 Reference manufacturing method 15
The compound (M-12) can be obtained by reacting the compound (M-2) with a compound represented by the formula (R-14) (hereinafter referred to as the compound (R-14)) in the presence of a base It can be manufactured.

[Wherein, the symbols have the same meanings as described above. ]
Compound (R-14) is a commercially available compound or can be produced according to a known method.
The reaction is usually carried out in a solvent. As a solvent used for reaction, ether, aromatic hydrocarbons, aprotic polar solvent, and these mixtures are mentioned, for example.
Examples of the palladium catalyst include allylpalladium (II) chloride and the like.
For the reaction, phenol is used as an additive and potassium tert-butoxide is used as a base.
In the reaction, the compound (R-14) is usually at a ratio of 1 to 10 moles, the palladium catalyst is usually at a ratio of 0.01 to 1 mole, and the phenol is preferably 1 to 5 with respect to 1 mole of the compound (M-2) The molar proportion, potassium tert-butoxide, is used in a proportion of 0.1 to 10 molar.
The reaction temperature is usually in the range of 40 ° C to 180 ° C. The reaction time is usually in the range of 0.1 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give a compound (M-12).

［式中、記号は前記と同じ意味を表す。］
反応は、参考製造法１５に記載の方法に準じて実施することができる。 Reference manufacturing method 16
Compound (M-13) can be produced by reacting compound (M-3) with compound (R-14) in the presence of a base.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Reference Production Method 15.

［式中、記号は前記と同じ意味を表す。］
はじめに、式（Ｍ−１４ａ）で示される化合物（以下、化合物（Ｍ−１４ａ）と記す。）の製造法について記す。
化合物（Ｍ−１４ａ）は、化合物（Ｍ−２）とチオ安息香酸とを銅触媒及び塩基の存在下で反応させることにより製造することができる。
反応は、通常溶媒中で行われる。反応に用いられる溶媒としては、例えばエーテル類、芳香族炭化水素類、非プロトン性極性溶媒、水及びこれらの混合物が挙げられる。
反応に用いられる銅触媒としては、塩化銅、臭化銅、及びヨウ化銅等が挙げられる。
反応に用いられる塩基としては、例えばアルカリ金属水素化物類、アルカリ金属炭酸塩類、及び有機塩基類が挙げられる。
反応には必要に応じて、配位子を加えてもよい。反応に用いられる配位子としては、２，２’−ビピリジン、２−アミノエタノール、８−ヒドロキシキノリン、及び１，１０−フェナントロリン等が挙げられる。
反応には、化合物（Ｍ−２）１モルに対して、チオ安息香酸が通常１〜１０モルの割合、銅触媒が通常０．０１〜０．５モルの割合、配位子が通常０．０１〜１モルの割合、塩基が通常０．１〜５モルの割合で用いられる。
反応温度は、通常−２０℃〜２００℃の範囲である。反応時間は通常０．１〜２４時間の範囲である。
反応終了後は、反応混合物に水を加え、有機溶媒で抽出し、有機層を乾燥、濃縮する等の後処理操作を行うことにより化合物（Ｍ−１４ａ）を得ることができる。 Reference manufacturing method 17
Compound (M-14) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
First, a method for producing a compound represented by the formula (M-14a) (hereinafter referred to as a compound (M-14a)) is described.
Compound (M-14a) can be produced by reacting compound (M-2) with thiobenzoic acid in the presence of a copper catalyst and a base.
The reaction is usually carried out in a solvent. As a solvent used for reaction, ether, aromatic hydrocarbons, aprotic polar solvent, water, and these mixtures are mentioned, for example.
As a copper catalyst used for reaction, copper chloride, copper bromide, copper iodide, etc. are mentioned.
Examples of the base used for the reaction include alkali metal hydrides, alkali metal carbonates, and organic bases.
If necessary, a ligand may be added to the reaction. As a ligand used for reaction, 2, 2'- bipyridine, 2-aminoethanol, 8-hydroxy quinoline, 1, 10- phenanthroline etc. are mentioned.
In the reaction, a ratio of usually 1 to 10 moles of thiobenzoic acid, a ratio of usually 0.01 to 0.5 moles of a copper catalyst, and a ratio of usually 0. The base is usually used in a proportion of 0.1 to 5 mol, at a ratio of 01 to 1 mol.
The reaction temperature is usually in the range of -20 ° C to 200 ° C. The reaction time is usually in the range of 0.1 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, extraction is performed with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give compound (M-14a).

Then, it describes about the manufacturing method of a compound (M-14).
The compound (M-14) can be produced, for example, according to the method described in WO 2011/068171, or the method described in Journal of Organic Chemistry, 1978, 43 (6), 1190-1192.

［式中、記号は前記と同じ意味を表す。］
これらの反応は、参考製造法１７に記載の方法に準じて実施することができる。 Reference manufacturing method 18
The compound represented by formula (M-15) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
These reactions can be carried out according to the method described in Reference Production Method 17.

［式中、記号は前記と同じ意味を表す。］
これらの反応は、製造法１に記載の方法に準じて実施することができる。 Reference manufacturing method 19
The compound represented by the formula (M-1b) and the compound represented by the formula (M-1c) can be produced by oxidizing a compound represented by the formula (M-1a) (hereinafter referred to as a compound (M-1a)) It can be manufactured.

[Wherein, the symbols have the same meanings as described above. ]
These reactions can be carried out according to the method described in Production Method 1.

［式中、記号は前記と同じ意味を表す。］
反応は、製造法２に記載の方法に準じて実施することができる。
化合物（Ｒ−１５）は、市販の化合物であるか、又は既知の方法を用いて製造することができる。 Reference manufacturing method 20
The compound (M-1a) is produced by reacting a compound represented by the formula (R-15) (hereinafter referred to as compound (R-15)) with a compound (R-16) in the presence of a base be able to.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production method 2.
Compound (R-15) is a commercially available compound or can be produced using a known method.

［式中、Ｒ⁵⁰はメチル基又はエチル基を表し、Ｒ⁵²及びＲ⁵⁴は、同一又は相異なり、Ｃ１−Ｃ６アルキル基を表し、Ｘ^dはフッ素原子、塩素原子、臭素原子、ヨウ素原子、ＢＦ₄又はＰＦ₆を表し、その他の記号は前記と同じ意味を表す。］ Reference manufacturing method 21
The compound represented by the formula (M-2b-1) (hereinafter referred to as a compound (M-2b-1)) can be produced according to the following scheme.

[Wherein, R ⁵⁰ represents a methyl group or an ethyl group, R ⁵² and R ⁵⁴ are the same or different, and represent a C 1 -C 6 alkyl group, and X ^d represents a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, Represents BF ₄ or PF ₆ , and the other symbols have the same meanings as described above. ]

A compound represented by the formula (M-17) (hereinafter referred to as a compound (M-17)) is a compound represented by the formula (M-16) (hereinafter referred to as a compound (M-16)), a compound represented by the formula (M-17) It can be produced by reacting a compound represented by R-17) (hereinafter referred to as compound (R-17)) in the presence of a base.
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include alcohols, ethers, aromatic hydrocarbons, aprotic polar solvents, and mixtures thereof.
As the base used for the reaction, for example, n-butyllithium, s-butyllithium, t-butyllithium, lithium diisopropylamide, lithium bis (trimethylsilyl) amide, sodium bis (trimethylsilyl) amide, potassium bis (trimethylsilyl) amide, potassium t-butoxide, sodium methoxide, sodium ethoxide and alkali metal hydrides can be mentioned.
In the reaction, the compound (R-17) is usually used in a proportion of 1 to 5 moles, and the base is usually used in a proportion of 1 to 5 moles, relative to 1 mole of the compound (M-16). Preferably, the compound (R-17) is used in a ratio of 1.0 to 1.1 mol, and the base is used in a ratio of 1 to 2 mol per 1 mol of the compound (M-16).
The reaction temperature is usually in the range of -78 ° C to 100 ° C. The reaction time is usually in the range of 0.5 to 12 hours.
After completion of the reaction, water is added to the reaction mixture, followed by extraction with an organic solvent, and post treatment operations such as drying and concentration of the organic layer to give a compound (M-17).
Compound (M-16) is a commercially available compound or can be produced by a known method.
The compound (R-17) is a commercially available compound or can be produced by the method described in Journal of Molecular Catalysis A: Chemical, 2011, 341 (1-2), 57.

  The compound (M-2b-1) is reacted with ammonia after reacting the compound (M-17) with the compound represented by the formula (R-18) (hereinafter referred to as the compound (R-18)) Can be manufactured by

It describes about the 1st process of making a compound (M-17) and a compound (R-18) react.
The reaction is usually carried out in a solvent. Solvents used for the reaction include, for example, ethers; aromatic hydrocarbons; halogenated hydrocarbons; alcohols; esters; nitriles; aprotic polar solvents; nitrogen-containing aroma such as pyridine, 2, 6-lutidine and the like Group compounds (hereinafter referred to as nitrogen-containing aromatic compounds) and mixtures thereof.
A base may be used for the reaction, and examples of the base include alkali metal carbonates, alkali metal hydrides, and organic bases.
When a base is used in the reaction, the base is usually used in a proportion of 1 to 10 moles relative to 1 mole of the compound (M-17).
In the reaction, the compound (R-18) is usually used in a proportion of 1 to 10 moles relative to 1 mole of the compound (M-17).
The reaction temperature is usually in the range of -50 to 200 ° C. The reaction time is usually in the range of 0.1 to 24 hours.
After completion of the reaction, the residue obtained by concentrating the reaction mixture is used as it is in the second step or after adding water to the reaction mixture, extraction with an organic solvent and subsequent treatment such as drying and concentration of the organic layer The residue obtained by performing the operation is used in the second step.

Subsequently, a second step of producing a compound (M-2b-1) by reacting the residue obtained in the first step with ammonia is described.
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include ethers, nitriles, alcohols, aprotic polar solvents, nitrogen-containing aromatic compounds and mixtures thereof.
Ammonia used for the reaction can be used as an aqueous solution or an alcohol solution.
In the reaction, ammonia is usually used at a ratio of 1 to 100 moles relative to 1 mole of the compound (M-17) used in the first step.
The reaction temperature is usually in the range of 0 to 100 ° C. The reaction time is usually in the range of 0.1 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, and the mixture is extracted with an organic solvent, and the organic layer is subjected to post-treatment procedures such as drying and concentration to give a compound (M-2b-1). .
Compound (R-18) can be produced according to the method described in WO 2009/054742.

［式中、Ｘ^eは塩素原子、臭素原子、ヨウ素原子、メチル基、ニトロ基又はトリフルオロメチル基を表し、その他の記号は前記と同じ意味を表す。］ Reference manufacturing method 22
The compound represented by the formula (M-2b-2) (hereinafter referred to as a compound (M-2b-2)) can be produced according to the following scheme.

[Wherein, X ^e represents a chlorine atom, a bromine atom, an iodine atom, a methyl group, a nitro group or a trifluoromethyl group, and the other symbols have the same meanings as described above. ]

The compound represented by the formula (M-20) (hereinafter referred to as the compound (M-20)) can be produced by reacting the compound (M-17) with ammonia.
The reaction is usually carried out in a solvent. Examples of the solvent used for the reaction include ethers, aromatic hydrocarbons, nitriles, alcohols, aprotic polar solvents, water and mixtures thereof.
The ammonia used for the reaction may use a gas, and may use an aqueous solution or an alcohol solution. In addition, carboxylic acid ammonium salts such as ammonium acetate; ammonium phosphates such as ammonium dihydrogen phosphate; ammonium carbonate; ammonium salts such as ammonium chloride may be used.
In the reaction, ammonia is usually used in a proportion of 0.1 to 100 mol per 1 mol of the compound (M-17).
The reaction temperature is usually in the range of 0 ° C to 200 ° C. The reaction time is usually in the range of 0.5 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, and the mixture is extracted with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give a compound (M-20).

Compound (M-2b-2) can be produced by reacting compound (M-20) with a compound represented by formula (R-19) (hereinafter referred to as compound (R-19)).
The reaction is usually carried out in a solvent. As the solvent used for the reaction, for example, ethers, aromatic hydrocarbons, halogenated hydrocarbons, alcohols, esters, nitriles, aprotic polar solvents, nitrogen-containing aromatic compounds and mixtures thereof are listed. It can be mentioned.
A base may be used for the reaction, and examples of the base include alkali metal carbonates, alkali metal hydrides, and organic bases.
When a base is used in the reaction, the base is usually used in a proportion of 1 to 10 moles relative to 1 mole of the compound (M-20).
In the reaction, the compound (R-19) is usually used in a proportion of 1 to 10 moles relative to 1 mole of the compound (M-20).
The reaction temperature is usually in the range of -50 to 200 ° C. The reaction time is usually in the range of 0.1 to 24 hours.
After completion of the reaction, water is added to the reaction mixture, and the mixture is extracted with an organic solvent, and the organic layer is subjected to post-treatment operations such as drying and concentration to give a compound (M-2b-2). .
A compound (R-19) can be manufactured according to the method as described in Organic Process Research & Development, 2005, 9, 141. or The Journal of Organic Chemistry 2000, 65, 4571-4574.

［式中、記号は前記と同じ意味を表す。］
これらの反応は、化合物（Ｍ−１６）に代えて化合物（Ｍ−１８）を用い、参考製造法２１に記載の方法に準じて実施することができる。 Reference manufacturing method 23
The compound represented by the formula (M-3b-1) (hereinafter referred to as a compound (M-3b-1)) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
These reactions can be carried out according to the method described in Reference Production Method 21 using compound (M-18) in place of compound (M-16).

［式中、記号は前記と同じ意味を表す。］
これらの反応は、化合物（Ｍ−１７）に代えて化合物（Ｍ−１９）を用い、参考製造法２２に記載の方法に準じて実施することができる。 Reference manufacturing method 24
The compound represented by the formula (M-3b-2) (hereinafter referred to as a compound (M-3b-2)) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
These reactions can be carried out according to the method described in Reference Production Method 22 using compound (M-19) in place of compound (M-17).

［式中、記号は前記と同じ意味を表す。］ Reference manufacturing method 25
A compound represented by the formula (M-22) (hereinafter referred to as a compound (M-22)) is reacted with a hydroxylamine after the compound (M-17) and the compound (R-18) are reacted Can be manufactured by

[Wherein, the symbols have the same meanings as described above. ]

  The reaction can be carried out according to the method for producing a compound (M-2b-1) from a compound (M-17) described in Reference Production Method 21 using hydroxylamine in place of ammonia.

［式中、記号は前記と同じ意味を表す。］
式（Ｍ−２３）で示される化合物（以下、化合物（Ｍ−２３）と記す）は、化合物（Ｍ−２ｂ）に代えて化合物（Ｍ−２２）を用い、参考製造法２に記載の方法に準じて製造することができる。
式（Ｍ−２４）で示される化合物（以下、化合物（Ｍ−２４）と記す）は、化合物（Ｍ−２ｃ）に代えて化合物（Ｍ−２３）を用い、参考製造法２に記載の方法に準じて製造することができる。
化合物（Ｍ−２５）は、化合物（Ｍ−２）に代えて化合物（Ｍ−２４）を用い、製造法２に記載の方法に準じて製造することができる。 Reference manufacturing method 26
Compound (M-25) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
A method described in Reference Production Method 2 using a compound (M-22) instead of the compound (M-2b) for the compound represented by the formula (M-23) (hereinafter referred to as the compound (M-23)) It can manufacture according to.
A method described in Reference Production Method 2 using a compound (M-23) instead of the compound (M-2c) for the compound represented by the formula (M-24) (hereinafter referred to as the compound (M-24)) It can manufacture according to.
Compound (M-25) can be produced according to the method described in production method 2 using compound (M-24) in place of compound (M-2).

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｍ−１６）に代えて化合物（Ｍ−１９）を用い、アンモニアに代えてヒドロキシルアミンを用い、参考製造法２１に記載の化合物（Ｍ−１７）から化合物（Ｍ−２ｂ−１）を製造する方法に準じて実施することができる。 Reference manufacturing method 27
A compound represented by the formula (M-26) (hereinafter referred to as a compound (M-26)) is reacted with a hydroxylamine after the compound (M-19) and the compound (M-18) are reacted It can be manufactured by

[Wherein, the symbols have the same meanings as described above. ]
In the reaction, compound (M-19) is used in place of compound (M-16), hydroxylamine is used in place of ammonia, and compound (M-2b) is prepared from compound (M-17) described in Reference Production Method 21. It can implement according to the method to manufacture 1).

［式中、記号は前記と同じ意味を表す。］
式（Ｍ−２７）で示される化合物（以下、化合物（Ｍ−２７）と記す）は、化合物（Ｍ−２ｂ）に代えて化合物（Ｍ−２６）を用い、参考製造法２に記載の方法に準じて製造することができる。
式（Ｍ−２８）で示される化合物（以下、化合物（Ｍ−２８）と記す）は、化合物（Ｍ−２ｃ）に代えて化合物（Ｍ−２７）を用い、参考製造法２に記載の方法に準じて製造することができる。
化合物（Ｍ−２９）は、化合物（Ｍ−２）に代えて化合物（Ｍ−２８）を用い、製造法２に記載の方法に準じて製造することができる。 Reference manufacturing method 28
Compound (M-29) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
A method described in Reference Production Method 2 using a compound (M-26) in place of the compound (M-2b) for the compound represented by the formula (M-27) (hereinafter referred to as the compound (M-27)) It can manufacture according to.
A method described in Reference Production Method 2 using a compound (M-27) in place of the compound (M-2c) for the compound represented by the formula (M-28) (hereinafter referred to as the compound (M-28)) It can manufacture according to.
Compound (M-29) can be produced according to the method described in production method 2 using compound (M-28) in place of compound (M-2).

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｒ−２）に代えて化合物（Ｍ−３１）を用い、化合物（Ｍ−２）に代えて化合物（Ｒ−１５）を用い、製造法４に記載の方法に準じて実施することができる。 Reference manufacturing method 29
In the compound (M-30), the compound represented by the formula (M-33) wherein Het is a group represented by the formula Het1 is produced by reacting the compound (M-31) with the compound (R-15) can do.

[Wherein, the symbols have the same meanings as described above. ]
The reaction is carried out according to the method described in Production Method 4 using Compound (M-31) in place of Compound (R-2) and using Compound (R-15) in place of Compound (M-2). can do.

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｒ−２）に代えて化合物（Ｍ−３２）を用い、化合物（Ｍ−２）に代えて化合物（Ｒ−１５）を用い、製造法４に記載の方法に準じて実施することができる。 Reference manufacturing method 30
In the compound (M-30), the compound represented by the formula (M-34) wherein Het is a group represented by the formula Het2 is produced by reacting the compound (M-32) with the compound (R-15) can do.

[Wherein, the symbols have the same meanings as described above. ]
The reaction is carried out according to the method described in Production Method 4 using Compound (M-32) in place of Compound (R-2) and using Compound (R-15) in place of Compound (M-2). can do.

［式中、記号は前記と同じ意味を表す。］
式（Ｍ−３６）で示される化合物（以下、化合物（Ｍ−３６）と記す）は、式（Ｍ−３５）で示される化合物（以下、化合物（Ｍ−３５）と記す）と化合物（Ｒ−１）とを反応させることにより製造することができる。反応は、化合物（Ｍ−２）に代えて化合物（Ｍ−３５）を用い、製造法２に記載の方法に準じて実施することができる。
化合物（Ｍ−３７）は、化合物（Ｍ−３６）とビス（ピナコラト）ジボロンとをパラジウム触媒及び塩基の存在下で反応させることにより製造することができる。反応は、例えばJournal of Organic Chemistry, 1995, (60), 7508-7510に記載の方法に準じて実施することができる。
化合物（Ｍ−３５）は市販の化合物であるか、又は既知の方法を用いて製造することができる。 Reference manufacturing method 31
The compound represented by the formula (M-37) (hereinafter referred to as compound (M-37)) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
The compound represented by the formula (M-36) (hereinafter referred to as compound (M-36)) is a compound represented by the formula (M-35) (hereinafter referred to as compound (M-35)) and the compound (R) It can manufacture by making it react with -1). The reaction can be carried out according to the method described in Production Method 2, using Compound (M-35) in place of Compound (M-2).
Compound (M-37) can be produced by reacting compound (M-36) with bis (pinacolato) diboron in the presence of a palladium catalyst and a base. The reaction can be carried out, for example, according to the method described in Journal of Organic Chemistry, 1995, (60), 7508-7510.
Compound (M-35) is a commercially available compound or can be produced using a known method.

［式中、記号は前記と同じ意味を表す。］
式（Ｍ−３９）で示される化合物（以下、化合物（Ｍ−３９）と記す）は、式（Ｍ−３８）で示される化合物（以下、化合物（Ｍ−３８）と記す）と化合物（Ｒ−１）とを反応させることにより製造することができる。反応は、化合物（Ｍ−２）に代えて化合物（Ｍ−３８）を用い、製造法２に記載の方法に準じて実施することができる。
化合物（Ｍ−４０）は、化合物（Ｍ−３９）とビス（ピナコラト）ジボロンとをパラジウム触媒及び塩基の存在下で反応させることにより製造することができる。反応は、例えばJournal of Organic Chemistry, 1995, (60), 7508-7510に記載の方法に準じて実施することができる。
化合物（Ｍ−３８）は市販の化合物であるか、又は既知の方法を用いて製造することができる。 Reference manufacturing method 32
The compound represented by the formula (M-40) (hereinafter referred to as a compound (M-40)) can be produced according to the following scheme.

[Wherein, the symbols have the same meanings as described above. ]
The compound represented by the formula (M-39) (hereinafter referred to as the compound (M-39)) is a compound represented by the formula (M-38) (hereinafter referred to as the compound (M-38)) and the compound (R) It can manufacture by making it react with -1). The reaction can be carried out according to the method described in Production Method 2, using Compound (M-38) in place of Compound (M-2).
Compound (M-40) can be produced by reacting compound (M-39) with bis (pinacolato) diboron in the presence of a palladium catalyst and a base. The reaction can be carried out, for example, according to the method described in Journal of Organic Chemistry, 1995, (60), 7508-7510.
Compound (M-38) is a commercially available compound or can be produced using a known method.

［式中、記号は前記と同じ意味を表す。］
反応は、製造法２０に記載の方法に準じて実施することができる。
式（Ｒ−２２）で示される化合物は、市販の化合物であるか、又は既知の方法を用いて製造することができる。 Reference manufacturing method 33
A compound represented by the formula (M-41) (hereinafter referred to as a compound (M-41)), a compound represented by the formula (M-42) (hereinafter referred to as a compound (M-42)), and a compound (M-42) -43) can be manufactured according to the following method.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production method 20.
The compound represented by the formula (R-22) is a commercially available compound or can be produced using a known method.

［式中、記号は前記と同じ意味を表す。］
反応は、製造法２０に記載の方法に準じて実施することができる。 Reference manufacturing method 34
A compound represented by the formula (M-44) (hereinafter referred to as a compound (M-44)), a compound represented by the formula (M-45) (hereinafter referred to as a compound (M-45)), and a compound (M) -46) can be manufactured according to the following method.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production method 20.

  Examples of the compound (M-36) include the following compounds.

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｒ−１）に代えて化合物（Ｒ−１６）を用い、製造法２に記載の方法に準じて実施することができる。 Reference manufacturing method 35
Compound (M-41) can be produced by reacting compound (M-2) with compound (R-16) in the presence of a base.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production Method 2, using Compound (R-16) in place of Compound (R-1).

［式中、記号は前記と同じ意味を表す。］
反応は、化合物（Ｒ−１）に代えて化合物（Ｒ−１６）を用い、製造法２に記載の方法に準じて実施することができる。 Reference manufacturing method 36
Compound (M-44) can be produced by reacting compound (M-3) with compound (R-16) in the presence of a base.

[Wherein, the symbols have the same meanings as described above. ]
The reaction can be carried out according to the method described in Production Method 2, using Compound (R-16) in place of Compound (R-1).

Next, specific examples of the present compound are shown below.
In the present specification, Me represents a methyl group, Et represents an ethyl group, Pr represents a propyl group, i-Pr represents an isopropyl group, Bu represents a butyl group, and c-Pr represents a cyclopropyl group. 1-CN-c-Pr represents a 1-cyanocyclopropyl group, c-Bu represents a cyclobutyl group, 1-CN-c-Bu represents a 1-cyanocyclobutyl group, Ph represents a phenyl group And Py2 represents a 2-pyridyl group, Py3 represents a 3-pyridyl group, Py4 represents a 4-pyridyl group, and Bn represents a benzyl group. When Ph, Py2, Py3 and Py4 have a substituent, the substituent is indicated before the symbol along with the position of substitution. For example, 4-CF ₃ -Py 2 represents a 4- (trifluoromethyl) -2-pyridyl group, 3,5- (CF ₃ ) ₂ -Ph represents a 3,5-bis (trifluoromethyl) phenyl group .

で示される化合物（以下、化合物（Ｌ−１）と記す）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1と記す）。 Formula (L-1):

In the compound represented by (hereinafter referred to as compound (L-1)), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is [Table 1] Compounds which are any of the substituents described in Table 6] (hereinafter referred to as compound group SX1).

In the compound (L-1), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6]. Compounds that are groups (hereinafter referred to as compound group SX2).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX3).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX4).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX5).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX6).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX7).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX8).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX9).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX10).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX11).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX12).

で示される化合物（以下、化合物（Ｌ−２）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX13と記す）。
化合物（Ｌ−２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX14と記す）。
化合物（Ｌ−２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX15と記す）。
化合物（Ｌ−２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX16と記す）。
化合物（Ｌ−２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX17と記す）。
化合物（Ｌ−２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX18と記す）。
化合物（Ｌ−２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX19と記す）。 Formula (L-2):

In the compound shown below (hereinafter referred to as compound (L-2)), A ¹ is CH, R ⁵ is a methyl group, and T is any of those described in [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX13).
In the compound (L-2), compounds wherein A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds It describes as group SX14).
In the compound (L-2), a compound in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX15).
In the compound (L-2), a compound in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX16).
In the compound (L-2), a compound in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX17).
In the compound (L-2), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX18).
In the compound (L-2), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX19).

で示される化合物（以下、化合物（Ｌ−３）と記す）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX20と記す）。
化合物（Ｌ−３）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX21と記す）。
化合物（Ｌ−３）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX22と記す）。
化合物（Ｌ−３）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX23と記す）。
化合物（Ｌ−３）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX24と記す）。
化合物（Ｌ−３）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX25と記す）。
化合物（Ｌ−３）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX26と記す）。
化合物（Ｌ−３）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX27と記す）。
化合物（Ｌ−３）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX28と記す）。
化合物（Ｌ−３）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX29と記す）。
化合物（Ｌ−３）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX30と記す）。
化合物（Ｌ−３）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX31と記す）。 Formula (L-3):

In the compound shown below (hereinafter referred to as compound (L-3)), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is [Table 1] to [Table 1] Compounds which are any of the substituents described in Table 6] (hereinafter referred to as compound group SX20).
In the compound (L-3), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] Compounds that are groups (hereinafter referred to as compound group SX21).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX22).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX23).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX24).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX25).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX26).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX27).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX28).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX29).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX30).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX31).

で示される化合物（以下、化合物（Ｌ−４）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX32と記す）。
化合物（Ｌ−４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX33と記す）。
化合物（Ｌ−４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX34と記す）。
化合物（Ｌ−４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX35と記す）。
化合物（Ｌ−４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX36と記す）。
化合物（Ｌ−４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX37と記す）。
化合物（Ｌ−４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX38と記す）。 Formula (L-4):

In the compound shown below (hereinafter referred to as compound (L-4)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX32).
In the compound (L-4), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX33).
In the compound (L-4), a compound in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX34).
In the compound (L-4), compounds wherein A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX35).
In the compound (L-4), compounds in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX36).
In the compound (L-4), compounds in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX37).
In the compound (L-4), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX38).

で示される化合物（以下、化合物（Ｌ−５）と記す）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX39と記す）。
化合物（Ｌ−５）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX40と記す）。
化合物（Ｌ−５）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX41と記す）。
化合物（Ｌ−５）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX42と記す）。
化合物（Ｌ−５）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX43と記す）。
化合物（Ｌ−５）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX44と記す）。
化合物（Ｌ−５）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX45と記す）。
化合物（Ｌ−５）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX46と記す）。
化合物（Ｌ−５）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX47と記す）。
化合物（Ｌ−５）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX48と記す）。
化合物（Ｌ−５）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX49と記す）。
化合物（Ｌ−５）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX50と記す）。 Formula (L-5):

In the compound shown below (hereinafter referred to as compound (L-5)), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is [Table 1] to [Table 1] Compounds which are any of the substituents described in Table 6] (hereinafter referred to as compound group SX39).
In the compound (L-5), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] Compounds that are groups (hereinafter referred to as compound group SX40).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX41).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX42).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX43).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX44).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX45).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX46).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX47).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX48).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX49).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are the substituents of (hereinafter, referred to as compound group SX50).

で示される化合物（以下、化合物（Ｌ−６）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX51と記す）。
化合物（Ｌ−６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX52と記す）。
化合物（Ｌ−６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX53と記す）。
化合物（Ｌ−６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX54と記す）。
化合物（Ｌ−６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX55と記す）。
化合物（Ｌ−６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX56と記す）。
化合物（Ｌ−６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX57と記す）。 Formula (L-6):

In the compound shown below (hereinafter referred to as compound (L-6)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX51).
In the compound (L-6), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds It describes as group SX52).
In the compound (L-6), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX53).
In the compound (L-6), a compound in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX54).
In the compound (L-6), a compound in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX55).
In the compound (L-6), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX56).
In the compound (L-6), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX57).

で示される化合物（以下、化合物（Ｌ−７）と記す）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX58と記す）。
化合物（Ｌ−７）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX59と記す）。
化合物（Ｌ−７）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX60と記す）。
化合物（Ｌ−７）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX61と記す）。
化合物（Ｌ−７）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX62と記す）。
化合物（Ｌ−７）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX63と記す）。
化合物（Ｌ−７）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX64と記す）。
化合物（Ｌ−７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX65と記す）。
化合物（Ｌ−７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX66と記す）。
化合物（Ｌ−７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX67と記す）。
化合物（Ｌ−７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX68と記す）。
化合物（Ｌ−７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX69と記す）。 Formula (L-7):

In the compound shown below (hereinafter referred to as compound (L-7)), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is [Table 1] to [Table 1] Compounds which are any of the substituents described in Table 6] (hereinafter referred to as compound group SX58).
In the compound (L-7), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] Compounds that are groups (hereinafter referred to as compound group SX59).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX60).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX61).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX62).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX63).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX64).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX65).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX66).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX67).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX68).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are the substituents of (hereinafter referred to as compound group SX69).

で示される化合物（以下、化合物（Ｌ−８）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX70と記す）。
化合物（Ｌ−８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX71と記す）。
化合物（Ｌ−８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX72と記す）。
化合物（Ｌ−８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX73と記す）。
化合物（Ｌ−８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX74と記す）。
化合物（Ｌ−８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX75と記す）。
化合物（Ｌ−８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX76と記す）。 Formula (L-8):

In the compound shown below (hereinafter referred to as compound (L-8)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX70).
In the compound (L-8), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX71).
In the compound (L-8), compounds in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX72).
In the compound (L-8), compounds in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX73).
In the compound (L-8), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX74).
In the compound (L-8), compounds in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX75).
In the compound (L-8), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX76).

で示される化合物（以下、化合物（Ｌ−９）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX77と記す）。 Formula (L-9):

In the compound shown below (hereinafter referred to as compound (L-9)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in Table 15 (hereinafter referred to as compound group SX77).

In the compound (L-9), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX78).
In the compound (L-9), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX79).
In the compound (L-9), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX80).
In the compound (L-9), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX81).
In the compound (L-9), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX82).
In the compound (L-9), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX83).
In the compound (L-9), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX84).
In the compound (L-9), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX85).
In the compound (L-9), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX86).
In the compound (L-9), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX87).
In the compound (L-9), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX88).
In the compound (L-9), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX89).
In the compound (L-9), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX90).

で示される化合物（以下、化合物（Ｌ−１０）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX91と記す）。
化合物（Ｌ−１０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX92と記す）。
化合物（Ｌ−１０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX93と記す）。
化合物（Ｌ−１０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX94と記す）。
化合物（Ｌ−１０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX95と記す）。
化合物（Ｌ−１０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX96と記す）。
化合物（Ｌ−１０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX97と記す）。
化合物（Ｌ−１０）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX98と記す）。
化合物（Ｌ−１０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX99と記す）。
化合物（Ｌ−１０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX100と記す）。
化合物（Ｌ−１０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX101と記す）。
化合物（Ｌ−１０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX102と記す）。
化合物（Ｌ−１０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX103と記す）。
化合物（Ｌ−１０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX104と記す）。 Formula (L-10):

In the compound shown below (hereinafter referred to as compound (L-10)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in Table 15 (hereinafter referred to as compound group SX91).
In the compound (L-10), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX92).
In the compound (L-10), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX93).
In the compound (L-10), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX94).
In the compound (L-10), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX95).
In the compound (L-10), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX96).
In the compound (L-10), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX97).
In the compound (L-10), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX98).
In the compound (L-10), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX99).
In the compound (L-10), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX100).
In the compound (L-10), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX101).
In the compound (L-10), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX102).
In the compound (L-10), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX103).
In the compound (L-10), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX104).

で示される化合物（以下、化合物（Ｌ−１１）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX105と記す）。
化合物（Ｌ−１１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX106と記す）。
化合物（Ｌ−１１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX107と記す）。
化合物（Ｌ−１１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX108と記す）。
化合物（Ｌ−１１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX109と記す）。
化合物（Ｌ−１１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX110と記す）。
化合物（Ｌ−１１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX111と記す）。
化合物（Ｌ−１１）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX112と記す）。
化合物（Ｌ−１１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX113と記す）。
化合物（Ｌ−１１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX114と記す）。
化合物（Ｌ−１１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX115と記す）。
化合物（Ｌ−１１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX116と記す）。
化合物（Ｌ−１１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX117と記す）。
化合物（Ｌ−１１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX118と記す）。 Formula (L-11):

In the compound shown below (hereinafter referred to as compound (L-11)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX105).
In the compound (L-11), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX106).
In the compound (L-11), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX107).
In the compound (L-11), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX108).
In the compound (L-11), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX109).
In the compound (L-11), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX110).
In the compound (L-11), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX111).
In the compound (L-11), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX112).
In the compound (L-11), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX113).
In the compound (L-11), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX114).
In the compound (L-11), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX115).
In the compound (L-11), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX116).
In the compound (L-11), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX117).
In the compound (L-11), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX118).

で示される化合物（以下、化合物（Ｌ−１２）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX119と記す）。
化合物（Ｌ−１２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX120と記す）。
化合物（Ｌ−１２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX121と記す）。
化合物（Ｌ−１２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX122と記す）。
化合物（Ｌ−１２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX123と記す）。
化合物（Ｌ−１２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX124と記す）。
化合物（Ｌ−１２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX125と記す）。
化合物（Ｌ−１２）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX126と記す）。
化合物（Ｌ−１２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX127と記す）。
化合物（Ｌ−１２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX128と記す）。
化合物（Ｌ−１２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX129と記す）。
化合物（Ｌ−１２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX130と記す）。
化合物（Ｌ−１２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX131と記す）。
化合物（Ｌ−１２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX132と記す）。 Formula (L-12):

In the compound shown below (hereinafter referred to as the compound (L-12)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX119).
In the compound (L-12), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX120).
In the compound (L-12), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX121).
In the compound (L-12), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX122).
In the compound (L-12), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX123).
In the compound (L-12), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX124).
In the compound (L-12), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX125).
In the compound (L-12), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX126).
In the compound (L-12), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX127).
In the compound (L-12), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX128).
In the compound (L-12), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX129).
In the compound (L-12), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX130).
In the compound (L-12), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX131).
In the compound (L-12), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX132).

で示される化合物（以下、化合物（Ｌ−１３）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX133と記す）。
化合物（Ｌ−１３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX134と記す）。
化合物（Ｌ−１３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX135と記す）。
化合物（Ｌ−１３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX136と記す）。
化合物（Ｌ−１３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX137と記す）。
化合物（Ｌ−１３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX138と記す）。
化合物（Ｌ−１３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX139と記す）。
化合物（Ｌ−１３）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX140と記す）。
化合物（Ｌ−１３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX141と記す）。
化合物（Ｌ−１３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX142と記す）。
化合物（Ｌ−１３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX143と記す）。
化合物（Ｌ−１３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX144と記す）。
化合物（Ｌ−１３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX145と記す）。
化合物（Ｌ−１３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX146と記す）。 Formula (L-13):

In the compound shown below (hereinafter referred to as compound (L-13)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds that are any of the substituents described in Table 15 (hereinafter referred to as compound group SX133).
In the compound (L-13), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX134).
In the compound (L-13), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX135).
In the compound (L-13), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX136).
In the compound (L-13), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX137).
In the compound (L-13), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX138).
In the compound (L-13), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX139).
In the compound (L-13), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX140).
In the compound (L-13), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX141).
In the compound (L-13), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX142).
In the compound (L-13), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX143).
In the compound (L-13), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX144).
In the compound (L-13), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX145).
In the compound (L-13), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX146).

で示される化合物（以下、化合物（Ｌ−１４）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX147と記す）。
化合物（Ｌ−１４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX148と記す）。
化合物（Ｌ−１４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX149と記す）。
化合物（Ｌ−１４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX150と記す）。
化合物（Ｌ−１４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX151と記す）。
化合物（Ｌ−１４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX152と記す）。
化合物（Ｌ−１４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX153と記す）。
化合物（Ｌ−１４）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX154と記す）。
化合物（Ｌ−１４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX155と記す）。
化合物（Ｌ−１４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX156と記す）。
化合物（Ｌ−１４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX157と記す）。
化合物（Ｌ−１４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX158と記す）。
化合物（Ｌ−１４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX159と記す）。
化合物（Ｌ−１４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX160と記す）。 Formula (L-14):

In the compound shown below (hereinafter referred to as compound (L-14)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX147).
In the compound (L-14), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX148).
In the compound (L-14), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX149).
In the compound (L-14), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX150).
In the compound (L-14), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX151).
In the compound (L-14), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX152).
In the compound (L-14), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX153).
In the compound (L-14), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX154).
In the compound (L-14), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX155).
In the compound (L-14), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX156).
In the compound (L-14), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX157).
In the compound (L-14), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX158).
In the compound (L-14), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX159).
In the compound (L-14), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX160).

で示される化合物（以下、化合物（Ｌ−１５）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX161と記す）。
化合物（Ｌ−１５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX162と記す）。
化合物（Ｌ−１５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX163と記す）。
化合物（Ｌ−１５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX164と記す）。
化合物（Ｌ−１５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX165と記す）。
化合物（Ｌ−１５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX166と記す）。
化合物（Ｌ−１５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX167と記す）。
化合物（Ｌ−１５）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX168と記す）。
化合物（Ｌ−１５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX169と記す）。
化合物（Ｌ−１５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX170と記す）。
化合物（Ｌ−１５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX171と記す）。
化合物（Ｌ−１５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX172と記す）。
化合物（Ｌ−１５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX173と記す）。
化合物（Ｌ−１５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX174と記す）。 Formula (L-15):

In the compound shown below (hereinafter referred to as compound (L-15)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX161).
In the compound (L-15), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX162).
In the compound (L-15), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX163).
In the compound (L-15), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX164).
In the compound (L-15), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX165).
In the compound (L-15), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX166).
In the compound (L-15), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX167).
In the compound (L-15), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX168).
In the compound (L-15), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX169).
In the compound (L-15), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX170).
In the compound (L-15), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX171).
In the compound (L-15), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX172).
In the compound (L-15), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX173).
In the compound (L-15), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX174).

で示される化合物（以下、化合物（Ｌ−１６）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX175と記す）。
化合物（Ｌ−１６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX176と記す）。
化合物（Ｌ−１６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX177と記す）。
化合物（Ｌ−１６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX178と記す）。
化合物（Ｌ−１６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX179と記す）。
化合物（Ｌ−１６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX180と記す）。
化合物（Ｌ−１６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX181と記す）。
化合物（Ｌ−１６）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX182と記す）。
化合物（Ｌ−１６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX183と記す）。
化合物（Ｌ−１６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX184と記す）。
化合物（Ｌ−１６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX185と記す）。
化合物（Ｌ−１６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX186と記す）。
化合物（Ｌ−１６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX187と記す）。
化合物（Ｌ−１６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX188と記す）。 Formula (L-16):

In the compound shown below (hereinafter referred to as compound (L-16)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX175).
In the compound (L-16), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX176).
In the compound (L-16), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX177).
In the compound (L-16), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX178).
In the compound (L-16), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX179).
In the compound (L-16), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX180).
In the compound (L-16), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX181).
In the compound (L-16), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX182).
In the compound (L-16), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX183).
In the compound (L-16), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX184).
In the compound (L-16), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX185).
In the compound (L-16), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX186).
In the compound (L-16), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX187).
In the compound (L-16), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX188).

で示される化合物（以下、化合物（Ｌ−１７）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX189と記す）。
化合物（Ｌ−１７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX190と記す）。
化合物（Ｌ−１７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX191と記す）。
化合物（Ｌ−１７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX192と記す）。
化合物（Ｌ−１７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX193と記す）。
化合物（Ｌ−１７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX194と記す）。
化合物（Ｌ−１７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX195と記す）。
化合物（Ｌ−１７）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX196と記す）。
化合物（Ｌ−１７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX197と記す）。
化合物（Ｌ−１７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX198と記す）。
化合物（Ｌ−１７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX199と記す）。
化合物（Ｌ−１７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX200と記す）。
化合物（Ｌ−１７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX201と記す）。
化合物（Ｌ−１７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX202と記す）。 Formula (L-17):

In the compound shown below (hereinafter referred to as compound (L-17)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX189).
In the compound (L-17), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX190).
In the compound (L-17), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX191).
In the compound (L-17), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX192).
In the compound (L-17), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX193).
In the compound (L-17), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX194).
In the compound (L-17), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX195).
In the compound (L-17), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX196).
In the compound (L-17), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX197).
In the compound (L-17), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX198).
In the compound (L-17), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX199).
In the compound (L-17), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX200).
In the compound (L-17), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX201).
In the compound (L-17), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX202).

で示される化合物（以下、化合物（Ｌ−１８）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX203と記す）。
化合物（Ｌ−１８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX204と記す）。
化合物（Ｌ−１８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX205と記す）。
化合物（Ｌ−１８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX206と記す）。
化合物（Ｌ−１８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX207と記す）。
化合物（Ｌ−１８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX208と記す）。
化合物（Ｌ−１８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX209と記す）。
化合物（Ｌ−１８）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX210と記す）。
化合物（Ｌ−１８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX211と記す）。
化合物（Ｌ−１８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX212と記す）。
化合物（Ｌ−１８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX213と記す）。
化合物（Ｌ−１８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX214と記す）。
化合物（Ｌ−１８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX215と記す）。
化合物（Ｌ−１８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX216と記す）。 Formula (L-18):

In the compound shown below (hereinafter referred to as compound (L-18)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX203).
In the compound (L-18), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX204).
In the compound (L-18), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX205).
In the compound (L-18), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX206).
In the compound (L-18), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX207).
In the compound (L-18), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX208).
In the compound (L-18), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX209).
In the compound (L-18), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX210).
In the compound (L-18), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX211).
In the compound (L-18), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX212).
In the compound (L-18), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX213).
In the compound (L-18), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX214).
In the compound (L-18), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX215).
In the compound (L-18), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX216).

で示される化合物（以下、化合物（Ｌ−１９）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX217と記す）。
化合物（Ｌ−１９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX218と記す）。
化合物（Ｌ−１９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX219と記す）。
化合物（Ｌ−１９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX220と記す）。
化合物（Ｌ−１９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX221と記す）。
化合物（Ｌ−１９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX222と記す）。
化合物（Ｌ−１９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX223と記す）。
化合物（Ｌ−１９）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX224と記す）。
化合物（Ｌ−１９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX225と記す）。
化合物（Ｌ−１９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX226と記す）。
化合物（Ｌ−１９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX227と記す）。
化合物（Ｌ−１９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX228と記す）。
化合物（Ｌ−１９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX229と記す）。
化合物（Ｌ−１９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX230と記す）。 Formula (L-19)

In the compound shown below (hereinafter referred to as compound (L-19)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX217).
In the compound (L-19), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX218).
In the compound (L-19), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX219).
In the compound (L-19), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX220).
In the compound (L-19), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX221).
In the compound (L-19), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX222).
In the compound (L-19), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX223).
In the compound (L-19), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX224).
In the compound (L-19), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX225).
In the compound (L-19), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX226).
In the compound (L-19), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX227).
In the compound (L-19), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 c} is a hydrogen atom, and R ^{3 b} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX228).
In the compound (L-19), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX229).
In the compound (L-19), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX230).

で示される化合物（以下、化合物（Ｌ−２０）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX231と記す）。
化合物（Ｌ−２０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX232と記す）。
化合物（Ｌ−２０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX233と記す）。
化合物（Ｌ−２０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX234と記す）。
化合物（Ｌ−２０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX235と記す）。
化合物（Ｌ−２０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX236と記す）。
化合物（Ｌ−２０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX237と記す）。
化合物（Ｌ−２０）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX238と記す）。
化合物（Ｌ−２０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX239と記す）。
化合物（Ｌ−２０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX240と記す）。
化合物（Ｌ−２０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX241と記す）。
化合物（Ｌ−２０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX242と記す）。
化合物（Ｌ−２０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX243と記す）。
化合物（Ｌ−２０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX244と記す）。 Formula (L-20):

In the compound shown below (hereinafter referred to as compound (L-20)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX231).
In the compound (L-20), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX232).
In the compound (L-20), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX233).
In the compound (L-20), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX234).
In the compound (L-20), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX235).
In the compound (L-20), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX236).
In the compound (L-20), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX237).
In the compound (L-20), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX238).
In the compound (L-20), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX239).
In the compound (L-20), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX240).
In the compound (L-20), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX241).
In the compound (L-20), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX242).
In the compound (L-20), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX243).
In the compound (L-20), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX244).

で示される化合物（以下、化合物（Ｌ−２１）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX245と記す）。
化合物（Ｌ−２１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX246と記す）。
化合物（Ｌ−２１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX247と記す）。
化合物（Ｌ−２１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX248と記す）。
化合物（Ｌ−２１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX249と記す）。
化合物（Ｌ−２１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX250と記す）。
化合物（Ｌ−２１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX251と記す）。
化合物（Ｌ−２１）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX252と記す）。
化合物（Ｌ−２１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX253と記す）。
化合物（Ｌ−２１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX254と記す）。
化合物（Ｌ−２１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX255と記す）。
化合物（Ｌ−２１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX256と記す）。
化合物（Ｌ−２１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX257と記す）。
化合物（Ｌ−２１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX258と記す）。 Formula (L-21):

In the compound shown below (hereinafter referred to as compound (L-21)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX245).
In the compound (L-21), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX246).
In the compound (L-21), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX247).
In the compound (L-21), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX248).
In the compound (L-21), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX249).
In the compound (L-21), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX250).
In the compound (L-21), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX251).
In the compound (L-21), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX252).
In the compound (L-21), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX253).
In the compound (L-21), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX254).
In the compound (L-21), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX255).
In the compound (L-21), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX256).
In the compound (L-21), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX257).
In the compound (L-21), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX258).

で示される化合物（以下、化合物（Ｌ−２２）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX259と記す）。
化合物（Ｌ−２２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX260と記す）。
化合物（Ｌ−２２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX261と記す）。
化合物（Ｌ−２２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX262と記す）。
化合物（Ｌ−２２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX263と記す）。
化合物（Ｌ−２２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX264と記す）。
化合物（Ｌ−２２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX265と記す）。
化合物（Ｌ−２２）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX266と記す）。
化合物（Ｌ−２２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX267と記す）。
化合物（Ｌ−２２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX268と記す）。
化合物（Ｌ−２２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX269と記す）。
化合物（Ｌ−２２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX270と記す）。
化合物（Ｌ−２２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX271と記す）。
化合物（Ｌ−２２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX272と記す）。 Formula (L-22):

In the compound shown below (hereinafter referred to as compound (L-22)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in Table 15 (hereinafter referred to as compound group SX259).
In the compound (L-22), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX260).
In the compound (L-22), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX261).
In the compound (L-22), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX262).
In the compound (L-22), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX263).
In the compound (L-22), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX264).
In the compound (L-22), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX265).
In the compound (L-22), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX266).
In the compound (L-22), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX267).
In the compound (L-22), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX268).
In the compound (L-22), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX269).
In the compound (L-22), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX270).
In the compound (L-22), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX271).
In the compound (L-22), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX272).

で示される化合物（以下、化合物（Ｌ−２３）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX273と記す）。
化合物（Ｌ−２３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX274と記す）。
化合物（Ｌ−２３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX275と記す）。
化合物（Ｌ−２３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX276と記す）。
化合物（Ｌ−２３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX277と記す）。
化合物（Ｌ−２３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX278と記す）。
化合物（Ｌ−２３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX279と記す）。
化合物（Ｌ−２３）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX280と記す）。
化合物（Ｌ−２３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX281と記す）。
化合物（Ｌ−２３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX282と記す）。
化合物（Ｌ−２３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX283と記す）。
化合物（Ｌ−２３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX284と記す）。
化合物（Ｌ−２３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX285と記す）。
化合物（Ｌ−２３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX286と記す）。 Formula (L-23):

In the compound shown below (hereinafter referred to as compound (L-23)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX273).
In the compound (L-23), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX274).
In the compound (L-23), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX275).
In the compound (L-23), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX276).
In the compound (L-23), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX277).
In the compound (L-23), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX278).
In the compound (L-23), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX279).
In the compound (L-23), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX280).
In the compound (L-23), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX281).
In the compound (L-23), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX282).
In the compound (L-23), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX283).
In the compound (L-23), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX284).
In the compound (L-23), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX285).
In the compound (L-23), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX 286).

で示される化合物（以下、化合物（Ｌ−２４）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX287と記す）。
化合物（Ｌ−２４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX288と記す）。
化合物（Ｌ−２４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX289と記す）。
化合物（Ｌ−２４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX290と記す）。
化合物（Ｌ−２４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX291と記す）。
化合物（Ｌ−２４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX292と記す）。
化合物（Ｌ−２４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX293と記す）。
化合物（Ｌ−２４）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX294と記す）。
化合物（Ｌ−２４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX295と記す）。
化合物（Ｌ−２４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX296と記す）。
化合物（Ｌ−２４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX297と記す）。
化合物（Ｌ−２４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX298と記す）。
化合物（Ｌ−２４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX299と記す）。
化合物（Ｌ−２４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX300と記す）。 Formula (L-24):

In the compound shown below (hereinafter referred to as compound (L-24)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX287).
In the compound (L-24), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX288).
In the compound (L-24), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX289).
In the compound (L-24), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX290).
In the compound (L-24), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX291).
In the compound (L-24), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX292).
In the compound (L-24), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX293).
In the compound (L-24), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX294).
In the compound (L-24), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX295).
In the compound (L-24), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX296).
In the compound (L-24), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX297).
In the compound (L-24), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX298).
In the compound (L-24), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX299).
In the compound (L-24), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX300).

で示される化合物（以下、化合物（Ｌ−２５）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX301と記す）。
化合物（Ｌ−２５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX302と記す）。
化合物（Ｌ−２５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX303と記す）。
化合物（Ｌ−２５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX304と記す）。
化合物（Ｌ−２５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX305と記す）。
化合物（Ｌ−２５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX306と記す）。
化合物（Ｌ−２５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX307と記す）。
化合物（Ｌ−２５）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX308と記す）。
化合物（Ｌ−２５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX309と記す）。
化合物（Ｌ−２５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX310と記す）。
化合物（Ｌ−２５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX311と記す）。
化合物（Ｌ−２５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX312と記す）。
化合物（Ｌ−２５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX313と記す）。
化合物（Ｌ−２５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX314と記す）。 Formula (L-25):

In the compound shown below (hereinafter referred to as compound (L-25)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX301).
In the compound (L-25), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX302).
In the compound (L-25), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX303).
In the compound (L-25), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX304).
In the compound (L-25), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX305).
In the compound (L-25), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX306).
In the compound (L-25), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX307).
In the compound (L-25), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX308).
In the compound (L-25), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX309).
In the compound (L-25), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX310).
In the compound (L-25), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX311).
In the compound (L-25), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX312).
In the compound (L-25), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX313).
In the compound (L-25), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX314).

で示される化合物（以下、化合物（Ｌ−２６）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX315と記す）。
化合物（Ｌ−２６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX316と記す）。
化合物（Ｌ−２６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX317と記す）。
化合物（Ｌ−２６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX318と記す）。
化合物（Ｌ−２６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX319と記す）。
化合物（Ｌ−２６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX320と記す）。
化合物（Ｌ−２６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX321と記す）。
化合物（Ｌ−２６）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX322と記す）。
化合物（Ｌ−２６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX323と記す）。
化合物（Ｌ−２６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX324と記す）。
化合物（Ｌ−２６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX325と記す）。
化合物（Ｌ−２６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX326と記す）。
化合物（Ｌ−２６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX327と記す）。
化合物（Ｌ−２６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX328と記す）。 Formula (L-26):

In the compound shown below (hereinafter referred to as compound (L-26)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX315).
In the compound (L-26), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX316).
In the compound (L-26), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX317).
In the compound (L-26), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX318).
In the compound (L-26), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX319).
In the compound (L-26), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX320).
In the compound (L-26), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX321).
In the compound (L-26), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX322).
In the compound (L-26), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX323).
In the compound (L-26), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX324).
In the compound (L-26), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX325).
In the compound (L-26), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX326).
In the compound (L-26), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX327).
In the compound (L-26), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX328).

で示される化合物（以下、化合物（Ｌ−２７）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX329と記す）。
化合物（Ｌ−２７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX330と記す）。
化合物（Ｌ−２７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX331と記す）。
化合物（Ｌ−２７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX332と記す）。
化合物（Ｌ−２７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX333と記す）。
化合物（Ｌ−２７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX334と記す）。
化合物（Ｌ−２７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX335と記す）。
化合物（Ｌ−２７）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX336と記す）。
化合物（Ｌ−２７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX337と記す）。
化合物（Ｌ−２７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX338と記す）。
化合物（Ｌ−２７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX339と記す）。
化合物（Ｌ−２７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX340と記す）。
化合物（Ｌ−２７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX341と記す）。
化合物（Ｌ−２７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX342と記す）。 Formula (L-27):

In the compound shown below (hereinafter referred to as compound (L-27)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX329).
In the compound (L-27), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX330).
In the compound (L-27), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX331).
In the compound (L-27), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX332).
In the compound (L-27), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX333).
In the compound (L-27), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX334).
In the compound (L-27), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX335).
In the compound (L-27), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX336).
In the compound (L-27), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX 337).
In the compound (L-27), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX 338).
In the compound (L-27), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX339).
In the compound (L-27), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX340).
In the compound (L-27), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX341).
In the compound (L-27), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX342).

で示される化合物（以下、化合物（Ｌ−２８）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX343と記す）。
化合物（Ｌ−２８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX344と記す）。
化合物（Ｌ−２８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX345と記す）。
化合物（Ｌ−２８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX346と記す）。
化合物（Ｌ−２８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX347と記す）。
化合物（Ｌ−２８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX348と記す）。
化合物（Ｌ−２８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX349と記す）。
化合物（Ｌ−２８）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX350と記す）。
化合物（Ｌ−２８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX351と記す）。
化合物（Ｌ−２８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX352と記す）。
化合物（Ｌ−２８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX353と記す）。
化合物（Ｌ−２８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX354と記す）。
化合物（Ｌ−２８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX355と記す）。
化合物（Ｌ−２８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX356と記す）。 Formula (L-28):

In the compound shown below (hereinafter referred to as compound (L-28)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX343).
In the compound (L-28), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX344).
In the compound (L-28), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX345).
In the compound (L-28), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX346).
In the compound (L-28), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX347).
In the compound (L-28), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX348).
In the compound (L-28), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX 349).
In the compound (L-28), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX350).
In the compound (L-28), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX351).
In the compound (L-28), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX352).
In the compound (L-28), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX353).
In the compound (L-28), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX354).
In the compound (L-28), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX355).
In the compound (L-28), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX356).

で示される化合物（以下、化合物（Ｌ−２９）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX357と記す）。
化合物（Ｌ−２９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX358と記す）。
化合物（Ｌ−２９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX359と記す）。
化合物（Ｌ−２９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX360と記す）。
化合物（Ｌ−２９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX361と記す）。
化合物（Ｌ−２９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX362と記す）。
化合物（Ｌ−２９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX363と記す）。
化合物（Ｌ−２９）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX364と記す）。
化合物（Ｌ−２９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX365と記す）。
化合物（Ｌ−２９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX366と記す）。
化合物（Ｌ−２９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX367と記す）。
化合物（Ｌ−２９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX368と記す）。
化合物（Ｌ−２９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX369と記す）。
化合物（Ｌ−２９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX370と記す）。 Formula (L-29):

In the compound shown below (hereinafter referred to as compound (L-29)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX357).
In the compound (L-29), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX358).
In the compound (L-29), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX359).
In the compound (L-29), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX360).
In the compound (L-29), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX361).
In the compound (L-29), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX362).
In the compound (L-29), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX363).
In the compound (L-29), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX364).
In the compound (L-29), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX365).
In the compound (L-29), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX366).
In the compound (L-29), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX367).
In the compound (L-29), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX368).
In the compound (L-29), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX369).
In the compound (L-29), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX370).

で示される化合物（以下、化合物（Ｌ−３０）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX371と記す）。
化合物（Ｌ−３０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX372と記す）。
化合物（Ｌ−３０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX373と記す）。
化合物（Ｌ−３０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX374と記す）。
化合物（Ｌ−３０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX375と記す）。
化合物（Ｌ−３０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX376と記す）。
化合物（Ｌ−３０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX377と記す）。
化合物（Ｌ−３０）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX378と記す）。
化合物（Ｌ−３０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX379と記す）。
化合物（Ｌ−３０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX380と記す）。
化合物（Ｌ−３０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX381と記す）。
化合物（Ｌ−３０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX382と記す）。
化合物（Ｌ−３０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX383と記す）。
化合物（Ｌ−３０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX384と記す）。 Formula (L-30):

In the compound shown below (hereinafter referred to as compound (L-30)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX371).
In the compound (L-30), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX372).
In the compound (L-30), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX 373).
In the compound (L-30), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX 374).
In the compound (L-30), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX375).
In the compound (L-30), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX376).
In the compound (L-30), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX377).
In the compound (L-30), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX378).
In the compound (L-30), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX379).
In the compound (L-30), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX380).
In the compound (L-30), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX381).
In the compound (L-30), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX382).
In the compound (L-30), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX383).
In the compound (L-30), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX384).

で示される化合物（以下、化合物（Ｌ−３１）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX385と記す）。
化合物（Ｌ−３１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX386と記す）。
化合物（Ｌ−３１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX387と記す）。
化合物（Ｌ−３１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX388と記す）。
化合物（Ｌ−３１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX389と記す）。
化合物（Ｌ−３１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX390と記す）。
化合物（Ｌ−３１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX391と記す）。
化合物（Ｌ−３１）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX392と記す）。
化合物（Ｌ−３１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX393と記す）。
化合物（Ｌ−３１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX394と記す）。
化合物（Ｌ−３１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX395と記す）。
化合物（Ｌ−３１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX396と記す）。
化合物（Ｌ−３１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX397と記す）。
化合物（Ｌ−３１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX398と記す）。 Formula (L-31):

In the compound shown below (hereinafter referred to as compound (L-31)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX385).
In the compound (L-31), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX386).
In the compound (L-31), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX387).
In the compound (L-31), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX388).
In the compound (L-31), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX 389).
In the compound (L-31), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX390).
In the compound (L-31), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX391).
In the compound (L-31), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX392).
In the compound (L-31), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX393).
In the compound (L-31), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX394).
In the compound (L-31), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX395).
In the compound (L-31), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX396).
In the compound (L-31), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX397).
In the compound (L-31), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX398).

で示される化合物（以下、化合物（Ｌ−３２）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX399と記す）。
化合物（Ｌ−３２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX400と記す）。
化合物（Ｌ−３２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX401と記す）。
化合物（Ｌ−３２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX402と記す）。
化合物（Ｌ−３２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX403と記す）。
化合物（Ｌ−３２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX404と記す）。
化合物（Ｌ−３２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX405と記す）。
化合物（Ｌ−３２）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX406と記す）。
化合物（Ｌ−３２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX407と記す）。
化合物（Ｌ−３２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX408と記す）。
化合物（Ｌ−３２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX409と記す）。
化合物（Ｌ−３２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX410と記す）。
化合物（Ｌ−３２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX411と記す）。
化合物（Ｌ−３２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX412と記す）。 Formula (L-32):

In the compound shown below (hereinafter referred to as compound (L-32)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX399).
In the compound (L-32), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX400).
In the compound (L-32), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX401).
In the compound (L-32), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX402).
In the compound (L-32), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX403).
In the compound (L-32), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX404).
In the compound (L-32), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX405).
In the compound (L-32), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX406).
In the compound (L-32), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX407).
In the compound (L-32), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX408).
In the compound (L-32), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX409).
In the compound (L-32), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX410).
In the compound (L-32), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX411).
In the compound (L-32), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX412).

で示される化合物（以下、化合物（Ｌ−３３）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX413と記す）。
化合物（Ｌ−３３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX414と記す）。
化合物（Ｌ−３３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX415と記す）。
化合物（Ｌ−３３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX416と記す）。
化合物（Ｌ−３３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX417と記す）。
化合物（Ｌ−３３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX418と記す）。
化合物（Ｌ−３３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX419と記す）。
化合物（Ｌ−３３）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX420と記す）。
化合物（Ｌ−３３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX421と記す）。
化合物（Ｌ−３３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX422と記す）。
化合物（Ｌ−３３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX423と記す）。
化合物（Ｌ−３３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX424と記す）。
化合物（Ｌ−３３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX425と記す）。
化合物（Ｌ−３３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX426と記す）。 Formula (L-33):

In the compound shown below (hereinafter referred to as compound (L-33)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX413).
In the compound (L-33), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX414).
In the compound (L-33), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX415).
In the compound (L-33), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX416).
In the compound (L-33), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX417).
In the compound (L-33), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX418).
In the compound (L-33), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX419).
In the compound (L-33), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX420).
In the compound (L-33), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX421).
In the compound (L-33), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX422).
In the compound (L-33), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX423).
In the compound (L-33), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX424).
In the compound (L-33), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX425).
In the compound (L-33), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX426).

で示される化合物（以下、化合物（Ｌ−３４）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX427と記す）。
化合物（Ｌ−３４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX428と記す）。
化合物（Ｌ−３４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX429と記す）。
化合物（Ｌ−３４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX430と記す）。
化合物（Ｌ−３４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX431と記す）。
化合物（Ｌ−３４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX432と記す）。
化合物（Ｌ−３４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX433と記す）。
化合物（Ｌ−３４）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX434と記す）。
化合物（Ｌ−３４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX435と記す）。
化合物（Ｌ−３４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX436と記す）。
化合物（Ｌ−３４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX437と記す）。
化合物（Ｌ−３４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX438と記す）。
化合物（Ｌ−３４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX439と記す）。
化合物（Ｌ−３４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX440と記す）。 Formula (L-34):

In the compound shown below (hereinafter referred to as compound (L-34)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX427).
In the compound (L-34), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX428).
In the compound (L-34), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX429).
In the compound (L-34), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX430).
In the compound (L-34), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX431).
In the compound (L-34), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX432).
In the compound (L-34), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX433).
In the compound (L-34), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX434).
In the compound (L-34), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX435).
In the compound (L-34), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX436).
In the compound (L-34), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX437).
In the compound (L-34), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX438).
In the compound (L-34), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX439).
In the compound (L-34), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX440).

で示される化合物（以下、化合物（Ｌ−３５）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX441と記す）。
化合物（Ｌ−３５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX442と記す）。
化合物（Ｌ−３５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX443と記す）。
化合物（Ｌ−３５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX444と記す）。
化合物（Ｌ−３５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX445と記す）。
化合物（Ｌ−３５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX446と記す）。
化合物（Ｌ−３５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX447と記す）。
化合物（Ｌ−３５）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX448と記す）。
化合物（Ｌ−３５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX449と記す）。
化合物（Ｌ−３５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX450と記す）。
化合物（Ｌ−３５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX451と記す）。
化合物（Ｌ−３５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX452と記す）。
化合物（Ｌ−３５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX453と記す）。
化合物（Ｌ−３５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX454と記す）。 Formula (L-35):

In the compound shown below (hereinafter referred to as compound (L-35)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX441).
In the compound (L-35), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX442).
In the compound (L-35), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX443).
In the compound (L-35), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX444).
In the compound (L-35), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX445).
In the compound (L-35), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX446).
In the compound (L-35), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX447).
In the compound (L-35), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX448).
In the compound (L-35), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX449).
In the compound (L-35), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX450).
In the compound (L-35), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX451).
In the compound (L-35), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX452).
In the compound (L-35), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX453).
In the compound (L-35), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX454).

で示される化合物（以下、化合物（Ｌ−３６）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX455と記す）。
化合物（Ｌ−３６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX456と記す）。
化合物（Ｌ−３６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX457と記す）。
化合物（Ｌ−３６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX458と記す）。
化合物（Ｌ−３６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX459と記す）。
化合物（Ｌ−３６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX460と記す）。
化合物（Ｌ−３６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX461と記す）。
化合物（Ｌ−３６）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX462と記す）。
化合物（Ｌ−３６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX463と記す）。
化合物（Ｌ−３６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX464と記す）。
化合物（Ｌ−３６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX465と記す）。
化合物（Ｌ−３６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX466と記す）。
化合物（Ｌ−３６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX467と記す）。
化合物（Ｌ−３６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX468と記す）。 Formula (L-36):

In the compound shown below (hereinafter referred to as compound (L-36)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX455).
In the compound (L-36), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX456).
In the compound (L-36), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX457).
In the compound (L-36), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX458).
In the compound (L-36), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX459).
In the compound (L-36), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX460).
In the compound (L-36), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX461).
In the compound (L-36), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX462).
In the compound (L-36), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX463).
In the compound (L-36), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX464).
In the compound (L-36), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX465).
In the compound (L-36), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX466).
In the compound (L-36), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX467).
In the compound (L-36), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX468).

で示される化合物（以下、化合物（Ｌ−３７）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX469と記す）。
化合物（Ｌ−３７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX470と記す）。
化合物（Ｌ−３７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX471と記す）。
化合物（Ｌ−３７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX472と記す）。
化合物（Ｌ−３７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX473と記す）。
化合物（Ｌ−３７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX474と記す）。
化合物（Ｌ−３７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX475と記す）。
化合物（Ｌ−３７）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX476と記す）。
化合物（Ｌ−３７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX477と記す）。
化合物（Ｌ−３７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX478と記す）。
化合物（Ｌ−３７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX479と記す）。
化合物（Ｌ−３７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX480と記す）。
化合物（Ｌ−３７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX481と記す）。
化合物（Ｌ−３７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX482と記す）。 Formula (L-37):

In the compound shown below (hereinafter referred to as compound (L-37)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX469).
In the compound (L-37), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX470).
In the compound (L-37), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX471).
In the compound (L-37), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX472).
In the compound (L-37), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX473).
In the compound (L-37), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX474).
In the compound (L-37), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX475).
In the compound (L-37), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX476).
In the compound (L-37), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX477).
In the compound (L-37), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX478).
In the compound (L-37), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX479).
In the compound (L-37), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX480).
In the compound (L-37), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX481).
In the compound (L-37), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX482).

で示される化合物（以下、化合物（Ｌ−３８）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX483と記す）。
化合物（Ｌ−３８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX484と記す）。
化合物（Ｌ−３８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX485と記す）。
化合物（Ｌ−３８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX486と記す）。
化合物（Ｌ−３８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX487と記す）。
化合物（Ｌ−３８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX488と記す）。
化合物（Ｌ−３８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX489と記す）。
化合物（Ｌ−３８）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX490と記す）。
化合物（Ｌ−３８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX491と記す）。
化合物（Ｌ−３８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX492と記す）。
化合物（Ｌ−３８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX493と記す）。
化合物（Ｌ−３８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX494と記す）。
化合物（Ｌ−３８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX495と記す）。
化合物（Ｌ−３８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX496と記す）。 Formula (L-38):

In the compound shown below (hereinafter referred to as compound (L-38)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX483).
In the compound (L-38), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX484).
In the compound (L-38), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX485).
In the compound (L-38), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX486).
In the compound (L-38), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX487).
In the compound (L-38), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX488).
In the compound (L-38), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX489).
In the compound (L-38), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX490).
In the compound (L-38), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX491).
In the compound (L-38), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX492).
In the compound (L-38), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX493).
In the compound (L-38), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX494).
In the compound (L-38), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX495).
In the compound (L-38), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX496).

で示される化合物（以下、化合物（Ｌ−３９）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX497と記す）。
化合物（Ｌ−３９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX498と記す）。
化合物（Ｌ−３９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX499と記す）。
化合物（Ｌ−３９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX500と記す）。
化合物（Ｌ−３９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX501と記す）。
化合物（Ｌ−３９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX502と記す）。
化合物（Ｌ−３９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX503と記す）。
化合物（Ｌ−３９）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX504と記す）。
化合物（Ｌ−３９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX505と記す）。
化合物（Ｌ−３９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX506と記す）。
化合物（Ｌ−３９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX507と記す）。
化合物（Ｌ−３９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX508と記す）。
化合物（Ｌ−３９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX509と記す）。
化合物（Ｌ−３９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX510と記す）。 Formula (L-39):

In the compound shown below (hereinafter referred to as compound (L-39)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX497).
In the compound (L-39), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX 498).
In the compound (L-39), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX499).
In the compound (L-39), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX500).
In the compound (L-39), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX501).
In the compound (L-39), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX502).
In the compound (L-39), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX503).
In the compound (L-39), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX504).
In the compound (L-39), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX505).
In the compound (L-39), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX506).
In the compound (L-39), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX507).
In the compound (L-39), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX508).
In the compound (L-39), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX509).
In the compound (L-39), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX510).

で示される化合物（以下、化合物（Ｌ−４０）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX511と記す）。
化合物（Ｌ−４０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX512と記す）。
化合物（Ｌ−４０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX513と記す）。
化合物（Ｌ−４０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX514と記す）。
化合物（Ｌ−４０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX515と記す）。
化合物（Ｌ−４０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX516と記す）。
化合物（Ｌ−４０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX517と記す）。
化合物（Ｌ−４０）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX518と記す）。
化合物（Ｌ−４０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX519と記す）。
化合物（Ｌ−４０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX520と記す）。
化合物（Ｌ−４０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX521と記す）。
化合物（Ｌ−４０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX522と記す）。
化合物（Ｌ−４０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX523と記す）。
化合物（Ｌ−４０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX524と記す）。 Formula (L-40):

In the compound shown below (hereinafter referred to as compound (L-40)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds that are any of the substituents described in Table 15 (hereinafter referred to as compound group SX511).
In the compound (L-40), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX512).
In the compound (L-40), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX513).
In the compound (L-40), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX514).
In the compound (L-40), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX515).
In the compound (L-40), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX516).
In the compound (L-40), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX517).
In the compound (L-40), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX518).
In the compound (L-40), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX519).
In the compound (L-40), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX520).
In the compound (L-40), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX521).
In the compound (L-40), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX522).
In the compound (L-40), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX523).
In the compound (L-40), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX524).

で示される化合物（以下、化合物（Ｌ−４１）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX525と記す）。
化合物（Ｌ−４１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX526と記す）。
化合物（Ｌ−４１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX527と記す）。
化合物（Ｌ−４１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX528と記す）。
化合物（Ｌ−４１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX529と記す）。
化合物（Ｌ−４１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX530と記す）。
化合物（Ｌ−４１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX531と記す）。
化合物（Ｌ−４１）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX532と記す）。
化合物（Ｌ−４１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX533と記す）。
化合物（Ｌ−４１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX534と記す）。
化合物（Ｌ−４１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX535と記す）。
化合物（Ｌ−４１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX536と記す）。
化合物（Ｌ−４１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX537と記す）。
化合物（Ｌ−４１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX538と記す）。 Formula (L-41):

In the compound shown below (hereinafter referred to as compound (L-41)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX525).
In the compound (L-41), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX526).
In the compound (L-41), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX527).
In the compound (L-41), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX528).
In the compound (L-41), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX529).
In the compound (L-41), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX530).
In the compound (L-41), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX531).
In the compound (L-41), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX532).
In the compound (L-41), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX533).
In the compound (L-41), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX534).
In the compound (L-41), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX535).
In the compound (L-41), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX536).
In the compound (L-41), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX537).
In the compound (L-41), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX538).

で示される化合物（以下、化合物（Ｌ−４２）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX539と記す）。
化合物（Ｌ−４２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX540と記す）。
化合物（Ｌ−４２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX541と記す）。
化合物（Ｌ−４２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX542と記す）。
化合物（Ｌ−４２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX543と記す）。
化合物（Ｌ−４２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX544と記す）。
化合物（Ｌ−４２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX545と記す）。
化合物（Ｌ−４２）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX546と記す）。
化合物（Ｌ−４２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX547と記す）。
化合物（Ｌ−４２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX548と記す）。
化合物（Ｌ−４２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX549と記す）。
化合物（Ｌ−４２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX550と記す）。
化合物（Ｌ−４２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX551と記す）。
化合物（Ｌ−４２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX552と記す）。 Formula (L-42):

In the compound shown below (hereinafter referred to as compound (L-42)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds that are any of the substituents described in Table 15 (hereinafter referred to as compound group SX539).
In the compound (L-42), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX540).
In the compound (L-42), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX541).
In the compound (L-42), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX542).
In the compound (L-42), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX543).
In the compound (L-42), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX544).
In the compound (L-42), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX545).
In the compound (L-42), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX546).
In the compound (L-42), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX547).
In the compound (L-42), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX548).
In the compound (L-42), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX549).
In the compound (L-42), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX550).
In the compound (L-42), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX551).
In the compound (L-42), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX552).

で示される化合物（以下、化合物（Ｌ−４３）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX553と記す）。
化合物（Ｌ−４３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX554と記す）。
化合物（Ｌ−４３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX555と記す）。
化合物（Ｌ−４３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX556と記す）。
化合物（Ｌ−４３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX557と記す）。
化合物（Ｌ−４３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX558と記す）。
化合物（Ｌ−４３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX559と記す）。
化合物（Ｌ−４３）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX560と記す）。
化合物（Ｌ−４３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX561と記す）。
化合物（Ｌ−４３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX562と記す）。
化合物（Ｌ−４３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX563と記す）。
化合物（Ｌ−４３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX564と記す）。
化合物（Ｌ−４３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX565と記す）。
化合物（Ｌ−４３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX566と記す）。 Formula (L-43):

In the compound shown below (hereinafter referred to as compound (L-43)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX553).
In the compound (L-43), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX554).
In the compound (L-43), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX555).
In the compound (L-43), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX556).
In the compound (L-43), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX557).
In the compound (L-43), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX558).
In the compound (L-43), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX559).
In the compound (L-43), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX560).
In the compound (L-43), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX561).
In the compound (L-43), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX562).
In the compound (L-43), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX563).
In the compound (L-43), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX564).
In the compound (L-43), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX565).
In the compound (L-43), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX566).

で示される化合物（以下、化合物（Ｌ−４４）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX567と記す）。
化合物（Ｌ−４４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX568と記す）。
化合物（Ｌ−４４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX569と記す）。
化合物（Ｌ−４４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX570と記す）。
化合物（Ｌ−４４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX571と記す）。
化合物（Ｌ−４４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX572と記す）。
化合物（Ｌ−４４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX573と記す）。
化合物（Ｌ−４４）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX574と記す）。
化合物（Ｌ−４４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX575と記す）。
化合物（Ｌ−４４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX576と記す）。
化合物（Ｌ−４４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX577と記す）。
化合物（Ｌ−４４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX578と記す）。
化合物（Ｌ−４４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX579と記す）。
化合物（Ｌ−４４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX580と記す）。 Formula (L-44):

In the compound shown below (hereinafter referred to as compound (L-44)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX567).
In the compound (L-44), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX568).
In the compound (L-44), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX569).
In the compound (L-44), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX570).
In the compound (L-44), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX571).
In the compound (L-44), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX572).
In the compound (L-44), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX573).
In the compound (L-44), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX574).
In the compound (L-44), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX575).
In the compound (L-44), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX576).
In the compound (L-44), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX577).
In the compound (L-44), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX578).
In the compound (L-44), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX579).
In the compound (L-44), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX580).

で示される化合物（以下、化合物（Ｌ−４５）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX581と記す）。
化合物（Ｌ−４５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX582と記す）。
化合物（Ｌ−４５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX583と記す）。
化合物（Ｌ−４５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX584と記す）。
化合物（Ｌ−４５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX585と記す）。
化合物（Ｌ−４５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX586と記す）。
化合物（Ｌ−４５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX587と記す）。
化合物（Ｌ−４５）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX588と記す）。
化合物（Ｌ−４５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX589と記す）。
化合物（Ｌ−４５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX590と記す）。
化合物（Ｌ−４５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX591と記す）。
化合物（Ｌ−４５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX592と記す）。
化合物（Ｌ−４５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX593と記す）。
化合物（Ｌ−４５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX594と記す）。 Formula (L-45):

In the compound shown below (hereinafter referred to as compound (L-45)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX581).
In the compound (L-45), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX582).
In the compound (L-45), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX583).
In the compound (L-45), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX584).
In the compound (L-45), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX585).
In the compound (L-45), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX586).
In the compound (L-45), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX587).
In the compound (L-45), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX588).
In the compound (L-45), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX589).
In the compound (L-45), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX 590).
In the compound (L-45), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX591).
In the compound (L-45), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX592).
In the compound (L-45), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX593).
In the compound (L-45), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX594).

で示される化合物（以下、化合物（Ｌ−４６）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX595と記す）。
化合物（Ｌ−４６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX596と記す）。
化合物（Ｌ−４６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX597と記す）。
化合物（Ｌ−４６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX598と記す）。
化合物（Ｌ−４６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX599と記す）。
化合物（Ｌ−４６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX600と記す）。
化合物（Ｌ−４６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX601と記す）。
化合物（Ｌ−４６）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX602と記す）。
化合物（Ｌ−４６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX603と記す）。
化合物（Ｌ−４６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX604と記す）。
化合物（Ｌ−４６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX605と記す）。
化合物（Ｌ−４６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX606と記す）。
化合物（Ｌ−４６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX607と記す）。
化合物（Ｌ−４６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX608と記す）。 Formula (L-46):

In the compound shown below (hereinafter referred to as compound (L-46)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX595).
In the compound (L-46), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX596).
In the compound (L-46), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX597).
In the compound (L-46), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX598).
In the compound (L-46), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX599).
In the compound (L-46), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX600).
In the compound (L-46), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX601).
In the compound (L-46), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX602).
In the compound (L-46), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX603).
In the compound (L-46), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX604).
In the compound (L-46), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX605).
In the compound (L-46), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX606).
In the compound (L-46), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX607).
In the compound (L-46), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX608).

で示される化合物（以下、化合物（Ｌ−４７）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX609と記す）。
化合物（Ｌ−４７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX610と記す）。
化合物（Ｌ−４７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX611と記す）。
化合物（Ｌ−４７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX612と記す）。
化合物（Ｌ−４７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX613と記す）。
化合物（Ｌ−４７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX614と記す）。
化合物（Ｌ−４７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX615と記す）。
化合物（Ｌ−４７）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX616と記す）。
化合物（Ｌ−４７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX617と記す）。
化合物（Ｌ−４７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX618と記す）。
化合物（Ｌ−４７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX619と記す）。
化合物（Ｌ−４７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX620と記す）。
化合物（Ｌ−４７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX621と記す）。
化合物（Ｌ−４７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX622と記す）。 Formula (L-47):

In the compound shown below (hereinafter referred to as compound (L-47)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in Table 15 (hereinafter referred to as compound group SX609).
In the compound (L-47), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX610).
In the compound (L-47), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX611).
In the compound (L-47), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX612).
In the compound (L-47), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX613).
In the compound (L-47), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX614).
In the compound (L-47), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX615).
In the compound (L-47), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX616).
In the compound (L-47), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX617).
In the compound (L-47), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX618).
In the compound (L-47), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX619).
In the compound (L-47), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX620).
In the compound (L-47), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX621).
In the compound (L-47), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX622).

で示される化合物（以下、化合物（Ｌ−４８）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX623と記す）。
化合物（Ｌ−４８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX624と記す）。
化合物（Ｌ−４８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX625と記す）。
化合物（Ｌ−４８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX626と記す）。
化合物（Ｌ−４８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX627と記す）。
化合物（Ｌ−４８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX628と記す）。
化合物（Ｌ−４８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX629と記す）。
化合物（Ｌ−４８）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX630と記す）。
化合物（Ｌ−４８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX631と記す）。
化合物（Ｌ−４８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX632と記す）。
化合物（Ｌ−４８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX633と記す）。
化合物（Ｌ−４８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX634と記す）。
化合物（Ｌ−４８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX635と記す）。
化合物（Ｌ−４８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX636と記す）。 Formula (L-48):

In the compound shown below (hereinafter referred to as compound (L-48)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX623).
In the compound (L-48), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX624).
In the compound (L-48), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX625).
In the compound (L-48), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX626).
In the compound (L-48), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX627).
In the compound (L-48), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX628).
In the compound (L-48), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX629).
In the compound (L-48), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX630).
In the compound (L-48), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX631).
In the compound (L-48), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX632).
In the compound (L-48), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX633).
In the compound (L-48), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX634).
In the compound (L-48), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX635).
In the compound (L-48), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX636).

で示される化合物（以下、化合物（Ｌ−４９）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX637と記す）。
化合物（Ｌ−４９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX638と記す）。
化合物（Ｌ−４９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX639と記す）。
化合物（Ｌ−４９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX640と記す）。
化合物（Ｌ−４９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX641と記す）。
化合物（Ｌ−４９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX642と記す）。
化合物（Ｌ−４９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX643と記す）。
化合物（Ｌ−４９）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX644と記す）。
化合物（Ｌ−４９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX645と記す）。
化合物（Ｌ−４９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX646と記す）。
化合物（Ｌ−４９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX647と記す）。
化合物（Ｌ−４９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX648と記す）。
化合物（Ｌ−４９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX649と記す）。
化合物（Ｌ−４９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX650と記す）。 Formula (L-49):

In the compound shown below (hereinafter referred to as compound (L-49)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX637).
In the compound (L-49), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX638).
In the compound (L-49), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX639).
In the compound (L-49), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX640).
In the compound (L-49), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX641).
In the compound (L-49), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX642).
In the compound (L-49), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX643).
In the compound (L-49), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX644).
In the compound (L-49), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX645).
In the compound (L-49), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX646).
In the compound (L-49), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX647).
In the compound (L-49), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX648).
In the compound (L-49), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX649).
In the compound (L-49), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX650).

で示される化合物（以下、化合物（Ｌ−５０）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX651と記す）。
化合物（Ｌ−５０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX652と記す）。
化合物（Ｌ−５０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX653と記す）。
化合物（Ｌ−５０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX654と記す）。
化合物（Ｌ−５０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX655と記す）。
化合物（Ｌ−５０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX656と記す）。
化合物（Ｌ−５０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX657と記す）。
化合物（Ｌ−５０）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX658と記す）。
化合物（Ｌ−５０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX659と記す）。
化合物（Ｌ−５０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX660と記す）。
化合物（Ｌ−５０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX661と記す）。
化合物（Ｌ−５０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX662と記す）。
化合物（Ｌ−５０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX663と記す）。
化合物（Ｌ−５０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX664と記す）。 Formula (L-50):

In the compound shown below (hereinafter referred to as compound (L-50)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX651).
In the compound (L-50), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX652).
In the compound (L-50), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX653).
In the compound (L-50), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX654).
In the compound (L-50), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX655).
In the compound (L-50), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX656).
In the compound (L-50), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX657).
In the compound (L-50), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as Compound Group SX658).
In the compound (L-50), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX659).
In the compound (L-50), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX660).
In the compound (L-50), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX661).
In the compound (L-50), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX662).
In the compound (L-50), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX663).
In the compound (L-50), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX664).

で示される化合物（以下、化合物（Ｌ−５１）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX665と記す）。
化合物（Ｌ−５１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX666と記す）。
化合物（Ｌ−５１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX667と記す）。
化合物（Ｌ−５１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX668と記す）。
化合物（Ｌ−５１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX669と記す）。
化合物（Ｌ−５１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX670と記す）。
化合物（Ｌ−５１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX671と記す）。
化合物（Ｌ−５１）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX672と記す）。
化合物（Ｌ−５１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX673と記す）。
化合物（Ｌ−５１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX674と記す）。
化合物（Ｌ−５１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX675と記す）。
化合物（Ｌ−５１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX676と記す）。
化合物（Ｌ−５１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX677と記す）。
化合物（Ｌ−５１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX678と記す）。 Formula (L-51):

In the compound shown below (hereinafter referred to as compound (L-51)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX665).
In the compound (L-51), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX666).
In the compound (L-51), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX667).
In the compound (L-51), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX668).
In the compound (L-51), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX669).
In the compound (L-51), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX670).
In the compound (L-51), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX671).
In the compound (L-51), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX 672).
In the compound (L-51), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX673).
In the compound (L-51), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX 674).
In the compound (L-51), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX675).
In the compound (L-51), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX676).
In the compound (L-51), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX677).
In the compound (L-51), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX678).

で示される化合物（以下、化合物（Ｌ−５２）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX679と記す）。
化合物（Ｌ−５２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX680と記す）。
化合物（Ｌ−５２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX681と記す）。
化合物（Ｌ−５２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX682と記す）。
化合物（Ｌ−５２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX683と記す）。
化合物（Ｌ−５２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX684と記す）。
化合物（Ｌ−５２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX685と記す）。
化合物（Ｌ−５２）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX686と記す）。
化合物（Ｌ−５２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX687と記す）。
化合物（Ｌ−５２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX688と記す）。
化合物（Ｌ−５２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX689と記す）。
化合物（Ｌ−５２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX690と記す）。
化合物（Ｌ−５２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX691と記す）。
化合物（Ｌ−５２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX692と記す）。 Formula (L-52):

In the compound shown below (hereinafter referred to as compound (L-52)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX679).
In the compound (L-52), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX680).
In the compound (L-52), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX 681).
In the compound (L-52), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX682).
In the compound (L-52), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX683).
In the compound (L-52), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX684).
In the compound (L-52), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX685).
In the compound (L-52), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX686).
In the compound (L-52), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX687).
In the compound (L-52), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX688).
In the compound (L-52), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX689).
In the compound (L-52), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX690).
In the compound (L-52), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX691).
In the compound (L-52), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX692).

で示される化合物（以下、化合物（Ｌ−５３）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX693と記す）。
化合物（Ｌ−５３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX694と記す）。
化合物（Ｌ−５３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX695と記す）。
化合物（Ｌ−５３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX696と記す）。
化合物（Ｌ−５３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX697と記す）。
化合物（Ｌ−５３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX698と記す）。
化合物（Ｌ−５３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX699と記す）。
化合物（Ｌ−５３）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX700と記す）。
化合物（Ｌ−５３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX701と記す）。
化合物（Ｌ−５３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX702と記す）。
化合物（Ｌ−５３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX703と記す）。
化合物（Ｌ−５３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX704と記す）。
化合物（Ｌ−５３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX705と記す）。
化合物（Ｌ−５３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX706と記す）。 Formula (L-53):

In the compound shown below (hereinafter referred to as compound (L-53)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX693).
In the compound (L-53), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX694).
In the compound (L-53), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX695).
In the compound (L-53), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX696).
In the compound (L-53), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX697).
In the compound (L-53), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX698).
In the compound (L-53), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX699).
In the compound (L-53), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX700).
In the compound (L-53), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX701).
In the compound (L-53), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX702).
In the compound (L-53), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX703).
In the compound (L-53), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX704).
In the compound (L-53), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX705).
In the compound (L-53), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX706).

で示される化合物（以下、化合物（Ｌ−５４）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX707と記す）。
化合物（Ｌ−５４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX708と記す）。
化合物（Ｌ−５４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX709と記す）。
化合物（Ｌ−５４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX710と記す）。
化合物（Ｌ−５４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX711と記す）。
化合物（Ｌ−５４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX712と記す）。
化合物（Ｌ−５４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX713と記す）。
化合物（Ｌ−５４）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX714と記す）。
化合物（Ｌ−５４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX715と記す）。
化合物（Ｌ−５４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX716と記す）。
化合物（Ｌ−５４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX717と記す）。
化合物（Ｌ−５４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX718と記す）。
化合物（Ｌ−５４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX719と記す）。
化合物（Ｌ−５４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX720と記す）。 Formula (L-54):

In the compound shown below (hereinafter referred to as compound (L-54)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX707).
In the compound (L-54), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX 708).
In the compound (L-54), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX709).
In the compound (L-54), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX710).
In the compound (L-54), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX711).
In the compound (L-54), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX712).
In the compound (L-54), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX713).
In the compound (L-54), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX714).
In the compound (L-54), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX715).
In the compound (L-54), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX716).
In the compound (L-54), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX717).
In the compound (L-54), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX 718).
In the compound (L-54), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX719).
In the compound (L-54), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX720).

で示される化合物（以下、化合物（Ｌ−５５）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX721と記す）。
化合物（Ｌ−５５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX722と記す）。
化合物（Ｌ−５５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX723と記す）。
化合物（Ｌ−５５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX724と記す）。
化合物（Ｌ−５５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX725と記す）。
化合物（Ｌ−５５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX726と記す）。
化合物（Ｌ−５５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX727と記す）。
化合物（Ｌ−５５）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX728と記す）。
化合物（Ｌ−５５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX729と記す）。
化合物（Ｌ−５５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX730と記す）。
化合物（Ｌ−５５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX731と記す）。
化合物（Ｌ−５５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX732と記す）。
化合物（Ｌ−５５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX733と記す）。
化合物（Ｌ−５５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX734と記す）。 Formula (L-55):

In the compound shown below (hereinafter referred to as compound (L-55)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX721).
In the compound (L-55), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX722).
In the compound (L-55), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX723).
In the compound (L-55), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX724).
In the compound (L-55), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX725).
In the compound (L-55), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX 726).
In the compound (L-55), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX727).
In the compound (L-55), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX728).
In the compound (L-55), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX729).
In the compound (L-55), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX730).
In the compound (L-55), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX731).
In the compound (L-55), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX732).
In the compound (L-55), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX733).
In the compound (L-55), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX734).

で示される化合物（以下、化合物（Ｌ−５６）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX735と記す）。
化合物（Ｌ−５６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX736と記す）。
化合物（Ｌ−５６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX737と記す）。
化合物（Ｌ−５６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX738と記す）。
化合物（Ｌ−５６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX739と記す）。
化合物（Ｌ−５６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX740と記す）。
化合物（Ｌ−５６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX741と記す）。
化合物（Ｌ−５６）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX742と記す）。
化合物（Ｌ−５６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX743と記す）。
化合物（Ｌ−５６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX744と記す）。
化合物（Ｌ−５６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX745と記す）。
化合物（Ｌ−５６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX746と記す）。
化合物（Ｌ−５６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX747と記す）。
化合物（Ｌ−５６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX748と記す）。 Formula (L-56):

In the compound shown below (hereinafter referred to as compound (L-56)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX735).
In the compound (L-56), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX736).
In the compound (L-56), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX737).
In the compound (L-56), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX738).
In the compound (L-56), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX739).
In the compound (L-56), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX740).
In the compound (L-56), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX741).
In the compound (L-56), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX742).
In the compound (L-56), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX743).
In the compound (L-56), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX744).
In the compound (L-56), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX745).
In the compound (L-56), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX746).
In the compound (L-56), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX747).
In the compound (L-56), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX 748).

で示される化合物（以下、化合物（Ｌ−５７）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX749と記す）。
化合物（Ｌ−５７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX750と記す）。
化合物（Ｌ−５７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX751と記す）。
化合物（Ｌ−５７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX752と記す）。
化合物（Ｌ−５７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX753と記す）。
化合物（Ｌ−５７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX754と記す）。
化合物（Ｌ−５７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX755と記す）。
化合物（Ｌ−５７）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX756と記す）。
化合物（Ｌ−５７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX757と記す）。
化合物（Ｌ−５７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX758と記す）。
化合物（Ｌ−５７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX759と記す）。
化合物（Ｌ−５７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX760と記す）。
化合物（Ｌ−５７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX761と記す）。
化合物（Ｌ−５７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX762と記す）。 Formula (L-57):

In the compound shown below (hereinafter referred to as compound (L-57)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX749).
In the compound (L-57), A ¹ is CH, R ⁵ is an ethyl group, R ^3b is a hydrogen atom, and R ^3c is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX750).
In the compound (L-57), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX751).
In the compound (L-57), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX752).
In the compound (L-57), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX753).
In the compound (L-57), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX754).
In the compound (L-57), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX755).
In the compound (L-57), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX756).
In the compound (L-57), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX757).
In the compound (L-57), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX758).
In the compound (L-57), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX759).
In the compound (L-57), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX760).
In the compound (L-57), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX761).
In the compound (L-57), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX762).

で示される化合物（以下、化合物（Ｌ−５８）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX763と記す）。
化合物（Ｌ−５８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX764と記す）。
化合物（Ｌ−５８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX765と記す）。
化合物（Ｌ−５８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX766と記す）。
化合物（Ｌ−５８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX767と記す）。
化合物（Ｌ−５８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX768と記す）。
化合物（Ｌ−５８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX769と記す）。
化合物（Ｌ−５８）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX770と記す）。
化合物（Ｌ−５８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX771と記す）。
化合物（Ｌ−５８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX772と記す）。
化合物（Ｌ−５８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX773と記す）。
化合物（Ｌ−５８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX774と記す）。
化合物（Ｌ−５８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX775と記す）。
化合物（Ｌ−５８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX776と記す）。 Formula (L-58):

In the compound shown below (hereinafter referred to as compound (L-58)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX763).
In the compound (L-58), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX764).
In the compound (L-58), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX765).
In the compound (L-58), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX766).
In the compound (L-58), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX767).
In the compound (L-58), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX768).
In the compound (L-58), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX769).
In the compound (L-58), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX770).
In the compound (L-58), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX771).
In the compound (L-58), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX772).
In the compound (L-58), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX773).
In the compound (L-58), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX774).
In the compound (L-58), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX775).
In the compound (L-58), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX776).

で示される化合物（以下、化合物（Ｌ−５９）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX777と記す）。
化合物（Ｌ−５９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX778と記す）。
化合物（Ｌ−５９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX779と記す）。
化合物（Ｌ−５９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX780と記す）。
化合物（Ｌ−５９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX781と記す）。
化合物（Ｌ−５９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX782と記す）。
化合物（Ｌ−５９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX783と記す）。
化合物（Ｌ−５９）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX784と記す）。
化合物（Ｌ−５９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX785と記す）。
化合物（Ｌ−５９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX786と記す）。
化合物（Ｌ−５９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX787と記す）。
化合物（Ｌ−５９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX788と記す）。
化合物（Ｌ−５９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX789と記す）。
化合物（Ｌ−５９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX790と記す）。 Formula (L-59):

In the compound shown below (hereinafter referred to as compound (L-59)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX777).
In the compound (L-59), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX778).
In the compound (L-59), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX779).
In the compound (L-59), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX780).
In the compound (L-59), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX781).
In the compound (L-59), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX782).
In the compound (L-59), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX783).
In the compound (L-59), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX784).
In the compound (L-59), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX785).
In the compound (L-59), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX786).
In the compound (L-59), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX787).
In the compound (L-59), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX788).
In the compound (L-59), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX 789).
In the compound (L-59), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX790).

で示される化合物（以下、化合物（Ｌ−６０）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX791と記す）。
化合物（Ｌ−６０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX792と記す）。
化合物（Ｌ−６０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX793と記す）。
化合物（Ｌ−６０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX794と記す）。
化合物（Ｌ−６０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX795と記す）。
化合物（Ｌ−６０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX796と記す）。
化合物（Ｌ−６０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX797と記す）。
化合物（Ｌ−６０）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX798と記す）。
化合物（Ｌ−６０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX799と記す）。
化合物（Ｌ−６０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX800と記す）。
化合物（Ｌ−６０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX801と記す）。
化合物（Ｌ−６０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX802と記す）。
化合物（Ｌ−６０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX803と記す）。
化合物（Ｌ−６０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX804と記す）。 Formula (L-60):

In the compound shown below (hereinafter referred to as compound (L-60)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX791).
In the compound (L-60), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX792).
In the compound (L-60), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX 793).
In the compound (L-60), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX794).
In the compound (L-60), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX795).
In the compound (L-60), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX796).
In the compound (L-60), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX 797).
In the compound (L-60), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX798).
In the compound (L-60), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX799).
In the compound (L-60), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX800).
In the compound (L-60), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX801).
In the compound (L-60), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX802).
In the compound (L-60), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX803).
In the compound (L-60), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX804).

で示される化合物（以下、化合物（Ｌ−６１）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX805と記す）。
化合物（Ｌ−６１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX806と記す）。
化合物（Ｌ−６１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX807と記す）。
化合物（Ｌ−６１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX808と記す）。
化合物（Ｌ−６１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX809と記す）。
化合物（Ｌ−６１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX810と記す）。
化合物（Ｌ−６１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX811と記す）。
化合物（Ｌ−６１）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX812と記す）。
化合物（Ｌ−６１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX813と記す）。
化合物（Ｌ−６１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX814と記す）。
化合物（Ｌ−６１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX815と記す）。
化合物（Ｌ−６１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX816と記す）。
化合物（Ｌ−６１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX817と記す）。
化合物（Ｌ−６１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX818と記す）。 Formula (L-61):

In the compound shown below (hereinafter referred to as compound (L-61)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX805).
In the compound (L-61), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX806).
In the compound (L-61), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX807).
In the compound (L-61), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX808).
In the compound (L-61), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX809).
In the compound (L-61), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX810).
In the compound (L-61), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX811).
In the compound (L-61), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX812).
In the compound (L-61), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX813).
In the compound (L-61), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX814).
In the compound (L-61), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX815).
In the compound (L-61), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX816).
In the compound (L-61), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX817).
In the compound (L-61), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX818).

で示される化合物（以下、化合物（Ｌ−６２）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX819と記す）。
化合物（Ｌ−６２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX820と記す）。
化合物（Ｌ−６２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX821と記す）。
化合物（Ｌ−６２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX822と記す）。
化合物（Ｌ−６２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX823と記す）。
化合物（Ｌ−６２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX824と記す）。
化合物（Ｌ−６２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX825と記す）。
化合物（Ｌ−６２）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX826と記す）。
化合物（Ｌ−６２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX827と記す）。
化合物（Ｌ−６２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX828と記す）。
化合物（Ｌ−６２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX829と記す）。
化合物（Ｌ−６２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX830と記す）。
化合物（Ｌ−６２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX831と記す）。
化合物（Ｌ−６２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX832と記す）。 Formula (L-62):

In the compound shown below (hereinafter referred to as compound (L-62)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX819).
In the compound (L-62), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX820).
In the compound (L-62), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX821).
In the compound (L-62), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX822).
In the compound (L-62), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX823).
In the compound (L-62), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX824).
In the compound (L-62), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX825).
In the compound (L-62), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX826).
In the compound (L-62), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX827).
In the compound (L-62), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX 828).
In the compound (L-62), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX829).
In the compound (L-62), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX830).
In the compound (L-62), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX831).
In the compound (L-62), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX832).

で示される化合物（以下、化合物（Ｌ−６３）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX833と記す）。
化合物（Ｌ−６３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX834と記す）。
化合物（Ｌ−６３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX835と記す）。
化合物（Ｌ−６３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX836と記す）。
化合物（Ｌ−６３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX837と記す）。
化合物（Ｌ−６３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX838と記す）。
化合物（Ｌ−６３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX839と記す）。
化合物（Ｌ−６３）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX840と記す）。
化合物（Ｌ−６３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX841と記す）。
化合物（Ｌ−６３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX842と記す）。
化合物（Ｌ−６３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX843と記す）。
化合物（Ｌ−６３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX844と記す）。
化合物（Ｌ−６３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX845と記す）。
化合物（Ｌ−６３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX846と記す）。 Formula (L-63):

In the compound shown below (hereinafter referred to as compound (L-63)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX833).
In the compound (L-63), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX834).
In the compound (L-63), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX 835).
In the compound (L-63), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX836).
In the compound (L-63), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX837).
In the compound (L-63), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX838).
In the compound (L-63), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX839).
In the compound (L-63), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX 840).
In the compound (L-63), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX841).
In the compound (L-63), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX842).
In the compound (L-63), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX843).
In the compound (L-63), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX844).
In the compound (L-63), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX845).
In the compound (L-63), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX846).

で示される化合物（以下、化合物（Ｌ−６４）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX847と記す）。
化合物（Ｌ−６４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX848と記す）。
化合物（Ｌ−６４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX849と記す）。
化合物（Ｌ−６４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX850と記す）。
化合物（Ｌ−６４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX851と記す）。
化合物（Ｌ−６４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX852と記す）。
化合物（Ｌ−６４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX853と記す）。
化合物（Ｌ−６４）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX854と記す）。
化合物（Ｌ−６４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX855と記す）。
化合物（Ｌ−６４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX856と記す）。
化合物（Ｌ−６４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX857と記す）。
化合物（Ｌ−６４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX858と記す）。
化合物（Ｌ−６４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX859と記す）。
化合物（Ｌ−６４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX860と記す）。 Formula (L-64):

In the compound shown below (hereinafter referred to as compound (L-64)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is a group represented by [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX847).
In the compound (L-64), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX848).
In the compound (L-64), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX849).
In the compound (L-64), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX850).
In the compound (L-64), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX851).
In the compound (L-64), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX852).
In the compound (L-64), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX853).
In the compound (L-64), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX854).
In the compound (L-64), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX855).
In the compound (L-64), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX856).
In the compound (L-64), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX857).
In the compound (L-64), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX858).
In the compound (L-64), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX859).
In the compound (L-64), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX860).

で示される化合物（以下、化合物（Ｌ−６５）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX861と記す）。
化合物（Ｌ−６５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX862と記す）。
化合物（Ｌ−６５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX863と記す）。
化合物（Ｌ−６５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX864と記す）。
化合物（Ｌ−６５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX865と記す）。
化合物（Ｌ−６５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX866と記す）。
化合物（Ｌ−６５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX867と記す）。
化合物（Ｌ−６５）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX868と記す）。
化合物（Ｌ−６５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX869と記す）。
化合物（Ｌ−６５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX870と記す）。
化合物（Ｌ−６５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX871と記す）。
化合物（Ｌ−６５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX872と記す）。
化合物（Ｌ−６５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX873と記す）。
化合物（Ｌ−６５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX874と記す）。 Formula (L-65):

In the compound shown below (hereinafter referred to as compound (L-65)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in Table 15 (hereinafter referred to as compound group SX861).
In the compound (L-65), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX862).
In the compound (L-65), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX863).
In the compound (L-65), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX864).
In the compound (L-65), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX865).
In the compound (L-65), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX866).
In the compound (L-65), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX867).
In the compound (L-65), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX868).
In the compound (L-65), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX869).
In the compound (L-65), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX870).
In the compound (L-65), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX871).
In the compound (L-65), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX872).
In the compound (L-65), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX873).
In the compound (L-65), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX874).

で示される化合物（以下、化合物（Ｌ−６６）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX875と記す）。
化合物（Ｌ−６６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX876と記す）。
化合物（Ｌ−６６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX877と記す）。
化合物（Ｌ−６６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX878と記す）。
化合物（Ｌ−６６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX879と記す）。
化合物（Ｌ−６６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX880と記す）。
化合物（Ｌ−６６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX881と記す）。
化合物（Ｌ−６６）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX882と記す）。
化合物（Ｌ−６６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX883と記す）。
化合物（Ｌ−６６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX884と記す）。
化合物（Ｌ−６６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX885と記す）。
化合物（Ｌ−６６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX886と記す）。
化合物（Ｌ−６６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX887と記す）。
化合物（Ｌ−６６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX888と記す）。 Formula (L-66):

In the compound shown below (hereinafter referred to as compound (L-66)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX875).
In the compound (L-66), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX876).
In the compound (L-66), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX877).
In the compound (L-66), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX878).
In the compound (L-66), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as compound group SX879).
In the compound (L-66), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX880).
In the compound (L-66), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX881).
In the compound (L-66), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX882).
In the compound (L-66), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX 883).
In the compound (L-66), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX884).
In the compound (L-66), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX885).
In the compound (L-66), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX886).
In the compound (L-66), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX887).
In the compound (L-66), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX888).

で示される化合物（以下、化合物（Ｌ−６７）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX889と記す）。
化合物（Ｌ−６７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX890と記す）。
化合物（Ｌ−６７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX891と記す）。
化合物（Ｌ−６７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX892と記す）。
化合物（Ｌ−６７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX893と記す）。
化合物（Ｌ−６７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX894と記す）。
化合物（Ｌ−６７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX895と記す）。
化合物（Ｌ−６７）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX896と記す）。
化合物（Ｌ−６７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX897と記す）。
化合物（Ｌ−６７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX898と記す）。
化合物（Ｌ−６７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX899と記す）。
化合物（Ｌ−６７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX900と記す）。
化合物（Ｌ−６７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX901と記す）。
化合物（Ｌ−６７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX902と記す）。 Formula (L-67):

In the compound shown below (hereinafter referred to as compound (L-67)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX889).
In the compound (L-67), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX890).
In the compound (L-67), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX891).
In the compound (L-67), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX892).
In the compound (L-67), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX893).
In the compound (L-67), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX894).
In the compound (L-67), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX895).
In the compound (L-67), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX896).
In the compound (L-67), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX897).
In the compound (L-67), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX898).
In the compound (L-67), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX899).
In the compound (L-67), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX900).
In the compound (L-67), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX901).
In the compound (L-67), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX902).

で示される化合物（以下、化合物（Ｌ−６８）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX903と記す）。
化合物（Ｌ−６８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX904と記す）。
化合物（Ｌ−６８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX905と記す）。
化合物（Ｌ−６８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX906と記す）。
化合物（Ｌ−６８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX907と記す）。
化合物（Ｌ−６８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX908と記す）。
化合物（Ｌ−６８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX909と記す）。
化合物（Ｌ−６８）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX910と記す）。
化合物（Ｌ−６８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX911と記す）。
化合物（Ｌ−６８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX912と記す）。
化合物（Ｌ−６８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX913と記す）。
化合物（Ｌ−６８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX914と記す）。
化合物（Ｌ−６８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX915と記す）。
化合物（Ｌ−６８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX916と記す）。 Formula (L-68):

In the compound shown below (hereinafter referred to as compound (L-68)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds which are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX903).
In the compound (L-68), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX904).
In the compound (L-68), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX905).
In the compound (L-68), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX906).
In the compound (L-68), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX 907).
In the compound (L-68), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX 908).
In the compound (L-68), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX909).
In the compound (L-68), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX910).
In the compound (L-68), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX911).
In the compound (L-68), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX912).
In the compound (L-68), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX913).
In the compound (L-68), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX914).
In the compound (L-68), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX915).
In the compound (L-68), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds that are substituents (hereinafter referred to as compound group SX916).

で示される化合物（以下、化合物（Ｌ−６９）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX917と記す）。
化合物（Ｌ−６９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX918と記す）。
化合物（Ｌ−６９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX919と記す）。
化合物（Ｌ−６９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX920と記す）。
化合物（Ｌ−６９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX921と記す）。
化合物（Ｌ−６９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX922と記す）。
化合物（Ｌ−６９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX923と記す）。
化合物（Ｌ−６９）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX924と記す）。
化合物（Ｌ−６９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX925と記す）。
化合物（Ｌ−６９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX926と記す）。
化合物（Ｌ−６９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX927と記す）。
化合物（Ｌ−６９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX928と記す）。
化合物（Ｌ−６９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX929と記す）。
化合物（Ｌ−６９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX930と記す）。 Formula (L-69):

In the compound shown below (hereinafter referred to as compound (L-69)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7]- Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX917).
In the compound (L-69), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX918).
In the compound (L-69), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX919).
In the compound (L-69), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX920).
In the compound (L-69), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX921).
In the compound (L-69), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX922).
In the compound (L-69), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds having one or more substituents (hereinafter referred to as compound group SX 923).
In the compound (L-69), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX924).
In the compound (L-69), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX925).
In the compound (L-69), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX926).
In the compound (L-69), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX 927).
In the compound (L-69), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX 928).
In the compound (L-69), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter referred to as compound group SX 929).
In the compound (L-69), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX930).

で示される化合物（以下、化合物（Ｌ−７０）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX931と記す）。
化合物（Ｌ−７０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX932と記す）。
化合物（Ｌ−７０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX933と記す）。
化合物（Ｌ−７０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX934と記す）。
化合物（Ｌ−７０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX935と記す）。
化合物（Ｌ−７０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX936と記す）。
化合物（Ｌ−７０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3bが水素原子であり、Ｒ^3cが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX937と記す）。
化合物（Ｌ−７０）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX938と記す）。
化合物（Ｌ−７０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX939と記す）。
化合物（Ｌ−７０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX940と記す）。
化合物（Ｌ−７０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX941と記す）。
化合物（Ｌ−７０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX942と記す）。
化合物（Ｌ−７０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX943と記す）。
化合物（Ｌ−７０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｒ^3cが水素原子であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX944と記す）。 Formula (L-70):

In the compound shown below (hereinafter referred to as compound (L-70)), A ¹ is CH, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is [Table 7] Compounds that are any of the substituents described in [Table 15] (hereinafter referred to as compound group SX931).
In the compound (L-70), A ¹ is CH, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds that are substituents (hereinafter referred to as compound group SX932).
In the compound (L-70), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX 933).
In the compound (L-70), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX934).
In the compound (L-70), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX935).
In the compound (L-70), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX936).
In the compound (L-70), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^{3 b} is a hydrogen atom, and R ^{3 c} is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX937).
In the compound (L-70), A ¹ is CH, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX938).
In the compound (L-70), A ¹ is CH, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are substituents (hereinafter referred to as compound group SX939).
In the compound (L-70), A ¹ is a nitrogen atom, R ⁵ is a methyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds which are the substituents of (hereinafter, referred to as compound group SX940).
In the compound (L-70), A ¹ is a nitrogen atom, R ⁵ is an ethyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX941).
In the compound (L-70), A ¹ is a nitrogen atom, R ⁵ is a propyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX942).
In the compound (L-70), A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, R ^3c is a hydrogen atom, and R ^3b is any one of [Table 7] to [Table 15]. Compounds each having a substituent (hereinafter referred to as a compound group SX943).
In the compound (L-70), A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, R ^3c is a hydrogen atom, and R ^3b is any of those described in [Table 7] to [Table 15] Compounds which are substituents (hereinafter referred to as compound group SX944).

で示される化合物（以下、化合物（Ｌ−７１）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX945と記す）。
化合物（Ｌ−７１）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX946と記す）。
化合物（Ｌ−７１）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX947と記す）。
化合物（Ｌ−７１）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX948と記す）。
化合物（Ｌ−７１）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX949と記す）。
化合物（Ｌ−７１）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX950と記す）。
化合物（Ｌ−７１）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX951と記す）。 Formula (L-71):

In the compound shown below (hereinafter referred to as compound (L-71)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds which are the substituents of (hereinafter referred to as compound group SX945).
In the compound (L-71), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX 946).
In the compound (L-71), compounds in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX947).
In the compound (L-71), compounds in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX948).
In the compound (L-71), a compound in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX 949).
In the compound (L-71), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX950).
In the compound (L-71), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX951).

で示される化合物（以下、化合物（Ｌ−７２）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX952と記す）。
化合物（Ｌ−７２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX953と記す）。
化合物（Ｌ−７２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX954と記す）。
化合物（Ｌ−７２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX955と記す）。
化合物（Ｌ−７２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX956と記す）。
化合物（Ｌ−７２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX957と記す）。
化合物（Ｌ−７２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX958と記す）。 Formula (L-72):

In the compound shown below (hereinafter referred to as compound (L-72)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX952).
In the compound (L-72), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX953).
In the compound (L-72), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX954).
In the compound (L-72), compounds in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX 955).
In the compound (L-72), compounds in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX956).
In the compound (L-72), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX957).
In the compound (L-72), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX 958).

で示される化合物（以下、化合物（Ｌ−７３）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX959と記す）。
化合物（Ｌ−７３）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX960と記す）。
化合物（Ｌ−７３）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX961と記す）。
化合物（Ｌ−７３）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX962と記す）。
化合物（Ｌ−７３）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX963と記す）。
化合物（Ｌ−７３）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX964と記す）。
化合物（Ｌ−７３）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX965と記す）。 Formula (L-73):

In the compound shown below (hereinafter referred to as compound (L-73)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds which are the substituents of (hereinafter referred to as compound group SX959).
In the compound (L-73), compounds wherein A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX 960).
In the compound (L-73), a compound in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX961).
In the compound (L-73), compounds in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX962.
In the compound (L-73), compounds in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX963).
In the compound (L-73), compounds wherein A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX964).
In the compound (L-73), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX965).

で示される化合物（以下、化合物（Ｌ−７４）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX966と記す）。
化合物（Ｌ−７４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX967と記す）。
化合物（Ｌ−７４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX968と記す）。
化合物（Ｌ−７４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX969と記す）。
化合物（Ｌ−７４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX970と記す）。
化合物（Ｌ−７４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX971と記す）。
化合物（Ｌ−７４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX972と記す）。 Formula (L-74):

In the compound shown below (hereinafter referred to as compound (L-74)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as compound group SX966).
In the compound (L-74), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX 967).
In the compound (L-74), a compound in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX 968).
In the compound (L-74), compounds wherein A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX969).
In the compound (L-74), a compound in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX 970).
In the compound (L-74), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX971).
In the compound (L-74), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX972).

で示される化合物（以下、化合物（Ｌ−７５）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX973と記す）。
化合物（Ｌ−７５）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX974と記す）。
化合物（Ｌ−７５）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX975と記す）。
化合物（Ｌ−７５）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX976と記す）。
化合物（Ｌ−７５）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX977と記す）。
化合物（Ｌ−７５）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX978と記す）。
化合物（Ｌ−７５）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX979と記す）。 Formula (L-75):

In the compound shown below (hereinafter referred to as compound (L-75)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds which are the substituents of (hereinafter referred to as compound group SX 973).
In the compound (L-75), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX 974).
In the compound (L-75), a compound in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX 975).
In the compound (L-75), a compound in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX976).
In the compound (L-75), compounds in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX977).
In the compound (L-75), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX978).
In the compound (L-75), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX979).

で示される化合物（以下、化合物（Ｌ−７６）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX980と記す）。
化合物（Ｌ−７６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX981と記す）。
化合物（Ｌ−７６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX982と記す）。
化合物（Ｌ−７６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX983と記す）。
化合物（Ｌ−７６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX984と記す）。
化合物（Ｌ−７６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX985と記す）。
化合物（Ｌ−７６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX986と記す）。 Formula (L-76):

In the compound shown below (hereinafter referred to as compound (L-76)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds which are the substituents of (hereinafter referred to as compound group SX 980).
In the compound (L-76), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX 981).
In the compound (L-76), a compound in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX 982).
In the compound (L-76), a compound in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX 983).
In the compound (L-76), compounds in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX 984).
In the compound (L-76), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX985).
In the compound (L-76), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX986).

で示される化合物（以下、化合物（Ｌ−７７）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX987と記す）。
化合物（Ｌ−７７）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX988と記す）。
化合物（Ｌ−７７）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX989と記す）。
化合物（Ｌ−７７）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX990と記す）。
化合物（Ｌ−７７）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX991と記す）。
化合物（Ｌ−７７）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX992と記す）。
化合物（Ｌ−７７）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX993と記す）。 Formula (L-77):

In the compound shown below (hereinafter referred to as compound (L-77)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX987).
In the compound (L-77), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX 988).
In the compound (L-77), a compound in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX 989).
In the compound (L-77), a compound in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX990).
In the compound (L-77), compounds in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX991).
In the compound (L-77), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX992).
In the compound (L-77), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX993).

で示される化合物（以下、化合物（Ｌ−７８）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX994と記す）。
化合物（Ｌ−７８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX995と記す）。
化合物（Ｌ−７８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX996と記す）。
化合物（Ｌ−７８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX997と記す）。
化合物（Ｌ−７８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX998と記す）。
化合物（Ｌ−７８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX999と記す）。
化合物（Ｌ−７８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1000と記す）。 Formula (L-78):

In the compound shown below (hereinafter referred to as compound (L-78)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX994).
In the compound (L-78), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX995).
In the compound (L-78), compounds in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX 996).
In the compound (L-78), compounds wherein A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX 997).
In the compound (L-78), compounds in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX998).
In the compound (L-78), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX 999).
In the compound (L-78), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX1000).

で示される化合物（以下、化合物（Ｌ−７９）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1001と記す）。
化合物（Ｌ−７９）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1002と記す）。
化合物（Ｌ−７９）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1003と記す）。
化合物（Ｌ−７９）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1004と記す）。
化合物（Ｌ−７９）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1005と記す）。
化合物（Ｌ−７９）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1006と記す）。
化合物（Ｌ−７９）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1007と記す）。 Formula (L-79):

In the compound shown below (hereinafter referred to as compound (L-79)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX1001).
In the compound (L-79), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds It describes as group SX1002).
In the compound (L-79), a compound in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1003).
In the compound (L-79), a compound in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1004).
In the compound (L-79), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1005).
In the compound (L-79), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1006).
In the compound (L-79), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX1007).

で示される化合物（以下、化合物（Ｌ−８０）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1008と記す）。
化合物（Ｌ−８０）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1009と記す）。
化合物（Ｌ−８０）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1010と記す）。
化合物（Ｌ−８０）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1011と記す）。
化合物（Ｌ−８０）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1012と記す）。
化合物（Ｌ−８０）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1013と記す）。
化合物（Ｌ−８０）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1014と記す）。 Formula (L-80):

In the compound shown below (hereinafter referred to as compound (L-80)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX1008).
In the compound (L-80), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds It describes as group SX1009).
In the compound (L-80), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1010).
In the compound (L-80), compounds in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1011).
In the compound (L-80), a compound in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1012).
In the compound (L-80), compounds in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1013).
In the compound (L-80), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX1014).

In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1015).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1016).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1017).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1018).
In the compound (L-1), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX1019).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1020).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1021).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1022).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1023).
In the compound (L-3), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are the substituents of (hereinafter referred to as compound group SX1024).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1025).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1026).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1027).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1028).
In the compound (L-5), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX1029).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1030).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1031).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1032).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1033).
In the compound (L-7), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX1034).

で示される化合物（以下、化合物（Ｌ−８１）と記す）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1035と記す）。
化合物（Ｌ−８１）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1036と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1037と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1038と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1039と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1040と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1041と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1042と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1043と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1044と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1045と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1046と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1047と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1048と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1049と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1050と記す）。
化合物（Ｌ−８１）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1051と記す）。 Formula (L-81):

In the compound shown below (hereinafter referred to as compound (L-81)), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is [Table 1] to [Table 1] Compounds which are any of the substituents described in Table 6] (hereinafter referred to as compound group SX1035).
In the compound (L-81), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6]. Compounds that are groups (hereinafter referred to as compound group SX1036).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1037).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1038).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1039).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1040).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX1041).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1042).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1043).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1044).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1045).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX1046).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as Compound Group SX1047).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1048).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1049).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1050).
In the compound (L-81), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX1051).

で示される化合物（以下、化合物（Ｌ−８２）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1052と記す）。
化合物（Ｌ−８２）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1053と記す）。
化合物（Ｌ−８２）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1054と記す）。
化合物（Ｌ−８２）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1055と記す）。
化合物（Ｌ−８２）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1056と記す）。
化合物（Ｌ−８２）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1057と記す）。
化合物（Ｌ−８２）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1058と記す）。 Formula (L-82):

In the compound shown below (hereinafter referred to as compound (L-82)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX1052).
In the compound (L-82), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX1053).
In the compound (L-82), compounds in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1054).
In the compound (L-82), compounds wherein A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1055).
In the compound (L-82), compounds in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1056).
In the compound (L-82), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1057).
In the compound (L-82), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX1058).

で示される化合物（以下、化合物（Ｌ−８３）と記す）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1059と記す）。
化合物（Ｌ−８３）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1060と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1061と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1062と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1063と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1064と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1065と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1066と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1067と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1068と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1069と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1070と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1071と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1072と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1073と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1074と記す）。
化合物（Ｌ−８３）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1075と記す）。 Formula (L-83):

In the compound shown below (hereinafter referred to as compound (L-83)), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is [Table 1] to [Table 1] Compounds which are any of the substituents described in Table 6 (hereinafter referred to as compound group SX1059).
In the compound (L-83), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6]. Compounds that are groups (hereinafter referred to as compound group SX1060).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1061).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1062).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1063).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1064).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as compound group SX1065).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1066).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1067).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as Compound Group SX1068).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1069).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX1070).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1071).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1072).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1073).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1074).
In the compound (L-83), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX1075).

で示される化合物（以下、化合物（Ｌ−８４）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1076と記す）。
化合物（Ｌ−８４）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1077と記す）。
化合物（Ｌ−８４）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1078と記す）。
化合物（Ｌ−８４）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1079と記す）。
化合物（Ｌ−８４）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1080と記す）。
化合物（Ｌ−８４）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1081と記す）。
化合物（Ｌ−８４）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1082と記す）。 Formula (L-84):

In the compound shown below (hereinafter referred to as compound (L-84)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX1076).
In the compound (L-84), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX1077).
In the compound (L-84), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1078).
In the compound (L-84), compounds in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1079).
In the compound (L-84), a compound in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1080).
In the compound (L-84), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1081).
In the compound (L-84), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX1082).

で示される化合物（以下、化合物（Ｌ−８５）と記す）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1083と記す）。
化合物（Ｌ−８５）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1084と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1085と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1086と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1087と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1088と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1089と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1090と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1091と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1092と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1093と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1094と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1095と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1096と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1097と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1098と記す）。
化合物（Ｌ−８５）において、Ａ¹が窒素原子であり、Ｒ⁴がメチル基であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1099と記す）。 Formula (L-85):

In the compound shown below (hereinafter referred to as compound (L-85)), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is [Table 1] to [Table 1] Compounds which are any of the substituents described in Table 6] (hereinafter referred to as compound group SX1083).
In the compound (L-85), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] Compounds that are groups (hereinafter referred to as compound group SX1084).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as Compound Group SX1085).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter, referred to as compound group SX1086).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as Compound Group SX1087).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1088).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as compound group SX1089).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1090).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1091).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1092).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1093).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as compound group SX1094).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1095).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1096).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1097).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1098).
In the compound (L-85), A ¹ is a nitrogen atom, R ⁴ is a methyl group, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX1099).

で示される化合物（以下、化合物（Ｌ−８６）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1100と記す）。
化合物（Ｌ−８６）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1101と記す）。
化合物（Ｌ−８６）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1102と記す）。
化合物（Ｌ−８６）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1103と記す）。
化合物（Ｌ−８６）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1104と記す）。
化合物（Ｌ−８６）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1105と記す）。
化合物（Ｌ−８６）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1106と記す）。 Formula (L-86):

In the compound shown below (hereinafter referred to as compound (L-86)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX1100).
In the compound (L-86), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds It describes as group SX1101).
In the compound (L-86), a compound in which A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any substituent described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1102).
In the compound (L-86), a compound in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1103).
In the compound (L-86), compounds in which A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1104).
In the compound (L-86), a compound in which A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1105).
In the compound (L-86), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX1106).

で示される化合物（以下、化合物（Ｌ−８７）と記す）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1107と記す）。
化合物（Ｌ−８７）において、Ａ¹がＣＨであり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1108と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1109と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1110と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1111と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1112と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が水素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1113と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1114と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1115と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1116と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1117と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1118と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1119と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1120と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1121と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1122と記す）。
化合物（Ｌ−８７）において、Ａ¹が窒素原子であり、Ｒ⁴が塩素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1123と記す）。 Formula (L-87):

In the compound shown below (hereinafter referred to as compound (L-87)), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is [Table 1] to [Table 1] Compounds which are any of the substituents described in Table 6] (hereinafter referred to as compound group SX1107).
In the compound (L-87), A ¹ is CH, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] Compounds that are groups (hereinafter referred to as compound group SX1108).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1109).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1110).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter, referred to as compound group SX1111).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1112).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a hydrogen atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX1113).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1114).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1115).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1116).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1117).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX1118).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1119).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an ethyl group, and T is any one of [Table 1] to [Table 6]. Compounds that are substituents (hereinafter referred to as compound group SX1120).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a propyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1121).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is an isopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds which are substituents (hereinafter referred to as compound group SX1122).
In the compound (L-87), A ¹ is a nitrogen atom, R ⁴ is a chlorine atom, R ⁵ is a cyclopropyl group, and T is any one of [Table 1] to [Table 6]. Compounds each having a substituent (hereinafter referred to as a compound group SX1123).

で示される化合物（以下、化合物（Ｌ−８８）と記す）において、Ａ¹がＣＨであり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1124と記す）。
化合物（Ｌ−８８）において、Ａ¹がＣＨであり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1125と記す）。
化合物（Ｌ−８８）において、Ａ¹が窒素原子であり、Ｒ⁵がメチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1126と記す）。
化合物（Ｌ−８８）において、Ａ¹が窒素原子であり、Ｒ⁵がエチル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1127と記す）。
化合物（Ｌ−８８）において、Ａ¹が窒素原子であり、Ｒ⁵がプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1128と記す）。
化合物（Ｌ−８８）において、Ａ¹が窒素原子であり、Ｒ⁵がイソプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1129と記す）。
化合物（Ｌ−８８）において、Ａ¹が窒素原子であり、Ｒ⁵がシクロプロピル基であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1130と記す）。 Formula (L-88):

In the compound shown below (hereinafter referred to as compound (L-88)), A ¹ is CH, R ⁵ is a methyl group, and T is any one of [Table 1] to [Table 6] Compounds each having a substituent (hereinafter referred to as a compound group SX1124).
In the compound (L-88), compounds in which A ¹ is CH, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as compounds Marked as group SX1125).
In the compound (L-88), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a methyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1126).
In the compound (L-88), compounds in which A ¹ is a nitrogen atom, R ⁵ is an ethyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1127).
In the compound (L-88), compounds wherein A ¹ is a nitrogen atom, R ⁵ is a propyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1128).
In the compound (L-88), compounds wherein A ¹ is a nitrogen atom, R ⁵ is an isopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (hereinafter referred to as It is written as compound group SX1129).
In the compound (L-88), compounds in which A ¹ is a nitrogen atom, R ⁵ is a cyclopropyl group, and T is any of the substituents described in [Table 1] to [Table 6] (below , And described as compound group SX1130).

で示される化合物（以下、化合物（Ｌ−８９）と記す）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが０であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1131と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが１であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1132と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1133と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1134と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1135と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1136と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1137と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1138と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1139と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1140と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1141と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1142と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが１であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1143と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1144と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1145と記す）。
化合物（Ｌ−８９）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1146と記す）。
化合物（Ｌ−８９）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが０であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1147と記す）。
化合物（Ｌ−８９）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが１であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1148と記す）。
化合物（Ｌ−８９）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1149と記す）。
化合物（Ｌ−８９）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1150と記す）。
化合物（Ｌ−８９）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1151と記す）。
化合物（Ｌ−８９）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1152と記す）。
化合物（Ｌ−８９）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1153と記す）。
化合物（Ｌ−８９）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1154と記す）。
化合物（Ｌ−８９）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが１であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1155と記す）。
化合物（Ｌ−８９）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1156と記す）。
化合物（Ｌ−８９）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1157と記す）。
化合物（Ｌ−８９）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1158と記す）。 Formula (L-89):

In the compound represented by (hereinafter referred to as compound (L-89)), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 0, f is 0, T is Compounds that are any of the substituents described in Tables 1 to 6 (hereinafter referred to as compound group SX1131).
In the compound (L-89), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 1 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1132).
In the compound (L-89), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1133).
In the compound (L-89), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1134).
In the compound (L-89), R ² is a methyl group, n is 1 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1135).
In the compound (L-89), R ² is a methyl group, n is 2 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1136).
In the compound (L-89), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter, referred to as compound group SX1137).
In the compound (L-89), R ² is a methyl group, n is 1 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1138).
In the compound (L-89), R ² is a methyl group, n is 2 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1139).
In the compound (L-89), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1140).
In the compound (L-89), R ² is a methyl group, n is 1 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1141).
In the compound (L-89), R ² is a methyl group, n is 2 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1142).
In the compound (L-89), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 1 and T is described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1143).
In the compound (L-89), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,3-tetrafluoropropoxy group and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1144).
In the compound (L-89), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1145).
In the compound (L-89), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1146).
In the compound (L-89), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 0, f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1147).
In the compound (L-89), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 1 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1148).
In the compound (L-89), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1149).
In the compound (L-89), R ² is an ethyl group, n is 1 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1150).
In the compound (L-89), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1151).
In the compound (L-89), R ² is an ethyl group, n is 1, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1152).
In the compound (L-89), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1153).
In the compound (L-89), R ² is an ethyl group, n is 1 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1154).
In the compound (L-89), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 1 and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1155).
In the compound (L-89), R ² is an ethyl group, n is 2, f is 1, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1156).
In the compound (L-89), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1157).
In the compound (L-89), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1158).

で示される化合物（以下、化合物（Ｌ−９０）と記す）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが０であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1159と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが１であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1160と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1161と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1162と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1163と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1164と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1165と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1166と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1167と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1168と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1169と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1170と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが１であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1171と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1172と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1173と記す）。
化合物（Ｌ−９０）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1174と記す）。
化合物（Ｌ−９０）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが０であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1175と記す）。
化合物（Ｌ−９０）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが１であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1176と記す）。
化合物（Ｌ−９０）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1177と記す）。
化合物（Ｌ−９０）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1178と記す）。
化合物（Ｌ−９０）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1179と記す）。
化合物（Ｌ−９０）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1180と記す）。
化合物（Ｌ−９０）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1181と記す）。
化合物（Ｌ−９０）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1182と記す）。
化合物（Ｌ−９０）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが１であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1183と記す）。
化合物（Ｌ−９０）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1184と記す）。
化合物（Ｌ−９０）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1185と記す）。
化合物（Ｌ−９０）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1186と記す）。 Formula (L-90):

In the compound represented by (hereinafter referred to as compound (L-90)), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 0, f is 0, T is Compounds which are any of the substituents described in Tables 1 to 6 (hereinafter referred to as compound group SX1159).
In the compound (L-90), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 1 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1160).
In the compound (L-90), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1161).
In the compound (L-90), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1162).
In the compound (L-90), R ² is a methyl group, n is 1 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1163).
In the compound (L-90), R ² is a methyl group, n is 2 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX 1164).
In the compound (L-90), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1165).
In the compound (L-90), R ² is a methyl group, n is 1 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1166).
In the compound (L-90), R ² is a methyl group, n is 2 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1167).
In the compound (L-90), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1168).
In the compound (L-90), R ² is a methyl group, n is 1 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1169).
In the compound (L-90), R ² is a methyl group, n is 2 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1170).
In the compound (L-90), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 1 and T is described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1171).
In the compound (L-90), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,3-tetrafluoropropoxy group and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1172).
In the compound (L-90), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1173).
In the compound (L-90), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1174).
In the compound (L-90), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 0, f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1175).
In the compound (L-90), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 1 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1176).
In the compound (L-90), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1177).
In the compound (L-90), R ² is an ethyl group, n is 1, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1178).
In the compound (L-90), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1179).
In the compound (L-90), R ² is an ethyl group, n is 1 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1180).
In the compound (L-90), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1181).
In the compound (L-90), R ² is an ethyl group, n is 1 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1182).
In the compound (L-90), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 1 and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1183).
In the compound (L-90), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,3-tetrafluoropropoxy group and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1184).
In the compound (L-90), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1185).
In the compound (L-90), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1186).

で示される化合物（以下、化合物（Ｌ−９１）と記す）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが０であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1187と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが１であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1188と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1189と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1190と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1191と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1192と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1193と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1194と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1195と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1196と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1197と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1198と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが１であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1199と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1200と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1201と記す）。
化合物（Ｌ−９１）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1202と記す）。
化合物（Ｌ−９１）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが０であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1203と記す）。
化合物（Ｌ−９１）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが１であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1204と記す）。
化合物（Ｌ−９１）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1205と記す）。
化合物（Ｌ−９１）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1206と記す）。
化合物（Ｌ−９１）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1207と記す）。
化合物（Ｌ−９１）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1208と記す）。
化合物（Ｌ−９１）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1209と記す）。
化合物（Ｌ−９１）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1210と記す）。
化合物（Ｌ−９１）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが１であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1211と記す）。
化合物（Ｌ−９１）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1212と記す）。
化合物（Ｌ−９１）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1213と記す）。
化合物（Ｌ−９１）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1214と記す）。 Formula (L-91):

In the compound shown below (hereinafter referred to as compound (L-91)), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 0, f is 0, T is Compounds which are any of the substituents described in Tables 1 to 6 (hereinafter referred to as compound group SX1187).
In the compound (L-91), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 1 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1188).
In the compound (L-91), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1189).
In the compound (L-91), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1190).
In the compound (L-91), R ² is a methyl group, n is 1 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1191).
In the compound (L-91), R ² is a methyl group, n is 2 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1192).
In the compound (L-91), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1193).
In the compound (L-91), R ² is a methyl group, n is 1 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1194).
In the compound (L-91), R ² is a methyl group, n is 2 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1195).
In the compound (L-91), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1196).
In the compound (L-91), R ² is a methyl group, n is 1 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1197).
In the compound (L-91), R ² is a methyl group, n is 2 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1198).
In the compound (L-91), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 1 and T is described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1199).
In the compound (L-91), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,3-tetrafluoropropoxy group and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1200).
In the compound (L-91), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And the compounds which are any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1201).
In the compound (L-91), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1202).
In the compound (L-91), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 0, f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1203).
In the compound (L-91), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 1 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1204).
In the compound (L-91), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1205).
In the compound (L-91), R ² is an ethyl group, n is 1 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1206).
In the compound (L-91), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1207).
In the compound (L-91), R ² is an ethyl group, n is 1 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1208).
In the compound (L-91), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1209).
In the compound (L-91), R ² is an ethyl group, n is 1 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1210).
In the compound (L-91), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 1 and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX 1211).
In the compound (L-91), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,3-tetrafluoropropoxy group and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1212).
In the compound (L-91), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1213).
In the compound (L-91), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1214).

で示される化合物（以下、化合物（Ｌ−９２）と記す）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが０であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1215と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが１であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1216と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1217と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1218と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1219と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1220と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1221と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1222と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1223と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1224と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1225と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1226と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが１であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1227と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1228と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1229と記す）。
化合物（Ｌ−９２）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1230と記す）。
化合物（Ｌ−９２）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが０であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1231と記す）。
化合物（Ｌ−９２）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが１であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1232と記す）。
化合物（Ｌ−９２）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1233と記す）。
化合物（Ｌ−９２）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1234と記す）。
化合物（Ｌ−９２）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1235と記す）。
化合物（Ｌ−９２）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1236と記す）。
化合物（Ｌ−９２）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1237と記す）。
化合物（Ｌ−９２）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1238と記す）。
化合物（Ｌ−９２）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが１であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1239と記す）。
化合物（Ｌ−９２）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1240と記す）。
化合物（Ｌ−９２）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1241と記す）。
化合物（Ｌ−９２）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1242と記す）。 Formula (L-92):

In the compound shown below (hereinafter referred to as compound (L-92)), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 0, f is 0, T is Compounds which are any of the substituents described in Tables 1 to 6 (hereinafter referred to as compound group SX1215).
In the compound (L-92), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 1 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1216).
In the compound (L-92), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1217).
In the compound (L-92), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1218).
In the compound (L-92), R ² is a methyl group, n is 1 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1219).
In the compound (L-92), R ² is a methyl group, n is 2 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1220).
In the compound (L-92), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1221).
In the compound (L-92), R ² is a methyl group, n is 1 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1222).
In the compound (L-92), R ² is a methyl group, n is 2 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1223).
In the compound (L-92), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1224).
In the compound (L-92), R ² is a methyl group, n is 1 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1225).
In the compound (L-92), R ² is a methyl group, n is 2 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1226).
In the compound (L-92), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 1 and T is described in [Table 1] to [Table 6]. The compound which is any substituent of (Hereinafter, it is described as compound group SX1227).
In the compound (L-92), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,3-tetrafluoropropoxy group and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1228).
In the compound (L-92), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1229).
In the compound (L-92), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1230).
In the compound (L-92), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 0, f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1231).
In the compound (L-92), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 1 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1232).
In the compound (L-92), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1233).
In the compound (L-92), R ² is an ethyl group, n is 1 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1234).
In the compound (L-92), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1235).
In the compound (L-92), R ² is an ethyl group, n is 1 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1236).
In the compound (L-92), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1237).
In the compound (L-92), R ² is an ethyl group, n is 1 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1238).
In the compound (L-92), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 1 and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1239).
In the compound (L-92), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,3-tetrafluoropropoxy group and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1240).
In the compound (L-92), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1241).
In the compound (L-92), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1242).

で示される化合物（以下、化合物（Ｌ−９３）と記す）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが０であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1243と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが１であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1244と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1245と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1246と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1247と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1248と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1249と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1250と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1251と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1252と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1253と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1254と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが１であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1255と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1256と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1257と記す）。
化合物（Ｌ−９３）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1258と記す）。
化合物（Ｌ−９３）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが０であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1259と記す）。
化合物（Ｌ−９３）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが１であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1260と記す）。
化合物（Ｌ−９３）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1261と記す）。
化合物（Ｌ−９３）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1262と記す）。
化合物（Ｌ−９３）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1263と記す）。
化合物（Ｌ−９３）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1264と記す）。
化合物（Ｌ−９３）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1265と記す）。
化合物（Ｌ−９３）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1266と記す）。
化合物（Ｌ−９３）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが１であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1267と記す）。
化合物（Ｌ−９３）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1268と記す）。
化合物（Ｌ−９３）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1269と記す）。
化合物（Ｌ−９３）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1270と記す）。 Formula (L-93):

In the compound shown below (hereinafter referred to as compound (L-93)), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 0, f is 0, T is Compounds that are any of the substituents described in Tables 1 to 6 (hereinafter referred to as compound group SX1243).
In the compound (L-93), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 1 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1244).
In the compound (L-93), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1245).
In the compound (L-93), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1246).
In the compound (L-93), R ² is a methyl group, n is 1 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1247).
In the compound (L-93), R ² is a methyl group, n is 2 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1248).
In the compound (L-93), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1249).
In the compound (L-93), R ² is a methyl group, n is 1 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1250).
In the compound (L-93), R ² is a methyl group, n is 2 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1251).
In the compound (L-93), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1252).
In the compound (L-93), R ² is a methyl group, n is 1 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1253).
In the compound (L-93), R ² is a methyl group, n is 2 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1254).
In the compound (L-93), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 1 and T is described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1255).
In the compound (L-93), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as compound group SX1256).
In the compound (L-93), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1257).
In the compound (L-93), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1258).
In the compound (L-93), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 0, f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1259).
In the compound (L-93), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 1 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1260).
In the compound (L-93), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1261).
In the compound (L-93), R ² is an ethyl group, n is 1, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1262).
In the compound (L-93), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX 1263).
In the compound (L-93), R ² is an ethyl group, n is 1 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1264).
In the compound (L-93), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1265).
In the compound (L-93), R ² is an ethyl group, n is 1 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1266).
In the compound (L-93), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 1 and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1267).
In the compound (L-93), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,3-tetrafluoropropoxy group and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1268).
In the compound (L-93), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1269).
In the compound (L-93), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1270).

で示される化合物（以下、化合物（Ｌ−９４）と記す）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが０であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1271と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが１であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1272と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1273と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1274と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1275と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1276と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1277と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1278と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1279と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1280と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1281と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、ｎが２であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1282と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが１であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1283と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1284と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1285と記す）。
化合物（Ｌ−９４）において、Ｒ²がメチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1286と記す）。
化合物（Ｌ−９４）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが０であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1287と記す）。
化合物（Ｌ−９４）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが１であり、ｆが０であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1288と記す）。
化合物（Ｌ−９４）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1289と記す）。
化合物（Ｌ−９４）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1290と記す）。
化合物（Ｌ−９４）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1291と記す）。
化合物（Ｌ−９４）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1292と記す）。
化合物（Ｌ−９４）において、Ｒ²がエチル基であり、ｎが０であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1293と記す）。
化合物（Ｌ−９４）において、Ｒ²がエチル基であり、ｎが１であり、ｆが０であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1294と記す）。
化合物（Ｌ−９４）において、Ｒ²がエチル基であり、Ｒ^3bが水素原子であり、ｎが２であり、ｆが１であり、Ｔが、［表１］〜［表６］に記載のいずれかの置換基である化合物（以下、化合物群SX1295と記す）。
化合物（Ｌ−９４）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３−テトラフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1296と記す）。
化合物（Ｌ−９４）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，３，３−ペンタフルオロプロポキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1297と記す）。
化合物（Ｌ−９４）において、Ｒ²がエチル基であり、ｎが２であり、ｆが１であり、Ｔが２，２，３，４，４，４−ヘプタフルオロブトキシ基であり、Ｒ^3bが、［表７］〜［表１５］に記載のいずれかの置換基である化合物（以下、化合物群SX1298と記す）。 Formula (L-94):

In the compound shown below (hereinafter referred to as compound (L-94)), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 0, f is 0, T is Compounds that are any of the substituents described in Tables 1 to 6 (hereinafter referred to as compound group SX1271).
In the compound (L-94), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 1 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1272).
In the compound (L-94), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1273).
In the compound (L-94), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1274).
In the compound (L-94), R ² is a methyl group, n is 1 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1275).
In the compound (L-94), R ² is a methyl group, n is 2 and f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1276).
In the compound (L-94), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1277).
In the compound (L-94), R ² is a methyl group, n is 1 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1278).
In the compound (L-94), R ² is a methyl group, n is 2 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as Compound Group SX1279).
In the compound (L-94), R ² is a methyl group, n is 0, f is 0, T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1280).
In the compound (L-94), R ² is a methyl group, n is 1 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1281).
In the compound (L-94), R ² is a methyl group, n is 2 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1282).
In the compound (L-94), R ² is a methyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 1 and T is described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1283).
In the compound (L-94), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,3-tetrafluoropropoxy group and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1284).
In the compound (L-94), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter, referred to as compound group SX1285).
In the compound (L-94), R ² is a methyl group, n is 2 and f is 1 and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1286).
In the compound (L-94), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 0, f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1287).
In the compound (L-94), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 1 and f is 0, and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1288).
In the compound (L-94), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1289).
In the compound (L-94), R ² is an ethyl group, n is 1, f is 0, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX 1290).
In the compound (L-94), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group, R ^3b is And compounds having any one of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1291).
In the compound (L-94), R ² is an ethyl group, n is 1 and f is 0, T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1292).
In the compound (L-94), R ² is an ethyl group, n is 0, f is 0, T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1293).
In the compound (L-94), R ² is an ethyl group, n is 1 and f is 0, and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1294).
In the compound (L-94), R ² is an ethyl group, R ^{3 b} is a hydrogen atom, n is 2 and f is 1 and T is as described in [Table 1] to [Table 6]. Compounds which are any of the substituents (hereinafter referred to as compound group SX1295).
In the compound (L-94), R ² is an ethyl group, n is 2, f is 1, T is a 2,2,3,3-tetrafluoropropoxy group, and R ^3b is Compounds that are any of the substituents described in Tables 7 to 15 (hereinafter referred to as Compound Group SX1296).
In the compound (L-94), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,3,3-pentafluoropropoxy group and R ^3b is And compounds having any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1297).
In the compound (L-94), R ² is an ethyl group, n is 2 and f is 1 and T is a 2,2,3,4,4,4-heptafluorobutoxy group, R Compounds in which ^3b is any of the substituents described in [Table 7] to [Table 15] (hereinafter referred to as compound group SX1298).

  All compounds in compound groups SX1 to SX1298 can be produced according to the methods described in the examples or production methods of the present specification.

The present compounds are described in the following group (a), group (b), group (c), group (d), group (e), group (f), group (g), group (h), group (i) and It can be used in combination or in combination with one or more components (hereinafter referred to as the present components) selected from the group consisting of group (j).
The said combined use or combined use means using the present compound and the present component simultaneously, separately or at time intervals.
When the present compound and the present component are used simultaneously, the present compound and the present component may be contained in separate formulations or may be contained in one formulation.
One aspect of the present invention is group (a), group (b), group (c), group (d), group (e), group (f), group (g), group (h), group (group i) and one or more components selected from the group consisting of group (j), and a composition containing the present compound (hereinafter referred to as composition A).

  Group (a) includes acetylcholinesterase inhibitors (eg carbamate insecticides, organophosphorus insecticides), GABAergic chloride ion channel antagonists (eg phenylpyrazole insecticides), sodium channel modulators (eg pyrethroid insecticides) Nicotinic acetylcholine receptor antagonistic modulators (eg, neonicotinoid insecticides), nicotinic acetylcholine receptor allosteric modulators, glutamatergic chloride ion channel allosteric modulators (eg, macrolide insecticides), juvenile hormone mimic , Multi-site inhibitor, chord organ TRPV channel modulator, mite growth inhibitor, mitochondrial ATP biosynthesis enzyme inhibitor, oxidative phosphorylation uncoupling agent, nicotinic acetylcholine receptor Channel blockers (eg, nereistoxin insecticides), chitin synthesis inhibitors, molting inhibitors, ecdysone receptor agonists, octopamine receptor agonists, inhibitors of mitochondrial electron transport complex I, II, III and IV, voltage dependence Sodium channel blockers, acetyl-CoA carboxylase inhibitors, ryanodine receptor modulators (eg, diamide insecticides), chord tone organ modulators, microbial insecticides, and other insecticidal, acaricidal and / or nematode active ingredients . These are described in the classification based on IRAC's mechanism of action.

  Group (b) includes nucleic acid synthesis inhibitors (eg, phenylamide fungicides, acyl amino acid fungicides), cell division and cytoskeleton inhibitors (eg, MBC fungicides), respiratory inhibitors (eg, QoI fungicides) , QiI fungicides), amino acid synthesis and protein synthesis inhibitors (eg, anilinopyridine fungicides), signal transduction inhibitors, lipid synthesis and membrane synthesis inhibitors, sterol biosynthesis inhibitors (eg, triazole, etc. DMI) And bactericidal agents), cell wall synthesis inhibitors, melanin synthesis inhibitors, plant defense inducers, other action point contact active disinfectants, microbial disinfectants, and other bactericidal active ingredients. These are described in the classification based on the mechanism of action of FRAC.

  Group (c) is a group of plant growth regulators.

  Group (d) is a group of safeners.

  Group (e) is a group of synergists.

  Group (f) is a group of repellent components consisting of a bird repellent component, an insect repellent component and an animal repellent component.

  Group (g) is a group of mollusc components.

  Group (h) is a group of insect pheromone.

  Group (i) includes acetyl CoA carboxylase (ACCase) inhibitor, acetolactate synthetase (ALS) inhibitor, photosynthetic (photosystem II) inhibitor, photosystem I electron conversion agent, protoporphyrinogen oxidase (PPO) Inhibitor, phytoene desaturation enzyme system (PDS) inhibitor, 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor, carotenoid biosynthesis inhibitor, EPSP synthetase inhibitor, glutamine synthetase inhibitor, dihydroptero Inic acid (DHP) synthetase inhibitor, microtubule polymerization inhibitor, mitotic / microtubule formation inhibitor, very long chain fatty acid (VLCFA) inhibitor, cellulose synthesis inhibitor, uncoupling agent, lipid synthesis inhibition It is a group consisting of agents, indole acetic acid like active agents, auxin transfer inhibitors, and other herbicidal active ingredients. These are described in the classification based on the mechanism of action of HRAC.

  Group (j) is a microorganism having a controlling effect on pests (eg, insecticidal activity, acaricidal activity, nematocidal activity, bactericidal activity, herbicidal activity etc.) or plant growth regulating effects such as rhizobia, mycorrhizal fungi etc. It is a group of materials.

Below, the example of the combination of this component and this compound is described. For example, alanicarb (s) + SX means the combination of alanicarb (s) and SX.
The abbreviation SX means any one of the present compounds selected from the compound groups SX1 to SX1298. In addition, all of the components described below are known components and can be obtained from commercially available preparations or can be produced by known methods. When the component is a microorganism, it can also be obtained from a bacteria depository. The numbers in parentheses indicate CAS RN (registered trademark).

A combination of the present component of the above group (a) with the present compound:
Abamectin + SX, acephate + SX, acequinocyl + SX, acetamiprid + SX, acetoprole + SX, acrinatrin (acrinathrin) + SX, acinonapyr (acySonapy) + Afidopyropene + SX, afoxolaner + SX, alaniccarb (alanycarb) + SX, aldicarb (aldicarb) + SX, allethrin (allethrin) + SX, alpha-cypermethrin (alpha-cypermethrin) + SX, alpha-endsulfan -endosulfan) + SX, aluminum phosphide + SX, amitraz-SX, azadirachtin (azadirachtin) + SX, azamethiphos (azamethiphos) + SX, azinphos-ethyl (azinphos-ethyl) + SX, azinphos-methyl (azinphos- (azinphos-) methyl) + SX, azocyclotin (azocyclotin) + SX, Celastrus angulatus bark (bark of Celastrus angulatus) + SX, bendiocarb (bendiocarb) + SX, benflu Trin (benfluthrin) + SX, Benfuracarb (benfuracarb) + SX, Bensultap (bensultap) + SX, Benzoximate (benzoximate) + SX, Benzpyrimoxan (benzpyrimoxan) + SX, Beta-cifluthrin (beta-cyfluthrin) + SX , Betacypermethrin (beta-cypermethrin) + SX, bifenazate + SX, bifenthrin + SX, bioallethrin + SX, bioresmethrin (bioresmethrin) + SX, bistrifluron + SX Borax (borax) + SX, boric acid (boric acid) + SX, broflanilide (broflanilide) + SX, bromopropylate + SX, buprofezin + SX, butocarboxim + SX, Butoxycarboxim + SX, cadusafos + SX, calcium phosphide + SX, carbaryl + SX, carbofuran + SX, carbosulfan + SX, Rutap hydrochloride (cartap hydrochloride) + SX, cartap (cartap) + SX, quinomethionate + SX, chlorantraniliprole + sX, chlordane (chlordane) + SX, chloretxifos (chlorethoxyfos) + pill, chlorfena (chlorfenapyr) + SX, chlorfenvinphos + SX, chlorfluazuron + SX, chlormephos (chlormephos) + SX, chlorpicrin (chloropicrin) + SX, chlorpyrifos (chlorpyrifos) + SX, chlorpyrifos-methyl) + SX, chromafenozide + SX, clofentezine + SX, clothianidin + SX, concanamycin A (concanamycin A) + SX, coumaphos (coumaphos) + SX, cryolite cryolite) + SX, cyanophos (cyanophos) + SX, cyantraniliprole (cyantraniliprole) + SX, cyclaniliprole (cycliciliprole) + SX, shiku Prothrin (cycloprothrin) + SX, cycloxaprid + SX, cienopyraphen (cyenopyrafen) + SX, cyflumethofen (cyflumethofen) + SX, cyfluthrin (cyfluthrin) + SX, cyhalodiamide (cyhalodiamide) + SX, cyhalothrin + (cyhexatin) + SX, cypermethrin + SX, cyphenothrin + SX, cyromazine + SX, dazomet + SX, deltamethrin + SX, demeton-S-methyl (demeton) -S-methyl) + SX, diafenthiuron + SX, diazinon + SX, dichlorvos + SX, dichloromezotiaz, dicohol (dicofol) + SX, dicrotophos (dicrotophos (dicrotophos) ) + SX, Diflovidazin + SX, Diflubenzuron + SX, Dimefluthrin + SX, Dimethoate + SX, Dimethylvinphos (dime) thylvinphos) + SX, dinotefuran + SX, disodium octaborate + SX, disulfoton (disulfoton) + SX, DNOC (2-methyl-4,6-dinitrophenol) + SX, doramectin (doramectin) + SX, dried leaves of dried leaves (dried leaves of Dryopteris filix-mas) + SX, emamectin benzoate (emamectin-benzoate) + SX, enpentrin (empenthrin) + SX, endosulfan (endosulfan) + SX, EPN (O-ethyl) O- (4-nitrophenyl) phenylphosphothioate) + SX, epsilon methofluthrin (epsilon-metofluthrin) + SX, epsilon monmofluorthrin (epsilon-momfluorothrin) + SX, esfenvalerate (esfenvalerate) + SX, ethiophene carb (ethiofencarb) + SX, ethion + SX, ethiprole + SX, ethoprophos (ethophrophos) + SX, etofenprox (Etofenprox) + SX, etoxazole + SX, extract of Artemisia absinsthium + SX , Cas sia nigricans extract (extract of Cassia nigricans) + SX, extract of Clitoria ternatea (extract of clitoria ternatea) + SX, extract of Symphytum officinale + SX, extract of Lily-scented (extracts or simulated blends of ambrosioides) + SX, extract of Tanacetum vulgare + SX, Stinging nettle extract (extract of Urtica dioica) + SX, mistletoe extract (extract of Viscum album) + SX, famhur (famphur) + SX, Fenamiphos + SX, fenazaquin + SX, fenbutatin oxide + SX, fennitrothion + SX, fenobucarb + SX, fenoxycarb + SX, fenpropatrin (fenpropathrin) ) + SX, fenpyroximate + SX, fenthion + SX, fenvalerate + SX, fipronil (fipronil) + SX, flometoqu (flometoqu) in) + SX, Flonicamid (flonicamid) + SX, fluacrypyrim + SX, fluazaindolizine (fluazaindolizine) + SX, fluazuron + SX, flubendiamide + SX, flucycloxuron ) + SX, flucythrinate + SX, fluensulfone + SX, flufenoprox + SX, flufenoxuron + SX, flufiprole + SX, flumethrin flumethrin) + SX, flupyradifurone + SX, flupyrimin + SX, fluralaner + SX, fluvalinate + SX, fluxamethamide + SX, holmethate (formetanate) + SX, (fosthiazate) + SX, framethrin (furamethrin) + SX, frathiocarb (furathiocarb) + SX, gamma cyhalothrin (gamma-cyhalothrin) + SX, GS-Omega / Kappa HXTX-Hv 1a peptide (GS-omega / kappa HXTX-Hv1a peptide) + SX, halfenprox (halfenprox) + SX, halofenozide + SX, heptafluthrin + SX, heptenophos (heptenophos) + SX, hexaful Muron (hexaflumuron) + SX, hexythiazolox + SX, potassium salt of hops beta acid (potassium salt of hop beta acid) + SX, hydramethylnon (hydramethylnon) + SX, hydroprene (hydroprene) + SX, imiciafos (imicyafoss (imicyafos) ) + SX, imidacloprid (imidacloprid) + SX, imidaclotiz (imidaclothiz) + SX, imiprothrin + SX, indoxacarb + SX, isocycloceram (isocycloseram) + SX, isofenphos (isofenphos) + SX Isoprocarb + SX, isopropyl O- (methoxyaminothiophosphoryl) salicylate (isopropyl-O- (methoxyaminothiophosphoryl) salicylate) + SX, isoxathion + SX Ivermectin + SX, kadethrin + SX, kappa-tefluthrin + SX, kappa bifenthrin + SX, kinoprene + SX, lambda cyhalothrin (lambda- cyhalothrin) + SX, lenoremycin + SX, lepimectin + SX, lime sulfur combination (lime sulfur) + SX, rotiranel (lotilaner) + SX, lufenuron (lufenuron) + SX, machine oil (machine oil) + SX, malathion (malthion) + SX, mecarbam (mecarbam) + SX, meperfluthrin (meperfluthrin) + SX, metaflumizone (metaflumizone) + SX, metam (metam) + SX, methamidophos (methamidophos) + SX, methidathion + SX, methiocarb + SX, methomyl + SX, methoprene + SX, methoxychlor + SX, methoxyfenozide + SX, methyl bromide + SX, metofuritin luthrin) + SX, metolcarb + SX, methoxadiazone (metoxadiazone) + SX, mevinphos (mevinphos) + SX, milbemectin + SX, milbemycin oxime (milbemycin oxime) + SX, montfluorothrin (moxulothrin) , Monocrotophos + SX, moxidectin + SX, nared + SX, neem oil (neem oil) + SX, nicotine (nicotine) + SX, nicotine sulfate (S-nicotine) + SX, nitenpyram (Nitenpyram) + SX, novaluron (SUV) + SX, Noviflumuron (S) + SX, American oilseed seed oil (Chlopodium anthelminticum) + SX, omethoate + SX, oxamyl (oxamyl) + SX , Oxazosulfyl (oxazosulfyl) + SX, oxydimeton methyl (oxydemeton-methyl) + SX, parathion (parathion) + SX, parathion methyl (parathion-methyl) + SX, permethrin (permethrin) + SX, phenothrin (p henothrin) + SX, phenthoate + SX, phorate (phorate) + SX, phosalone (phosalone) + SX, phosmet (phosmet) + SX, phosphamidon (phosphamidon) + SX, phosphine (phosphine) + SX, phoxim (phoximm) ) + SX, pirimicarb (pirimicarb) + SX, pirimiphos-methyl (pirimiphos-methyl) + SX, prallethrin + SX, profenophos (profenofos) + SX, profluthrin + SX, propargite + SX, propetamphos ( propetamphos) + SX, propoxur + SX, propylene glycol alginate + SX, prothiophos (prothiofos) + SX, pyflubumide + SX, pimetrozine + SX, pyraclofos + SX, pyrethrin + SX, pyridaben + SX, pyridalyl + SX, pyridaphenthion + SX, pyrifluquinazone + S X, pyrimidifen + SX, pyriminostorobin + SX, pyriprole + P + SX, pyriproxyfen + SX, quinalphos (Quinalphos) + SX, resmethrin + SX, rotenone (rotenone) + SX, ryanodine (ryanodine) + SX, salalane (sarolaner) + SX, seramectin (selamectin) + SX, sigma-cypermethrin (sigma-cypermethrin) + SX, silafluofen (silafluofen) + SX, sodium borate (sodium) borate) + SX, sodium metaborate (sodium metaborate) + SX, spinetoram (spinetoram) + SX, spinosad (spinosad) + SX, spirodiclofen (spirodiclofen) + SX, spiromesifen (spiromesifen) + SX, spiropidione (spiropidion (spiropidion) ) + SX, Spirotetramat (spirotetramat) + SX, sulfluramid (sulfluramid) + SX, sulfotep (sulfotep) + SX, sulfoxaflor (sulfofaflor) + SX, sulfur (sulfur) + SX, sulfuryl fluoride (sulfuryl fluoride) + SX, tartar emetic + SX, tau-fluvalinate (tau-fluvalinate) + SX, tebufenozide + SX, tebufenpyrad (tebufenpyrad) + SX, tebupilimphos (tebupirimfos) + tefrubenz (te
flubenzuron) + SX, tefluthrin (tefluthrin) + SX, temephos (temephos) + SX, terbufos (terbufos) + SX, terpene component (terpene constituents of the extract of chenopodium ambrosioides near ambrosioides, Brand name: Terploid) 460) + SX, tetrachlorantraniliprole + SX, tetrachlorvinphos (tetrachlorovinphos) + SX, tetradiphone (tetradifon) + SX, tetramethrin (tetramethrin) + SX, tetramethylfluthrin (tetramethylfluthrin) + SX , Tetraniliprole (tetraniliprole) + SX, theta-cypermethrin (theta-cypermethrin) + SX, thiacloprid (thiacloprid) + SX, thiamethoxam + SX, thiocyclam (thiocyclam) + SX, thiodicarb (thiocathiob) Fanox (thiofanox) + SX, thiometon (thiometon) + SX, thiosultap disodium salt (thiosultap-disodium) + SX, thiosultap Sodium salt (thiosultap-monosodium) + SX, tiozazafen (tioxazafen) + SX, tolfenpyrad (tolfenpyrad) + SX, tralomethrin + SX, transfluthrin + SX, triazamate + SX, triazophos (triazophos (triazophos) ) + SX, trichlorfon (tricholfon) + SX, triflumezopyrim + SX, triflumuron (triflumuron) + SX, trimethacarb + SX, ticlopirazoflor (tyclopyrazoflor) + SX, vamidothion + , Shrimp oyster wood extract ingredient (wood extract of Quasisia amara) + SX, XMC (3,5-dimethylphenyl N-methylcarbamate) + SX, xylylcarb (xylylcarb) + SX, zetacipermethrin (zeta-cypermethrin) + SX, phosphorylated Zinc (zinc phosphide) + SX, N- [3-chloro-1- (pyridin-3-yl) -1H-pyrazol-4-yl] -N-ethyl-3- (3,3,3-trifluoropropanesulfinyl) propanamide (1477923-37-7) + SX, 4- [5- (3,5-dichlorophenyl) -5- (trifluoromethyl) -4, 5-d ihydro-1,2-oxazol-3-yl] -2-methyl-N- (1-oxothitan-3-yl) benzamide (1241050-20-3) + SX, 3-methoxy-N- (5- {5 -(Trifluoromethyl) -5- [3- (trifluoromethyl) phenyl] -4,5-dihydro-1,2-oxazol-3-yl} indan-1-yl) propanamide (1118626-57-5) + SX, N -[2-bromo-6-chloro-4- (1,1,1,2,3,3,3-heptafluoropropan-2-yl) phenyl] -3- {ethyl [(pyridin-4-yl) carbonyl] amino} -2-methoxybenzamide (1429513-53-0) + SX, N- [2-bromo-6-chloro-4- (1,1,1,2,3,3,3-heptafluoropropan-2-yl) phenyl] -3- [ethyl (4-cyanobenzoyl) amino] -2-methoxybenzamide (1609007-65-9) + SX, N- [2-bromo-6- (difluoromethoxy) -4- (1,1,1,6 2,3,3,3-heptafluoropropan-2-yl) phenyl] -3- {methyl [(pyridin-4-yl) carbonyl] amino} -2-methoxybenzamide (1630969-78-6) + SX, 1- { 2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl) sulfanyl] phenyl} -3- (trifluoromethyl) -1H-1,2,4-triazol-5-amine (885026-50-6) ) + SX, N-ethyl-5-methyl-1- (3-methylbutan-2-yl) -N- (pyridazin-4-yl) -1H-pyrazole-4-carboxamide (1403615-77-9) + SX , BT crop protein Cry1Ab (BT crop protein Cry1Ab) + SX, BT crop protein Cry1Ac ( BT crop protein Cry1Ac) + SX, BT crop protein Cry1Fa (BT crop protein Cry1Fa) + SX, BT crop protein Cry1A. 105 (BT crop protein Cry1A. 105) + SX, BT crop protein Cry2Ab (BT crop protein Cry2Ab) ) + SX, BT crop protein Vip3A (BT crop protein Vip3A) + SX, BT crop protein mCry3A (BT crop protein Cry3A) + SX, BT crop protein Cry3Ab (BT crop protein Cry3Ab) + SX, BT crop protein Cry3Bb (BT crop protein Cry3Bb) + SX, BT crop protein Cry34Ab1 / Cry35Ab1 (BT crop protein Cry34Ab1 / Cry35Ab1) + SX.

A combination of the present component of the above group (b) with the present compound:
Acibenzolar S methyl (acibenzolar-S-methyl) + SX, aldimorph (aldimorph) + SX, amethoctradin + SX, aminopyrifen + SX, amisulbrom + SX, anilazine (anilazine) + SX, Azaconazole (azaconazole) + SX, azoxystrobin (azoxystrobin) + SX, basic copper sulfate (basic copper sulfate) + SX, benalaxyl (benalaxyl) + SX, benalaxyl M (benalaxyl-M) + SX, benodanyl (benodanil) + SX, benomyl + SX, benthiavalicarb + SX, benthiavalicca isopropyl (benthivalicarb-isopropyl) + SX, benzovindiflupyr + SX, binapakryl (binacapryl) + SX, Biphenyl + SX, bitertanol + SX, bixafen + SX, blasticidin-S + SX, Bordeaux mixture + SX, boscalid + SX, bromothalonil b romothalonil) + SX, bromconazole (bromuconazole) + SX, bupirimate + SX, captafol + SX, captan (captan) + SX, carbendazim (carbendazim) + SX, carboxin + SX, Carpropamide (carpropamid) + SX, chinomethionat (chinomethionat) + SX, Chitin (chitin) + SX, Chloroneb (chlorob) + SX, Chlorothalonil + SX, Chlorozolinte (chlozolinate) + SX, Colletochlorin B ) + SX, copper (II) acetate (copper (II) acetate) + SX, copper (II) hydroxide (copper (II) hydroxide) + SX, basic copper chloride (copper oxychloride) + SX, copper sulfate (II) ) (copper (II) sulfate) + SX, coumoxystrobin (coxoxystrobin) + SX, cyazofamide (cyazofamid) + SX, cyflufenamide (cyflufenamid) + SX, cymoxanyl (cymoxanil) + SX, cyproconazole (cyproconazole) + SX , Cyprodinil + SX, dichlobentiazox ) + SX, dichlofluanid + SX, diclocymet + SX, diclomezine + SX, dichloran + sX, dietofencarb + SX, difenoconazole (difenoconazole) + + SX diflumetorim) + SX, dimethaclone (dimethachlone) + SX, dimethirimol (dimethirimol) + SX, dimethomorph (dimethomorph) + SX, dimoxystrobin + SX, diniconazole (diniconazole) + SX, diniconazole M (diniconazole-M) + SX, dinocap (Dinocap) + SX, dipotassium hydrogenphosphate + SX, dipymethitrone + SX, dithianone (dithianon) + SX, bis (ethylenediamine copper (II)) complex salt of dodecylbenzenesulfonate (dodecylbenzenesulfonic acid) acid bisethylenediamine copper (II) salt) + SX, dodemorph + SX, dodine + SX, edifenphos + SX, air Xastrobin (enoxastrobin) + SX, epoxiconazole (epoxiconazole) + SX, etaconazole (etaconazole) + SX, etaboboxam (ethaboxam) + SX, etlyimol (ethirimol) + SX, etridiazole + SX, tea tree extract (extract from Melaleuca alternifolia) + SX, extract from Reynoutria sachalinensis + SX, extract from cotyledons of Gaucher bean seedlings (extract from the cotyledons of lupine plantlets ("BLAD")) + SX, garlic extract (extract of Allium sativum) + SX, extract of Equisetum arvense + SX, extract of Tropaeolum majus + SX, famoxadone (Famoxadone) + SX, fenamidone (fenamidone) + SX, phenaminstrobin (fenaminstrobinbin ) + SX, fenarimol (fenarimol) + SX, fenbuconazole (fenbuconazole) + SX, fenfuram (fenfuram) + SX, fenhexamid (fenhexamid) + SX, fenoxa Le (fenoxanil) + SX, fenpiclonil + SX, fenpicoxamide + SX, fenpropidin + SX, fenpropimorph + SX, fenpyrazamine + SX, acetic acid Triphenyltin (fentin acetate) + SX, Triphenyltin chloride (fentin chloride) + SX, Triphenyltin hydroxide (fentin hydroxide) + SX, Ferbam (ferbam) + SX, Ferimzone (ferimzone) + SX, Florylpico Xamide (florylpicoxamide) + SX, fluazinam (fluazinam) + SX, fludioxonil + SX, flufenoxystrobin + SX, fluindapyr + SX, flumorph + SX, fluopicolide + SX, fluopyram + SX, fluopimomide + SX, fluoroimide + SX, fluoxapiprolin (fluoxapiprolin) + SX, fluoxastrobin (fluoxastrobin ) + SX, fluquinconazole + SX, flusilazole + SX, flusulfamide + SX, flutianil + SX, flutolanil + SX, flutriafol + SX, Fluxapiroxad (Fluxapyroxad) + SX, Folpet (Folpet) + SX, Fosetyl (Fosetyl) + SX, Fosetil-Aluminium + SX, Fuberidazole (Fuberidazole) + SX, Fralaxyl (Furaloxyl) + SX, Flametopil furamatepyr) + SX, guazatine + SX, hexaconazole (hexaconazole) + SX, hymexazole + SX, imazalil (imazalil) + SX, imibenconazole (imibenconazole) + SX, iminectazine (iminoctadine) , Iminoctadine triacetate + SX, inpyrfluxam + SX, iodocarb + iSoc, ipconazole (ipconazole) + Sx, ipfen trifluconazo (Ipfentrifluconazole) + SX, ipflufenoquin + SX, iprobenphos (iprobenfos) + SX, iprodione (Iprodione) + SX, iprovalicarb + SX, isofetamide (isofetamid) + SX, isoflucicum ( isoflucypram) + SX, isoprothiolane + SX, isopyrazam + SX, isotianil (isotianil) + SX, kasugamycin + SX, kresoxim-methyl (kresoxim-methyl) + SX, laminarin +, lamirin + Leaves and bark of Quercus + SX, mancozeb + SX, mandestrobin + SX, mandipropamid + SX, maneb (maneb) + SX, mefentrifluconazole (mefentrifluconazole) ) + SX, mepanipyrim (mepanipyrim) + SX, mepronil (mepronil) + SX, meptyldino cup (meptyldinocap) + SX, metalaxyl (metalaxyl) + SX, metalaxyl M (metalaxyl-M) + SX, metconazole (metconazole) + SX, metasulfocarb (methasulfocarb) + SX, methiram (metiram) + SX, metominostrobin (metominostrobin) + SX, metrafenone (metrafenone) + SX, methyltetraprole (metyltetraprole) + SX , Machine oils (mineral oils) + SX, microbutanil (myclobutanil) + SX, naftifine (naftifine) + SX, nuarimol (nuarimol) + SX, octilinone + SX, ofurace + SX, orysastrovin + SX, oxadixyl (oxadixyl) + SX, oxathiapiproline (oxathiapiprolin) + SX, oxine-copper + SX, oxolinic acid + SX, oxpoconazole (oxpoconazole) + SX, oxosconazole fumaric acid Salt (oxpoconazole fumarate) + SX, oxycarboxin + SX, oxytetracycline (oxytetracycline) + SX, pefrazoate (pefurazoate) + SX, penconazole (penconazole) + SX, pencil Ron (pencycuron) + SX, penflufen + SX, penthiopyrad + SX, phenamacril + SX, phosphorous acid + SX, phthalide + SX, picalbutrazox ( picarbutrazox) + SX, picoxystrobin + SX, piperaline (piperalin) + SX, polyoxins (polyoxins) + SX, potassium hydrogencarbonate (potassium hydrogencarbonate) + SX, potassium dihydrogenphosphate (potassium dihydrogenphosphate) + SX, Probenazole + SX, Prochloraz + SX, Procymidone + SX, Propamidine + SX, Propamocarb + SX, Propiconazole + SX, Propineb + SX, proquinazid + SX, prothiocarb + SX, prothioconazole (prothioconazole) + SX, pydiflumetofen (pydiflumetofen) + SX, pyraclostrobin (pyra clostrobin) + SX, pyrametostrobin (pyrametostrobin) + SX, pyraoxystrobin + SX, pyrapropoyne + SX, pyraziflumide + SX, pyrazophos (pyrazophos) + SX, pyribencarb + + SX, pyributicarb + SX, pyridachlomethyl + SX, pyrifenox + SX, pyrimethanil + SX, pyrimorph + SX, pyriophenone + SX, pyrizoxazole pyrisoxazole) + SX, pyroxilone (pyroquilon) + SX, Quillaja plant extract (Quillaja extract) + SX, quinconazole (quinconazole) + SX, quinofumelin + SX, quinoxyfen (quinoxyfen) + SX, quintozene (quintozene) + SX, Saponins of Chenopodium quinoa + SX, Sedaxane + SX, Silthiofam + SX, Simeconazole (simeconazole) + SX, Carbonate Sodium hydrogencarbonate + SX, spiroxamine + SX, streptomycin + SX, sulfur + SX, tebuconazole + SX, tebufuroquin + SX, teclophthalam + , Tecnazene + SX, terbinafine (terbinafine) + SX, tetraconazole (tetraconazole) + SX, thiabendazole (Siabendazole) + SX, thifluzamide + SX, thiophanate (thiophenate) + SX, thiophthalate ) + SX, thiuram (thiram) + SX, thymol (thymol) + SX, thiazinyl (tiadinil) + SX, tolclofos-methyl (tolclofos-methyl) + SX, tolfenpyrad (tolfenpyrad) + SX, tolprocarb (tolprocarb) + SX, toril Fluanid (tolylfluanid) + SX, triadimefon (triadimefon) + SX, triadimenol (triadimenol) + SX, triazoxide (triazoxide) + SX, triclopyrica Rub (triclopyricarb) + SX, tricyclazole + SX, tridemorph (tridemorph) + SX, trifloxystrobin + SX, triflumizole + SX, triforine (triforine) + SX, triticonazole (triticonazole) + SX, validamycin + SX, valifenalate + SX, vinclozolin + SX, mustard powder (yellow mustard powder) + SX, zinc thiazole + SX, zineb (zineb) + SX Ziram + SX, zoxamide + SX, 3- (difluoromethyl) -N-methoxy-1-methyl-N-[(1R) -1-methyl-2- (2,3,6-trichlorophenyl) ) Ethyl] -1H-pyrazole-4-carboxamide (1639015-48-7) + SX, 3- (Difluoromethyl) -N-methoxy-1-methyl-N-[(1S) -1-methyl-2- (2) , 3,6-Trichlorophenyl) ethyl] -1H-pyrazole-4-carboxamide (1639015-49-8) + SX, 3- (difluoromethyl) -1-methyl-N- (1,1,3-trimethyl-2, 3-dihydro-1H-inden-4-yl) -1H-pyrazole-4-carboxamide (141573-94-6) + SX, 3- (difluoromethyl) -N-[(3R) -7-fluoro-1, 1,3-trimethyl-2,3-dihydro-1H-inden-4-yl] -1-methyl-1H-pyrazole-4-carboxamide (1513466-73-3) + SX, N '-[4-({ 3-[(4-chlorophenyl) methyl] -1,2,4-thiadiazol-5-yl} oxy
) -2,5-dimethylphenyl] -N-ethyl-N-methylmethanimidamide (1202781-91-6) + SX, 4- (2-bromo-4-fluorophenyl) -N- (2-chloro-6-fluorophenyl)- 1,3-dimethyl-1H-pyrazol-5-amine (1362477-26-6) + SX, 2- [6- (3-fluoro-4-methoxyphenyl) -5-methylpyridine-2-yl] quinazoline (125705- 97-5) + SX, 5-fluoro-2-[(4-methylphenyl) methoxy] pyrimidin-4-amine (1174376-25-0) + SX, 5-fluoro-4-imino-3-methyl-1- tosyl-3,4-dihydropyrimidin-2 (1H) -one (1616664-98-2) + SX, N '-(2,5-dimethyl-4-phenoxyphenyl) -N-ethyl-N-methylmethanimidamide (1052688-31) -9) + SX, N '-{4-[(4,5-dichlorothiazol-2-yl) oxy] -2,5-dimethylphenyl-N-ethyl-N-methylmethanimidamide (929908-57-6) + SX , ethyl (2Z) -3-amino-2-cyano-3-phenylacrylate (39491-78-6) + SX, N-[(2-chlorothiazol-5-yl) methyl] -N-ethyl-6-methoxy- 3-nitropyridine-2-amine (1446247-98-8) + SX, α- [3- (4-chloro-2-fluorophenyl) -5- (2,4-difluorophenyl) -1,2-oxazol-4- yl] -3-pyridinemethanol (1229605-96-2) + SX, (αS)-[3- (4-chloro-2-fluorophenyl) -5- (2,4-difluorophenyl) -1,2-oxazol-4 -yl] -3-pyridinemethanol (1229606- 46-5) + SX, (αR)-[3- (4-chloro-2-fluorophenyl) -5- (2,4-difluorophenyl) -1,2-oxazol-4-yl] -3-pyridinemethanol (1229606) -02-3) + SX, 2-{[3- (2-chlorophenyl) -2- (2,4-difluorophenyl) oxiran-2-yl] methyl} -2,4-dihydro-3H-1,2, 4-triazole-3-thione (1342260-19-8) + SX, 2-{[(2R, 3S) -3- (2-chlorophenyl) -2- (2,4-difluorophenyl) oxiran-2-yl] methyl} -2,4-dihydro-3H-1,2,4-triazole-3-thione (1638897-70-7) + SX, 2-{[(2S, 3R) -3- (2-chlorophenyl)- 2- (2,4-difluorophenyl) oxiran-2-yl] methyl} -2,4-dihydro-3H-1,2,4-triazole-3-thione (1638897-71-8) + SX, 2- { [(2R, 3R) -3- (2-chlorophenyl) -2- (2,4-difluorophenyl) oxiran-2-yl] methyl} -2,4-dihydro-3H-1,2,4-triazole-3 -thione (1638897-72-9) + SX, 2-{[(2S, 3S) -3- (2-chlorophenyl) -2- (2,4-difluorophenyl) oxiran-2-yl] methyl} -2, 4-dihydro-3H-1,2,4-triazole-3-thione (1638897-73-0) + SX, 1-{[3- (2-chlorophenyl) -2- (2,4-difluorophenyl) oxiran- 2-yl] methyl} -1H-1,2,4-triazol-5-yl thiocyanate (1342260-26-7) + SX, 1-{[(2R, 3S) -3- (2-chlorophenyl) -2 -(2,4-difluorophenyl) oxiran-2-yl] methyl} -1H-1,2,4-triazol-5-yl t hiocyanate (1638897-82-1) + SX, 1-{[(2S, 3R) -3- (2-chlorophenyl) -2- (2,4-difluorophenyl) oxiran-2-yl] methyl} -1H-1 , 2,4-triazol-5-yl thiocyanate (1638897-84-3) + SX, 1-{[(2R, 3R) -3- (2-chlorophenyl) -2- (2,4-difluorophenyl) oxiran- 2-yl] methyl} -1H-1,2,4-triazol-5-yl thiocyanate (1638897-86-5) + SX, 1-{[(2S, 3S) -3- (2-chlorophenyl) -2 -(2,4-difluorophenyl) oxiran-2-yl] methyl} -1H-1,2,4-triazol-5-yl thiocyanate (1638897-89-8) + SX, 5- (4-chlorobenzyl) -2 -(chloromethyl) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1394057-11-4) + SX, (1R, 2S, 5S) -5 -(4-chlorobenzyl) -2- (chloromethyl) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1801930-06-2) + SX, ( 1S, 2R, 5R) -5- (4-chlorobenzyl) -2- (chloromethyl) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1801930- 07-3) + SX, (1R, 2R, 5R) -5- (4-chlorobenzyl) -2- (chloromethyl) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1801919-53-8) + SX, (1S, 2S, 5S) -5- (4-chlorobenzyl) -2- (chloromethyl) -2-methyl-1- (1H-1,2,5 4-triazol-1-ylmethyl) cyc lopentan-1-ol (1801919-54-9) + SX, (1R, 2R, 5S) -5- (4-chlorobenzyl) -2- (chloromethyl) -2-methyl-1- (1H-1,2,5 4-triazol-1-ylmethyl) cyclopentan-1-ol (1801919-55-0) + SX, (1S, 2S, 5R) -5- (4-chlorobenzyl) -2- (chloromethyl) -2-methyl-1 -(1H-1,2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1801919-56-1) + SX, (1R, 2S, 5R) -5- (4-chlorobenzyl) -2- ( chloromethyl) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1801919-57-2) + SX, (1S, 2R, 5S) -5- ( 4-chlorobenzyl) -2- (chloromethyl) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1801919-58-3) + SX, methyl 3- [(4-chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentane-1-carboxylate (1791398-02-1) + SX, methyl (1R, 2S, 3S) -3-[(4-chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentane-1-carboxylate ( 2080743-90-2) + SX, methyl (1S, 2R, 3R) -3-[(4-chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H-1,2,4-triazol-) 1-ylmethyl) cyclopentane-1-carboxylate (2080743-91-3) + SX, methyl (1R, 2R, 3R) -3-[(4-chlorophenyl) methyl] -2- hydroxy-1-methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentane-1-carboxylate (208074-92-4) + SX, methyl (1S, 2S, 3S) -3- [ (4-chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentane-1-carboxylate (2080743-93-5) + SX, methyl ( 1R, 2R, 3S) -3-[(4-chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentane-1-carboxylate (2080743 -94-6) + SX, methyl (1S, 2S, 3R) -3-[(4-chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H-1,2,4-triazol-1 -ylmethyl) cyclopentane-1-carboxylate (2080743-95-7) + SX, methyl (1R, 2S, 3R) -3-[(4-chlorophenyl) methyl] -2-hydroxy-1-methyl-2- (1H -1,2,4-Triazol-1-ylmethyl) cyclopentane-1-carboxylate (2081061-22-3) + SX, methyl (1S, 2R, 3S) -3-[(4-chlorophenyl) methyl] -2- hydroxy-1-methyl-2- (1H-1,2,4-triazol-1-ylmethyl) cyclopentane-1-carboxylate (2081061-23-4) + SX, 2- (chloromethyl) -5- (4-fluorobenzyl) ) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1394057-13-6) + SX, (1R, 2S, 5S) -2- (chloromethyl) ) -5- (4-Fluorobenzyl) -2-methyl-1- (1H-1,2,4-triazole) -1-ylmethyl) cyclopentan-1-ol (1801930-08-4) + SX, (1S, 2R, 5R) -2- (chloromethyl) -5- (4-fluorobenzyl) -2-methyl-1- (1H) -1,2,4-Triazol-1-ylmethyl) cyclopentan-1-ol (1801930-09-5) + SX, (1R, 2R, 3R) -2- (chloromethyl) -5- (4-fluorobenzyl)- 2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1638898-08-4) + SX, (1S, 2S, 3S) -2- (chloromethyl)- 5- (4-fluorobenzyl) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1638898-10-8) + SX, (1R, 2R, 3S ) -2- (chloromethyl) -5- (4-fluorobenzyl) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1638898-13-1) + SX, (1S, 2S, 5R) -2- (chloromethyl) -5- (4-fluorobenzyl) -2-methyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1638898-16-4) + SX, (1R, 2S, 5R) -2- (chloromethyl) -5- (4-fluorobenzyl) -2-methyl-1- (1H-1,2,4-triazol-1) -ylmethyl) cyclopentan-1-ol (1638898-20-0) + SX, (1S, 2R, 5S) -2- (chloromethyl) -5- (4-fluorobenzyl) -2-methyl-1- (1H-1) , 2,4-triazol-1-ylmethyl) cyclopentan-1-ol (1638898-24-4) + SX, 2- [2-chloro-4- (4-chlorophenoxy) phenyl] -1- (1H-1, 2,4-triazol-1-yl) pent-3-yn-2 -ol + SX, (R) -2- [2-chloro-4- (4-chlorophenoxy) phenyl] -1- (1H-1,2,4-triazol-1-yl) pent-3-yn-2 -ol (1801919-59-4) + SX, (R) -2- [4- (4-chlorophenoxy) -2- (trifluoromethyl) phenyl] -1- (1H-1,2,4-triazol-1-) yl) propan-1-ol (1616236-94-2) + SX, 1- [4- (4-chlorophenoxy) -2- (trifluoromethyl) phenyl] -1-cyclopropyl-2- (1H-1,2,4 -triazol-1-yl) ethanol + SX, (R) -1- [4- (4-chlorophenoxy) -2- (trifluoromethyl) phenyl] -1-cyclopropyl-2- (1H-1,2,4-triazole -1-yl) ethanol (1801919-60-7) + SX, (R) -2- [4- (4-chlorophenoxy) -2- (trifluoromethyl) phenyl] -3-methyl-1- (1H-1, 2,4-triazol-1-yl) butan-2-ol (1801919-61-8) + SX, methyl ({2-methyl-5- [1- (4-methoxy-2-methylphenyl) -1H-pyrazol -3-yl] phenyl} methyl) carbamate (1605879-98-8) + SX, 2- (difluoromethyl) -N- [1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl Pyridine-3-carboxamide (1616231-21-4) + SX, 2- (difluoromethyl) -N-[(3R) -1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl Pyridine-3-carboxamide (1616239-33-8) + SX, 2- (Difluoromethyl) -N- [3-ethyl-1,1-dimethyl-2,3-dihydro-1H-inden-4-yl] pyridine -3-carboxamide (1847 460-02-9) + SX, 2- (difluoromethyl) -N-[(3R) -3-ethyl-1,1-dimethyl-2,3-dihydro-1H-inden-4-yl] pyridine-3- carboxamide (1952305-97-3) + SX, 2- (difluoromethyl) -N- [3-propyl-1,1-dimethyl-2,3-dihydro-1H-inden-4-yl] pyridine-3-carboxamide ( 1847460-05-2) + SX, 2- (difluoromethyl) -N-[(3R) -3-propyl-1,1-dimethyl-2,3-dihydro-1H-inden-4-yl] pyridine-3- carboxamide (1952306-00-1) + SX, (2E, 3Z) -5-{[1- (4-chlorophenyl) -1H-pyrazol-3-yl] oxy} -2- (methoxyimino) -N, 3- dimethylpent-3-enamide (1445331-27-0) + SX.

A combination of the present component of the above group (c) with the present compound:
1-methylcyclopropene + SX, 1,3-diphenylurea + SX, 2,3,5-triiodobenzoic acid + SX, IAA ((1H-indol-3-yl) acetic acid) + SX, IBA (4- (1H-indol -3-yl) butyric acid + SX, MCPA (2- (4-chloro-2-methylphenoxy) acetic acid) + SX, MCPB (4- (4-chloro-2-methylphenoxy) butyric acid) + SX, 4 -CPA (4-chlorophenoxyacetic acid) + SX, 5-aminolevulinic acid hydrochloride + SX, 6-benzylaminopurine + SX, abscisic acid + SX, AVG (aminoethoxyvinylglycine) + SX, ancimidol (ancymidol) + SX, butoralin (butralin) + SX, calcium carbonate + SX, calcium chloride + SX, calcium formate + SX, calcium peroxide + SX, calcium sulfurate + SX, sulfuric acid Calcium sulfate + SX, Chlormequat-chloride + SX, Chlorpropham + SX, Choline chloride + SX, Cloprop + SX, Cyanamide + SX, Ranilide (cyclanilide) + SX, daminozide + SX, decane-1-ol (decan-1-ol) + SX, diclorp (dichlorprop) + SX, dikegulac + SX, dimethipin (dimethipin) + SX , Diquat + SX, ethephon + SX, ethychlozate + SX, flumetralin + SX, flurprimidol + SX, holchlorphenuron (forchlorfenuron) + SX, ) + SX, Gibberellin A (Gibberellin A) + SX, Gibberellin A3 (Gibberellin A3) + SX, Inabenfide (inabenfide) + SX, Kinetin (Kinet) + SX, lipochitooligosaccharide + SX, lipochitooligosaccharide SP104, + hydrazide) + SX, mefluidide + SX, mepiquat-chloride + SX, oxidized glutathione (oxidized glutathione) + SX, paclobutrazol + SX, pendy Talin (pendimethalin) + SX, prohexadione calcium (prohexandione-calcium) + SX, prohydrojasmon (prohydrojasmon) + SX, pyraflufen-ethyl (pyraflufen-ethyl) + SX, sintofen + SX, 1-naphthalene Sodium acetate (sodium 1-naphthaleneacetate) + SX, sodium cyanate (sodium cyanate) + SX, streptomycin (streptomycin) + SX, thidiaazuron + SX, triapenthenol + SX, tribphos (Tribufos) + SX , Trinexapac-ethyl (trinexapac-ethyl) + SX, uniconazole P (uniconazole-P) + SX, 2- (naphthalen-1-yl) acetamide (2- (naphthalen-1-yl) acetamide) + SX, [4 -Oxo-4- (2-phenylethyl) amino] butyric acid + SX, 5- (trifluoromethyl) benzo [b] thiophene-2-carboxylic acid methyl + SX, 3-[(6-chloro-4-phenylquinazoline -2 -Yl) amino] -1-propanol + SX, strigolactone + SX, (1E) -1-[[1- [3,5-bis (trifluoromethyl) phenyl]-described in WO 2018/145979 4-Methyl-5-oxo-2H-pyrrol-2-yl] oxymethylene] -3,3a, 4,8b-tetrahydroindeno [2,1-b] pyrrol-2-one + SX, International Publication No. 2018/145979 (2R) -1- [3,5-bis (trifluoromethyl) phenyl] -4-methyl-2-[(E)-(2-oxo-4,8b-dihydro-3aH-indeno [2,1] described in (b) furan-1-ylidene) methoxy] -2H-pyrrol-5-one + SX, (2S) -1- [3,5-bis (trifluoromethyl) phenyl]-described in WO 2018/145979 4-methyl-2-[(E)-(2-oxo-4,8b-dihydro-3aH-indeno [2,1-b] furan-1-ylidene) methoxy] -2H-pyrrol-5-one + SX .

A combination of the present component of the above group (d) with the present compound:
Aridochlor (allidochlor) + SX, benoxacor (benoxacor) + SX, Cloquintoset (cloquintocet) + SX, Cloquintoset mexyl (cloquintocet-mexyl) + SX, Siometenyl (cyometrinil) + SX, cyprosulfamide (cyprosulfamide) + SX, dichlormid + SX, dicyclonone + SX, dimepiperate (Dimepiperate) + SX, disulfoton (disulfoton) + SX, dimron (Dymron) + SX, fenchlorazole + SX, fenchlorazole Ethyl (fenchlorazole-ethyl) + SX, fenclorim + SX, flurazole (flurazole) + SX, furilazole + SX, fluxofenim (fluxofenim) + SX, hexim (Hexim) + SX, isoxadifen (isoxadifen) + SX , Isoxadiphenethyl (isoxadifen-ethyl) + SX, mecoprop (mecoprop) + SX, mefenpyr (mefenpyr) + SX, mefenpyrethyl (mefenpyr-ethyl) + SX, mefenpyr Chill (mefenpyr-diethyl) + SX, mephenate + SX, metchamifene (Metcamifen) + SX, oxabetrinil + SX, 1,8-Naphthalic anhydride (1,8-naphthalic anhydride) + SX, 1 , 8-octamethylenediamine + SX, AD-67 (4- (dichloroacetyl) -1-oxa-4-azaspiro [4.5] decane) + SX, CL-304415 (4-carboxy- 3,4-dihydro-2H-1-benzopyran-4-acetic acid) + SX, CSB (1-bromo-4-[(chloromethyl) sulfonyl] benzene) + SX, DKA-24 (2,2-dichloro-N -[2-oxo-2- (2-propenylamino) ethyl] -N- (2-propenyl) acetamide) + SX, MG 191 (2- (dichloromethyl) -2-methyl-1,3-dioxolane) + SX, MG -838 (2-propenyl 1-oxa-4-azaspiro [4.5] decane-4-carbodithioate) + SX, PPG-1292 (2,2-dichloro-N- (1,3-dioxan-2-ylmethyl) -N -(2-propenyl) acetamide) + SX, R-28725 (3- (dichloroacetyl) -2,2-dimethyl-1,3-oxazolidine) + SX, R-29148 (3- (dichloroacetyl) -2,2, 5-trimethyl-1,3-oxazolidine) + SX, TI-35 (1- (dichloroacetyl) azepane) + SX.

Combinations of the present component of the above group (e) with the present compound:
1-dodecyl-1H-imidazole (1-dodecyl-1H-imidazole) + SX, N- (2-ethylhexyl) -8,9,10-trinolborn-5-ene-2,3-dicarboximide (N -(2-ethylhexyl) -8,9,10-trinorborn-5-ene-2,3-dicarboxamide + SX, bucarpolate + SX, N, N-dibutyl-4-chlorobenzenesulfonamide (N, N -dibutyl-4-chlorobenzenesulfonate) + SX, dietholate + SX, diethylmaleate (diethylmaleate) + SX, piperonyl butoxide + SX, piperonyl cyclonene + SX, piprotal + SX, propyl isome + SX, safroxan + SX, sesamex + SX, sesamolin + SX, sulphoxide (Sulfoxide) + SX, Verbutin + SX, DMC (1,1 1-bis (4-chlorophenyl) ethanol) + SX, FDMC (1,1-bis (4-chlorophenyl) -2,2,2-trifluoroethanol) + SX, ETN (1,2-bis (4-chlorophenyl) ethanol) epoxy-1,2,3,4-tetrahydronaphthalene) + SX, ETP (1,1,1-trichloro-2,3-expoxypropane) + SX, PSCP (phenyl salicylen cyclic phosphate) + SX, TBPT (S, S, S -tributyl phosphorotrithioate) + SX, TPP (triphenyl phosphate) + SX.

A combination of the present component of the above group (f) with the present compound:
Anthraquinone (anthraquinone) + SX, chloralose + SX, acrep (acrep) + SX, butopyronoxyl + SX, camphor (camphor) + SX, d-camphor (d-camphor) + SX, carboxide (carboxide) ) + SX, dibutyl phthalate + SX, deet + SX, dimethyl carbate + SX, dimethyl phthalate + SX, dibutyl succinate + SX , Dibutyl adipate + SX, ethohexadiol + SX, hexamidide + SX, icaridin (icaridin) + SX, methoquin-butyl (methoquin-butyl) + SX, methyl neodecanamide (Methylneodecanamide) + SX, 2- (octylthio) ethanol (2- (octylthio) ethanol) + SX, butoxypolypropylene glycol (butoxypolyglycol glycol) + SX, oxamate + SX, quwenzhi + SX, quyingding + SX, zengxiaon + SX, Les Bemid (rebemide) + SX, copper naphthenate (copper naphthenate) + SX, zinc naphthenate (zinc naphthenate) + SX.

Combinations of the present component of the above group (g) with the present compound:
Bis (tributyltin) oxide (bis (tributyltin) oxide) + SX, allicin (allicin) + SX, bromoacetamide (bromoacetamide) + SX, cloetocarb (s) + SX, copper sulfate (S copper sulfate) + SX, fentin (fentin) ) + SX, iron (III) phosphate (ferric phosphate) + SX, metalaldehyde + SX, niclosamide (niclosamide) + SX, pentachlorophenol + SX, sodium pentachlorophenoxide + SX, tazimcarb + SX, tralopyril + SX, trifenmorph + SX.

Combinations of the Compound of the Above Group (h) with the Compound:
(E) -2-hexenal + SX, (E) 2-octadecenal + SX, (E) -4-tridecen-1-yl acetate + SX, (E) 5-decen-1-yl acetate + SX, (E) -5-decen-1-ol + SX, (E) -3, 3-dimethylcyclohexylideneacetaldehyde + SX, (E) -7-dodecen-1-yl acetate + SX, (E) -8-dodecen-1 -yl acetate + SX, (E) -9-dodecen-1-yl acetate + SX, (E) -10-hexadecenal + SX, (E) -11-hexadecen-1-yl acetate + SX, (E)- 11-tetradecen-1-yl acetate + SX, (E) -11-tetradecen-1-ol + SX, (E) -4-tridecen-1-yl acetate + SX, (E) -6-methylhept-2- en-4-ol + SX, (Z) -2- (3, 3-dimethylcyclohexylidene) ethanol + SX, (Z) 4-decen-1-yl acetate + SX, (Z) -4-tridecen-1- yl acetate + SX, (Z) -5-decen-1-yl acetate + SX, (Z) -5-decen-1-ol + SX, (Z) -7-tetradecenal + SX, (Z) -7- dodecen-1-yl acetate + SX, (Z) -8-dodecen-1-yl acetate + SX, (Z) -9-dodecen-1-yl acetate + SX, (Z) -8-dodecen-1-ol + SX, (Z) -9-hexadecenal + SX, (Z) -10-hexadecen-1-yl acetate + SX, (Z) -11-hexadecen-1-ol + SX, (Z) -11-hexadecenal + SX, (Z) -11-hexadecen-1-yl acetate + SX, (Z) -11-octadecenal + SX, (Z) -13-octadecenal + SX, (Z) -hexad ec-13-en-11-yn-1-yl acetate + SX, (Z) -13-octadecenal + SX, (Z) -icos-13-en-10-one + SX, (Z) -7-tetradecenal + SX, (Z) -tetradec-9-en-1-ol + SX, (Z) -9-tetradecen-1-yl acetate + SX, (Z) -11-tetradecen-1-yl acetate + SX, ( Z) -13-icosen-10-one + SX, (Z, E) -7,11-hexadecadien-1-yl acetate + SX, (Z, E) -9,12-tetradecadien-1-yl acetate + SX , (E, Z) -4,10-tetradecadien-1-yl acetate + SX, (E, E) -8,10-dodecadien-1-ol + SX, (E, E) -10,12-hexadecadienal + SX, (E, E) -9, 11-tetradecadien-1-yl acetate + SX, (E, Z) -2, 13-octadecadien-1-ol + SX, (E, Z) -3, 13-octadecadien -1-ol + SX, (E, Z) -2,13-octadecadien-1-yl acetate + SX, (E, Z) -3,13-octadecadien-1-yl acetate + SX, (E, Z) -7,9-dodecadien-1-yl acetate + SX, (E, E) -7,9-dodecadien-1-yl acetate + SX, (Z, E) -9,12-tetradecadien-1-yl acetate + SX, (Z, E) -9, 11-tetradecadien-1-yl acetate + SX, (Z, E) -7, 11-hexadecadien-1-yl acetate + SX, (Z, Z) -3, 13- octadecadien-1-ol + SX, (Z, Z) -4, 7-decadien-1-yl acetate + SX, (Z, Z) -3, 13-octadecadien-1-yl acetate + SX, (Z, Z) ) -7,11-hexadecadien-1-yl acetat e + SX, (Z, Z, E) -7, 11, 13-hexadecatrinal + SX, (5R) -5-[(1Z) -1-decen-1-yl] dihydro-2 (3H) -furanone + SX, (2R, 5R) -ethyl-1,6-dioxaspiro [4,4] nonane + SX, (2R, 5S) -ethyl-1,6-dioxaspiro [4,4] nonane + SX, (4R, 8R ) -4,8-dimethyldecanal + SX, (4R, 8S) -4,8-dimethyldecanal + SX, 2,4-dimethyl-5-ethyl-6,8-dioxabicyclo [3,2,1] octane + SX, (-)-4-methyl-3-heptanol + SX, 1,7-dioxaspiro [5,5] undecane + SX, 3-carene + SX, 3-methylcyclohex-2-en-1-one + SX, 14- methyloctadec-1-ene + SX, 4-methylnonan-5-ol + SX, 4-methylnonan-5-one + SX, 4- (3-oxobutyl) phenyl acetate + SX, dodecyl acetate + SX, dodeca-8, 10 -dien-1-yl acetate + SX, ethyl (2E, 4Z) -decadienoate + SX, ethyl 4-methyloctanoate + SX, methyl 2, 6, 10-trimethyldodecanoate + SX, tetradecan-1-ol + SX, tetradec-11 -en-1-ol + SX, tetradec-11-en-1-yl acetate + SX, tridec-4-en-1-yl acetate + SX, (3S, 6R) -3-methyl-6-isopropenyl-9 -decen-1-yl acetate + SX, (3S, 6S) -3-methyl-6-isopropenyl-9-decen-1-yl acetate + SX, alpha-multistriatin + SX, alpha-pinene + SX, endo-brevicomin + SX, exo-brevicomin + SX, camphene + SX, coddlelure + SX, codlemone + SX, cuelure + SX, disparlure + SX, dominicalure + SX, eugenol + SX, farnesol + SX, ferrolure + SX, frontalin + + gossyplure + SX, grandlure + SX, grandlure I + SX, grandlure II + SX, grandlure III + SX, grandlure IV + SX, hexalure + SX, ipsdienol + SX, ipsenol + SX, japonilure + SX, lineatin + SX, litlue + SX looplure + SX, medurere + SX, megatomoic acid + SX, methyl eugenol + SX, muscalure + SX, nerolidol + SX, orfralure + SX, oryctalure + SX, ostramone + SX, rhyncolure + SX, siglure + +, sulcatol + SX, trimedlure + SX, trimedlure A + SX, trimedlure B1 + SX, trimedlure B2 + SX, trimedlure C + SX, trunc-call + SX, (E) -verbanol + SX, (Z) -verbanol + SX, trans-verbenol + SX, (S) -verbenone + SX.

Combinations of the Compound of the Group (i) with the Compound:
2,3,6-TBA (2,3,6-trichlorobenzoic acid) + SX, 2,3,6-TBA dimethyl ammonium (2,3,6-TBA-dimethylammonium) + SX, 2,3,6-TBA Lithium salt (2,3,6-TBA-lithium) + SX, 2,3,6-TBA potassium salt (2,3,6-TBA-potassium) + SX, 2,3,6-TBA sodium salt (2 , 3,6-TBA-sodium) + SX, 2,4-D + SX, 2,4-D choline salt (2,4-D choline salt) + SX, 2,4-D BAPMA salt (2, 4 -DN, N-bis (3-aminopropyl) methylamine salt) + SX, 2,4-D 2-butoxypropyl (2,4-D-2-butoxypropyl) + SX, 2,4-D 2-ethylhexyl (2 , 4-D-2-ethylhexyl) + SX, 2,4-D 3-butoxypropyl (2,4-D-3-butoxypropyl) + SX, 2,4-D ammonium (2,4-D-ammonium) + SX, 2,4-D butytyl (2,4-D-butyl) + SX, 2,4-D butyl (2,4-D-butyl) + SX, 2,4-D diethylammonium (2,4 -D-diethylammonium) + SX, 2,4-D dimethylammonium (2,4-D-dimethylammonium) + SX, 2,4-D diolamine salt (2,4-D-diolamine) + SX, 2, 4 -D dodecyl ammonium (2,4-D-dodecyl lammonium) + SX, 2,4-D ethyl (2,4-D-ethyl) + SX, 2,4-D hep Ammonium (2,4-D-heptylammonium) + SX, 2,4-D isobutyl (2,4-D-isobutyl) + SX, 2,4-D isooctyl (2,4-D-isooctyl) + SX, 2,4-D isopropyl (2,4-D-isopropyl) + SX, 2,4-D isopropyl ammonium (2,4-D-isopropylammonium) + SX, 2,4-D lithium salt (2,4-D) -lithium) + SX, 2,4-D meptyl (2,4-D-mepty) + SX, 2,4-D methyl (2,4-D-methyl) + SX, 2,4-D octyl (2) , 4-D-octyl) + SX, 2,4-D pentyl (2,4-D-pentyl) + SX, 2,4-D-propyl (2,4-D-propyl) + SX, 2,4- D sodium salt (2,4-D-sodium) + SX, 2,4-D tefuryl (2,4-D-tefuryl) + SX, 2,4-D tetradecyl ammonium (2,4-D-tetradecylammonium) + SX, 2,4-D triethylammonium (2,4-D-triethylammonium) + SX, 2,4-D tris (2-hydroxypropyl) ammonium (2,4-D-tris (2-hydroxypropyl) ammonium) + SX, 2,4-D trolamine salt (2,4-D-trolamine) + SX, 2,4-DB + SX, 2,4-DB choline salt (2,4-DB choline salt) + SX, 2 , 4-DB BAPMA salt (2,4-DB N, N-bis (3-aminopropyl) methylamine salt) + SX, 2,4-DB butyl (2,4-DB-butyl) + SX, 2,4-DB dimethylammonium (2,4-DB-dimethylammonium) + SX, 2,4-DB isooctyl (2,4-) DB-isoctyl) + SX, 2,4-DB potassium salt (2,4-DB-potassium) + SX, 2,4-DB sodium salt (2,4-DB-sodium) + SX, acetochlor (acetochlor) + SX, Acifluorfen (acifluorfen) + SX, Acifluorfen Sodium Salt (acifluorfen-sodium) + SX, Aclonifen (Aclonifen) + SX, ACN (2-amino-3-chloronaphthalene-1,4-dione) + SX , Alachlor + SX, alloxydim + SX, ametrine (ametryn) + SX, amicarbazone (amicarbazone) + SX, amidosulfuron (Amidosulfuron) + SX, aminocyclopyrachlor (aminocyclopyrachol) + SX, amino Cyclopyracyl methyl (aminocyclopyrachlor-methyl) + SX, aminocyclopyraclor potassium salt (aminocyclopyrachlor-potassium) + SX, aminopyralid (aminopyralid) + SX, aminopyralidcholine salt (amino pyralid choline salt) + SX, aminopyralid potassium salt (aminopyralid-potassium) + SX, aminopyralid tris (2-hydroxypropyl) ammonium (aminopyralid-tris (2-hydroxypropyl) ammonium)) + SX, amiprophos methyl (amiprophos -methyl) + SX, amitrole (amitrole) + SX, anilophos (anilofos) + SX, asulam (asulam) + SX, atrazine (atrazine) + SX, azaphenidine (azafenidin) + SX, azimsulfuron (azimsulfuron) + SX, beflubutamide (beflubutamid) + SX, benazolin-ethyl (benazolin-ethyl) + SX, bencarbazone (bencarbazone) + SX, benfluralin + SX, benfuresate + SX, bensulfuron (bensulfuron) + SX, bensulfuron-methyl (bensulfuron) methyl) + SX, bensulide + SX, bentazon (venta) + SX, benthiocarb + SX, benzfendizone + SX, benzobicycone (benzobicyc) lon) + SX, benzophenap (benzofenap) + SX, benzthiazuron (benzthiazole) + SX, bialaphos (bialafosbialaphos) + SX, bicyclopyrone + SX, bifenox + SX, bispyribac + SX, Bispyribac sodium salt (bispyribac-sodium) + SX, bixlozone + SX, bromacil (bromacil) + SX, bromobutide + SX, bromophenoxim + SX, bromoxynil + SX, bromoxynil Octanoate (bromoxynil-octanoate) + SX, butachlor (+), SX, butafenacil (+) SX, butamifos (+) SX, butroxydim (butroxydim) + SX, butylate (+) SX, caffenstrole (cafenstrole) + SX, carbetamide + SX, carfentrazone (carfentrazone) + SX, carfentrazone ethyl (carfentrazone-ethyl) + SX, chloromethoxyphen (chlomethoxyfen) + SX, Chloramben (chloramben) + SX, chloridazon (chloridazon) + SX, chlorimuron (chlorimuron) + SX, chlorimuron ethyl (chlorimuron-ethyl) + SX, chlorbromuron (chlorobromuron) + SX, chlorotoluron + sx, chloroxron (chloroxuron) + SX, chlorpropham + SX, chlorsulfuron (chlorosulfuron) + SX, chlorthal dimethyl (chlorothal-dimethyl) + SX, chlorthiamide + SX, cinidone (cinidon) + SX, cinidone ethyl (Cinidon-ethyl) + SX, Cinmethylin + SX, Cinosulfuron (Cinosulfuron) + SX, Clethodim (clethodim) + SX, Clodinafop (clodinafop) + SX, Clodinafop Propargyl (clodinafop-propargyl) + SX, Chromazone clomazone) + SX, clomeprop + SX, clopyralid + SX, clopyralid choline salt + SX, clopyralid methyl (clopyralid-methyl) + SX, clopyralidolamine salt (clopyralid-olamine) + SX, clopyralid potassium salt (clopyralid-potassium) + SX, clopyralid tris (2-hydroxypropyl) ammonium (clopyralid-tris (2-hydroxypropyl) ammonium) + SX, chloran lam ( cloransulam) + SX, cloransulam methyl (cloransulam-methyl) + SX, cumyluron + SX, cyanazine (cyanazine) + SX, cycloate + SX, cyclopyranyl (cyclopyranil) + SX, cyclopyrimolate ( cyclopyrimorate) + SX, cyclosulfamuron + SX, cycloxydim + SX, cyhalofop (cyhalofop) + SX, cyhalofop-butyl + SX, dalapon + SX, dazomet ( dazomet) + SX, desmedipham + SX, desmetryn + SX, dialate (di-allate) + SX, dicamba (dicamba) + SX, dicamba choline salt + SX, dicamba BAPMA Salt (dicamba N, N-bis (3-aminopropyl) methylamine salt) + SX, dicambatrolamine salt (dicamba-trolamine) + SX, dicamba diglycolamine salt (dicamba-diglycolamine) + SX, dicamba dimethyl ammonium ( dicamba-dimethylammonium) + SX, dicambadiol amine salt (dicamba-diolamine) + SX, dicamba isopropylammonium (dicamba-isopropylammonium) + SX, dicamba methyl (dicamba-methyl) + SX, dicambaolamine salt (dicamba-olamine) + SX, dicamba potassium salt (dicamba-potassium) + SX, dicamba sodium salt (dicamba-sodium) + SX, diclobenil (dichlobenil) + SX, dicloprop choline salt (dichlorprop choline salt) + SX, dicloprop BAPMA salt (dichlorprop N, N-bis (3-aminopropyl) methylamine salt) + SX, dicloprop 2-ethylhexyl (dichlorprop-2-ethylhexyl) + SX, diclopropbutytyl (dichlorprop-butotyl) + SX, dicloprop dimethyl ammonium (Dichlorprop-dimethylammonium) + SX, dicloprop ethylammonium (dichlorprop-ethylammonium) + SX, dicloprop isoctyl (dichlorprop-isoctyl) + SX, dicloprop methyl (dichlorprop-methyl) + SX, dicloprop P (dichlorprop- P) + SX, dicloprop P choline salt (dichlorprop-P choline salt) + SX, dicloprop P BAPMA salt (dichlorprop-P N, N-bis (3-aminopropyl) methylamine salt) + SX, dicloprop P 2- Ethyl hexyl (dichlorprop-P-2-ethylhexyl) + SX, dicloprop P dimethylammonium (dichlorprop-P-dimethylammonium) + SX, dicloprop potassium salt (dichlorprop-potassium) + SX, dicloprop sodium salt (dichlorprop-sodium) + SX, Diclofop + SX, Diclofop-methyl + SX, Diclosulam + SX, Difenoxuron + SX, Difenzoquat + SX, Diflufenika (diflufenican) + SX, diflufenzopyr (diflufenzopyr) + SX, diflufenzopyr sodium salt (diflufenzopyr-sodium) + SX, dimeflon (dimefuron) + SX, dimepiperate (dimepiperate) + SX, dimethachlor (dimethachlor) + SX , Dimethamethrin (dimethametryn) + SX, dimethenamid (dimethenamid) + SX, dimethenamid P (dimethenamid-P) + SX, dinitramine + SX, dinoseb + SX, dinoterb + SX, diphenamide (diphenamide) + SX, diquat-dibromide (diquat-dibromide) + SX, DSMA (disodium methylarsonate) + SX, dithiopyr (dithiopyr) + SX, diuron (diuron) + SX, DNOC (2-methyl-4, 6-dinitrophenol) + SX , Esprocarb + SX, ethalfluralin + SX, etamethulfuron (ethametsulfuron) + SX, etamethsulfuron-methyl (ethametsulfuron-methyl) + SX, ethidimuron + SX, ethofumesate (ethofumesate + SX, Toxifene Ethyl (Ethoxyfen-Ethyl) + SX, Ethoxysulfuron (Ethoxysulfuron) + SX, Etobenzanide (Etobenzanid) + SX, Fenoxaprop (Fenoxaprop) + SX, Fenoxaprop-Ethyl (fenoxaprop-ethyl) + SX, Fenoxax Prop P (fenoxaprop-P) + SX, fenoxaprop P ethyl (fenoxaprop-P-ethyl) + SX, fenoxasulfone (fenoxasulfone) + SX, fenquinotrione + SX, fentrazamide + SX, Phenuron (fenuron) + SX, floproprop M (flamprop-M) + SX, flazasulfuron (flazasulfuron) + SX, florasulam (florasulam) + SX, florpirauxifen (florpyrauxifen) + SX, florpirauxifene benzyl ( florpyrauxifen-benzyl) + SX, fluazifop + SX, fluazifop-butyl + SX, fluazifop P (fluazifop-P) + SX, fluazifop-butyl (fluazifop-P-butyl) + SX, Luazolate (fluazolate) + SX, flucarbazone (flucarbazone) + SX, flucarbazone sodium salt (flucarbazone-sodium) + SX, flucetosulfuron (flucetosulfuron) + SX, flufenacet (flufenacet) + SX, flufenpyr (flufenpyr) + SX, flufenpyrethyl (flufenpyr-ethyl) + SX, flumetsulam + SX, flumetsulam (flumetsulam) + SX, flumimicrorac (flumiclorac) + SX, flumiclolac pentyl (flumiclorac-pentyl) + SX, flumi Oxazine (flumioxazin) + SX, fluometuron + SX, fluoroglycophene ethyl (fluoroglycofen-ethyl) + SX, flupoxam + SX, flupropanate + SX, flupyrsulfuron (flupyrsulfuron) + SX , Flupyrsulfuron-methyl-sodium + SX, flurenol + SX, fluridone + SX, flurochloridone (flurochloridone) ) + SX, fluoxypyr (fluroxypyr) + SX, fluoxypyrmeptyl (fluroxypyr-meptyl) + SX, flurtamon (flurtamone) + SX, fluthiaset (fluthiacet) + SX, fluthiacet methyl (fluthiacet)
-methyl) + SX, fomesafen (fomesafen) + SX, fomesafen sodium (fomesafen-sodium) + SX, foramsulfuron (foramsulfuron) + SX, fosamine (fosamine) + SX, glufosinate + SX, glufosinate ammonium Salt (glufosinate-ammonium) + SX, glufosinate P (glufosinate-P) + SX, glufosinate P ammonium salt (glufosinate-P-ammonium) + SX, glufosinate P sodium salt (glufosinate-P-sodium) + SX, glyphosate (glyphosphate) ) + SX, glyphosate choline salt (Glyphosate choline salt) + SX, glyphosate guanidine derivative salts (Glyphosate guanidine derivative salts) + SX, glyphosate isopropylamine salt (Glyphosate isopropylamine salt) + SX, glyphosate BAPMA salt N-glyphosphate (3-aminopropyl) methylamine salt) + SX, glyphosate ammonium salt (glyphosate-ammonium) + SX, glyphosate diammonium salt (glyphosate-diammonium) + SX, glypho Sodium phosphate (glyphosate-potassium) + SX, glyphosate sodium salt (glyphosate-sodium) + SX, glyphosate trimethium salt (glyphosate-trimethylsulfonylium) + SX, halauxifen (halauxifen) + SX, halauxifene methyl (halauxifen-methyl ) + SX, halosafen (halosafen) + SX, halosulfuron (halosulfuron) + SX, halosulfuron methyl (halosulfuron-methyl) + SX, haloxyfop (haloxyfop) + SX, haloxyfop-etoyl (haloxyfop-etotyl) + SX, Haloxyfop methyl (haloxyfop-methyl) + SX, Haloxyfop P (haloxyfop-P) + SX, Haloxyfop P etytyl (haloxyfop-P-etotyl) + SX, Haloxyfop P methyl (haloxyfop-P-methyl) + SX, Hexazinone hexazinone) + SX, imazamethabenz (imazamethabenz) + SX, imazamethabenzmethyl (imazamethabenz-methyl) + SX, imazamox (imazamox) + SX, imazamox ammonium salt (imazamox-ammonium) + SX, Imazapic (imazapic) + SX, imazapic ammonium salt (imazapic-ammonium) + SX, imazapyr (imazapyr) + SX, imazapyr isopropyl ammonium salt (imazapyr-isopropylammonium) + SX, imazaquin (imazaquin) + SX, imazaquin Kinammonium salt (imazaquin-ammonium) + SX, imazethapyr (imazethapyr) + SX, imazethapyr ammonium salt (imazethapyr-ammonium) + SX, imazosulfuron (imazosulfuron) + SX, indanofan (indanofan) + SX, indazifram (indifulam) SX, iodosulfuron (iodosulfuron) + SX, iodosulfuron methyl sodium (iodosulfuron-methyl-sodium) + SX, iodinesulfuron (iofensulfuron) + SX, ionfensulfuron sodium (iofensulfuron-sodium) + SX, ioxynil (ioxynil (ioxynil n) ) + SX, ioxynil octanoate (ioxynil-octanoate) + SX, ipfencarbazone (ipfencarbazone) + SX, isoproturon + SX, Isouron + SX, isoxaben + SX, isoxachlortole + SX, isoxafultole + SX, lactofen + SX, lenacil + SX, linuron linuron) + SX, maleic acid hydrazide (maleic hydrazide) + SX, MCPA choline salt (MCPA choline salt) + SX, MCPA BAPMA salt (MCPA N, N-bis (3-aminopropyl) methylamine salt) + SX, MCPA 2- Ethylhexyl (MCPA-2-ethylhexyl) + SX, MCPA Buttyl (MCPA-butyl) + SX, MCPA butyl (MCPA-butyl) + SX, MCPA Dimethylammonium (MCPA-dimethylammonium) + SX, MCPA Diolamine Salt (MCPA-diolamine salt ) + SX, MCPA ethyl (MCPA-ethyl) + SX, MCPA isobutyl (MCPA-isobutyl) + SX, MCPA isooctyl (MCPA-isoctyl) + SX, MCPA isopropyl (MCPA-isopropyl) + SX, MCPA methyl (MCPA-methyl) ) + SX, MCPA Allamine Salt (MCPA-olamine) + SX, MCPA Sodium Salt (MCPA-sodium) + SX, MCPA Trolamine Salt (MCPA-trolamine) + SX, M CPB (4- (4-chloro-2-methylphenoxy) butanoic acid) + SX, MCPB choline salt (MCPB choline salt) + SX, MCPB BAPMA salt (MCP B N, N-bis (3-aminopropyl) methylamine salt) + SX , MCPB ethyl (MCPB-ethyl) + SX, MCPB methyl (MCPB-methyl) + SX, MCPB sodium salt (MCPB-sodium) + SX, mecoprop choline salt (mecoprop choline salt) + SX, mecoprop BAPMA salt (mecoprop N salt , N-bis (3-aminopropyl) methylamine salt) + SX, mecoprop 2-ethylhexyl (mecoprop-2-ethylhexyl) + SX, mecoprop dimethylammonium (mecoprop-dimethylammonium) + SX, mecoprop diol amine salt (mecoprop-diolamine) ) + SX, mecoprop-ethadyl + SX, mecoprop isoctyl (mecoprop-isoctyl) + SX, mecoprop methyl (mecoprop-methyl) + SX, mecoprop potassium salt (mecoprop-potassium) + SX , Mecoprop sodium salt (mecoprop-sodium) + SX, mecoproptrolamine salt (mecoprop-trolamine) + SX, mecop P (mecoprop-P) + SX, mecoprop P choline salt (mecoprop-P choline salt) + SX, mecoprop P 2-ethylhexyl (mecoprop-P-2-ethylhexyl) + SX, mecoprop P dimethyl ammonium (mecoprop-P -dimethylammonium) + SX, mecoprop P-isobutyl (mecoprop-P-isobutyl) + SX, mecoprop P potassium salt (mecoprop-P-potassium) + SX, mefenacet + SX, mesosulfuron (mesosulfuron) + SX, mesosulfuron methyl (mesosulfuron-methyl) + SX, mesotrione + SX, metam (metam) + SX, metamifop + SX, metamitron + SX, metazachlor (metazachlor) + SX, metazosulfuron (metazosulfuron) + SX , Methabenzthiazole + SX, methiozolin + SX, methyldymron + SX, metobromuron + SX, metolachlor + SX, methosul (metosulsu) am) + SX, metoxuron + SX, metabuzin (metribuzin) + SX, methsulfuron (metsulfuron) + SX, metsulfuron methyl (metsulfuron-methyl) + SX, molinate (molinate) + SX, monolinuron (monolinuron) + SX , Naproanilide + SX, Napropamide + SX, Napropamide M (napropamide-M) + SX, Naptalam + SX, Neburon (neburon) + SX, Nicosulfuron (nicosulfuron) + SX, norflurazon (norflurazon ) + SX, oleic acid + SX, orbencarb + SX, orthosulfamuron + SX, oryzalin + SX, oxadiargyl + SX, oxadiazone + SX , Oxasulfuron (OXasulfuron) + SX, Oxadiclomefone + SX, Oxyfluorfen (oxyfluorfen) + SX, Paraquat (paraquat) + SX, Paraquat dichloride + SX, PE Rate (pebulate + SX, pelargonic acid + SX, pendimethalin + SX, penoxsulam + SX, pentanochlor + SX, pentoxazone (Pentoxazone) + SX, petoxamide ( pethoxamid) + SX, phenisopham + SX, fenmedipham + SX, picloram, picororinafen (picolinafen) + SX, pyrocolinafen (picolinafen) + SX, pinoxaden (pinoxaden) + SX , Piperophos + SX, pretilachlor + SX, primisulfuron (primisulfuron) + SX, primisulfuron methyl (primisulfuron-methyl) + SX, prodiamine (prodiamine) + SX, profluazole (profluazol) + SX, Propoxydim (profoxydim) + SX, Prometon (prometon) + SX, Promethrin (prometryn) + SX, Propachlor (propachlor) + SX, Propanil (propanil) + SX, Propaquihop (propa quizafop) + SX, propazine + SX, propham + SX, propisochlor + SX, propoxycarbazone + SX, propoxycarbazone sodium salt + SX, Propyrisulfuron + SX, propyzamide + SX, prosulfocarb + SX, prosulfuron (prosulfuron) + SX, pyraclonil + SX, pyrasulfotole + SX, pyrazolynate ) + SX, pyrazosulfuron (pyrazosulfuron) + SX, pyrazosulfuron-ethyl (pyrazosulfuron-ethyl) + SX, pyrazoxyfen (pyrazoxyfen) + SX, pyribenzoxim + SX, pyributicarb (pyributicarb) + SX, pyridiol , Pyridate + SX, pyriftalid + SX, pyriminobac (pyriminobac) + SX, pyriminobac-methyl (pyriminobac-methyl) + SX, Pyrimisulfan (pyrimisulfan) + SX, pyrithiobac (SX), pyrithiobac sodium salt (pyrithiobac-sodium) + SX, pyroxasulfone (pyroxasulfone) + SX, pyroxsulam (pyroxsulam) + SX, quinclorac (quinclorac) + SX, quinmerac + SX, quizalohop (quizalofop) + SX, quizalohop-ethyl (quizalofop-ethyl) + SX, quizalohop-tefuryl (quizalofop-tefuryl) + SX, quizalohop P (quizalofop-P) + SX, quizalohop P ethyl (quizalofop-P-ethyl) + SX, quizalo hop P tefuryl (quizalofop-P-tefuryl) + SX, rimsulfuron (rimsulfuron) + SX, saflufenacil (saflufenacil) + SX, cetoxidim (sethoxydim) + SX , EPTC (S-ethyl N, N-dipropylcarbamothioate) + SX, siduron (siduron) + SX, simazine (simazine) + SX, simetryn (simetryn) + SX, S-metolachlor (S-metolachlor) + SX, MSMA ( sodium hydrogen methylarsonate + SX, sulcotrione (s ulcotrione) + SX, sulfentrazone + SX, sulfometuron + SX, sulfometuron-methyl + SX, sulfosulfuron + SX, sweat + SX, TCA (2,2,2-trichloroacetic acid) + SX, tebutam + SX, tebuthiuron + SX, tefuryltrione + SX, tembotrione + SX, tepraloxydim (tepraloxydim) + SX, terbacil + SX, terbumeton + SX, terbutylazine + SX, terbutryn + SX, taktomemin A (thaxtomin A) + SX, tenilchlor (thenylchlor) + SX, thiazopyr ) + SX, thidiazimin + SX, thiencarbazone (thiencarbazone) + SX, thiencarbazone methyl (thiencarbazone-methyl) + SX, thifensulfuron + SX, thifensulfuron methyl (thifensulfuron-methyl) + SX , Thiafenacil (Tiafenacil) + SX, Thiocarbasil (Tiocarbazil) + SX, Tolpyralate (Tolpyralate) + SX, Topramezone (topramezone) + SX, Tralcoxydim (tralkoxydim) + SX, Triafamone (triafamone) + SX, Tri-Alate + SX, triasulfuron + SX, triaziflam + SX, tribenuron + SX, tribenuron-methyl + SX, triclopyr + SX, triclopyrbutyl ( triclopyr-butotyl) + SX, triclopyr-ethyl + SX, triclopyr-triethylammonium + SX, tridiphane + SX, trietazine + SX, trifloxysulfuron (trifloxysulfuron) ) + SX, trifloxysulfuron sodium salt (trifloxysulfuron-sodium) + SX, trifludimoxazine + SX, trifluralin + SX, Flusulfuron (triflusulfuron) + SX, triflusulfuron methyl (triflusulfuron-methyl) + SX, tritosulfuron (tritosulfuron) + SX, burnerate (vernolate) + SX, 2-[(2,4-dichlorophenyl) methyl]- 4,4-dimethyl-1,2-oxazolidin-3-one + SX, Ethyl [(3- {2-chlor
o-4-fluoro-5- [3-methyl-4- (trifluoromethyl) -2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl] phenoxy} pyridin-2-yl) oxy] acetate (353292-31-6) + SX.

Combinations of the Compound of the Group (j) with the Compound:
(Abrariata caucasica) + SX, aquaria spp. (Acuaria spp.) + SX, Agamelmis decaudata (Agamermis decaudata) + SX, Agrobacterium radiobacter strain K1026 (Agrobacterium radiobacter strain K1026) + SX, Aumobacterium radiobactus strain K84 (Agrobacterium radiobacter strain K84) + SX, Agrobacterium vitis strain VAR 03-1 (Agrobacterium vitis strain VAR 03-1) + SX, Allantonea spp. (Allantone spp.) + SX, Altanaria des toluene 59 strains (Alternaria destruens strain 59) + SX, Alternaria destruens + SX, Ampellomyces quisqualis strain AQ 10 (Amemelomyces quisqualis strain AQ10) + SX, Amfimel miss spp. (Amhimermiss spp.) + SX, Ars Robotris dactyloides (Arthrobotrys dactyloides) + SX, Arturobotrys superba (Arthrobotrys superba) + SX, Asherosonia allerodes (Aschersonia aleyrodes) + SX, Aspergillus flavus AF36 strain (Aspergillus flavus strain AF36) + SX, Aspergillus flavus strain NRRL 21 882 (Aspergillus flavus strain NRRL 21 882) + SX, aureobasidium pullulans DSM14940 strains. , Aureobasidium pullulans DSM 14941 strain (Aureobasidium pullulans strain DSM 14941) + SX, Azopyrilium (Azopirillum) + SX, azorhizobium caulinodans ZB-SK-5 strain (Azorhizobiuma caulinodans strain ZB-SK-5) + SX, Strain (Azotobacter chroococcum strain H23) + SX, Azotobacter chroocucum + SX, Azotobacter cyst (Azotobacter cyst) + SX, Azotobacter vinelan ate strain 24 (Azot SX, Bacillus acidocaldarius + SX, Bachi L. acidoterrestris + SX, Bacillus albolactis + SX, Bacillus alcalophilus + SX, Bacillus alvei + SX, Bacillus aminoglucosidicus (Bacillus aminoglucosidicus) + SX, Bacillus aminovorans (Bacillus aminovorans) + SX, Bacillus amyloliquefaciens (AveoTM EZ Nematicide) (Bacillus amyloliquefaciens (AveoTM EZ Nematicide)) + SX, Bacillus amyloliquefaciens (AveoTM EZ Nematicide) Faciens AT332 strain (Bacillus amyloliquefaciens strain AT332) + SX, Bacillus amyloliquefaciens B3 strain (Bacillus amyloliquefaciens strain B3) + SX, Bacillus amyloliquefaciens strain D747 (Bacillus amyloliquefaciens strain D747) + SX, Bacillus amilo, Liquefaciens DB101 strain (Bacillus amyloliquefaciens strain DB101) + SX, Bacillus amyloliquefaciene DB102 strain (Bacillus amyloliquefaciens strain DB102) + SX, Bacillus amyloliquefaciens FZB strain (Bacillus amyloliquefaciens strain FZB24) + SX, Bacillus amyloliquefaciens strain FZB42 (Bacillus amyloliquefaciens strain FZB42), Ens GB03 strain (Bacillus amyloliquefaciens strain GB03) + SX, Bacillus amyloliquefaciens strain IN937a (Bacillus amyloliquefaciens strain IN937a) + SX, Bacillus amyloliquefaciens strain MBI 600 (Bacillus amyloliquefaciens strain MBI600) Faciens strain QST 713 (Bacillus amyloliquefaciens strain QST 713) + SX, Bacillus amyloliquefaciens isolate B 246 strain (Bacillus amyloliquefaciens isolate strain B 246) + SX, Bacillus amyloliquefaciens strain F 727 (Bacillus amyloliquefaciens strain FX, SX, Bacillus amyloliquefaciens plantarum subspecies strain D747 (Bacillus a myloliquefaciens subsp. Plantarum strain D747) + SX, Bacillus amylolyticus + SX, Bacillus aneuronilyticus + SX, Bacillus agri (Bacillus agri) + SX, Bacillus atrophaeus (Bacillus atrophaeus) atrophaeus) + SX, Bacillus azotoformans + SX, Bacillus badius (Bacillus badius) + SX, Bacillus cereus strain BP01 (Bacillus cereus strain BP01) + SX, Bacillus cereus CNCM I-1562 ( Bacillus cereus CNCM strain I-1562) + SX, Bacillus quitanosporus strain AQ 746 (Bacillus chitinosporus strain AQ 746) + SX, Bacillus quitinosporus CM-1 strain (Bacillus chitinosporus strain CM-1) + SX, Bacillus circulans (Bacillus circulans) ) + SX, Bacillus coagulans strain TQ 33 (Bacillus coagulans strain TQ 33) + SX, Bacillus fostidiosas (Bacillus fastidiosus) + SX, Bacillus · Films GB-126 strain (Bacillus firmus strain GB-126) + SX, Bacillus films I-1582 strain (Bacillus firmus strain I-1582) + SX, Bacillus lacticola (Bacillus lactola) + SX, Bacillus lactimulbas (Bacillus firmicola) Bacillus lactimorbus) + SX, Bacillus lactis + SX, Bacillus lautus + SX, Bacillus lentimorbus + SX, Bacillus lentus + SX, Bacillus licheniformis HB -2 strains (Bacillus licheniformis strain HB-2) + SX, Bacillus licheniformis strain SB 3086 (Bacillus licheniformis strain SB 3086) + SX, Bacillus marocanus (Bacillus maroccanus) + SX, Bacillus medusa (Bacillus medusa) + SX, Bacillus · Megathelium strain YFM3.25 (Bacillus megaterium strain YFM3.25) + SX, Battisul-methylotrophicus BAC-9912 (Bacillus methylotrophicus strain BAC-9912) + SX, Bacillus methiens (Baci llus metiens) + SX, Bacillus mojavensis strain SR11 (Bacillus mojavensis strain SR11) + SX, Bacillus mycoides strain AQ 726 (Bacillus mycoides strain AQ 726) + SX, Bacillus mycoides isolate J (Bacillus mycoides isolate J) + SX, Bacillus · Nematode (Bacillus nematocida) + SX, Bacillus nigrificans (S. c ) + SX, Bacillus pumilus strain AQ 717 (Bacillus pumilus strain AQ 717) + SX, Bacillus pumilus strain BUF-33 (Bacillus pumilus strain BUF-33) + SX, Bacillus pumilus strain GB 34 (Bacillus pumilus strain GB34 strain) + SX , Bacillus pumilus QST2808 strain (Bacillus pumilus strain QST2808) + SX, Bacillus siamensis (Bacillus siamensis) + SX, Bacillus simplex CGF 2856 strain (Bacillus s implex strain CGF 2856) + SX, Bacillus smithii + SX, Bacillus sp. strain AQ 175 (Bacillus sp. strain AQ 175) + SX, Bacillus sp. strain AQ 177 (Bacillus sp. strain AQ 177) + SX, Bacillus sp. Strain AQ 178 (Bacillus sp. Strain AQ 178) + SX, Bacillus sphaericus strain 2362 (Bacillus sphaericus strain 2362) + SX, Bacillus sphaericus ABTS 1743 (Bacillus sphaericus strain ABTS 1743) + SX, Bacillus sphaericus serotype H5a5b strain (Bacillus sphaericus Serotype strain H5a5b) + SX, Bacillus subtilis AQ153 strain (Bacillus subtilis strain AQ153) + SX, Bacillus subtilis AQ 743 strain (Bacillus subtilis strain AQ 743) + SX, Bacillus subtilis D747 strain (Bacillus subtilis strain D747) + SX, Bacillus · S. subtilis strain DB101 (Bacillus subtilis strain DB101) + SX, B. subtilis strain FZB24 (Bacillus subtilis strain FZB24) + SX, B. subtilis strain GB03 (Bacillus subtilis strain GB03) + SX, Bactyl · S. subtilis HAI 0404 strain (Bacillus subtilis strain HAI 0404) + SX, Bacillus subtilis IAB / BS03 strain (Bacillus subtilis strain IAB / BS03) + SX, B. subtilis MBI 600 (Bacillus subtilis strain MBI 600) + SX, Bacillus subtilis QST 30002 AQ 30002 strain (Bacillus subtilis strain QST 30002 / AQ 30002) + SX, Bacillus subtilis QST 30004 / AQ 30004 strain (Bacillus subtilis strain QST 30004 / AQ 30004) + SX strain, B. subtilis strain QST 713 (Bacillus subtilis strain QST 713) + SX, SX strain (Bacillus subtilis strain QST 714) + SX, Bacillus subtilis var Amyloliquefaciens FZB24 (Bacillus subtilis var. Amyloliquefaciens strain FZB24) + SX, Bacillus subtilis strain Y1336 (Bacillus subtilis strain Y1336) + SX, Bacillus subtilis subspecies Natto (Bacillus subtillis subsp. Natto) + SX, Bacillus tequilenensis strain NII-0943 (Bacillus tequilenensis strain NII- 0943) + SX, Bacillusュ ー リ ュ ー ン シ ス シ AQ 52 (Bacillus thuringiensis strain AQ 52) + SX, Bacillus thuringiensis BD # 32 (Bacillus thuringiensis strain BD # 32) + SX, bacillus thuringiensis CR-371 (Bacillus thuringiensis strain CR- 371) + SX, Bacillus thuringiensis strain EX 297 512 (Bacillus thuringiensis strain EX 297 512) + SX, Bacillus thuringiensis strain E. subspecies ABTS-1857 (Bacillus thuringiensis subsp. Aizawai strain ABTS-1857) + SX, Bacillus thuringiensis sp. Subspecies GC -91 strain (Bacillus thuringiensis subsp. Aizawai strain GC-91) + SX, Bacillus thuringiensis subsp. Serotype H-7 (Bacillus thuringiensis subsp. Aizawai Serotype H-7) + SX, Bacillus thuringiensis cristae subsp. Species ABTS 351 (Bacillus thuringiensis subsp. Kurstaki strain ABTS 351) + SX, Bacillus thuringiensis cristae subsp. BMP 123 (Bac Bacillus thuringiensis subsp. Kurstaki strain BMP123) + SX, Bacillus thuringiensis cristarch subsp. strain EG234 (Bacillus thuringiensis subsp. Kurstaki strain EG234) + SX, Bacillus thuringiensis subsp. EG7841) + SX, Bacillus thuringiensis · cristaea subsp. EVB 113-19 (Bacillus thuringiensis subsp. Kurstaki strain EVB 113-19) + SX, Bacillus thuringiensis cristae subsp. F 810 (Bacillus thuringiensis subsp. Kurstaki strain F810) + SX, Bacillus thuringiensis cristaea subsp. HD-1 strain (Bacillus thuringiensis subsp. Kurstaki strain HD-1) + SX, Bacillus thuringiensis subsp. PB54 strain (Bacillus thuringiensis subsp. Kurstaki strain PB54) + SX , Bacillus thuringiensis cristae subsp. Strain SA-11 (Bacillus thuringiensis subsp. Kurstaki strain SA-11) + SX, Bacillus thuringiensis cristarch subsp. strain SA-12 (Bacillus thuringiensis subsp. Kurstaki strain SA-12) + SX, Bacillus thuringiensis morisoni subspecies (Bacillus thuringiensis subsp. morrisoni) + SX, Bacillus thuringiensis subsp. Strain NB176 (Bacillus thuringiensis subsp. Tenebriosis strain NB 176) + SX, Bacillus thuringiensis thuringiensis subsp. Strain MPPL 002 (Bacillus thuringiensis subsp. Thuringiensis strain MPPL 002) + SX, Bacillus sp. Thuringiensis korumeri variety (Bacillus thuringiensis subsp. Var. Colmeri) + SX, Bacillus thuringiensis dermostasis variant 24-91 strain (Bacillus thuringiensis subsp. Var. Darmstadiensis strain 24-91) + SX, Bacillus thuringiensis・ Dendrolimus variant (Bacillus thuringiensis subsp. Var. Dendrolimus) + SX, Bacillus thuri Genshisu Galleria variants (Bacillus thuringiensis subsp. Var. Galleriae) + SX, Bacillus thuringiensis Isla Ellen cis subspecies BMP144 share (Bacillus thuringiensis subsp. Israelensis strain BMP144) + SX, Bacillus
S. thuringiensis israelensis subspec. AM65-52 strain (Bacillus thuringiensis subsp. Israelensis strain AM 65-52) + SX, Bacillus thuringiensis japonensis variety buibui strain (Bacillus thuringiensis subsp. Var. Japonensis strain buibui) + SX , Bacillus thuringiensis aezipti variant (Bacillus thuringiensis subsp. Var. Aegypti) + SX, Bacillus thuringiensis 7216 variant (Bacillus thuringiensis var. 7216) + SX, Bacillus thuringiensis San Diego variant M-7 strain (Bacillus thuringiensis var. sandiego strain M-7) + SX, Bacillus thuringiensis T36 variant (Bacillus thuringiensis var. T36) + SX, Bacillus uniflagellate + SX, Bacillus uniflagellatus + SX, bacteria spp. (bacteria spp.) + SX, a bacteriophage of Mycobacterium mychiganesis (bacteriophage of Clavibac ter michiganesis) + SX, Bacteriophage active against Xanthomonas campestris pv. vesicatoria and Pseudomonas syringae pv. tomato + SX, Bacteriophage active against Clavibacter michiganensis subsp. SX, Bovelia basiana strain ATCC 74040 (Beauvelia bassiana strain ATCC 74040) + SX, Bovelia basiana strain GHA (Beauvelia bassiana strain GHA) + SX, bovelia basiana strain PPRI 5339 (Beauvelia bassiana strain PPRI 5 339) + Beauveria brongniartii) + SX, Bedingia siridicola (Beddingia siridicola) + SX, Bobienema spp. (Bovienema spp.) + SX, Brevibacillus brevis strain 2904 (Brevibacillus brevis strain 2904) + SX, Brevibacillus brevis strain SS86-3 (Brevibacillus brevis strain SS86-3) + SX, Brevibacillus brevis strain SS86-4 (Brevibacillus brevis strain SS86-4) + SX, Brevi Bacillus brevis strain SS86-5 (Brevibacillus brevis strain SS86-5) + SX, Brevibacillus laterosporus strain ATCC 64 (Brevibacillus laterosporus strain ATCC 64) + SX, Brevibacillus laterosporus BPM 3 strain (Brevibacillus lateros probulus) Strains (Brevibacilus latrosporus strain strain G4) + SX, Brevibacillus lateros laterosporus strain strain latinosporus strain NCIMB strain 1419 (Brevibacillus laterosporus strain strain NCIMB strain 1419; Brevibacillus laterosporus strain strain NCIMB strain 1419; Brevibacillus latiosporus strain strain NCIM ) + SX, Burkholderia cepacia-Wisconsin type J 82 (Burkholderia cepacia type Wisconsin strain J 82) + SX, Burkholderia cepacia-Wisconsin type M 54 (Burkholderia cepacia type Wisconsin strain M 54) + SX, Burkholderia · Sephasia (Burkhol deria cepacia) + SX, Burkholderia gradii strain BA-7 (Burkholderia gladii strain BA-7) + SX, Burkholderia linagesis A 396 (Burkholderia rinojensis strain A 396) + SX, Cameronia spp. (Cameronia spp.) + SX, Dian Thistle fangas (Canadian thistle fungus) + SX, Candida oleophila O strain (Candida oleophila strain O) + SX, Candida cytoana (Candida saitoana) + SX, Candida spp. (Candida spp.) + SX, Ketomium cupreum + SX, Chitodiodiella ovofilamenta + SX, Chromobacterium subtsugae strain PRAA4-1T (Chromobacterium subtsugae strain PRAA4-1T) + SX, cladosporium・ Cladosporoides H39 strain (Cladosporium cladosporioides strain H39) + SX, Clonostachys rosea + SX, Conidiobolus obscurus (Conidiobolus obscurus) + SX, Conio Sillium minitans CGMCC 83 25 (Coniothyrium minitans strain CGMCC 8325) + SX, Coniocilli minitons CON / M / 91-08 (Coniothyrium minitans strain CON / M / 91-08) + SX, Contrentien sp sp. (Contratylenchus spp.) + SX, Cryptococcus albidus (cryptococcus albidus) + SX, Colicimelmis spp. (Culicimermis spp.) + SX, Dactylella ellipsospora + SX, D. (Delftia acidovorans strain RAY 209) + SX, Dilophosphora alopecuri + SX, Diprotriaena spp. (Diplotriaena spp.) + SX, Empidomermis spp. + SX, Erwinia carotovora subsp. Carotobola CGE 234 M (Erwinia carotovora subsp. Carotovora strain CGE 234 M 403) + SX, Filip Ebi mermis rape sandra (Filipjevimermis leipsandra) + SX, Fusarium oxysporum Fo 47 strain (Fusarium oxysporum strain Fo 47) + SX, Fusarium praliferatum (Fusarium proliferatum) + SX, Gastromello miss spp. (Gastromermis spp.) + SX, Gl (Gliocladium catenulatum strain J1446) + SX, Gluconacetobacter diazotrophicus (Gluconacetobacter diazotrophicus) + SX, Gongylonema spp. (Gongylone spp. + SX, Harpin protein (Harpin protein) + SX, Heterolabditis bacteriophora + SX, Heterolabditis baujardi (Heterorhabditis baujardi) + SX, Heterolabditis heliothisis (Heterorhabditis heliothisi + , Heterolabditis Indica (Heterorha bditis indica) + SX, Heterolabditis marelatus + SX, Heterolabditis megidis + SX, Heterolabditis zealandica (Heterorhabditis zealandica) + SX, + SX, Hirstella minnesotensis (Hirsutella minnesotensis) + SX, Hirstella rossiliensis (Hirsutella rsiliensis) + SX, Hirstella thompsonii (Hirsutella thompsonii) + SX, Hydromelmis spp. (Hydromermis spp.) + SX, Isaria Fumosorosea (Isaria fumosorosea) + SX, Isomermis spp. (Isomermis spp.) + SX, Lactobacillus acidophilus + SX, Lactobacillus brevis (Lactobacillus brevis) + SX, Lactobacillus plantarium Lactobacillus spp. (Lactobacillus spp.) + SX, Lagenidium giganteum (Lage) nidium giganteum) + SX, Lecanicillium ・ Lecani KV 01 strain (Lecanicillium lecanii KV 01) + SX, Conidia of Lecanicillium ・ lecani strain DAOM198499 (Lecanicillium lecanii conidia of strain DAOM198499) + SX, Recanicillium ・ Lecani DAOMl ich of strain DAOM216596) + SX, Lecanicillium musk potassium Ve6 strain (Lecanicillium muscarium (previously Verticillium lecanii) strain Ve6) + SX, Limomelmis spp. (Limnomermis spp.) + SX, Rhizobacterium antibiotics strain 13-1 ( Lysobacter antibioticus strain 13-1) + SX, Lysobacter enzymogenes C3 strain (Lysobacter enzymogenes strain C3) + SX, Maupasina weissi + SX, Melmis nigrescens (Mermis nigrescens) + SX, Mesomermis spp.) + SX, Metarhizium anisopriae strain F 52 (Metarhizium anisopliae strain F 52) + SX, Metarhidium anisopriae Lidham variant (Metarhizium anisopliae var. Acridum) + SX, metalidium anisopriae anisopliae variant BIPESCO 5 / F52 strain (Metarhizium anisopliae var. -Dimerium (metschnikowia dimerum) + SX, methyconia bifurcticola NRRLY-30752 (Metschnikowia fructicola strain NRRLY-30752) + SX, Microsphaeropsis ochracea + SX, monaculosporium SX, Mucor hiemalis + SX, Muscodor albus strain 620 (Muscodor albus strain 620) + SX, Muscodor albus QST 20799 strain (Muscodor albus strain QST 20799) + SX, Muscodor albus SA13 strain (Muscodor albus strain strain SA13) + SX, Muscodor roseus strain A3-5 (Muscodor roseus strain A3-5) + SX, Myotesium Verkaria AARC-0255 strain (Myrothecium verrucaria strain AARC-0255) + SX, Neomesomelmis spp. (Neomesomermis spp.) + SX, Neoparasitylenchus rugulosi (Neoparasis lenchus rugulosi) + SX, Nomuraea Lily CG128 strain (Nomuratraini + SX, Nomura Air Lily GU 87401 (Nomuraea rileyi strain GU 87401) + SX, Nomura Air Lily SA 86101 (Nomuraea rileyi strain SA 86101) + SX, Nomura Air Lily SR 86 151 (Nomuraea rileyi strain SR86151) + SX, Strain (Nomuraea rileyi strain VA9101) + SX, Nosema locustae (Nosema locustae) + SX, Octomyo mermis spp. Fumosoroseus Apopka 97 (now known as Isaria fumosorosa Apopka 97) (Paecilomyces fumosoroseus Apopka strain 97, Now, Isaria fumosorosea Apop ka strain 97) + SX, Peklomyces lilacinas 251 strain (Paecilomyces lilacinus strain 251) + SX, Pekimyces tenuipes strain T1 (Paecilomyces tenuipes strain T1) + SX, Pequilomyces Qalioti Q-09 strain (Paecilomytrains Q-09) ) + SX, Paenibacillus alvei 2771 strain (Paenibacillus alvei strain 2771) + SX, Paenibacillus alvei strain 46C3 (Paenibacillus alvei strain 46C3) + SX, Paenibacillus alvei III2E strain (Paenibacillus alvei strain) -1A strain (Paenibacillus alvei strain III3DT-1A) + SX, Paenibacillus alvei strain T36 (Paenibacillus alvei strain T36) + SX, Paenibacillus macerans + SX, Paenibacillus polymixer AC-1 strain -1) + SX, Paenibacillus polymyxa strain BS-0105 (Paenibacillus polymyxa strain BS-0105) + SX, Paenibacillus popiria (Paenibacillus popilliae) + SX, Pandora delphacis (Pandora delphacis) + SX, Pantoea agglomerans strain E 325 (Pantoea agglomerans strain E 325) + SX, Pantoea bagans C9-1 (Pantoea vagans strain C 9-1) + SX, Para (Parasitaphelenchus spp.) + SX, Parasite rehab divis spp. (Parasitorhabditis spp.) + SX, Parasity lenchus spp. (Parasity lenchus spp.) + SX, P. pasteuria nishizawae Pn1 strain (Pasteuria nishizawae strain Pn1) + SX, Pasteuria penetrans + SX, Pasteuria ramose (Pasteuria ramose) + SX, Pasteuria usgae + SX, Pectobacterium carotovorum + + Burialiae ATCC 22 348 strain (Penicillium bilaiae strain ATCC 22348) + SX, Penicillium citrium VFI-51 strain (Penicillium citrinum strain VFI-51) + SX, Penicillium Vermiculatum (Penicillium vermiculatum) + SX, Pertilimermis culicis (Perutilimermis culicis) + SX, Pasteuria toyneii (Pasteuria thoynei) + SX, Fasmarabu ditis herma phrodita (Phasmarhabditi)
s hermaphrodita) + SX, Ferrebiopsis gigantea VRA 1992 (phlebiopsis gigantea strain VRA 1992) + SX, Physaloptera spp. (Pichia anomala strain WRL-076) + SX, Pichia gillierumonde Z1 strain (pichia guilliermondii strain Z1) + SX, Pichia gillierumonde Z8 strain (pichia guilliermondii strain Z8) + SX, poconia chlamydosporia isolate cholach strain PC10) + SX, Poconia chlamydosporia + SX, Protollella spp. (Protrellatus spp.) + SX, Pseudomonas aeruginosa strain PN1 (Pseudomonas aeruginosa strain PN1) + SX, Pseudomonas aeruginosa aeruginosa strain WS-1) + SX, Pseudomonas aureofaciens TX-1 strain (Pseudomonas aureofaciens strain TX-1) + SX, Pseudomonas Pseudomonas cepacia type J82 strain (Pseudomonas cepacia type Wisconsin strain J82) + SX, Pseudomonas cepacia Wisconsin type M 54 strain (Pseudomonas cepacia type Wisconsin strain M54) + SX, Pseudomonas chlorola fisu 63-28 strains 28) + SX, Pseudomonas chlororaphis AFS 009 strain (Pseudomonas chlororaphis strain AFS009) + SX, Pseudomonas chlorolaphys MA 342 strain (Pseudomonas chlororaphis strain MA 342) + SX, Pseudomonas fluorescens strain 1629 RS strain Pseudomonas fluorescens strain A506 (pseudomonas fluorescens strain A506) + SX, Pseudomonas fluorescens strain CL145A (pseudomonas fluorescens strain CL145A) + SX, Pseudomonas fluorescens strain G 7090 (Pseudomonas fluorescens strain 7010) B XJ3 strain (Pseudomonas fluorescens biover B strain XJ3) + SX, Pseudomonas fluorescens biover B strain XS 18 (Pseudomonas fluorescens biover B strain XS 18) + SX, Pseudomonas fluorescens biover A LRS 12 strain (Pseudomonas fluorescens biover A strain LRS 12) + proradix) + SX, Pseudomonas putida (Pseudomonas putida) + SX, Pseudomonas reactive (Pseudomonas reactans) + SX, Pseudomonas resinovorans + SX, Pseudomonas rhodosia HAI-0804 strain (Pse SX, Pseudomonas sp. CAB-02 (Pseudomonas sp. Strain CAB-02) + SX, Pseudomonas syringae strain 742 RS (Pseudomonas syringae strain 742 RS) + SX, Pseudomonas syringae MA-4 (Pseudomonas syringae strain MA-4) + SX, Pseudozyma flocculosa strain PF-A22UL (Pseudozyma flocculosa strain PF-A22UL) + SX, Puterigoder Titer spp. (Pterygodermatites spp.) + SX, Puccinia thlaspeos strain woad (Puccinia thlaspeos strain woad) + SX, Pull pleiocillium lilacinum + SX, Pycium oliganum DV 74 strain + SX, Pythium oligand Rum M1 strain (Pythium oligodrum strain M1) + SX, Rhodococcus globerulus strain AQ 719 (Rhodococcus globerulus strain AQ 719) + SX, Romanomelmis spp. (Romanomer mis spp.) + SX, S. cerevisiae strain LASO2) + SX, Sclerotinia minor IMI 3414 (sclerotinia minor strain IMI 3414) + SX, Serratia entomophila + SX, 35 Serratia marcescens 35 (Serratia marcescens strain 35) + Strain (Serratia marcescens strain SRM) + SX, Seuratum cadarachense + SX, Sphael lary (Sphaerulariopsis spp.) + SX, Spirura gaiannensis (Spirura guianensis) + SX, Sporothrix insectorum + SX, Stainernema bibionis (Steinernema bibionis) + SX, Stine SX, Steinernema fertiae (Steinernema feltiae) + SX, Steinernema graseri (Steinernema glaseri) + SX, Steinernema Krassei (Steinernema kraussei) + SX, Steinernema riobrave (Steinernema riobrave) + Electrophoresis SX, Steinernema scarabaei (Steinernema scarabaei) + SX, Steinernema siamkayai (Steinernema siamkayai) + SX, Steiner Neema spp. (Steinernema spp. Ashizyska Ss RL-110 T strain (Streptomyces acidiscabies strain RL-110 T) + SX, Streptomyces candidas strain Y 21007-2 (Streptomyces candidus strain Y 21 07-2) + SX, Streptomyces colombiensis + SX, Streptococcus Myces gallus strain QST 6047 (Streptomyces galbus strain QST 6047) + SX, Streptomyces goshikiensis + SX, Streptomyces griseoviridis strain K 61 (Streptomyces griseoviridis strain K 61) + SX, Streptococcus Streptomyces lavendulae + SX, Streptomyces lydicus strain WYCD108US (Streptomyces lydicus strain WYCD108US) + SX, Streptomyces lydicus strain WYEC108 (Streptomyces lydicus strain WYEC108) + SX, Streptomyces Streptomyces rimosus + SX, Streptomyces limosus Seticus (Streptomyces saraceticus) + SX, Streptomyces sp. NRRL No. B-30145 (Streptomyces sp. Strain NRRL No. B-30145) + SX, Streptomyces sp. WYE 20 (Streptomyces sp. Strain WYE 20) + SX, Streptomyces sp. WYE 324 strain (Streptomyces sp. Strain WYE 324) + SX, Streptomyces venezuelae + SX, Subaru spp. (Subulura spp.) + SX, Salpretilenx • Elongatius (Sulphuretylenchus elongatus) + SX, Talaromyces flavus SAY-Y-94-01 strain (Talaromyces flavus strain SAY-Y-94-01) + SX, Talaromyces flavus V117b strain (Talaromyces flavus strain V117b) + SX, (Tetrameres spp.) + SX, Telohania solenopsis + SX, Thiobacillus spp. R) + SX, Trichoderma asperumum strain ICC012 (Trichoderma asperellum strain ICC 012) + SX, Trichoderma asperumum T25 strain (Trichoderma asperellum T25) + SX, Trichoderma asperumum T34 strain (Trichoderma asperellum muscle) -1 strain (Trichoderma asperellum strain SKT-1) + SX, Trichoderma aspereum TV 1 strain (Trichoderma asperellum strain TV1) + SX, Trichoderma atroviride strain CNCM 1-1237 (Trichoderma atroviride strain CNCM 1-1237) + · SX Atroviride LC52 strain (Trichoderma atroviride strain LC52) + SX, Trichoderma atroviride IMI 206040 strain (Trichoderma atroviride strain IMI 206040) + SX, Trichoderma atroviride SC1 strain (Trichoderma atroviride) Trichoderma atroviride strain SKT-1) + SX, Trichoderma atroviride strain T11 (Trichoderma atroviride strain T11) + SX, Trichoderma gumsi ICC 080 (Trichoderma gamsii strain ICC 080) + SX, Trichoderma harzianum 21 strain (Trichoderma harzianum strain 21) + SX, Trichoderma harzianum DB 104 strain (Trichoderma harzianum strain DB 104) + 14944 strain (Trichoderma harzianum strain DSM 14944) + SX, Trichoderma harzianum strain ESALQ-1303 (Trichoderma harzianum strain ESALQ-1303) + SX, strain Trichoderma harzianum ESALQ-1306 (Trichoderma harzianum strain DSHC) Harsianum IIHR-Th-2 strain (Trichoderma harzianum strain IIHR-Th-2) + SX, Trichoderma harzianum ITEM 908 strain (Trichoderma harzianum strain ITEM 908) + SX, Trichoderma harzianum kd strain (Trichoderma harzianum strain) + SX, Trichoderma harzianum strain Harsianum MO1 strain (Trichoderma harzianum strain MO1) + SX, Trichoderma harzianum SF strain (Trichoderma harzianum strain SF) + SX, Trichoderma harzianum strain T22 (Trichoderma harzianum strain T22) + SX, Trichoderma harzianum strain T39 (Trichoderma harzianum strain T39) + SX, Trichoderma harzianum strain T78 (Trichoderma harzianum strain T23), (Trichoderma harzianum strain TH35) + SX, Trichoderma harzianum lifa (Trichoderma harzianum rifai) + SX, Trichoderma koningii (Trichoderma koningii) + SX, Trichoderma lignorum (Trichoderma lignorum) Trichoderma strain IMI206039) + SX, Trichoderma spp. (Trichoderma spp.) + SX, Trichoderma stromachicum + SX, Trichoderma virens strain G-41 (Trichoderma virens strain G-41) + SX, Trichoderma vibrense GL- 21 strains (Trichoderma virens strain GL-21, formaly Gliocladium virens GL-21) + SX, Trichodella・ Biride (Trichoderma viride) + SX, Tsukamella ・ Paurometabola (Tsukamurella paurometabola) + SX, Tifara facorrhiza strain 94671 (Typhula phacorrhiza strain 94671) + SX, urochladium oudemansii HRU 3 strain (Ulocladavitracitracitracilium Strain Q-09 (Vairimorpha spp. Strain Q-09) + SX, Barriovorax paradox CGF 4526 (Variovorax paradoxus strain GF 4526) + SX, Verticillium alboarum WCS 850 (Verticillium alboatrum strain WCS 850) + SX, Verti Sillium chlamydosporium (Verticillium chlamydosporium) + SX, Verticillium dahliae + SX, Verticillium lecani strain NCIM 1312 (Verticillium lecani strain NCIM 1312) + SX, Virgibacillus pantothenicus ATCC 14 576 strain ATCC 14576) + SX, Virgibacillus pantothenicus DSM 491 strain (Virgibacillus pantothen ticus strain DSM 491) + SX, Xanthomonas campestris pv Poae + SX, Xanthomonas campestris (Xanthomonas campestris) + SX, Xenolabdas luminescence (Xenorhabdus luminescens), a ligand , Zoototra radicans + SX, Adxophiles orana granulosis virus BV-0001 strain (Adoxophys orana granulosis virus strain BV-0001) + SX, Agrotis segegium nuclear polyhedrosis virus (Agrotis segetum nuclearivirus, )) + SX, Anagraoha falcifera nuclear polyhedrosis virus (Anagraoha falcifera NPV) + SX, Anticarsia gematalis nucleopolyhedrovirus (Anticarsia gemmatalis mNPV) + SX, Autographa california nucleopolyhedrovirus (Autographa californica mNPV) + SX, Bistone and suppressor nuclear polyhedrosis virus ( Biston suppressaria NPV) + SX, Bombyx mori nuclear polyhedrosis virus (Bombyx mori NPV) + SX, Cryptofrebbia leukotreta granular disease virus (Cryptophlebia leucotreta GV) + SX, Sidia pomonera granular disease virus V 15 strain (Cydia
pomonella GV strain V15) + SX, C. pomonella granulosis virus V22 strain (Cydia pomonella GV strain V22) + SX, Dendrolimus punctatus cytoplasmic polyhedra virus (Dendrolimus punctatus cypovirus) + SX, Helicoverpa armigera virus VV -0003 strain (Helicoverpa armigera NPV strain BV-0003) + SX, Helicoverpa zea nuclear polyhedrosis virus (Helicoverpa zea NPV)) + SX, Leucoma salicis nuclear polyhedrosis virus (Leucoma salicis NPV) + SX, lymantria · Dispar nuclear polyhedrosis virus (Lymantria dispar NPV) + SX, Mamastra brassicae nuclear polyhedrosis virus (Mamestra brassicae NPV) + SX, Mamastra configurata nuclear polyhedrosis virus (Mamestra configurata NPV) + SX, neodiplyon・ Abientis nuclear polyhedrosis virus (Neodiprion abietis NPV) + SX, Neodiprion ・ recontaly nuclear polyhedrosis virus (Neodiprion lecontei) NPV)) + SX, Neodiplyon sertifer nuclear polyhedrosis virus (Neodiprion sertifer NPV)) + SX, Orgyia pseudotsugata nuclear polyhedrosis virus (Orgyia pseudotsugata NPV) + SX, Pepino mosaic virus CH2 strain 1906 Isolates (pepino mosaic virus strain CH2 isolate 1906) + SX, P. trichypaea operculella granulosis virus (Phthorimaea operculella GV)) + SX, P. piraes rapae G. disease virus (Pieris rapae GV)) + SX, Progia internktera granules Disease virus (Plodia interpunctella GV) + SX, Plutella xylostella granule disease virus (Plutella xylostella GV) + SX, Chenopodium granule disease virus (Plutella xylostella GV) + SX, Spodoptera albra nuclear polyhedrosis virus (Spodoptera albula mNPV) ) + SX, Spodoptera Ex. Nuclear polyhedrosis virus (Spodoptera exempta mNPV)) + SX, Spodoptera Ex. Nuclear polyhedrosis virus BV-0004 strain (Spodoptera exigua mNPV strain BV-0004) + SX, Spodoptera frugiperda nuclear polyhedrosis virus (Spodoptera frugiperda mNPV) + SX, Spodoptera littoralis nuclear polyhedrosis virus (Spodoptera littoralis mNPV) + SX, Spoptella sp. Ritudinal nuclear polyhedrosis virus (Spodoptera litura NPV) + SX, tobacco mild green tobamovirus U2 strain (Tobacco mild tobamovirus strain U2) + SX, Zucchini yellow spot mosaic virus weak strain (Zucchini Yellow Mosaik Virus weak strain) + SX , Acalospora sp. (Acaulospora spp.) + SX, Ambispora sp. (Ambispora spp.) + SX, Archiospora sp. (Archaeospora spp.) + SX, Claroideoglomus spp. (Formerly Glomus spp.) + SX, Claroideoglomus etunicatum (formerly Glomus etunicatum) + SX, Claroideoglomus claroideum, Formerly Glomus claroideum + SX, Diversispora sp. (Diversispora spp.) + SX, Entrophospora spp. + SX, Funeriformis sp. (Funneliformis spp., Formerly Glomus spp.) ) + SX, Fanelliformis mosseae (Funneliformis mosseae, formerly Glomus mosseae) + SX, Geochiphon sp. (Geosiphon spp.) + SX, Gigaspora sp. (Gigaspora spp.) + SX, Gigaspora margarita (Gigaspora) margarita) + SX, Gigaspora rosea + SX, Glomus spp. + SX, Glomus aggregatum + SX, Glomus deserticola (Glomus deserticola) + SX, Glomus monosporum Glomus monosporum) + SX, Pacispora spp. + SX, Paraglomus sp. (Paraglomus spp.) + SX, Paraglomus brasillianum (formerly Glomus brasillianum) + SX, Lacocetra sp. ) + SX, Lai Fagus sp. (Rhizophagus spp., Formerly Glomus spp.) + SX, Reizofagus claras (Rhizophagus clarus, formerly Glomus clarum) + SX, Lysophaga intratraradices (formerly Glomus intraradices) + SX, Lysophagus intraradisis strain RTI-801 + SX, Lysophagus irregularis (Rhizophagus irregularis, formerly Glomus intraradices) + SX, Lysophagus irregularis strain DAOM 197198 (Rhizophagus irregularis strain DAOM 197198) + SX, Scutellospora sp .) + SX, Azorhizobium sp. (Azorhizobium spp.) + SX, Azorhizobium caulinodans + SX, Azospirillum amazonense (Azospirillum amazonense) + SX, Azospirilum brushense (Azospirillum bramil spirase) Lence XOH strain (Azospirillum brasilense strain XOH) + SX, Azospiri B. brasilens Ab-V5 strain (Azospirillum brasilense strain Ab-V5) + SX, Azospirillum brasilens Ab-V6 strain (Azospirillum brasilense strain Ab-V6) + SX, Azospirillum caulinodans + SX, azospirilum Halopraepherens (Azospirillum halopraeferens) + SX, Azospirillum irakense + SX, Azospirillum lipoferum (Azospirillum lipoferum) + SX, Bradyrhizobium sp. (Bradyrhizobium spp.) + SX, (Bradyrhizobium elkanii) + SX, Bradyrhizobium elcani strain SEMIA 587 (Bradyrhizobium elkanii strain SEMIA 587) + SX, Brady rhizobium elcani strain SEMIA 5019 (Bradyrhizobium elkanii strain SEMIA 5019) Japonicum (Bradyrhizobium japonicum) + SX, Brady Rhizobium japonicum TA-11 strain (Bradyrhizobium japonicum strain TA -11) + SX, Bradyrhizobium japonicum USDA 110 strain (Bradyrhizobium japonicum strain USDA 110) + SX, Brady rhizobium liooningense + SX, Brady rhizobium lupini (Bradyrhizobium lupini) SX, Bradyrhizobium sp. (Arakis) (S. arachis) + SX, Brady Rhizobium sp. (Bigna) (Bradyrhizobium sp. (Vigna)) + SX, Delftia acidovorans + SX, Delftia acidovorans strain RAY 209 (Delftia acidovorans strain RAY 209) + SX, Methylobacterium sp. Mesorhizobium roti (Mesorhizobium loti) + SX, Mesorhizobium (Mesorhizobium spp.) + SX, Rhizobium etri (Rhizobium etli) + SX, Rhizobium galager (Rhizobium gal) egae) + SX, Rhizobium leguminosarum bv. Phaseri (Rhizobium leguminosarum bv. Phaseoli) + SX, Rhizobium legumino salm bv. Rhizobium leguminosarum bv. + SX, Rhizobium trifolii + SX, Rhizobium tropici + SX, Sinorhizobium fredii + SX, Sinorhizobium meliloti + SX.

  The mixing ratio of the present compound to the present component is not particularly limited, but the weight ratio (the present compound: the present component) is 1000: 1 to 1: 1000, 500: 1 to 1: 500, 100: 1 to 100 1: 100, 90: 1, 80: 1, 70: 1, 60: 1, 50: 1, 40: 1, 30: 1, 20: 1, 10: 1, 9: 1, 8: 1, 7: 1, 6: 1, 5: 1, 4: 1, 3: 1, 2: 1, 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1: 6, 1: 7, 1: 8, 1: 9, 1:10, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90 and the like.

  The present compound can be used in combination or in combination with chemical fertilizers (eg, ammonium sulfate, ammonium phosphate, ammonium nitrate, urea, sodium chloride).

  When the present compound or composition A is used as a harmful arthropod control composition, it is usually used as a composition further containing an inert carrier (hereinafter referred to as composition B). Composition B is usually prepared by mixing the present compound or composition A with an inert carrier such as a solid carrier, liquid carrier, gaseous carrier and the like, and adding a surfactant and other pharmaceutical auxiliaries as necessary. Emulsion, oil, powder, granule, wettable, flowable, microcapsule, aerosol, smoke, poison bait, resin formulation, shampoo, paste, foam, carbon dioxide, tablet Etc. are formulated. These preparations may be used as processed into mosquito coil, electric mosquito mat, liquid mosquito formula, fuming agent, fumigant, sheet preparation, spot-on agent, oral treatment agent. Composition B usually contains 0.0001 to 95% by weight of the present compound or composition A.

  Examples of solid carriers include clays (kaolin clay, diatomaceous earth, bentonite, acid clay, etc.), dry silica, wet silica, talc, ceramics, and other inorganic minerals (sericite, quartz, sulfur, activated carbon, calcium carbonate, etc.) Fine powders and particles such as chemical fertilizers (ammonium sulfate, phosphate, nitrate, urea, salt), etc., and synthetic resins (polyesters such as polypropylene, polyacrylonitrile, polymethyl methacrylate, polyethylene terephthalate, etc., nylon-6, And nylon resins such as nylon-11 and nylon-66, polyamide resins, polyvinyl chloride, polyvinylidene chloride, vinyl chloride-propylene copolymers and the like.

  Examples of liquid carriers include water, alcohols (methanol, ethanol, isopropyl alcohol, butanol, hexanol, benzyl alcohol, ethylene glycol, propylene glycol, phenoxyethanol etc.), ketones (acetone, methyl ethyl ketone, cyclohexanone etc.), aromatic hydrocarbons (Toluene, xylene, ethylbenzene, dodecylbenzene, phenylxylylethane, methylnaphthalene etc.), aliphatic hydrocarbons (hexane, cyclohexane, kerosene, light oil etc.), esters (ethyl acetate, butyl acetate, isopropyl myristate, Ethyl oleate, diisopropyl adipiglycerinate, diisobutyl adipate, propylene glycol monomethyl ether acetate, etc., nitriles (acetonitrile, Sobutyronitrile etc., Ethers (diisopropyl ether, 1,4-dioxane, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, diethylene glycol monomethyl ether, propylene glycol monomethyl ether, dipropylene glycol monomethyl ether, 3-methoxy-3-methyl-1 -Butanol and the like), amides (DMF, dimethylacetamide and the like), sulfoxides (DMSO and the like), propylene carbonate and vegetable oils (soybean oil, cottonseed oil and the like).

  Gaseous carriers include, for example, fluorocarbons, butane gas, LPG (liquefied petroleum gas), dimethyl ether and carbon dioxide gas.

  Examples of surfactants include nonionic surfactants such as polyoxyethylene alkyl ether, polyoxyethylene alkyl aryl ether, polyethylene glycol fatty acid ester, and anions such as alkyl sulfonate, alkyl benzene sulfonate, and alkyl sulfate. Surfactants may be mentioned.

  As other pharmaceutical adjuvants, fixing agents, dispersing agents, coloring agents, antifreeze agents, stabilizers and the like, specifically, for example, casein, gelatin, saccharides (starch, gum arabic, cellulose derivative, alginic acid etc.), lignin Derivatives, bentonite, synthetic water-soluble polymers (polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylic acids, etc.), isopropyl acid phosphate, 2,6-di-tert-butyl-4-methylphenol and BHA (2-tert-butyl- A mixture of 4-methoxyphenol and 3-tert-butyl-4-methoxyphenol). As a coloring agent, a red pigment, a blue pigment, a green pigment, a yellow pigment and the like can be mentioned. Specifically, monazole red, cyanine green, Prussian blue, brilliant blue and the like can be mentioned. In particular, in the case of granules and fine granules, a coloring agent can be added to facilitate identification of granules and fine granules during or after application. In addition, when the composition of the present invention is applied to plant seeds and vegetative organs, a coloring agent can be added to facilitate confirmation of application.

Examples of the base material of the resin preparation include vinyl chloride polymers and polyurethanes, and these base materials may, if necessary, be phthalic acid esters (dimethyl phthalate, dioctyl phthalate etc.), adipic acid esters, A plasticizer such as stearic acid may be added. The resin preparation is obtained by kneading the present compound into the base material using a common kneading apparatus and then molding it by injection molding, extrusion molding, press molding and the like, and if necessary through further steps such as molding and cutting. It can be processed into resin preparations such as plate-like, film-like, tape-like, net-like and string-like. These resin preparations are processed, for example, as animal collars, animal ear tags, sheet preparations, drawstrings, horticultural posts.
Examples of substrates for poison bait include cereal flour, vegetable oil, sugar, crystalline cellulose and the like, and further, if necessary, antioxidants such as dibutyl hydroxytoluene and nordihydroguaiaretic acid, preservatives such as dehydroacetic acid and the like Also, an anti-mistake agent for children and pets such as capsicum powder, a cheese flavor, an onion flavor, a pest-inducing flavor such as peanut oil, etc. are added.

  Harmful by applying the effective amount of the present compound or composition B directly to harmful arthropods and / or to the habitat of harmful arthropods (plant, plant cultivation carrier, in house, animal body etc. It can control arthropods. The term "habitat" here includes not only places where harmful arthropods live, but also places where it is expected to live. When controlling harmful arthropods, they are usually used in the form of composition B.

  The plant cultivation carrier is a support for plants and may be any material from which plants can grow, and examples thereof include soil, a mat for raising seedlings, and water. Specific materials of the soil and the mat for raising seedlings include, for example, sand, pumice, vermiculite, diatomaceous earth, gel-like substance, polymer substance, rock wool, glass wool, wood chips and bark.

  When composition B is used for controlling arthropod pests in the agricultural field, the application rate is the type of plant to be applied, the type and frequency of occurrence of noxious arthropods to be controlled, the formulation form, the application time, the application method, It can be widely varied depending on the application site, weather conditions, etc. Usually, the application amount of the active ingredient is 1 to 10000 g per ha. When the composition B is formulated as an emulsion, a wettable powder, a flowable, etc., it is usually diluted with water so that the concentration of the active ingredient becomes 0.01 to 10000 ppm, and applied. Is usually applied as it is.

  These formulations and their dilutions may be sprayed directly onto plants, such as harmful arthropods or crops to be protected from harmful arthropods, and harmful arthropods that inhabit the soil of cultivated land The soil may be treated to control.

  In addition, the resin preparation processed into a sheet or string can be treated by a method such as wrapping around a crop, spreading it in the vicinity of a crop, spreading it on stock soil, or the like.

When the composition B is used for controlling harmful arthropods that live in a house, the application rate thereof is usually 0.01 to 1000 mg in terms of the amount of the present compound per 1 m ² of treated area when treated on a surface When treating in space, the amount of the present compound per 1 m ³ of treatment space is usually 0.01 to 500 mg. When the composition B is formulated into an emulsion, a wettable powder, a flowable, etc., it is usually diluted with water so as to have an active ingredient concentration of 0.1 to 10000 ppm, and applied. Apply smoke agent, poison bait etc. as it is.

  When composition B is used for ectoparasite control of small animals such as cattle, horses, pigs, sheep, goats, chickens, etc., dogs, cats, rats, mice, etc., it is used for animals by known veterinary methods can do. As a specific method of use, for the purpose of systemic suppression, for example, it is administered by tablet, feed mixing, suppository, injection (intramuscular, subcutaneous, intravenous, intraperitoneal etc.) and is intended for non-systemic suppression. In this case, for example, oil or aqueous solution is sprayed, pour-on treatment or spot-on treatment is performed, the animal is washed with a shampoo preparation, or the resin preparation is used as a collar or ear tag and attached to the animal. The amount of the present compound when administered to an animal is usually in the range of 0.1 to 1000 mg per 1 kg of animal weight.

  In the present invention, plants include whole plants and specific parts of plants. Specific parts of plants include, for example, shoots, flowers, ears, fruits, trunks, branches, crowns, seeds, vegetative organs and seedlings.

  The vegetative organ means the plant roots, stems, leaves, etc. that have the ability to grow when the site is separated from the main body and installed in the soil. As the vegetative reproductive organs, for example, tuberous root, creeping root, bulb, corm or solid bulb, tuber, tuber, rhizome, stolon Rhizophores, cane cuttings, propagule and vine cutting. In addition, a toothpick is also called a runner (runner), and a basket is also called a sprout and is divided into a broad bud and a bulbil (bulbil). "Vine" means shoots such as sweet potato and yam (collectively referred to as leaves and stems, shoot). The bulbs, corms, tubers, rhizomes, stem fragments, rhizomes or tuberous roots are collectively referred to as bulbs. Cultivation of potato starts by planting tubers in the soil, but the tubers used are generally called seed potatoes.

  Seedlings include seedling and sapling.

  As a processing method of the composition B, for example, foliage treatment, soil treatment, root treatment, shower treatment, smoke treatment, water surface treatment, seed treatment and hydroponic solution treatment can be mentioned.

As a foliage treatment, for example, a method of treating composition B on the surface of foliage, trunk, fruit, flower or ear is mentioned.
Examples of the root treatment include a method of immersing the root in a drug solution containing the composition B, and a method of adhering a solid preparation containing the composition B to the root of a plant.
The soil treatment includes, for example, soil spraying, soil mixing, and chemical solution irrigation to the soil. In addition, as the place where soil treatment is done, for example, planting hole, cutting, near planting hole, near cutting, whole area of cultivation area, near plant part, between plants, under trunk, main trunk, growing soil, seedling box, raising seedling Trays, nursery beds, etc. may be mentioned. As the treatment time, for example, before sowing, at the time of sowing, after sowing, the nursery season, before planting, at planting, and after the planting, the growing stage and the like can be mentioned. In the above-mentioned soil treatment, the composition B may be treated at the same time on a plant, or a solid fertilizer such as a paste fertilizer containing the composition B may be applied to the soil. Moreover, you may mix with irrigation liquid, for example, the injection | pouring to irrigation equipment (a irrigation tube, a irrigation pipe, a sprinkler etc.), mixing in the interrow spring water, mixing in a water culture medium etc. are mentioned. In addition, it is possible to previously mix the irrigation solution and the active ingredient and treat it using, for example, the above-mentioned irrigation method or other appropriate irrigation methods such as watering, springing and the like.
As a shower process, the method of showering the diluted liquid of the composition B to the fruit after harvest is mentioned, for example.
An example of the smoke treatment is a method in which the diluted solution of the composition B is misted and scattered in the air to be attached to the stems and leaves or fruits of a plant.
As the water surface treatment, for example, a method of spraying a solid preparation containing a drug solution or composition B containing composition B in a flooded paddy field can be mentioned.
Seed treatment includes, for example, treatment of composition B on seeds or vegetative organs, and in detail, for example, a suspension of composition B is atomized and sprayed on the surface of seeds or vegetative organs. Spraying treatment, smearing treatment for applying composition B to seeds or vegetative reproductive organs, immersion treatment for immersing seeds in a drug solution of composition B for a certain period of time, coating seeds or vegetative reproductive organs with a carrier containing composition B Methods (film coating treatment, pellet coating treatment, etc.). The above-mentioned vegetative and reproductive organs include, in particular, a seed meal.
As the hydroponic solution treatment, for example, a method of mixing or mixing a drug solution containing the composition B or a solid preparation containing the composition B into the hydroponic solution (hydroponic fluid mixing treatment, hydroponic fluid mixing treatment, etc.), etc. Can be mentioned.

  More specifically, the treatment method of the composition B is planting hole treatment (planting hole spraying, planting hole treated soil mixing), planting root treatment (planting plant dispersion, planting source soil mixing, planting source irrigation, planting season late half season stock Original treatment), Planting groove treatment (planting groove dispersion, planting groove soil mixing), Graining treatment (graining dispersion, Graining soil mixing, Growth period graining dispersion), Graining treatment at the time of seeding (Sowing time dispersion, Sowing at the time of sowing (mixed soil), whole treatment (whole soil spraying, whole soil mixing), side treatment, water surface treatment (water surface application, water application after flooding, water surface application), other soil spraying treatment (growing season foliar surface spraying, Spraying under the crown or around the main trunk, spraying on the soil surface, mixing on the soil surface, spraying on the burrow, spraying on the surface of the buttocks, spraying between the stocks, etc., other irrigation treatment Drip irrigation, chemical treatment), nursery box processing (nursery box dispersion, nursery box irrigation, nursery box chemical liquid spring) Seedling tray treatment (seedling tray spreading, seedling tray irrigation, seedling tray medical solution watering), seedling treatment (seedling spreading, seedling irrigation, seedling seedling spreading, seedling soaking), mixed treatment with soil (soil mixing, soiling before seeding) Mixing, sowing before sowing, sowing after sowing, soaking after sowing, soaking, soaking (otherwise), other treatments (mixing of soil, mixing with soil, mixing with soil, mixing with soil, mixing with soil, planting treatment, spraying of flower bunches, mixing with paste fertilizer , Mixing with hydroponic solution, mixing with hydroponic solution, etc.

  When the present compound is applied to seeds or vegetative organs, the application rate of the present compounds is usually 0.001 to 100 g, preferably 0.01 to 50 g, more preferably 0.1, per 1 kg of seeds or vegetative organs. ~ 10 g. In addition, when the present ingredient is added to the present compound and applied, the application rate per one ingredient is usually 0.001 to 100 g, preferably 0.01 to 50 g, more preferably 1 kg of seed or vegetative organ. , 0.1 to 10 g.

  Composition B can be used as a control agent for arthropod pests in agricultural lands such as fields, paddy fields, orchards, and non-agricultural lands such as lawns and forests.

Examples of plants for which composition B can be used include agricultural products such as: corn, rice, wheat, barley, rye, oats, sorghum, cotton, soybean, peanuts, buckwheat, sugar beet, rape, canola, sunflower, sugar cane, tobacco , Rye wheat, kidney beans, lima beans, cowpeas, mung bean, vaccines, safflower beans, bamboo azuki beans, moth beans, tapary beans, broad beans, peas, peas, chickpeas, lentils, lupine, pigeons, alfalfa, etc.
Vegetables; Solanaceous vegetables (eggplant, tomato, pepper, pepper, potato, bell pepper), Cucurbitaceous vegetables (cucumber, pumpkin, zucchini, watermelon, melon, squash etc), cruciferous vegetables (Japanese radish, turnip, horseradish, Korabi rabi, Chinese cabbage, cabbage, mustard, broccoli, cauliflower etc., Asteraceae vegetables (burdocks, sea urchins, artichoke, lettuce etc), Liliaceae vegetables (Leeks, onions, garlic, asparagus), Seriaceae vegetables (carrot, Parsley, celery, American buckwheat, etc.) Arazaceae vegetables (spinach, persimmon etc.), scorpionaceous vegetables (sesame, mint, basil, lavender etc.), strawberries, sweet potato, yam, taro etc., florets, houseplants,
Fruits; Fruits (apples, pears, Japanese pears, cullins, quince etc.), Core fruits (momo, plums, nectarines, jujubes, apricots, prunes etc.), citrus fruits (palms, oranges, lemons, limes, grapefruits) Etc), nuts (nuts, walnuts, hazelnuts, almonds, pistachios, cashews, macadamias etc), berries (blueberries, cranberries, blackberries, raspberries etc), grapes, oysters, olives, loquats, bananas, coffee, etc. Date palm, coconut palm, etc.
Trees other than fruit trees; tea, mulberry, flowering trees, street trees (astera, birch, dogwood, eucalyptus, eucalyptus, ginkgo, lilac, maple, oak, poplar, persimmon, perennial, fusarium, plananas, persimmon, perianthus, birch, fir tree, tsuga, nezu, pine, Spruce, yew) etc.,
Shiva, grass.

  The variety of plants described above is not particularly limited as long as it is a variety generally cultivated.

  The aforementioned plants may be plants that can be produced by natural mating, plants that can be generated by mutation, F1 hybrid plants, transgenic plants (also referred to as genetically modified plants). These plants generally exhibit resistance to herbicides, accumulation of toxic substances to pests (also referred to as pest resistance), susceptibility control to diseases (also referred to as disease resistance), increased yield potential, biological and abiotic It has properties such as improvement in resistance to stress factors, quality modification of products (for example, increase or decrease in content of components, change in composition, improvement in storage stability or processability).

  The F1 hybrid plant is a one-time hybrid obtained by crossing two different lines of varieties, and is generally a plant having a characteristic of heterosis with a trait superior to either of the parents. With a transgenic plant, a foreign gene is introduced from another organism such as a microorganism, and is given characteristics such that it can not be easily obtained by cross breeding, mutagenesis or natural recombination in a natural environment. Plant.

Techniques for producing the above-mentioned plants include, for example, conventional breeding techniques; genetic recombination techniques; genome breeding techniques; new breeding techniques; genome editing techniques. Conventional breeding techniques are techniques for obtaining plants having desirable properties by mutation or mating. In genetic engineering, a gene (DNA) of interest is taken out of an organism (eg, a microorganism) and introduced into the genome of another target organism to impart new properties to the organism or a plant Antisense technology or RNA interference technology that imparts new or improved properties by silencing other present genes. The genome breeding technology is a technology for making breeding efficient using genome information, and includes DNA markers (also called genomic markers or genetic markers) breeding technology and genomic selection. For example, DNA marker breeding is a method of selecting a progeny having a desired trait gene of interest from a large number of mating progeny using a DNA marker that is a DNA sequence that is a marker of the presence position on the genome of a particular trait gene. is there. By analyzing mating progeny using a DNA marker at the time of seedling, it has a feature that the time required for breeding can be effectively shortened.
In addition, genomic selection is a method of creating a prediction formula from phenotype and genomic information obtained in advance, and predicting characteristics from the prediction formula and genomic information without evaluating the phenotype, which contributes to the efficiency of breeding. It is a possible technology. New breeding techniques (new breeding techniques) is a generic term for breeding techniques combined with molecular biological techniques. For example, cis / endogenesis, oligonucleotide-directed mutagenesis, RNA-dependent DNA methylation, genome editing, grafting to GM rootstock or scion, reverse breeding, agroinfiltration, seed production technology (Seed Production) Technology such as Technology, SPT). The genome editing technology is a technology for converting genetic information in a sequence-specific manner, and deletion of a base sequence, substitution of an amino acid sequence, introduction of a foreign gene and the like are possible. As the tool, for example, zinc finger nuclease (Zinc-Finger, ZFN) capable of sequence-specific DNA cleavage, TALEN (TALEN), Crisper Cassane (Crisper / Cas9), Crisper cP1 (CRISPER / Cpf1) And meganuclease (Meganuclease). In addition, there are sequence-specific genome modification techniques such as CAS9 nickase and Target-AID created by modifying the aforementioned tools.

  The aforementioned plants are, for example, registration of genetically modified crops (http://www.isaaa.org/) in the electronic information site of the International Agribio Agency (INTERNATINAL SERVICE for the ACQUISITION of AGRI-BIOTECH APPLICATIONS, ISAAA). Plants listed in the database (GM APPROVAL DATABASE) can be mentioned. More specifically, for example, herbicide-resistant plants, pest-resistant plants, disease-resistant plants, quality modification of products (for example, increase or decrease of the content of components, change of composition, improvement of preservative property or processability) plants There are fertile trait-altering plants, abiotic stress-tolerant plants, or plants with altered traits related to growth and yield.

Examples of herbicide tolerant plants are listed below.
Mechanisms of resistance to herbicides, for example, reduce the affinity between the herbicide and its target; rapid metabolism (degradation, modification, etc.) of the herbicide by expression of enzymes that inactivate the herbicide; And uptake into plants; and inhibition of herbicide transfer in plants.

Plants to which herbicide resistance has been imparted by genetic engineering techniques are, for example, protoporphyrinogen oxidase (hereinafter abbreviated as PPO) herbicides such as flumioxazin; 4-hydroxyphenylpyruvate such as isoxaflutole, mesotrione, etc. Dioxygenase (hereinafter abbreviated as HPPD) inhibitor; Imidazolinone herbicides such as imazethapyr etc. Acetolactate synthetase (hereinafter abbreviated as ALS) inhibitors such as sulfonylurea herbicides such as thifensulfuron methyl etc. such as glyphosate etc. 5-enolpyruvyl shikimate-3-phosphate synthetase (hereinafter abbreviated as EPSPS) inhibitor; glutamine synthetase inhibitor such as glufosinate; auxin type herbicide such as 2,4-D, dicamba; bromoxynil etc Some plants have been given resistance to oxynyl herbicides. Preferred herbicide-resistant transgenic plants are grains such as wheat, barley, rye, oats, canola, sorghum, soybean, rice, rapeseed, sugar beet, sugar cane, grape, lentil, sunflower, alfalfa, pome fruit, kernel fruit, Coffee, tea, strawberry, shiba, tomato, potato, cucumber, lettuce and other vegetables, more preferably wheat, barley, rye, oats and other grains, soybean, rice, Vine, tomato, potato, pomegranate is there.
The specific herbicide-tolerant plants are shown below.
Glyphosate herbicide resistant plants: Glyphosate resistant EPSPS gene (CP4 epsps) from Agrobacterium tomefaciens strain CP4 (Agrobacterium tumefaciens strain CP4), glyphosate N-acetyltransferase gene from Bacillus lichenifomis by shuffling technology Glyphosate N-acetyltransferase gene (gat 4601 or gat 4621) with enhanced metabolic activity, glyphosate oxidase gene (goxv 247) from Ochrobacterum anthropi strain LBAA, or glyphosate resistance from maize (Zea mays) It is obtained by introducing any one or more of EPSPS genes (mepsps or 2 mepsps) having a mutation. Main plants are, for example, alfalfa (Medicago sativa), Argentine canola (Brassica napus), cotton (Gossypium hirsutum L.), creeping bentgrass (Agrostis stolonifera), corn (Zea mays L.) polish canola (Brassica rapa), Potato (Solanum tube HDDrosum L.), soybean (Glycine max L.), sugar beet (Beta vulgaris) and wheat (Triticum aestivum) can be mentioned. Several glyphosate resistant plants are commercially available. For example, genetically modified plants into which CP4 epsps have been introduced are trade names including "Roundup Ready (registered trademark)", and genetically modified plants into which gat 4601 or gat 4621 have been introduced are "Optimum (registered trademark) GAT (trademark)", " Under the trade names such as Optimum (registered trademark) Gly canola, etc., transgenic plants into which mepsps or 2 mepsps have been introduced are sold under the trade name "GlyTol (trademark)". As a more specific glyphosate-resistant plant, for example, corn is "Roundup Ready (trademark) Maize", "Roundup Ready (trademark) 2 Maize", "Agrisure (trademark) GT", "Agrisure (trademark) GT / CB / LL "," Agrisure (TM) GT / RW "," Agrisure (TM) 3000 GT "," YieldGard (TM) VT (TM) Rootworm (TM) RR2 "and" YieldGard (TM) VT Triple "; Ready (TM) Soybean "and" Optimum GAT (TM) ";Cotton" Roundup Ready (TM) Cotton "," Roundup Ready (TM) Flex Cotton "and" GlyTol (TM) ";Canola" Roundup Ready (TM) " Canola "and" Optimum (registered trademark) Gly canola ";Alfalfa" Roundup Ready (R) Alfalfa ";Rice" Roundup Ready Rice "; Sugar cane" Roundup Ready (R) sugarbeet "and" InVigor (R) sugarbeet " Wheat sold under the trade name "Roundup ReadyTM wheat" (Triticum aestivum) It has been.
Lyphosinate herbicide resistant plants: gene (bar) of phosphinothricin N-acetyltransferase (Phosphinothricin N-acetyltransferase, hereinafter abbreviated as PAT) from Streptomyces hygroscopicus, Streptomyces biridocro The PAT gene (pat) derived from Mogenes (Streptomyes viridochromogenes) or any one or more of the synthesized PAT genes (pat syn) derived from Streptomyces viridochromogenes strain Tu494 (Streptomyces viridochromogenes strain Tu494) It is obtained by introducing. Main plants include, for example, argentina canola (Brassica napus), chicory (Cichorium intybus) cotton (Gossypium hirsutum L.), corn (Zea mays L.) polish canola (Brassica rapa), rice (Oryza sativa L.), soybean (Glycine max L.) and sugar beet (Beta vulgaris). Several glufosinate resistant plants are commercially available. For example, transgenic plants into which bar or pat has been introduced are sold under trade names including "LibertyLink (trademark)", "InVigor (trademark)", or "WideStrike (trademark)". More specific glyphosate resistant plants are, for example, corn “Roundup ReadyTM 2”, “Liberty LinkTM”, “HerculexTM I”, “Herculex RW”, “Herculex XTRATM” "Agrisure (TM) GT / CB / LL", "Agrisure (TM) CB / LL / RW" and "Bt10"; Cotton "FiberMax (TM) Liberty Link (TM)"; Rice "Liberty Link (TM) Canola is "inVigor (TM) Canola"; soybean is "Liberty Link (TM) Soybean"; sugar cane is sold under the trade name "Liberty Link (TM) sugarbeet".
Oxynyl herbicide (eg, bromoxynil) resistant plant: obtained by introducing a nitrilase gene (bxn) derived from Klebsiella pneumoniae subsp. Ozaenae. Main plants include, for example, Argentine canola (Brassica napus), cotton (Gossypium hirsutum L.) and tobacco (Nicotiana tabacum L.). Several oxynyl herbicide resistant plants are commercially available. For example, it is sold under the trade name including "Navigator (trademark)" or "BXN (trademark)". More specific oxynyl herbicide-tolerant plants are, for example, sold under the trade names “BXNTM Cotton” for cotton; and “NavigatorTM Cotton” for Argentine canola.
ALS herbicide resistant plants: Carnations (Dianthus caryophyllus) into which ALS herbicide resistant ALS gene (surB) derived from tobacco (Nicotiana tabacum) is introduced as a selective marker are, for example, "Moondust (trademark)", "Moonshadow (trademark) , "Moonshade (trademark)", "Moonlite (trademark)", "Moonaqua (trademark)", "Moonvista (trademark)", "Moonique (trademark)", "Moonpearl (trademark)", "Moonberry (trademark)" Or it is marketed under the trade name "Moonvelvet (trademark)". Ama (Linum usitatissumum L.) introduced with ALS herbicide resistant ALS gene (als) derived from Arabidopsis thaliana is marketed, for example, under the trade name “CDC Triffid Flax”. Corn (Zea mays L.) resistant to sulfonylurea type and imidazolinone type herbicides introduced with ALS herbicide resistant ALS gene (zm-hra) derived from corn is, for example, “OptimumTM GATTM” Marketed under the brand name. A soybean tolerant to an imidazolinone type herbicide into which an ALS herbicide resistant type ALS gene (csr1-2) derived from Arabidopsis thaliana has been introduced is marketed, for example, under the trade name "Cultivance". Soybeans into which ALS herbicide resistant ALS gene (gm-hra) derived from soybean (Glycine max) has been introduced are, for example, trademarks of "Treus (trademark)", "Plenish (trademark)" and "Optimum GAT (trademark)" Sold by name. There is also a cotton into which ALS herbicide resistant ALS gene (S4-HrA) derived from tobacco (Nicotiana tabacum cv. Xanthi) has been introduced.
: Obtained by introducing the HPPD gene (avhppd-03) derived from oat (Avena sativa). For example, soybeans into which a PAT gene (pat) derived from Streptomyces viridochromogenes was introduced at the same time as the above-mentioned genes are “Herbicide-tolerant Soybean line” as soybeans resistant to mesotrione and glyphosate. Sold under trade name.
2,4-D resistant plants: corn introduced with the aryloxyalkanoate dioxygenase gene (aad-1) from Sphingobium herbicidovorans (Sphingobium herbicidovorans) is, for example, Trademarks are sold under the trade name Maize. Soybeans and cottons into which the allyloxyalkanoate dioxigenase gene (aad-12) derived from Delftia acidovorans is introduced are known, for example, marketed under the trade name "Enlist (trademark) Soybean" ing.
Dicamba herbicide resistant plant: obtained by introducing a dicamba monooxygenase gene (dmo) derived from Stenotrophomonas maltophilia strain DI-6 (Stenotrophomonas maltophilia strain DI-6). Soybean and cotton into which the above gene has been introduced are known. A soybean (Glycine max L.) into which a glyphosate resistant EPSPS gene (CP4 epsps) derived from Agrobacterium tomefaciens strain CP4 (Agrobacterium tumefaciens strain CP4) has been introduced at the same time as the above gene is disclosed, for example, in “Genuity (R) Roundup”. It is marketed under the trade name ReadyTM 2 XtendTM.
Further plants modified for herbicides are widely known, eg alfalfa resistant to glyphosate, apple, barley, eucalyptus, flax, grapes, lentils, rape, pea, potato, rice, sugar beet, sunflower , Tobacco, tomato mushibasa and wheat (see, for example, US 5188642, US 4940835, US 5633435, US 5804425, US 5627061); beans, cotton, soybeans, peas, potato, sunflower, tomato, tobacco, corn which are resistant to dicamba; Sorghum and sugar cane (see, for example, WO 2008/051633, US 7105724 and US 5670454); soybean, sugar beet, potato, tomato and tobacco resistant to glufosinate (see, eg, US 6376754, US 5646024, US 5561236); 2,4-D Resistant to cotton, peppers and apples , Tomato, sunflower, tobacco, potato, corn, cucumber, wheat, soybean, sorghum and miscellaneous cereals (see, for example, US6153401, US6100446, WO2005 / 107437, US5608147 and US5670454); ALS-inhibiting herbicides (for example, sulfonylurea herbicides) (Or imidazolinone herbicide), canola, corn, millet, barley, cotton, mustard, lettuce, lentils, melon, millet, oats, natata, potato, rice, rye, sorghum, soybean Sugar beet, sunflower, tobacco, tomato and wheat (see, for example, US5013659, WO2006 / 060634, US4761373, US5304732, US6211438, US6211439 and US6222100), particularly rice tolerant to imidazolinone herbicides, aceto Mutations specific to lactic acid synthesis gene (acetohydroxy acid synthase gene) , S 653 N, S 654 K, A 122 T, S 653 (At) N, S 654 (At) K, A 122 (At) T (see, eg, US 2003/0217381, WO 2005/020673); HPPD inhibiting herbicide (eg, isoxaflu) Barley, sugarcane, rice, which is resistant to the isoxazole herbicides such as tol; triketone herbicides such as sulcotrione and mesotrione; and pyrazole herbicides such as pyrazolinate) or diketonitriles of the decomposition products of isoxaflutole. Corn, tobacco, soybean, cotton, rapeseed, sugar beet, wheat and potato (see, for example, WO 2004/055191, WO 1996/38567, WO 1997/049816 and US 6791014); and wheat, soybean, which is resistant to PPO-inhibiting herbicides. Cotton, sugar beet, rapeseed, rice, corn, sorghum, sugar cane and sugar beet (eg, US 2002/0073443, US 2008/0052798, Pest Management Science, 61, 2005, 277-285).

  As a plant to which herbicide resistance has been imparted by conventional breeding techniques or genome breeding techniques, for example, rice “Clearfield® Rice” resistant to imidazolinone-based ALS-inhibiting herbicides such as imazethapyr and imazamox , Wheat "Clearfield (registered trademark) Wheat", sunflower "Clearfield (registered trademark) Sunflower", lentil "Clearfield (registered trademark) lentils" and canola "Clearfield (registered trademark) canola" (manufactured by BASF); Soybean "STS soybean" resistant to sulfonylurea-type ALS-inhibiting herbicides such as methyl; corn "SR corn" resistant to acetyl-CoA carboxylase inhibitors such as trione oxime type herbicides and aryloxyphenoxypropionic acid type herbicides (Also known as "Poast Protected® corn"); eg, Tribe Sunflower "ExpressSun (R)" resistant to sulfonylurea herbicides such as Ron; rice "Provisia (R) Rice" resistant to acetyl CoA carboxylase inhibitors such as xalohop; and photosystem II inhibitors And canola "Triazine Tolerant Canola"; and sorghum "Igrowth (trademark)" resistant to imidazolinone type herbicides.

  Canola "Su Canola (registered trademark)" having sulfonylurea herbicide resistance using Rapid Trait Development System (RTDS (registered trademark)) as a plant to which herbicide resistance has been imparted by genome editing technology Can be mentioned. RTDS (registered trademark) corresponds to oligonucleotide-directed mutagenesis in genome editing technology, and is designed to cut DNA in plants via Gene Repair Oligonucleotide (GRON), ie, a chimeric oligonucleotide of DNA and RNA. Is a technology that can introduce mutations. Other examples include corn with reduced herbicide resistance and phytic acid content by deleting the endogenous gene IPK1 using zinc finger nuclease (see, eg, Nature 459, 437-441 2009); Examples include rice which has been rendered herbicide resistant using casane (see, eg, Rice, 7, 5 2014).

Examples of plants to which herbicide resistance has been imparted by the new breeding technology include, for example, soybeans which have been imparted with properties of GM rootstock to scion by using a breeding technique using grafts. Specifically, there may be mentioned soybeans (see Weed Technology 2013, 27, 412.) in which glyphosate resistance is imparted to non-transgenic soybean scions by using glyphosate resistant Roundup Ready (R) soybean as a rootstock. .

  Examples of pest resistant plants are listed below.

For example, a plant that has been rendered resistant to lepidopteran pests by genetic engineering technology encodes delta-endotoxin (δ-endotoxin), which is an insecticidal protein derived from soil bacteria Bacillus thuringiensis (hereinafter abbreviated as Bt bacteria). Maize (Zea mays L.), soybean (Glycine max L.), cotton (Gossypium hirsutum L.), rice (Oryza sativa L.), poplar (Populus sp.), Tomato (Lycopersicon esculentum), Eggplant (Solanum melongena) and sugar cane (Saccharum sp.) Are mentioned. Examples of delta-endotoxin imparting resistance to lepidopteran insect pests include Cry1A, Cry1Ab, modified Cry1Ab (partially deleted Cry1Ab), Cry1Ac, Cry1Ab-Ac (a hybrid protein in which Cry1Ab and Cry1Ac are fused), Cry1C, Cry1F, Cry1Fa2 (Modified cry1F), moCry1F (Modified Cry1F), Cry1A. 105 (a hybrid protein in which Cry1Ab, Cry1Ac, Cry1F is fused), Cry2Ab2, Cry2Ae, Cry9C, Vip3A and Vip3Aa20.
Examples of plants that have been rendered resistant to coleoptera by a genetic engineering technique include corn and potatoes into which a gene encoding delta-endotoxin, which is an insecticidal protein derived from soil bacteria Bt bacteria, has been introduced. Examples of delta-endotoxin imparting resistance to coleopteran pests include Cry3A, mCry3A (modified Cry3A), Cry3Bb1, Cry34Ab1, Cry35Ab1, Cry6A, Cry6Aa and mCry6Aa (modified Cry6Aa).
For example, a plant that has been rendered resistant to a Dipteran pest by genetic recombination technology is a maize plant into which a synthetic gene encoding a hybrid protein eCry3.1Ab, which is a fusion of Cry3A derived from soil bacteria Bt bacteria and Cry1Ab, is Cotton (Gossypium hirsutum L.) into which a gene encoding a trypsin inhibitor CpTI from Zea mays L.) and cowpea (Vigna unguiculata) has been introduced. Furthermore, there are poplars etc. into which a gene encoding an API that is protease inhibitor protein A derived from Squid (Sagittaria sagittifolia) has been introduced, showing resistance to a wide range of pests.
Insecticidal proteins that impart insect resistance to plants include hybrid proteins of the above insecticidal proteins, partially deficient proteins, and modified proteins. A hybrid protein is made by the combination of different domains of multiple insecticidal proteins using genetic recombination technology, and Cry1Ab-Ac and Cry1A. 105 mag is known. As proteins in which a part has been deleted, Cry1 Ab etc. in which a part of the amino acid sequence has been deleted are known. As modified proteins, proteins in which one or more amino acids of natural delta-endotoxin are substituted, such as Cry1Fa2, moCry1F and mCry3A are known. The modified protein also includes the case where a protease recognition sequence not existing in nature is inserted into the toxin, for example, Cry3A055 (WO2003 / 018810) in which the cathepsin G-recognition sequence is inserted into the Cry3A toxin. Reference).
Monsanto has developed a cotton (event MON 88702) into which a modified BT protein Cry51Aa2 (Cry51Aa2.834_16) has been introduced by genetic recombination technology, and it is known that Lysus species such as Lygus lineolaris and the hemipods such as aphids and Frankliniella It is resistant to thrips such as genus species.
In addition, as insecticidal proteins that impart insect resistance to plants by genetic engineering techniques, for example, insecticidal proteins derived from Bacillus cereus or Bacillus popilliae; plant insecticidal proteins Vip1, Vip2 , Vip3 (as subclasses, Vip3Aa to Vip3Aj, Vip3Ba, Vip3B and Vip3Ca are known, and specifically, for example, Vip3Aa20 and Vip3Aa61 are known) and Vip4; Photorhabdus luminescence (Photorhabdus luminescens) etc. Insecticidal protein derived from bacteria such as Nematode symbionts (colonides forming colonies on nematodes) such as Xenorhabdus spp. Such as Photorhabdus spp. Or Xenorhabdus nematophilus; Scorpion toxin, spider toxin , Toxins produced by animals including insect specific neurotoxins such as bee toxins; Toxins produced by filamentous fungi such as Leptomyces toxin; Plant lectins such as pea lectin, barley lectin, snowdrop lectin; agglutinin; proteases such as trypsin inhibitor, serine protease inhibitor, patatin, cystatin, papain inhibitor Inhibitors; ribosomal inactivating proteins (RIPs) such as lysine, corn-RIP, abrin, lupine, saporin, briodin; steroids such as 3-hydroxysteroid oxidase, ecdysteroid-UDP-glucosyltransferase, cholesterol oxidase Metabolic enzymes; ecdysone inhibitors; HMG-CoA reductase; Ion channel inhibitors such as sodium channel inhibitors and calcium channel inhibitors; Juvenile hormone esterase; Diuretic hormone Receptor; stilbene synthase; bicycloalkyl benzyl synthase; it includes and glucanase; chitinases.

In addition, plants that have been rendered pest resistant by introducing one or more insecticidal protein genes are already known, and some plants are commercially available.
As an example of pest-resistant cotton, "BollgardTM cotton", which expresses the insecticidal protein Cry1Ac derived from Bt bacteria, "BXNTM Plus BollgardTM Cotton", "BXNTM Plus" Bollgard (TM) Cotton "," JK 1 "," Roundup Ready (TM) Bollgard (TM) Cotton "and" Ingard (TM) ";" Herculex "which expresses the insecticidal protein modified Cry1F (Cry1Fa2) from Bt bacteria Trademark "I" and "HerculexTM CB";"VIPCOTTMCotton" expressing the insecticidal protein Vip3A from Bt bacteria; "Bollgard II (trademark) expressing the insecticidal proteins Cry1Ac and Cry2Ab from Bt bacteria ) "cotton", "Roundup Ready (TM) Bollgard II (TM) Cottont", "Roundup Ready (TM) Flex (TM) Bollgard II (TM) Cotton", and "Fivermax (TM) Liberty Link (TM) Bollgard II (TM) “Bollgard III®” expressing the insecticidal proteins Cry1Ac, Cry2Ab and Vip3A derived from Bacillus subtilis B. And "Bollgard (R) III x Roundup Ready (TM) Flex (TM)"; VIPCOT (TM) Roundup Ready Flex (TM) Cotton, which expresses the insecticidal proteins Vip3A and Cry1Ab from Bt bacteria; “VIPCOT® Cotton” expressing the insecticidal proteins Vip3A and Cry1Ac of the following; “WideStrikeTM Cotton” which expresses the insecticidal proteins Cry1Ac and Cry1F derived from Bt bacteria, “WideStrikeTM Roundup ReadyTM” Cotton "and" Widestrike (TM) Roundup Ready Flex (TM) Cotton ";" TwinLink (TM) Cotton "and" Glytol (TM) x Twinlink (TM) "expressing the insecticidal proteins Cry1Ab and Cry2Ae from Bt bacteria; "Widestrike (registered trademark) 3" and "Widestrike (trademark) x Roundup Ready Flex (trademark) x VIPCOT (trademark) Cotton" expressing the insecticidal proteins Cry1Ac, Cry1F and Vip3A derived from Bacillus subtilis; GlytolTM x Twin Expressing the Proteins Cry1Ab, Cry2Ae and Vip3A link (trademark) x VIPCOT (trademark) Cotton "is marketed.
As an example of corn which has been imparted with pest resistance, “YieldGard® Rootworm RW”, “YieldGard® RW + RR”, “YieldGard® trademark VT (which represents the insecticidal protein Cry3Bb1 derived from Bt bacteria), Trademarks RootwormTM RR2 ”and“ MaxGardTM ”;“ YieldGard® VT Triple ”and“ YieldGardTM Plus with RR ”expressing the insecticidal proteins Cry3Bb1 and Cry1Ab from Bt bacteria; Bt "Bt Xtra (trademark) Maize" which expresses the insecticidal protein Cry1Ac derived from bacteria; "YieldGard Plus (registered trademark)" which expresses the insecticidal protein Cry1Ab and Cry3Bb1 derived from Bt bacteria; insecticidal protein Cry1Ab derived from Bt bacteria "Bt10", "Liberty Link (TM) Yieldgard (TM) Maize", "Agrisure (TM) GT / CB / LL" and "YieldGard (TM) CB + RR" to be expressed; insecticidal protein Cry1A. 105 and Cry2Ab2 expressing “YieldGardTM VT ProTM” and “GenuityTM VT Double ProTM”; “Agrisure® RW” expressing the insecticidal protein mCry3A derived from Bt bacteria “AgrisureTM GT / RW”; “StarlinkTM Maize” which expresses the insecticidal protein Cry9C derived from Bt bacterium; “YieldGardTM” which expresses the insecticidal protein Cry1Ab derived from Bt bacterium; MaizeGard (TM), "NaturGard KnockOut (TM)", "Maximizer (TM)", "Roundup Ready (TM) YieldGard (TM) maize", "Agrisure (TM) CB / LL" and "Mavera (TM) YieldGard""Agrisure®3122" which expresses the insecticidal proteins Cry1Ab, Cry1F, modified Cry3A, Cyr34Ab1 and Cyr35Ab1 derived from Bt bacteria; Agrisure® which expresses the insecticidal protein Vip3Aa20 derived from Bt bacteria Trademarks "Viptera";"Agri expressing the insecticidal proteins Vip3Aa20 and Cry1Ab derived from Bt bacteria" sure® Viptera® 2100 ”and“ Agrisure® Viptera® 3110 ”; the insecticidal protein Vip3Aa20 derived from Bt bacteria, Cry1Ab, and“ Agrisure® Viptera ”expressing modified Cry3A "Agrisure (trademark) 3100", "Agrisure (registered trademark) Viptera (trademark) 3111) and" Agrisure (registered trademark) Viptera (trademark) 4 "; an insecticidal protein Vip3Aa20 derived from Bt bacteria, Cry1Ab and modified Cry1F expressing "Agrisure (registered trademark) Duracade (trademark)" expressing the insecticidal protein eCry3.1Ab (a chimeric protein of Cry3A-Cry1Ab) derived from Bt bacteria; and the insecticidal protein derived from Bt bacteria eCry3.1Ab (a chimeric protein of Cry3A-Cry1Ab), modified Cry3A, Cry1Ab and “Agrisure® DuracadeTM 5122” expressing modified Cry1F; insecticidal protein eBry3.1B (Cry3A-Cry1Ab) derived from Bt bacteria (Chimeric protein), modified Cry3A, modified Cry1Ab and Vip3A variants “Agrisure® Duracade® 5222”; “Herculex® RW” expressing the insecticidal proteins Cyr34Ab1 and Cyr35Ab1 from Bt bacteria; expressing the insecticidal proteins Cyr34Ab1, Cyr35Ab1 and Cry1F from Bt bacteria “Herculex XTRA®”; insecticidal protein Cry1A. 105, “Genuity® VT Triple ProTM” expressing Cry2Ab2 and Cry3Bb1; insecticidal protein Cry1F, Cry2Ab, Cyr34Ab1, Cyr35Ab1, Cry3Bb1 and Cry1A. "Genuity (R) SmartStax (TM)", which expresses E. 105; insecticidal protein-modified Cry1F, Cry2Ab and Cry1A. 105 expressing "Power Core (trademark)"; Insecticidal protein modified Cry1F, Cyr34Ab1 and Cyr35Ab derived from Bt bacteria "Herculex XTRA (trademark) RR"; Insecticidal protein modified Cry1F, Cyr34Ab1, Cyr35Ab1 derived from Bt bacterium , Optimum® Intrasect Xtreme, which expresses Cry1Ab and modified Cry3A; “Optimum® Intrasect XTRA”, which expresses insecticidal protein-modified Cry1F, Cyr34Ab1, Cyr35Ab1 and Cry1Ab from Bacillus subtilis Bt; “Optimum® TRIsect” expressing the insecticidal protein modified Cry1F and modified Cyr3A is commercially available.
As examples of other pest resistant plants, the potato "Atlantic NewLeafTM potato", "NewLeafTM Russet Burbank potato", "Lugovskoi plus", which expresses the insecticidal protein Cry3A derived from Bt fungus, “Elizaveta plus”, “Hi-Lite NewLeafTM Y potato, Superior NewLeafTM potato” and “Shepody NewLeafTM Y potato”; rice “hanyou” which expresses the insecticidal proteins Cry1Ab and Cry1Ac derived from Bt bacteria 63 "and" Huahui-1 ";soybean" Intacta (TM) Roundup Ready (trademark) 2 Pro "expressing the insecticidal protein Cry1Ac derived from Bt bacterium; eggplant" BARI Bt expressing the insecticidal protein Cry1Ac derived from Bt bacterium Begun-1, -2, -3 and -4 "are commercially available.
Also, for example, corn “YieldGard corn rootworm”, “YieldGard VT”, “Herculex RW”, “Herculex Rootworm” and “Agrisure CRW” having resistance to corn rootworm; corn having resistance to cornborer “YieldGard corn” “Borer”, “YieldGard plus”, “YieldGard VT Pro”, “Agrisure CB / LL”, “Agrisure 3000GT”, “Hercules I”, “Hercules II”, “KnockOut”, “NatureGard” and “StarLink”; Western Bean Maize "Herculex I", "Herculex Xtra", "NewLeaf", "NewLeaf Y" and "NewLeaf Plus" resistant to cut worms, corn borers, black cut worms and fall army worms; against corn borers and corn root worms Resistant maize “YieldGard Plus”; resistant to S. tabaci Ta "Bollgard I" and "Bollgard II"; Bogus moth, cotton ball worm, fall army worm, beet army worm, cabbage looper, soybean looper and pink ball worm resistant to "Bollgard II", "WideStrike ( Trademarks "and" VipCot ";potato" NewLeaf "," NewLeaf Y "and" NewLeaf Plus "having tobacco tin mega resistance, eggplant" Bt brinjal "having resistance to egg borer, fruit bowler and cotton ball worm," Dumaguete " Long Purple "and" Mara "(see, for example, US Pat. No. 5,128,130) are known.
Further plants with insecticide resistance are generally known, such as, for example, Sankameiga resistant rice (see, for example, Molecular Breeding, Vol. 18 (2006), No. 1), Lepidopterous lettuce (see, for example). U.S. Pat. No. 5,349,124), rice having resistance to Lepidoptera (for example, Nica rice moth, P. vulgare L.), rice shoots, Kovenomea, rice case worms, and rice army worms) (see, for example, WO 2001/021821). Methods for producing such plants are generally known to the person skilled in the art and are described, for example, in the abovementioned publications.

  Plants which have been rendered insect-resistant by RNA interference technology include lepidopteran pests (eg corn borers, cut worms such as corn ear worms, black cut worms and fall army worms) and coleopteran pests (corn root worms) Maize that is resistant to is marketed or developed under the brand name "SmartStax (registered trademark)", "SmartStax (registered trademark) Pro" or "Genuity (registered trademark) SmartStax Pro".

For example, as a plant to which insect resistance has been imparted by conventional breeding techniques or genome breeding techniques, for example, the aphid resistance gene “Rag1 (Resistance to Aphis glycines 1)” gene or “Rag2 (Resistance to Aphis glycines) 2) "Soybean which is resistant to soybean aphids (Aphis glycines) having a gene (see J. Econ. Entomol., 2015, 108, 326.); soybean which is resistant to soybean cyst nematode (Heterodera glycines) (Phytopathology) , 2016, 106, 1444.); cotton (J. Nematol., 2009, 41, 140) showing resistance to Nematodes nematode (Meloidogyne incognita); rice "Kanto BPH 1" showing resistance to yellow-tailed planthoppers; Examples include soybean "Fukuminori" that exhibits resistance.

  These pest resistant plants are given resistance to any harmful insects (in particular, lepidopteran, coleoptera, dipteran insects, beetles), harmful spiders and harmful nematodes It is done. The pest-resistant plants are preferably cereals (eg wheat, barley, rye, oats), corn, canola, sorghum, soybean, rice, rapeseed, sugar beet, sugar cane, grape, lentil, sunflower, alfalfa, It is selected from fruits, kernel fruits, peanuts, coffee, tea, strawberries, turf, vegetables (eg, tomato, potato, cucurbitaceous plant and lettuce), more preferably soybean, corn, tomatoes, rice and rice It is selected from cereals (eg wheat, barley, rye and oats) and most preferably from soybeans, rice, corn and cereals (eg wheat, barley, rye and oats).

  Examples of plants that are given disease resistance are listed below.

Plants which have been rendered disease resistant by genetic engineering, for example, express so-called "pathogenicity related proteins" (PRP, see for example EP 0392225) or so-called "antifungal proteins" (AFP, see, eg, US6864068) Is a plant that Various antifungal proteins with activity against phytopathogenic fungi have been isolated from specific plant species and are common knowledge. Examples of such anti-pathogenic substances and plants from which such anti-pathogenic substances can be synthesized are known, for example, from EP 03992225, WO 1993/05153, WO 1995/33818 and EP 0 353 191. Plants resistant to fungicidal pathogens, viral pathogens and bacterial pathogens are produced by introducing plant resistance genes. A number of resistance genes have been identified, isolated and used to improve plant resistance, such as, for example, producing tobacco mosaic virus (TMV) resistant tobacco plants N gene introduced into tobacco lines susceptible to TMV (see, eg, US Pat. No. 5,571,706), Prf gene introduced into plants to obtain enhanced pathogen resistance (see, eg, WO 1998/02545), And the Rps2 gene derived from Arabidopsis thaliana (see, eg, WO 1995/028423) used to create resistance to bacterial pathogens such as Pseudomonas syringae. Plants showing a systemic acquired resistance response were obtained by introducing a nucleic acid molecule encoding the TIR domain of the N gene (see, eg, US Pat. No. 6,630,618). Further examples of known resistance genes include the Xa21 gene (see, for example, US5952485, US5977434, WO1999 / 009151, WO1996 / 022375), which has been introduced into many rice varieties, Rcg1 for Colletotrichum resistance. Gene (see, eg, US 2006/225152), prp1 gene (see, eg, US 5859332, WO 2008/017706), ppv-cp gene (see, eg, US PP15, 154 Ps) for introducing resistance to plumpox virus, P1 Genes (see, eg, US5968828), Genes such as Blbl, Blb2, Blb3, RB2 and Rpi-vnt1 for introducing resistance to Phytophthora infestans in potato (see, eg, US7148397), LRPKml gene (See, eg, WO 1999/064600), P1 gene for potato virus Y resistance (see, eg, US5968828), HA5-1 gene (see, eg, US5877403 and US6046384), potato virus X (PVX), Ja. Geimovirus Y (PVY), the PIP gene for introducing broad resistance to viruses such as potato leaf curl virus (PLRV) (see, for example, EP0707069), as well as Arabidopsis NI 16 for obtaining fungal resistance. Genes, genes such as the ScaM4 gene and the ScaM5 gene (see, for example, US6706952 and EP1018553). Beans resistant to bean golden mosaic virus (hereinafter referred to as BGMV) are plants which have been rendered resistant by RNA interference technology, and are double-stranded RNA genes of replication proteins. It shows resistance to BGMV by introducing (sense and antisense ac1 gene) and inhibiting the synthesis of BGMV replication protein. Methods for producing such plants are generally known to the person skilled in the art and are described, for example, in the abovementioned publications.
Antipathogenic substances that can be expressed by such plants include, for example, ion channel blockers (sodium channel blockers, calcium channel blockers etc); viral KP1, KP4 and KP6 toxins; stilbene synthase; bibenzyl synthase Chitinases; glucanases; so-called "pathogenicity related proteins"(PRP; see, for example, EP 0 339 225 25); antipathogenic substances produced by microorganisms (eg, peptide antibiotics, heterocyclic antibiotics (eg, WO 1995/033818) And protein or polypeptide agents involved in plant pathogen protection (so-called "plant disease resistance genes" described in WO 2003/000906)).
Antipathogenic substances produced by plants can protect plants from various pathogenic microorganisms such as fungi, viruses and bacteria. Useful plants of increasing interest in connection with the present invention are cereals (eg wheat, barley, rye and oats), soybeans, corn, rice, rapeseeds, pomegranates, kernel fruits, peanuts, coffee, tea, strawberries Vines and vegetables (eg tomato, potato), cucurbitaceous plants, papayas, melons, lentils and lettuce, more preferably soybeans, tomatoes, rice and cereals (eg wheat, barley, It is selected from rye and oats, most preferably from soybeans, rice and cereals such as wheat, barley, rye and oats.
Plants having resistance to fungal pathogens are, for example, soybeans having resistance to soybean rust (Phakopsora pachyrhizi and Phakopsora meibomiae) (see, for example, WO 2008/017706); Phytophthora infestans). Resistant cotton, tomato, potato, and other solanaceous plants (see, for example, US Pat. No. 5,853,332, US Pat. No. 7,148,397, EP 1334979); corn having resistance to Colletotrichum, such as Colletotrichum graminicola (for example, US2006 / 225152)); apples having resistance to apple scab (venturia inaequalis) (see, for example, WO 1999/064600); , Fusarium poae, fusarium acuminatum, fusarium plants having resistance to equiseti) (for example rice, wheat, barley, rye, corn, oats, potatoes, melons, soybeans and sorghum) (see for example US 6646184, EP 1477557); corn with extensive fungicidal resistance And soybeans (especially wheat, rye, barley, oats, rye, rice), tobacco, sorghum, sugar cane, potatoes etc. (see, for example, US5859332, US5689046, US6706952, EP1018553 and US6020129).
Plants having resistance to bacterial pathogens are, for example, rice having resistance to xylella fastidiosa (see, for example, US6232528); rice, cotton, soybean having resistance to bacterial wilt Plants such as potato, sorghum, corn, wheat, barley, sugar cane, tomato and pepper (see, for example, WO2006 / 42145, US5952485, US5977434, WO1999 / 09151, WO1996 / 22375); resistance to Pseudomonas syringae There is a tomato having sex (see, for example, Can. J. Plant Path., 1983, 5: 251-255).
Plants having resistance to viral pathogens are, for example, nuclear fruits having resistance to plum pox virus (for example, plum, almond, apricot, cherry, peach, nectarine) (for example, US PP15154Ps, EP0626449) See for example); potato with resistance to potato virus Y (see eg US5968828); potato, tomato, cucumber and tomato resistant to tomato spotted wilt virus Plants such as legumes (see, for example, EP 0626449, US 5973135); Corns resistant to corn streak disease virus (maize streak virus) (see, for example, US Pat. No. 6,040,496); papaya ring spot virus (See, for example, S5877403, US Pat. No. 6,046,384) having resistance to Cucurbitaceous plants having resistance to cucumber mosaic virus (eg, cucumber, melon, watermelon and pumpkin) and solanaceous plants (eg, potato, tobacco, tomato, eggplant, paprika, pepper and pepper) (eg, US6849780 Cucurbitaceae plants resistant to watermelon mosaic virus (watermelon mosaic virus 2) and zucchini yellow mosaic virus (zucchini yellow mosaic virus) (eg cucumber, melon, watermelon and pumpkin) (see eg US Pat. Viruses such as cigar virus (potato with resistance to potato leafroll virus (see, for example, US 5576202); potato virus X (potato virus X), potato virus Y (potato virus Y)), potato leafroll virus (potato leafroll virus) Potatoes with broad resistance to (eg, E See P. 070 70 69); Beans resistant to Bean golden mosaic virus (see, eg, Mol Plant Microbe Interact. 2007 Jun; 20 (6): 717-26).
Some plants are resistant to antibiotics (eg, kanamycin, neomycin and ampicillin). Naturally occurring bacterial nptII genes express enzymes that block the action of the antibiotics kanamycin and neomycin. The ampicillin resistance gene, ampR (also known as blaTEM1) is derived from the bacterium Salmonella paratyphi and is used as a marker gene in transformation of microorganisms and plants. ampR is involved in the synthesis of beta-lactamase, an enzyme that neutralizes antibiotics of the penicillin group, including ampicillin. Plants having resistance to antibiotics include, for example, potato, tomato, flax, canola, rape, rape seed and corn (eg, Plant Cell Reports, 20, 2001, 610-615, Trends in Plant Science, 11, 2006, 317-319, Plant Molecular Biology, 37, 1998, 287-296, Mol Gen Genet., 257, 1998, 606-13. Plant Cell Reports, 6, 1987, 333-336, Federal Register (USA), Vol. 60, No. 113, 1995, p. 31139. Federal Register (USA), vol. 67, No. 226, 2002, p. 70392, Federal Register (USA), vol. 88, 1998, 25194, Federal Register (USA), 60, No. 141, 1995, 37870, Canadian Food Inspection Agency, FD / OFB-095-264-A, October 1999, FD / OFB-099-127-A, see October 1999). Preferably, the above mentioned plants are selected from soybeans, tomatoes and cereals (eg wheat, barley, rye and oats), most preferably from soybeans and cereals (eg wheat, barley, rye and oats) Ru.
Plants that have been rendered resistant to plant virus diseases that can be obtained are, for example, papaya "Rainbow", "SunUp" and "Huanong No. 1" that are resistant to Papaya ringspot virus. ; Potato “Innate® Hibernate”, “Innate® Glaciate” and “Innate® Acclimate” showing resistance to Phytophthora infestans; Potato virus Y And / or potato "Newleaf.TM." That is resistant to potato leaf curl virus (PLRV).

  Resistant to rice blast (Magnaporthe oryzae) as a plant that has been rendered resistant to disease resistance by conventional breeding techniques or genome breeding techniques; resistance to sheath blight (Rhizoctonia solani) Rice which has been given resistance; wheat which has been given resistance to leaf rust (Puccinia triticina); wheat which has been given resistance to yellow rust (Puccinia striiformis f. Sp. Tritici); black rust (Puccinia graminis f. wheat which has been rendered resistant to sp. tritici); wheat which has been rendered resistant to powdery mildew (Blumeria graminis f. sp. tritici); wheat which has been rendered resistant to leaf blight (Zymoseptoria tritici); Wheat which has been rendered resistant to downy mildew (Stagonospora nodorum); wheat which has been rendered resistant to yellow spot (Pyrenophora tritic-repentis); powdery mildew (Blumeria graminis f. Sp. Barley with resistance to Hordei; Barley with resistance to minor rust (Puccnia hordei); Barley with resistance to net blotch (Pyrenophora teres); against Barley (Rhynchosporium commune) Resistant barley; barley conferred resistance to Ramularia collo-cygni; Corn conferred resistance to anthracnose (Anthracnose stalk rot); Gray leaf spot disease (Gray leaf) corn which has been rendered resistant to spot; corn which has been rendered resistant to Goss's wilt; corn which has been rendered resistant to Fusarium stalk rot; Asia. Soybean resistant to soybean rust (Asian soybean rust); resistance to soybean stem blight (phytophthora rot) Soybean conferred; Soybean conferred resistance to sudden death syndrome; Pepper conferred resistance to plague (Phytophthora); lettuce conferred resistance to powdery mildew; Tomato (Bacterial wilt) resistant tomato; Gemini virus (Geminivirus) resistant tomato; Downy mildew resistant lettuce; Clubroot disease (Clubroot) Cruciferous plants such as rapeseed, cabbage, brussels sprouts, cauliflower, colored green (Borekale), broccoli, etc. which are given resistance to rice; rapeseed, cabbage, brussels sprouts, cauliflower Brassicaceae plants such as colored green (Borekale) and broccoli; Melon vines caused by Fusarium oxysporum f. Sp. Melonis Mention may be made of melon (see, for example, WO 2009/000736) that is given resistance to mildew.

  As a plant to which disease resistance has been imparted by genome editing technology, it is possible to use a tarden and crisper castane to delete the powdery mildew resistance gene (MILDEW RESISTACE LOCUS O, hereinafter abbreviated as MLO), Disease-resistant bread wheat (see, for example, Nat. Biotech., 32, 947-951 2014); powdery mildew caused by deletion of the SlMLO1 gene, which is one of the MLOs, using crisper castane Slmlo 1 tomato (Tomelo) showing resistance (see, eg, Scientific Reports 7, Article number: 482 2017); Xanthomonas oryzae (Xanthomonas oryzae causing rice blight blight disease) by editing the OsSWEET14 gene in rice using tarene 30, which is resistant to pv. Oryzae) (see Nat. Biotechnol. 30, 390-392 2012); by modifying the OsERF 922 gene in rice using Crisper cassinin Rice showing resistance to Magnaporthe oryzae causing rice blast (PLoS ONE 11: e0154027. Doi: 10.1371 / journal.pone. 0154 027 2016); recessive eIF 4 E (true true) using crisper castane A cucumber (Mol. PlantPathol. 17,) which is resistant to cucumber vein yellowing virus (CVYV), zucchini yellow mosaic virus (ZYMV), papaya ringspot virus-type W (PRSV-W) by disruption of nuclear translation initiation factor 4E) gene 7 1140-1153 (see 2016); soybeans that show resistance to soybean foot blight caused by Phytophthora sojae by disruption of the RXLR effector gene (Avr4 / 6) using Crisper Cassane (Mol Plant Pathol 17 (1) 127-139 (see 2016).

  As a plant that has been given disease resistance by new breeding technology, the gene for Rvi6 (previously called HcrVf2) that is resistant to apple mold disease (Apple scab) caused by Venturia inaequalis is introduced using cisgenesis Apple that is resistant to cast mildew (see, for example, Plant Biotech. J., 12, 2-9, 2014); An example in which the properties of GM rootstock, which is a breeding technique using grafts, are given to scion Sweet cherry (Plant Biotech. J., 12, 1319-) which transferred its property from a non-transgenic scion to a transgenic non-transgenic rootstock that is resistant to infection with Prunus necrotic ringspot virus. 1328 2014)).

Examples of plants with altered product quality are listed below.
By quality modification of the product is meant an increase or decrease in the synthesis of the modified component or the synthesis amount of the component as compared to the corresponding wild-type plant. For example, vitamins, amino acids, proteins and starches, modified plants with increased or decreased content of various oils, and modified plants with reduced nicotine content.

  For example, a plant in which the quality of the product has been modified by genetic recombination technology is a double chain of S-adenosyl-L-methionine: trans-caffeoyl CoA 3-methyltransferase (ccomt) gene from alfalfa involved in lignin production Alfalfa with reduced lignin content by introducing RNA gene and reducing lignin content by RNA interference; Triacylglycerides containing lauric acid by introducing 12: 0 ACP thioesterase gene from laurier (Umbellularia californica) involved in fatty acid synthesis Canola “LauricalTM Canola” with increased content; Suppressing the expression of the same gene by introducing a partial gene (gm-fad2-1) of ω-6 desaturase from soybean, which is a fatty acid desaturase, Soybean "PlenishTM" or "TreusTM" with increased oleic acid content; Produce double-stranded RNA of the acyl-acyl carrier protein thioesterase gene (fatb1-A) from Izu and double-stranded RNA of the δ-12 desaturase gene (fad2-1A) from soybean Soybean "Vistive Gold (trademark)" whose saturated fatty acid content has been reduced by introducing a gene; δ-6 desaturase gene derived from primrose (Pj. D6D) and δ-12 desaturase gene derived from Neurospora crassa (Nc. Fad3) Genetically modified soybean in which stearidonic acid, which is one of ω3 fatty acids, was produced by introducing p53; by introducing the thermostable alpha-amylase gene (amy 797 E) of Thermococcales sp. For starch degradation Maize "Enogen (registered trademark)" with enhanced production of bioethanol; Maize "Mavera (TM) Maize" and "Mavera (TM) YieldGard (TM) Maize with enhanced lysine production by introducing the dihydrodipicolinate synthetase gene (cordapA) from Corynebacterium glutamicum ; The potato "Amflora (trademark)" in which the amylose content in starch granules is decreased and the amylopectin content is increased by introducing the antisense gene gbss of potato synthase-derived starch synthase (granule-bound starch synthase enzame, GBSS) “Starch Potato”; Introduction of genes pLh and pR1 that generate double-stranded RNA of transcription factor genes PhL and R1 that promote the degradation of starch from potato by the degradation of starch and gene Asn1 involved in asparagine production Inhibition of asparagine synthesis by introducing the gene asn1 that generates double-stranded RNA (carcinogenicity caused by heating To reduce the accumulation of asparagine and reducing sugars involved in the formation of acrylamide (the carcinogenic substance) and the gene ppo5 that generates the double-stranded RNA of the polyphenol oxidase gene Ppo5 derived from potato is used to suppress the black spot formation. "Innate (R) Culturali", "Innate (R) Generate", "Innate (R) Accelerate", "Innate (R) Invigorate", "Innate (R) Glaciate", "Innate (R) Acclimate "and" Innate® Hibernate "; tobacco whose nicotine content has been reduced by introducing the antisense gene (NtQPT1) of the quinolinate phosphoribosyltransferase gene QpTase from tobacco (Nicotiana tabacum); Synthesis of phytoene synthase gene (psy) and carotenoids from Narcissus pseudonarcissus) Rice that can produce β-carotene in the endosperm tissue and harvest vitamin A-containing rice by introducing the carotene desaturase gene (crt1) derived from soil bacteria (Erwinia uredovora) and expressing it specifically in the endosperm There is golden rice (Golden rice). Besides, for example, potato and corn with modified amylopectin content (see, for example, US 6784338, US 2007/0261136, WO 1997/04471); oil content modified canola, corn, cotton, grape, cattail , Cowpea (catalpa), rice, soybean, rapeseed, wheat, sunflower, bitter gourd, safflower and vernonia (for example, US7294759, US7157621, US581526, US6441278, US5723761, US6380462, US6365802, US6974898, WO2001) Sunflower with increased fatty acid content (see, eg, US Pat. No. 6,084,164); soybean, with reduced allergen content (see, eg, US Pat. No. 6,864,362); tobacco with reduced nicotine content (see, eg, US Pat. See, eg, US 2006/018 5684, WO 2005/000352 and WO 2007/064636); canola and soy with increased lysine content (eg Bio / Technolog) y 13, 1995, see 577-582); Corn and soybeans with modified methionine, leucine, isoleucine and / or valine composition (see, for example, US6946589, US6905877); soybeans with increased sulfur amino acid content See, for example, EP 0 929 685, WO 1997/041 239); leaf-specific expression of 3'-phosphoadenosine-5'-phosphosulphate reductase from Escherichia coli (3'-Phosphoadenosine-5'-phosphophosphate reductase) To increase the content of free amino acids (eg, asparagine, aspartic acid, serine, threonine, alanine, histidine and glutamic acid) corn with increased methionine content (see PNAS, 2017, 114 (43), 11386). Tomato (see, eg, US Pat. No. 6,727,411); corn with increased amino acid content (see, eg, WO 05/077117); potato, corn with modified starch content And rice (see, for example, WO 1997/044471 and US 7317146); tomato, corn, grapes, alfalfa, apples, legumes and peas with modified flavonoid content (see, for example, WO 00/04175); containing phenolic compound Corn, rice, sorghum, cotton and soy (see eg US 2008/0235829); tomato and canola with increased content of vitamin A (see eg US 6797498, US 7348167); content of vitamin E Increased tomato, canola, soybean, wheat, sunflower, rice, corn, barley and rye (see, eg, US 7348167, WO 2004/058934); alfalfa with modified flavonoid content, apple, bean, corn, grape, tomato and There is a pea (see, for example, WO 00/04175). Methods for producing such plants are generally known to the person skilled in the art and are described, for example, in the abovementioned publications. Preferably, the plants are selected from soybeans, canola, tomatoes, rice and cereals (eg wheat, barley, rye and oats), most preferably from soybeans, canola, rice and wheat, barley.

  Rape "Nexera® Canola" producing unsaturated omega-9 fatty acids as plants whose product quality has been modified by conventional breeding techniques or genome breeding techniques; soybeans with reduced allergen content "Yumeminori"; Rice intended for modification to a good taste, for example, rice "Yumepirika" having a reduced amylose content is commercially available. Also, citrus fruits in which the characteristics of fruits (for example, the weight of fruits, the degree of aroma, the degree of succulent and the degree of sweetness) have been modified by genomic selection are known (see Scientific Reports 7, 4721 2017).

  Plants modified in nutrient utilization of plants are, for example, plants in which the assimilation or metabolism of nitrogen or phosphorus is enhanced. Plants having nitrogen assimilation ability and nitrogen utilization ability enhanced by genetic engineering techniques are, for example, canola, corn, wheat, sunflower, rice, tobacco, soybean, cotton, alfalfa, tomato, wheat, potato, sugar beet, sugar cane and It is selected from rapeseed (see, for example, WO 1995/009911, WO 1997/030163, US6084153, US5955651 and US6864405). Examples of plants whose phosphorus uptake has been improved by genetic engineering include alfalfa, barley, canola, corn, cotton, tomato, rapeseed, rice, soybean, sugar beet, sugar cane, sunflower, wheat and potato (for example, US741711, See US 2005/0137386). Methods for producing such plants are generally known to the person skilled in the art and are described, for example, in the abovementioned publications. Preferably, the plants are selected from soybeans, tomatoes and cereals (eg wheat, barley, rye and oats), most preferably from soybeans, rice, corn and wheat.

  Examples of the plant whose fertility trait and the like have been modified by genetic recombination techniques include plants having a male sterility and a fertility restoration trait imparted to the plant. For example, maize and chicory having a male-sterile trait imparted by expressing a ribonuclease gene (barnase) derived from Bacillus amyloliquefaciens in a tapetum cell of silkworm; DNA adenine methylase gene (dam) derived from E. coli Maize which has been given a male sterility trait by introducing it; introduced an alpha-amylase gene (zm-aa1) from corn which gives a male sterility trait and a ms45 protein gene (ms45) from a corn which gives a fertility restoration trait Which controls the fertility trait by performing transformation: a canola which has been imparted with a fertility recovery function by expressing a ribonuclease inhibitor protein gene (barstar) derived from Bacillus subtilis in a tapetum cell of a moth; and a Bacillus which gives a male sterility trait Ribonuclease gene (b There is a canola whose fertility trait has been controlled by expressing a ribonuclease inhibitory protein gene (barstar) derived from Bacillus bacteria which imparts an arnase) and a fertility recovery trait. In addition, there are tomato, rice, mustard, wheat, soybean and sunflower which have been given a fertile trait by genetic recombination technology (for example, US6720481, US6281348, US5659124, US6399856, US7349222, US7230168, US6072102, EP1135982, WO2001 See WO 92/040 949)). Methods for producing such plants are generally known to the person skilled in the art and are described, for example, in the abovementioned publications. Preferably, the plants are selected from corn, canola, soybeans, tomatoes and cereals (eg wheat), most preferably from corn, canola, soybeans, rice, wheat.

  Abiotically stress-tolerant plants are drought, high salinity, high light intensity, high UV radiation, chemical contamination (eg high heavy metal concentration), low temperature or high temperature, limited nutrients (ie nitrogen, phosphorus) Plants that exhibit increased resistance to abiotic stress conditions such as feeding and population stress (see, eg, WO 2000/004173, WO 2007/131699, CA 2521729 and US 2008/0229448).

  Plants which have been rendered abiotic stress resistant by genetic engineering techniques are, for example, rice, maize, soybean, sugar cane, alfalfa, wheat, tomato, potato, barley, rapeseed, beans, oats, sorghum, which are resistant to drought. Cotton (see, eg, WO 2005/048693, WO 2008/002480 and WO 2007/030001); Corn, soybean, wheat, cotton, rice, rapeseed and alfalfa resistant to low temperature (see, eg, US 4731499 and WO 2007/112122); Examples thereof include rice, cotton, potato, soybean, wheat, barley, rye, sorghum, alfalfa, grape, tomato, sunflower and tobacco (see, for example, US7256326, US7034139, WO / 2001/030990) having high salt tolerance. In addition, there is corn “DroughtGard (registered trademark)” (Monsanto product) into which a cold shock protein gene cspB of Bacillus subtilis has been introduced.

  For example, a plant that has been given abiotic stress resistance by conventional breeding techniques or genome breeding techniques, for example, corn having "drought tolerance" has "Agrisure Artesian (registered trademark)" and "Optimum (registered trademark)". It is developed under the trade name of AQUAmax (registered trademark).

  Among the plants to which other traits have been imparted are plants whose maturation traits have been modified. Modification of maturation characteristics includes, for example, delayed ripening, delayed softening and premature maturation. Mating characteristics are modified by genetic recombination technology, and plants are improved in shelf life, for example, by introducing the S-adenosylmethione hydrolase gene (sam-K) from E. coli bacteriophage T3 related to ethylene production of plant hormones Melon and tomato; a gene lacking a part of ACC synthase gene from tomato involved in ethylene production of plant hormone, ACC deaminase gene from Pseudomonas chlororaphis which decomposes ACC which is an ethylene precursor, cell wall Of the tomato-derived polygalacturonase gene that degrades pectin, or by introducing any one or more of the tomato-derived ACC oxidase genes involved in the production of ethylene. Improved tomato; of the polygalacturonase gene from tomato There are tomatoes shelf-life by introducing a gene pg for generating heavy chain RNA was improved "FLAVR SAVR (TM)". Other examples of plants whose maturation characteristics have been modified by genetic engineering techniques are, for example, tomato, melon, raspberry, strawberry, muskmelon, pepper and papaya whose ripening is delayed (for example, US 5767376, US7084321, US6107548, US5981831 WO 1995/035387, US 5952546, US 5512466, WO 1997/001952, WO 1992/008798 and Plant Cell. 1989, 53-63 (see Plant Molecular Biology, 50, 2002). Methods for producing such plants are generally known to the person skilled in the art and are described, for example, in the abovementioned publications. Preferably, the plants are fruits (e.g. tomatoes, vines, melons, papayas, bananas, peppers, raspberries and strawberries); kernel fruits (e.g. cherry, apricots and peaches); pome fruits (e.g. apples and And citrus fruits (eg citron, lime, orange, pomelo, grapefruit, and mandarin), more preferably tomato, melon, papaya, vine, apple, banana, orange and strawberry; Most preferably, they are tomato, melon and papaya.

  For example, a plant to which other quality modifications have been imparted by genetic recombination technology is endogenous phytin by introducing a 3-phytase gene (phyA) derived from Aspergillus niger, which is a phytic acid degrading enzyme of the plant. Canola "Phytasede (R) Canola" with enhanced acid degradation; Dihydrodoflavonol-4-reductase gene from Petunia hybrida, an enzyme that produces the blue pigment delphinidin and its derivatives, and petunia, pansy Carnation "Moondust (trademark)" whose flower color is controlled to blue by introducing a flavonoid-3 ', 5'-hydroxylase gene derived from (Viola wittrockiana), Salvia (Salvia splendens), or Carnation, "Moondust (trademark)", "Moonshadow ( Trademarks "," MoonshadeTM "," MoonliteTM "," Moonaqua " “MoonvistaTM”, “MooniqueTM”, “MoonpearlTM”, “MoonberryTM” and “MoonvelvetTM”; enzymes that produce the blue pigment delphinidin and its derivatives A rose whose flower color was controlled to blue by introducing an anthocyanin-5-acyltransferase gene from a certain torenia (Torenia sp.) And a flavonoid-3,5'-hydroxylase gene from pansy; modified cedar pollen Rice having an immune tolerance action by introducing an antigen protein gene (7 crp) of rice; corn having enhanced degradation of endogenous phytic acid by introducing a 3-phytase gene (phyA) derived from black mold; Cotton that produces high-quality fibers with improved fiber microneader, increased fiber strength, uniform length and color, etc. For example, see WO1996 / 26639, US7329802, US6472588 and WO2001 / 17333) there is.

  Examples of plants modified in terms of plant growth and yield include plants with enhanced growth ability. For example, plants whose traits related to growth and yield have been modified by genetic engineering techniques are enhanced in plant growth by introducing a gene (bbx32) encoding a transcription factor that controls circadian origin from Arabidopsis thaliana, and as a result As a result, soybean ear weights increase by introducing a transcription factor gene (athb17) belonging to the homeodomain-leucine 14-zipper (HD-Zip) family class II HD-Zip II) from Arabidopsis thaliana. As a result, corn having high yield is being developed.

  As a plant whose quality has been modified by genome editing technology, the zinc finger nuclease is used to lack the IPK1 gene encoding inositol 1,3,4,5,6-pentakisphosphate 2-kinase which is an enzyme of phytic acid biosynthesis By removing the phytic acid content of corn "ZFN-12 maize"; browning resistance was conferred by deleting the gene encoding polyphenol oxidase, using crisper casnain Mushrooms (see, for example, Nature., Vol 532, 21 APRIL 2016).

  A plant whose quality has been modified by a new breeding technique is, for example, using cisgenesis to introduce into a new apple cultivar a low-polyphenol oxidase (enzyme that causes browning) -producing gene sequence GEN-03 isolated from apple An apple "Arctic (R)" with reduced expression of polyphenol oxide and not browning; tomato rootstock with salt tolerance, as an example to give the scion the properties possessed by GM rootstock which is a variety improvement technology using grafts The tomato which gave salt tolerance to the tomato of non-transgenic scion by using (see Physiol Plantarum, 124, 465-475, 2005).

  In rice, genes showing resistance to many diseases, pests and abiotic stress are known, and production of resistant varieties into which they are introduced is popular. As genes showing resistance to diseases and abiotic stress in rice, for example, BPH1, BPH2, BPH3, BPH4, BPH5, BPH6, BPH7, BPH8, BPH9, BPH10, BPH11, BPH12, BPH13, BPH14, BPH15, BPH17, for example. , BPH18, BPH19, BPH20, BPH22, BPH23, BPH24, BPH25, BPH26, BPH28, BPH29, BPH32, BPH32, qBPH-12, qBPHR-1, qBPHR-3, qBPHR-8, qBPHR-5-1qBPHR-5 -2qBPHR-11-1, qBPHR-11-2 etc. resistance plant resistance genes such as WBPH1, WBPH2, WBPH3, WBPH4, WBPH5, WBPH6, OVC, qOVA-5-2, qOVA1-3, qOVA5-1 etc Sex varieties: Qsbph2b, Qsbph3, Qsbph3b, Qsbph3c, Qsbph3d, Qsbph4, Qsbph8, Qsbph11, Qsbph11d, Qsbph11e, Qsbph11g, Qsbph11h, etc. , GLH9, GLH10, GLH11, GLH13, GRH1, GRH2, GRH2, GRH3, GRH4, GRH5, Zlh1, Zlh2, Zlh3, qGRH-4, qGRH-2, qGRH-5, qGRH-6, qGRH-11, qGRH- 3 resistance genes such as leafhopper resistance genes; resistance genes for resistance such as SB etc. Pii, PI65, PIZT, PI24, PI29, PI25, Pi-jnw1, PB1, PIQ6, PID3, PI67, PITQ5, PITP, PITQ6, PLM2, PISE3, IPI, PISE1, PI157, PIQ4, PI21, PIA, PIK, PIKUR, PIKUR1, PIKUR2, PI3, PIF, PIZH, PIR4, PIR7, PI30, PI, PIGD2, PIG, PIGD3, PIGD1, PIZ, PI (PI18, PI18) , PI17, PI20, PI1, PI19, PI5, PISH, PI9, PI21, PI22, PI22, PI44, PI22, PI13, PII, PIB1, PIQ1, PIQ2, PIQ3, PIIS1, PII2, PI62, PI12, IPI3, PI14, PI15 , PI16, PIT, PI11, PI6, PI23, PI11, PIIS2, PIIS2, PIB2, PI12, PI39, PITA, PIR2-3, PIR9-2, PIR12-2, PIRF2-1, qRBR-2, qRBR-3 , PI27, PI28, PI26, PIGM, PI47, PI7, PI56, PI49, PI34, PIKG, PIKG, PI38, PI32, PI31, PI46, PIX, PIXY, Pita3, PI41, PI42, PI42, PI2, PI36, PI37, PIKH, PIKM , PIKP, PI35, PIZ5, PIB2, PI43, PI51, PI51, PID1, PIY1, PIY2, PI55-2, PICO39, PI55-1, PIBH8, PIR7A, PIR7B, PID2, PI3 3, qBFR4-1, qBFR4-2, qRBR-2, qRBR-3, qRBR-8, qRBR-1-1, qRBR-1-3, qRBR-7-1, qRBR-7-2, qRBR-9- 1, blast resistance genes such as qRBR-9-2, qRBR-9-3, qRBR-1-2, qRBR-1-4; stripe leaf blight resistance genes such as STVA, STVB, Stvb-i; XA21D, XA, XA40, XA NM, XA8, XA33, XA35, XA36, XA37, XA7, XA3, XA25, XA29, XA29, XA30, XA31, XA32, XA38, XA39, XA11, XA11, XA16, XA16, XA16, XA16, XA17 , Leaf blight resistance genes such as XA20, XA14, XA2, XA12, XA1, XA, XA, XAH, XA10, XA23, XA22, XA24, XA21, SERRT13, XA4, XA5, XA13, etc .; sheath blight resistance genes such as qSB-3, qSB-7, qSB-11, qSB-9-1; sesame leaf blight resistance genes such as CE; yellow dwarf disease resistance genes such as YDV; such as BSV Black streak atrophy disease resistance genes; high temperature climbing resistance genes such as Amy1A, Amy1C, Amy3A, Amy3B; low amylose genes such as dul3, qAC9.3, rsr1, Wx and Wx1-1; such as AP01, SCM2, Sd1 etc Lodging resistance gene Panicle germination resistance genes such as Sdr4; low temperature resistance genes such as CTB1, CTB2 and qLTG3-1; drought resistance genes such as Dro1; DEP1, Cn1a, GPS, SPIKE, PTB1, TAWAWA1, WFP, IPA1, GS3, GS5, GS6 , GL3.1, GW2, GW8, qGL3, qSS7, qSW5 and other genes related to seed number or genes; genes that modulate photoperiod reactivity such as Hd1, Ghd8, DTH8; endosperm powdery properties such as FLO4, PDIL1 Genes; lipoxygenase-deleted (reduced old rice odor) genes such as LOX3; genes related to amylopectin chain length such as Alk etc. are known. Rice varieties in which one or more of these genes have been simultaneously incorporated have been developed or marketed.

  The aforementioned plants can be treated with abiotic stress resistance, disease resistance, weeding as described above using genetic recombination technology, conventional breed improvement technology, genome breeding technology, new breeding technology or genome editing technology etc. Antibiotic resistance, pest resistance, growth and yield traits, modification of nutrient utilization, quality modification of products, lines with two or more kinds of fertility traits, etc., and plants with similar or different properties Also included are plants to which two or more properties possessed by the parent line have been imparted.

Commercial plants which have been rendered resistant to two or more herbicides are, for example, cotton “GlyTolTM LibertyLinkTM” and “GlyTolTM LibertyLinkTM” resistant to glyphosate and glufosinate; glyphosate Corn “Roundup ReadyTM LibertyLinkTM Maize” with tolerance and glufosinate tolerance; soybean “EnlistTM Soybean” with glufosinate resistance and 2,4-D resistance; soybean “genuity with glyphosate resistance and dicamba” ® Roundup ReadyTM 2 XtendTM ”; Corn and soybean“ Optimum GATTM ”with glyphosate resistance and ALS inhibitor resistance; 3 herbicides: glyphosate, glufosinate and 2,4-D Genetically modified soybeans "Enlist E3 (TM)" and "Enlist (TM) Roundup Ready 2 Yield (R)" that are resistant; glyphosate Corn "Enlist® Roundup Ready® Corn 2" resistant to 2,4-D and allyloxyphenoxypropionic acid based (FOPs) herbicides; glyphosate, 2,4-D and allyloxyphenoxypropionic acid Maize "Enlist (TM) Roundup Ready (R) Corn 2" that is resistant to line (FOPs) herbicides; Cotton "Bollgard II (R) XtendFlex (TM) Cotton" that is resistant to dicamba, glyphosate and glufosinate; Cotton “EnlistTM Cotton” resistant to 3 herbicides of glyphosate, glufosinate and 2,4-D; resistant to 3 herbicides of glyphosate, glufosinate and HPPD herbicides (eg isoxaflutole) There is a soybean "Liberty Link (registered trademark) GT27 (trademark)". In addition, cotton resistant to both glufosinate and 2,4-D; cotton resistant to both glufosinate and dicamba; corn resistant to both glyphosate and 2,4-D; glyphosate and HPPD herbicides Soybeans resistant to both; glyphosate, glufosinate, 2,4-D, allyloxyphenoxypropionic acid (FOPs) herbicides and corn resistant to cyclohexadione (DIMs) herbicides have also been developed.
Commercial plants that have been rendered herbicide resistant and pest resistant are, for example, corn “YieldGard Roundup Ready” and “YieldGard Roundup Ready 2” having glyphosate resistance and resistance to cornballer; glufosinate resistance and cornballer resistance Maize “Agrisure CB / LL” with sex; corn “Yield Gard VT Root worm / RR2” with glyphosate resistance and corn root worm resistance; corn with glyphosate resistance and corn root worm and corn bola resistance Maize "Hielcule I" with "Gield Gard VT Triple"; glufosinate resistance and lepidopteran resistance to corn (Cry1F) (eg, resistance to Western bean cut worms, corn borers, black cut worms and fall army worms) Glyphosa Corn “YieldGard Corn Rootworm / Roundup Ready 2” with resistance and corn rootworm resistance; glufosinate resistance and resistance to corn coleopteran pests (Cry3A) (eg, Western corn rootworm, Northern corn rootworm and Mexican corn root Corn "Agrisure GT / RW" with resistance to worms; resistance to glufosinate and resistance to coleopteran pests of corn (Cry34 / 35Ab1) (eg, resistance to Western corn rootworm, Northern corn rootworm and Mexican corn rootworm Corn) “Herculex RW” with glyphosate resistance; corn “Yield Gard VT Root worm / RR2” with glyphosate resistance and corn rootworm resistance; dicamba resistance, glyphosate resistance, glyphosate resistance and cotton lepidopteran resistance ( For example There are cotton "Bollgard 3 (R) XtendFlex (registered trademark)" having bollworm acids and tobacco budworm, the resistance) against such armyworm acids.

  Commercial plants that have been given disease resistance and pest resistance are, for example, potato virus "Phytovirus Y" resistance and pest resistance, and the potato "Hi-Lite NewLeafTM Y Potato". “NewLeafTM Y Russet Burbank Potato” and “Shepody NewLeafTM Y Potato”; Potato leaf pill (Potato leafroll virus) resistant and pest resistant potato “NewLeafTM Plus Russet” Burbank Potato.

  Commercial plants given the characteristics of herbicide resistance and product quality modification are, for example, canola “InVigorTM Canola” given the glufosinate resistance and dwarf trait; the glufosinate tolerance and dwarf trait Maize "InVigor (TM) Maize"; glyphosate resistant and soybean "Vistive Gold (TM)" modified in oil content.

  Examples of commercial plants having three or more traits are glyphosate resistant, glufosinate resistant and lepidopteran insect resistant (Cry1F) (i.e. against Western bean cut worms, corn borers, black cut worms and fall army worms) Resistant) corn "Herculex I / Roundup Ready 2"; glyphosate resistant, corn rootworm resistant and cornbowl resistant corn "YieldGard Plus / Roundup Ready 2"; glyphosate resistant, glufosinate resistant and cornboler resistant Corn "Agrisure GT / CB / LL" with glufosinate; glufosinate resistant, lepidopteran pest resistant (Cry1F) and coleopteran pest resistant (Cry34 / 35Ab1) (ie Western bean cut worm, corn borer, black cut worm and fall army Harm order harm such as worms And corn (Herculex Xtra) having resistance to coleopteran pests such as Western corn rootworm, Northern corn rootworm, Mexican corn rootworm, etc .; glufosinate resistant, corn borer resistant (Cry1Ab) and coleopteran pest resistant (Cry3A) Maize “Agrisure CB / LL / RW” (ie, resistant to Western corn rootworm, Northern corn rootworm and Mexican corn rootworm); glyphosate resistant, corn borer resistant (Cry1 Ab) and coleopteran pest resistant ( Corn "Agrisure (TM) 3000 GT" with Cry3A) (i.e. resistance to Western corn rootworm, Northern corn rootworm and Mexican corn rootworm); against glyphosate resistant, corn rootworm and European corn borer Maize "Mavera high-value corn" with high resistance and high lysine traits; harming the ground such as European corn browler, South western corn browler, corn ear worm, fall army worm, black cut worm and / or western bean worm Corn “Optimum® LeptraTM” resistant to pests; glyphosate resistant, glyphosate resistant, frogeye leaf spot resistant, soybean sudden death syndrome (Sudden Death Syndrome) resistant, soybean stem Resistance to southern stem canker, resistance to soybean stem rot (Phytophthora root rot), resistance to southern root-knot nematode, resistance to soybean sclerotia white mold, resistance to soybean leaf rot (brown) stem rot) resistance, soybean cyst nematode (soybea) Soybean “Credenz® soybean” resistant to n cyst nematode, ameliorated iron chlorosis, and altered chloride sensitivity; confer multiple herbicide resistance and pest resistance In order to correspond to the weed and pest occurrence situation in the field in each region, the “Stoneville (R) Cotton” (ST5517GLTP, ST4848GLT, ST4949GLT, ST5020GLT, ST5115GLT, ST6182GLT, ST4747GLB2, ST4946GLB2, and ST6448GLB2) There are two varieties).

Commercially available or developed plants are listed below (A1 to A556). In parentheses, [plant name, event name, event code, trade name (Tradename)] is meant. Also, NA means "no information" or "unavailable information". Many of these plants can be found in the registration database (GM APPROVAL DATABASE) (http://www.isaaa.org/) in the electronic information site of the International Agribio Agency (INTERNATINAL SERVICE for the ACQUISITION of AGRI-BIOTECH APPLICATIONS, ISAAA). It is listed in
A1: [alfalfa, J101, MON-00101-8, Roundup Ready (registered trademark) Alfalfa], A2: [alfalfa, J101 x J163, MON-00101-8 x MON-00163-7, Roundup Ready (registered trademark) Alfalfa], A3: [Alfalfa, J163, MON-00163-7, Roundup ReadyTM Alfalfa], A4: [Alfalfa, KK179, MON-00179-5, HarvXtraTM], A5: [Alfalfa, KK179 x J101, MON -00179-5 x MON-00101-8], A6: [Apple, GD743, OKA-NB001-8, Arctic (TM) "Golden Delicious" Apple], A7: [Apple, GS784, OKA-NB002-9, Arctic (Trademark), A8: [Apple, NF 872, OKA-NB003-1, Arctic (TM) Fuji Apple], A9: [Argentina Canola, 23-18-17 (Event 18), CGN-89111-8, Laurical ( Trademarks Canola], A10: [Argentina Canola, 23-198 (Event 23), CGN-89465-2, LauricalTM Canola], A11: [Argentina Canola, 61061, DP-061061-7], A12: [A12: [ Argentine canola, 73496, DP-073496-4, Optimum (registration Standard) Gly canola], A13: [Argentina Canola, 73496 x RF3, DP-073496-4 x ACS-BN003-6, NA], A14: [Argentina Canola, GT200 (RT200), MON-89249-2, Roundup Ready] (TM) Canola, A15: [Argentina Canola, GT73 (RT73), MON-00073-7, Roundup ReadyTM Canola], A16: [Argentina Canola, HCN10 (Topas 19/2), NA, Liberty Link ( Trademark Independence (TM), A17: [Argentina Canola, HCN28 (T45), ACS-BN008-2, InVigor (TM) Canola], A18: [Argentina Canola, HCN28 x MON88302, ACS-BN008-2 x MON- 88302-9, InVigorTM x TruFle xTM Roundup ReadyTM Canola, A19: [Argentina Canola, HCN 92 (Topas 19/2), ACS-BN 007-1, Liberty LinkTM InnovatorTM ], A20: [Argentina Canola, HCN 92 x MON 88 302, ACS-BN 007-1 x MON-88 302-9, Liberty Link (TM) Innovator (TM) x TruFle x (trademark) ) Roundup Ready (TM) Canola], A21: [Argentina Canola, MON 88302, MON-88302-9, TruFle x (TM) Roundup Ready (TM) Canola], A22: [Argentina Canola, MON88302 x MS 8 x RF3, MON- 88302-9 x ACS-BN005-8 x ACS-BN 003-6, InVigorTM x TruFle xTM Roundup ReadyTM Canola, A23: [Argentina Canola, MON88302 x RF3, MON-88302-9 x ACS-BN 003-6, NA], A24: [Argentina Canola, MPS 961, NA, Phytased (TM) Canola], A25: [Argentina Canola, MPS 962, NA, Phytased (TM) Canola], A26: [Argentina Canola, MPS 963 , NA, Phytased (TM) Canola], A27: [Argentina Canola, MPS 964, NA, Phytased (TM) Canola], A28: [Argentina Canola, MPS 965, NA, Phytased (TM) Canola], A29: [Argentina Canola, MS1 (B91-4), ACS-BN004-7, InVigorTM Canola], A30: [Al Tiny canola, MS1 x MON 88302, ACS-BN004-7 x MON-88302-9, InVigorTM x TruFle xTM Roundup ReadyTM Canola, A31: [Argentina Canola, MS1 x RF1 (PGS1), ACS-BN004-7 x ACS-BN001-4, InVigorTM Canola, A32: [Argentina Canola, MS1 x RF1 (PGS2), ACS-BN004-7 x ACS-BN002-5, InVigorTM Canola] , A33: [Argentina Canola, MS1 x RF3, ACS-BN004-7 x ACS-BN003-6, InVigor (TM) Canola], A34: [Argentina Canola, MS8, ACS-BN 005-8, InVigor (TM) Canola] , A35: [Argentina Canola, MS8 x MON 88302, ACS-BN005-8 x MON-88302-9, InVigorTM x TruFle xTM Roundup ReadyTM Canola], A36: [Argentina Canola, MS8 x RF3] , ACS-BN005-8 x ACS-BN003-6, InVigor (TM) Canola, A37: [Argentina Canola, MS8 x RF3 x GT73 (RT73), ACS-BN005-8 x ACS-BN003-6 x MON-00073. -7, NA], A38: [A Zentin canola, OXY-235, ACS-BN 011-5, Navigator (TM) Canola], A39: [Argentina Canola, PHY14, NA, NA], A40: [Argentina Canola, PHY23, NA, NA], A41: [Argentina Canola, PHY35, NA, NA], A42: [Argentina Canola, PHY36, NA, NA], A43: [Argentina Canola, RF1 (B93-101), ACS-BN001-4, InVigorTM Canola], A44: [Argentina Canola, RF1 x MON88302, CS-BN001-4 x MON-88302-9, InVigorTM x TruFle xTM Roundup ReadyTM Canola], A45: [Argentina Canola, RF2 (B94-2) , ACS-BN002-5, InVigor (TM) Canola], A46: [Argentina Canola, RF2 x MON 88 302, ACS-BN002-5 x MON-88302-9, InVigor (TM) x TruFle x (TM) Roundup Ready (TM) ) Canola], A47: [Argentina Canola, RF3, ACS-BN003-6, InVigorTM Canola], A48: [beans, EMBRAPA 5.1, EMB-PV051-1, NA], A 49: [Carnation, 11 (7442), FLO-07442-4, Moondust (trademark)], A50: [Carnation, 11363 (1363A), FLO-11363-1, Moonshadow (trademark)],
A51: [Carnation, 1226A (11226), FLO-11226-8, Moonshade (trademark)], A52: [Carnation, 123.2.2 (40619), FLO-40619-7, Moonshade (trademark)], A53: [Carnation, , 123.2.38 (40644), FLO-40644-4, Moonlite (TM), A54: [Carnation, 123.8.12, FLO-40689-6, Moonaqua (TM)], A55: [Carnation, 123.8.8 ( 40685), FLO-40685-1, Moonvista (trademark), A56: [Carnation, 1351A (11351), FLO-11351-7, Moonshade (trademark)], A57: [Carnation, 1400A (11400), FLO-11400. -2, Moonshade (trademark), A58: [Carnation, 15, FLO-00015-2, Moondust (trademark)], A59: [Carnation, 16, FLO-00016-3, Moondust (trademark)], A60: [ Carnation, 19907, IFD-19907-9, MooniqueTM], A61: [Carnation, 25947, IFD-25947-1, MoonpearlTM], A62: [Carnation, 25958, IFD-25958-3, Moonberry ( Trademarks], A63: [Kernesh , 26407, IFD-26407-2, Moonvelvet (trademark), A 64: [Carnation, 4, FLO-00004-9, Moondust (trademark)], A 65: [Carnation, 66, FLO-00066-8, NA] A66: [Carnation, 959A (11959), FLO-11959-3, MoonshadeTM], A67: [Carnation, 988A (11988), FLO-11988-7, MoonshadeTM], A68: [Chicoli, RM3] -3, NA, SeedLink (trademark), A69: [Chicoli, RM3-4, NA, SeedLink (trademark)], A70: [Chicoli, RM3-6, NA, SeedLink (trademark)], A71: (cotton, 19-51a, DD-01951A-7, NA], A72: [cotton, 281-24-236, DAS-24236-5, NA], A73: [cotton, 281-24-236 x 3006-210-23 ( MX B-13), DAS-24236-5 x DAS-21023-5, WideStrike (trademark) Cotton], A74: [cotton, 281-24-236 x 3006-210-23 x COT102 x 81910, DAS-24236- 5 x DAS-21023-5 x SYN-IR102-7 x DAS-81910-7, NA], A75: [cotton, 3006-210-23, DAS-21023-5, NA], A76: [cotton, 3006-] 210-23 x 281-24-236 x MON 1445, DAS-21023-5 x DAS-24236-5 x MON-01445-2, WideStrike (trademark) ) Roundup ReadyTM Cotton], A77: [Water, 3006-210-23 x 281-24-236 x MON88913, DAS-21023-5 x DAS-24236-5 x NAMON-88913-8, WidestrikeTM Roundup ReadyFlex (Cotton), A78: [cotton, 3006-210-23 x 281-24-236 x MON88913 x COT102, DAS-21023-5 x DAS-24236-5 x MON-88913-8 x SYN-IR102-7. , Widestrike (R) RoundupReadyFlex (TM) Cotton, A79: [Rat, 31707, NA, BXN (R) PlusBollgard (R) Cotton], A80: [Rat, 31803, NA, BXN (R) PlusBollgard (R) Cotton ], A81: [cotton, 31807 x 31808, NA, NA], A82: [cotton, 31807, NA, BXNTM PlusBollgardTM Cotton], A83: [cotton, 31808, NA, BXNTM PlusBollgard] (Cotton), A84: [cotton, 42317, NA, BXN (TM) PlusBollgard (TM) Cotton], A85: [cotton, 81910, DAS-81910-7, NA], A86: [cotton, BNLA-601 , NA, NA], A87: [cotton, BXN 10211 (10211), BXN-10211-9, NA], A88: [cotton, BXN 10215 (10215), BXN-10215-4NA, BXNTM Cottonin], A89: [Water BXN102 Cotton 22 (10222), BXN-10222-2, BXN (Cotton) Cotton, A90: [Cotton, BXN 10224 (10224), BXN-10224-4NA, BXN Cotton,] A91: Cotton, COT 102 ( IR102), SYN-IR102-7, VIPCOT (trademark) Cotton], A92: [cotton, COT102xCOT67B, SYN-IR102-7NAxNASYN-IR67B-1, VIPCOT (trademark) Cotton], A93: [cotton, COT102 x COT67B x MON 88 913, SYN-IR102-7NA x NASYN-IR67 B-1NA x NAMON-88913-8, VIPCOT (TM) RoundupReadyFle x (TM) Cotton], A94: [cotton, COT102 x MON15985, SYN-IR102-7NA x NAMON-15985-7, Bollgard (registered trademark) III], A95: [cotton, COT102 x MON15985 x MON88913, SYN-IR102-7NA x NAMON-15985-7NA x NAMON-88913-8, Bollgard (registered trademark) III x RoundupReady (trademark) Flex (trademark), A96: [Cotton, COT102 x MON15985 x MON88913 x MON88701, SYN-IR102-7NA x NAMON-15985-7NA x NAMON-88913-8NA x NAMONNA88701-3, NA], A97 : [Cotton, COT 67B (IR67B), SYN-IR67B-1, NA], A98: [cotton, Event 1, NA, JK1], A99: [cotton, GFMCry1A, GTL-GFM311-7, NA], A100: [W , GHB119, BCS-GH005-8, NA],
A101: [cotton, GHB614, BCS-GH002-5, GlyTol (trademark)], A102: [cotton, GHB614 x LLCotton25, BCS-GH002-5NA x NAACS-GH001-3, GlyTol (trademark) LibertyLink (trademark)], A103: [cotton, GHB 614 x LLCotton 25 x MON 15985, BCS-GH002-5NA x NAACS-GH001-3 NA x NAMON-15985-7, NA], A104: [cotton, GHB 614 x MON 15985, BCS-GH002-5 NA x NAMON-15985 , NA], A105: [cotton, GHB614 x T304-40 x GHB119, BCS-GH002-5NA x NABCS-GH004-7NA x NABCS-GH005-8, Glytol (trade mark) x Twinlink (trade mark)], A106: [cotton GHB 614 x T304-40 x GHB119 x COT102, BCS-GH002-5NA x NABCS-GH004-7NA x NABCS-GH005-8NA x NASYN-IR102-7, Glytol x Twinlink x x VIPCOT x Cotton ], A107: [cotton, GK12, NA, NA], A108: [cotton, LLCotton25, ACS-GH001-3NA, FibermaxTM LibertyLinkTM], A109: [cotton, LLCotton25 x MON15985, ACS-GH001] -3NA x NAMON-15985-7, Fiberma x (TM) LibertyLink (TM) Bollgard II (TM)], A110: [cotton, MLS9124, NA, NA], A111: [cotton, MON1076] , MON-89924-2, Bollgard (TM) Cotton], A112: [cotton, MON 1445, MON-01445-2, RoundupReady (TM) Cotton], A113: [cotton, MON15985, MON-15985-7, Bollgard II (TM) ) Cotton: A114: [cotton, MON15985 x MON 1445, MON-15985-7NA x NAMON-01445-2, RoundupReady (TM) Bollgard II (TM) Cotton], A115: [cotton, MON1698, MON-89383-1, RoundupReady] (Cotton), A116: [cotton, MON531, MON-00531-6, Bollgard (TM) Cotton, Ingard (TM)], A117: [cotton, MON531 x MON 1445, MON-0531-6NA x NAMON-01445- 2, RoundupReady (trademark) Bollgard (trademark) Cotton], A118: [cotton, MON757, MON-00757-7, Bollgard (trademark) Cotton], A119: [cotton, MON88701, MONNA88701-3, NA], A120: [ Cotton, MON88701 x MON 88913, MONNA 88701-3NA x NAMON-88913-8, NA], A121: [Cotton, MON88701 x MON 88913 x MON15985, MONNA 88701-3 NA x NAMON-88913-8 NA x NAMON-15985-7, Bollgard II (Registration Trademarks) XtendFlexTM Cotton], A122: [Rat, MON 88913, MON-88913-8, Roundup ReadyTM F] lex (trademark) Cotton], A123: [cotton, MON88913 x MON15985, MON-88913-8NA x NAMON-15985-7, RoundupReady (trademark) Flex (trademark) Bollgard II (trademark) Cotton], A124: [cotton, NgweChi6Bt, NA, NgweChi6Bt], A125: [cotton, SGK 321, NA, NA], A126: [cotton, T303-3, BCS-GH003-6, NA], A127: [cotton, T304-40, BCS-GH004-7, NA], A128: [cotton, T304-40 x GHB119, BCS-GH004-7NA x NABCS-GH005-8, TwinLink (TM) Cotton], A129: [creeping bent glass, ASR 368, SMG-36800-2, NA] , A130: [Aubergine, BtBrinjalEvent EE1, BtBrinjalEvent EE1, BARIBtBegun-1, -2, -3 and -4], A131: [Eucalyptus, H421, H421, GMEucalyptus], A132: [Ama, FP967 (CDCTriffid), CDC-FL001-2 , CDCTriffidFla x], A133: [Lent bean, RH44, RH44, Clearfield (R) lentil], A134: [corn, 32138, DP-32138-132138, 2138 SPTmaintainer], A135: [corn, 3272, SYN-E3272-5. , Enogen (trademark), A136: [corn, 3272 x Bt11, SYN-E3272-5 x S YN-BT011-1, NA], A137: [corn, 3272 x Bt11 x GA21, SYN-E3272-5 x SYN-BT011-1 x MON-00021-9, NA], A138: [corn, 3272 x Bt11 x MIR604, SYN-E3272-5 x SYN-BT011-1 x SYN-IR604-5, NA], A139: [corn, 3272 x BT11 x MIR604 x GA21, SYN-E3272-5 x SYN-BT011-1 x SYN- IR604-5 x MON-00021-9, NA], A140: [corn, 3272 x Bt11 x MIR604 x TC1507 x 5307 x GA21, SYN-E3272-5 x SYN-BT011-1 x SYN-IR604-5 x DAS- 01507-1 x SYN-05307-1 x MON-000201-9, NA], A141: [corn, 3272 x GA21, SYN-E3272-5 x MON-00021-9, NA], A142: [corn, 3272 x MIR604, SYN-E3272-5 x SYN-IR604-5, NA], A143: [corn, 3272 x MIR604 x GA21, SYN-E3272-5 x SYN-IR604-5 x MON-00021-9, NA], A144 : Corn, 33121, DP-033121-3, NA], A145: [corn, 4114, DP-004114-3, NA], A146: [corn, 5307, SYN-05307-1, Agrisure (registered trademark) Duracade ( Trademarks], A 147: [corn, 5307] x GA21, SYN-05307-1 x MON-00021-9, NA], A148: [corn, 5307 x MIR604 x Bt11 x TC1507 x GA21, SYN-05307-1 x SYN-IR604-5 x SYN-BT011-1 x DAS-01507-1 x MON-00021-9, Agrisure (registered trademark) Duracade (trademark) 5122], A 149: [corn, 5307 x MIR604 x Bt11 x TC1507 x GA21 x MIR162, SYN-05307-1 x SYN- IR604-5 x SYN-BT011-1 x DAS-01507-1 x MON-00021-7 x SYN-IR 162-4, Agrisure (R) Duracade (TM) 5222], A150: [corn, 59122, DAS-59122] -7, Hercule x TM RW],
A151: [corn, 59122 x DAS 40278, DAS-59122-7 x DAS-40278-9, NA], A152: [corn, 59122 x GA21, DAS-59122-7 x MON-00021-9, NA], A153: [Corn, 59122 x MIR604, DAS-59122-7 x SYN-IR604-5, NA], A154: [corn, 59122 x MIR604 x GA21, DAS-59122-7 x SYN-IR604-5 x MON-00021-9] , NA], A155: [corn, 59122 x MIR604 x TC1507, DAS-59122-7 x SYN-IR604-5 x DAS-01507-1, NA], A156: [corn, 59122 x MIR604 x TC1507 x GA21, DAS] -59122-7 x SYN-IR604-5 x DAS-01507-1 x MON-00021-9, NA], A 157: [corn, 59122 x MON 810, DAS-59122-7 x MON-00810-6, NA], A158: [corn, 59122 x MON810 x MIR604, DAS-59122-7 x MON-00810-6 x SYN-IR604-5, NA], A159: [corn, 59122 x MON810 x NK603, DAS-59122-7 x MON] -00810-6 x MON-00603-6, NA], A160: [corn, 59122 x MON 810 x NK603 x MIR604, DAS-59122-7 x MON-00810-6 x MON-00603-6 x SYN-IR604-5 , NA], A 161: [Tumolo C, 59122 x MON88017, DAS-59122-7 x MON-88017-3, NA], A162: [corn, 59122 x MON88017 x DAS 40278, DAS-59122-7 x MON-88017-3 x DAS-40278-9, NA], A163: [corn, 59122 x NK603, DAS-59122-7 x MON-00603-6, Herculex (R) WRoundupReady (TM) 2], A164: [corn, 59122 x NK603 x MIR604, DAS-59122- 7 x MON-00603-6 x SYN-IR604-5, NA], A165: [corn, 59122 x TC1507 x GA21, DAS-59122-7 x DAS-01507-1 x MON-00021- 9, NA], A166 : [Corn, 676, PH-000676-7, NA], A167: [corn, 678, PH-000678-9, NA], A168: [corn, 680, PH-000680-2, NA], A169: [ Corn, 98140, DP-098140-6, OptimumTM GAT (trademark), A170: [corn, 98140 x 59122, DP-098140-6 x DAS-59122-7, NA], A 171: [corn, 98140] x TC1507, DP-098140-6 x DAS-01507-1, NA], A172: [corn, 98140 x TC1507 x 59122, DP-098140-6 x DAS-01507-1 x DAS-59122-7, NA] A173: [corn, Bt10, NA, Bt10], A174: [corn, Bt11 (x 4334 CBR, x 4734 CBR), SYN-BT011-1, AgrisureTM CB / LL], A 175: [corn, Bt 11 x 5307, SYN-BT011-1 x SYN-05307-1, NA], A176: [corn, Bt11 x 5307 x GA21, SYN-BT011-1 x SYN-05307-1 x MON-00021-9, NA], A177: [ Corn, Bt11 x 59122, SYN-BT011-1 x DAS-59122-7, NA], A178: [Corn, Bt11 x 59122 x GA21, SYN-BT011-1 x DAS-59122-7 x MON-00021-9, NA], A179: [corn, Bt11 x 59122 x MIR604, SYN-BT011-1 x DAS-59122-7 x SYN-IR604-5, NA], A180: [corn, Bt11 x 59122 x MIR604 x GA21, SYN- BT011-1 x DAS-59122-7 x SYN-IR604-5 x MON-00021-9, NA], A181: [corn, Bt11 x 59122 x MIR604 x TC1507, SYN-BT011-1 x DAS-59122-7 x SYN-IR604-5 x DAS-01507-1, NA], A182: [corn, BT11 x 59122 x MIR604 x TC1507 x GA21, SYN-BT011-1 x DAS-59122-7 x SYN-IR604-5 x DAS- 01507-1 x MON-00021-9, Agrisure 3122], A183: [corn, Bt11 x 59122 x TC1507, SYN-BT011-1 x DAS-59122-7 x DAS-01507-1, NA], A184: [corn, Bt11 x 59122 x TC1507 x GA21] , SYN-BT011-1 x DAS-59122-7 x DAS-01507-1 x MON-00021-9, NA], A185: [corn, Bt11 x GA21, SYN-BT011-1 x MON-00021-9, Agrisure (Trademark) GT / CB / LL], A186: [corn, Bt11 x MIR162, SYN-BT011-1 x SYN-IR162-4, Agrisure (registered trademark) Viptera (trademark) 2100], A187: [corn, Bt11 x MIR162 x 5307, SYN-BT011-1 x SYN-IR162-4 x SYN-05307-1, NA], A188: [corn, Bt11 x MIR162 x 5307 x GA21, SYN-BT011-1 x SYN-IR162-4 x SYN-05307-1 x MON-00021-9, NA], A189: [corn, Bt11 x MIR162 x GA21, SYN-BT011-1 x SYN-IR162-4 x MON-00021-9, Agrisure (registered trademark) Viptera (Trademark) 3110], A190: [corn, BT11 x MIR162 x MIR604, SYN-BT011-1 x SYN-IR162-4 x SYN-IR604-5, Agrisure (registered trademark) Viptera (trademark) 3100], A191: [ Corn flour , BT11 x MIR162 x MIR604 x 5307, SYN-BT011-1 x SYN-IR162-4 x SYN-IR604-5 x SYN-05307-1, NA], A192: [corn, Bt11 x MIR162 x MIR604 x 5307 x GA21 , SYN-BT011-1 x SYN-IR162-4 x SYN-IR604-5 x SYN-05307-1 x MON-00021-9, NA], A193: [corn, Bt11 x MIR162 x MIR604 x GA21, SYN-BT011 -1 x SYN-IR162-4 x SYN-IR604-5 x MON-00021-9, Agrisure (R) Viptera (TM) 3111, Agrisure (R) Viptera (TM) 4], A194: [corn, Bt11] x MIR162 x MIR604 x MON89034 x 5307 x GA21, SYN-BT011-1 x SYN-IR162-4 x SYN-IR604-5 x MON-89034-3 x SYN-05307-1 x MON-00021-9, NA], A195: [corn, BT11 x MIR162 x MIR604 x TC1507, SYN-BT011-1 x SYN-IR162-4 x SYN-IR604-5 x DAS-01507-1, NA] A196: [corn, BT11 x MIR162 x MIR604 x TC1507 x 5307, SYN-BT011-1 x SYN-IR162-4 x SYN-IR604-5 x DAS-01507-1 x SYN-05307-1, NA], A197: [corn, Bt11 x MIR162 x MIR604 x TC1507] x GA21, SYN-BT011-1 x SYN-IR162-4 x SYN-IR604-5 x DAS-01507-1 x MON-00021-9, NA], A198: [corn, Bt11 x MIR162 x MON89034, SYN-BT011-1 x SYN-IR162-4 x MON-89034-3, NA], A199: [Corn, Bt11 x MIR162 x MON89034 x GA21, SYN-BT011-1 x SYN-IR162-4 x MON-89034-3 x MON-00021-9, NA], A200: [corn, Bt11 x MIR162 x TC1507, SYN -BT011-1 x SYN-IR162-4 x DAS-01507-1, NA],
A201: [corn, Bt11 x MIR162 x TC1507 x 5307, SYN-BT011-1 x SYN-IR162-4 x DAS-01507-1 x SYN-05307-1, NA] A202: [corn, Bt11 x MIR162 x TC1507] x 5307 x GA21, SYN-BT011-1 x SYN-IR162-4 x DAS-01507-1 x SYN-05307-1 x MON-00021-9, NA], A203: [corn, Bt11 x MIR162 x TC1507 x GA21 , SYN-BT011-1 x SYN-IR162-4 x DAS-01507-1 x MON-00021-9, Agrisure (TM) Viptera 3220], A204: [corn, Bt11 x MIR604, SYN-BT011-1 x SYN-IR604 -5, Agrisure (TM) CB / LL / RW], A205: [corn, Bt11 x MIR604 x 5307, SYN-BT011-1 x SYN-IR604-5 x SYN-05307-1, NA], A206: [corn Bt11 x MIR604 x 5307 x GA21, SYN-BT011-1 x SYN-IR604-5 x SYN-05307-1 x MON-00021-9, NA], A207: [corn, BT11 x MIR604 x GA21, SYN-BT011 -1 x SYN-IR604-5 x MON-00021-9, Agrisure (TM) 3000 GT], A208: [corn, Bt11 x MIR604 x TC1507, SYN-BT011-1 x SYN-IR604-5 x DAS-01507-1 , NA], A209: [corn, Bt11 x MIR604 x TC1507 x 5307, SYN-BT011-1 x SYN-IR604-5 x DAS-01507-1 x SYN-05307-1, NA], A210: [corn, Bt11 x MIR604 x TC1507 x GA21, SYN-BT011- 1 x SYN-IR604-5 x DAS-01507-1 x MON-00021-9, NA], A211: [corn, Bt11 x MON89034, SYN-BT011-1 x MON-89034-3, NA], A212: [ Corn, Bt11 x MON89034 x GA21, SYN-BT011-1 x MON-89034-3 x MON-00021-9, NA], A213: [Corn, Bt11 x TC1507, SYN-BT011-1 x DAS-01507-1, NA], A214: [corn, Bt11 x TC1507 x 5307, SYN-BT011-1 x DAS-01507-1 x SYN-05307-1, NA], A215: [corn, Bt11 x TC1507 x 5307 x GA21, SYN- BT011-1 x DAS-01507-1 x SYN-05307-1 x MON-00021-9, NA], A216: [corn, Bt11 x TC1507 x GA21, SYN-BT011-1 x DAS-01507-1 x MON- 00021-9, NA], A217: [corn, Bt 176 (176), SYN-EV 176-9, NaturGard KnockOut (TM), Max imizer (TM)], A218: [corn, BVLA430101, NA, NA], A219: [Corn, CBH-351, ACS-Z M004-3, Starlink (trademark) Maize], A220: [corn, DAS40278, DAS-40278-9, Enlist (trademark) Maize], A221: [corn, DAS40278 x NK603, DAS-40278-9 x MON-00603- 6, NA], A222: [corn, DBT418, DKB-89614-9, Bt X tra (trademark) Maize], A 223: [corn, DLL 25 (B 16), DKB-89790-5, NA], A 224: [corn , GA21, MON-00021-9, RoundupReady (trademark) Maize, Agrisure (trademark) GT], A225: [corn, GA21 x MON810, MON-00021-9 x MON-00810-6, RoundupReady (trademark) YieldGard (trademark) ) Maize], A226: [corn, GA21 x T25, MON-00021- 9 x ACS-ZM003-2, NA], A227: [corn, HCEM485, HCEM485, NA], A228: [corn, LY038, REN-00038] -3, Mavera (TM) Maize], A 229: [corn, LY038 x MON 810, REN-00038-3 x MON-00810-6, Mavera (TM) YieldGard (TM) Maize], A 230: [corn, MIR 162, SYN -IR162-4, Agrisure (TM) Viptera], A231: [corn, MI R162 x 5307, SYN-IR162-4 x SYN-05307-1, NA], A232: [corn, MIR162 x 5307 x GA21, SYN-IR162-4 x SYN-05307-1 x MON-00021-9, NA] , A233: [corn, MIR162 x GA21, SYN-IR162-4 x MON-00021-9, NA], A234: [corn, MIR162 x MIR604, SYN-IR162-4 x SYN-IR604-5, NA], A235 : [Corn, MIR162 x MIR604 x 5307, SYN-IR162-4 x SYN-IR604-5 x SYN-05307-1, NA], A236: [corn, MIR162 x MIR604 x 5307 x GA21, SYN-IR162-4 x SYN-IR604-5 x SYN-05307-1 x MON-00021-9, NA], A237: [corn, MIR162 x MIR604 x GA21, SYN-IR162-4 x SYN-IR604-5 x MON-00021-9, NA], A238: [corn, MIR162 x MIR604 x TC1507 x 5307, SYN-IR162-4 x SYN-IR604-5 x DAS-01507-1 x SYN-05307-1, NA], A239: [corn, MIR162 x MIR604 x TC1507 x 5307 x GA21, SYN-IR162-4 x SYN-IR604-5 x DAS-01507-1 x SYN-05307-1 x MON-00021-9, NA], A240: [corn, MIR162 x MIR604 x TC1507 x GA21, SYN-IR162-4 x SYN-IR604-5 x DAS -01507-1 x MON-00021-9, NA], A241: [corn, MIR162 x MON89034, SYN-IR162-4 x MON-89034-3, NA], A242: [corn, MIR162 x MON89034 x GA21, SYN -IR162-4 x MON-89034-3 x MON-00201- 9, NA], A243: [corn, MIR162 x NK603, SYN-IR162-4 x MON-00603-6, NA], A244: [corn, MIR162 x TC1507, SYN-IR162-4 x DAS-01507-1, NA], A245: [corn, MIR162 x TC1507 x 5307, SYN-IR162-4 x DAS-01507-1 x SYN-05307-1 NA], A246: [corn, MIR162 x TC1507 x 5307 x GA21, SYN-IR162-4 x DAS-01507-1 x SYN-05307-1 x MON-00021-9, NA], A247: [corn, MIR162 x TC1507 x GA21 , SYN-IR162-4 x DAS-01507-1 x MON-00021-9, NA], A248: [corn, MIR604, SYN-IR604-5, Agrisure (TM) RW], A249: [corn, MIR604 x 5307] , SYN-IR604-5 x SYN-05307-1, NA], A250: [corn, MIR604 x 5307 x GA21, SYN-IR604-5 x SYN-05307-1 x MON-00021-9, NA],
A251: [corn, MIR604 x GA21, SYN-IR604-5 x MON-00021-9, Agrisure (trade mark) GT / RW], A252: [corn, MIR604 x NK603, SYN-IR604-5 x MON-00603-6 , NA], A253: [corn, MIR604 x TC1507, SYN-IR604-5 x DAS-01507-1, Optimum (R) TRIsect (trademark)], A254: [corn, MIR604 x TC1507 x 5307, SYN-IR604 -5 x DAS-01507-1 x SYN-05307-1, NA], A255: [corn, MIR604 x TC1507 x 5307 x GA21, SYN-IR604-5 x TC1507 x SYN-05307-1 x MON-00021-9 , NA], A256: [corn, MIR604 x TC1507 x GA21, SYN-IR604-5 x TC1507 x MON-00021-9, NA], A257: [corn, MON801 (MON80100), MON801, NA], A258: [ Corn, MON802, MON-80200-7, NA], A259: [corn, MON809, PH-MON-809-2, NA], A260: [corn, MON810, MON-00810-6, YieldGardTM, MaizeGard] (Trademark), A261: [corn, MON810 x MIR162, MON-00810-6 x SYN-IR162-4, NA], A262: [corn, MON 810 x MIR162 x NK603, MON-00810-6 x SYN-IR162-4 x MON-00603-6, NA], A263: [corn, MON810 x MIR604, MON-00810-6 x SYN-IR604-5, NA] , A264: [corn, MON810 x MON88017, MON-00810-6 x MON-88017-3, YieldGard (TM) VTTriple], A265: [corn, MON810 x NK603 x MIR604, MON-00810-6 x MON-00603- 6 x SYN-IR604-5, NA], A266: [corn, MON832, NA, RoundupReady (TM) Maize], A267: [corn, MON863, MON-00863-5, YieldGard (TM) Rootworm RW, MaxGard (TM) ], A268: [corn, MON863 x MON810, MON-00863-5 x MON-00810-6, YieldGard (TM) Plus], A269: [corn, MON863 x MON810 x NK603, MON-00603-6 x MON-] 00800-6 x MON-00863-5, YieldGard (TM) Plus with RR], A270: [corn, MON863 x NK603, MON-00863-5 x MON-00603-6, YieldGardTM RW + RR], A271: [ Corn, MON87403, MON87403-1, NA], A272: [corn, MON87411, MON-87411-9, NA], A273 [Corn, MON87419, MON87419-8, NA], A274: [corn, MON87427, MON-87427-7, RoundupReady (TM) Maize], A275: [corn, MON87427 x 59122, MON-87427-7 x DAS-59122 -7, NA], A276: [corn, MON87427 x MON88017, MON-87427-7 x MON-88017-3, NA], A277: [corn, MON87427 x MON88017 x 59122, MON-87427-7 x MON-88017 -3 x DAS-59122-7, NA], A278: [corn, MON87427 x MON89034, MON-87427-7 x MON-89034-3, NA], A279: [corn, MON87427 x MON89034 x 59122, MON-87427] -7 x MON-89034-3 x DAS-59122-7, NA], A280: [corn, MON87427 x MON89034 x MON88017, MON-87427-7 x MON-89034-3 x MON-88017-3, NA], A281: [corn, MON87427 x MON89034 x MON88017 x 59122, MON-87427-7 x MON-89034-3 x MON-88017-3 x 59122, NA], A282: [corn, MON87427 x MON89034 x NK603, MON-87427] -7 x MON-89034-3 x MON-00603-6, NA], A283: [corn, MON87427 x MON89034 x T C1507, MON-87427-7 x MON-89034-3 x DAS-01507-1, NA], A284: [corn, MON87427 x MON89034 x TC1507 x 59122, MON-87427-7 x MON-89034-3 x DAS- 01507-1 x DAS-59122-7, NA], A285: [corn, MON87427 x MON89034 x TC1507 x MON87411 x 59122, MON-87427-7 x MON-89034-3 x DAS-01507-1 x MON-87411-] 9 x DAS-59122-7, NA], A286: [corn, MON87427 x MON89034 x TC1507 x MON88017, MON-87427-7 x MON-89034-3 x DAS-01507-1 x MON-88017-3, NA] A287: [corn, MON87427 x MON89034 x MIR162 x NK603, MON-87427-7 x MON-89034-3 x SYN-IR162-4 x MON-00603-6, NA] A288: [corn, MON87427 x MON89034 x TC1507 x MON88017 x 59122, MON-87427-7 x MON-890734-3 x DAS-01507-1 x MON-88017-3 x DAS-59122-7, NA], A289: [corn, MON87427 x NK603, MON- 87427-7 x MON-00603-6, NA], A290: [corn, MON87427 x TC1507, MON-87427-7 x DAS-01507-1, NA], A291: [corn, MON87427 x TC1507 x 59122, MON- 87427-7 x DAS-0 1507-1 x DAS-59122-7, NA], A292: [corn, MON87427 x TC1507 x MON88017, MON-87427-7 x DAS-01507-1 x MON-88017-3, NA], A293: [corn, MON87427 x TC1507 x MON88017 x 59122, MON-87427-7 x DAS-01507-1 x MON-88017-3 x DAS-59122-7, NA], A294: [corn, MON87460, MON-87460-4, Genuity ( Registered trademark DroughtGard (registered trademark)], A295: [corn, MON87460 x MON88017, MON-87460-4 x MON-88017-3, NA], A296: [corn, MON87460 x MON89034 x MON88017, MON-87460-4 x MON-89034-3 x MON-88017-3, NA], A297: [corn, MON87460 x MON89034 x NK603, MON-87460-4 x MON-89034-3 x MON-00603-6, NA], A298: [ Corn, MON87460 x NK603, MON-87460-4 x MON-00603-6, NA], A 299: [corn, MON 88017, MON-88017-3, YieldGardTM VTTM RootwormTM RR2], A300 [Corn, MON88017 x DAS40278, MON-88017-3 x DAS-40278-9, NA],
A301: [corn, MON89034, MON-89034-3, YieldGard (TM) VTPro (TM)], A302: [corn, MON89034 x 59122, MON-89034-3 x DAS-59122-7, NA], A303: [ Corn, MON89034 x 59122 x DAS 40278, MON-89034-3 x DAS-59122-7 x DAS-40278-9, NA, A304: [corn, MON89034 x 59122 x MON88017, MON-89034-3 x DAS-59122-] 7 x MON-88017-3, NA], A305: [corn, MON89034 x 59122 x MON88017 x DAS 40278, MON-89034-3 x DAS-59122-7 x MON-88017-3 x DAS-40278-9, NA] , A306: [corn, MON89034 x DAS40278, MON-89034-3 x DAS-40278-9, NA], A307: [corn, MON89034 x MON87460, MON-89034-3 x MON-87460-4, NA], A308 [Corn, MON89034 x MON88017, MON-89034-3 x MON-88017-3, Genuity (R) VTTriplePro (TM)], A309: [Corn, MON89034 x MON88017 x DAS40278, MON-89034-3 x MON- 88011-3 x DAS-40278-9, NA], A310: [corn, MON89034 x NK603, MON-89034-3 x MON-00603-6. , Genuity (R) VTDoublePro (TM)], A311: [corn, MON89034 x NK603 x DAS 40278, MON-89034-3 x MON-00603-6 x DAS-40278-9, NA], A312: [corn, MON89034] x TC1507, MON-89034-3 x DAS-01507-1, NA], A313: [corn, MON89034 x TC1507 x 59122, MON-89034-3 x DAS-01507-1 x DAS-59122-7, NA], A314: [corn, MON89034 x TC1507 x 59122 x DAS 40278, MON-89034-3 x DAS-01507-1 x DAS-59122-7 x DAS-40278-9, NA] A315: [corn, MON89034 x TC1507 x DAS40278] , MON-89034-3 x DAS-01507-1 x DAS-40278-9, NA], A316: [corn, MON89034 x TC1507 x MON88017, MON-89034-3 x DAS-01507-1 x MON-88017-3. , NA], A317: [corn, MON89034 x TC1507 x MON88017 x 59122, MON-89034-3 x DAS-01507-1 x MON-88017-3 x DAS-59122-7, Genuity (R) SmartSta x (trademark) ], A318: [corn, MON89034 x TC1507 x MON88017 x 59122 x DAS 40278, MON-89034-3 x DAS-01507-1 x MON-88017-3 x DAS-59122-7 x D] AS-40278-9, NA], A319: [corn, MON89034 x TC1507 x MON88017 x DAS40278, MON-89034-3 x DAS-01507-1 x MON-88017-3 x DAS-59122-7 x DAS-40278-] 9, NA], A320: [corn, MON89034 x TC1507 x NK603, MON-89034-3 x DAS-01507-1 x MON-00603-6, PowerCore (trademark)], A321: [corn, MON89034 x TC1507 x NK603] x DAS40278, MON-89034-3 x DAS-01507-1 x MON-00603-6 x DAS-40278-9, NA], A322: [corn, MON89034 x TC1507 x NK603 x MIR162, MON-89034-3 x DAS -01507-1 x MON-00603-6 x SYN-IR162-4, NA], A323: [corn, MON89034 x TC1507 x NK603 x MIR162 x DAS 40278, MON-89034-3 x DAS-01507-1 x MON-00603 -6 x SYN-IR162-4 x DAS-40278-9, PowerCore (registered trademark) x MIR162 x Enlist (registered trademark)], A324: [corn, MON89034 x GA21, MON-89034-3 x MON-00210-9, NA] ], A325: [corn, MS3, ACS-ZM001-9, InVigorTM Maize], A326: [corn, MS6, ACS-ZM 005-4, InVigorTM Maize], A327: [corn, MZHG0JG, SYN-000JG-2, NA], A328: [corn, MZIR098, SYN-00098-3, NA], A329: [corn, NK603, MON-00603-6, RoundupReady (trademark) 2Maize], A330: [ Corn, NK603 x MON810 x 4114 x MIR604, MON-00603-6 x MON-00810-6 x DP004114-3 x SYN-IR604-4, NA], A331: [corn, NK603 x MON810, MON-00603-6 x MON-00810-6, YieldGard (TM) CB + RR], A332: [corn, NK603 x T25, MON-00603-6 x ACS-ZM003-2, RoundupReady (TM) LibertyLink (TM) Maize], A333: [ Corn, T14, ACS-ZM002-1, LibertyLinkTM Maize, A334: [corn, T25, ACS-ZM003-2, LibertyLinkTM Maize], A335: [corn, T25 x MON810, ACS-ZM003- 2 x MON-00810-6, LibertyLink (TM) Yieldgard (TM) Maize], A336: [corn, TC1507, DAS-01507-1, Herculex (TM) I, Herculex (TM) CB], A337: [ Maize, TC1507 × 59122 × MON 810 × MIR604 × NK603, DAS-01507-1 × DAS-59122-7 × MON-00 810-6 × SYN-IR604-5 × MON-00603-6, OptimumTM Intrasect X treme], A 338: [corn, TC1507 × MON 810 × MIR604 × NK603, DAS-01507-1 × MON-00810-6 × SYN-IR604-5 x MON-00603-6, NA], A339: [corn, TC1507 x 5307, DAS-01507-1 x SYN-05307-1, NA], A340: [corn, TC1507 x 5307 x GA21, DAS-01507-1 x SYN-05307-1 x MON-00021-9, NA], A341: [corn, TC1507 x 59122, DAS-01507-1 x DAS-59122-7, Hercule x X TRA (trademark)] , A342: [corn, TC1507 x 59122 x DAS 40278, DAS-01507-1 x DAS-59122-7 x DAS-40278-9, NA], A343: [corn, TC1507 x 59122 x MON810, DAS-01507-1 x DAS-59122-7 x MON-00810-6, Optimum (R) AcreMax (R) X tra], A344: [corn, TC1507 x 59122 x MON 810 x MIR604, DAS-01507-1 x DAS-59122-] 7 x MON-00810-6 x SYN-IR604-5, Optimum (registered trademark) AcreMax (registered trademark) X Treme], A345: [corn, TC1507 x 59122 x MON810 x NK603, DAS-01507-1 x DAS- 59122-7 x M ON-00810-6 x MON-00603-6, Optimum (trademark) Intrasect X TRA], A346: [corn, TC1507 x 59122 x MON88017, DAS-01507-1 x DAS-59122-7 x MON-88017-3, NA], A347: [corn, TC1507 x 59122 x MON88017 x DAS-01507-1 x DAS-59122-7 x MON-88017-3 x DAS-40278-9, NA], A348: [corn, TC1507 x 59122 x NK603, DAS-01507-1 x DAS-59122-7 x MON-00603-6, Hercule x X TRA (TM) RR], A 349: [corn, TC1507 x 59122 x NK603 x MIR604, DAS-01507-1 x DAS-59122-7 x MON-00603-6 x SYN-IR604-5, NA], A 350: [corn, TC1507 x DAS 40278, DAS-01507-1 x DAS-40278-9, NA],
A351: [corn, TC1507 x GA21, DAS-01507-1 x MON-00021-9, NA], A352: [corn, TC1507 x MIR162 x NK603, DAS-01507-1 x SYN-IR162-4 x MON-00603. -6, Optimum (registered trademark) Leptra (trademark)], A353: [corn, TC1507 x MIR604 x NK603, DAS-01507-1 x SYN-IR604-5 x MON-00603-6, Optimum (trademark) TRIsect], A354: [corn, TC1507 x MON810, DAS-01507-1 x MON-00, NA], A355: [corn, TC1507 x MON810 x MIR162, DAS-01507-1 x MON-00810-6 x SYN-IR162-4. , NA], A356: [corn, TC1507 x MON810 x MIR162 x NK603, DAS-01507-1 x MON-00810-6 x SYN-IR162-4 x MON-00603-6, NA], A357: [corn, TC1507] x MON810 x MIR604, DAS-01507-1 x MON-00810-6 x SYN-IR604-5, NA], A358: [corn, TC1507 x MON810 x NK603, DAS-01507-1 x MON-00810-6 x MON] -00603-6, Optimum (TM) Intrasect], A359: [corn, TC1507 x MON 810 x NK603 x MIR604, DAS-01507-1 x MON-00810-6 x MON-00603-6 x SYN-IR604-5, NA] ] , A360: [corn, TC1507 x MON88017, DAS-01507-1 x MON-88017-3, NA], A361: [corn, TC1507 x MON88017 x DAS40278, DAS-01507-1 x MON-88017-3 x DAS- 40278-9, NA], A362: [corn, TC1507 x NK603, DAS-01507-1 x MON-00603-6, Hercule x (TM) IRR], A363: [corn, TC1507 x NK603 x DAS 40278, DAS-01507 -1 x MON-00603-6 x DAS-40278-9, NA], A364: [corn, TC6275, DAS-06275-8, NA], A365: [corn, VCO-01981-5, VCO-01981-5. , NA], A366: [corn, DK404SR, DK404SR, NA], A367: [corn, EXP1910IT, EXP1910IT, NA], A368: [melon, MelonA, NA, NA], A369: [melon, MelonB, NA, NA] ], A370: [Papaya, 55-1, CUH-CP 551-8, Rainbow, SunUp], A371: [Papaya, 63-1, CUH-CP631-7, NA], A 372: [Papaya, Huanong No. 1, NA] , Huanong No. 1], A 373: [Papaya, X 17-2, UFL-X 17 CP-6, NA], A 374: [Petunia, Petunia-CHS, NA, NA], A 375: [Pla , C-5, ARS-PLMC5-6, NA], A376: [polished canola, HCR-1, NA, NA], A377: [polished canola, ZSR 500, NA, Hysyn 101 RRoundup-Ready (trademark)], A378: [ Polish canola, ZSR 502, NA, Hysyn 101 RR Roundup-Ready (trademark)], A 379: [polish canola, ZSR 503, NA, Hysyn 101 RRoundup-Ready (trademark)], A 380: [poplar, Btpoplar, poplar 12 (Populus nigra), NA, NA], A381: [Popla, Hybridpoplarclone 741, NA, NA], A382: [potato, 1210 amk, NA, Lugovskoiplus], A383: [potato, 2904/1 kgs, NA, Elizavetaplus], A384: [potato, AM04-1020, BPS-A1020] -5, StarchPotato], A385: [potato, ATBT 04-27, NMK-89367-8, AtlanticNewLeaf (TM) potato], A386: [potato, ATBT 04-30, NMK-89613-2, AtlanticNewLeaf (TM) potato], A387: [potato, ATBT 04-31, NMK-89170-9, AtlanticNewLeaf (TM) potato], A388: [potato, ATBT 04-36, NMK-89279-1, AtlanticNewLeaf (TM) po tato], A389: [potato, ATBT 04-6, NMK-89761-6, AtlanticNewLeafTM potato], A390: [potato, BT06, NMK-89812-3, NewLeafTM RushetBurbank potato], A391: [potato, BT10, NMK-89175-5, NewLeaf (R) RussetBurbankpotato], A392: [potato, BT12, NMK-89601-8, NewLeaf (R) RussetBurbankpotato], A393: [potato, BT16, NMK-89167-6, NewLeaf ( Trademarks: RussetBurbank potato], A394: [potato, BT17, NMK-89593-9, NewLeaf (R) RussetBurbank potato], A395: [potato, BT18, NMK-89906-7, NewLeaf (R) RussetBurbank potato], A396: [potato, BT23, NMK-89675-1, NewLeaf (trademark) RussetBurbankpotato], A397: [potato, E12, SPS-00E12-8, Innate (registered trademark) Culture], A398: [potato, E24, SPS-00E24-2, NA ], A399: [potato, EH 92-527-1, BPS-25271 EH 92-527-1-9, Amflora (trademark)], A400: [potato, F10, SPS-00F10-7, Innate (registered trademark) Generate],
A401: [potato, F37, SPS-00F37-7, NA], A402: [potato, G11, SPS-00G11-9, NA], A403: [potato, H37, SPS-00H37-9, NA], A404: [Potato, H50, SPS-00H50-4, NA], A405: [potato, HLMT15-15, NA, Hi-LiteNewLeafTM Ypotato], A406: [potato, HLMT15-3, NA, Hi-LiteNewLeafTM ) Ypotato], A407: [potato, HLMT 15-46, NA, Hi-Lite NewLeaf (TM) Ypotato], A408: [potato, J3, SPS-000J3-4, Innate (R) Accelerate], A409: [potato, J55, SPS-00J55-2, NA], A410: [potato, J78, SPS-00J78-7, NA], A411: [potato, RBMT15-101, NMK-89653-6, NewLeaf (trademark) YRussetBurbankpotato], A412 [A potato: RBMT 21-129, NMK-89684-1, NewLeafTM PlusRussetBurbankpotato], A413: [potato, RBMT 21-152, NA, NewLeafTM PlusRussetBurbank potato], A 414: [potato, RBMT 21-350, NMK- 89185-6, NewLeaf (TM) PlusRussetBurbankpotato] A415: [potato, RBMT 22-082, NMK-89896-6, NewLeafTM PlusRussetBurbankpotato], A416: [potato, RBMT 22-186, NA, NewLeafTM PlusRussetBurbankpotato], A417: [potato, RBMT 22-238, NA , NewLeafTM PlusRussetBurbankpotato], A418: [potato, RBMT 22-262, NA, NewLeafTM PlusRussetBurbankpotato], A419: [potato, SEMT15-02, NMK-89935-9, ShepodyNewLeafTM Ypotato], A420: [Potato, SEMT 15-07, NA, Shepody NewLeafTM Ypotato], A421: [potato, SEMT 15-15, NMK-89930-4, ShepodyNewLeafTM Ypotato], A 422: [potato, SPBT 02-5, NMK-89576 -1, Superior NewLeafTM potato], A 423: [potato, SPBT 02-7, NMK-89724-5, Superior NewLeafTM potato], A 424: [potato, TIC-AR 233-5, TIC-AR 233-5, NA ], A425: [potato, V11, SPS-00V11-6, Innate (registered trademark) Invigorate], A426: [potato, W8, SPS-000W8-4, Innate (registered trademark) Glac] iate], A427: [potato, X17, SPS-00 X 17-5, Innate (R) Acclimate], A428: [potato, Y9, SPS-000Y9-7, Innate (R) Hibernate], A429: [Rice, 7 Crp # 10, NA, NA], A430: [rice, GMShanyou63, NA, BTShanyou 63], A431: [rice, Huahui-1 / TT51-1, NA, Huahui-1], A432: [rice, LLRICE06 , ACS-OS001-4, LibertyLinkTM rice], A433: [rice, LLRICE601, BCS-OS003-7, LibertyLinkTM rice], A434: [rice, LLRICE62, ACS-OS002-5, LibertyLinkTM ) Rice], A435: [rice, Tarommolaii + cry1Ab, NA, NA], A436: [rice, CL121 x CL141 x CF x 51, CL121 x CL141 x CF x 51, Clearfield (R) Rice], A 437: [ Rice, IMINTA-1 x IMINTA-4, IMINTA-1 x IMINTA-4, Clearfield (registered trademark) Rice], A438: [rice, PWC16, PWC16, NA], A439: [rose, WKS82 / 130-4-1 , IFD-52401-4, NA], A440: [Rose, WKS 92 / 130-9-1, IFD-52901-9, NA], A441: [Soybean, 260-05 (G94-1, G94-19, G168 ), DD-026005-3, NA], A442 [Soybean, A2704-12, ACS-GM005-3, LibertyLink (trademark) soybean], A443: [soybean, A2704-21, ACS-GM004-2, LibertyLink (trademark) soybean], A444: [soybean, A5554-127 , ACS-GM006-4, LibertyLink (trademark) soybean], A445: [soybean, A5554-35, ACS-GM008-6, LibertyLink (trademark) soybean], A446: [soybean, CV127, BPS-CV127-9, Culture ], A447: [soybean, DAS 44406-6, DAS-44406-6, NA], A448: [soybean, DAS68416-4, DAS-68416-4, Enlist (trade mark) Soybean], A449: [soybean, DAS68416-4. x MON89788, DAS-68416-4 x MON-89788-1, NA], A450: [soybean, DAS81419, DAS-81419-2, NA],
A451: [soybean, DAS81419 x DAS 44406-6, DAS-81419-2 x DAS-44406-6, NA], A452: [soybean, DP305423, DP-305423-1, Treus (trademark) or Plenish (trademark)] , A453: [soybean, DP305423 x GTS40-3-2, DP-305423-1 x MON-04032-6, NA], A454: [soybean, DP356043, DP-356043-5, OptimumGAT (trademark)], A455: [Soybean, FG72 (FG072-2, FG072-3), MST-FG072-3, NA], A456: [Soybean, FG72 x A5554-127, MST-FG072-3 x ACS-GM006-4, Liberty Link (registration Trademarks] GT 27 (trademark), A 457: [soybean, GTS 40-3-2 (40- 3 2), MON-04032-6, RoundupReady (trademark) soybean], A458: [soybean, GU262, ACS-GM003- 1, LibertyLink (trademark) soybean], A459: [soybean, IND-00410-5, IND-00410-5, VerdecaHB4Soybean], A460: [soybean, MON87701, MON-87701-2, NA], A461: [soybean, MON87701 x MON89788, MON-87701-2 x MON-89788-1, IntactaTM RoundupReadyTM 2Pro], A462: [soybean, MON87705, MON-87705-6, VistiveGoldTM], A463: [soybean , MON87705 x MON87708, MO N-87705-6 x MON-87708-9, NA], A464: [soybean, MON87705 x MON87708 x MON89788, MON-87705-6 x MON-87708-9 x MON-89788-1, NA], A465: soybean , MON87705 x MON89788, MON-87705-6 x MON-89788-1, NA], A466: [soy, MON 87708, MON-87708-9, Genuity (R) RoundupReady (trademark) 2 X tend (trademark)], A 467: [soybean, MON87708 x MON89788, MON-87708-9 x MON-89788-1, Roundup Ready 2 X tend (registered trademark)], A468: [soy, MON87712, MON-87712-4, NA], A469: [Soybean, MON87751, MON-87751-7, NA], A470: [Soybean, MON87751 x MON87701 x MON87708 x MON89788, MON-87751-7 x MON-87701-2 x MON87708 x MON89788, NA], A471: [Soybean , MON87769, MON87769-7, NA], A 472: [soybean, MON87769 x MON89788, MON-87769-7 x MON-89788-1, NA], A 473: [soy, MON89788, MON-89788-1, Genuity (registration Trademarks Roundup Ready 2 YieldTM], A 474: [soybean, SYHT0H2, SYN-000H2-5, Herbicide-tolerantSoybeanline], A475: [soybean, W62, ACS-GM002-9, Li bertyLinkTM soybean], A476: [soybean, W98, ACS-GM001-8, LibertyLinkTM soybean], A477: [soybean, OT96-15, OT96-15, NA], A478: [pepo pumpkin (Cucurbitapepo) , CZW3, SEM-0 CZW3-2, NA], A479: [pepo pumpkin (Cucurbita pepo), ZW20, SEM-0 ZW20-7, NA], A480: [sugar beet, GTSB77 (T9100152), SY-GTSB77-8, InVigor ( Trademarks sugarbeet], A481: [sugar beet, H7-1, KM-000 H71-4, Roundup Ready (trademark) sugarbeet], A 482: [sugar beet, T120-7, ACS-BV001-3, LibertyLink (trademark) sugarbeet], A483: [sugar cane, CTB141175 / 01-A, CTB141175 / 01-A, NA], A484: [sugar cane, NXI-1T, NXI-1T, NA], A485: [sugar cane, NXI-4T, NXI-4T, NA ], A 486: [Sugar cane, NXI-6T, NXI-6T, NA], A487: [Sunflower, X81359, X81359, Clearfield (R) Sunflower], A488: [Sweet Pepper, PK-SP01, X81359, NA], A489: [Tobacco, C / F / 93 / 08-02, NA, NA], A490: [Tobacco, Vector 21-41, NA, NA], A491: [ Mato, 1345-4, NA, NA], A492: [Tomato, 35-1-N, NA, NA], A493: [Tomato, 5345, NA, NA], A494: [Tomato, 8338, CGN-89322- 3, NA], A495: [Tomato, B, SYN-0000B-6, NA], A496: [Tomato, Da, SYN-000DA-9, NA], A497: [Tomato, DaDongNo9, NA, NA], A498 [Tomato, F (1401F, h38F, 11013F, 7913F), SYN-0000F-1, FLAVRSAVR (trademark)], A499: [Tomato, FLAVRSAVR, CGN-89564-2, FLAVRSAVR (trademark)], A500: [Tomato Huafan No1, NA, NA],
A501: [Tomato, PK-TM8805R (8805R), NA, NA], A502: [Wheat, MON71800, MON-71800-3, RoundupReadyTM wheat], A503: [Wheat, AP205CL, AP205CL, Clearfield® ) Wheat], A504: [Wheat, AP602CL, AP602CL, Clearfield (R) Wheat], A 505: [Wheat, BW255-2 x BW238-3, BW255-2 x BW238-3, Clearfield (R) Wheat], A506: [Wheat, BW7, BW7, Clearfield® Wheat], A507: [Wheat, Teal 11A, Teal 11A, Clearfield® Wheat], A508: [Wheat, SWP965001, SWP965001, NA], A509: [Maize: , NA, NA, Agrisure Artesian (trademark), A510: [corn, NA, NA, Optimum (registered trademark) AQUAmax (registered trademark)], A511: [canola, NA, NA, SU canola (registered trademark)], A512: [canola, NA, NA, Nexera (registered trademark) Canola], A513: [soy, NA, NA, STS soybean], A514: "corn, NA, NA, SR corn", A514: "sunflower, NA, NA, ExpressSun (registration Trademarks ", A515: [rice, NA, NA, Golden rice], A516: [corn, NA, NA, Poast Protected (registered trademark) corn], A517: [sunflower, NA, NA, ExpressSun (registered trademark)] , A518: [rice, NA, NA, Provisia (registered trademark) Rice], A519: [canola, NA, NA, Triazinon Tolerant Canola], A520: [corn, NA, NA, SmartStax (registered trademark) Pro], A521: [Soybean, NA, NA, Credenz (registered trademark) soybean], A 522: [corn, TC1507 x 59122, DAS-01507-1 x DAS-59122-7, Optimum (registered trademark) AcreMax (registered trademark) 1], A523 : [Corn, 4114 x MON 810 x MIR604, DP-004114-3 x MON-00810-6 x SYN-IR 604-5, Qrome (TM)], A 524: [Cotton, NA, NA, Stoneville (R) Cotton ST 5517 GLTP ], A525: [cotton, NA, NA, Stoneville (registered trademark) Cotton ST 4848 GLT], A526: [cotton, NA, NA, Stoneville (registered trademark) Cotton ST 4949 GLT], A 527: [cotton, NA, NA, Stoneville (registered) Trademarks Cotton ST5020 GLT], A 528: [Watana, NA, NA, Stoneville Trademarks Cotton ST 5115 GLT], A 529: [cotton, NA, NA, Stoneville (registered trademark) Cotton ST 6182 GLT], A 530: [cotton, NA, NA, Stoneville (registered trademark) Cotton ST 4747 GLB 2], A 531: [cotton, NA, NA , Stoneville (R) Cotton ST 4946 GLB2], A 532: [cotton, NA, NA, Stoneville (R) Cotton ST 6448 GLB 2], A 533: [soy, NA, NA, Enlist E3 (TM)], A534: [soy, NA , NA, Enlist (trademark) Roundup Ready 2 Yield (registered trademark)], A 535: [corn, NA, NA, Enlist (trademark) Roundup Ready (registered trademark) Corn 2], A 536: (corn, NA, NA, Smartstax) (Registered trademark) Enlist (trademark), A537: [corn, NA, NA, Powercore (registered trademark) Enlist (trademark)], A538: (cotton, NA, NA, Enlist (trademark) Cotton), A539: [ Cotton, NA, NA, Bollgard 3 (registered trademark) XtendFlex (registered trademark), A 540: [corn, NA, NA, SmartStax (registered trademark) RIB Complete (registered trademark) Corn], A 541: [corn, NA, NA , VT Double PRO (registered trademark) RIB Co mplete (R) Corn [Corne], A 542: [Corn, NA, NA, VT Double PRO (R) Corn], A 543: [Corne, NA, NA, Genuity (R) VT Triple PRO (R) RIB Complete Corn], A544: [corn, NA, NA, Trecepta (trademark) Corn], A545: [soybean, NA, NA, Fukuminori], A546: [soybean, NA, NA, Yumeminori], A547: [corn, NA , NA, ZFN-12 maize], A548: [rice, NA, NA, wimpy], A549: [rice NA, NA, Kanto BPH1], A550: [cotton, NA, MON88702, NA], A551: [ Soybean, DP305423xMON87708, DP-305423-1xMON-87708-9, NA], A552: [Soybean, DP305423xMON87708xMON89788, DP-305423-1xMON-87708-9xMON-89788-1, x] NA], A553: [soybean, DP305423 x MON89788, DP-305423-1 x MON-89788-1, NA], A554: [cotton, 3006-210-23 x 281-24-236 x MON88913 x COT102 x 81910, DAS-21023-5 x DAS-24236-5 x MON-88913-8 x SYN-IR102-7], A555: [cotton, GHB811, BCS-GH811-4, NA], A556: [sorghum, NA, NA, NA] Igrowth (Trademark)].

  The composition A or the composition B can be applied to the above-mentioned modified plants A1 to A556 or the cultivation site thereof. When applying the composition A or the composition B to the above-mentioned plant, it is more preferable to apply it to the seed or vegetative organ.

  In the case of treating composition B on seeds or vegetative organs, it is preferable to use a composition containing at least one bactericidal component selected from group (b) among composition B in particular. At this time, commercially available treated seeds or vegetative organs may be used.

  When the composition B is applied to seeds or vegetative organs, manganese, copper, zinc and the like may be simultaneously treated. The seeds or vegetative organs treated with composition B are sown or planted in the field in the usual manner.

  Composition B can effectively control a wide range of objects in cereal fields, vegetable fields, floriculture fields, orchards or non-agricultural lands where ordinary cultivation or no-tillage cultivation is performed.

  When the composition B is applied to sugar cane, in the cultivation of sugar cane, those cut so as to have one node may be used as a sugar cane stalk fragment, and the size of the sugar cane stalk fragment may be 2 cm to You may use 15 cm, preferably 3 cm to 8 cm. Cultivation techniques for sugar cane using such stem fragments are known (WO 09/000398, WO 09/000399, WO 09/000400, WO 09/000401, WO 09/000402), and are practiced under the trade name Plene®. Ru.

  When the composition B is applied to rice, it may be applied to a nursery, may be applied to a paddy field, or may be applied to rice seeds. The above-described nursery site includes a nursery box or a nursery tray for paddy rice and a nursery.

  When applying the composition B to a nursery box, the application time is not particularly limited as long as it is a nursery period from sowing of rice to transplanting. The time when the composition B is treated to the nursery box at the time of sowing may be not only on the day of sowing but also several days before or several days after sowing. The composition B may be treated at the time of transplantation into a nursery box not only on the day of transplantation but also on any day from several days before transplantation to the day of transplantation. In the nursery period, the seedlings to be transplanted are any of young seedlings (seedlings around 2.5 leaf stage), middle seedlings (seedlings around 3.5 leaf stage) or adult seedlings (seedlings around 4.5 leaf stage) Although it varies depending on the weather conditions and also changes depending on weather conditions etc., the composition B can be applied in any case. As a method for treating composition B in a nursery box, for example, a method in which kneaded granules or sand-coated granules are applied to a nursery box, a method in which a solution of composition B is irrigated in a nursery box can be mentioned. Composition B can also be treated on floor soil or soil covering, or mixed with bed soil or soil covering and treated. Generally, for example, how to treat pesticides during the nursery period. It is called pre-seeding bed mixing, pre-seeding treatment at sowing seeding, post-sowing treatment at sowing seeding, greening treatment, treatment on the day of transplantation, and simultaneous treatment on transplantation. Composition B may be treated into a nursery box by any of the treatment methods described above. There is no restriction | limiting in particular as a raising seedling culture medium, if it is the cultivation soil for rice seedling raising seedlings, You may use raising seedling mats other than soil. Seedlings to which the composition B is applied may be cultivated by pool raising seedling.

  When the composition B is applied to a paddy field, it may be used for transplanting rice or may be used for direct sowing. Although the method of applying to the paddy field is not particularly limited, for example, the method of applying the composition B to rice stems and leaves, the method of applying to the paddy field soil, and the method of applying to the water surface of the flooded paddy field are mentioned Be Moreover, it can also be applied labor-saving with the supply of water by processing a chemical solution such as an emulsion or a flowable to the inflow source of water to the paddy field such as a water port or an irrigation device. As a time of applying to a rice foliage part, any time from a seedling raising period to a harvest may be sufficient. The preparations to be used include preparations to be applied in the form of powders, fine granules and the like, and flowables, dry flowables, wettables, water dispersible granules, SE agents, water solvents, water granules, solutions, micro There may be mentioned emafusion agents, EW agents, oils, surf agents or emulsions. The spraying device may be any commonly used device, such as a hand-operated sprayer, a power spreader, a pancrus player, a radio control helicopter, a manned helicopter or the like. Inventive compositions may also be sprayed by hand without the use of a spraying device.

  As a method of applying the composition B to the paddy field soil, a method of treating the entire surface of the paddy field soil (entire surface treatment), a method of treating the ditch provided at the time of sowing rice (sowing groove treatment) A method of treating to 10 cm, a method of treating in the form of streaks or dots in the vicinity of rice plants or seeds (lateral streak treatment), and the like.

  When the composition B is applied to a paddy field soil, it may be applied simultaneously with agricultural materials such as paste fertilizers and granular fertilizers, or mixed with these agricultural materials and then applied. The composition B may be applied before seeding or transplantation, simultaneously with seeding or transplantation, or immediately after seeding or immediately after transplantation.

  When applied simultaneously with sowing or transplantation, application may be performed using attachment attached to the planter or transplanter, or may be applied by other methods. Moreover, in the case of whole surface treatment, it may be a period until water injection after sowing or transplantation, mid-drying period, or intermittent irrigation period. When the composition B is used, the soil surface of the paddy field may be in a dry state, or the soil surface may be wet but not in a flooded state (water depth: 0 cm). When applied to the water surface of a flooded paddy field, it may be applied at any time after sowing or transplanting to harvest, as long as the water depth can be maintained under normal rice management.

  When composition B is used for direct seeding cultivation of rice, rice seeds are coated with a covering material such as iron powder (iron oxide powder, reduced iron powder, atomized iron powder, electrolytic iron powder, etc.), calcium peroxide, molybdenum, molybdenum compound, etc. It may be processed. These covering materials may be used alone or in combination with each other at an arbitrary ratio, and if necessary, they may be used as an aid such as calcined gypsum or montmorillonite for the purpose of increasing the amount or improving adhesion to rice seeds. Agents can be added. A mixture of calcium peroxide, calcined gypsum and mineral powder is available as a commercial product, and examples thereof include Carper powder and granules 16 (manufactured by Hodogaya UPL Co., Ltd.). Here, a rice seed means the seed of the rice of the state before sowing to soils, such as a paddy field.

  When the composition B is treated to rice seeds, the rice seeds can be directly sown and cultivated in dry fields, wet fields and paddy fields, and can also be sown and grown in a nursery box. As the above-mentioned paddy field, a paddy field in a flooded or wet soil state can be mentioned. A flooded paddy field refers to a paddy field that has been plowed, put in water, plucked, etc., and then put in water as necessary. A paddy field in a wet soil state refers to a paddy field in which the amount of water is maintained to the same extent as in a flooded state by performing drainage treatment and the like from the flooded state, and the soil surface is exposed. Composition B can be applied to rice seeds, or rice seeds before emergence can be immersed in a solution containing composition B, or a solution containing composition B in emergence rice seeds Can also be sprayed. Also, in any of the treatment methods, the composition B may contain one or more types of health hazard reducing components selected from group (d).

  The seeding machine used for sowing rice is not particularly limited as long as it is generally used for direct seeding cultivation of rice such as paddy rice, upland rice, etc. For example, direct seeding machine NDS-6 for iron coating (iron Maki-chan, Kubota Co., Ltd., direct-seeding machine for iron coating NDS-8 (Ironuki-chan, Kubota Co., Ltd.), Direct-sowing dedicated machine for iron coating EP4-TC (Cute Ironmaki-chan, Kubota Co., Ltd.), multipurpose work machine RG6 (Yanmar Co., Ltd.), multipurpose work machine RG8 (Yanmar Co., Ltd.), high precision seeding machine PZV60 (made by Iseki Agro Co., Ltd.), and high precision seeding machine PZV80 (made by Izeki Agrochemical Co., Ltd.).

  Iron or its oxide (hereinafter referred to as iron and its oxide as coating material A) as a coating material for treating rice seeds is preferably in the form of powder. Examples of the powdery covering material A include reduced iron powder, atomized iron powder, electrolytic iron powder and iron oxide powder, and these are commercially available. Moreover, these can also be used in mixture of 2 or more types. In the present invention, the use of reduced iron powder and / or iron oxide powder is preferred. In addition, the iron powder obtained by reducing iron oxide or iron salt with hydrogen etc. is a reduced iron powder, and the iron powder obtained by injecting a high pressure water jet of 8 to 20 MPa to the flow of molten iron is atomized iron powder, sulfuric acid Iron is precipitated from a solution such as iron by electrolysis to obtain electrolytic iron flakes, which are crushed by a rod mill or vibration mill and annealed to obtain iron powder, which is called electrolytic iron powder. Iron oxide is an oxide of iron having an oxidation number of II and / or III. Although the particle size of the coating material A used for this invention is not specifically limited, It is preferable to adjust and use it for particle size 10-100 micrometers. As the covering material A which can be obtained as a commercial product, for example, DAE1K iron powder (DOWA (Dowa) IP (IP) Creation Co., Ltd. made), DSP 317 iron powder (DOWA (Dowa) IP (IP) creation Co., Ltd.), Iron powder for agriculture (made by Daitetsu Industries Co., Ltd.), iron powder for agriculture (made by Tetsugen Co., Ltd.), and hematite (made by DOWA (Dowa) IP (IP) Creation Co., Ltd.) can be mentioned.

When the composition B is treated to rice seeds, it may be mixed with calcined gypsum. For example, when the composition B and the covering material A are treated on rice seeds, calcined gypsum may be used as a supplement. Such calcined gypsum may be any powdery calcium sulfate hemihydrate (CaSO ₄ .1 / 2H ₂ O), and such calcined gypsum is commercially available, for example, KTS-1 (Manufactured by Yoshino Gypsum Sales Co., Ltd.) and KTS-25 (manufactured by Yoshino Gypsum Sales Co., Ltd.). In addition, a mixture of the covering material A and the calcined gypsum may be used, and such a mixture is available as a commercial product, and examples thereof include DAE1K mix (manufactured by DOWA IP).

  The coating of rice seeds with coating material A can take various forms, but generally, a method known as a method of coating of rice seeds with iron powder (“iron coated spring water direct seeding manual 2010”, independent) It is carried out by the same operation as the administrative corporation of Agricultural and Food Industry Research Institute, March 2010, ISBN 978-4-903078-05-2. Specifically, after immersing dried rice seeds before germination in water (sometimes called soaking) and draining, the above-mentioned rice seeds are coated with covering material A and, if necessary, calcined gypsum. Do. The order of the treatment of the covering material A and the calcined gypsum may be any point first, and the mixture of the covering material A and the calcined gypsum may be simultaneously treated. After these treatments, if necessary, they are further coated with a calcined gypsum as a finish, and usually, they are placed on a plate or the like placed on a flat surface and dried by, for example, shade drying.

  The amount of coating material A used for rice seeds is usually 100 to 2000 g of coating material A with respect to 1000 g of dry weight of rice seeds. In addition, the amount of calcined gypsum in the case of powder coating treatment with calcined gypsum is usually 5 to 100 g with respect to 1000 g of dry weight of rice seed, and the amount of calcined gypsum in the case of powder coating treatment with calcined gypsum as a finish The amount is usually 0 to 50 g based on 1000 g of dry weight of rice seed.

  The calcium peroxide may be prepared by preparing calcium peroxide alone as a powder having a particle size of 10 to 150 μm, but if necessary, a composition in which mineral powder such as montmorillonite or calcined gypsum is mixed as an auxiliary material Can also be used. The calcium peroxide-containing composition is commercially available, and examples thereof include Carper powder granules 16 (manufactured by Hodogaya UPL Co., Ltd.).

  Although the dressing treatment of rice seeds using calcium peroxide can take various forms, generally, a method known as a method for dressing treatment of rice seeds using calcium peroxide (JP-A-61-015805) and The same operation is performed. Specifically, the dried rice seeds before germination are dipped in water (sometimes referred to as immersion), drained, and then the rice seeds are treated with calcium peroxide powder or a composition containing calcium peroxide. . After these treatments, they are usually placed on a plate or the like placed on a flat surface and dried by shading.

  The amount of the calcium peroxide or calcium peroxide-containing composition used for rice seeds is usually 100 to 1000 g in terms of calcium peroxide alone, with respect to 1000 g of dry weight of rice seeds.

  Examples of molybdenum and molybdenum compounds include molybdenum alone, molybdenum oxide, molybdic acid and its salts, molybdophosphoric acid and its salts, molybdosilicic acid and its salts. Examples of molybdic acid salts include calcium molybdate, magnesium molybdate, ammonium molybdate, sodium molybdate and potassium molybdate. Examples of molybdophosphate include ammonium molybdophosphate, sodium molybdophosphate and potassium molybdophosphate. Such molybdenum and molybdenum compounds are commercially available, and examples thereof include molybdenum trioxide (Nippon Inorganic Chemical Industry Co., Ltd.).

  The treatment of rice seeds with molybdenum and a molybdenum compound can take various forms, but generally, it is carried out by the same operation as a method (WO 2011/0093341) known as a treatment method of rice seeds with molybdenum and a molybdenum compound . Specifically, it is mixed with a coating material containing iron powder and / or calcium peroxide, which is prepared in a solution and immersed in rice seed, which is fixed to rice seed surface using an adhesive such as polyvinyl alcohol, etc. Operations such as dressing on rice seeds.

  In particular, “bengara molybdenum coating” is known that is treated on rice seed by mixing a molybdenum compound such as molybdenum trioxide, iron oxide powder (sometimes called “bengara powder”) and water resistant polyvinyl alcohol (Yoshitaka Hara) 2013. Improvement of Rice Seedling Establishment on Sulfate-Applied Submerged Soil by Seed Coating with Seed Coating with Poorly Soluble Mollybdenum Compounds. Plant Prod. Sci. 16 (3): 271-275), the method is also preferably carried out in the present invention.

  The amount of molybdenum and molybdenum compound used per rice seed is usually 0.01 to 10 mol in terms of molybdenum based on 1000 g of dry weight of rice seed.

Examples of the combination with the present compound or composition A coating material for treating rice seeds include the following.
SX + iron oxide powder, SX + reduced iron powder, SX + iron oxide powder + reduced iron powder, SX + calcium peroxide, SX + molybdenum compound, SX + molybdenum compound + iron oxide powder, SX + molybdenum trioxide, SX + molybdenum trioxide + iron oxide powder, SX + iron oxide powder + calcined gypsum, SX + reduced iron powder + calcined gypsum, SX + iron oxide powder + reduced iron powder + calcined gypsum, SX + calcium peroxide + calcined gypsum, composition A + iron oxide powder, composition A + reduced iron powder, Composition A + Iron Oxide Powder + Reduced Iron Powder, Composition A + Calcium Peroxide, Composition A + Molybdenum Compound, Composition A + Molybdenum Compound + Iron Oxide Powder, Composition A + Molybdenum Trioxide, Composition A + Molybdenum Trioxide + Iron Oxide Powder, composition A + iron oxide powder + calcined gypsum, composition A + reduced iron powder + calcined gypsum, composition A + iron oxide powder + reduced iron powder + calcined gypsum, composition A + calcium peroxide + calcined gypsum.
Here, as the present components contained in the composition A, in particular, isotianil, flamethopyr, impirfluxam, etaboxam, benomyl, oxolinic acid, clothianidin, fenitrothion, cartap hydrochloride, oxazosulfil, tetraniriprole, crotol Lantrani liprole, cyantrani liprole, triflumesopyrim, flupyrimine and ethiprole are preferred.

  According to the order of the treatment to rice seeds of the above combination, the rice seed may be treated with the present compound or composition A and then the coating material may be treated, or after the rice seed is treated with the coating material, the compound or composition A may be treated, or the present compound or composition A and the coating material may be treated simultaneously. Here, when the composition A is treated, the order of treatment of the present compound and the present component and the coating material contained in the composition A may be the order of the present compound, the present component and the coating material, or the present compound, The coating material may be in the order of the component, the order of the component, the compound, the coating material, the order of the component, the coating material, the compound, or the coating material The present compound may be in the order of the component, or the coating material may be in the order of the component or the compound. Alternatively, rice seed may be treated simultaneously with the present compound, the present component and a coating material.

  When the composition B is applied to rice, the germination of rice seeds may be performed by immersion in water, or may be performed by immersion in water and holding in a wet state. The wet state means a state in which part or all of the surface of the rice seed after immersion in water can be in contact with the outside air, and the water of the rice seed can be retained. For example, in the wet state, rice seeds after immersion in water are coated with a breathable material such as rice straw or cloth, and then watering is performed on the coated material as needed, or the rice seeds are dipped in water. It is realized by storing rice seed as it is in the material of the net-like body or bag-like body used at the time of carrying out.

  When the composition B is used for rice, a fertilizer can also be used in combination. Examples of such fertilizers include Rakuichi (registered trademark, Sumitomo Chemical Co., Ltd.), Sumishort (registered trademark, Sumitomo Chemical Co., Ltd.) and Super SR Coat (registered trademark, Sumitomo Chemical Co., Ltd.). When using a fertilizer together, it may be fertilized to the whole cultivation soil of rice before sowing, and may be fertilized to the whole cultivation soil of rice after sowing or in a growing season. In addition, it may be fertilized in the form of grooves along the lines to be sown at the time of sowing (sometimes called side-line fertilization).

  When the composition B is applied to rice, whether applied to a nursery, a paddy field or a seed, disinfected seeds can be used to control seed-borne diseases and pests. Specifically, prochloraz, triflumizole, peflazoate, oxolinic acid, ipconazole, fludioxonil, kasugamycin hydrochloride, cupric hydroxide, basic copper chloride, fenitrothion, cartap hydrochloride etc. Group (a) and Group (a) b) One or more insecticide components and / or bactericidal components selected from the above, or Trichoderma atroviride SKT-1 strain, Talaromyces flavus SAY-Y-94-01 strain, Pseudomonas sp. CAB-02 strain, Bacillus symplex CGF 2856 It is a component of one or more types of microbial materials selected from the group (j) such as stocks, etc., and seeds subjected to immersion treatment, smear treatment or dressing treatment can be used.

  When one or more of cartap hydrochloride and methaldehyde are applied to a paddy field before seeding rice, a paddy field before transplanting rice, a paddy field after seeding rice, or a paddy field after transplanting rice, the spiny mussels and the monosnails are effective Control. In addition, weeds generated in the paddy field can be controlled by treating one or more herbicidal active ingredients selected from group (i). The application time of the herbicidal active ingredient is not particularly limited, as long as the herbicidal active ingredient does not cause any problem to the rice.

  As one or more herbicidal active ingredients selected from group (i) which can be used in the paddy field, for example, azimsulfuron, bensulfuron methyl, chlorimuron ethyl, cyclosulfamuron, ethoxysulfuron, flucetosulfuron, halosulfuron methyl , Imazosulfuron, orthosulfamurone, propylasulfuron ethyl, cinosulfuron methyl, methasulfuron methyl, methazosulfuron, besiocarb, molinate, esprocarb, pyributycarb, dimepiperate, suepor, buttilol, pretilacurol, tenilcurol, simetryn, dimethamethrin, methyldimerone, Propanil, Mefenacet, Flufenaset, Clomeprop, Naproanilide, Bromobutide, Dimron, Cumyuron, Etovenzani , Bentazone, tridiphane, carfentrazone ethyl, fenchlorazole ethyl, isoxadiphenethyl, fentrazamide, chromazone, maleic acid hydrazide, pyridate, oxadiclomephone, synmethyline, benfrense, oxadiazone, oxadiargyl, pentoxazone, cyhalohop butyl, Caffentrol, Ipphencarbazone, Pyriminobac methyl, bisbiribac sodium, pyrimisulfan, triaphamone, triafamone, pyribenzoxime, pyriphthalide, indanophane, ACN, benzobicyclone, tefuryltrione, mesotrione, fenquinotrione, dithiopyr, dalapirone, chlorchiamide , Penoxsulam, anilophos, bensulide, butamiphos, phenoxasulfone, benzophenap Pyrazolinate, pyrazolxifene, imazamethabenz, imazamethabenzmethyl, imazamox methyl, imazamox ammonium salt, imazapic, imazapic ammonium salt, imazapyr, imazaquin, imazetapyr, pendimethalin, fenoxapropethyl, fenoxaprop P-ethyl, metamihop, pyraclonyl, quinclorac, 2,4-D and salts thereof, MCP and salts thereof, MCPA and salts thereof, MCPA and salts thereof, MCPB and salts thereof, piperophos, fluoxypyr, cyclopimolate, benzobicyclone, florpirauxifene -Benzyl, florpyrauxifene and Thaxtomin A can be mentioned.

  The rice which can use the composition B refers to cultivars Oryza sativa, Oryza glaberrima and their hybrids among annual plants of the genus Oryza, and any of japonica species, jabanica species and indica species Also, any of glutinous rice, glutinous rice, sake rice, and feed rice may be used. The variety of rice is not particularly limited, and it may be a variety created by crossing, as exemplified in the above-mentioned plant variety, or may be a variety created by genetic engineering technology. When applied to varieties to which herbicide resistance, pest resistance or disease resistance has been imparted, a particularly labor-saving control method can be adopted. In addition, it may be a multi-line in which a plurality of varieties in which different resistance genes are integrated are mixed and cultivated.

  Composition A, which comprises one or more herbicidal active ingredients selected from group (i) and one or more safening ingredients selected from group (d), may contain all the active ingredients in one preparation. It may be a plurality of preparations consisting of a preparation containing one active ingredient and a preparation containing a plurality of active ingredients, or all the active ingredients may be separate preparations. For example, before or after planting a seed or plant reproductive organ treated with one or more kinds of safeners selected from group (d) into soil, the soil is treated with the herbicidally active component selected from group (i), and then this Methods include applying the compounds to harmful arthropods, habitats of harmful arthropods, plants or soil. Also, in that case, commercially available seeds treated with one or more types of safeners selected from group (d) may be purchased and used.

  Composition A containing one or more herbicidal active ingredients selected from group (i) and one or more plant growth regulating components selected from group (c) contains all the active ingredients in one preparation. It may be a plurality of preparations consisting of a preparation containing one active ingredient and a preparation containing a plurality of active ingredients, or all the active ingredients may be separate preparations. When applying a plurality of formulations, they may be applied to harmful arthropods, habitats of harmful arthropods, plants or soil at the same time or different times. For example, before or after planting seeds or plant reproductive organs treated with one or more plant growth regulating components selected from group (c) into soil, the soil is treated with the herbicidally active component selected from group (i), The method includes applying the present compound to harmful arthropods, habitats of harmful arthropods, plants or soil. In that case, commercially available seeds treated with one or more kinds of plant growth regulating components selected from group (c) may be purchased and used.

  Composition A containing one or more herbicidal active ingredients selected from group (i) may contain all the active ingredients in one preparation, and a plurality of preparations containing one active ingredient and a plurality of active ingredients It may be a plurality of formulations consisting of the formulation containing them, or all active ingredients may be separate formulations. When applying a plurality of formulations, they may be applied to harmful arthropods, habitats of harmful arthropods, plants or soil at the same time or different times. The application time of the herbicidal active ingredient is, for example, as follows.

  When treating one or more herbicidal active ingredients selected from group (i) before seeding seeds or planting vegetative organs or seedlings, the herbicidal active ingredients are treated 50 days before sowing or planting From immediately before sowing or planting, preferably from 30 days before sowing or planting to just before sowing or planting, more preferably from 20 days before sowing or planting to just before sowing or planting, It is from 10 days before sowing or planting to immediately before sowing or planting.

  In the case of treating one or more herbicidal active ingredients selected from group (i) after sowing of seeds, or after planting of vegetative organs or seedlings, the treatment time of the herbicidal active ingredients is preferably immediately after sowing or planting And 50 days after sowing or planting, more preferably immediately after sowing or planting to 3 days after sowing or planting.

  At the same time as seeding of seeds or planting of vegetative organs or seedlings, one or more components selected from group (i) can be treated.

  When one or more herbicidal active ingredients selected from group (i) are treated after sowing of soybean seeds, the treatment time of the herbicidal active ingredients is, for example, from before sprouting to the flowering stage of soybean. Among the pre-emergence stage to the flowering stage of soybean, preferably the pre-emergence stage of soybean to the time of six double leaves, more preferably the pre-emergence stage of soybean to the three-phase combination leaves.

  When one or more herbicidal active ingredients selected from group (i) are treated after sowing of corn seeds, the treatment time of the herbicidal active ingredients is, for example, from before budding to 12 leaf stages, preferably from before budding to During the leaf stage, more preferably between the pre-emergence and 6 leaf stages. The leaf age of corn is determined by the leaf color method (Leaf Collar Method).

  When one or more herbicidal active ingredients selected from group (i) are treated before sowing of cotton seeds, the herbicidal active ingredient is treated from 50 days before sowing to just before sowing, preferably from 30 days before sowing Between immediately before sowing, more preferably between 20 days before sowing and just before sowing. When treating one or more herbicidal active ingredients selected from group (i) after sowing of cotton seeds, the treatment time of the herbicidal active ingredients is from immediately after sowing to 70 days after sowing, preferably 30 days after sowing The period is up to 50 days after, for example, from the pre-emergence to the flowering phase of cotton, preferably from the start of lignification of the stem base of cotton to the time of 20 cm from the base of lignification.

  When one or more herbicidal active ingredients selected from group (i) are treated prior to planting of sugar cane, the treating time of the herbicidal active ingredient is preferably 40 days before planting day, preferably 30 days of planting day. The period is from before to immediately before, more preferably from 20 to before immediately before the day of planting. When treating one or more herbicidal active ingredients selected from group (i) after planting of sugarcane, the treatment time of the herbicidal active ingredient is from immediately after planting to 40 days after planting, preferably sowing or planting immediately after planting It is from 20 days after, more preferably from immediately after planting to 10 days after planting.

  Depending on the application of the composition B, depending on the plant species or plant varieties, their growing place and growing conditions (soil, climate, growing season, nutrients), increase the rate of establishment of plants, increase the growth of plants, high temperature or Improved low temperature tolerance or tolerance, drought, excessive humidity or improved tolerance to salt contained in water or soil, improved flowering ability, improved harvestability, enhanced maturation, increased yield, seeds or Increase in fruit number, size or weight, increase in plant height, increase in plant weight, increase in leaf greenness, increase in number of healthy leaves, increase in leaf area, faster flowering, flowering number or fruit set Increasing the number, increasing the fruiting rate, improving the quality of the harvested product and / or increasing the nutritive value, increasing the sugar content in the fruit, improving the gluten strength, improving the storage stability of the harvested product, and And / or improvement of processability may be possible

When the composition B is applied to a place where rice is grown, the application amount of the composition B is usually 5000 g or less, preferably 1000 g or less, per 10 hours sowing area (cultivation area), and is contained in the composition B The total amount of the present compound or composition A is usually at most 1000 g, preferably at most 500 g. In addition, the total amount of the present compound or composition A contained in the composition B per 1 m ^{2 of} a place where rice is grown is usually 0.05 to 1000 g, preferably 0.5 to 200 g.

  When the composition B is applied to a rice growing box, the application amount of the composition B is the total amount of the present compound or the composition A contained in the composition B. 1 box of raising box (about 60 cm wide, about 30 cm long) The amount is usually 0.1 to 35 g, preferably 0.2 to 20 g.

  Composition B When applied to seeds or vegetative reproductive organs, the application rate of composition B is usually 0.001 to 100 g, preferably 0.02 to 50 g, per kg of seed or vegetative organ. The total amount of the present compound or composition A to be contained is usually 0.000001 to 50 g, preferably 0.0001 to 30 g, per kg of the seed or vegetative organ. Here, the weight of the seed or vegetative organ means the weight of the seed or vegetative organ before applying the composition B before sowing or planting.

  When the composition B is to be applied to seeds or vegetative organs, an adjuvant may be mixed with the composition B, if necessary. When the composition B is applied, the present compound and the present component may be applied separately, before or after planting the seed or vegetative organ to which the present compound or the present component is attached to the cultivation carrier, The other may be applied to the cultivation support.

  The weight ratio of the applied amount of the present compound to the applied amount of the present component in the composition A is the type of plant to be protected, type and frequency of occurrence of harmful arthropods to be controlled, phytopathogenic microorganisms or weeds The weight ratio can be appropriately adjusted according to the form, application time, application method, application place, weather conditions and the like. For example, in the field of agriculture, when applied to plants (in particular, foliage, seeds, vegetative reproductive organs) or when applied to cultivation carriers (in particular, soil) for cultivating plants, the following weight ratios may be mentioned.

With regard to the components contained in group (a), (the present compound): (one or more components selected from group (a)) = 1: 1000 to 1000: 1, preferably 100, regardless of the presence or absence of other components. 1 to 1: 100, for example, 1:50, 1:40, 1:30, 1:20, 1:10, 1: 9, 1: 8, 1: 7, 1: 6, 1 : 5, 1: 4, 1: 3, 1: 2, 1: 1, 2: 1, 2: 1, 3: 1, 5: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1 10: 1, 20: 1, 30: 1, 40: 1, 50: 1;
With respect to the components contained in group (b), (the present compound): (one or more components selected from group (b)): 1: 100 to 10,000: 1, preferably, regardless of the presence or absence of other components Is in the range of 1:10 to 1000: 1, more preferably in the range of 1: 1 to 100: 1, for example 1:50, 1:20, 1:10, 1: 5, 1: 3, 1: 2 1: 1, 2: 1, 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 20: 1, 50: 1, 60 : 1, 70: 1, 80: 1, 90: 1, 100: 1, 200: 1, 300: 1, 400: 1, 500: 1, 600: 1, 700: 1, 800: 1, 900: 1 ;
With regard to the components contained in group (c), (the present compound): (one or more components selected from group (c)) = 1: 1000 to 1000: 1, preferably 100, regardless of the presence or absence of other components. 1 to 1: 100, for example, 1:50, 1:40, 1:30, 1:20, 1:10, 1: 9, 1: 8, 1: 7, 1: 6, 1: 5, 1: 4, 1: 3, 1: 2, 1: 1, 2: 1, 2: 1, 3: 1, 5: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 20: 1, 30: 1, 40: 1, 50: 1;
With regard to the components contained in the group (d), (the present compound): (one or more components selected from the group (d)): 1: 1000 to 1000: 1, preferably 100, regardless of the presence or absence of other components. 1 to 1: 100, for example, 1:50, 1:40, 1:30, 1:20, 1:10, 1: 9, 1: 8, 1: 7, 1: 6, 1 : 5, 1: 4, 1: 3, 1: 2, 1: 1, 2: 1, 2: 1, 3: 1, 5: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1 10: 1, 20: 1, 30: 1, 40: 1, 50: 1;
With respect to the components contained in group (e), (the present compound): (one or more components selected from group (e)): 1: 1000 to 10,000: 1, preferably, regardless of the presence or absence of other components Is in the range of 1: 100 to 100: 1, for example, 1:50, 1:40, 1:30, 1:20, 1:10, 1: 9, 1: 8, 1: 7, 1: 6 1: 5, 1: 4, 1: 3, 1: 2, 1: 1, 2: 1, 2: 1, 3: 1, 5: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9 : 1, 10: 1, 20: 1, 30: 1, 40: 1, 50: 1;
With regard to the components contained in group (f), (the present compound): (one or more components selected from group (f)) = 1: 1000 to 1000: 1, preferably 100, regardless of the presence or absence of other components. For example, 1:50, 1:40, 1:30, 1:20, 1:10, 1: 9, 1: 8, 1: 7, 1: 6 1: 5, 1: 4, 1: 3, 1: 2, 1: 1, 2: 1, 2: 1, 3: 1, 5: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9 : 1, 10: 1, 20: 1, 30: 1, 40: 1, 50: 1;
With regard to the components contained in group (g), (the present compound): (one or more components selected from group (g)) = 1: 1000 to 1000: 1, preferably 1 regardless of the presence or absence of other components. : 100 to 100: 1, for example, 1:50, 1:40, 1:30, 1:20, 1:10, 1: 9, 1: 8, 1: 7, 1: 6, 1 : 5, 1: 4, 1: 3, 1: 2, 1: 1, 2: 1, 2: 1, 3: 1, 5: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1 10: 1, 20: 1, 30: 1, 40: 1, 50: 1;
With regard to the components contained in group (h), (the present compound): (one or more components selected from group (h)) = 1: 1000 to 1000: 1, preferably 1 regardless of the presence or absence of other components. : 100 to 100: 1, for example, 1:50, 1:40, 1:30, 1:20, 1:10, 1: 9, 1: 8, 1: 7, 1: 6, 1 : 5, 1: 3, 1: 2, 1: 1, 2: 1, 3: 1, 4: 1, 5: 1, 10: 1, 20: 1, 30: 1, 40: 1, 50: 1 ;
With regard to the components contained in group (i), (the present compound): (one or more components selected from group (i)) = 1: 1000 to 1000: 1, preferably 1 regardless of the presence or absence of other components. : 100 to 100: 1, for example, 1:50, 1:40, 1:30, 1:20, 1:10, 1: 9, 1: 8, 1: 7, 1: 6, 1 : 5, 1: 3, 1: 2, 1: 1, 2: 1, 2: 1, 3: 1, 5: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1 20: 1, 30: 1, 40: 1, 50: 1.

The components selected from group (j) are usually prepared by culture methods known in the art. For example, when the component selected from group (j) is bacteria or fungi, it is prepared by a known medium and known fermentation method in the art. In the case of viruses or nematodes, they are prepared by culture methods known in the art. When this component is a bacterium or filamentous fungus, the preparation thereof is 1 × 10 ⁴ to 1 × 10 ¹³ CFU (colony forming unit), preferably 1 × 10 ⁸ to 1 × 10 ¹² CFU of this component per gram. including. When this component is a virus, the preparation is preferably at 1 × 10 ⁴ to 1 × 10 ¹³ embedding bodies (occlurion bodies, sometimes referred to as Obs), preferably 1 × 10 ⁸ to 1 ×. It contains this component of 10 ¹² embedding bodies (sometimes referred to as occluding bodies, Obs). When the component is a nematode, the preparation contains 1 × 10 ⁴ to 1 × 10 ¹³ individuals / g, preferably 1 × 10 ⁸ to 1 × 10 ¹² individuals / g of the component.

  When the composition B contains a component selected from group (j), (the present compound): (one or more components selected from group (j)) = 1: 10000 regardless of the presence or absence of other components. And preferably in the range of 1: 1000 to 1000: 1, for example, 1: 900, 1: 800, 1: 700, 1: 600, 1: 500, 1: 400, 1: 300, 1 : 200, 1: 100, 1:50, 1:40, 1:30, 1:10, 1: 9, 1: 8, 1: 7, 1: 6, 1: 5, 1: 4, 1: 3 1: 2, 1: 1, 2: 1, 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 20: 1, 30 : 1, 40: 1, 50: 1, 100: 1, 200: 1, 300: 1, 400: 1, 500: 1. The weight ratio of one or more components selected from group (j) means the total weight of the preparation of one or more components selected from group (j). For example, a weight ratio of 1: 500 means 500 parts by weight of a preparation of one or more components selected from group (j) relative to 1 part by weight of the compound.

  Composition B is effective against harmful arthropods such as harmful insects and harmful mites, harmful nematodes, and harmful molluscs. Examples of harmful arthropods, harmful nematodes and harmful molluscs include, for example, the following.

  Hemiptera (Hemiptera): Hemetobiunka (Laodelphax striatellus), Tobiirounka (Nilaparvata lugens), Sejirounka (Sogatella furcifera), Maize's deer (Peregrinus maidis), Lobluntia (Javesella pellucida), Black-footed Michalica Planthopper family (Delphacidae); African green leafhopper (Nephotettix cincticeps), Yellow-tailed green leafhopper (Nephotettix virescens), Black-nosed green leafhopper (Nephotettix nigropictus), Yellow-tailed leafhopper (Recilia dorsalis), Black-tailed leafy caribbean , Corn leaf hopper (Dalbulus maidis), White leafhopper (Cofana spectra), etc., leafhopper family (Cicadelidae); Mahanarva posticata, Mahanarva fimbriolata et al., Cercopidae (Cercopidae); Beetles (Aphis fabae), soybean aphids (Aphis glycines), cotton aphids (Aphis gossypii), European apple aphids (Aphis pomi), black-and-white aphids (Aphis spiraecola), green-billed aphids (Myzus persicae), blue-winged aphids , Radish aphids (brevicoryne brassicae), Rosy apple aphid (Dysaphis plantaginea), imago radish aphids (Lipaphis erysimi), tulip pokeweed aphids (Macrosiphum euphorbiae), potato pokeweed aphids (Macrosiphum euphorbiae), potato pokeweed aphid (Alacorth cichalis). Aphids (Rhopalosiphum padi), corn aphids (Rhopalosiphum maidis), red-handed aphids (Toxoptera Citricida), Pectinous aphids (Hyalopterus pruni), Hynollus aphid (Melanaphis sacc) Aphididae (Aphididae), such as hari), the black-winged aphid (Tetraneura nigriabdominalis), the canned cotton aphid (Ceratovacuna lanigera), and the apple cottonseed (Eriosoma lanigerum), etc .; Phylloxera (Phylloxera notabilis), Southern pecan leaf phylloxera (Phylloxera russellae) and other nematodes (Phylloxeridae); Rice black bug (Scotinophara lurida), Malayan rice black bug (Scotinophara coarctata), Blue-streak bug (Nezara antennata), Scutellaria bug (Eysarcoris aeneus), Scutellariass stag Bug (Eysarcoris lewisi), Blue-streak bug (Eysarcoris lewisi) Red-headed Bug (Eysarcoris annamita), Brown-headed Bug (Halyomorpha halys), Brown-headed Bug (Nezara viridula), Brown stink bug (Euschistus heros), Red banded stink bug (Piezodorus guildinii), Oebalus pugnax, Dichelodermidae, etc. ; Burrower brown bug (Scaptocoris castanea), etc .; Russidae (Cydnidae); Spermatozoa (Riptortus pestestris), Spermatozoa (Leptocorisa chinensis), Spermatozoa (Leptocorisa acuta) Esperiidae (Alydidae); Helicidae (Coreidae), such as Cletus punctiger, Leptoglossus australis, etc .; Etc.) (Ly) Gaeidae); Trichonotylus caulistialium; Trichonotylus caelestialium; Akathys mosquitoes (Stenotus rubrovittatus); Bacterial wingworms (Bemisia tabaci), orange leafhopper (Dialeurodes citri), orange leafhopper (Aleurocanthus spiniferus), white leaf lice (Aleurocanthus camelliae), white leaf lice (Pealius euroyae), etc. Abgrallaspis cyanophylli), Red-backed scale insect (Aonidiella aurantii), Yellow-backed scale insect (Diaspidiotus perniciosus), Red-backed scale insect (Pseudaulacaspis pentagona), Red-winged scale insect (Unaspis yanonensis) Red scale insect (Unaspis citri) etc., Marukabidae (Diaspididae); Ruby rotifer (Ceroplastes rubens) etc. Catidae (Coccidae); Family (Margarodidae); Plasmodium (Phenacoccus solani), Plasmodium (Phenacoccus sorenopsis), Plasmodium (Planococcus kraunhiae), Plasmodium (Pseudococcus comstocki), Plasmodium (Planococcus) Pseudococcus calceolariae, Pseudococcus longispinus, P. coccidae (Pseudococcidae), such as Tuttlemya bug (Brevennia rehi), etc .; rytreae), nashi-kishi lice (Cacopsylla pyrisuga), Chinese pear lice (Cacopsylla chinensis), potato short-tailed lice (Bacterica cockerelli), pear psylla (Cacopsylla pyricola), etc. (Psyllidae); Marmorata), Stephanitis nashi, and Stephanitis pyrioides, etc. (Tingidae); Bedflies (Cimex lectularius), Nettite bedflies (Cimex lectularius), etc. Bedflies (Cimicidae) And the like (Cicadidae) of Brazil, etc .; Brazilian Red-handed Turtle (Triatoma infestans), Venezuelan Red-handed Turtle (Rhodonius prolixus), etc. Red-tailed Family (Reduviidae) Triatoma sp. (Triatoma spp.).

  Lepidoptera: Chilo suppressalis, Darkheaded stem borer (Chilo polychrysus), White stem borer (Scirpophaga innotata), Itten's tree magnolia (Scirpophaga incertulas), Rupela albina, Kobnomiga (Cnaphatailicalis) Casino meiga (Marasmia exigua), cotton moth (Notarcha derogata), foxtail moth (Ostrinia furnacalis), European corn borer (Ostrinia nubilalis), black-tailed moth (Hellula undulis), Monquil chronome moth (Herpetogramma lucitose, Pe) Caseworm (Nymphula depunctalis), Sugarcane borer (Diatraea saccharalis), etc. (Crambidae); (Cadr A coctella (Pyralidae), such as Spodoptera litura, Spodoptera exigua, Mythimna separata, Mamestra brassicae, Spurge (Sesamia inferens), acenescens), Spodoptera frugiperda, African Sparrow (Spodoptera exempta), Tamayaga (Agrotis ipsilon), Tamana Guinuba (Autographa nigrisigna), Inainuwaba (Plusia festucae), Soybean loopitraceus. spp., Heliothis virescens, Heliothis spp., Helicoverpa armigera, Helicoverpa zea etc. Helicoverpa spp., Velvetbean caterpillar (Anticarsia gemmat) alis), Cotton leafworm (Alabama argillacea), Hop vine borer (Hydraecia immanis) etc .; Noctuidae (Noctuidae); dimorpha), legume mincing moth (Leguminivora glycinivorella), azuxamushi moth (Matsumuraeses azukivora), apple coccomon moth (Adoxophyes orana fasciata), kanokoc mon maimai (Adoxophys honmai), chahamaki (Homona magnima trich.) Anthracis (Tortricidae) such as (Cydia pomonella), Kanshashinhami (Tetramoera schistaceana), Bean Shoot Borer (Epinotia aporema), Citrus fruit borer (Ecdytopha aurantiana), etc .; Hosoga ( Gracillariidae); Carposinidae such as Carposina sasakii; Coffee Leaf miner (Leucoptera coffeella), Peach Haemogriga (Lyonetia clerkella), Gimmon Hamogriga (Lyonetia prunifoliella) etc. Lymantriidae (Lymantriidae) such as Lymantrilia sp. (Leumantis spp.), Euproctis pseudoconspersa (Euproctis pseudoconspersa) etc .; Pstilidae (Plutellidae) such as Monaga (Plutella xylostella); lineatella), Hemcystogramma triannulella, cotton moth (Pectinophora gossypiella), potato moth (Phthoremaea operculella), Tuta absoluta et al. (Gelechidae); Kastonia such as Telchin licus) Family (Castniidae); Coccidae (Cossidae), such as Cossus insularis; Coleoptera (Geometridae) such as Y. (Escotis selenaria); (Sphingopodidae) such as masinissa); Sphingidae (Sphingidae) such as Acherontia lachesis; Nokona feralis; ; Nematode (Hesperiidae), such as ladybug (Parnara guttata); Helicidae (Tinedae), such as liga (Tinea translucens), and liga (Tineola bisselliella).

  Thysanopteran (Thysanoptera): Thripsidae (Frankliniella occidentalis), Thripsidae (Thrips palmi), Chalyssus thrips (Scirtothrips dorsalis), Locust Thrips (Trips tabaci), Hydrangea thripsus (Frankliniella intronacea) , Thripidae such as Echinothrips americanus etc .; Thripsidae (Phlaeothripidae) such as Haekohrips aculeatus.

  Diptera (Diptera): Anemoneid family (Anthomyiidae) such as fly (Delia platura), onion fly (Delia antiqua), sugar beet fly (Pegomya cunicularia), etc .; Rice leafminer fly (Agromyza oryzae), tomato leafminer fly (Liriomyza sativae), bean leafminer fly (Liriomyza trifolii), leafminer fly (Chromatomyia horticola), etc. leafworm family (Agromyzidae); Bactrocera cucurbitae), Citrus fruit fly (Bactrocera dorsalis), Nassy fruit fly (Bactrocera latiphrons), Olive fruit fly (Bactrocera oleae), Quinceland fruit fly (Bactrocera tryoni), Citrus fruit fly (Ceratitis capitole) Fruit fly family (Tephritidae), such as Rhacochlaena japonica; rice hydride fly (Hydrellia griseola), rhubarb littlefish (Hydrellia philippina), rice floury fly (Hydrellia sasakii), etc. Drosophila (Drosophila suzukii) etc .; Drosophila family (Drosophilidae); Oopidae flyfish (Megaselia spiracularis) etc. (Lepidoptera: Phoridae); (Sciaridae); Hecyon fly (Mayetiola destructor), inocynoidea (Orseolia oryzae), etc. (Cecidomyiidae); Diopsis macrophthalma etc. (Diopsidae); cranefly (Tipula ol eracea), European cranefly (Tipula paludosa) and other gunfishes (Tipulidae); ), Black locust mosquitoes (Culex vishnui), Aedes albopictus, Aedes aegypti, Anopheles sinesis, Anopheles gambiae, and Anopheles stephenelicel , Anopheles sundaicus, Anopheles arabiensis, Anopheles funestus, Anopheles darlingi, Anopheles farauti, Anopheles minimus et al. (Culicidae); trigonus) etc House fly (Muscidae); housefly (Muscidae), such as house fly (Musca domestica), house fly (Muscina stabulans), house fly (Stomoxys calcitrans), house fly (Haematobia irritans), etc. (Muscidae); Chironomus plumosus, Chironomus yoshimatsui, Hyrocythus (Glyptotendipes tokunagai), and the like Chironomidae (Chironomidae), and the Hymenididae (Fannidae).

  Coleoptera (Coleoptera): Western corn rootworm (Diabrotica virgifera virgifera), Southern corn rootworm (Diabrotica undecimpunctata howardi), Northern corn rootworm (Diabrotica barberi), Mexican corn rootworm (Diabrotica virgifera zeae), Banded Cucumber Beetle (Diababrotica) balteata), Cucurbit Beetle (Diabrotica speciosa), Bean Leaf Beetle (Cerotoma trifurcata), Culex Trifoliata (Oulema melanopus), Uri Hama (Aulacophora femoralis), Chrysomelidae (Phyllotreta striolata), Cabbagel flea beetle (Phyllotreta pusilla), Cabbage stem flea beetle (Psylliodes chrysocephala), Colorado potato beetle (Leptinotarsa decemlineata), Indreum oivensis (Oulema oryzae), grape colapice (Colaspis brunnea), corn flare be Le (Chaetocnema pulicaria), Sweet potato beetle (Chaetocnema confinis), Potato flare beetle (Epitrix cucumeris), Green leaf beetle (Dicladispa armigera), southern corn leaf beetle (Myochrous denticollis), ツ mac mac mac L Seedcorn beetle (Chrysomelidae) such as (Epitrix hirtipennis); Seedcorn beetle (Stenolophus lecontei), Slender seedcornee (Clivina impressifrons) etc. Carabidae (Caribidae); ), Pea beetles (Popillia japonica), snails (Heptophylla picea), European chafer (Rhizotrogus majalis), black marsh (Tomarus gibbosus), Holotrichia sp., Phylollica sp. .) Scarabaeidae (Scarabaeidae) such as Diloboderus (Diloboderus spp.) Such as Diloboderus abderus, etc .; (Sitophilus zeamais), Scotch weevil (Sitophilus oryzae), Scolypus solanacea (Sitophilus granarius), Scotch weevil (Echinocnemus squameus), Cossus weevil (Lissorhoptrus oryzophilus), Scotch weevil (Rhabscelus citratimichium) Weevil (Sphenophorus venatus), Southern Corn Billbug (Sphenophorus callosus), Soybean stalk weevil (Sternechus subsignatus), Sugarcane weevil (Sphenophorus levis), Rusted weevil (Scepticus griseus), Tobiiro gourd tanzo Acaranthus genus (Aracanthus spp.), Such as Aricanthus spp., Such as Acaranthus mourei, cotton root bril, Family (Curculionidae); Tricholium castaneum, Trifolium contrisus (Tribolium confusum), Aphididae (Alphitobius diaperinus), etc. Trichomycidae (Tenebrionidae); ; Bostrychidae, such as Lyctus brunneus, Rhizopperta dominica, and the like; Bostrychidae; Pstoidae (Ptinidae); White-backed rice (Melanotus okinawensis), Tobiiro-nama-so-kokeki (Agriotes fuscicollis), Combi-eating (Melanotus legatus), Genus Anchostus (Anchastus spp.), Conoders sp. Beetle family (Elateridae) such as Rimonius sp. (Limonius spp.), Aeolus spp., Etc; maculates, black-and-white catfish (Trogoderma granarium), etc .; Dermestidae; tobacco beetles (Lasioderma serricorne); Family (Laemophloeida e); Anemoneaceae family (Silvanidae), such as saw palmetto (Oryzaephilus surinamensis).

  Orthoptera (Orthoptera): Toocta grasshopper (Locusta migratoria), Toroca grasshopper (Dociostaurus maroccanus), Australia Tobibatata (Chortoicetes terminifera), Red-footed grasshopper (Nomadacris septemfasciata), Brown Locust (Locustana pardalis Licil acitivi Locust (Calliptamus italicus), Differential grasshopper (Melanoplus differentialis), Two striped grasshopper (Melanoplus bivittatus), Migratory grasshopper (Melanoplus sanitil at victelium, as well as MelimothiCellitechimel at the delicelli quel atl ), Yellow-winged locust (Gastrimargus musicus), Spur-throated locust (Austracris guttulosa), Kobayinago (Oxya yezoensis), Hanekinainago (Oxya japonica), Trichophyton (Patanga succincta) et al. ntalis) et al. (Gryllotalpidae); European green cricket (Acheta domestica); Emma cricket (Teleogryllus emma) et al. cricket (Gryllidae); Mormon cricket (Anabrus simplex) et al.

  Hymenoptera (Hymenoptera): Japanese gossip (Athalia rosae), Japanese black-billed wasp (Athalia japonica), etc. (Tenthredinidae); Fireflies (Solenopsis invicta), Red-winged Ants (Solenopsis geminata), etc. Tolushinella (Solenopsis spp.) leaf-cutting ant (Atta capiguara) et al. (Atta spp.), Anemone spp. (Acromyrmex spp.), Scorpionfish (Paraponera clavata), Ruriari (Ochetellus glaber), Scutellariae (Monomorium pharaonis), Argentine ants (Linepithemahumile) ), Black-headed ants (Formica fusca japonica), amme-ants (Pristomyrmex punctutus), red-winged ants (Pheidole noda), yellow-headed ants (Pheidole megacephala), black-necked ants (Camponotus japonicus), red-winged ants (Camponotus obscuripes), etc. Pogonomyr (Pogonomyrmex occidentalis) etc. mex), a long-eared family (Wasmania auropunctata) etc., a family of long-eared family members (Wasmania), such as a long-necked ant (Anoplolepis gracilipes) etc. (Formicidae); ), Vespa velutina, Polistes jokahamae, etc. (Vespidae); Momino giant bee (Urocerus gigas), such as the bee family (Siricidae), Ariidae (Bethylidae).

  Cockroach (Blattodea): German cockroach (Blattella germanica) and other German cockroaches (Blattellidae); (Blattidae); Yamato termites (Reticulitermes speratus), house termites (Coptotermes formosanus), American termites (Incisitermes minor), Dicta termites (Cryptotermes domesticus), Typhoon termites (Odontotermes formosanus), Ornithophorids (Neotermes termiensis) Glyptotermes satsumensis), Phytotermite (Glyptotermes nakajimai), Catan termite (Glyptotermes fuscus), Ophiotermite (Hodotermopsis sjostedti), Nychotermite (Coptotermes guangzhouensis), Nymph Li (Reticulitermes amamianus), Miyatake termite (Reticulitermes miyatakei), Cameron termite (Reticulitermes kanmonensis), Takasago termite (Nasutitermes takasagoensis), Nitobe termite (Pericapritermes nitobei), Musashi termi (Sinocapritimates mecih ).

  Flea order (Siphonaptera): Pulex genus such as human flea (Pulex irritans), cat flea (Ctenocephalides felis), Ctenocephalides genus such as dog flea (Ctenocephalides canis), Xenopsylla genus such as Xenopsylla cheopis etc. Of the genus Tonga, et al., Of the genus Echidnophaga such as chicken flea (Echidnophaga gallinacea), and of the genus Nosopsyllus such as the European mouse flea (Nosopsyllus fasciatus).

Echinodermata (Psocodae): Pediculus genus such as head lice (Pediculus humanus capitis) etc., Phtirus genus such as a whitefly (Pthirus pubis) etc., Haemtopinus erysternus such as the pig louse (Haematopinus eurysternus), Haematopinus genus such as the pig lice (Haematopinus suis) etc., sheep lice (Dalmalini ovis) Damelinia bovis (Dalalinina bovis) etc., Dalinaria spp. (Linognathus vituli), sheep trunk parasitoids (Linognathus ovillus) Linognathus spp., Etc. Solenopotes sp. Menopon, Trimenopon spp., Trinoton spp., Trichodectes such as Trichodectes canis etc., Felicola genus such as Felicola subrostratus etc., Bovicola such as Boschis bovis (Bovicola bovis), Chicken The genus Menacanthus, such as the great leaf lice (Menacanthus stramineus), Lenneckella spp., Lepikentron spp., Urosu catfish (Liposcelis subfuscas), Hirata chiatata (Liposcelis bostrychophilus), Sommen chiatata (Liposcelis simulans), Konatate (Liposceli itself) And so on (Poposcelididae).
.

  Spots eye order (Thysanura): Spots family (Lepismatidae) such as Yamatosimi (Ctenoepisma villosa), American iris (Lepisma saccharina).

  Acarids (Acari): Two-spotted spider mite (Tetranychus urticae), Kanzawa spider mite (Tetranychus kanzawai), Eurasian spider mite (Tetranychus evansi), red-eared spider mite (Panonychus citri), apple red spider mite (Panonychus ulmi), Oligonychus family ; Scutellaris mite (Aculops pelekassi), Scutellaris mite (Phyllocoptruta citri), Tomato snail (Aculops lycopersici), Scutellaris mite (Calacarus carinatus), Scutellariae ica (Acaphylla theavagrans), Disapproval Aculus schlechtendali), Aceria diospyri, Aceria tosichella, Shevtchenkella sp. Eriophyidae such as Schizoctella (Shevtchenkella sp.); Nevis (Tenuipalpidae), such as Nicis (Daciphysidae); Tenderidae (Tuckerelidae); Ticks (Ixodidae), such as Haemaphysalis longicornis, Haemaphysalis longicorchis, Haemaphysalis americanus (Haemaphylalis americanus), Chicks (Dermacentor variabilis), Dermacentor taiwanicus), Dermacentor and Deranicentors such as Dermacentor andersoni, Dermacentor spp. Black-tailed ticks (Ixodes pacificus), Ixodes holocyclus (Ixodes holocyclus) etc. Ixodes genus, Lone Stark (Amblyomma americanum), Amblyomma maculatum (Amblyomma maculatum) etc. Amblyomma genus, Ophid tick (Rhipicephalus us) microplus), Boophilus annulatus and other Boophilus spp., Rhipicephalus sanguineus, Rhipicephalus appendiculatus such as Rhipicephalus spp .; Such as Trichophagus similis); such as the family Acaridae; Acaridae; Acaridae; Acaridae (Acaridae); Red-tailed mite (Cheyletiella yasguri), such as Cheyletidae; Argas genus, such as long-tailed mite (Argas persicus), Ornitrodus hermsi (Ornithodorus hermsi), Ornithodorus tulikata (Ornithodorus t) such as Oricthodorus such as Uricata), Psoroptes ovis, Psoroptes such as Psoroptes equi etc, Knemidocoptes mutans such as Knemidocoptes spp. Notoedres spp. Notoedres muris et al., Sarcoptes scabiei et al. Sarcoptes spp., Octodectes cynotis et al. Otodectes spp. Derpyssus (Hypodectes spp.), Pterolichus spp., Cytotodes spp., Laminosioptes spp. House mite (Ornithonyssus b Ornithonyssus such as acoti), Varroa such as the honeybee mite (Varroa jacobsoni), the genus Cyrothya tick (Cheyletiella yasguri), a group of the genus Cheyletiella such as the blue-toothed mite (Chyletiella blakei), such as the genus Orynithos chleetia (Ornithochechiletia spp.) Demodex canis), Demodex cati etc. Demodex genus, Myobia genus (Myobia spp.), Psorergates spp. Trombicula genus such as scutellaris).

Arachnida (Araneae): Anemone family (Eutichuridae) such as Chehiracanthium japonicum etc .; A hymenodontid family (Theridiidae) such as Latrodectus hasseltii.
Obiayasuda (Polydesmida): Nephetidae (Oxidus gracilis), Red-crested cod (Nedyopus tambanus), etc.
Isopoda: Armadillidiidae, such as Armadillium vulgare.
Lipopoda (Chilopoda): The Scutigera such as Thereuonema hilgendorfi; Scolopendra subspinipes, such as Scorpendridae; Stomopendidae;
Gastropoda (Gastropoda): Black-tailed slugs (Limax marginatus), black-and-white slugs (Limax flavus), etc. (Limacidae); Monopidae (Ampullariidae) of the family; Monopidae (Lymnaeidae), such as the black-and-white alga (Austropheplella).

  Nematoda (Nematoda): Aphelenchoides sp. (Aphelenchoides besseyi) etc. Aphelenchoididae (Aphelenchoididae); similis) and the like (Pratylenchidae); Javanese Nematode (Meloidogyne javanica), Sweet potato Nematode (Meloidogyne incognita), Northern Nematode (Meloidogyne hapla), Soybean cyst nematode (Heterodera glycines), White-tailed nematode (Globodera pallida) and other Heteroderidae (Heteroderidae); Rotylenchulus reniformis et al. Hoprelaimidae (Hoplolaimidae); strawberry mesenchu (Nothotylenchus acris), dichilenx jipsashi (D Anguinaceae (Anguinidae) such as itylenchus dipsaci; Tylenculidae (Tylenchulidae) such as Tylenchulus seminetrans; Parasita aphelench (Parasitaphelenchidae) such as Bursaphelenchus xylophilus.

The intraspecific variation is not limited for the above-mentioned harmful arthropods such as harmful insects and harmful mites, harmful molluscs and harmful nematodes. That is, it also includes harmful arthropods, harmful molluscs and harmful nematodes that have become less sensitive (also referred to as resistant) to specific insecticides, acaricides, molluscicides and nematocides. Be Examples of the insecticide, the acaricide, the molluscicide and the nematocide include groups a1 to a18.
Group a1: Acetylcholinesterase inhibitors alaniccarb (alanycarb), aldicarb (aldicarb), bendiocarb (bendiocarb), benfuracarb (benfuracarb), butocarboxim (butocarboxim), butoxycarboxim (butoxycarboxim), carbaryl (carbaryl: NAC), Carbofuran (carbofuran), carbosulfan (carbosulfan), ethiophene carb (ethiofencarb), fenobucarb (fenobucarb: BPMC), formetanate (formetanate), furathiocarb (furathiocarb), isoprocarb (isoprocarb: MIPC), methiocarb (methiocarb (methiocarb), methiocarb (methiocarb) , Metolcarb, oxamyl (oximyl), pirimicarb, propoxur (propoxur: PHC), thiodicarb (thiodicarb), thiophanox (thiofanox), triazamate (triazamate), trimetamate Lube (trimethacarb), xylylcarb (acephate), azamethiphos (azamethiphos), azinphos-ethyl (azinphos-ethyl), azinphos-methyl (azinphos-methyl), kadusaphos (cadusafos), chlorethoxifos (chlorethofos) ), Chlormephos (chlormephos), chlorpyrifos (chlorpyrifos), chlorpyrifos-methyl (chlorpyrifos-methyl), coumaphos (coumaphos), cyanophos (cyanophos: CYAP), demeton-S-methyl (demeton-S-methyl), diazinon (diazinon), Dichlorvos (DDVP), dicrotophos, dimethoate, dimethoate, dimethylvinphos, disulfoton (disulfoton), EPN, ethion, ethoprophos (ethoprophos), fenfur (famphur), fenamiphos (f enamiphos), fenitrothion (MEP), fenthion (MPP), phosthiazate (fosthiazate), heptenophos (heptenophos), imiciaphos (imicyafos), isofenphos (isofenphos), isopropyl-O- (methoxyaminothiophosphoryl) salicylate (isopropyls) -O- (methoxyaminothiophosphoryl) salicylate), isoxathion, malathion (malathion), mecarbam (mecarbam), methamidophos (methhamidophos), methidathion (DMTP), mevinphos (mevinphos), monocrotophos (monocrotophos), : BRP), omethoate, oxydemeton-methyl, parathion, parathion-methyl, phenthoate (PAP), phorate, phosalone, phosalone Met (phosmet: PMP), phosphamidon (phosphamidon), phoxim (phoxim), pirimiphos-methyl (pirimiphos-methyl), profenophos (profenofos), propetamphos (propetamphos), prothiophos (prothiofos), pyraclofos (pyraclofos), pyridophenthione (Quinalphos), sulfotep (sulfotep), tebupirimphos (tebupirimfos), temephos (temephos), terbuphos (terbufos), tetrachlorvinphos (tetrachlorvin phos), thiometon (thiometon), triazophos (triazophos), trichlorphone (trichellorfon: DEP) A group consisting of (vamidothion).
Group a2: a group consisting of the GABAergic chloride channel antagonists ethiprole (etiprole), fipronil (fipronil) and flufiprole.
Group a3: sodium channel modulators acuritathrin (acrinathrin), allethrin (allethrin), bifenthrin (bifenthrin), kappa bifenthrin (kappa-bifenthrin), bioallethrin (bioallethrin), bioresmethrin (bioresmethrin), cycloprothrin (cycloprothrin), sifluthrin (Cyfluthrin), beta-cyfluthrin (beta-cyfluthrin), cyhalothrin (cyhalothrin), gamma cyhalothrin (gamma-cyhalothrin), lambda cyhalothrin (lambda-cyhalothrin), cypermethrin (cypermethrin), alpha cypermethrin (alpha- cypermethrin, betacypermethrin (beta-cypermethrin), theta-cypermethrin (theta-cypermethrin), zeta-cypermethrin (zeta-cypermethrin), sigma-cypermethrin (sigma-cypermethrin), cypenothrin (cyphenothrin), deltamethrin (deltame) thrin), empenthrin, emphenthrin, esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucythrinate, flumethrin, fluvalinate (fluvalinate) fluvalinate, taufluvalinate (tau-fluvalinate), halfenprox (halfenprox), heptafluthrin (heptafluthrin), imiprotorin (imiprothrin), cadestrin (kadethrin), meperfluthrin (meperfluthrin), montfluorothrin (mofluorothrin), permethrin ( permethrin), phenothrin, prallethrin, pyrethrins, pyrethrins, resmethrin, silafluofen, tefluthrin, kappa-tefluthrin , Tetramethrin (tetramethrin), tetramethylfluthrin (tetrafluthrin), tralomethrin (tralomethrin), transfluthrin (transfluthrin), benfluthrin (benfluthrin), flufenprox (flufenoprox), flumethrin (flumethrin), framethrin (furamethrin), methofutrin ( metofluthrin), profluthrin (profluthrin) and dimefluthrin (dimefluthrin).
Group a4: Nicotinic acetylcholine receptor competitive modulator acetamiprid (acetamiprid), clothianidin (clothianidin), dinotefuran (dinotefuran), imidacloprid (imidacloprid), nitenpyram (nitenpyram), tiacloprid (thiacloprid), thiamethoxime, , Sulfoxafol (sulfoxaflor), cycloxaprid (cycloxaprid), triflumezopyrim (triflumezopyrim), dichloromethothiaz (dicloromezotiaz) and flupyrimin.
Group a5: a group consisting of the nicotinic acetylcholine receptor allosteric modulators spinosad and spinetoram.
Group a6: glutamatergic chloride ion channel allosteric modulators abamectin (abamectin), emamectin benzoate (emamectin-benzoate), lepimectin (lepimectin), milbemectin (milbemectin), dimadectin (dimadectin), doramectin (doramectin), eprinomectin (eprinomectin) A group consisting of ivermectin, latidectin, selamectin, milbemycin D, moxidectin and nemadectin.
Group a7: a group consisting of juvenile hormones mimic hydroprene (hydroprene), kinoprene (kinoprene), methoprene (methoprene), fenoxycarb and pyriproxyfen.
Group a8: A group consisting of the chord organelle TRPV channel modulators pimetrozine (Pymetrozine) and pyrifluquinazon (Pyrifluquinazon).
Group a9: microorganism-derived insect midgut inner membrane disrupter Bacillus sphaericus (Bacillus sphaericus), Bacillus thuringiensis strain BD # 32 (Bacillus thuringiensis strain BD # 32), Bacillus thuringiensis strain AQ52 (Bacillus thuringiensis strain AQ52), Bacillus thuringiensis subspecies ABTS-1857 (Bacillus thuringiensis subsp. Aizawai strain ABTS-1857), Bacillus thuringiensis cristae subsp. Strain HD-1 (Bacillus thuringiensis subsp. Kurstaki strain HD-1), Bacillus thuringiensis subsp. Bacillus thuringiensis cristarch subsp. BMP 123 (Bacillus thuringiensis subsp. Kurstaki strain BMP 123), Bacillus thuringiensis ssp. Tenebriosis subsp. NB 176 (Bacillus thuringiensis subsp. Tenebriosis strain NB 176), Bacillus thuringiensis Isla elensis variant (Bacillus thuringiensis var. israelensis), Bacillus thuringi Sua aegypti (Bacillus thuringiensis var. Aegypti), Bacillus thuringiensis var. Colmeri, Bacillus thuringiensis var. Darmstadiensis, Bacillus thuringiensis var. (Bacillus thuringiensis var. Dendrimus variant (Bacillus thuringiensis var. Dendrolimus), Bacillus thuringiensis galleriae (Bacillus thuringiensis var. Galleriae), Bacillus thuringiensis japonensis variant (Bacillus thuringiensis var. Japonensis), Bacillus thuringiensis morisoni subspecies ( Bacillus thuringiensis subsp. Morrisoni), Bacillus thuringiensis, San Diego variant (Bacillus thuringiensis var. San diego), Bacillus thuringiensis thuringiensis subsp. Strain MPPL 002 (Bacillus thuringiensis subsp. Thuringiensis strain MPPL 0 02), Bacillus thuringiensis 7216 variant (Bacillus thuringiensis var. 7216), Bacillus thuringiensis T36 variant (Bacillus thuringiensis var. T36), Delta-endotoxin imparting resistance to lepidopteran insects (eg, Cry1A, Cry1Ab) Modified Cry1 Ab (partially deleted Cry1 Ab), Cry1 Ac, Cry1 Ab-Ac (hybrid protein in which Cry1 Ab and Cry1 Ac are fused), Cry1 C, Cry1 F, Cry1 Fa2 (modified cry1 F), moCry1 F (modified Cry1 F) , Cry1A. 105 (Cry1 Ab, Cry1 Ac, a hybrid protein fused to Cry1 F), Cry2 Ab2, Cry2 Ae, Cry9 C, Vip3 A, Vip3 Aa20), and Delta-endotoxins that confer resistance to coleoptera insects (e.g. A group consisting of Cry3Bb1, Cry34Ab1, Cry35Ab1).
Group a10: a group consisting of the oxidative phosphorylation decouplers chlorfenapyr which perturb the proton gradient and sulfluramid.
Group a11: Nicotinic acetylcholine receptor channel blocker Bensultap, cartap, cartap hydrochloride, thiocyclam, thiosultap disodium salt, thiosultap-disodium salt, thiosultap monosodium salt A group consisting of thiosultap-monosodium).
Group a12: Chitin biosynthesis inhibitors bistrifluron (chlorfluazuron), diflubenzuron (diflubenzuron), flucycloxuron (flucycloxuron), flufenoxuron (flufenoxuron), hexaflumuron (hexaflumuron), A group consisting of lufenuron, novalurone, noviflumuron, teflubenzuron, triflumuron and buprofezin.
Group a13: a group consisting of a molt inhibitor cyromazine.
Group a14: a group consisting of a molting hormone (ecdysone) receptor agonist chromafenozide, halofenozide, methoxyfenozide and tebufenozide.
Group a15: a group consisting of the voltage-gated sodium channel blocker drug indoxacarb and metaflumizone.
Group a16: Group consisting of the acetyl-CoA carboxylase inhibitors spirodiclofen, spiromesifen and spirotetramat.
Group a17: ryanodine receptor modulator chlorantraniliprole (chlororantriliprole), cyanantranilprole (cyantraniliprole), cyclaniliprole, cyclobenzilide (flubendiamide), tetraniliprole (tetraniliprole), cyhalodiamide (cyhalodiamide) A group consisting of tetrachlorantraniliprole (tetrachloroantraniliprole).
Group a18: A group consisting of the chord tone organ modulator Flonicamide.

  Factors causing the decrease in sensitivity include [1] decrease in skin permeability, [2] metabolic enhancement, and [3] target protein amino acid substitution. The metabolic enhancement of [2] means, for example, increased activity of metabolic enzymes (also called detoxifying enzymes) such as cytochrome P450, carboxylesterase and glutathione S transferase. In [3], the target protein may have one or more amino acid substitutions. Moreover, as a factor of sensitivity reduction, it may have any one or more of [1] reduction of skin permeability, [2] metabolism enhancement, and [3] amino acid substitution of target protein.

Examples of harmful arthropods such as harmful insects and harmful mites that have decreased sensitivity, harmful molluscs and harmful nematodes include, for example, the following.
Hemiptera having reduced sensitivity to one or more compounds selected from group a2;
Hemiptera having reduced sensitivity to one or more compounds selected from group a4;
Hemiptera having reduced sensitivity to one or more compounds selected from group a8;
Hemiptera having reduced sensitivity to one or more compounds selected from group a12;
Hemiptera that have reduced sensitivity to one or more compounds selected from group a2 and one or more compounds selected from group a4;
Hemiptera that have reduced sensitivity to one or more compounds selected from group a2 and one or more compounds selected from group a8;
One or more compounds selected from group a2, and hemiptera having reduced sensitivity to buprofezin belonging to group a12;
Hemiptera that have reduced sensitivity to one or more compounds selected from group a4 and one or more compounds selected from group a8;
One or more compounds selected from group a4, and hemiptera having reduced sensitivity to buprofezin belonging to group a12;
One or more compounds selected from group a8, and a hemiptera having reduced sensitivity to buprofezin belonging to group a12;
Hemiptera that have reduced sensitivity to one or more compounds selected from group a2, one or more compounds selected from group a4, and one or more compounds selected from group a8;
One or more compounds selected from group a2, one or more compounds selected from group a4, and a hemiptera having reduced sensitivity to buprofezin belonging to group a12;
One or more compounds selected from group a2, one or more compounds selected from group a8, and a hemiptera having reduced sensitivity to buprofezin belonging to group a12;
One or more compounds selected from group a4, one or more compounds selected from group a8, and a hemiptera having reduced sensitivity to buprofezin belonging to group a12;
One or more compounds selected from group a2, one or more compounds selected from group a4, one or more compounds selected from group a8, and a hemiptera having reduced sensitivity to buprofezin belonging to group a12;
A plant family with reduced sensitivity to one or more compounds selected from group a2;
A plant family with reduced sensitivity to one or more compounds selected from group a4;
A plant family with reduced sensitivity to one or more compounds selected from group a8;
A plant family with reduced sensitivity to one or more compounds selected from group a12;
A plant family with reduced sensitivity to one or more compounds selected from group a2 and one or more compounds selected from group a4;
One or more compounds selected from group a2; and the plant beetle group having reduced sensitivity to pimetrozine belonging to group a8;
One or more compounds selected from group a2, and the planthopper family having reduced sensitivity to buprofezin belonging to group a12;
One or more compounds selected from group a4; and the plant beetle group having reduced sensitivity to pimetrozine belonging to group a8;
One or more compounds selected from group a4, and the planthopper family with reduced sensitivity to buprofezin belonging to group a12;
One or more compounds selected from the group a2, one or more compounds selected from the group a4, and a plant beetle having reduced sensitivity to pimetrozine belonging to the group a8;
One or more compounds selected from the group a2, one or more compounds selected from the group a4, and the planthopper family having reduced sensitivity to buprofezin belonging to the group a12;
One or more compounds selected from group a2, pimetrozine belonging to group a8, and the planthopper family reduced in sensitivity to buprofezin belonging to group a12;
One or more compounds selected from the group a4, pimetrozine belonging to the group a8, and the planthopper family reduced in sensitivity to buprofezin belonging to the group a12;
One or more compounds selected from the group a2, one or more compounds selected from the group a4, pimetrozine belonging to the group a8, and the planthopper family reduced in sensitivity to buprofezin belonging to the group a12;
Brown planthopper, Sejironka, or Hymetobiunka with reduced sensitivity to one or more compounds selected from group a2;
Brown planthopper, Sejironka, or Hymetobiunka with reduced sensitivity to one or more compounds selected from group a4;
Brown planthopper, Sejironka, or Hymetobiunka with reduced sensitivity to one or more compounds selected from group a8;
Tobileunuka, Sejironka, or Hymetobiunca with reduced sensitivity to one or more compounds selected from group a12;
One or more compounds selected from group a2 and one or more compounds selected from group a4 with reduced sensitivity to the planthopper, sejironka, or himetobiunka;
One or more compounds selected from group a2, and P. indica, P. serotensis or P. indica having reduced sensitivity to pimetrozine belonging to group a8;
One or more compounds selected from group a2, and a plant tree plant that has reduced sensitivity to buprofezin belonging to group a12, a plant locust plant, a plant locust plant, or a plant locust plant;
One or more compounds selected from group a4, and a plant tree plant that has reduced sensitivity to pimetrozine belonging to group a8, pterocarp or pterocarp.
One or more compounds selected from group a4, and a plant tree plant that has reduced sensitivity to buprofezin belonging to group a12, a plant locust plant, a plant locust plant, or a plant locust plant;
One or more compounds selected from the group a2, one or more compounds selected from the group a4, and a brown planthopper with reduced sensitivity to pimetrodin belonging to the group a8;
One or more compounds selected from the group a2, one or more compounds selected from the group a4, and the brown planthopper having a reduced sensitivity to buprofezin belonging to the group a12;
One or more compounds selected from group a2, pimetrogins belonging to group a8, and bulimia nervosa with reduced sensitivity to buprofezin belonging to group a12;
One or more compounds selected from group a4, pimetrogins belonging to group a8, and bulimia nervosa with reduced sensitivity to buprofezin belonging to group a12;
One or more compounds selected from group a2, one or more compounds selected from group a4, pimetrodins belonging to group a8, and bulimia nervosa having reduced sensitivity to buprofezin belonging to group a12;
Aphididae having reduced sensitivity to one or more compounds selected from group a3;
Aphididae having reduced sensitivity to one or more compounds selected from group a8;
Aphid with reduced sensitivity to one or more compounds selected from group a3 and one or more compounds selected from group a4;
An aphid with reduced sensitivity to one or more compounds selected from group a3 and one or more compounds selected from group a8;
An aphid with reduced sensitivity to one or more compounds selected from group a4 and one or more compounds selected from group a8;
Aphid with reduced sensitivity to one or more compounds selected from group a3, one or more compounds selected from group a4, and one or more compounds selected from group a8;
Cotton aphid or peach aphid with reduced sensitivity to one or more compounds selected from group a3;
Cotton aphid or peach aphid having reduced sensitivity to one or more compounds selected from group a4;
Cotton aphid or peach aphid having reduced sensitivity to one or more compounds selected from group a8;
One or more compounds selected from group a3, and cotton aphids or green peach aphids having reduced sensitivity to one or more compounds selected from group a4;
One or more compounds selected from group a3, and cotton aphids or green peach aphids having reduced sensitivity to one or more compounds selected from group a8;
One or more compounds selected from group a4, and cotton aphids or green peach aphids having reduced sensitivity to one or more compounds selected from group a8;
One or more compounds selected from the group a3, one or more compounds selected from the group a4, and a cotton aphid or a peach aphid having reduced sensitivity to one or more compounds selected from the group a8;
A reduced order sensitivity to one or more compounds selected from group a14;
A reduced order sensitivity to one or more compounds selected from group a15;
A reduced order sensitivity to one or more compounds selected from group a17;
A compound having reduced sensitivity to one or more compounds selected from group a14, and one or more compounds selected from group a17;
Monascus having reduced sensitivity to one or more compounds selected from group a15;
Monascus having reduced sensitivity to one or more compounds selected from group a17;
Kobunameiga with reduced sensitivity to one or more compounds selected from group a14;
Kobunameiga having reduced sensitivity to one or more compounds selected from group a17;
Kobunomeiga having reduced sensitivity to one or more compounds selected from group a14, and one or more compounds selected from group a17;
Chahamaki with reduced sensitivity to one or more compounds selected from group a14;
Chahamaki with reduced sensitivity to one or more compounds selected from group a17;
A reduced sensitivity to one or more compounds selected from group a14;
A reduced sensitivity to one or more compounds selected from group a17;
A reduced sensitivity to one or more compounds selected from group a14, and one or more compounds selected from group a17;
Coleoptera having reduced sensitivity to one or more compounds selected from group a2;
Coleoptera having reduced sensitivity to one or more compounds selected from group a3;
Coleoptera having reduced sensitivity to one or more compounds selected from group a4;
Coleoptera having reduced sensitivity to one or more compounds selected from group a9;
Coleoptera having reduced sensitivity to one or more compounds selected from group a17;
Coleoptera having reduced sensitivity to one or more compounds selected from group a2 and one or more compounds selected from group a4;
A crop which has reduced sensitivity to one or more compounds selected from group a2;
A crop which has reduced sensitivity to one or more compounds selected from group a3;
A leaf beetle having reduced sensitivity to one or more compounds selected from group a4;
A leaf beetle having reduced sensitivity to one or more compounds selected from group a9;
A leaf beetle having reduced sensitivity to one or more compounds selected from group a17;
Pheasidae having reduced sensitivity to one or more compounds selected from group a2 and one or more compounds selected from group a4;
A locust beetle having reduced sensitivity to one or more compounds selected from group a2;
A reduced inodenocarid that is less sensitive to one or more compounds selected from group a4;
At least one compound selected from group a2, and at least one compound selected from group a4;
Reduced susceptibility to one or more compounds selected from group a2;
Reduced susceptibility to one or more compounds selected from group a3;
Reduced susceptibility to one or more compounds selected from group a4;
Reduced susceptibility to one or more compounds selected from group a9;
Reduced susceptibility to one or more compounds selected from group a17;
Diabrotica virgifera virgifera with reduced sensitivity to one or more compounds selected from group a2;
Diabrotica virgifera virgifera with reduced sensitivity to one or more compounds selected from group a3;
Diabrotica virgifera virgifera with reduced sensitivity to one or more compounds selected from group a4;
Diabrotica virgifera virgifera with reduced sensitivity to one or more compounds selected from group a9;
Diabrotica virgifera virgifera with reduced sensitivity to one or more compounds selected from group a17;
Diabrotica undecimpunctata howardi with reduced sensitivity to one or more compounds selected from group a2;
Diabrotica undecimpunctata howardi with reduced sensitivity to one or more compounds selected from group a3;
Diabrotica undecimpunctata howardi with reduced sensitivity to one or more compounds selected from group a4;
Diabrotica undecimpunctata howardi with reduced sensitivity to one or more compounds selected from group a9;
Diabrotica undecimpunctata howardi with reduced sensitivity to one or more compounds selected from group a17;
Diabrotica barberi with reduced sensitivity to one or more compounds selected from group a2;
Diabrotica barberi with reduced sensitivity to one or more compounds selected from group a3;
Diabrotica barberi with reduced sensitivity to one or more compounds selected from group a4;
Diabrotica barberi having reduced sensitivity to one or more compounds selected from group a9;
Diabrotica barberi with reduced sensitivity to one or more compounds selected from group a17;
Diabrotica speciosa having reduced sensitivity to one or more compounds selected from group a2;
Diabrotica speciosa with reduced sensitivity to one or more compounds selected from group a3;
Diabrotica speciosa with reduced sensitivity to one or more compounds selected from group a4;
Diabrotica speciosa with reduced sensitivity to one or more compounds selected from group a9;
Diabrotica speciosa with reduced sensitivity to one or more compounds selected from group a17;
Colorado potato beetle with reduced sensitivity to one or more compounds selected from group a2;
Colorado potato beetle with reduced sensitivity to one or more compounds selected from group a3;
Colorado potato beetle with reduced sensitivity to one or more compounds selected from group a4;
Colorado potato beetle with reduced sensitivity to one or more compounds selected from group a17;
A reduced sensitivity to one or more compounds selected from group a3;
A reduced sensitivity to one or more compounds selected from group a4;
A reduced sensitivity to one or more compounds selected from group a17;
Phyllotreta cruciferae with reduced sensitivity to one or more compounds selected from group a3;
Phyllotreta cruciferae with reduced sensitivity to one or more compounds selected from group a4;
Phyllotreta cruciferae with reduced sensitivity to one or more compounds selected from group a17;
Phyllotreta pusilla with reduced sensitivity to one or more compounds selected from group a3;
Phyllotreta pusilla with reduced sensitivity to one or more compounds selected from group a4;
Phyllotreta pusilla with reduced sensitivity to one or more compounds selected from group a17;
Psylliodes chrysocephala with reduced sensitivity to one or more compounds selected from group a3;
Psylliodes chrysocephala with reduced sensitivity to one or more compounds selected from group a4;
Psylliodes chrysocephala with reduced sensitivity to one or more compounds selected from group a17;
Psylliodes punctulata with reduced sensitivity to one or more compounds selected from group a3;
Psylliodes punctulata with reduced sensitivity to one or more compounds selected from group a4;
Psylliodes punctulata with reduced sensitivity to one or more compounds selected from group a17;
Weevil family with reduced sensitivity to one or more compounds selected from group a2;
Weevil family with reduced sensitivity to one or more compounds selected from group a4;
Weevil family with reduced sensitivity to one or more compounds selected from group a2 and one or more compounds selected from group a4;
Rice weevil with reduced sensitivity to one or more compounds selected from group a2;
Rice water weevil with reduced sensitivity to one or more compounds selected from group a4;
Rice water weevil with reduced sensitivity to one or more compounds selected from group a2 and one or more compounds selected from group a4;
Click beetle family with reduced sensitivity to one or more compounds selected from group a2;
Click beetle family with reduced sensitivity to one or more compounds selected from group a3;
Click beetle family with reduced sensitivity to one or more compounds selected from group a4;
Reduced sensitivity to one or more compounds selected from group a2;
Reduced sensitivity to one or more compounds selected from group a3;
Reduced sensitivity to one or more compounds selected from group a4;
Reduced susceptibility to one or more compounds selected from group a2;
Reduced susceptibility to one or more compounds selected from group a3;
Reduced susceptibility to one or more compounds selected from group a4;
Reduced sensitivity to one or more compounds selected from group a2;
Reduced sensitivity to one or more compounds selected from group a3;
Reduced sensitivity to one or more compounds selected from group a4;
Reduced sensitivity to one or more compounds selected from group a2;
Reduced sensitivity to one or more compounds selected from group a3;
Reduced sensitivity to one or more compounds selected from group a4;
Konoders of reduced sensitivity to one or more compounds selected from group a2;
Conodes with reduced sensitivity to one or more compounds selected from group a3;
Conodes with reduced sensitivity to one or more compounds selected from group a4;
A reduced susceptibility to one or more compounds selected from group a2;
A reduced susceptibility to one or more compounds selected from group a3;
A reduced susceptibility to one or more compounds selected from group a4;
Rimonius with reduced sensitivity to one or more compounds selected from group a2;
Limonius with reduced sensitivity to one or more compounds selected from group a3;
Rimonius with reduced sensitivity to one or more compounds selected from group a4;
Reduced sensitivity to one or more compounds selected from group a2;
Reduced sensitivity to one or more compounds selected from group a3;
Reduced sensitivity to one or more compounds selected from group a4;

Examples of harmful insects and harmful arthropods such as harmful mites, harmful mollusks and harmful nematodes such as harmful mites that have decreased in sensitivity due to amino acid substitution at the target site include, for example, the following.
Cotton aphid with R81T amino acid substitution in β subunit of nicotinic acetylcholine receptor; green peach aphid with amino acid substitution of R81T in β subunit of nicotinic acetylcholine receptor;
Monagus having an amino acid substitution of G4946E at the ryanodine receptor;
Monagus having an amino acid substitution of F1845Y or V1848I in the sodium channel;
Sejironuka having an amino acid substitution of A2'N at the GABA receptor;

  The compounds and compositions A can also be used to protect plants from plant diseases caused by insect-borne viruses or insect-borne bacteria.

Such insect-borne viruses include, for example, the following.
Rice hatching virus (Rice tungro spherical virus), rice tungro bacillus virus (Rice tungro bacilliform virus), rice grassy stunt virus (Rice grassy stunt virus), rice ragged stunt virus (Rice ragged stunt virus), rice streak dead virus ( Rice stripe virus), Rice black streaked dwarf virus, Rice southern black streaked dwarf virus, Rice gall dwarf virus, Rice hoja disease (Rice hoja) blanca virus), rice yellow leaf virus (Rice yellow stunt virus), rice yellow mottle virus, rice dwarf virus, wheat cereals northern virus (Northern cereal mosaic virus) barley yellow dwarf virus (Barley yellow dwarf virus), Barley mild mosaic virus, Barley yellow dwarf virus (Barley yellow dwarf virus-PAV), Ruiki萎 RPS virus (Cereal yellow dwarf virus-RPS), wheat yellow leaves virus (Wheat yellow leaf virus), Oat sterile dwarf virus, Wheat streak mosaic virus,
Maize dwarf mosaic virus (Maize dwarf mosaic virus), Maize stripe virus, Maize chlorotic mottle virus, Maize chlorotic dwarf virus, Maize rayado fino virus, Sugar cane mosaic virus (Sugarcane mosaic virus), Fiji disease virus, Sugarcane yellow leaf virus Mosaic virus (Soybean mild mosaic virus), Cyet necrotic virus (Cycas necrotic stunt), Soybean dwarf virus (Soybean dwarf virus), Japanese dander virus (Milk vetch dwarf virus), Soybean mosaic virus (Soybean mosaic virus), alfalfa Mosaic virus (Alfalfa mosaic virus), kidney bean macula yellow spot virus (Bean yellow mosaic virus), kidney bean mosaic virus (Bean common mosaic virus), kidney bean southern mosaic virus (Southern bean mosaic virus), peanut blossom virus (Peanut stunt virus), Sorama Wilt virus 1 (Broad bean wilt virus 1), Broad bean wilt virus 2 (Broad bean wilt virus 2), Broad bean necrosis virus (Broad bean necrosis virus), Broad bean yellow vein virus (Broad bean yellow vein virus), Clover yellow vein virus (Clover yellow vein virus), Peanut mottle virus, Tobacco streak virus, Bean pod mottle virus, Cowpea chlorotic mottle virus, Mung bean yellow mosaic virus, Soybean crinkle leaf virus ,,
Tomato chlorosis virus (Tomato chlorosis virus), tomato spotted wilt virus, tomato yellow leaf curl virus (Tomato yellow leaf curl virus), tomato aspermy virus (Tomato aspermy virus), tomato infectious virus Chlorosis virus (Tomato infectious chlorosis virus), potato leaf roll virus (Potato leafroll virus), potato Y virus (Potato virus Y), melon yellow spot virus (Melon yellow spot virus), melon spot spot virus (Melon necrotic spot virus) ), Watermelon mosaic virus (Watermelon mosaic virus), cucumber mosaic virus (Cucumber mosaic virus), zucchini yellow mosaic virus (Zucchini yellow mosaic virus), turnip mosaic virus (Turnip mosaic virus), turnip yellow mosaic virus (Turnip yellow mosaic virus) ), Cauliflower mosaic virus Cauliflower mosaic virus, Lettuce mosaic virus, Celery mosaic virus, Beet mosaic virus, Cucurbit chlorotic yellows virus, Capsicum leaf yellow virus (Capsicum chlorosis virus), Beet pseudo yellows virus (Beet pseudo yellows virus), Leek yellow stripe virus (Leak yellow stripe virus), Onion yellow dwarf virus (Onion yellow dwarf virus), Sweet potato feather mosaic disease (Sweet potato feathery mottle virus) ), Sweet potato shukuyo mosaic virus, strawberry mottle virus, strawberry mild yellow edge virus, strawberry pseudo mild yellow edge virus (strawberry pseudo mild yellow edge virus) ), One Goklinkle virus (Strawberry crinkle virus), Strawberry vein banding virus (Strawberry vein banding virus), Japanese plum ring virus (plum pox virus), Chrysanthemum stem necrosis virus (Chrysanthemum stem necrosis virus), Impatiens Neem spotted virus (Impatiens) Necrotic spot virus, Iris yellow spot virus, Lily mottle cirus, Lilly symptomless virus, tulip mosaic virus etc. (Tulip mosaic virus)

Examples of insect-borne bacteria include the following.
Rice yellow dwarf phytoplasma (Candidatus Phytoplasma oryzae), Candidatus Phytoplasma asteris, Maize bushy stunt phytoplasma, citrus greening fungus Asian type (Candidatus Liberbacter asiaticus), citrus greening fungus African type (Candidatus Liberbacter aflicanus), Type (Candidatus Liberbacter americanus) etc.

  The present compound and composition A also have a food damage suppressing effect, a repellent effect, an oviposition suppressing effect, an infertility effect, a next generation production suppressing effect, a mating behavior inhibitory effect, a molting inhibitory effect, and an emergence inhibiting effect. As a result, the crop can be protected from damage by harmful arthropods such as harmful insects and harmful mites, harmful molluscs and harmful nematodes.

  Composition B controls plant diseases caused by phytopathogenic microorganisms such as fungi, Oomycetes, Phytomyxea and bacteria when the bactericidal active ingredients are contained as the components. You can do it. Examples of fungi (fungi) include Ascomycota, Basidiomycota, Blasocladiomycota, Chhytridiomycota, Mucoromycota and Olpidiomycota. Specifically, for example, the following may be mentioned. The parentheses show the scientific names of phytopathogenic microorganisms that cause each disease.

Diseases of rice: blast disease (Pyricularia oryzae), sesame leaf blight (Cochliobolus miyabeanus), sheath blight (Rhizoctonia solani), dreadling blight (Gibberella fujikuroi), yellow dwarf (Sclerophthora macrospora) Ear blight (Epicoccum nigrum), seedling blight (Trichoderma viride, Rhizopus oryzae);
Diseases of wheat: powdery mildew (Blumeria graminis), mildew (Fusarium graminearum, Fusarium avenaceum, Fusarium culmorum, Microdochium nivale), leaf rust (Puccinia striiformis), black rust (Puccinia graminis), red rust (Puccinia recond) ), Red snow blight (Microdochium nivale, Microdochium majus), snow blight scaly (Typhula incarnata, Typhula ishikariensis), naked scab (Ustilago tritici), spiny scab (Tilletia caries, Tilletia controversa), eye disease (Pseudocercosporella herpotrichoides), leaf blight (Septoria tritici), blight (Stagonospora nodorum), yellow spot (Pyrenophora tritici-repentis), seedling blight (Rhizoctonia solani) due to Rhizoctonia spp., Blight (Gaeumannomyces graminis , Blast (Pyricularia graminis-tritici);
Diseases of barley: powdery mildew (Blumeria graminis), mildew (Fusarium graminearum, Fusarium avenaceum, Fusarium culmorum, Microdochium nivale), yellow rust (Puccinia striiformis), black rust (Puccinia graminis), small rust (Puccinia) hordei), bare smut (Ustilago nuda), cloud disease (Rhynchosporium secalis), web blight (Pyrenophora teres), spotted disease (Cochliobolus sativus), leaf blight (Pyrenophora graminea), ramularia leaf spot disease (Ramularia collo-cygni) ), Rhizoctonia spp. Seedling blight (Rhizoctonia solani);
Diseases of corn: rust (Puccinia sorghi), southern rust (Puccinia polysora), soot (Setosphaeria turcica), tropical rust (Physopella zeae), sesame leaf blight (Cochliobolus heterostrophus), anthracnose (Colletotrichum graminicola) Gray leaf spot disease (Cercospora zeae-maydis), brown spot disease (Kabatiella zeae), Phaeosphaeria leaf spot disease (Phaeosphaeria maydis), Diplodia disease (Stenocarpella maydis, Stenocarpella macrospora), Stochlot disease (Fusarium graminearum, Fusarium verticilioides, Colletotrichum graminicola), Blotch (Ustilago maydis), Physoderma maydis);
Diseases of cotton: anthracnose (Colletotrichum gossypii), mildew (Ramularia areola), black spot (Alternaria macrospora, Alternaria gossypii), Black root rot (Thielaviopsis basicola);
Diseases of coffee: rust (Hemileia vastatrix), leaf spot disease (Cercospora coffeicola);
Diseases of rapeseed: sclerotis disease (Sclerotinia sclerotiorum), black spot (Alternaria brassicae), root rot (Phoma lingam), light leaf spot disease (Pyrenopeziza brassicae);
Diseases of sugarcane: rust (Puccinia melanocephela, Puccinia kuehnii), panicle sickness (Ustilago scitaminea);
Diseases of sunflower: rust (Puccinia helianthi), downy mildew (Plasmopara halstedii);
Diseases of citrus: black spot (Diaporthe citri), scab (Elsinoe fawcetti), green mold (Penicillium digitatum), blue mold (Penicillium italicum), phytophthora (Phytophthora parasitica, Phytophthora citrophthora), Aspergillus spp. ;
Diseases of apple: Monilia disease (Monilinia mali), decay disease (Valsa ceratosperma), powdery mildew (Podosphaera leucotricha), spotted leaf disease (Alternaria alternata apple pathotype), scab (Venturia inaequalis), anthracnose (Glomerella cinguliculitalium) acutatum), diplocarp (Diplocarpon mali), ring blight (Botryosphaeria berengeriana), plague (Phytophtora cactorum), scab (Gymnosporangium juniperi-virginianae, Gymnosporangium yamadae);
Diseases of pear: scab (Venturia nashicola, Venturia pirina), black spot (Alternaria alternata Japanese pear pathotype), red star (Gymnosporangium haraeanum);
Diseases of peaches: Blight disease (Monilinia fructicola), Blight disease (Cladosporium carpophilum), homoposis rot (Phomopsis sp.), Leaf rot (Taphrina deformans);
Diseases of grapes: black rot (Elsinoe ampelina), late rot (Glomerella cingulata, Colletotrichum acutatum), powdery mildew (Uncinula necator), rust (Phakopsora ampelopsidis), blacklot disease (Guignardia bidwellii), downy mildew ( Plasmopara viticola);
Diseases of oysters: Anthrax (Gloeosporium kaki, Colletotrichum acutatum), deciduous disease (Cercospora kaki, Mycosphaerella nawae);
Diseases of Cucurbita species: Anthracnose (Colletotrichum lagenarium), powdery mildew (Sphaerotheca fuliginea), spine blight (Didymella bryoniae), brown leaf blight (Corynespora cassiicola), scab (Fusarium oxysporum), downy mildew (Pseudonospora cuensis) ), Plague (Phytophthora capsici), seedling blight (Pythium sp.);
Diseases of tomato: Ring blight (Alternaria solani), leaf blight (Cladosporium fulvum), leaf blight (Pseudocercospora fuligena), plague (Phytophthora infestans), powdery mildew (Leveillula taurica);
Diseases of eggplant: Browning blight (Phomopsis vexans), powdery mildew (Erysiphe cichoracearum);
Diseases of cruciferous vegetables: black spot (Alternaria japonica), white spot (Cercosporella brassicae), root scab (Plasmodiophora brassicae), downy mildew (Peronospora parasitica), white rust (Albugo candida);
Diseases of leek: rust (Puccinia allii);
Diseases of soybean: purpura (Cercospora kikuchii), mildew (Elsinoe glycines), black spot (Diaporthe phaseolorum var. Sojae), rust (Phakopsora pachyrhizi), brown ring disease (Corynespora cassiicola), anthracnose (Colletotrichus glycines) , Colletotrichum truncatum, leaf rot (Rhizoctonia solani), brown disease (Septoria glycines), spot disease (Cercospora sojina), sclerotia sclerotiorum, powdery mildew (Microsphaera diffusa), stem blight (Phytophothojae) , Downy mildew (Peronospora manshurica), sudden death (Fusarium virguliforme), black root rot (Calonectria ilicicola), Diaporthe / Phomopsis complex (Diaporthe longicolla);
Diseases of bean: sclerotis disease (Sclerotinia sclerotiorum), rust (Uromyces appendiculatus), horn disease (Phaeoisariopsis griseola), anthracnose (Colletotrichum lindemuthianum), root rot (Fusarium solani);
Diseases of peanut: black spot (Cercospora personata), brown spot (Cercospora arachidicola), white scab (Sclerotium rolfsii), black root rot (Calonectria ilicicola);
Diseases of pea: powdery mildew (Erysiphe pisi), root rot (Fusarium solani);
Diseases of potato: summer plague (Alternaria solani), plague (Phytophthora infestans), green rot (Phytophthora erythroseptica), powdery mildew (Spongospora subterranea f. Sp. Subterranea), half-body wilt (Verticillium albo-atrumVerticillic) dahliae, Verticillium nigrescens), Dry rot (Fusarium solani), Carcinomatosis (Synchytrium endobioticum);
Disease of strawberry: powdery mildew (Sphaerotheca humuli);
Diseases of tea: net blister blight (Exobasidium reticulatum), white scab (Elsinoe leucospila), gray blight (Pestalotiopsis sp.), Anthracnose (Colletotrichum theae-sinensis);
Tobacco diseases: red star disease (Alternaria longipes), anthracnose (Colletotrichum tabacum), downy mildew (Peronospora tabacina), plague (Phytophthora nicotianae);
Diseases of sugar beet: brown spot (Cercospora beticola), leaf blight (Thanatephorus cucumeris), root rot (Thanatephorus cucumeris), black root disease (Aphanomyces cochlioides), rust (Uromyces betae);
Diseases of rose: scab (Diplocarpon rosae), powdery mildew (Sphaerotheca pannosa); diseases of chrysanthemum: Brown disease (Septoria chrysanthemi-indici), white rust (Puccinia horiana);
Diseases of onion: Botrytis cinerea (Botrytis cinerea, Botrytis byssoidea, Botrytis squamosa), Gray rot (Botrytis allii), Microbial rot (Botrytis squamosa); Diseases of various crops: Botrytis cinerea (Botrytis cinerea) ), Sclerotinia sclerotiorum, seedling blight (Pythium aphanidermatum, Pythium irregulare, Pythium ultimum);
Diseases of radish: black spot (Alternaria brassicicola);
Diseases of Shiva: Dollar spot disease (Sclerotinia homoeocarpa), brown patch disease, large patch disease (Rhizoctonia solani), fire blight (Pythium aphanidermatum);
Diseases of banana: Sigatoka disease (Mycosphaerella fijiensis, Mycosphaerella musicola);
Diseases of lentils: Ascochyta disease (Ascochyta lentis);
Diseases of chickpea: Ascochyta disease (Ascochyta rabiei);
Diseases of peppers: Anthrax (Colletotrichum scovillei);
Diseases of mango: Anthrax (Colletotrichum acutatum);
Diseases of fruit trees: white root rot (Rosellinia necatrix), purple root rot (Helicobasidium mompa);
Diseases of fruits such as apples and pears after harvest: Mucorlot disease (Mucor piriformis); Aspergillus, Penicillium, Fusarium, Gibberella, Triboderella, Thielaviopsis, Rhizopus, Mucor, Corticium, Phoma, Seed disease caused by Rhizoctonia genus, Diplodia genus, etc. or disease at the early stage of growth;
Viral disease: Big vein disease of lettuce mediated by Olpidium brassicae, viral diseases of various crops mediated by the genus Polymyxa (eg Polymyxa betae and Polymyxa graminis);
Diseases caused by bacteria: rice seedling blight (Burkholderia plantarii), spotted blight of cucumber (Pseudomonas syringae pv. Lachrymans), eggplant blight (Ralstonia solanacearum), citrus blight (Xanthomonas citritri) ), Chinese cabbage soft rot (Erwinia carotovora), potato scab (Streptomyces scabiei), corn Goss's wilt disease (Clavobacter michiganensis), grape, olive, peach Pierce disease (Xylella fastidiosa), apple, peach, cherry, And others (Agrobacterium tumefaciens).

  For the above-mentioned phytopathogenic microorganisms, intraspecific variation is not particularly limited. That is, it also includes those having reduced sensitivity (also referred to as resistance) to a specific microbicide. The reduction in sensitivity may be one having a mutation at the target site (acting point mutation) or may be due to a factor that is not a working point mutation (non-acting point mutation). For the action point mutation, mutation of the nucleic acid sequence (open reading frame) corresponding to the amino acid sequence of the protein results in amino acid substitution in the target site protein, deletion of the suppressor sequence in the promoter region, or enhancer Mutations such as amplification of sequence, increase in copy number of gene, etc. include those in which the protein at the target site is overexpressed. Non-acting point mutations include, for example, enhancement of the excretory function by which the bactericide flowing into the cell is excreted from the cell by the ABC transporter, the MFS transporter, and the like. Moreover, the detoxification by metabolism of a microbicide is also mentioned.

  Examples of the above-mentioned specific bactericidal agents include, for example, nucleic acid synthesis inhibitors (for example, phenylamide bactericidal agents, acylamino acid bactericidal agents, DNA topoisomerase type II bactericidal agents), mitotic and cell division inhibitors (for example, MBC fungicides, N-phenylcarbamate biocides), respiratory inhibitors (eg, QoI biocides, QiI biocides, SDHI biocides), inhibitors of amino acid synthesis and protein synthesis (eg, anilinopyrimidine fungicides), Signal transduction inhibitors (eg, phenylpyrrole fungicides, dicarboximide fungicides), inhibitors of lipid synthesis and cell membrane synthesis (eg, phosphorothiolate fungicides, dithiolane fungicides, aromatic hydrocarbon fungicides, Heteroaromatic fungicides, carbamate fungicides), sterol biosynthesis inhibitors (eg, triazole DM etc.) Bactericide, hydroxyanilide bactericide, aminopyrazolinone bactericide), cell wall synthesis inhibitor (eg, polyoxin bactericide, carboxamide bactericide), melanin synthesis inhibitor (eg, MBI-R bactericide) And MBI-D germicides, MBI-P germicides, as well as other germicides such as cyanoacetamide oxime germicides, phenylacetamide germicides.

Examples of the amino acid substitution at the target site include the following.
Cytochrome b: G143A, F129L or G137R;
The Cyp51 protein includes A311G, A379G, A381G, A410T, A61V, D107V, D134G, D282E, D411N, E297K, F120L, F219S, F449S, F489L, F495I, G138C / R / S, G312A, G412A, G432S, G434C, G444G, G448 / Δ, G462A, G464S, G484S, G510C, G54E / K / R / V / W, G54W, H147Y, H303Y, H399P, I145F, I330T, I381V / Δ, I471T, I475T, K142R, K143E, K147Q, K175N, K197N , L50S, L98H, M145L, M220K / I / T / V, M288L, N125I, N178S, N22D, N22H, N513K, P216L, P384S, P141L, Q141H, Q88H, S188N, S208T, S297T, S405F, S508T, S508T, S508T, S508T, S508T, S508T , S524T, S52T, S79T, T289A, T440A, T454P, T469S, V101F, V136A / C / G, V490L, Y121F, Y131F / H, Y132F / H / N, Y134F, Y134F, Y136F, Y137F, Y140F / H, Y145F , Y431C, Y459C / D / N / S / P / Δ, Y461D, Y461D / H / S, Y463D / H / N, Y491H or Y68N;
β-tubulin: H6L / Y, Y50C / N / S, Q134K, A165V, E198A / D / G / K / L / Q / V, F200Y, M257L, F200Y, F167Y, Q73R or L240F;
SdhB: H277R / Y, P225H / F / L / T, N230I, H272L / R / V / Y, H278Y / R, H249L / N / Y, H273Y, N225I / T, T268I / A, I269V, H242R, H257L or T253I;
SdhC: H134R, P80H / L, A85V, S73P, T90I, I86F, N88S, H154Y / R, K49E, R64K, N75S, G79R, S135R, N87S, H153R, H146R, I29V, N33T, N34T, T79I / N, 80I A84V, N86K / S / A, G90R, R151T / S, H152R, I161S, G169D or H151R;
SdhD: H133R, H132R, S89P, G109V, D124E / N, H134R, G138V, D145G, I50F, M114V or D129E;
OS-1 (Shk1): E753K, G420D, I365N / R / S, V368F, Q369H / P, N373S, T447S, F267L, L290S, T765R, Q777R, T489I, E599K or G736Y;
ERG 27: S9 G, F 26 S, P 57 A, T 63 I, G 170 R, V 192 I, L 195 F, N 196 T, A 210 G, I 232 M, P 238 S / Δ, P 250 S, P 269 S, Y408S, F412I / S / V / C, A461S or R496T.

  Moreover, the followings are mentioned as a phytopathogenic microorganism and its host plant whose sensitivity to a bactericidal agent is reduced by overexpression of the Cyp51 gene. Wheat Septoria tritici (Reference: Pest Management Science. 2012. 68 (7). 1034-1040), Barley Rhynchosporium secalis (Reference: Molecular Bilogy and Evolution. 2014. 31 (7). 1793-1802) Soybean Phakopsora pachyrhizi (Reference: Pest Management Science. 2014. 70 (3). 378-388), Apple Venturia inaequalis (Reference: Phytopathology. 2016. 106 (6). 562-571), Citrus Penicillium digitatum (Reference Literature: Applied and Environmental Microbiology. 2000. 66 (8). 3421-3426).

  The phytopathogenic microorganism which can be controlled by the composition B containing a bactericidal active ingredient as the present ingredient may have a plurality of the above amino acid substitutions. In this case, the plurality of amino acid substitutions may be the same protein or different proteins. Moreover, you may have multiple non-acting point mutations or working point mutations. For example, phytopathogenic microorganisms that cause amino acid substitutions of G143A, F129L and G137R in cytochrome b; phytopathogenic microorganisms that have amino acid substitutions of G143A in cytochrome b and A311G in Cyp51; Phytopathogenic microorganism having an amino acid substitution of F129L and having an amino acid substitution of A311G in Cyp51; having an amino acid substitution of G143A and F129L in cytochrome b and an amino acid substitution of H6L / Y in β-tubulin Phytopathogenic microorganisms in which the Cyp51 gene is overexpressed.

As a plant pathogenic microbe which has an action point mutation, the following is mentioned, for example.
Alternaria alternata having an amino acid substitution of G143A in cytochrome b;
Alternaria arborescens having amino acid substitution of G143A in cytochrome b;
Alternaria solani having an amino acid substitution of F129L in cytochrome b;
Alternaria tomato having an amino acid substitution of G143A in cytochrome b;
Botryotinia fuckeliana having amino acid substitution of G143A in cytochrome b;
Glomerella graminicola having an amino acid substitution of G143A in cytochrome b;
Corynespora cassiicola having an amino acid substitution of G143A in cytochrome b;
Cercospora beticola having an amino acid substitution of G143A in cytochrome b;
Cercospora sojina having an amino acid substitution of G143A in cytochrome b;
Cladsporium carpophilum having an amino acid substitution of G143A in cytochrome b;
Colletotrichum graminicola having an amino acid substitution of G143A in cytochrome b;
Glomerella cingulata having an amino acid substitution of G143A in cytochrome b;
Blumeria graminis f. Sp. Hordei having an amino acid substitution of G143A in cytochrome b
Blumeria graminis f. Sp. Tritici having an amino acid substitution of G143A in cytochrome b;
Parastagonospora nodorum having amino acid substitution of G143A in cytochrome b;
Monographella nivalis having an amino acid substitution of G143A in cytochrome b;
Microdochium majus having an amino acid substitution of G143A in cytochrome b, nivale;
Mycosphaerella fijiensis having an amino acid substitution of G143A in cytochrome b;
Didymella rabiei having an amino acid substitution of G143A in cytochrome b;
Phakopsora pachyrhizi with amino acid substitution of F129L in cytochrome b;
Plasmopara viticola having an amino acid substitution of F129L or G143A in cytochrome b;
Pleospora allii having an amino acid substitution of G143A in cytochrome b;
Podosphaera fusca with amino acid substitution of G143A in cytochrome b;
Podosphaera xanthii having an amino acid substitution of G143A in cytochrome b;
Pseudoperonospora cubensis having amino acid substitution of G143A in cytochrome b;
Magnaporthe oryzae having amino acid substitution of F129L or G143A in cytochrome b;
Pyrenophora teres having an amino acid substitution of F129L in cytochrome b;
Pyrenophora tritici-repentis having amino acid substitution of F129L, G137R or G143A in cytochrome b;
Pythium aphanidermatum with amino acid substitution of F129L on cytochrome b;
Thanatephorus cucumeris having amino acid substitution of F129L or G143A in cytochrome b;
Ramularia collo-cygni having an amino acid substitution of G143A in cytochrome b;
Rhynchosporium secalis having an amino acid substitution of G143A in cytochrome b;
Rhizoctonia solani having an amino acid substitution of F129L in cytochrome b;
Zymoseptoria tritici having an amino acid substitution of F129L, G137R or G143A in cytochrome b;
Erysiphe necator having amino acid substitution of G143A in cytochrome b;
Venturia inaequalis having an amino acid substitution of G143A in cytochrome b;
Ajellomyces capsulatus with amino acid substitution of Y136F in Cyp 51;
Aspergillus flavus having an amino acid substitution of Y132N, K197N, D282E, M288L, T469S, H399P, D411N or T454P in Cyp51;
For Cyp 51, N22D, S52T, G54E / K / R / V / W, Y68N, Q88H, L98H, V101F, Y121F, N125I, G138C / R / S, Q141H, H147Y, P216L, F219S, M220K / I / T / V, Aspergillus fumigatus having an amino acid substitution of T289A, S297T, P394L, Y431C, G432S, G434C, T440A, G448S, Y491H or F495I;
Aspergillus parasiticus having an amino acid substitution of G54W in Cyp 51;
Candida albicans having an amino acid substitution of A61V, Y132F / H, K143E, S405F, F449S, G464S, R467K or I471T in Cyp 51;
Cercospora beticola having an amino acid substitution of E297K, I330T or P384S in Cyp 51;
Blumeria graminis f. Sp. Hordei having an amino acid substitution of Y136F, K147Q or S509T in Cyp51;
Blumeria graminis f. Sp. Tritici having an amino acid substitution of S79T, Y136F, or K175N in Cyp 51;
Filobasidiella neoformans having an amino acid substitution of Y145F or G484S in Cyp51;
Monilinia fructicola, with amino acid substitution of Y136F in Cyp51,
Mycosphaerella fijiensis having an amino acid substitution of Y136F, A313G, A381G, Y461D, G462A or Y463D / H / N in Cyp51;
Phakopsora pachyrhizi having an amino acid substitution of F120L, Y131F / H, K142R, I145F or I475T in Cyp51;
Puccinia triticina having an amino acid substitution of Y134F in Cyp 51;
Pyrenophora teres with amino acid substitution of F489L in Cyp 51;
Pyrenopeziza brassicae with amino acid substitution of S508T in Cyp 51;
Saccharomyces cerevisiae having an amino acid substitution of Y 140 F / H in Cyp 51;
For Cyp 51, L50S, D107V, D134G, V136A / C / G, Y137F, M145L, N178S, S188N, S208T, N284H, H303Y, A311G, G312A, A379G, I381V, A410T, G412A, Y459C / D / N / S / S / S / S Zymoseptoria tritici with amino acid substitution of P / Δ, G460D / Δ, Y461D / H / S, V490L, G510C, N513K or S524T;
Erysiphe necator having an amino acid substitution of Y136F at Cyp 51;
Emericella nidulans having amino acid substitutions of H6L / Y, Y50N / S, Q134K, A165V, E198D / K / Q, F200Y or M257L in β-tubulin;
Botryotinia fuckeliana having an amino acid substitution of E198A / G / K / V or F200Y in β-tubulin;
Cochliobolus heterostrophus having an amino acid substitution of F167Y in β-tubulin;
Cercospora beticola having an amino acid substitution of F167Y or E198A in β-tubulin;
Gibberella fujikuroi having an amino acid substitution of Y50N, E198V or F200Y in β-tubulin;
Gibberella zeae with amino acid substitutions of Y50C, Q73R, F167Y, E198K / L / Q or F200Y in β-tubulin;
Helminthosporium solani having an amino acid substitution of E198A / Q in β-tubulin;
Hypomyces odoratus having an amino acid substitution of Y50C in β-tubulin;
Parastagonospora nodorum having an amino acid substitution of H6Y in β-tubulin;
Monilinia fructicola having an amino acid substitution of H6Y or E198 A / K in β-tubulin;
Monilinia laxa with an amino acid substitution of L240F in β-tubulin;
Microdochium majus having an amino acid substitution of E198A in β-tubulin, nivale;
Mycosphaerella fijiensis having an amino acid substitution of E198A in β-tubulin;
Neurospora crassa having amino acid substitution of F167Y or E198G in β-tubulin;
Penicillium aurantiogriseum having an amino acid substitution of E198A / K or F200Y in β-tubulin;
Penicillium expansum with amino acid substitutions of F167Y or E198A / K / V in β-tubulin;
Penicillium italicum having an amino acid substitution of E198 K or F200 Y in β-tubulin;
Pyrenopeziza brassicae having an amino acid substitution of L240F in β-tubulin;
Rhynchosporium secalis having an amino acid substitution of E198G / K or F200Y in β-tubulin;
Sclerotinia homoeocarpa having an amino acid substitution of E198 A / K in β-tubulin;
Sclerotinia sclerotiorum having an amino acid substitution of E198A in β-tubulin;
Zymoseptoria tritici having an amino acid substitution of E198 A / G in β-tubulin;
Venturia inaequalis having an amino acid substitution of E198A / K, F200Y or L240F in β-tubulin;
Alternaria alternata having an amino acid substitution of H277R / Y in SdhB;
Alternaria solani, which has an amino acid substitution of H277R / Y in SdhB,
Botryotinia fuckeliana having amino acid substitution of P225H / F / L / T, N230I or H272L / R / V / Y in SdhB;
Corynespora cassiicola having an amino acid substitution of H278Y / R in SdhB;
Stagonosporopsis cucurbitacearum having an amino acid substitution of H277R / Y in SdhB;
Eurotium oryzae with H249 L / N / Y amino acid substitution in SdhB;
Pyrenophora teres with amino acid substitution of H277Y in SdhB;
Sclerotinia sclerotiorum having an amino acid substitution of H273Y in SdhB;
Zymoseptoria tritici having an amino acid substitution of N225I / T, H273Y, T268I / A or I269V in SdhB;
Erysiphe necator with amino acid substitution of H242R in SdhB;
Ustilago maydis with H257L amino acid substitution in SdhB;
Venturia inaequalis with T253I amino acid substitution in SdhB;
Alternaria alternata having an amino acid substitution of H134R in SdhC;
Botryotinia fuckeliana having amino acid substitution of P80H / L or A85V in SdhC;
Corynespora cassiicola having an amino acid substitution of S73P in SdhC;
Eurotium oryzae with T90 I amino acid substitution in SdhC;
Phakopsora pachyrhizi having an amino acid substitution of I86F, N88S or H154Y / R in SdhC;
Pyrenophora teres having an amino acid substitution of K49E, R64K, N75S, G79R, H134R or S135R in SdhC;
Ramularia collo-cygni having an amino acid substitution of N87S, H146R or H153R in SdhC;
Sclerotinia sclerotiorum having an amino acid substitution of H146R in SdhC;
Zymoseptoria tritici with amino acid substitutions of I29V, N33T, N34T, T79I / N, W80S, A84V, N86K / S / A, G90R, R151T / S, H152R or I161S in SdhC;
Erysiphe necator having an amino acid substitution of G169D in SdhC;
Venturia inaequalis with amino acid substitution of H151R in SdhC;
Alternaria alternata having an amino acid substitution of H133R in SdhD;
Alternaria solani having an amino acid substitution of H133R in SdhD;
Botryotinia fuckeliana with H132R amino acid substitution in SdhD;
Corynespora cassiicola having an S89P or G109V amino acid substitution in SdhD;
Eurotium oryzae with amino acid substitution of D124E in SdhD;
Pyrenophora teres having amino acid substitution of D124E / N, H134R, G138V or D145G in SdhD;
Sclerotinia sclerotiorum having an amino acid substitution of H132R in SdhD;
Zymoseptoria tritici having an amino acid substitution of I50F, M114V or D129E in SdhD;
Phytophthora capsici having an amino acid substitution of Q1077K or V1109L / M in CesA3;
Phytophthora drechsleri having an amino acid substitution of V1109L in CesA3;
Phytophthora infestans having an amino acid substitution of G1105A / V or V1109L in CesA3;
Plasmopara viticola having an amino acid substitution of G1105 S / V in CesA3;
Pseudoperonospora cubensis having an amino acid substitution of G1105 V / W in CesA3;
Alternaria brassicicola having an E753 K amino acid substitution in OS-1 (Shk1);
Alternaria longipes having G420D amino acid substitution in OS-1 (Shk1);
Botryotinia fuckeliana having amino acid substitution of I365N / R / S, V368F, Q369H / P, N373S or T447S in OS-1 (Shk1);
Pleospora allii having an amino acid substitution of F267L, L290S, T765R or Q777R in OS-1 (Shk1);
Sclerotinia sclerotiorum having an amino acid substitution of T489I, E599 K or G736Y in OS-1 (Shk1);
For ERG27, S9G, F26S, P57A, T63I, G170R, V192I, L195F, N196T, A210G, I232M, P238S / Δ, P250S, P269L, P298Δ, V309M, A314V, S336C, E368D, N369D, E375KA378T Botryotinia fuckeliana with amino acid substitution of S, Y408S, F412I / S / V / C, A461S or R496T.

  Composition B can also control weeds when the herbicidally active ingredient is contained as the ingredient. Weed in the present invention means a plant whose growth is not desirable at that location. Examples of weeds include the following.

Nettle weeds (Urticaceae): Hemerocallis (Urtica urens)
Scutellaris weed (Polygonaceae): Scutellaria vulgaris (Polygonum convolvulus), Sanaetade (Polygonum lapathifolium), American Scutellariae (Polygonum pensylvanicum), Harutade (Polygonum persicaria), Inutade (Polygonum longisetum), Psyllium (Polygonium) , Japanese gooseberry (Polygonum cuspidatum), sand snail (Rumex japonicus), longhorn snail (Rumex crispus), redwood snail (Rumex obtusifolius), sorrel (Rumex acetosa)
Prunusaceae weed (Portulacaceae): Prunella (Portulaca oleracea)
Horse mackerel weed (Caryophyllacea): chickweed (Stellaria media), calf commonwealth (Stellaria aquatica), minnow grass (Cerastium holosteoides), holly sand grass (Cerastium glomeratum), spiny grass (Spergula arvensis), mantemese
Pomegranate weed (Molluginaceae): Curcuma longiflorum (Mollugo verticillata)
Rhipicemum weeds (Chenopodiaceae): Scutellariae (Chenopodium album), Scutellariae (Chenopodium ambrosioides), Broomsticks (Kochia scoparia), Noharahijiki (Salsola kali), Atriplex spp.

Amaranthus weed (Amaranthaceae): Amaranthus (Amaranthus retroflexus), Amaryllis vulgaris (Amaranthus viridis), Cannilla (Amaranthus lividus), Hari-biru (Amaranthus spinosus), Horny Algaan Tow (Amaranthus hybridus), Amaranthus patulus, water hemp (Amaranthus tuberculatus = Amaranthus rudis = Amaranthus tamariscinus), Amaranth (Amaranthus blitoides), Amaranthus deflexus, Amaranthus fulensis (Amaranthus quititeich) ), Sanguinaria (Alternanthera tenella)
Poppyaceous weed (Papaveraceae): Poppy rhubarb (Papaver rhoeas), longhorn bream (Papaver dubium), rhizophora (Argemone mexicana)
Brassicaceae weed (Brassicaceae): Red nodone (Raphanus raphanistrum), radish (Raphanus sativus), noharagarashi (Sinapis arvensis), Pheasant (Capsella bursa-pastoris), Indian mustard (Brassica juncea), Aplysia (Brassica napus) (Descurainia pinnata), Burrowing pokeweed (Rorippa islandica), Kirehyung Garashi (Rorippa sylvestris), Gumbai Nazuna (Thlaspi arvense), Porridge (Myagrum rugosum), Mamaguni Nazuna (Lepidium virginicum), Caracuna Diana
Amaryllid weed (Capparaaceae): Cleome affinis

Leguminous weeds (Fabaceae): Kusanam (Aeschynomene indica), Zigzag jointed vetch (Aeschynomene rudis), American hornflower (Sesbania exaltata), Evisgusa (Cassia obtusifolia), Habasou (Cassia occidentalis), Jusuhagi (Desmodium timausium) adsendens), Illinois nuissimus (Desmodium illinoense), white clover (Trifolium repens), kudzu (Pueraria lobata), prickly pear (Vicia angustifolia), raccoon dog (Indigofera hirsuta), indigofera trulensis Vigna sinensis)
Anemoneid weed (Oxalidaceae): Anemonefish (Oxalis corniculata), Ottachi anemone (Oxalis strica), Oxalis oxidella (Oxalis oxyptera)
Freshwater weed (Geraniaceae): American Fuuro (Geranium carolinense), Dutch Fuuro (Erodium cicutarium)
Euphorbiaceae weed (Euphorbiaceae): Euphorbia helioscopia, Euphorbia maculata, Euphorbia humistrata, Euphorbia esula, Euphorbia hetraphylla, E. (Acalypha australis), Tropic croton (Croton glandulosus), Lobdo Croton (Croton lobatus), Brazil (Phyllanthus corcovadensis), Castor bean (Ricinus communis)

Malvaceous weeds (Malvaceae): Hevea (Abutilon theophrasti), Anemone deer (Sida rhombivoria), Maruba King deer (Sida cordifolia), American gore deer (Sida spinosa), fern Gurabiobi (Sida glaziovii), fern ), Ginseng (Hibiscus trionum), Amaryllis (Anoda cristata), Ekinoaki (Malvastrum coromandelianum)
Red-winged weeds (Onagraceae): Cleavage (Ludwigia epilobioides), red-winged lizard (Ludwigia octovalvis), soleid pokeweed (Ludwigia decurre)
Scutellaris Weed (Sterculiaceae): Prunus cypress (Waltheria indica)
Violet family weeds (Violaceae): persimmon (Viola arvensis), wild pansy (Viola tricolor)
Cucurbitaceae weed (Cucurbitaceae): Arecili (Sicyos angulatus), wild cucumber (Echinocystis lobata), wild bitter gourd (Momordica charantia)
Sprurgeon weeds (Lythraceae): Ammenia multiflora, Ammannia auriculata, Ammannia coccinea, Amitya (Lythrum salicaria), Orbita (Lythrum salicaria)
Shrimp Weed (Elatinaceae): Shrimp (Elatine triandra), California Waterwort (Elatine californica)

Seriaceae Weeds (Apiaceae): Seri (Oenanthe javanica), Nora Carrot (Daucus carota), Ginseng (Conium maculatum)
Ucogillaceous weed (Araliaceae): Hydocotyle sibthorpioides, Brazil-dove Medusa (Hydrocotyle ranunculoides)
Amataceous weed (Ceratophyllaceae): A pine (Ceratophyllum demersum)
Hagoromomoaceae Weed (Cabombaceae): Hagoromomo (Cabomba caroliniana)
Allium spinosa weed (Haloragaceae): Blue-faced duck (Myriophyllum aquaticum), Fusamo (Myriophyllum verticillatum), water mill foils (Myriophyllum spicatum, Myriophyllum heterophyllum etc)
Saturnia weed (Sapindaceae): Fusarium viper (Cardiospermum halicacabum)
Primrose weed (Primulaceae): Red-tailed riparian (Anagallis arvensis)
Sturgeon weed (Asclepiadaceae): Oorange cotton (Asclepias syriaca), honey wine milk weed (Ampelamus albidus)
Raccoon weeds (Rubiaceae): catch weed bed straws (Galium aparine), yam gras (Galium spurium var. Echinospermon), hirohafutabamugera (Spermacoce latifolia), brazil coriander (Richardia brasiliensis), winged falconite weed (Borrelia alata)

Convolvulus weed (Convolvulaceae): morning glory (Ipomoea nil), morning glory (Ipomoea hederacea), Marva morning glory (Ipomoea purpurea), Maruba american morning glory (Ipomoea hederacea var. , Noosaagaou (Ipomoea acuminata), Tsutano Haruko (Ipomoea hederifolia), Marubarukou (Ipomoea coccinea), Lepoucho (Ipomoea quamoclit), Ipomoea grandifolia (Ipomoea grandifolia), Ipomoea Aristolotiafolicotrithioliciol , Convolvulus arvensis, Calystegia hederacea, Convolvulus (Calystegia japonica), Eurasian Convolvulus (Merremia hedeacea), Hairy Wood Rose (Merremia aegyptia), Roadside Wood Rose (Merremi) a cissoides), asagao (Jacquemontia tamnifolia)
Purple family weed (Boraginaceae): Forget-me-not (Myosotis arvensis)
Lamiaceae weed (Lamiaceae): Lamium purpureum, Lamium amplexicaule, Leonotis nepetaefolia, Hyptis suaveolens, Hyptis lophanta (Hyptis lophatihichus)

Solanaceous weeds (Solanaceae): Datura stramonium, Solanum nigrum, Solanum americanum, American solanum pylanthum, Sornum sarachioides, Solanum thaliana , Squirrel eggplant (Solanum aculeatissimum), wild tomato (Solanum sisymbriifolium), warunaby (Solanum carolinense), physalis (Physalis angulata), smooth ground cherries (Physalis subglabrata), iosennari (Nicandra physaloides)
Scutellaria weed (Scrophulariaceae): Veronica hederaefolia, Veronica persica, Veronica arvensis, Azena (Lindernia ducuma), Azena (Lindernia dubia), Azetulifolius, as a extract (Dopatrium junceum), moth (Gratiola japonica),
Plantain weeds (Plantaginaceae): Planago asiatica, Planago lanceolata, Planago major, Planago major, Callitrice palustris

  Asteraceae weeds (Asteraceae): Monarch (Xanthium pensylvanicum), Monarch (Xanthium occidentale), Monarch (Xanthium italicum), Wild sunflower (Helianthus annuus), Chamomile (Matricaria chamomilla), Orysia camphor (Matricaria perforitum) ), Orso-Shak (Matricaria matricarioides), Mugwort (Artemisia princeps), Sesmus Artemisia vulgaris, Chinese Mugwort (Artemisia verlotorum), Scutellaria altissima (Solidago altissima), Daniocarpus (Taraxacum officigate), (Galinsoga parviflora), Spermella (Senecio vulgaris), Senecio braziliensis (Senecio brasiliensis), Senecio grisebachi (Senecio grisebachii), Alethysmium (Conyza bonariensis), Oalenossy (C) onyza smatrensis), sweet potato (Conyza canadensis), ragweed (Ambrosia artemisiaefolia), mulberry (Ambrosia trifida), taukogi (Bidens tripartita), kosendangusa (Bidens pilosa), americanifoliates Squid thistle (Cirsium arvense), American thistle (Cirsium vulgare), Maria thistle (Silybum marianum), Squirrel (Carduus nutans), Scutellariae (Lactuca serriola), Scutellariae (Sonchus oleraceus), Scutellaria japonicus (Sonchus asper), beach creeping eye Wedelia glauca), perforate blackfoot (Melampodium perfoliatum), russula (Emilia sonchifolia), Shiozakisou (Tagetes minuta), Paracless (Blainvillea latifolia), Kotobukiiku (Tridax procumbens), Jerva Poco Rosa (Porophyllum ruderale), Paraguay Starbar (Acanthospermum australe), Bristley Starr Bar (Acanthospermum hispidum), Heussium (Cardiospermum halicacabum), Cuckweed Thistle (Ageratum conyzoides), Common bones set (Eupium politraceifolium) , Dand Borody (Erechtites hieracifolia), American Everlasting (Gamochaeta spicata), V. vulgaricus (Gnaphalium spicatum), Jagelia Hitra (Jaegeria hirta), Scutellariae (Parthenium hysterophorus), Menafimo (Sieges becitalitalis) Takasaburo (Eclipta prostrata), American Takasaburo (Eclipta alba), Persimmon (Centipeda minima),

Amaryllidaceae Weed (Alismataceae): Squid River (Sagittaria pygmaea), Omodaka (Sagittaria trifolia), P. edulis (Sagittaria sagittifolia), Tyrin Omodaka (Sagitaria montevidensis), Aeginashi (Sagittaria alitraceiium) aquatica)
Livulinaceae (Limnocharitaceae): Livularia (Limnocharis flava)
Tochikagami weed (Hydrocharitaceae): Frog bit (Limnobium spongia), Chromo (Hydrilla verticillata), common water nymph (Najas guadalupensis)
Araceae Weed (Araceae): Bianchi duckweed (Pistia stratiotes)
Duckweed weeds (Lemnaceae): Duckweed (Lemna aoukikusa), Duckweed (Spirodela polyrhiza), Geniaceae (Wolffia spp)
Phyllaceae weeds (Potamogetonaceae): Psyllium (Potamogeton distinctus), pond weeds (Potamogeton crispus, Potamogeton illinoensis, Stuckenia pectinata etc.)
Lilium weed (Liliaceae): Wild onion (Allium canadense), Wild garlic (Allium vineale), Nobil (Allium macrostemon)
Water weed: Water hyacinth (Eichhornia crassipes), Hemp helex (Heteranthera limosa), water hyacinth (Monochoria korsakowii), Allium (Monochoria vaginalis)
Achillea (Commelinaceae): Tussock (Commelina communis), Marubatu (Commela bengharensis), Electo dei Flower (Commelina erecta), Iboxa (Murdannia keisak)

  Grass weeds (Poaceae): Echinochloa crus-galli, Echinochloa oryzicola, Echinochloa crus-galli var formosensis, Late water glass (Echinochloa oryzoides), Echinochloa colona (Echinochloa colony) Echinochloa crus-pavonis), Enokologosa (Setaria viridis), Achinoenokologosa (Setaria faberi), Echinochloach (Setaria glauca), American Enokologa (Setaria geniculata), Redfinches (Digitaria ciliaris), Large Club Grass (Digitaria sanguignalis) Digitaria horizonis), Squidweed (Digitaria insularis), Echinochon (Eleusine indica), Hevea gore (Poa annua), Hevea goreii (Poa trivialis), Hevea gossypium (Poa pratensis), Hevea gore (Alospecurus alealis) opecurus myosuroides), oats (Avena fatua), sorghum (Sorghum halepense), sage cane (Sorghum vulgare), sage wheat (Agropyron repens), oat wheat (Lolium multiflorum), oat omugi (Lolium perenne) Bromus catharticus, Bromus sterilis, Bromus japonicus, Bromus secalinus, Bromus tectorum, Horonium jubatum, Goat's moths Kusashiyoshi (Phalaris minor), silky bent grass (Apera spica-venti), oxabibi (Panicum dichotomiflorum), Texas panicum (Panicum texanum), Gineakibi (Panicum maximum), Meriken Nibuki (Brachiaria platyphylla), Ruzigrass (Brachiaria zizi) , Alexandergrass (Brachiaria plantaginea), Surinamegrass (Brachiaria decumbens), Parrisedgrass (Brachiaria brizantha), Columbiagrass (Brachiaria humidicola), Shinchnoiiga (Cenchrus echinatus), Himekri noiga (Cenchrus pauciflorus), Narcobie (Eriochium vitela) setosum, African rhododendron (Chloris gayana), Rhododendron (Chlorisvirgata), Eragrostis pilosa, Rhynchelitrum repens, Dactyloctenium aegyptium, Dichylose moth, Oryza sativa), American spruce (Paspalum notatum), coastal sand pars (Paspalum maritimum), xylem (Paspalum distichum), red mullet (Pennisetum clandestinum), Hosoba chikara Horse mackerel (Pennisetum setosum), hornwort (Rottboellia cochinchinensis), Azegaya (Leptochloa chinensis), Oniyazegaya (Leptochloa fascicularis), Itazegaya (Leptochloa filiformis), Amazon sprangle top (Leptochloa panico tiveica) , Ezonosayanukoukagusa (Leersia oryzoides), Uchigaya (Glyceria leptorrhiza), Mushioregusa (Glyceria acutiflora), Erythrothus (Glyceria maxima), Agaves gytiviolich, (Gastrotechifolico) , (Eremochloa ophiuroides), P. vulgaris (Festuca arundinacea), P. vulgaris (Festuca rubra), Timothy (Imperata cylindrica), Miscanthus (Miscanthus sinensis), Switchgrass (Panicum virgatum), Bas (Zoysia japonica)

Cactus weed (Cyperus microiria), Chypericus ciliatum (Cyperus microiria), Cyperus icri (Cyperus icri), Cyperus icri (Cyperus icri), Chyperus icri (Cyperus diffus.) (Cyperus odoratus), Cyperus cerotis, Chyperus rotundus, Cyperus esculentus, Kyllinga brevillima, Hidreich (Fimbristilitativeici), acicularis), criogwai (Eleocharis kuroguwai), firefly (Schoenoplectiella hotarui), dogflies (Schoenoplectiella juncoides), rockfish (Schoenoplectiella wallichii), black-tailed eagle (Schoenoplectiella mucronatus), kungare (Schoenoplectiella triangulatus), pulp (Schoenoplectiella nipponicus), Sankakui (Schoenoplectiella triqueter), Koukiyagara (Bolboschoenus koshevnikovii), Ukiyagara (Bolboschoenus fluviatilis)
Horse mackerel weed (Equisetaceae): Japanese horsetail (Equisetum arvense), Inugina (Equisetum palustre)
Salamander weed (Salviniaceae): Salamander (Salvinia natans)
Amaryllidaceae weeds (Azollaaceae): Scutellaria japonicus (Azolla japonica), Scutellariae (Azolla imbricata)
Dendrobaceae (Marsileaceae): Dendless (Marsilea quadrifolia)
Others: filamentous algae (Pithophora, Cladophora), mosses, mosses, spiny mosses, cyanobacteria, ferns, permanent crops (pear fruits, stone fruits, berries, nuts, nuts, citrus, hops, grapes, etc.) Sucker (sucker).

  For the above-mentioned weeds, the variation in the species is not particularly limited. That is, it also includes those which show reduced sensitivity to certain herbicides (also referred to as resistance). The reduction in sensitivity may be one having a mutation at the target site (acting point mutation) or may be due to a factor that is not a working point mutation (non-acting point mutation). For the action point mutation, mutation of the nucleic acid sequence (open reading frame) corresponding to the amino acid sequence of the protein results in an amino acid substitution in the protein which is the target site, deletion of the suppressor sequence in the promoter region, enhancer sequence The target site protein is overexpressed by mutations such as amplification of the gene or increase in the copy number of the gene. Non-acting mutations include metabolic enhancement, absorptivity, dyspnea, and efflux. As a factor for enhancing the metabolism, those having enhanced activities of metabolic enzymes such as cytochrome P450 monooxygenase, allyl acyl amidase, esterase, glutathione S transferase and the like can be mentioned. Excretion includes transport to the vacuole by the ABC transporter.

Examples of the amino acid substitution at the target site include the following.
ALS: Ala122Thr, Ala122Val, Ala122Tyr, Pro197Ser, Pro197His, Pro197Thr, Pro197Arg, Pro197Leu, Pro197Gln, Pro197Ala, Pro197Ale, Ala205Val, Ala205Pal, Arg377His, Trp574Leu, Trp574G4u, Trp574Met, Ser653Thrs
ACCase: Ile 1781 Leu, Ile 1781 Val, Ile 1781 Thr, Trp 1999 Cys, Trp 1999 Leu, Ala 2004 Val, Trp 2027 Cys, Ile 2041 Asn, Ile 2041 Val, Asp 2078 Gly or Cys 2088 Arg;
PPX2: Gly210Δ, Arg98Leu, Arg98Met, Arg98Gly, Arg98His, Gly399Ala;
EPSP: Thr102Ile, Pro106Ser, Pro106Ala or Pro106Leu.

  The weed which can be controlled by the composition B containing the herbicidally active ingredient as the present ingredient may have a plurality of the above amino acid substitutions. In this case, the plurality of amino acid substitutions may be the same protein or different proteins. Moreover, you may have multiple non-acting point mutations or working point mutations.

Examples of weeds having action point mutations include the following.
A. having an amino acid substitution of Gly210Δ, Arg98Met, Arg98Gly or Gly399Ala in PPX2;
Waterhemp having amino acid substitution of Gly210Δ, Arg98Met, Arg98Gly or Gly399Ala in PPX2;
A ragweed having an amino acid substitution of Arg98Leu in PPX2;
Boomugi having an amino acid substitution of Arg98His in PPX2;
Double-handed having in the EPSP an amino acid substitution of Thr 102 Ile, Pro 106 Ser, Pro 106 Ala or Pro 106 Leu;
A boumberry having an amino acid substitution of Thr102Ile, Pro106Ser, Pro106Ala or Pro106Leu in EPSP;
Susukimeshibai having an amino acid substitution of Thr102Ile, Pro106Ser, Pro106Ala or Pro106Leu in EPSP;
ヒ with the amino acid substitution of Thr102Ile, Pro106Ser, Pro106Ala or Pro106Leu in EPSP;
Recession having an amino acid substitution of Thr102Ile, Pro106Ser, Pro106Ala or Pro106Leu in EPSP;

  The above-mentioned Oonagawoto, water hemp and ragweed show resistance to PPO inhibitors such as lactofen, fomethafen and flumioxazine.

Other weeds include the following.
The overexpression of the EPSP gene results in a decreased sensitivity to glyphosate.
Resistance to Glyphosate associated with ABC Transporter.

  The composition B containing a herbicidally active ingredient as the present ingredient can particularly effectively control the above-described A. vulgaris L., B. pygella, B. bovis, A. vulgare, A. vulgaris, A. vulgaris, and A. vulgaris.

  In addition, composition B containing a herbicidally active ingredient as the present ingredient can effectively control glyphosate-resistant hives that have amino acid substitutions of Thr102Ile and Pro106Ser in EPSP, ginseng, boumbi, susukimehishiba, hyumodoki, and hideobie. it can.

Hereinafter, the present invention will be described in more detail by production examples, formulation examples, test examples and the like, but the present invention is not limited to these examples.
First, production examples of the present compound are shown.

中間体Ａ−１：¹H-NMR (CDCl₃) δ: 8.50 (1H, dd), 7.85 (1H, dd), 7.75 (1H, dd), 7.35-7.31 (2H, m), 2.88 (2H, q), 1.26 (3H, t). Reference Production Example 1-1
Under an argon atmosphere, 3.75 g of 6-chloro-2-fluoropyridin-3-ylboronic acid, 4.66 g of 2-bromo-3- (ethylsulfanyl) pyridine, [1,1-bis (diphenylphosphino) ferrocene] palladium A mixture of 0.77 g dichloride, 13.5 g tripotassium phosphate, 20 mL DMF, and 2 mL water was stirred at 80 ° C. for 9 hours. After cooling to room temperature, water was added to the mixture, and the mixture was extracted with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography to obtain 2.9 g of Intermediate A-1 shown below.

Intermediate A-1: ¹ H-NMR (CDCl ₃ ) δ: 8.50 (1H, dd), 7.85 (1H, dd), 7.75 (1H, dd), 7.35-7.31 (2H, m), 2.88 (2H, 2H) q), 1.26 (3H, t).

中間体Ｂ−１：¹H-NMR (CDCl₃) δ: 8.53 (1H, dd), 8.46 (1H, d), 7.76 (1H, dd), 7.34 (1H, dd), 7.20 (1H, d), 2.87 (2H, q), 1.25 (3H, t). Reference Production Example 1-2
Using 6-chloro-4-fluoropyridin-3-ylboronic acid pinacol ester instead of 6-chloro-2-fluoropyridin-3-ylboronic acid, according to the method described in Reference Production Example 1-1, The indicated intermediate B-1 was obtained.

Intermediate B-1: ¹ H-NMR (CDCl ₃ ) δ: 8.53 (1 H, dd), 8.46 (1 H, d), 7.76 (1 H, dd), 7.34 (1 H, dd), 7.20 (1 H, d) , 2.87 (2H, q), 1.25 (3H, t).

中間体Ａ−２：¹H-NMR (CDCl₃) δ: 8.47 (1H, dd), 7.69 (1H, dd), 7.59 (1H, d), 7.31-7.26 (6H, m), 7.04 (1H, d), 5.42 (2H, s), 2.78 (2H, q), 1.17 (3H, t). Reference Production Example 2-1
Under ice-cooling, to a mixture of 2.9 g of Intermediate A-1, 0.43 g of sodium hydride (60% oily) and 10 mL of DMF, 1.1 mL of benzyl alcohol was dropped, and the mixture was stirred at 0 ° C. for 5 hours. To the mixture was added water and extracted with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography to obtain 3.31 g of Intermediate A-2 shown below.

Intermediate A-2: ¹ H-NMR (CDCl ₃ ) δ: 8.47 (1 H, dd), 7.69 (1 H, dd), 7.59 (1 H, d), 7.31-7.26 (6 H, m), 7.04 (1 H, d), 5.42 (2H, s), 2.78 (2H, q), 1.17 (3H, t).

中間体Ｂ−２：¹H-NMR (CDCl₃) δ: 8.50 (1H, dd), 8.22 (1H, s), 7.71 (1H, dd), 7.31-7.29 (6H, m), 6.96 (1H, s), 5.14 (2H, s), 2.81 (2H, q), 1.20 (3H, t). Reference Production Example 2-2
The compound manufactured according to the method as described in the reference manufacture example 2-1, and its physical-property value are shown below.

Intermediate B-2: ¹ H-NMR (CDCl ₃ ) δ: 8.50 (1 H, dd), 8.22 (1 H, s), 7.71 (1 H, dd), 7.31-7.29 (6 H, m), 6.96 (1 H, s), 5.14 (2H, s), 2.81 (2H, q), 1.20 (3H, t).

中間体Ｂ−３：¹H-NMR (CDCl₃) δ: 8.92 (1H, dd), 8.42 (1H, dd), 8.19 (1H, s), 7.57 (1H, dd), 7.31-7.29 (3H, m), 7.23-7.21 (2H, m), 7.01 (1H, s), 5.10 (2H, s), 2.90 (2H, q), 1.10 (3H, t). Reference Production Example 2-3
0.8 g of mCPBA (purity 70%) was added to a mixture of 0.53 g of Intermediate B-2 and 15 mL of chloroform under ice-cooling, and the mixture was stirred at 0 ° C. to room temperature for 5 hours. To this mixture was added aqueous sodium thiosulfate solution, and the mixture was extracted with chloroform. The obtained organic layer was washed with a saturated aqueous solution of sodium hydrogen carbonate, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 0.35 g of Intermediate B-3 shown below.

Intermediate B-3: ¹ H-NMR (CDCl ₃ ) δ: 8.92 (1 H, dd), 8.42 (1 H, dd), 8.19 (1 H, s), 7.57 (1 H, dd), 7.31-7.29 (3 H, m), 7.23-7.21 (2H, m), 7.01 (1H, s), 5.10 (2H, s), 2.90 (2H, q), 1.10 (3H, t).

中間体Ａ−６：¹H-NMR (CDCl₃) δ: 8.91 (1H, dd), 8.40 (1H, dd), 7.63 (1H, d), 7.55 (1H, dd), 7.30-7.24 (5H, m), 7.08 (1H, d), 5.50-5.28 (2H, m), 2.78-2.71 (2H, m), 0.92 (3H, t). Reference Production Example 2-4
The compounds produced according to the method described in Reference Production Example 2-3 and the physical properties thereof are shown below.

Intermediate A-6: ¹ H-NMR (CDCl ₃ ) δ: 8.91 (1 H, dd), 8.40 (1 H, dd), 7.63 (1 H, d), 7.55 (1 H, dd), 7.30-7.24 (5 H, 5) m), 7.08 (1 H, d), 5. 50-5. 28 (2 H, m), 2. 78-2.71 (2 H, m), 0.92 (3 H, t).

中間体Ａ−３：¹H-NMR (CDCl₃) δ: 8.44 (1H, d), 8.39 (1H, dd), 7.85 (1H, dd, J = 8.1, 1.5 Hz), 7.30 (1H, dd), 6.94 (1H, d), 2.94 (2H, q), 1.29 (3H, t). Reference Production Example 3-1
A mixture of 3.31 g of intermediate A-2 and 10 mL of concentrated hydrochloric acid was stirred at 80 ° C. for 1.5 hours. After cooling to room temperature, 2M aqueous sodium hydroxide solution was added to the mixture to adjust the pH to 4. The precipitated solid was collected by filtration to obtain 2.03 g of an intermediate A-3 shown below.

Intermediate A-3: ¹ H-NMR (CDCl ₃ ) δ: 8.44 (1 H, d), 8. 39 (1 H, dd), 7. 85 (1 H, dd, J = 8.1, 1.5 Hz), 7.30 (1 H, dd) , 6.94 (1H, d), 2.94 (2H, q), 1.29 (3H, t).

中間体Ａ−７：¹H-NMR (CDCl₃) δ: 8.91 (1H, dd), 8.41 (1H, dd), 7.64 (1H, d), 7.58 (1H, dd), 6.68 (1H, d), 3.37 (2H, q), 1.30 (3H, t). Reference Production Example 3-1A
The compound manufactured according to the method as described in the reference manufacture example 3-1, and its physical-property value are shown below.

Intermediate A-7: ¹ H-NMR (CDCl ₃ ) δ: 8.91 (1 H, dd), 8.41 (1 H, dd), 7.64 (1 H, d), 7.58 (1 H, dd), 6.68 (1 H, d) , 3.37 (2H, q), 1.30 (3H, t).

中間体Ａ−２１：¹H-NMR (CDCl₃) δ: 8.84 (1H, d), 8.37 (1H, d), 7.59 (1H, d), 6.64 (1H, d), 3.40 (2H, q), 1.33 (3H, t).

Intermediate A-21: ¹ H-NMR (CDCl ₃ ) δ: 8.84 (1 H, d), 8. 37 (1 H, d), 7. 59 (1 H, d), 6. 64 (1 H, d), 3. 40 (2 H, q) , 1.33 (3H, t).

中間体Ａ−２５：¹H-NMR (CDCl₃) δ: 9.13 (1H, s), 8.61 (1H, s), 7.62 (1H, d), 6.64 (1H, d), 3.46-3.43 (2H, m), 1.35 (3H, t).

Intermediate A-25: ¹ H-NMR (CDCl ₃ ) δ: 9.13 (1H, s), 8.61 (1H, s), 7.62 (1H, d), 6.64 (1H, d), 3.46-3. 43 (2H, 2H) m), 1.35 (3H, t).

中間体Ａ−３９：¹H-NMR (CDCl₃) δ: 8.63 (1H, d), 7.87-7.85 (1H, m), 7.73-7.68 (2H, m), 7.04 (1H, d), 3.18-3.02 (2H, m), 1.07 (3H, t). Reference Production Example 3-2
A mixture of 10 g of intermediate A-38 and 30 mL of concentrated hydrochloric acid was stirred at reflux for 16 hours. After cooling to room temperature, toluene was added and concentrated under reduced pressure. The resulting solid was washed with hexane to give 8 g of Intermediate A-39 shown below.

Intermediate A-39: ¹ H-NMR (CDCl ₃ ) δ: 8.63 (1 H, d), 7.87-7.85 (1 H, m), 7.73-7. 3.02 (2H, m), 1.07 (3H, t).

Reference Production Example 3-2A
The compounds produced according to the method described in Reference Production Example 3-2 and the physical properties thereof are shown below.

中間体Ｂ−１６：¹H-NMR (CDCl₃) δ: 8.87 (1H, s), 8.34 (1H, s), 8.26 (1H, s), 7.89 (1H, s), 3.24-3.18 (2H, m), 1.30 (3H, t).

Intermediate B-16: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1H, s), 8.34 (1H, s), 8.26 (1H, s), 7.89 (1H, s), 3.24-3.18 (2H, 2H) m), 1.30 (3H, t).

中間体Ｂ−２０：¹H-NMR (CDCl₃) δ: 9.16 (1H, s), 8.60 (1H, s), 8.29 (1H, s), 7.66 (1H, s), 3.25-3.19 (2H, m), 1.32-1.26 (3H, m).

Intermediate B-20: ¹ H-NMR (CDCl ₃ ) δ: 9.16 (1H, s), 8.60 (1H, s), 8.29 (1H, s), 7.66 (1H, s), 3.25-3.19 (2H, 2H) m), 1.32-1.26 (3H, m).

中間体Ａ−４４

Intermediate A-44

中間体Ａ−４７

Intermediate A-47

中間体Ｂ−４：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.61 (1H, dd), 8.54 (1H, s), 7.62 (1H, dd), 6.94 (1H, s), 3.08 (2H, q), 1.18 (3H, t). Reference Production Example 3-3
A mixture of 0.35 g of intermediate B-3, 100 mg of 10% palladium carbon, and 5 mL of ethyl acetate was stirred under a hydrogen atmosphere for 3 hours. The reaction mixture was filtered through Celite (registered trademark) and concentrated under reduced pressure to give 0.11 g of Intermediate B-4 shown below.

Intermediate B-4: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.61 (1 H, dd), 8.54 (1 H, s), 7.62 (1 H, dd), 6.94 (1 H, s) , 3.08 (2H, q), 1.18 (3H, t).

中間体Ａ−４：¹H-NMR (CDCl₃) δ: 8.45 (1H, dd), 7.69 (1H, dd), 7.42 (1H, d, J = 7.5 Hz), 7.24 (1H, dd), 6.43 (1H, d), 3.76 (3H, s), 2.88 (2H, q), 1.26 (3H, t). Reference Production Example 4-1
A mixture of 1.0 g of intermediate A-3, 0.28 mL of methyl iodide, 1.82 g of cesium carbonate and 10 mL of DMF was stirred at 0 ° C. for 3.5 hours. To the mixture was added water and extracted with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography to obtain 0.55 g of Intermediate A-4 shown below.

Intermediate A-4: ¹ H-NMR (CDCl ₃ ) δ: 8.45 (1 H, dd), 7.69 (1 H, dd), 7.42 (1 H, d, J = 7.5 Hz), 7.24 (1 H, dd), 6.43 (1H, d), 3.76 (3H, s), 2.88 (2H, q), 1.26 (3H, t).

中間体Ａ−５：¹H-NMR (CDCl₃) δ: 8.45 (1H, d), 7.70 (1H, d), 7.40 (1H, d), 7.23 (1H, dd), 6.40 (1H, d), 4.39-4.38 (2H, m), 2.91-2.85 (2H, m), 1.37 (3H, t), 1.25 (3H, t). Reference Production Example 4-2
The compound manufactured according to the method as described in the reference manufacture example 4-1, and its physical-property value are shown below.

Intermediate A-5: ¹ H-NMR (CDCl ₃ ) δ: 8.45 (1 H, d), 7.70 (1 H, d), 7. 40 (1 H, d), 7.23 (1 H, dd), 6.40 (1 H, d) , 4.39-4.38 (2H, m), 2.91-2.85 (2H, m), 1.37 (3H, t), 1.25 (3H, t).

中間体Ｂ−５：¹H-NMR (CDCl₃) δ: 8.93 (1H, dd), 8.45 (1H, dd), 8.16 (1H, s), 7.60 (1H, dd), 6.95 (1H, s), 3.83 (3H, s), 2.93 (2H, q), 1.19 (3H, t).

Intermediate B-5: ¹ H-NMR (CDCl ₃ ) δ: 8.93 (1 H, dd), 8.45 (1 H, dd), 8.16 (1 H, s), 7.60 (1 H, dd), 6.95 (1 H, s) , 3.83 (3H, s), 2.93 (2H, q), 1.19 (3H, t).

中間体Ａ−４０

Intermediate A-40

で示される化合物において、Ｒ⁵、Ａ¹、Ｒ³、及びｎの組合せが［表１７］に記載のいずれかの組合せである化合物。
［表１７］

中間体Ａ−８：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.34 (1H, dd), 7.52 (1H, dd), 7.39 (1H, d), 6.46 (1H, d), 4.25 (2H, m), 3.53-3.42 (2H, m), 1.85-1.74 (2H, m), 1.33 (3H, t), 1.01 (3H, t).
中間体Ａ−９：¹H-NMR (CDCl₃) δ: 8.86 (1H, dd), 8.33 (1H, dd), 7.51 (1H, dd), 7.33 (1H, d), 6.42 (1H, d), 5.18-5.14 (1H, m), 3.55-3.41 (2H, m), 1.65-1.61 (6H, m), 1.33 (3H, t).
中間体Ａ−１０：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.34 (1H, dd), 7.52 (1H, dd), 7.39 (1H, d), 6.46 (1H, d), 4.28 (2H, t), 3.48 (2H, q), 1.78-1.69 (2H, m), 1.45-1.42 (2H, m), 1.33 (3H, t), 0.97 (3H, t).
中間体Ａ−１１：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.33 (1H, dd), 7.52 (1H, dd), 7.43 (1H, d), 6.49 (1H, d), 5.98-5.89 (1H, m), 5.27-5.20 (2H, m), 4.95-4.89 (2H, m), 3.47 (2H, q), 1.32 (3H, t).
中間体Ａ−１２：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.35 (1H, dd), 7.53 (1H, dd), 7.45 (1H, d), 6.51 (1H, d), 5.11-5.00 (2H, m), 3.47 (2H, q), 2.27 (1H, t), 1.33 (3H, t).
中間体Ａ−１３：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.35 (1H, dd), 7.52 (1H, dd), 7.40 (1H, d), 6.47 (1H, d), 4.23-4.20 (2H, m), 3.48-3.44 (2H, m), 1.34-1.30 (4H, m), 0.56-0.52 (4H, m).
中間体Ａ−１４：¹H-NMR (CDCl₃) δ: 8.88 (1H, dd), 8.35 (1H, dd), 7.55 (1H, dd), 7.47 (1H, d), 6.56 (1H, d), 5.03 (2H, br s), 3.40 (2H, q), 1.32 (3H, t).
中間体Ａ−１５：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.33 (1H, dd), 7.52 (1H, dd), 7.45 (1H, d), 7.33-7.27 (5H, m), 6.51 (1H, d), 5.64-5.42 (2H, m), 3.40-3.37 (2H, m), 1.25 (3H, t).
中間体Ａ−１６：¹H-NMR (CDCl₃) δ: 8.88 (1H, dd), 8.36 (1H, dd), 7.66 (1H, s), 7.55 (1H, dd), 7.44 (1H, d), 6.52 (1H, d), 5.57-5.47 (2H, m), 3.54-3.37 (2H, m), 1.36 (3H, t).
中間体Ａ−２２：¹H-NMR (CDCl₃) δ: 8.81 (1H, d), 8.33 (1H, d), 7.41 (1H, d), 6.50 (1H, d), 3.74 (3H, s), 3.50-3.46 (2H, m), 1.35 (3H, t).
中間体Ａ−２６：¹H-NMR (CDCl₃) δ: 9.10 (1H, s), 8.57 (1H, s), 7.46 (1H, d), 6.53 (1H, d), 3.75 (3H, s), 3.52 (2H, q), 1.36 (3H, t).
中間体Ａ−３７：¹H-NMR (CDCl₃) δ: 8.86 (1H, d), 8.34 (1H, d), 7.52-7.49 (1H, m), 7.40 (1H, d), 6.48 (1H, d), 3.72 (3H, s), 3.43 (2H, q), 1.31 (3H, t).
中間体Ａ−４２：¹H-NMR (CDCl₃) δ: 9.10 (1H, d), 8.55 (1H, d), 7.44 (1H, d), 6.50 (1H, d), 4.38 (2H, q), 3.61-3.54 (2H, m), 1.38 (3H, t), 1.37 (3H, t). Formula (MA-1):

In the compounds represented by, the combination of R ⁵ , A ¹ , R ³ and n is any combination described in [Table 17].
[Table 17]

Intermediate A-8: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.34 (1 H, dd), 7.52 (1 H, dd), 7.39 (1 H, d), 6.46 (1 H, d) , 4.25 (2H, m), 3.53-3.42 (2H, m), 1.85-1.74 (2H, m), 1.33 (3H, t), 1.01 (3H, t).
Intermediate A-9: ¹ H-NMR (CDCl ₃ ) δ: 8.86 (1 H, dd), 8.33 (1 H, dd), 7.51 (1 H, dd), 7.33 (1 H, d), 6.42 (1 H, d) , 5.18-5.14 (1H, m), 3.55-3.41 (2H, m), 1.65-1.61 (6H, m), 1.33 (3H, t).
Intermediate A-10: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.34 (1 H, dd), 7.52 (1 H, dd), 7.39 (1 H, d), 6.46 (1 H, d) , 4.28 (2H, t), 3.48 (2H, q), 1.78-1.69 (2H, m), 1.45-1.42 (2H, m), 1.33 (3H, t), 0.97 (3H, t).
Intermediate A-11: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.33 (1 H, dd), 7.52 (1 H, dd), 7.43 (1 H, d), 6.49 (1 H, d) , 5.98-5.89 (1H, m), 5.27-5.20 (2H, m), 4.95-4.89 (2H, m), 3.47 (2H, q), 1.32 (3H, t).
Intermediate A-12: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.35 (1 H, dd), 7.53 (1 H, dd), 7.45 (1 H, d), 6.51 (1 H, d) , 5.11-5.00 (2H, m), 3.47 (2H, q), 2.27 (1H, t), 1.33 (3H, t).
Intermediate A-13: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.35 (1 H, dd), 7.52 (1 H, dd), 7.40 (1 H, d), 6.47 (1 H, d) , 4.23-4.20 (2H, m), 3.48-3.44 (2H, m), 1.34-1.30 (4H, m), 0.56-0.52 (4H, m).
Intermediate A-14: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1 H, dd), 8.35 (1 H, dd), 7.55 (1 H, dd), 7.47 (1 H, d), 6.56 (1 H, d) , 5.03 (2H, br s), 3.40 (2H, q), 1.32 (3H, t).
Intermediate A-15: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.33 (1 H, dd), 7.52 (1 H, dd), 7.45 (1 H, d), 7.33-7.27 (5 H, 5) m), 6.51 (1H, d), 5.64-5.42 (2H, m), 3.40-3.37 (2H, m), 1.25 (3H, t).
Intermediate A-16: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1 H, dd), 8.36 (1 H, dd), 7.66 (1 H, s), 7.55 (1 H, dd), 7.44 (1 H, d) , 6.52 (1H, d), 5.57-5.47 (2H, m), 3.54-3.37 (2H, m), 1.36 (3H, t).
Intermediate A-22: ¹ H-NMR (CDCl ₃ ) δ: 8.81 (1 H, d), 8.33 (1 H, d), 7.41 (1 H, d), 6.50 (1 H, d), 3.74 (3 H, s) , 3.50-3.46 (2H, m), 1.35 (3H, t).
Intermediate A-26: ¹ H-NMR (CDCl ₃ ) δ: 9.10 (1 H, s), 8. 57 (1 H, s), 7.46 (1 H, d), 6.53 (1 H, d), 3. 75 (3 H, s) , 3.52 (2H, q), 1.36 (3H, t).
Intermediate A-37: ¹ H-NMR (CDCl ₃ ) δ: 8.86 (1H, d), 8.34 (1H, d), 7.52-7.49 (1H, m), 7.40 (1H, d), 6.48 (1H, 1H, d) d), 3.72 (3H, s), 3.43 (2H, q), 1.31 (3H, t).
Intermediate A-42: ¹ H-NMR (CDCl ₃ ) δ: 9.10 (1 H, d), 8.55 (1 H, d), 7.44 (1 H, d), 6.50 (1 H, d), 4.38 (2 H, q) , 3.61-3.54 (2H, m), 1.38 (3H, t), 1.37 (3H, t).

中間体Ａ−４５：¹H-NMR (CDCl₃) δ: 7.93 (1H, d), 7.30 (1H, d), 6.52-6.40 (2H, m), 3.70 (3H, s), 3.37-3.30 (2H, m), 3.13 (6H, s), 1.27 (3H, t).

Intermediate A-45: ¹ H-NMR (CDCl ₃ ) δ: 7.93 (1H, d), 7.30 (1H, d), 6.52-6.40 (2H, m), 3.70 (3H, s), 3.37-3.30 ( 2H, m), 3.13 (6H, s), 1.27 (3H, t).

中間体Ａ−４８

Intermediate A-48

で示される化合物において、Ｒ⁵、Ａ¹、Ｒ³、及びｎの組合せが［表１８］に記載のいずれかの組合せである化合物。
［表１８］

中間体Ｂ−９：¹H-NMR (CDCl₃) δ: 8.88 (1H, dd), 8.38 (1H, dd), 7.56 (1H, s),
7.53 (1H, dd), 6.62 (1H, s), 4.15-4.09 (2H, m), 3.49-3.39 (2H, m), 1.48 (3H, t), 1.30 (3H, t).
中間体Ｂ−１０：¹H-NMR (CDCl₃) δ: 8.88 (1H, dd), 8.38 (1H, dd), 7.53 (1H, s), 7.52 (1H, dd), 6.61 (1H, s), 4.10-3.92 (2H, m), 3.51-3.36 (2H, m), 1.93-1.84 (2H, m), 1.30 (3H, t), 1.01 (3H, t).
中間体Ｂ−１１：¹H-NMR (CDCl₃) δ: 8.88 (1H, dd), 8.38 (1H, dd), 7.52 (1H, dd), 7.52 (1H, s), 6.62 (1H, s), 4.07 (2H, br s), 3.44 (2H, br s), 1.84-1.81 (2H, m), 1.43-1.40 (2H, m), 1.30 (3H, t), 0.98 (3H, t).
中間体Ｂ−１２：¹H-NMR (CDCl₃) δ: 8.88 (1H, dd), 8.37 (1H, dd), 7.54-7.52 (2H, m), 6.63 (1H, s), 6.00-5.90 (1H, m), 5.39 (1H, d), 5.27 (1H, d), 4.70-4.64 (2H, m), 3.49-3.44 (2H, m), 1.31 (3H, t).
中間体Ｂ−１３：¹H-NMR (CDCl₃) δ: 8.89 (1H, dd), 8.39 (1H, dd), 7.63 (1H, s), 7.53 (1H, dd), 6.63 (1H, s), 4.01-3.88 (2H, m), 3.50-3.37 (2H, m), 1.33-1.28 (4H, m), 0.74-0.70 (2H, m), 0.45 (2H, m).
中間体Ｂ−１７：¹H-NMR (CDCl₃) δ: 8.80 (1H, d), 8.34 (1H, d), 7.53 (1H, s), 6.63 (1H, s), 3.77 (3H, s), 3.57-3.49 (2H, m), 1.35 (3H, t).
中間体Ｂ−２１：¹H-NMR (CDCl₃) δ: 9.16 (1H, d), 8.68 (1H, d), 8.17 (1H, s), 6.98 (1H, s), 3.85 (3H, s), 2.96 (2H, q), 1.22 (3H, t).
中間体Ｂ−２２：¹H-NMR (CDCl₃) δ: 8.90 (1H, dd), 8.41 (1H, dd), 7.64 (1H, s), 7.53 (1H, dd), 6.62 (1H, s), 5.02-4.96 (1H, m), 3.41-3.29 (2H, m), 1.49 (6H, d), 1.29-1.25 (3H, m).
中間体Ｂ−２３：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.37 (1H, dd), 7.62 (1H, s), 7.52 (1H, dd), 7.43-7.33 (3H, m), 7.26-7.22 (2H, m), 6.65 (1H, s), 5.27-5.23 (2H, m), 3.52-3.41 (2H, m), 1.32 (3H, t).
中間体Ｂ−２４：¹H-NMR (CDCl₃) δ: 8.89 (1H, dd), 8.38 (1H, dd), 7.54 (1H, dd), 7.53 (1H, s), 6.64 (1H, s), 4.41-4.22 (2H, m), 3.44-3.37 (2H, m), 2.77-2.63 (2H, m), 1.30 (3H, t) . Formula (MB-1):

In the compounds shown by, the combination of R ⁵ , A ¹ , R ³ , and n is any combination described in [Table 18].
[Table 18]

Intermediate B-9: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1 H, dd), 8.38 (1 H, dd), 7.56 (1 H, s),
7.53 (1H, dd), 6.62 (1H, s), 4.15-4.09 (2H, m), 3.49-3. 39 (2H, m), 1.48 (3H, t), 1.30 (3H, t).
Intermediate B-10: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1 H, dd), 8.38 (1 H, dd), 7.53 (1 H, s), 7.52 (1 H, dd), 6.61 (1 H, s) , 4.10-3.92 (2H, m), 3.51-3.36 (2H, m), 1.93-1.84 (2H, m), 1.30 (3H, t), 1.01 (3H, t).
Intermediate B-11: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1 H, dd), 8.38 (1 H, dd), 7.52 (1 H, dd), 7.52 (1 H, s), 6.62 (1 H, s) , 4.07 (2H, br s), 3.44 (2H, br s), 1.84-1.81 (2H, m), 1.43-1.40 (2H, m), 1.30 (3H, t), 0.98 (3H, t).
Intermediate B-12: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1 H, dd), 8.37 (1 H, dd), 7.54-7.52 (2 H, m), 6.63 (1 H, s), 6.00-5.90 1H, m), 5.39 (1H, d), 5.27 (1H, d), 4.704-4.64 (2H, m), 3.49-3.44 (2H, m), 1.31 (3H, t).
Intermediate B-13: ¹ H-NMR (CDCl ₃ ) δ: 8.89 (1 H, dd), 8.39 (1 H, dd), 7.63 (1 H, s), 7.53 (1 H, dd), 6.63 (1 H, s) , 4.01-3.88 (2H, m), 3.50-3.37 (2H, m), 1.33-1.28 (4H, m), 0.74-0.70 (2H, m), 0.45 (2H, m).
Intermediate B-17: ¹ H-NMR (CDCl ₃ ) δ: 8.80 (1 H, d), 8.34 (1 H, d), 7.53 (1 H, s), 6.63 (1 H, s), 3. 77 (3 H, s) , 3.57-3.49 (2H, m), 1.35 (3H, t).
Intermediate B-21: ¹ H-NMR (CDCl ₃ ) δ: 9.16 (1H, d), 8.68 (1H, d), 8.17 (1H, s), 6.98 (1H, s), 3.85 (3H, s) , 2.96 (2H, q), 1.22 (3H, t).
Intermediate B-22: ¹ H-NMR (CDCl ₃ ) δ: 8.90 (1 H, dd), 8.41 (1 H, dd), 7.64 (1 H, s), 7.53 (1 H, dd), 6.62 (1 H, s) , 5.02-4.96 (1H, m), 3.41-3.29 (2H, m), 1.49 (6H, d), 1.29-1 .25 (3H, m).
Intermediate B-23: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.37 (1 H, dd), 7.62 (1 H, s), 7.52 (1 H, dd), 7.43-7.33 (3 H, m), 7.26-7.22 (2H, m), 6.65 (1H, s), 5.27-5.23 (2H, m), 3.52-3.41 (2H, m), 1.32 (3H, t).
Intermediate B-24: ¹ H-NMR (CDCl ₃ ) δ: 8.89 (1H, dd), 8.38 (1H, dd), 7.54 (1H, dd), 7.53 (1H, s), 6.64 (1H, s) , 4.41-4.22 (2H, m), 3.44-3.37 (2H, m), 2.77-2.63 (2H, m), 1.30 (3H, t).

中間体Ａ−１７：¹H-NMR (CDCl₃) δ: 8.86 (1H, dd), 8.32 (1H, dd), 7.51 (1H, dd), 7.38 (1H, d), 6.43 (1H, d), 3.52 (2H, q), 2.99-2.95 (1H, m), 1.36 (3H, t), 1.32-1.31 (2H, m), 1.03-1.00 (2H, m). Reference Production Example 5
A mixture of 0.4 g of intermediate A-7, 0.48 g of copper (II) acetate, 0.43 g of cesium carbonate, 0.23 g of cyclopropylboronic acid, 0.3 mL of pyridine and 2.7 mL of xylene at 110 ° C. Stir for 20 hours. The resulting mixture was allowed to cool to room temperature, filtered through Celite (registered trademark), and the filtrate was concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography to obtain 37 mg of an intermediate A-17 shown below.

Intermediate A-17: ¹ H-NMR (CDCl ₃ ) δ: 8.86 (1 H, dd), 8.32 (1 H, dd), 7.51 (1 H, dd), 7.38 (1 H, d), 6.43 (1 H, d) , 3.52 (2H, q), 2.99-2.95 (1H, m), 1.36 (3H, t), 1.32-1.31 (2H, m), 1.03-1.00 (2H, m).

中間体Ａ−１８：¹H-NMR (CDCl₃) δ: 8.14 (1H, d) , 7.06 (1H, d), 4.74 (2H, s), 4.13 (3H, s), 3.28 (2H, q), 1.44 (3H, t). Reference Production Example 6-1
To a mixture of 0.5 g of methyl 6-chloro-2-methoxynicotinate, 5 mL of ethyl methyl sulfone and 12 mL of THF, 5 mL of lithium hexamethyldisilazide (1.1 M THF solution) was dropped at -10 ° C. The resulting mixture was stirred for 20 minutes and then 1 mL of 6 N hydrochloric acid was added. To the resulting mixture was added water and extracted with ethyl acetate. The resulting organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography to obtain 0.6 g of Intermediate A-18 shown below.

Intermediate A-18: ¹ H-NMR (CDCl ₃ ) δ: 8.14 (1 H, d), 7.06 (1 H, d), 4.74 (2 H, s), 4. 13 (3 H, s), 3. 28 (2 H, q) , 1.44 (3H, t).

中間体Ｂ−６：¹H-NMR (CDCl₃) δ: 8.69 (1H, s), 6.98 (1H, s), 4.67 (2H, s), 4.06 (3H, s), 3.26 (2H, q), 1.44 (3H, t). Reference Production Example 6-2
The compounds produced according to the method described in Reference Production Example 6-1 and the physical properties thereof are shown below.

Intermediate B-6: ¹ H-NMR (CDCl ₃ ) δ: 8.69 (1H, s), 6.98 (1H, s), 4.67 (2H, s), 4.06 (3H, s), 3.26 (2H, q) , 1.44 (3H, t).

中間体Ｃ−２：¹H-NMR (CDCl₃) δ: 8.81 (1H, s), 4.68 (2H, s), 4.17 (3H, s), 3.26 (2H, q), 2.61 (3H, s), 1.44 (5H, t).

Intermediate C-2: ¹ H-NMR (CDCl ₃ ) δ: 8.81 (1H, s), 4.68 (2H, s), 4.17 (3H, s), 3.26 (2H, q), 2.61 (3H, s) , 1.44 (5H, t).

中間体Ａ−１９：¹H-NMR (CDCl₃) δ: 7.67 (1H, d), 6.98 (1H, d), 6.11 (2H, br s), 4.83 (1H, s), 4.02 (3H, s), 3.07 (2H, q), 1.41 (3H, t). Reference Production Example 7-1
A mixture of 2.96 g of Intermediate A-18, 5.0 g of ammonium acetate, 0.15 mL of acetic acid and 13 mL of methanol was stirred at 65 ° C. for 6 hours. The resulting mixture was cooled to room temperature and then added to 2% aqueous sodium hydroxide solution. The precipitated solid was filtered, and the obtained solid was washed with water and dried under reduced pressure to obtain 2.7 g of an intermediate A-19 represented by the following formula.

Intermediate A-19: ¹ H-NMR (CDCl ₃ ) δ: 7.67 (1H, d), 6.98 (1H, d), 6.11 (2H, br s), 4.83 (1H, s), 4.02 (3H, s) ), 3.07 (2H, q), 1.41 (3H, t).

中間体Ｂ−１４：¹H-NMR (CDCl₃) δ: 8.28 (1H, s), 6.91 (1H, s), 5.95 (2H, s), 4.81 (1H, s), 3.95 (3H, s), 3.08 (2H, q), 1.42 (3H, t). Reference Production Example 7-2
The compounds produced according to the method described in Reference Production Example 7-1 and the physical properties thereof are shown below.

Intermediate B-14: ¹ H-NMR (CDCl ₃ ) δ: 8.28 (1H, s), 6.91 (1H, s), 5.95 (2H, s), 4.81 (1H, s), 3.95 (3H, s) , 3.08 (2H, q), 1.42 (3H, t).

中間体Ｃ−３：¹H-NMR (CDCl₃) δ: 8.38 (1H, s), 6.08 (2H, br), 4.87 (1H, s), 4.06 (3H, s), 3.08 (2H, q), 2.58 (3H, s), 1.41 (3H, t).

Intermediate C-3: ¹ H-NMR (CDCl ₃ ) δ: 8.38 (1H, s), 6.08 (2H, br), 4.87 (1H, s), 4.06 (3H, s), 3.08 (2H, q) , 2.58 (3H, s), 1.41 (3H, t).

中間体Ａ−２０：¹H-NMR (CDCl₃) δ: 8.84 (1H, d), 8.43 (1H, d), 7.60 (1H, d), 7.06 (1H, d), 3.91 (3H, s), 2.97-2.87 (2H, m), 1.21 (3H, t). Reference Production Example 8-1
A mixture of 0.90 g of sodium hydride (60% oily) and 25 mL of DMF was cooled to 0 ° C. and 2.71 g of intermediate A-19 dissolved in 5 mL of DMF was added dropwise. The resulting mixture was stirred at 0 ° C. for 30 minutes, then 6.60 g of 2-chloro-1,3-bis (dimethylamino) trimethinium hexafluorophosphate was added, and stirred at 60 ° C. for 2 hours. The resulting mixture was allowed to cool to room temperature, water was added, and the mixture was extracted with ethyl acetate. The resulting organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was subjected to silica gel chromatography to obtain 2.48 g of Intermediate A-20 shown below. Incidentally, 2-chloro-1,3-bis (dimethylamino) trimethinium hexafluorophosphate was produced according to the method described in J. Org. Chem., 2000, 65, 4571.

Intermediate A-20: ¹ H-NMR (CDCl ₃ ) δ: 8.84 (1 H, d), 8.43 (1 H, d), 7. 60 (1 H, d), 7.06 (1 H, d), 3.91 (3 H, s) , 2.97-2.87 (2H, m), 1.21 (3H, t).

中間体Ｂ−１５：¹H-NMR (CDCl₃) δ: 8.86 (1H, d), 8.43 (1H, d), 8.14 (1H, s), 6.95 (1H, s), 3.83 (3H, s), 2.93 (2H, q), 1.21 (3H, t). Reference Production Example 8-2
The compounds produced according to the method described in Reference Production Example 8-1 and the physical properties thereof are shown below.

Intermediate B-15: ¹ H-NMR (CDCl ₃ ) δ: 8.86 (1H, d), 8.43 (1H, d), 8.14 (1H, s), 6.95 (1H, s), 3.83 (3H, s) , 2.93 (2H, q), 1.21 (3H, t).

中間体Ａ−２４：¹H-NMR (CDCl₃) δ: 9.14 (1H, d), 8.69 (1H, d), 7.62 (1H, d), 7.09 (1H, d), 3.92 (3H, s), 2.98-2.93 (2H, m), 1.22 (3H, t). Reference Production Example 8-3
2-Chloro-1,3-bis (dimethylamino) trimethinium hexafluorophosphate is replaced by 2-trifluoromethyl-1,3-bis (dimethylamino) trimethinium hexafluorophosphate as described in Reference Production Example 8-1. The compound manufactured according to the method of, and its physical-property value are shown below.

Intermediate A-24: ¹ H-NMR (CDCl ₃ ) δ: 9.14 (1H, d), 8.69 (1H, d), 7.62 (1H, d), 7.09 (1H, d), 3.92 (3H, s) , 2.98-2.93 (2H, m), 1.22 (3H, t).

中間体Ｂ−１９：¹H-NMR (CDCl₃) δ: 9.16 (1H, d), 8.68 (1H, d), 8.17 (1H, s), 6.98 (1H, s), 3.85 (3H, s), 2.96 (2H, q), 1.22 (3H, t).

Intermediate B-19: ¹ H-NMR (CDCl ₃ ) δ: 9.16 (1 H, d), 8. 68 (1 H, d), 8. 17 ( ¹ H, s), 6. 98 (1 H, s), 3. 85 (3 H, s) , 2.96 (2H, q), 1.22 (3H, t).

中間体Ｃ−４：¹H-NMR (CDCl₃) δ: 9.15 (1H, d), 8.67 (1H, d), 8.29 (1H, s), 3.97 (3H, s), 3.02-2.99 (2H, m), 2.62 (3H, s), 1.23 (3H, t).

Intermediate C-4: ¹ H-NMR (CDCl ₃ ) δ: 9.15 (1H, d), 8.67 (1H, d), 8.29 (1H, s), 3.97 (3H, s), 3.02-2.99 (2H, 2) m), 2.62 (3H, s), 1.23 (3H, t).

中間体Ｂ−７：¹H-NMR (CDCl₃) δ: 8.93 (1H, dd), 8.45 (1H, dd), 8.16 (1H, s), 7.59 (1H, dd), 6.95 (1H, s), 3.83 (3H, s), 2.93 (2H, q), 1.19 (3H, t). Reference Production Example 9-1
To a mixture of 0.84 mL of DMF and 24 mL of chloroform was dropwise added 0.92 mL of oxalyl chloride under ice-cooling. The resulting mixture was stirred under ice-cooling for 15 minutes and then stirred at room temperature for 2 hours. The resulting mixture was ice-cooled again, and 2.8 mL of butyl vinyl ether was added and stirred for 1 hour. The resulting mixture was warmed to room temperature and stirred for 2 hours. To the resulting mixture was added sequentially 1.00 g of Intermediate B-6 and 3.5 mL of triethylamine under ice-cooling. The resulting mixture was stirred at room temperature for 3 hours, saturated aqueous ammonium chloride solution was added, and the mixture was extracted with chloroform. The resulting organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. 13 mL of ethanol and 1.4 mL of 30% aqueous ammonia were sequentially added to the obtained residue. The resulting mixture was stirred at 60 ° C. for 9 hours and then concentrated under reduced pressure. Water was added to the obtained residue, and extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The obtained residue was subjected to column chromatography to obtain 0.87 g of Intermediate B-7 represented by the following formula.

Intermediate B-7: ¹ H-NMR (CDCl ₃ ) δ: 8.93 (1 H, dd), 8.45 (1 H, dd), 8.16 (1 H, s), 7.59 (1 H, dd), 6.95 (1 H, s) , 3.83 (3H, s), 2.93 (2H, q), 1.19 (3H, t).

中間体Ａ−２７：¹H-NMR (CDCl₃) δ: 8.91 (1H, dd), 8.45 (1H, dd), 7.61 (1H, d), 7.57 (1H, dd), 7.06 (1H, d), 3.91 (3H, s), 2.96-2.88 (2H, m), 1.19 (3H, t). Reference Production Example 9-2
The compounds produced according to the method described in Reference Production Example 9-1 and the physical properties thereof are shown below.

Intermediate A-27: ¹ H-NMR (CDCl ₃ ) δ: 8.91 (1 H, dd), 8.45 (1 H, dd), 7.61 (1 H, d), 7.57 (1 H, dd), 7.06 (1 H, d) , 3.91 (3H, s), 2.96-2.88 (2H, m), 1.19 (3H, t).

中間体Ａ−２３：¹H-NMR (CDCl₃) δ: 9.13 (1H, d), 8.69 (1H, d), 7.51 (1H, d), 5.67 (1H, d), 4.51 (2H, t), 3.52 (3H, s), 3.49-3.43 (2H, m), 1.37 (12H, s), 1.34 (3H, t). Reference Production Example 10-1
0.45 g of the present compound A-18 (described in Preparation Example 1A), 0.37 g of bis (pinacolato) diboron, 0.09 g of tris (dibenzylideneacetone) dipalladium (0), 2-dicyclohexylphosphino-2 ′, A mixture of 0.14 g of 4 ′, 6′-triisopropylbiphenyl, 0.29 g of potassium acetate and 9 mL of 1,2-dimethoxyethane was stirred at 70 ° C. for 30 minutes under a nitrogen atmosphere. To the resulting mixture was added water at room temperature and extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained solid was washed with hexane to give 0.52 g of Intermediate A-23 represented by the following formula.

Intermediate A-23: ¹ H-NMR (CDCl ₃ ) δ: 9.13 (1H, d), 8.69 (1H, d), 7.51 (1H, d), 5.67 (1H, d), 4.51 (2H, t) , 3.52 (3H, s), 3.49-3.43 (2H, m), 1.37 (12H, s), 1.34 (3H, t).

中間体Ｂ−１８：¹H-NMR (CDCl₃) δ: 9.12 (1H, d), 8.69 (1H, d), 7.36 (1H, s), 5.86 (1H, s), 4.47 (2H, t), 3.59-3.55 (5H, m), 1.35-1.26 (15H, m). Reference Production Example 10-2
The compounds produced according to the method described in Reference Production Example 10-1 and the physical properties thereof are shown below.

Intermediate B-18: ¹ H-NMR (CDCl ₃ ) δ: 9.12 (1H, d), 8.69 (1H, d), 7.36 (1H, s), 5.86 (1H, s), 4.47 (2H, t) , 3.59-3.55 (5H, m), 1.35-1.26 (15H, m).

中間体Ａ−３０

Intermediate A-30

中間体Ｂ−２６：¹H-NMR (CDCl₃) δ: 7.66 (1H, s), 3.42 (3H, s), 3.33 (3H, s), 1.32 (12H, s).

Intermediate B-26: ¹ H-NMR (CDCl ₃ ) δ: 7.66 (1 H, s), 3.42 (3 H, s), 3.33 (3 H, s), 1.32 (12 H, s).

中間体Ａ−２８：¹H-NMR (CDCl₃) δ: 7.68 (1H, d), 5.46 (1H, d), 4.46 (2H, t), 3.55 (3H, s). Reference Production Example 11-1
To a mixture of 27.28 g of 3-bromo-6-chloro-1-methylpyridin-2 (1H) -one, 47.94 g of cesium carbonate and 100 mL of DMF under ice cooling, 2,2,3,3,3-pentafluoro 19.32 g of 1-propanol was added dropwise and stirred at room temperature for 3 hours. To the resulting mixture was added water and extracted with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was washed successively with water and hexane to give 39.41 g of Intermediate A-28 shown below.

Intermediate A-28: ¹ H-NMR (CDCl ₃ ) δ: 7.68 (1 H, d), 5.46 (1 H, d), 4.46 (2 H, t), 3.55 (3 H, s).

中間体Ａ−２９：¹H-NMR (CDCl₃) δ: 7.93 (1H, s), 4.85 (2H, t), 3.52 (3H, s). Reference Production Example 11-2
The compounds produced according to the method described in Reference Production Example 11-1 and the physical properties thereof are shown below.

Intermediate A-29: ¹ H-NMR (CDCl ₃ ) δ: 7.93 (1 H, s), 4.85 (2 H, t), 3.52 (3 H, s).

中間体Ａ−４１：¹H-NMR (CDCl₃) δ: 8.46 (1H, d), 7.91 (1H, d), 7.54 (1H, d), 7.43 (1H, t), 5.72 (1H, d), 4.52 (2H, t), 3.53 (3H, s), 3.11-3.06 (2H, m), 1.23 (3H, t).

Intermediate A-41: ¹ H-NMR (CDCl ₃ ) δ: 8.46 (1 H, d), 7. 91 (1 H, d), 7.54 (1 H, d), 7.43 (1 H, t), 5.72 (1 H, d) , 4.52 (2H, t), 3.53 (3H, s), 3.11-3.06 (2H, m), 1.23 (3H, t).

中間体Ａ−３１：¹H-NMR (CDCl₃) δ: 7.69 (1H, t), 7.51 (1H, dd), 7.44 (1H, d), 7.38 (1H, d), 5.65 (1H, d), 4.53 (2H, t), 3.57 (3H, s). Reference Production Example 12-1
2.0 g of intermediate A-28, 1.24 g of 2-fluoro-4- (trifluoromethyl) phenylboronic acid, [1,1′-bis (diphenylphosphino) ferrocene] dichloropalladium (II) dichloromethane adduct A mixture of 0.44 g, 3.79 g tripotassium phosphate, 15 mL 1,2-dimethoxyethane, and 1.5 mL water was stirred at 80 ° C. for 3 hours. The resulting mixture was allowed to cool to room temperature, water was added, and the mixture was extracted with ethyl acetate. The resulting organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography to obtain 0.53 g of Intermediate A-31 shown below.

Intermediate A-31: ¹ H-NMR (CDCl ₃ ) δ: 7.69 (1H, t), 7.51 (1H, dd), 7.44 (1H, d), 7.38 (1H, d), 5.65 (1H, d) , 4.53 (2H, t), 3.57 (3H, s).

中間体Ａ−３４：¹H-NMR (CDCl₃) δ: 7.84 (1H, d), 7.64 (1H, t), 7.47 (1H, d), 7.42 (1H, d), 4.93 (2H, t), 3.54 (3H, s). Reference Production Example 12-2
The compounds produced according to the method described in Reference Production Example 12-1 and the physical properties thereof are shown below.

Intermediate A-34: ¹ H-NMR (CDCl ₃ ) δ: 7.84 (1 H, d), 7. 64 (1 H, t), 7. 47 (1 H, d), 7.42 (1 H, d), 4. 93 (2 H, t) , 3.54 (3H, s).

中間体Ａ−３２：¹H-NMR (CDCl₃) δ: 7.54 (1H, s), 7.41 (1H, d), 7.36 (1H, d), 7.28 (1H, d), 6.12 (1H, d), 3.69 (3H, s), 3.03 (2H, q), 2.92 (2H, q), 1.46 (3H, t), 1.28 (3H, t). Reference Production Example 13-1
Under ice-cooling, 0.39 mL of ethanethiol was added dropwise to a mixture of 1.13 g of intermediate A-31, 0.23 g of sodium hydride (60% oily) and 10 mL of DMF, and the mixture was stirred at 60 ° C. for 9 hours. To the resulting mixture was added water and extracted with ethyl acetate. The resulting organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography to obtain 0.65 g of Intermediate A-32 shown below.

Intermediate A-32: ¹ H-NMR (CDCl ₃ ) δ: 7.54 (1H, s), 7.41 (1H, d), 7.36 (1H, d), 7.28 (1H, d), 6.12 (1H, d) , 3.69 (3H, s), 3.03 (2H, q), 2.92 (2H, q), 1.46 (3H, t), 1.28 (3H, t).

中間体Ａ−３５：¹H-NMR (CDCl₃) δ: 7.79 (1H, s), 7.57 (1H, s), 7.44 (1H, d), 7.34 (1H, d), 3.58 (3H, s), 3.26 (2H, q), 2.94 (2H, q), 1.44 (3H, t), 1.29 (3H, t). Reference Production Example 13-2
The compounds produced according to the method described in Reference Production Example 13-1 and the physical properties thereof are shown below.

Intermediate A-35: ¹ H-NMR (CDCl ₃ ) δ: 7.79 (1H, s), 7.57 (1H, s), 7.44 (1H, d), 7.34 (1H, d), 3.58 (3H, s) , 3.26 (2H, q), 2.94 (2H, q), 1.44 (3H, t), 1.29 (3H, t).

中間体Ａ−３３：¹H-NMR (CDCl₃) δ: 8.30 (1H, d), 7.94 (1H, dd), 7.46 (1H, d), 7.42 (1H, d), 7.24 (1H, d), 3.90 (3H, s), 3.40-3.34 (4H, m), 1.42 (3H, t), 1.34 (3H, t). Reference Production Example 14-1
To a mixture of 0.61 g of Intermediate A-32 and 30 mL of chloroform was added 1.63 g of mCPBA (purity 70%, 30% water) under ice-cooling, and stirred at 0 ° C. to room temperature for 25 hours. To the resulting mixture was added aqueous sodium thiosulfate solution, and the mixture was extracted with chloroform. The resulting organic layer was washed with saturated aqueous sodium hydrogen carbonate solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography to obtain 0.65 g of Intermediate A-33 shown below.

Intermediate A-33: ¹ H-NMR (CDCl ₃ ) δ: 8.30 (1H, d), 7.94 (1H, dd), 7.46 (1H, d), 7.42 (1H, d), 7.24 (1H, d) , 3.90 (3H, s), 3.40-3.34 (4H, m), 1.42 (3H, t), 1.34 (3H, t).

中間体Ａ−３６：¹H-NMR (CDCl₃) δ: 9.25 (1H, s), 8.36 (1H, d), 7.92 (1H, dd), 7.51 (1H, d), 7.34 (1H, d), 3.40 (3H, s), 3.25 (2H, q), 1.29 (3H, t). Reference Production Example 14-2
The compounds produced according to the method described in Reference Production Example 14-1 and the physical properties thereof are shown below.

Intermediate A-36: ¹ H-NMR (CDCl ₃ ) δ: 9.25 (1 H, s), 8. 36 ( ¹ H, d), 7. 92 (1 H, dd), 7.51 (1 H, d), 7.34 (1 H, d) , 3.40 (3H, s), 3.25 (2H, q), 1.29 (3H, t).

中間体Ａ−３８：¹H-NMR (CDCl₃) δ: 8.46 (1H, d), 7.96 (1H, d), 7.62 (1H, d), 7.48 (1H, t), 7.10 (1H, d), 3.93 (3H, s), 2.87-2.72 (2H, m), 1.17 (3H, t). Reference Production Example 15
A compound produced according to the method described in Reference Production Example 9-1 using hydroxylamine in place of 30% aqueous ammonia and the physical properties thereof are shown below.

Intermediate A-38: ¹ H-NMR (CDCl ₃ ) δ: 8.46 (1H, d), 7.96 (1H, d), 7.62 (1H, d), 7.48 (1H, t), 7.10 (1H, d) , 3.93 (3H, s), 2.87-2.72 (2H, m), 1.17 (3H, t).

中間体Ｃ−１：¹H-NMR (CDCl₃) δ: 8.82 (1H, s), 4.10 (3H, s), 3.89 (3H, s), 2.59 (3H, s). Reference Production Example 16
To a mixture of 8.38 g of 4-methoxy-2- (methylthio) pyrimidine-5-carboxylic acid and 90 mL of methanol was added 9 mL of thionyl chloride under ice-cooling, and the mixture was stirred at 85 ° C. for 3 hours. The resulting mixture was allowed to cool to room temperature and concentrated. To the obtained residue was added saturated aqueous sodium bicarbonate solution, and the mixture was extracted with ethyl acetate. The resulting organic layer was dried over anhydrous sodium sulfate and concentrated to give 4.18 g of Intermediate C-1 shown below.

Intermediate C-1: ¹ H-NMR (CDCl ₃ ) δ: 8.82 (1H, s), 4.10 (3H, s), 3.89 (3H, s), 2.59 (3H, s).

中間体Ｃ−５：¹H-NMR (CDCl₃) δ: 9.17 (1H, d), 8.66 (1H, d), 8.34 (1H, s), 4.01 (3H, s), 3.05-2.98 (2H, m), 1.26 (3H, t). Reference Production Example 17
A mixture of 0.52 mL of sulfuryl chloride and 32 mL of chloroform was added dropwise over 30 minutes to a mixture of 0.51 g of Intermediate C-4 and 26 mL of acetonitrile under ice-cooling. The resulting mixture was stirred under ice-cooling for 1 hour, then warmed to room temperature and stirred for 6 hours. To the resulting mixture was added saturated aqueous sodium bicarbonate solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated. The obtained residue was subjected to silica gel column chromatography to obtain 0.50 g of an intermediate C-5 shown below.

Intermediate C-5: ¹ H-NMR (CDCl ₃ ) δ: 9.17 (1H, d), 8.66 (1H, d), 8.34 (1H, s), 4.01 (3H, s), 3.05-2.98 (2H, 2H, s) m), 1.26 (3H, t).

本化合物Ａ−２：¹H-NMR (CDCl₃) δ: 8.44 (1H, dd), 7.68 (1H, dd), 7.51 (1H, d), 7.22 (1H, dd), 5.63 (1H, d), 4.51 (2H, t), 3.55 (3H, s), 2.88 (2H, q), 1.26 (3H, t). Production Example 1
To a mixture of 0.65 g of Intermediate A-4, 0.11 g of sodium hydride (60% oily) and 10 mL of DMF under ice cooling, 0.28 mL of 2,2,3,3,3-pentafluoro-1-propanol Was added dropwise and stirred at room temperature for 3.5 hours. To the mixture was added water and extracted with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography (methanol: ethyl acetate = 1: 19) to obtain 0.73 g of the present compound A-2 shown below.

Present compound A-2: ¹ H-NMR (CDCl ₃ ) δ: 8.44 (1 H, dd), 7.68 (1 H, dd), 7.51 (1 H, d), 7.22 (1 H, dd), 5.63 (1 H, d) , 4.51 (2H, t), 3.55 (3H, s), 2.88 (2H, q), 1.26 (3H, t).

で示される化合物において、Ｔ、Ｒ⁵、Ａ¹、Ｒ³、及びｎの組合せが［表１９］に記載のいずれかの組合せである化合物。 Production Example 1A
The compounds produced according to the method described in Production Example 1 and the physical properties thereof are shown below.
Formula (A-1):

In the compound shown by these, the compound whose combination of T, R ⁵ , A ¹ , R ³ and n is any combination described in [Table 19].

本化合物Ａ−４：¹H-NMR (CDCl₃) δ: 8.44 (1H, dd), 7.68 (1H, dd), 7.49 (1H, d), 7.22 (1H, dd), 5.60 (1H, d), 4.50 (2H, t), 4.22 (2H, q), 2.88 (2H, q), 1.28 (3H, t), 1.26 (3H, t).
本化合物Ａ−６：¹H-NMR (CDCl₃) δ: 8.86 (1H, d), 8.35 (1H, d), 7.52-7.47 (2H, m), 6.12-5.85 (1H, m), 5.70 (1H, d), 4.46 (2H, t), 3.52 (3H, s), 3.40 (2H, q), 1.29 (3H, t).
本化合物Ａ−７：¹H-NMR (CDCl₃) δ: 8.85 (1H, d), 8.34 (1H, d), 7.51-7.47 (2H, m), 5.69 (1H, d), 5.14-4.97 (1H, m), 4.94-4.38 (2H, m), 3.59-3.39 (5H, m), 1.29 (3H, t).
本化合物Ａ−８：¹H-NMR (CDCl₃) δ: 8.86 (1H, d), 8.34 (1H, d), 7.52-7.47 (2H, m), 5.68 (1H, d), 4.54 (2H, t), 3.52 (3H, s), 3.42 (2H, br), 1.29 (3H, t).
本化合物Ａ−９：¹H-NMR (CDCl₃) δ: 8.85 (1H, d), 8.34 (1H, d), 7.51-7.47 (2H, m), 5.67 (1H, d), 4.55 (2H, t), 3.52 (3H, s), 3.47-3.39 (2H, m), 1.29 (3H, t).
本化合物Ａ−１０：¹H-NMR (CDCl₃) δ: 8.85 (1H, d), 8.34 (1H, d), 7.49 (2H, d), 5.66 (1H, d), 4.54 (2H, t), 3.52 (3H, s), 3.47-3.39 (2H, m), 1.29 (3H, t).
本化合物Ａ−１１：¹H-NMR (CDCl₃) δ: 8.85 (1H, d), 8.35 (1H, d), 7.49 (2H, m), 5.71 (1H, d), 4.78 (1H, br), 3.51 (3H, s), 3.44 (2H, br), 1.59 (3H, d), 1.29 (3H, t).
本化合物Ａ−１７：¹H-NMR (CDCl₃) δ: 8.88 (1H, d), 8.36 (1H, d), 7.78 (1H, s), 7.56-7.54 (2H, m), 6.78 (1H, s), 6.41 (1H, d), 3.47 (2H, br), 3.35 (3H, s),1.34 (3H, t).
本化合物Ａ−１８：¹H-NMR (CDCl₃) δ: 8.80 (1H, d), 8.33 (1H, d), 7.50 (1H, d), 5.69 (1H, d), 4.52 (2H, t), 3.53 (3H, s), 3.50-3.44 (2H, m), 1.34 (3H, t).
本化合物Ａ−１９：¹H-NMR (CDCl₃) δ: 8.86 (1H, dd), 8.34 (1H, dd), 7.50 (1H, dd) , 7.49 (1H, d), 5.66 (1H, d), 4.50 (2H, dd), 4.09 (2H, t), 3.51-3.44 (2H, m), 1.74-1.65 (2H, m), 1.32 (3H, t), 0.96 (3H, t).
本化合物Ａ−２０：¹H-NMR (CDCl₃) δ: 8.86 (1H, dd), 8.35 (1H, dd), 7.49 (1H, dd), 7.44 (1H, d), 5.62 (2H, d), 4.50 (2H, t), 3.48-3.41 (2H, m), 1.52-1.50 (6H, m), 1.31 (3H, t).
本化合物Ａ−２１：¹H-NMR (CDCl₃) δ: 8.86 (1H, dd), 8.34 (1H, dd), 7.49 (1H, dd), 7.48 (1H, d), 5.65 (1H, d), 4.50 (2H, t), 4.12 (2H, t), 3.47 (2H, m), 1.67-1.61 (2H, m), 1.39-1.33 (5H, m), 0.94 (3H, t).
本化合物Ａ−２２：¹H-NMR (CDCl₃) δ: 8.86 (1H, dd), 8.34 (1H, dd), 7.51 (1H, d), 7.50 (1H, dd), 5.88 (1H, dddd), 5.68 (1H, d), 5.21-5.16 (2H, m), 4.81-4.68 (2H, m), 4.49 (2H, t), 3.50-3.44 (2H, m), 1.30 (3H, t).
本化合物Ａ−２３：¹H-NMR (CDCl₃) δ: 8.35 (1H, d), 7.88 (1H, dd), 7.46 (1H, d), 7.39 (1H, d), 5.67 (1H, d), 4.52 (2H, t), 3.54 (3H, s), 3.30 (2H, q), 1.27 (3H, t).
本化合物Ａ−２４：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.35 (1H, dd),
7.55-7.50 (2H, m), 5.71 (1H, d), 4.89 (2H, m), 4.56 (2H, t), 3.49-3.47 (2H, m), 2.17-2.15 (1H, m), 1.32 (3H, t).
本化合物Ａ−２５：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.35 (1H, dd), 7.52-7.48 (2H, m), 5.67 (1H, d), 4.52 (2H, t), 4.10-3.97 (2H, m), 3.50-3.43 (2H, m), 1.32 (3H, t), 1.26-1.21 (1H, m), 0.53-0.47 (2H, m), 0.44-0.39 (2H, m).
本化合物Ａ−２７：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.36 (1H, dd), 7.57 (1H, d), 7.53 (1H, dd), 5.74 (1H, d), 4.85 (2H, br), 4.54 (2H, t), 3.40 (2H, q), 1.31 (3H, t).
本化合物Ａ−３２：¹H-NMR (CDCl₃) δ: 8.85 (1H, dd), 8.32 (1H, dd), 7.49 (1H, dd), 7.47 (1H, d), 5.60 (1H, d), 4.48 (2H, t), 3.55-3.49 (2H, m), 2.81-2.75 (1H, m), 1.35 (3H, t), 1.24-1.20 (2H, m), 0.94-0.85 (2H, m).
本化合物Ａ−３９：¹H-NMR (CDCl₃) δ: 9.09 (1H, s), 8.57 (1H, s), 7.56 (1H, d), 5.72 (1H, d), 4.54 (2H, t), 3.54 (3H, s), 3.53 (2H, q), 1.36 (3H, t).
本化合物Ａ−４１：¹H-NMR (CDCl₃) δ: 8.88 (1H, dd), 8.36 (1H, dd), 7.55 (1H, s), 7.55-7.52 (2H, m), 5.71 (1H, d), 5.35 (2H, br, 4.55 (2H, t), 3.45 (2H, m), 1.35 (3H, t).
本化合物Ａ−４２：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.34 (1H, dd), 7.53 (1H, d), 7.50 (1H, dd), 7.35-7.23 (5H, m), 5.69 (1H, d), 5.43-5.25 (2H, m), 4.45 (2H, t), 3.41 (2H, q), 1.27 (3H, t).
本化合物Ａ−５５：¹H-NMR (CDCl₃) δ: 9.09 (1H, d), 8.57 (1H, d), 7.56 (1H, d), 6.01 (1H, tt), 5.74 (1H, d), 4.50 (2H, t), 3.56-3.50 (2H, m), 3.55 (3H, s), 1.35 (3H, t).
本化合物Ａ−５９：¹H-NMR (CDCl₃) δ: 9.09 (1H, d), 8.55 (1H, d), 7.54 (1H, d), 5.70 (1H, d), 4.53 (2H, t), 4.20 (2H, q), 3.58 (2H, q), 1.37 (3H, t), 1.28 (3H, t).
本化合物Ｃ−１：¹H-NMR (CDCl₃) δ: 8.84 (1H, d), 8.34 (1H, d), 7.47 (2H, d), 5.57 (1H, d), 4.04 (2H, br), 3.58 (3H, s), 3.42 (2H, br), 1.53 (2H, br), 1.29 (3H, t), 1.17 (2H, br).
本化合物Ｃ−２：¹H-NMR (CDCl₃) δ: 8.85 (1H, d), 8.35 (1H, d), 7.50-7.48 (2H, m), 5.65 (1H, d), 4.00 (2H, s), 3.57 (3H, s), 3.43 (2H, br), 1.58 (3H, s), 1.54 (3H, s), 1.29 (3H, t).
本化合物Ｃ−７：¹H-NMR (CDCl₃) δ: 8.80 (1H, d), 8.34 (1H, d), 7.50 (1H, d), 5.66 (1H, d), 4.02 (2H, s), 3.58 (3H, s), 3.51-3.44 (2H, m), 1.55 (3H, s), 1.55 (3H, s), 1.34 (3H, t).
本化合物Ｃ−８：¹H-NMR (CDCl₃) δ: 8.80 (1H, d), 8.34 (1H, d), 7.48 (1H, d), 5.59 (1H, d), 4.05 (2H, br), 3.59 (3H, s), 3.51-3.43 (2H, m), 1.54 (2H, dd), 1.33 (3H, t), 1.19 (2H, dd). [Table 19]

Present compound A-4: ¹ H-NMR (CDCl ₃ ) δ: 8.44 (1H, dd), 7.68 (1H, dd), 7.49 (1H, d), 7.22 (1H, dd), 5.60 (1H, d) , 4.50 (2H, t), 4.22 (2H, q), 2.88 (2H, q), 1.28 (3H, t), 1.26 (3H, t).
Present compound A-6: ¹ H-NMR (CDCl ₃ ) δ: 8.86 (1H, d), 8.35 (1H, d), 7.52-7.47 (2H, m), 6.12-5.85 (1H, m), 5.70 (5 1H, d), 4.46 (2H, t), 3.52 (3H, s), 3.40 (2H, q), 1.29 (3H, t).
Present compound A-7: ¹ H-NMR (CDCl ₃ ) δ: 8.85 (1H, d), 8.34 (1H, d), 7.51-7.47 (2H, m), 5.69 (1H, d), 5.14-4.97 ( 1H, m), 4.94-4.38 (2H, m), 3.59-3. 39 (5H, m), 1.29 (3H, t).
Present compound A-8: ¹ H-NMR (CDCl ₃ ) δ: 8.86 (1H, d), 8.34 (1H, d), 7.52-7.47 (2H, m), 5.68 (1H, d), 4.54 (2H, d) t), 3.52 (3H, s), 3.42 (2H, br), 1.29 (3H, t).
Present compound A-9: ¹ H-NMR (CDCl ₃ ) δ: 8.85 (1H, d), 8.34 (1H, d), 7.51-7.47 (2H, m), 5.67 (1H, d), 4.55 (2H, d) t), 3.52 (3H, s), 3.47-3. 39 (2H, m), 1.29 (3H, t).
Present compound A-10: ¹ H-NMR (CDCl ₃ ) δ: 8.85 (1 H, d), 8.34 (1 H, d), 7. 49 (2 H, d), 5. 66 (1 H, d), 4.54 (2 H, t) , 3.52 (3H, s), 3.47-3. 39 (2H, m), 1.29 (3H, t).
Present compound A-11: ¹ H-NMR (CDCl ₃ ) δ: 8.85 (1H, d), 8.35 (1H, d), 7.49 (2H, m), 5.71 (1H, d), 4.78 (1H, br) , 3.51 (3H, s), 3.44 (2H, br), 1.59 (3H, d), 1.29 (3H, t).
Present compound A-17: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1H, d), 8.36 (1H, d), 7.78 (1H, s), 7.56-7.54 (2H, m), 6.78 (1H, 1) s), 6.41 (1H, d), 3.47 (2H, br), 3.35 (3H, s), 1.34 (3H, t).
Present compound A-18: ¹ H-NMR (CDCl ₃ ) δ: 8.80 (1 H, d), 8.33 (1 H, d), 7. 50 (1 H, d), 5. 69 (1 H, d), 4.52 (2 H, t) , 3.53 (3H, s), 3.50-3.44 (2H, m), 1.34 (3H, t).
Present compound A-19: ¹ H-NMR (CDCl ₃ ) δ: 8.86 (1H, dd), 8.34 (1H, dd), 7.50 (1H, dd), 7.49 (1H, d), 5.66 (1H, d) , 4.50 (2H, dd), 4.09 (2H, t), 3.51-3.44 (2H, m), 1.74-1.65 (2H, m), 1.32 (3H, t), 0.96 (3H, t).
Present compound A-20: ¹ H-NMR (CDCl ₃ ) δ: 8.86 (1 H, dd), 8.35 (1 H, dd), 7.49 (1 H, dd), 7.44 (1 H, d), 5.62 (2 H, d) , 4.50 (2H, t), 3.48-3.41 (2H, m), 1.52-1.50 (6H, m), 1.31 (3H, t).
Present compound A-21: ¹ H-NMR (CDCl ₃ ) δ: 8.86 (1 H, dd), 8.34 (1 H, dd), 7.49 (1 H, dd), 7.48 (1 H, d), 5.65 (1 H, d) , 4.50 (2H, t), 4.12 (2H, t), 3.47 (2H, m), 1.67-1.61 (2H, m), 1.39- 1.33 (5H, m), 0.94 (3H, t).
Present compound A-22: ¹ H-NMR (CDCl ₃ ) δ: 8.86 (1H, dd), 8.34 (1H, dd), 7.51 (1H, d), 7.50 (1H, dd), 5.88 (1H, dddd) , 5.68 (1H, d), 5.21-5.16 (2H, m), 4.81-4.68 (2H, m), 4.49 (2H, t), 3.50-3.44 (2H, m), 1.30 (3H, t).
Present compound A-23: ¹ H-NMR (CDCl ₃ ) δ: 8.35 (1H, d), 7.88 (1H, dd), 7.46 (1H, d), 7.39 (1H, d), 5.67 (1H, d) , 4.52 (2H, t), 3.54 (3H, s), 3.30 (2H, q), 1.27 (3H, t).
Present compound A-24: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.35 (1 H, dd),
7.55-7.50 (2H, m), 5.71 (1H, d), 4.89 (2H, m), 4.56 (2H, t), 3.49-3.47 (2H, m), 2.17-2.15 (1 H, m), 1.32 ( 3H, t).
Present compound A-25: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1H, dd), 8.35 (1H, dd), 7.52-7.48 (2H, m), 5.67 (1H, d), 4.52 (2H, d) t), 4.10-3.97 (2H, m), 3.50-3.43 (2H, m), 1.32 (3H, t), 1.26-1.21 (1H, m), 0.53-0.47 (2H, m), 0.44-0.39 ( 2H, m).
Present compound A-27: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1H, dd), 8.36 (1H, dd), 7.57 (1H, d), 7.53 (1H, dd), 5.74 (1H, d) , 4.85 (2H, br), 4.54 (2H, t), 3.40 (2H, q), 1.31 (3H, t).
Present compound A-32: ¹ H-NMR (CDCl ₃ ) δ: 8.85 (1 H, dd), 8.32 (1 H, dd), 7.49 (1 H, dd), 7.47 (1 H, d), 5.60 (1 H, d) , 4.48 (2H, t), 3.55-3.49 (2H, m), 2.81-2.75 (1H, m), 1.35 (3H, t), 1.24-1.20 (2H, m), 0.94-0.85 (2H, m) .
Present compound A-39: ¹ H-NMR (CDCl ₃ ) δ: 9.09 (1H, s), 8.57 (1H, s), 7.56 (1H, d), 5.72 (1H, d), 4.54 (2H, t) , 3.54 (3H, s), 3.53 (2H, q), 1.36 (3H, t).
Present compound A-41: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1 H, dd), 8.36 (1 H, dd), 7.55 (1 H, s), 7.55 to 7.52 (2 H, m), 5.71 (1 H, d), 5.35 (2H, br, 4.55 (2H, t), 3.45 (2H, m), 1.35 (3H, t).
Present compound A-42: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.34 (1 H, dd), 7.53 (1 H, d), 7.50 (1 H, dd), 7.35-7.23 (5 H, m), 5.69 (1H, d), 5.43-5.25 (2H, m), 4.45 (2H, t), 3.41 (2H, q), 1.27 (3H, t).
Present compound A-55: ¹ H-NMR (CDCl ₃ ) δ: 9.09 (1H, d), 8.57 (1H, d), 7.56 (1H, d), 6.01 (1H, tt), 5.74 (1H, d) , 4.50 (2H, t), 3.56-3.50 (2H, m), 3.55 (3H, s), 1.35 (3H, t).
Present compound A-59: ¹ H-NMR (CDCl ₃ ) δ: 9.09 (1H, d), 8.55 (1H, d), 7.54 (1H, d), 5.70 (1H, d), 4.53 (2H, t) , 4.20 (2H, q), 3.58 (2H, q), 1.37 (3H, t), 1.28 (3H, t).
The present compound C-1: ¹ H-NMR (CDCl ₃ ) δ: 8.84 (1H, d), 8.34 (1H, d), 7.47 (2H, d), 5.57 (1H, d), 4.04 (2H, br) , 3.58 (3H, s), 3.42 (2H, br), 1.53 (2H, br), 1.29 (3H, t), 1.17 (2H, br).
The present compound C-2: ¹ H-NMR (CDCl ₃ ) δ: 8.85 ( ¹ H, d), 8. 35 (1 H, d), 7.50-1.48 (2 H, m), 5. 65 (1 H, d), 4.00 (2 H, s), 3.57 (3H, s), 3.43 (2H, br), 1.58 (3H, s), 1.54 (3H, s), 1.29 (3H, t).
Present compound C-7: ¹ H-NMR (CDCl ₃ ) δ: 8.80 (1 H, d), 8.34 (1 H, d), 7. 50 (1 H, d), 5. 66 (1 H, d), 4.02 (2 H, s) , 3.58 (3H, s), 3.51-3.44 (2H, m), 1.55 (3H, s), 1.55 (3H, s), 1.34 (3H, t).
The present compound C-8: ¹ H-NMR (CDCl ₃ ) δ: 8.80 (1 H, d), 8.34 (1 H, d), 7. 48 (1 H, d), 5. 59 (1 H, d), 4.05 (2 H, br) , 3.59 (3H, s), 3.51-3.43 (2H, m), 1.54 (2H, dd), 1.33 (3H, t), 1.19 (2H, dd).

本化合物Ａ−５３：¹H-NMR (CDCl₃) δ: 7.94 (1H, d), 7.38 (1H, d), 6.79 (1H, d), 5.60 (1H, d), 4.47 (2H, t), 3.49 (3H, s), 3.47-3.27 (2H, m), 3.17 (6H, s), 1.26 (3H, t).

Present compound A-53: ¹ H-NMR (CDCl ₃ ) δ: 7.94 (1H, d), 7.38 (1H, d), 6.79 (1H, d), 5.60 (1H, d), 4.47 (2H, t) , 3.49 (3H, s), 3.47-3.27 (2H, m), 3.17 (6H, s), 1.26 (3H, t).

本化合物Ａ−５０：¹H-NMR (CDCl₃) δ: 8.42 (1H, d), 7.58 (1H, d), 6.91 (1H, d), 5.60 (1H, d), 4.48 (2H, t), 3.52 (3H, s), 3.27-3.25 (2H, m), 3.05 (6H, s), 1.03 (3H, t).

Present compound A-50: ¹ H-NMR (CDCl ₃ ) δ: 8.42 (1H, d), 7.58 (1H, d), 6.91 (1H, d), 5.60 (1H, d), 4.48 (2H, t) , 3.52 (3H, s), 3.27-3.25 (2H, m), 3.05 (6H, s), 1.03 (3H, t).

で示される化合物において、Ｔ、Ｒ⁵、Ａ¹、Ｒ³、及びｎの組合せが［表２０］に記載のいずれかの組合せである化合物。 Formula (B-1):

In the compound shown by these, the compound whose combination of T, R ⁵ , A ¹ , R ³ and n is any combination described in [Table 20].

本化合物Ｂ−１：¹H-NMR (CDCl₃) δ: 8.86 (1H, dd), 8.36 (1H, dd), 7.51 (1H, dd), 7.36 (1H, s), 5.88 (1H, s), 4.49 (2H, t), 3.60-3.48 (5H, m), 1.33 (3H, t).
本化合物Ｂ−２：¹H-NMR (CDCl₃) δ: 9.09 (1H, d), 8.57 (1H, d), 7.40 (1H, s), 5.89 (1H, s), 4.50 (2H, t), 3.63-3.58 (2H, m), 3.60 (3H, s), 1.37 (3H, t).
本化合物Ｂ−４：¹H-NMR (CDCl₃) δ: 8.88 (1H, dd), 8.38 (1H, dd), 7.51 (1H, dd), 7.38 (1H, s), 5.87 (1H, s), 4.49 (2H, t), 3.94 (2H, q), 3.52-3.42 (2H, m), 1.40 (3H, t), 1.31 (3H, t).
本化合物Ｂ−５：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.37 (1H, dd), 7.51 (1H, dd), 7.36 (1H, s), 5.87 (1H, s), 4.48 (2H, t), 3.91-3.79 (2H, m), 3.54-3.40 (2H, m), 1.83-1.74 (2H, m), 1.31 (3H, t), 0.96 (3H, t).
本化合物Ｂ−６：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.37 (1H, dd), 7.51 (1H, dd), 7.36 (1H, s), 5.87 (1H, s), 4.49 (2H, t), 3.94-3.80 (2H, m), 3.53-3.39 (2H, m), 1.77-1.70 (2H, m), 1.42-1.34 (2H, m), 1.30 (3H, t), 0.95 (3H, t).
本化合物Ｂ−７：¹H-NMR (CDCl₃) δ: 8.80 (1H, d), 8.34 (1H, d), 7.35 (1H, s), 5.86 (1H, s), 4.48 (2H, t), 3.57 (3H, s), 3.59-3.52 (2H, m), 1.35 (3H, t).
本化合物Ｂ−８：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.36 (1H, dd), 7.51 (1H, dd), 7.36 (1H, s), 5.90 (1H, ddt), 5.88 (1H, s), 5.32 (1H, d), 5.24 (1H, d), 4.48 (2H, t), 4.48 (2H, d), 3.53-3.44 (2H, m), 1.32 (3H, t).
本化合物Ｂ−９：¹H-NMR (CDCl₃) δ: 8.88 (1H, dd), 8.38 (1H, dd), 7.51 (1H, dd), 7.46 (1H, s), 5.88 (1H, s), 4.49 (2H, t), 3.81-3.69 (2H, m), 3.52-3.40 (2H, m), 1.31 (3H, t), 1.26-1.16 (1H, m), 0.69-0.64 (2H, m), 0.39-0.35 (2H, m).
本化合物Ｂ−１０：¹H-NMR (CDCl₃) δ: 8.89 (1H, dd), 8.40 (1H, dd), 7.52 (1H, dd), 7.51 (1H, s), 5.88 (1H, s), 4.81-4.74 (1H, m), 4.50 (2H, t), 3.43-3.35 (2H, m), 1.45 (6H, d), 1.28 (3H, t).
本化合物Ｂ−１１：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.37 (1H, dd), 7.51 (1H, dd), 7.48 (1H, s), 7.39-7.32 (3H, m), 7.25-7.22 (2H, m), 5.89 (1H, s), 5.05 (2H, s), 4.42 (2H, t), 3.53-3.41 (2H, m), 1.31 (3H, t).
本化合物Ｂ−１２：¹H-NMR (CDCl₃) δ: 8.88 (1H, dd), 8.37 (1H, dd), 7.53 (1H, dd), 7.37 (1H, s), 5.89 (1H, s), 4.51 (2H, t), 4.21-4.06 (2H, m), 3.46-3.39 (2H, m), 2.66-2.55 (2H, m), 1.30 (3H, t). [Table 20]

The present compound B-1: ¹ H-NMR (CDCl ₃ ) δ: 8.86 (1H, dd), 8.36 (1H, dd), 7.51 (1H, dd), 7.36 (1H, s), 5.88 (1H, s) , 4.49 (2H, t), 3.60-3.48 (5H, m), 1.33 (3H, t).
Present compound B-2: ¹ H-NMR (CDCl ₃ ) δ: 9.09 (1 H, d), 8. 57 (1 H, d), 7. 40 (1 H, s), 5. 89 (1 H, s), 4.50 (2 H, t) , 3.63-3.58 (2H, m), 3.60 (3H, s), 1.37 (3H, t).
Present compound B-4: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1 H, dd), 8.38 (1 H, dd), 7.51 (1 H, dd), 7.38 (1 H, s), 5.87 (1 H, s) , 4.49 (2H, t), 3.94 (2H, q), 3.52-3.42 (2H, m), 1.40 (3H, t), 1.31 (3H, t).
Present compound B-5: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.37 (1 H, dd), 7.51 (1 H, dd), 7.36 (1 H, s), 5.87 (1 H, s) , 4.48 (2H, t), 3.91-3.79 (2H, m), 3.54-3.40 (2H, m), 1.83-1.74 (2H, m), 1.31 (3H, t), 0.96 (3H, t).
Present compound B-6: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.37 (1 H, dd), 7.51 (1 H, dd), 7.36 (1 H, s), 5.87 (1 H, s) , 4.49 (2H, t), 3.94-3.80 (2H, m), 3.53-3.39 (2H, m), 1.77-1.70 (2H, m), 1.42-1.34 (2H, m), 1.30 (3H, t) , 0.95 (3H, t).
Present compound B-7: ¹ H-NMR (CDCl ₃ ) δ: 8.80 (1 H, d), 8.34 (1 H, d), 7. 35 (1 H, s), 5. 86 (1 H, s), 4. 48 (2 H, t) , 3.57 (3H, s), 3.59-3.52 (2H, m), 1.35 (3H, t).
Present compound B-8: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1H, dd), 8.36 (1H, dd), 7.51 (1H, dd), 7.36 (1H, s), 5.90 (1H, ddt) , 5.88 (1H, s), 5.32 (1H, d), 5.24 (1H, d), 4.48 (2H, t), 4.48 (2H, d), 3.53-3.44 (2H, m), 1.32 (3H, t) ).
Present compound B-9: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1H, dd), 8.38 (1H, dd), 7.51 (1H, dd), 7.46 (1H, s), 5.88 (1H, s) , 4.49 (2H, t), 3.81-3.69 (2H, m), 3.52-3.40 (2H, m), 1.31 (3H, t), 1.26-1.16 (1H, m), 0.69-0.64 (2H, m) , 0.39-0.35 (2H, m).
Present compound B-10: ¹ H-NMR (CDCl ₃ ) δ: 8.89 (1 H, dd), 8.40 (1 H, dd), 7.52 (1 H, dd), 7.51 (1 H, s), 5. 88 (1 H, s) , 4.81-4.74 (1H, m), 4.50 (2H, t), 3.43-3.35 (2H, m), 1.45 (6H, d), 1.28 (3H, t).
Present compound B-11: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1H, dd), 8.37 (1H, dd), 7.51 (1H, dd), 7.48 (1H, s), 7.39-7.32 (3H, m), 7.25-7.22 (2H, m), 5.89 (1H, s), 5.05 (2H, s), 4.42 (2H, t), 3.53-3.41 (2H, m), 1.31 (3H, t).
Present compound B-12: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1 H, dd), 8.37 (1 H, dd), 7.53 (1 H, dd), 7.37 (1 H, s), 5. 89 (1 H, s) , 4.51 (2H, t), 4.21-4.06 (2H, m), 3.46-3.39 (2H, m), 2.66-2.55 (2H, m), 1.30 (3H, t).

本化合物Ａ−１：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.36 (1H, dd), 7.51 (1H, dd), 7.51 (1H, d), 5.69 (1H, d), 4.52 (2H, t), 3.53 (3H, s), 3.47-3.41 (2H, m), 1.31 (3H, t). Production Example 2
The present compound A-1 shown below was obtained according to the method described in Reference Production Example 2-3 using the present compound A-2 instead of the intermediate B-2.

The present compound A-1: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.36 (1 H, dd), 7.51 (1 H, dd), 7.51 (1 H, d), 5.69 (1 H, d) , 4.52 (2H, t), 3.53 (3H, s), 3.47-3.41 (2H, m), 1.31 (3H, t).

本化合物Ａ−５：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.34 (1H, dd), 7.50-7.49 (2H, m), 5.66 (1H, d), 4.51 (2H, t), 4.21-4.18 (2H, m), 3.53-3.45 (2H, m), 1.32 (3H, t), 1.27 (3H, t). Production Example 2A
The compounds produced according to the method described in Production Example 2 and the physical properties thereof are shown below.

Present compound A-5: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.34 (1 H, dd), 7.50 to 7.49 (2 H, m), 5. 66 (1 H, d), 4.51 (2 H, t), 4.21-4.18 (2H, m), 3.53-3.45 (2H, m), 1.32 (3H, t), 1.27 (3H, t).

本化合物Ａ−３４：¹H-NMR (CDCl₃) δ: 8.89 (1H, dd), 8.36 (1H, dd), 7.81 (1H, s), 7.55 (1H, dd), 4.92 (2H, br), 3.51 (3H, s), 3.42 (2H, q), 1.33 (3H, t).

Present compound A-34: ¹ H-NMR (CDCl ₃ ) δ: 8.89 (1H, dd), 8.36 (1H, dd), 7.81 (1H, s), 7.55 (1H, dd), 4.92 (2H, br) , 3.51 (3H, s), 3.42 (2H, q), 1.33 (3H, t).

本化合物Ａ−３：¹H-NMR (CDCl₃) δ: 8.73 (1H, dd), 8.35 (1H, dd), 7.69 (1H, d, J = 8.2 Hz), 7.50 (1H, dd), 5.73 (1H, d), 4.55 (2H, t), 3.54 (3H, s), 3.38-3.31 (1H, m), 2.89-2.86 (1H, m), 1.40 (3H, t). Production Example 3
Under ice-cooling, 0.06 g of mCPBA (purity 70%) was added to a mixture of 0.1 g of the present compound A-2 and chloroform, and the mixture was stirred at 0 ° C to room temperature for 3 hours. To this mixture was added aqueous sodium thiosulfate solution, and the mixture was extracted with chloroform. The obtained organic layer was washed with saturated aqueous sodium hydrogen carbonate solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel column chromatography (methanol: ethyl acetate = 1: 19) to obtain 0.08 g of the present compound A-3 shown below.

Present compound A-3: ¹ H-NMR (CDCl ₃ ) δ: 8.73 (1 H, dd), 8.35 (1 H, dd), 7.69 (1 H, d, J = 8.2 Hz), 7.50 (1 H, dd), 5.73 (1H, d), 4.55 (2H, t), 3.54 (3H, s), 3.38-3.31 (1H, m), 2.89-2.86 (1H, m), 1.40 (3H, t).

本化合物Ａ−３３：¹H-NMR (CDCl₃) δ: 8.76 (1H, dd), 8.38 (1H, dd), 7.97 (1H, s), 7.55 (1H, dd), 4.99-4.91 (2H, m), 3.52 (3H, s), 3.27-3.23 (1H, m), 2.87-2.83 (1H, m), 1.37 (3H, t). Production Example 3A
The compounds produced according to the method described in Production Example 3 and the physical properties thereof are shown below.

Present compound A-33: ¹ H-NMR (CDCl ₃ ) δ: 8.76 (1H, dd), 8.38 (1H, dd), 7.97 (1H, s), 7.55 (1H, dd), 4.99-4.91 (2H, m), 3.52 (3H, s), 3.27-3.23 (1H, m), 2.87-2.83 (1H, m), 1.37 (3H, t).

本化合物Ａ−２８：¹H-NMR (CDCl₃) δ: 8.63 (1H, d), 7.94 (1H, d), 7.47 (1H, d), 5.67 (1H, d), 4.54-4.48 (2H, m), 3.52 (3H, s), 3.41-3.35 (2H, m), 2.06-1.99 (1H, m), 1.29 (3H, t), 1.16-1.13 (2H, m), 0.87-0.82 (2H, m). Production Example 4-1
0.1 g of the present compound A-18, 56 mg of cyclopropylboronic acid, 32 mg of [1,1′-bis (diphenylphosphino) ferrocene] dichloropalladium (II) dichloromethane adduct, 0.23 g of tripotassium phosphate, toluene 1 A mixture of .5 mL and 0.4 mL water was stirred at 100.degree. C. for 2 hours. The resulting mixture was allowed to cool to room temperature, water was added, and the mixture was extracted with ethyl acetate. The resulting organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was subjected to silica gel chromatography (ethyl acetate: hexane = 3: 1) to obtain 89 mg of the present compound A-28 shown below.

Present compound A-28: ¹ H-NMR (CDCl ₃ ) δ: 8.63 (1H, d), 7.94 (1H, d), 7.47 (1H, d), 5.67 (1H, d), 4.54-4.48 (2H, 2H, d) m), 3.52 (3H, s), 3.41-3.35 (2H, m), 2.06-1.99 (1H, m), 1.29 (3H, t), 1.16-1.13 (2H, m), 0.87-0.82 (2H, 2) m).

本化合物Ａ−２９：¹H-NMR (CDCl₃) δ: 9.03 (1H, d), 8.48 (1H, d), 7.65-7.61 (2H, m), 7.56 (1H, d), 7.23 (2H, dd), 5.71 (1H, d), 4.53 (2H, t), 3.55 (3H, s), 3.50-3.43 (2H, m), 1.34 (3H, t). Production Example 4-2
The compounds produced according to the method described in Production Example 4-1 and the physical properties thereof are shown below.

Present compound A-29: ¹ H-NMR (CDCl ₃ ) δ: 9.03 (1H, d), 8.48 (1H, d), 7.65-7.61 (2H, m), 7.56 (1H, d), 7.23 (2H, d) dd), 5.71 (1 H, d), 4.53 (2 H, t), 3.55 (3 H, s), 3.50-3.43 (2 H, m), 1.34 (3 H, t).

本化合物Ｂ−３：¹H-NMR (CDCl₃) δ: 8.62 (1H, d), 7.94 (1H, d), 7.33 (1H, s), 5.89 (1H, s), 4.48 (2H, t), 3.56 (3H, s), 3.48 (2H, q), 2.04-2.00 (1H, m), 1.31 (3H, t), 1.16-1.14 (2H, m), 0.86-0.81 (2H, m).

Present compound B-3: ¹ H-NMR (CDCl ₃ ) δ: 8.62 (1H, d), 7.94 (1H, d), 7.33 (1H, s), 5.89 (1H, s), 4.48 (2H, t) , 3.56 (3H, s), 3.48 (2H, q), 2.04-2.00 (1H, m), 1.31 (3H, t), 1.16-1.14 (2H, m), 0.86-0.81 (2H, m).

本化合物Ａ−３１：¹H-NMR (CDCl₃) δ: 9.50 (1H, d), 9.02 (1H, dd), 8.99 (1H, d), 8.13 (1H, dd), 7.99 (1H, dd), 7.59 (1H, d), 5.72 (1H, d), 4.54 (2H, t), 3.56-3.50 (2H, m), 3.55 (3H, s), 1.37 (3H, t).

Present compound A-31: ¹ H-NMR (CDCl ₃ ) δ: 9.50 (1H, d), 9.02 (1H, dd), 8.99 (1H, d), 8.13 (1H, dd), 7.99 (1H, dd) , 7.59 (1H, d), 5.72 (1H, d), 4.54 (2H, t), 3.56-3.50 (2H, m), 3.55 (3H, s), 1.37 (3H, t).

本化合物Ａ−４４ Production Example 4-3
A compound produced by using the present compound A-47 instead of the present compound A-18 according to the method described in Production Example 4-1 and physical property values thereof are shown below.

Present compound A-44

本化合物Ａ−４５：¹H-NMR (CDCl₃) δ: 8.34 (1H, d), 8.06-8.02 (2H, m), 7.82 (1H, d), 7.53 (1H, d), 7.14 (2H, t), 5.68 (1H, d), 4.51 (2H, t), 3.53 (3H,m), 3.48-3.44 (2H, m), 1.19 (3H, t).

Present compound A-45: ¹ H-NMR (CDCl ₃ ) δ: 8.34 (1H, d), 8.06-8.02 (2H, m), 7.82 (1H, d), 7.53 (1H, d), 7.14 (2H, d) t), 5.68 (1H, d), 4.51 (2H, t), 3.53 (3H, m), 3.48-3.44 (2H, m), 1.19 (3H, t).

本化合物Ａ−４３：¹H-NMR (CDCl₃) δ: 9.35 (1H, s), 8.10 (1H, d), 7.60 (1H, d), 7.55 (1H, d), 5.79 (1H, d), 4.55 (2H, t), 3.62 (3H, s), 3.24-3.14 (2H, m), 1.32 (3H, t). Production Example 5-1
A mixture of 1.68 g of intermediate A-23, 1.87 g of sodium acetate, 12 mL of THF, 0.4 mL of 30% aqueous hydrogen peroxide and 6 mL of water was stirred at 0 ° C. for 1 hour. To the resulting mixture, 3 mL of saturated sodium thiosulfate was added and stirred for 1 hour. To the resulting mixture was added saturated aqueous ammonium chloride solution at room temperature, and the mixture was extracted with chloroform. The resulting organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography (ethyl acetate) to obtain 0.94 g of the present compound A-43 represented by the following formula.

Present compound A-43: ¹ H-NMR (CDCl ₃ ) δ: 9.35 (1 H, s), 8. 10 (1 H, d), 7. 60 (1 H, d), 7.55 (1 H, d), 5. 79 (1 H, d) , 4.55 (2H, t), 3.62 (3H, s), 3.24-3.14 (2H, m), 1.32 (3H, t).

本化合物Ａ−４０：¹H-NMR (CDCl₃) δ: 8.75 (1H, d), 8.20 (1H, dd), 8.17-8.16 (1H, m), 7.81-7.76 (1H, m), 7.53 (1H, d), 7.10 (1H, dd), 7.07 (1H, d), 5.68 (1H, d), 4.52 (2H, t), 3.58-3.36 (2H, m), 3.54 (3H, s), 1.33 (3H, t). Production Example 6
A mixture of 0.25 g of the present compound A-43, 0.17 g of 2-iodopyridine, 0.02 g of copper (I) iodide, 0.04 g of 1-butylimidazole, 0.16 g of potassium carbonate and 3 mL of toluene under reflux 7 Stir for hours. The resulting mixture was allowed to cool to room temperature, then filtered through Celite (registered trademark), and the filtrate was concentrated. The resulting residue was subjected to silica gel chromatography (ethyl acetate: hexane = 1: 2) to obtain 0.08 g of the present compound A-40 represented by the following formula.

Present compound A-40: ¹ H-NMR (CDCl ₃ ) δ: 8.75 (1H, d), 8.20 (1H, dd), 8.17-8.16 (1H, m), 7.81-7.76 (1H, m), 7.53 (7.51 1H, d), 7.10 (1H, dd), 7.07 (1H, d), 5.68 (1H, d), 4.52 (2H, t), 3.58-3.36 (2H, m), 3.54 (3H, s), 1.33 (3H, t).

本化合物Ａ−３５：¹H-NMR (CDCl₃) δ: 8.53 (1H, d), 7.81 (1H, d), 7.47 (1H, d), 5.66 (1H, d), 4.50 (2H, t), 4.21-4.15 (2H, m), 3.52 (3H, s), 3.43-3.34 (2H, m), 1.49 (3H, t), 1.30 (3H, t). Production Example 7-1
Under ice-cooling, 49 μL of iodoethane was added to a mixture of 180 mg of the present compound A- 43, 199 mg of cesium carbonate and 1 mL of DMF, and the mixture was stirred at room temperature for 4 hours. Water was added to the obtained mixture, and the precipitated solid was filtered, and the obtained solid was washed with water and then dried under reduced pressure to obtain 150 mg of the present compound A-35 shown below.

Present compound A-35: ¹ H-NMR (CDCl ₃ ) δ: 8.53 (1H, d), 7.81 (1H, d), 7.47 (1H, d), 5.66 (1H, d), 4.50 (2H, t) , 4.21-4.15 (2H, m), 3.52 (3H, s), 3.43-3.34 (2H, m), 1.49 (3H, t), 1.30 (3H, t).

本化合物Ａ−３６：¹H-NMR (CDCl₃) δ: 8.53 (1H, d), 7.81 (1H, d), 7.47 (1H, d), 5.65 (1H, d), 4.50 (2H, t), 4.09-4.04 (2H, m), 3.52 (3H, s), 3.43-3.35 (2H, m), 1.92-1.83 (2H, m), 1.31 (3H, t), 1.08 (3H, t). Production Example 7-2
The compounds produced according to the method described in Production Example 7-1 and the physical properties thereof are shown below.

Present compound A-36: ¹ H-NMR (CDCl ₃ ) δ: 8.53 (1H, d), 7.81 (1H, d), 7.47 (1H, d), 5.65 (1H, d), 4.50 (2H, t) , 4.09-4.04 (2H, m), 3.52 (3H, s), 3.43-3.35 (2H, m), 1.92-1.83 (2H, m), 1.31 (3H, t), 1.08 (3H, t).

本化合物Ａ−３７：¹H-NMR (CDCl₃) δ: 8.49 (1H, d), 7.79 (1H, d), 7.47 (1H, d), 5.65 (1H, d), 4.72-4.66 (1H, m), 4.50 (2H, t), 3.53 (3H, s), 3.44-3.34 (2H, m), 1.41 (6H, br), 1.30 (3H, t).

Present compound A-37: ¹ H-NMR (CDCl ₃ ) δ: 8.49 (1H, d), 7.79 (1H, d), 7.47 (1H, d), 5.65 (1H, d), 4.72-4.66 (1H, 1H, d) m), 4.50 (2H, t), 3.53 (3H, s), 3.44-3.34 (2H, m), 1.41 (6H, br), 1.30 (3H, t).

本化合物Ａ−３８：¹H-NMR (CDCl₃) δ: 8.62 (1H, d), 7.90 (1H, d), 7.48 (1H, d), 5.68 (1H, d), 4.59 (2H, t), 4.52 (2H, t), 3.53 (3H, s), 3.42 (2H, q), 1.32 (3H, t).

Present compound A-38: ¹ H-NMR (CDCl ₃ ) δ: 8.62 (1H, d), 7.90 (1H, d), 7.48 (1H, d), 5.68 (1H, d), 4.59 (2H, t) , 4.52 (2H, t), 3.53 (3H, s), 3.42 (2H, q), 1.32 (3H, t).

本化合物Ａ−１２：¹H-NMR (CDCl₃) δ: 8.88 (1H, d), 8.34 (1H, d), 7.57-7.50 (2H, m), 6.74 (1H, d), 3.64 (3H, s), 3.46-3.37 (2H, m), 1.29 (3H, t). Production Example 8-1
A mixture of 700 mg of intermediate A-37, 285 mg of copper powder, 2.65 g of heptafluoropropyl iodide and 10 mL of DMSO was stirred at 140 ° C. for 16 and a half hours in a closed vessel. The resulting mixture was cooled to room temperature, ethyl acetate was added and filtered through Celite®. The obtained filtrate was extracted with ethyl acetate and water. The resulting organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The resulting residue was subjected to silica gel chromatography (ethyl acetate: hexane = 2: 3) to give 437 mg of the present compound A-12 represented by the following formula.

Present compound A-12: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1H, d), 8.34 (1H, d), 7.57-7.50 (2H, m), 6.74 (1H, d), 3.64 (3H, d) s), 3.46-3.37 (2H, m), 1.29 (3H, t).

本化合物Ａ−１３：¹H-NMR (CDCl₃) δ: 8.88 (1H, d), 8.34 (1H, d), 7.57-7.51 (2H, m), 6.77 (1H, d), 3.64 (3H, s), 3.46-3.42 (2H, m), 1.33 (3H, t). Production Example 8-2
The compounds produced according to the method described in Production Example 8-1 and the physical properties thereof are shown below.

Present compound A-13: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1H, d), 8.34 (1H, d), 7.57-7.51 (2H, m), 6.77 (1H, d), 3.64 (3H, d) s), 3.46-3.42 (2H, m), 1.33 (3H, t).

本化合物Ａ−１４：¹H-NMR (CDCl₃) δ: 8.89-8.83 (2H, m), 8.36 (1H, d), 7.97 (1H, d), 7.85 (1H, d), 7.55-7.54 (2H, m), 6.30 (1H, d), 3.58-3.42 (5H, m), 1.35 (3H, t). Production Example 9
A compound produced according to the method described in Production Example 4-1 using Intermediate A-37 instead of the present compound A-18, and physical properties thereof are shown below.

Present compound A-14: ¹ H-NMR (CDCl ₃ ) δ: 8.89-8.83 (2H, m), 8.36 (1H, d), 7.97 (1H, d), 7.85 (1H, d), 7.55-7.54 ( 2H, m), 6.30 (1H, d), 3.58-3.42 (5H, m), 1.35 (3H, t).

本化合物Ａ−１５：¹H-NMR (CDCl₃) δ: 9.02 (1H, s), 8.90 (2H, m), 8.36 (1H, d), 8.02 (1H, s), 7.54 (2H, d), 6.31 (1H, d), 3.56-3.48 (2H, m), 3.42 (3H, s),1.33 (3H, t).

Present compound A-15: ¹ H-NMR (CDCl ₃ ) δ: 9.02 (1H, s), 8.90 (2H, m), 8.36 (1H, d), 8.02 (1H, s), 7.54 (2H, d) , 6.31 (1 H, d), 3.56-3.48 (2 H, m), 3.42 (3 H, s), 1.33 (3 H, t).

本化合物Ａ−１６：¹H-NMR (CDCl₃) δ: 8.88 (1H, d), 8.37 (1H, d), 7.76 (1H, d), 7.69-7.62 (3H, m), 7.54-7.46 (2H, m), 6.31 (1H, d), 3.56-3.48 (2H, m), 3.42 (3H, s), 1.33 (3H, t).

Present compound A-16: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1H, d), 8.37 (1H, d), 7.76 (1H, d), 7.69-7.62 (3H, m), 7.54-7.46 ( 2H, m), 6.31 (1H, d), 3.56-3.48 (2H, m), 3.42 (3H, s), 1.33 (3H, t).

本化合物Ａ−３０ Production Example 10
In accordance with the method described in Production Example 7-1, using intermediate A-36 instead of the present compound A-43 and using 2,2,3,3,3-pentafluoropropyl triflate instead of iodoethane The present compound A-30 shown below was prepared.

Present compound A-30

本化合物Ａ−２６：¹H-NMR (CDCl₃) δ: 8.46 (1H, dd), 7.81 (1H, s), 7.70 (1H, dd), 7.26 (1H, dd), 4.92 (2H, t), 3.52 (3H, s), 2.90 (2H, q), 1.27 (3H, t). Production Example 11
An intermediate A-30 is used in place of 2-fluoro-4- (trifluoromethyl) phenylboronic acid, and a 2-bromo-3-ethylthiopyridine is used in place of the intermediate A-28. The present compound A-26 represented by the following formula was produced according to the method described in 1.

Present compound A-26: ¹ H-NMR (CDCl ₃ ) δ: 8.46 (1 H, dd), 7.81 (1 H, s), 7.70 (1 H, dd), 7.26 (1 H, dd), 4.92 (2 H, t) , 3.52 (3H, s), 2.90 (2H, q), 1.27 (3H, t).

本化合物Ａ−４６：¹H-NMR (CDCl₃) δ: 7.86 (1H, d), 7.63 (1H, d), 6.49 (1H, d), 5.68 (1H, d), 4.53 (2H, t), 3.48 (3H, s), 3.25 (2H, q), 1.24 (3H, t).
Production Example 12
A mixture of 10 g of Intermediate A-41 and 50 mL of acetic anhydride was stirred at 150 ° C. for 16 hours in a closed vessel. The resulting mixture was cooled to room temperature and acetic anhydride was concentrated off under reduced pressure. Methanol 70 mL and concentrated hydrochloric acid were added to the obtained reaction mixture, and it stirred at 60 degreeC for 16 hours. The resulting mixture was cooled to room temperature and the methanol was concentrated off under reduced pressure. The resulting reaction mixture was extracted with water, saturated aqueous sodium hydrogen carbonate solution and ethyl acetate to obtain 7 g of the present compound A-46 represented by the following formula.

Present compound A-46: ¹ H-NMR (CDCl ₃ ) δ: 7.86 (1H, d), 7.63 (1H, d), 6.49 (1H, d), 5.68 (1H, d), 4.53 (2H, t) , 3.48 (3H, s), 3.25 (2H, q), 1.24 (3H, t).

本化合物Ａ−４７：1H-NMR (CDCl3) δ: 8.46 (1H, d), 7.52 (1H, d), 7.27 (1H, m), 5.69 (1H, d), 4.51 (2H, t), 3.62 (2H, m), 3.57 (3H, s), 1.36 (3H, t). Production Example 13
To a mixture of 4 g of the present compound A, 3.7 mL of triethylamine, and 15 mL of dichloromethane was added dropwise 2.5 mL of trifluoromethanesulfonic anhydride under ice-cooling, and the mixture was stirred at 0 ° C. to room temperature for 16 hours. To the mixture was added water and extracted with dichloromethane. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 4 g of the present compound A-47 shown below.

Present compound A-47: 1H-NMR (CDCl3) δ: 8.46 (1H, d), 7.52 (1H, d), 7.27 (1H, m), 5.69 (1H, d), 4.51 (2H, t), 3.62 (2H, m), 3.57 (3H, s), 1.36 (3H, t).

本化合物Ａ−５６：¹H-NMR (CDCl₃) δ: 8.76 (1H, d), 8.51 (1H, d), 7.47 (1H, d), 6.76 (1H, s), 5.65 (1H, d), 4.50 (2H, t), 3.52 (3H, s), 3.47-3.41 (2H, m), 1.54 (9H, s), 1.33 (3H, t). Production Example 14
100 mg of the present compound A-18, 31 mg of tert-butyl carbamate, 11 mg of 2-dicyclohexylphosphino-2 ′, 4 ′, 6′-triisopropylbiphenyl, 4 mg of palladium (II) acetate, 99 mg of cesium carbonate, and dioxane 1. 7 mL of the mixture was stirred at 100 ° C. for 3 hours under nitrogen atmosphere. To the resulting mixture was added water at room temperature and extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was subjected to silica gel chromatography (ethyl acetate: hexane = 1: 1) to obtain 100 mg of the present compound A-56 represented by the following formula.

Present compound A-56: ¹ H-NMR (CDCl ₃ ) δ: 8.76 (1H, d), 8.51 (1H, d), 7.47 (1H, d), 6.76 (1H, s), 5.65 (1H, d) , 4.50 (2H, t), 3.52 (3H, s), 3.47-3.41 (2H, m), 1.54 (9H, s), 1.33 (3H, t).

本化合物Ａ−５７：¹H-NMR (CDCl₃) δ: 8.83 (1H, d), 8.49 (1H, d), 7.49 (1H, d), 6.99 (1H, s), 5.67 (1H, d), 4.51 (2H, t), 3.84 (3H, s), 3.53 (3H, s), 3.49-3.37 (2H, m), 1.33 (3H, t). Production Example 14-1
The compounds produced according to the method described in Production Example 14 and the physical properties thereof are shown below.

Present compound A-57: ¹ H-NMR (CDCl ₃ ) δ: 8.83 (1H, d), 8.49 (1H, d), 7.49 (1H, d), 6.99 (1H, s), 5.67 (1H, d) , 4.51 (2H, t), 3.84 (3H, s), 3.53 (3H, s), 3.49-3. 37 (2H, m), 1.33 (3H, t).

本化合物Ａ−５８：¹H-NMR (CDCl₃) δ: 8.81 (1H, d), 8.50 (1H, d), 7.49 (1H, d), 6.97 (1H, s), 5.66 (1H, d), 4.51 (2H, t), 4.28 (2H, q), 3.53 (3H, s), 3.50-3.37 (2H, m), 1.34 (3H, t), 1.33 (3H, t).

Present compound A-58: ¹ H-NMR (CDCl ₃ ) δ: 8.81 (1H, d), 8.50 (1H, d), 7.49 (1H, d), 6.97 (1H, s), 5.66 (1H, d) , 4.51 (2H, t), 4.28 (2H, q), 3.53 (3H, s), 3.50-3.37 (2H, m), 1.34 (3H, t), 1.33 (3H, t).

本化合物Ａ−６０：¹H-NMR (CDCl₃) δ: 8.92 (1H, d), 8.59 (1H, d), 8.24 (1H, s), 7.48 (1H, d), 5.68 (1H, d), 4.51 (2H, t), 3.53 (3H, s), 3.48-3.36 (2H, m), 1.63-1.57 (1H, m), 1.32 (3H, t), 1.15-1.11 (2H, m), 0.94-0.90 (2H, m).

Present compound A-60: ¹ H-NMR (CDCl ₃ ) δ: 8.92 (1H, d), 8.59 (1H, d), 8.24 (1H, s), 7.48 (1H, d), 5.68 (1H, d) , 4.51 (2H, t), 3.53 (3H, s), 3.48-3.36 (2H, m), 1.63-1.57 (1H, m), 1.32 (3H, t), 1.15-1.11 (2H, m), 0.94 -0.90 (2H, m).

本化合物Ａ−６２：¹H-NMR (CDCl₃) δ: 8.29 (1H, d), 7.60 (1H, d), 7.46 (1H, d), 5.63 (1H, d), 4.50 (2H, t), 4.03 (2H, br), 3.53 (3H, s), 3.39-3.32 (2H, m), 1.30 (3H, t). Production Example 15
A mixture of 1.31 g of the present compound A-56, 1.8 mL of trifluoroacetic acid, and 5 mL of chloroform was stirred at 60 ° C. for 1 hour. To the resulting mixture was added 10 N aqueous sodium hydroxide under ice cooling, and the mixture was extracted with chloroform. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 1.08 g of the present compound A-62 represented by the following formula.

Present compound A-62: ¹ H-NMR (CDCl ₃ ) δ: 8.29 (1H, d), 7.60 (1H, d), 7.46 (1H, d), 5.63 (1H, d), 4.50 (2H, t) , 4.03 (2H, br), 3.53 (3H, s), 3.39-3.32 (2H, m), 1.30 (3H, t).

本化合物Ａ−６１：¹H-NMR (CDCl₃) δ: 8.90 (1H, d), 8.47 (1H, d), 7.51 (1H, d), 5.68 (1H, d), 4.52 (2H, t), 3.53 (3H, s), 3.50-3.44 (2H, m), 1.34 (3H, t). Production Example 16
At a room temperature, 0.06 mL of tert-butyl nitrite was added dropwise to a mixture of 200 mg of the present compound A, 152 mg of copper (II) bromide, and 1.1 mL of acetonitrile, and the mixture was stirred for 1 hour. To the resulting mixture was added water and extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was subjected to silica gel chromatography (ethyl acetate: hexane = 1: 1) to give 139 mg of the present compound A-61 represented by the following formula.

Present compound A-61: ¹ H-NMR (CDCl ₃ ) δ: 8.90 (1H, d), 8.47 (1H, d), 7.51 (1H, d), 5.68 (1H, d), 4.52 (2H, t) , 3.53 (3H, s), 3.50-3.44 (2H, m), 1.34 (3H, t).

本化合物Ａ−４８：¹H-NMR (CDCl₃) δ: 8.86 (1H, d), 8.33 (1H, d), 7.53 (1H, d), 5.70 (1H, d), 4.52 (2H, t), 3.91 (2H, s), 3.53 (3H, s), 3.47 (2H, q), 1.34 (3H, t). Production Example 17
1.00 g of the present compound A-18, (trimethylsilyl) acetonitrile 0.7 mL, zinc fluoride 0.27 g, 4,5'-bis (diphenylphosphino) -9,9'-dimethylxanthene 0.25 g, tris A mixture of 0.2 g of dibenzylideneacetone) dipalladium (0) and 7 mL of DMF was stirred at 140 ° C. for 3 hours. The resulting mixture was cooled to room temperature, water was added and extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography (ethyl acetate: hexane = 2: 1) to obtain 0.34 g of the present compound A-48 represented by the following formula.

Present compound A-48: ¹ H-NMR (CDCl ₃ ) δ: 8.86 (1H, d), 8.33 (1H, d), 7.53 (1H, d), 5.70 (1H, d), 4.52 (2H, t) , 3.91 (2H, s), 3.53 (3H, s), 3.47 (2H, q), 1.34 (3H, t).

本化合物Ａ−５４：¹H-NMR (CDCl₃) δ: 8.88 (1H, d), 8.14 (1H, d), 7.50 (1H, d), 5.69 (1H, d), 4.52 (2H, t), 3.53 (3H, s), 3.44 (2H, q), 1.32 (3H, t), 1.26 (2H, t), 0.88 (2H, t). Production Example 18
A mixture of 0.24 g of the present compound A-48, 0.13 mL of 1,2-dibromoethane, 0.50 g of cesium carbonate, and 4 mL of acetonitrile was stirred under reflux for 9 hours. To the resulting mixture was added water and extracted with ethyl acetate. The resulting organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to silica gel chromatography (ethyl acetate) to obtain 0.13 g of the present compound A-54 represented by the following formula.

Present compound A-54: ¹ H-NMR (CDCl ₃ ) δ: 8.88 (1H, d), 8.14 (1H, d), 7.50 (1H, d), 5.69 (1H, d), 4.52 (2H, t) , 3.53 (3H, s), 3.44 (2H, q), 1.32 (3H, t), 1.26 (2H, t), 0.88 (2H, t).

で示される化合物において、Ｔ、Ｒ⁵、Ａ³、Ｒ^3b、及びＲ^3cの組合せが［表２１］に記載のいずれかの組合せである化合物。 Production Example 19
The compound manufactured according to the method as described in manufacture example 1-28, and its physical-property value are shown below.
Formula (C-1):

In the compounds represented by, the combination of T, R ⁵ , A ³ , R ^3b , and R ^3c is any combination described in [Table 21].

本化合物Ａ−４９
本化合物Ａ−５１：¹H-NMR (CDCl₃) δ: 8.12 (1H, d), 7.42 (1H, d), 6.79 (1H, d), 5.63 (1H, d), 4.48 (2H, t), 4.41-4,35 (2H, m), 3.50 (3H, s), 3.22-3.13 (2H, m), 1.36 (3H, t), 1.31-1.24 (3H, m).
本化合物Ａ−５２：¹H-NMR (CDCl₃) δ: 8.10 (1H, d), 7.41 (1H, d), 6.74 (1H, d), 5.63 (1H, d), 5.34-5.30 (1H, m), 4.48 (2H, t), 3.58-3.35 (5H, m), 1.38-1.27 (9H, m).
本化合物Ｃ−３：¹H-NMR (CDCl₃) δ: 8.63 (1H, d), 7.94 (1H, d), 7.47 (1H, d), 5.64 (1H, d), 4.00 (2H, s), 3.58 (3H, s), 3.43-3.34 (2H, m), 2.05-1.99 (1H, m), 1.55 (3H, s), 1.55 (3H, s), 1.29 (3H, t), 1.15-1.13 (2H, m), 0.87-0.82 (2H, m).
本化合物Ｃ−４：¹H-NMR (CDCl₃) δ: 9.03 (1H, d), 8.48 (1H, d), 7.65-7.61 (2H, m), 7.56 (1H, d), 7.25-7.20 (2H, m), 5.69 (1H, d), 4.03 (2H, s), 3.60 (3H, s), 3.51-3.43 (2H, m), 1.56 (3H, s), 1.56 (3H, s), 1.34 (3H, t).
本化合物Ｃ−５：¹H-NMR (CDCl₃) δ: 8.63 (1H, d), 7.94 (1H, d), 7.45 (1H, d), 5.56 (1H, d), 4.04 (2H, d), 3.58 (3H, s), 3.42-3.33 (2H, m), 2.03-2.00 (1H, m), 1.53 (2H, dd), 1.29 (3H, t), 1.18 (2H, dd), 1.15-1.12 (2H, m), 0.87-0.82 (2H, m).
本化合物Ｃ−６：¹H-NMR (CDCl₃) δ: 9.02 (1H, d), 8.48 (1H, d), 7.63 (2H, dd), 7.54 (1H, d), 7.22 (2H, t), 5.61 (1H, d), 4.07 (2H, br), 3.61 (3H, s), 3.50-3.43 (2H, m), 1.55 (2H, dd), 1.34 (3H, t), 1.19 (2H, dd).
本化合物Ａ−６５：：¹H-NMR (CDCl₃) δ: 9.13-9.11 (1H, dd), 8.58-8.56 (1H, dd), 7.86 (1H, s), 4.93-4.90 (2H, m), 3.54-3.48 (2H, m), 3.52 (3H, s), 1.37 (3H, t).
本化合物Ａ−７４：：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.34 (1H, dd),
7.53-7.49 (2H, m), 5.68 (1H, d), 5.57-5.53 (2H, m), 4.53 (2H, t), 3.50-3.44 (5H, m), 1.32 (3H, t).
本化合物Ａ−７５：：¹H-NMR (CDCl₃) δ: 8.68 (1H, d), 8.16 (1H, d), 7.49 (1H, d), 5.67 (1H, d), 4.51 (2H, t), 3.52 (3H, s), 3.43-3.39 (2H, m), 2.48 (3H, s), 1.31 (3H, t).
本化合物Ａ−８１：¹H-NMR (CDCl₃) δ: 8.87 (1H, dd), 8.34 (1H, dd), 7.61 (1H, s), 7.55 (1H, dd), 4.76-4.71 (2H, m), 3.60 (3H, s), 3.53-3.48 (2H, m), 1.35 (3H, t).
本化合物Ｃ−９：¹H-NMR (CDCl₃) δ: 9.09 (1H, d), 8.57 (1H, d), 7.56 (1H, d), 5.70 (1H, d), 4.03 (2H, s), 3.60 (3H, s), 3.54 (2H, q), 1.56 (3H, s), 1.55 (3H, s), 1.36 (3H, t).
本化合物Ｃ−１０：¹H-NMR (CDCl₃) δ: 9.08 (1H, d), 8.57 (1H, d), 7.53 (1H, d), 5.62 (1H, d), 4.07 (2H, br), 3.61 (3H, s), 3.53 (2H, q), 1.56-1.54 (2H, m), 1.35 (3H, t), 1.21-1.17 (2H, m). [Table 21]

Present compound A-49
Present compound A-51: ¹ H-NMR (CDCl ₃ ) δ: 8.12 (1H, d), 7.42 (1H, d), 6.79 (1H, d), 5.63 (1H, d), 4.48 (2H, t) , 4.41-4, 35 (2H, m), 3.50 (3H, s), 3.22-3.13 (2H, m), 1.36 (3H, t), 1.31-1.24 (3H, m).
Present compound A-52: ¹ H-NMR (CDCl ₃ ) δ: 8.10 (1H, d), 7.41 (1H, d), 6.74 (1H, d), 5.63 (1H, d), 5.34-5.30 (1H, d) m), 4.48 (2H, t), 3.58-3.35 (5H, m), 1.38-1.27 (9H, m).
Present compound C-3: ¹ H-NMR (CDCl ₃ ) δ: 8.63 (1H, d), 7.94 (1H, d), 7.47 (1H, d), 5.64 (1H, d), 4.00 (2H, s) , 3.58 (3H, s), 3.43-3.34 (2H, m), 2.05-1.99 (1H, m), 1.55 (3H, s), 1.55 (3H, s), 1.29 (3H, t), 1.15-1.13 (2H, m), 0.87-0.82 (2H, m).
The present compound C-4: ¹ H-NMR (CDCl ₃ ) δ: 9.03 (1 H, d), 8.48 (1 H, d), 7.65-7.61 (2 H, m), 7.56 (1 H, d), 7.25-7.20 ( 2H, m), 5.69 (1H, d), 4.03 (2H, s), 3.60 (3H, s), 3.51-3.43 (2H, m), 1.56 (3H, s), 1.56 (3H, s), 1.34 (3H, t).
Present compound C-5: ¹ H-NMR (CDCl ₃ ) δ: 8.63 (1 H, d), 7. 94 (1 H, d), 7. 45 (1 H, d), 5.56 (1 H, d), 4.04 (2 H, d) , 3.58 (3H, s), 3.42-3.33 (2H, m), 2.03-2.00 (1H, m), 1.53 (2H, dd), 1.29 (3H, t), 1.18 (2H, dd), 1.15-1.12 (2H, m), 0.87-0.82 (2H, m).
Present compound C-6: ¹ H-NMR (CDCl ₃ ) δ: 9.02 (1H, d), 8.48 (1H, d), 7.63 (2H, dd), 7.54 (1H, d), 7.22 (2H, t) , 5.61 (1H, d), 4.07 (2H, br), 3.61 (3H, s), 3.50-3.43 (2H, m), 1.55 (2H, dd), 1.34 (3H, t), 1.19 (2H, dd) ).
The present compound A-65 :: ¹ H-NMR (CDCl ₃ ) δ: 9.13-9.11 (1H, dd), 8.58-8.56 (1H, dd), 7.86 (1H, s), 4.93-4.90 (2H, m) , 3.54-3.48 (2H, m), 3.52 (3H, s), 1.37 (3H, t).
The present compound A-74 :: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.34 (1 H, dd),
7.53-7.49 (2H, m), 5.68 (1H, d), 5.57-5.53 (2H, m), 4.53 (2H, t), 3.50-3.44 (5H, m), 1.32 (3H, t).
The present compound A-75 :: ¹ H-NMR (CDCl ₃ ) δ: 8.68 (1 H, d), 8. 16 (1 H, d), 7. 49 (1 H, d), 5. 67 (1 H, d), 4.51 (2 H, t ), 3.52 (3H, s), 3.43-3.39 (2H, m), 2.48 (3H, s), 1.31 (3H, t).
Present compound A-81: ¹ H-NMR (CDCl ₃ ) δ: 8.87 (1 H, dd), 8.34 (1 H, dd), 7.61 (1 H, s), 7.55 (1 H, dd), 4.76-4. 71 (2 H, m), 3.60 (3H, s), 3.53-3.48 (2H, m), 1.35 (3H, t).
Present compound C-9: ¹ H-NMR (CDCl ₃ ) δ: 9.09 (1H, d), 8.57 (1H, d), 7.56 (1H, d), 5.70 (1H, d), 4.03 (2H, s) , 3.60 (3H, s), 3.54 (2H, q), 1.56 (3H, s), 1.55 (3H, s), 1.36 (3H, t).
The present compound C-10: ¹ H-NMR (CDCl ₃ ) δ: 9.08 (1 H, d), 8. 57 (1 H, d), 7.53 (1 H, d), 5.62 (1 H, d), 4.07 (2 H, br) , 3.61 (3H, s), 3.53 (2H, q), 1.56-1.54 (2H, m), 1.35 (3H, t), 1.21-1.17 (2H, m).

で示される化合物において、Ｔ、Ｒ⁵、Ａ¹、Ａ²、Ａ⁴、Ｒ^3a、Ｒ^3b、及びＲ^3cの組合せが［表２２］に記載のいずれかの組合せである化合物。 Formula (D-1):

Compounds in which T, R ⁵ , A ¹ , A ² , A ⁴ , R ^3a , R ^3b , and R ^3c in any of the combinations described in [Table 22].

本化合物Ｂ−１３：¹H-NMR (CDCl₃) δ: 8.52 (1H, d), 7.81 (1H, d), 7.32 (1H, s), 5.86 (1H, s), 4.47 (2H, t), 4.21-4.14 (2H, m), 3.55 (3H, s), 3.52-3.45 (2H, m), 1.48 (3H, t), 1.32 (3H, t).
本化合物Ｂ−１４：¹H-NMR (CDCl₃) δ: 8.08 (1H, d), 7.59 (1H, d), 7.44 (1H, s), 6.08 (1H, s), 4.55 (2H, t), 3.62 (3H, s), 3.31-3.20 (2H, m), 1.34 (3H, t).
本化合物Ｂ−１７：¹H-NMR (CDCl₃) δ: 8.94 (1H, dd), 8.33 (1H, dd), 7.61 (1H, dd), 6.04 (1H, s), 4.54 (2H, t), 3.83 (3H, s), 3.49 (2H, q), 1.36 (3H, t). [Table 22]

Present compound B-13: ¹ H-NMR (CDCl ₃ ) δ: 8.52 (1H, d), 7.81 (1H, d), 7.32 (1H, s), 5.86 (1H, s), 4.47 (2H, t) , 4.21-4.14 (2H, m), 3.55 (3H, s), 3.52-3.45 (2H, m), 1.48 (3H, t), 1.32 (3H, t).
Present compound B-14: ¹ H-NMR (CDCl ₃ ) δ: 8.08 (1 H, d), 7.59 (1 H, d), 7.44 (1 H, s), 6.08 (1 H, s), 4.55 (2 H, t) , 3.62 (3H, s), 3.31-3.20 (2H, m), 1.34 (3H, t).
Present compound B-17: ¹ H-NMR (CDCl ₃ ) δ: 8.94 (1 H, dd), 8.33 (1 H, dd), 7.61 (1 H, dd), 6.04 (1 H, s), 4.54 (2 H, t) , 3.83 (3H, s), 3.49 (2H, q), 1.36 (3H, t).

本化合物Ｂ−１５：¹H-NMR (CDCl₃) δ: 8.54 (1H, dd), 7.79 (1H, dd), 7.32 (1H, dd), 6.07 (1H, s), 4.53 (2H, t), 3.84 (3H, s), 2.91 (2H, q), 1.26 (3H, t).

Present compound B-15: ¹ H-NMR (CDCl ₃ ) δ: 8.54 (1 H, dd), 7.79 (1 H, dd), 7.32 (1 H, dd), 6.07 (1 H, s), 4.53 (2 H, t) , 3.84 (3H, s), 2.91 (2H, q), 1.26 (3H, t).

本化合物Ｂ−１６：¹H-NMR (CDCl₃) δ: 8.84 (1H, dd), 8.42 (1H, dd), 7.61 (1H, dd), 6.13 (1H, s), 4.57 (2H, t), 3.87 (3H, s), 3.29-3.21 (1H, m), 2.91-2.87 (1H, m), 1.37 (3H, t).

Present compound B-16: ¹ H-NMR (CDCl ₃ ) δ: 8.84 (1 H, dd), 8.42 (1 H, dd), 7.61 (1 H, dd), 6.13 (1 H, s), 4.57 (2 H, t) , 3.87 (3H, s), 3.29-3.21 (1 H, m), 2.91-2.87 (1 H, m), 1.37 (3 H, t).

で示される化合物９ｇを加え、０℃で３時間撹拌した。得られた混合物に水を加え、酢酸エチルで抽出した。得られた有機層を無水硫酸ナトリウムで乾燥し、減圧下で濃縮した。得られた残渣をシリカゲルクロマトグラフィーに付し、０．５ｇの下式で示される中間体Ａ−４３及び０．４ｇの下式で示される中間体Ａ−４６を得た。

中間体Ａ−４３：¹H-NMR (CDCl₃) δ: 8.01 (1H, d), 7.50 (1H, d), 6.98 (1H, d), 6.53 (1H, d), 3.89 (3H, s), 3.13 (6H, s), 2.96-2.86 (2H, m), 1.16 (3H, t). Reference Production Example 16
A mixture of 8 g of intermediate A-19 and 50 mL of DMF was cooled to 0 ° C. and 2.8 g of sodium hydride (60%, oily) was added. The resulting mixture is stirred at 0 ° C. for 30 minutes, and then the formula (D):

9 g of a compound shown by the following were added, and stirred at 0.degree. To the resulting mixture was added water and extracted with ethyl acetate. The resulting organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was subjected to silica gel chromatography to obtain 0.5 g of intermediate A-43 represented by the following formula and 0.4 g of intermediate A represented by the following formula.

Intermediate A-43: ¹ H-NMR (CDCl ₃ ) δ: 8.01 (1H, d), 7.50 (1H, d), 6.98 (1H, d), 6.53 (1H, d), 3.89 (3H, s) , 3.13 (6H, s), 2.96-2.86 (2H, m), 1.16 (3H, t).

中間体Ａ−４６：¹H-NMR (CDCl₃) δ: 8.47 (1H, d), 7.69 (1H, d), 7.00-6.98 (2H, m), 3.95 (3H, s), 3.21-3.13 (2H, m), 3.05 (6H, s), 0.99 (3H, t).

Intermediate A-46: ¹ H-NMR (CDCl ₃ ) δ: 8.47 (1H, d), 7.69 (1H, d), 7.00-6.98 (2H, m), 3.95 (3H, s), 3.21-3.13 ( 2H, m), 3.05 (6H, s), 0.99 (3H, t).

本化合物Ａ−６３：¹H-NMR (CDCl₃) δ: 9.58 (1H, d), 9.07 (1H, d), 7.62 (1H, d), 7.47 (2H, s), 5.74 (1H, d), 4.54 (2H, t), 3.62-3.55 (2H, m), 3.55 (3H, s), 1.40 (3H, t). Production Example 20
2.50 g of the present compound A-18, 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene 629 mg, palladium (II) acetate 122 mg, N, N-diisopropylethylamine 2.8 mL, and toluene 19 mL A mixture of 3.67 g of 2,4,6-trichlorophenyl formate and 17 mL of toluene was added dropwise over 6 hours to the mixture at 100 ° C. under a nitrogen atmosphere. The resulting mixture was stirred at 100 ° C. for 2 hours and then brought to room temperature. To the resulting mixture was added water and extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was subjected to column chromatography (ethyl acetate: hexane = 1: 1) to obtain 1.61 g of the present compound A-63 shown below.

Present compound A-63: ¹ H-NMR (CDCl ₃ ) δ: 9.58 (1H, d), 9.07 (1H, d), 7.62 (1H, d), 7.47 (2H, s), 5.74 (1H, d) , 4.54 (2H, t), 3.62-3.55 (2H, m), 3.55 (3H, s), 1.40 (3H, t).

本化合物Ａ−６４：¹H-NMR (CDCl₃) δ: 9.28 (1H, d), 8.83 (1H, d), 7.66 (1H, d), 5.83 (1H, d), 4.57 (2H, t), 3.61 (3H, s), 3.53-3.45 (2H, m), 1.41 (3H, t). Production Example 21
Under ice-cooling, 169 mg of lithium hydroxide monohydrate was added to a mixture of 1.31 g of the present compound A, 11 mL of THF, and 5.5 mL of water, and the mixture was stirred at room temperature for 30 minutes. Water was added to the resulting mixture and washed with ethyl acetate. The resulting aqueous layer was acidified with 6N hydrochloric acid and extracted with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 0.85 g of the present compound A-64 shown below.

Present compound A-64: ¹ H-NMR (CDCl ₃ ) δ: 9.28 (1H, d), 8.83 (1H, d), 7.66 (1H, d), 5.83 (1H, d), 4.57 (2H, t) , 3.61 (3H, s), 3.53-3.45 (2H, m), 1.41 (3H, t).

本化合物Ａ−６６：¹H-NMR (CDCl₃) δ: 9.40 (1H, d), 8.89 (1H, d), 7.57 (1H, d), 5.71 (1H, d), 4.52 (2H, t), 4.01 (3H, s), 3.56-3.52 (2H, m), 3.53 (3H, s), 1.36 (3H, t). Production Example 22
To a mixture of 126 mg of the present compound A-64, 2 mL of chloroform and 16 μL of DMF was added 46 μL of oxalyl chloride under ice-cooling, and the mixture was stirred at room temperature for 1 hour. To the resulting mixture was added 0.5 mL of methanol under ice-cooling, and the mixture was stirred at room temperature for 2 hours. To the resulting mixture was added saturated aqueous sodium bicarbonate solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 0.12 g of the present compound A-66 shown below.

Present compound A-66: ¹ H-NMR (CDCl ₃ ) δ: 9.40 (1H, d), 8.89 (1H, d), 7.57 (1H, d), 5.71 (1H, d), 4.52 (2H, t) , 4.01 (3H, s), 3.56-3.52 (2H, m), 3.53 (3H, s), 1.36 (3H, t).

本化合物Ａ−６７：¹H-NMR (CDCl₃) δ: 9.40 (1H, d), 8.88 (1H, d), 7.56 (1H, d), 5.71 (1H, d), 4.53 (2H, t), 4.47 (2H, q), 3.54 (2H, q), 3.53 (3H, s), 1.44 (3H, t), 1.36 (3H, t). Production Example 22-1
The compounds produced according to the method described in Production Example 22 and the physical properties thereof are shown below.

Present compound A-67: ¹ H-NMR (CDCl ₃ ) δ: 9.40 (1H, d), 8.88 (1H, d), 7.56 (1H, d), 5.71 (1H, d), 4.53 (2H, t) , 4.47 (2H, q), 3.54 (2H, q), 3.53 (3H, s), 1.44 (3H, t), 1.36 (3H, t).

本化合物Ａ−６８：¹H-NMR (CDCl₃) δ: 9.38 (1H, d), 8.86 (1H, d), 7.55 (1H, d), 5.71 (1H, d), 5.37-5.31 (1H, m), 4.53 (2H, t), 3.54-3.52 (5H, m), 1.42 (6H, d), 1.36 (3H, t).

Present compound A-68: ¹ H-NMR (CDCl ₃ ) δ: 9.38 (1H, d), 8.86 (1H, d), 7.55 (1H, d), 5.71 (1H, d), 5.37-5. 31 (1H, d) m), 4.53 (2 H, t), 3.54-3.52 (5 H, m), 1.42 (6 H, d), 1. 36 (3 H, t).

本化合物Ａ−７１：¹H-NMR (CDCl₃) δ: 9.22 (1H, d), 8.64 (1H, d), 7.54 (1H, d), 6.27 (1H, br), 5.70 (1H, d), 4.52 (2H, t), 3.53 (3H, s), 3.50 (2H, q), 3.08 (3H, d), 1.34 (3H, t).

Present compound A-71: ¹ H-NMR (CDCl ₃ ) δ: 9.22 (1H, d), 8.64 (1H, d), 7.54 (1H, d), 6.27 (1H, br), 5.70 (1H, d) , 4.52 (2H, t), 3.53 (3H, s), 3.50 (2H, q), 3.08 (3H, d), 1.34 (3H, t).

本化合物Ａ−７０：¹H-NMR (CDCl₃) δ: 9.26 (1H, d), 8.71 (1H, d), 7.55 (1H, d), 6.31 (1H, br), 5.84 (1H, br), 5.71 (1H, d), 4.53 (2H, t), 3.51 (2H, q), 3.54 (3H, s), 1.34 (3H, t).

Present compound A-70: ¹ H-NMR (CDCl ₃ ) δ: 9.26 (1 H, d), 8. 71 ( ¹ H, d), 7.55 (1 H, d), 6.31 (1 H, br), 5. 84 (1 H, br) , 5.71 (1 H, d), 4.53 (2 H, t), 3.51 (2 H, q), 3.54 (3 H, s), 1.34 (3 H, t).

本化合物Ａ−７２：¹H-NMR (CDCl₃) δ: 8.93 (1H, d), 8.39 (1H, d), 7.53 (1H, d), 5.69 (1H, d), 4.52 (2H, t), 3.54-3.45 (2H, m), 3.54 (3H, s), 3.17 (3H, s), 3.08 (3H, s), 1.33 (3H, t).

Present compound A-72: ¹ H-NMR (CDCl ₃ ) δ: 8.93 (1H, d), 8.39 (1H, d), 7.53 (1H, d), 5.69 (1H, d), 4.52 (2H, t) , 3.54-3.45 (2H, m), 3.54 (3H, s), 3.17 (3H, s), 3.08 (3H, s), 1.33 (3H, t).

本化合物Ａ−７３：¹H-NMR (CDCl₃) δ: 9.20 (1H, d), 8.58 (1H, d), 7.53 (1H, d), 6.41 (1H, br), 5.70 (1H, d), 4.52 (2H, t), 3.53-3.46 (2H, m), 3.53 (3H, s), 2.98-2.92 (1H, m), 1.33 (3H, t), 0.96-0.91 (2H, m), 0.71-0.67 (2H, m).

Present compound A-73: ¹ H-NMR (CDCl ₃ ) δ: 9.20 (1H, d), 8.58 (1H, d), 7.53 (1H, d), 6.41 (1H, br), 5.70 (1H, d) , 4.52 (2H, t), 3.53-3.46 (2H, m), 3.53 (3H, s), 2.98-2.92 (1H, m), 1.33 (3H, t), 0.96-0.91 (2H, m), 0.71 -0.67 (2H, m).

本化合物Ａ−６９：¹H-NMR (CDCl₃) δ: 9.04 (1H, d), 8.63 (1H, d), 7.51 (1H, d), 5.68 (1H, d), 4.51 (2H, t), 3.52 (3H, s), 3.46 (2H, q), 1.33 (3H, t). Production Example 23
A mixture of 200 mg of the present compound A-61, 178 mg of sodium iodide, 15 mg of copper (I) iodide, 22 mg of trans-N, N'-dimethylcyclohexane-1,2-diamine and 1.3 mL of dioxane at 2 ° C. Stir for hours. To the resulting mixture was added water at room temperature and extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was subjected to column chromatography (ethyl acetate: hexane = 1: 1) to obtain 160 mg of the present compound A-69 shown below.

Present compound A-69: ¹ H-NMR (CDCl ₃ ) δ: 9.04 (1H, d), 8.63 (1H, d), 7.51 (1H, d), 5.68 (1H, d), 4.51 (2H, t) , 3.52 (3H, s), 3.46 (2H, q), 1.33 (3H, t).

本化合物Ａ−７６：¹H-NMR (CDCl₃) δ: 9.14 (1H, d), 8.58 (1H, d), 7.50 (1H, d), 5.66 (1H, d), 4.50 (2H, t), 4.45 (2H, s), 3.52 (3H, s), 3.45 (2H, q), 1.57 (9H, s), 1.33 (3H, t). Production Example 24
0.5 g of the present compound A-61, tert-butyl carbazate 0.2 g, 2- (dicyclohexylphosphino) -3,6-dimethoxy-2 ', 4', 6'-triisopropyl-1,1'- 90 mg of tris (dibenzylideneacetone) dipalladium (0) was added to a mixture of 54 mg of biphenyl, 0.97 g of cesium carbonate, and 6.6 mL of dioxane, and the mixture was stirred at 100 ° C. for 1.5 hours. To the resulting mixture was added water at room temperature and extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was subjected to column chromatography (ethyl acetate: hexane = 1: 1) to obtain 0.21 g of the present compound A-76 shown below.

Present compound A-76: ¹ H-NMR (CDCl ₃ ) δ: 9.14 (1H, d), 8.58 (1H, d), 7.50 (1H, d), 5.66 (1H, d), 4.50 (2H, t) , 4.45 (2H, s), 3.52 (3H, s), 3.45 (2H, q), 1.57 (9H, s), 1.33 (3H, t).

本化合物Ａ−７７：¹H-NMR (CDCl₃) δ: 8.45 (1H, d), 7.92 (1H, d), 7.59 (1H, d), 5.84 (1H, d), 5.39 (2H,br), 4.57 (2H, t), 3.56 (3H, s), 3.25 (2H, q), 1.27 (3H, t). Production Example 25
A mixture of 0.27 g of the present compound A-76, 0.18 mL of trifluoroacetic acid, and 1.5 mL of chloroform was stirred at 60 ° C. for 5 hours. The resulting mixture was brought to room temperature and concentrated under reduced pressure to obtain a crude purified product of the present compound A-77 shown below.

Present compound A-77: ¹ H-NMR (CDCl ₃ ) δ: 8.45 (1 H, d), 7. 92 (1 H, d), 7. 59 (1 H, d), 5. 84 (1 H, d), 5. 39 (2 H, br) , 4.57 (2H, t), 3.56 (3H, s), 3.25 (2H, q), 1.27 (3H, t).

本化合物Ａ−７８：¹H-NMR (CDCl₃) δ: 9.26 (1H, d), 8.78 (1H, s), 8.68 (1H, d), 7.59 (1H, d), 5.73 (1H, d), 4.55 (2H, t), 3.60-3.53 (5H, m), 1.38 (3H, t). Production Example 26
0.15 g of ammonium formate and 1 mL of ethyl orthoformate were added to the present compound A-77, and the mixture was stirred under reflux for 6 hours. To the resulting mixture was added water at room temperature and extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was subjected to column chromatography (ethyl acetate) to obtain 35 mg of the present compound A-78 and 0.13 g of the present compound A-79 shown below.

Present compound A-78: ¹ H-NMR (CDCl ₃ ) δ: 9.26 (1H, d), 8.78 (1H, s), 8.68 (1H, d), 7.59 (1H, d), 5.73 (1H, d) , 4.55 (2H, t), 3.60-3.53 (5H, m), 1.38 (3H, t).

本化合物Ａ−７９：¹H-NMR (CDCl₃) δ: 9.26 (1H, d), 8.74 (1H, s), 8.67 (1H, d), 8.22 (1H, s), 7.57 (1H, d), 5.73 (1H, d), 4.54 (2H, t), 3.58-3.50 (5H, m), 1.37 (3H, t).

Present compound A-79: ¹ H-NMR (CDCl ₃ ) δ: 9.26 (1H, d), 8.74 (1H, s), 8.67 (1H, d), 8.22 (1H, s), 7.57 (1H, d) , 5.73 (1H, d), 4.54 (2H, t), 3.58-3.50 (5H, m), 1.37 (3H, t).

本化合物Ａ−８０：1H-NMR (CDCl3) δ: 8.44 (1H, dd), 7.71 (1H, dd), 7.63 (1H, s), 7.26 (1H, dd), 4.70 (2H, t), 3.62 (3H, s), 2.90 (2H, q), 1.27 (3H, t). Production Example 27
A mixture of 1.0 g of the present compound A-2, 0.45 g of N-bromosuccinimide, and 10 mL of DMF was stirred at room temperature for 2 hours. To the resulting mixture was added saturated aqueous sodium bicarbonate solution, and the mixture was extracted with ethyl acetate. The obtained organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated. The resulting residue was subjected to silica gel column chromatography (methanol: chloroform = 1: 9) to obtain 0.74 g of the present compound A-80 shown below.

The present compound A-80: 1 H-NMR (CDCl3) δ: 8.44 (1H, dd), 7.71 (1H, dd), 7.63 (1H, s), 7.26 (1H, dd), 4.70 (2H, t), 3.62 (3H, s), 2.90 (2H, q), 1.27 (3H, t).

本化合物Ａ−８３：¹H-NMR (CDCl₃) δ: 8.80 (1H, dd), 8.46 (1H, dd), 7.97 (1H, d), 7.52 (1H, dd), 5.86 (1H, d), 4.60 (2H, t), 3.77-3.69 (1H, m), 3.57 (3H, s), 3.44-3.39 (1H, m), 1.61 (3H, t). Production Example 28
A mixture of 1.5 g of the present compound A-2, 1.02 g of N-bromosuccinimide, 0.55 g of potassium tert-butoxide, 0.21 g of cyanamide and 30 mL of methanol was stirred at room temperature for 5 hours. To the resulting mixture was added water and extracted with ethyl acetate. The obtained organic layer was concentrated under reduced pressure to obtain 0.93 g of the present compound A-83.

Present compound A-83: ¹ H-NMR (CDCl ₃ ) δ: 8.80 (1H, dd), 8.46 (1H, dd), 7.97 (1H, d), 7.52 (1H, dd), 5.86 (1H, d) , 4.60 (2H, t), 3.77-3.69 (1H, m), 3.57 (3H, s), 3.44-3. 39 (1H, m), 1.61 (3H, t).

で示される化合物において、Ｔ、Ａ²、Ａ³、Ｑ⁵、Ｑ⁶、Ｒ^3b、及びＲ^3cの組合せが［表２３］に記載のいずれかの組合せである化合物。 Production Example 29
The compounds that can be produced according to the method described in Production Examples 1 to 28 are shown below.
Formula (E-1)

In the compound shown by these, the compound whose combination of T, A ² , A ³ , Q ⁵ , Q ⁶ , R ^3b and R ^3c is any combination described in [Table 23].

[Table 23]

で示される化合物において、Ｔ、Ａ²、Ａ⁴、Ｑ⁵、Ｑ⁶、Ｒ^3b、及びＲ^3cの組合せが［表２４］に記載のいずれかの組合せである化合物。 Formula (F-1)

In the compound shown by these, the compound whose combination of T, A ² , A ⁴ , Q ⁵ , Q ⁶ , R ^3b and R ^3c is any combination described in [Table 24].

[Table 24]

  Examples of the composition A include the following. The abbreviation SX means any one of the present compounds selected from the compound groups SX1 to SX1298.

  In Group 1, the combination of SX and the present component is a combination of any of the following "list of two active ingredients" and is composed of composition A comprising 2 parts of SX and 0.5 parts of the present component .

  In the “two active ingredient list”, for example, SX + spine tram means a combination of SX and spine tram.

"2 active ingredient list":
SX + Spinetram, SX + Clothianidin, SX + Isotianil, SX + Flamethopill, SX + Impilfulxamm, SX + Orysastrobin, SX + Fushalide, SX + Validamycin A, SX + Fushalide, SX + Validamycin A, SX + Azoxystist Robin.

  In Group 2, the combination of SX and the present component is any combination of the above-mentioned "list of 2 active ingredients" and is composed of composition A comprising 2 parts of SX and 1.5 parts of the present component .

  In Group 3, the combination of SX and the present component is any combination of the above-mentioned "list of 2 active ingredients", and is composed of Composition A consisting of 1 part SX and 1 part the present component.

  Group 4 is a composition A wherein the combination of SX and the present component is any combination of the above-mentioned "list of 2 active ingredients" and which comprises 1 part of SX and 2 parts of the present component.

  In group 5, the combination of SX and the present component is any combination of the above-mentioned "list of 2 active ingredients", and is composed of composition A comprising 2 parts of SX and 7 parts of the present component.

  In group 6, the combination of SX and the present component is any combination of the above-mentioned "list of 2 active ingredients", and is composed of composition A consisting of 1 part SX and 5 parts of the present component.

  In Group 7, the combination of SX and the present component is any combination of the above-mentioned "list of 2 active ingredients", and is composed of Composition A consisting of 1 part SX and 15 parts of the present component.

  In Group 8, the combination of SX and the present component is any combination of the above-mentioned "list of 2 active ingredients", and is composed of composition A comprising 1 part SX and 3 parts of the present component.

  In Group 9, the combination of SX and the present component is a combination of any of the above-mentioned "list of 2 active ingredients" and is composed of composition A comprising 5 parts of SX and 6.6 parts of the present component .

  In group 10, the combination of SX and the present component is any combination of the above-mentioned "list of 2 active ingredients", and is composed of composition A consisting of 1 part SX and 4 parts of the present component.

  In group 11, the combination of SX and the present component is any combination of the above-mentioned "list of 2 active ingredients", and is composed of composition A comprising 5 parts of SX and 8 parts of the present component.

  Group 12 is a combination of SX, this component 1 and this component 2 is any combination of the following "3 active ingredient list", 2 parts of SX, 0.5 parts of this component 1 and 1.5 It comprises a composition A consisting of the present component 2 of part.

  In the "3 active ingredient list", for example, SX + spinetoram + clothianidin means a combination of SX, spinetoram and clothianidin, this component 1 is spinetoram, and this component 2 is clothianidin.

"3 active ingredient list":
SX + Spine Tram + Clothianidin,
SX + Spinetrum + Isotianil,
SX + Spine Tram + Flametopill,
SX + Spine Tram + Impilful Kissam,
SX + Spine Tram + Olysastrovin,
SX + Clothianidin + Isotianil,
SX + Clothianidin + Flamethopyr,
SX + Clothianidin + Impilful Kissam,
SX + Clothianidin + Orisastrovin,
SX + Isotianil + Flamethopyr,
SX + Isotianil + Impilfulxam,
SX + Clothianidin + Fushalide,
SX + Clothianidin + Validamycin A,
SX + fushalide + validamycin A,
SX + Ferimzon + Hushalide,
SX + Clothianidin + Fushalide,
SX + Clothianidin + Validamycin A,
SX + Fushalide + Ferimson,
SX + Fushalide + Validamycin A, SX + Chlorantraniliprole + Clothianidin,
SX + chlorantranilipurol + imidacloprid,
SX + chlorantranilipurol + thiamethoxam,
SX + chlorantranilipurol + thiacloprid,
SX + Chlorantranilipurol + Full Pirazine Diflon,
SX + Chlorantranilipurol + Triflumesopyrim,
SX + chlorantranilipurol + flupyrimine,
SX + Chlorantraniliprole + Brofuranilide,
SX + Chlorantraniliprole + Tefluthrin,
SX + chlorantraniliprole + bifenthrin,
SX + Cyantrani Liprol + Clothianidin,
SX + cyantrani liprole + imidacloprid,
SX + Cyantrani Liprol + Thiamethoxam,
SX + cyantrani liprole + thiacloprid,
SX + Cyantrani Liprol + Full Pirazine Diflon,
SX + Cyantrani Liprol + Triflumeso Pirim,
SX + Cyantraniriprole + Flupyrimine,
SX + Cyantraniriprole + Brofuranilide,
SX + Cyantraniliprol + Tefluthrin,
SX + cyantolaniliprole + bifenthrin,
SX + tetraniliprole + clothianidin,
SX + tetraniriprole + imidacloprid,
SX + tetraniriprole + thiamethoxam,
SX + tetraniliprole + thiacloprid,
SX + tetraniriprole + full pyrazine difuro,
SX + Tetraniriprole + Triflumesopyrim,
SX + tetraniriprole + flupyrimine,
SX + tetraniriprole + brofuranilide,
SX + tetraniliprole + tefluthrin,
SX + tetraniriprole + bifenthrin,
SX + Clothianidin + Brofuranilide,
SX + Clothianidin + Tefluthrin,
SX + Clothianidin + Bifenthrin,
SX + imidacloprid + brofuranilide,
SX + imidacloprid + tefluthrin,
SX + thiamethoxam + bifenthrin,
SX + Thiamethoxam + Brofuranilide,
SX + Thiamethoxam + Tefluthrin,
SX + thiamethoxam + bifenthrin,
SX + Thiacloprid + Brofuranilide,
SX + Thiacloprid + Tefluthrin,
SX + Thiacloprid + Bifenthrin,
SX + Flupyrazifron + Brofuranilide,
SX + Flupyrazifron + Tefluthrin,
SX + flupyrazifron + bifenthrin,
SX + Triflumesopyrim + Brofuranilide,
SX + Triflumesopyrim + Tefluthrin,
SX + Triflumesopyrim + Bifenthrin,
SX + flupyrimine + brofranilide,
SX + Flupyrimine + Tefluthrin,
SX + flupyrimine + bifenthrin,
SX + Bacillus firmus strain I-1582 + clothianidin,
SX + Bacillus firmus strain I-1582 + imidacloprid,
SX + Bacillus firmus strain I-1582 + Thiamethoxam,
SX + Bacillus firmus strain I-1582 + Thiacloprid,
SX + Bacillus firmus strain I-1582 + flupyrazine,
SX + Bacillus firmus strain I-1582 + flupyrimine,
SX + Bacillus firmus strain I-1582 + Triflumesopyrim,
SX + Bacillus firmus strain I-1582 + chlorantranilipurol,
SX + Bacillus firmus strain I-1582 + Cyantraniriprole,
SX + Bacillus firmus strain I-1582 + tetraniriprole,
SX + Bacillus firmus strain I-1582 + Tefluthrin,
SX + Bacillus firmus strain I-1582 + bifenthrin,
SX + Bacillus firmus strain I-1582 + fipronil,
SX + Bacillus firmus strain I-1582 + brofuranilide,
SX + Pasteuria nishizawae strain Pn1 + clothianidin,
SX + Pasteuria nishizawae strain Pn1 + Imidacloprid,
SX + Pasteuria nishizawae strain Pn1 + Thiamethoxam,
SX + Pasteuria nishizawae strain Pn1 + Thiacloprid,
SX + Pasteuria nishizawae strain Pn1 + full pyrazine difuro,
SX + Pasteuria nishizawae strain Pn1 + flupyrimine,
SX + Pasteuria nishizawae strain Pn1 + Triflumeso Pirim,
SX + Pasteuria nishizawae strain Pn1 + chlorantraniliriprole,
SX + Pasteuria nishizawae strain Pn1 + Cyan trani lip pro,
SX + Pasteuria nishizawae strain Pn1 + tetraniriprole,
SX + Pasteuria nishizawae strain Pn1 + Tefluthrin,
SX + Pasteuria nishizawae strain Pn1 + bifenthrin,
SX + Pasteuria nishizawae strain Pn1 + fipronil,
SX + Pasteuria nishizawae strain Pn1 + Brofuranilide,
SX + Bradyrhizobium japonicum strain TA-11 + clothianidin,
SX + Bradyrhizobium japonicum strain TA-11 + imidacloprid,
SX + Bradyrhizobium japonicum strain TA-11 + thiamethoxam,
SX + Bradyrhizobium japonicum strain TA-11 + Thiacloprid,
SX + Bradyrhizobium japonicum strain TA-11 + full pyrazine difuro,
SX + Bradyrhizobium japonicum strain TA-11 + flupyrimine,
SX + Bradyrhizobium japonicum strain TA-11 + Triflumesopyrim,
SX + Bradyrhizobium japonicum strain TA-11 + chlorantraniliriprole,
SX + Bradyrhizobium japonicum strain TA-11 + cyantrani liprole,
SX + Bradyrhizobium japonicum strain TA-11 + tetraniriprole,
SX + Bradyrhizobium japonicum strain TA-11 + tefluthrin,
SX + Bradyrhizobium japonicum strain TA-11 + bifenthrin,
SX + Bradyrhizobium japonicum strain TA-11 + fipronil,
SX + Bradyrhizobium japonicum strain TA-11 + brofuranilide,
SX + Bacillus thuringiensis strain EX297512 + clothianidin,
SX + Bacillus thuringiensis strain EX297512 + imidacloprid,
SX + Bacillus thuringiensis strain EX297512 + thiamethoxam,
SX + Bacillus thuringiensis strain EX297512 + Thiacloprid,
SX + Bacillus thuringiensis strain EX297512 + flupyrazifron,
SX + Bacillus thuringiensis strain EX297512 + flupyrimine,
SX + Bacillus thuringiensis strain EX297512 + Triflumesopyrim,
SX + Bacillus thuringiensis strain EX297512 + chlorantranilipurol,
SX + Bacillus thuringiensis strain EX297512 + cyantrani riprole,
SX + Bacillus thuringiensis strain EX297512 + tetraniriprole,
SX + Bacillus thuringiensis strain EX297512 + tefluthrin,
SX + Bacillus thuringiensis strain EX297512 + bifenthrin,
SX + Bacillus thuringiensis strain EX297512 + fipronil,
SX + Bacillus thuringiensis strain EX297512 + brofuranilide,
SX + Penicillium bilaiae + Clothianidin,
SX + Penicillium bilaiae + Imidacloprid,
SX + Penicillium bilaiae + Thiamethoxam,
SX + Penicillium bilaiae + Thiacloprid,
SX + Penicillium bilaiae + full pyrazine difuro,
SX + Penicillium bilaiae + flupyrimine,
SX + Penicillium bilaiae + Triflumesopilim,
SX + Penicillium bilaiae + Chlorantranilipurol,
SX + Penicillium bilaiae + cyantrani lip prol,
SX + Penicillium bilaiae + Tetraniriprole,
SX + Penicillium bilaiae + Tefluthrin,
SX + Penicillium bilaiae + Bifenthrin,
SX + Penicillium bilaiae + fipronil,
SX + Penicillium bilaiae + Brofuranilide,
SX + Sinorhizobium meliloti + Clothianidin,
SX + Sinorhizobium meliloti + imidacloprid,
SX + Sinorhizobium meliloti + Thiamethoxam,
SX + Sinorhizobium meliloti + Thiacloprid,
SX + Sinorhizobium meliloti + flupyrazifron,
SX + Sinorhizobium meliloti + flupyrimine,
SX + Sinorhizobium meliloti + Triflumesopilim,
SX + Sinorhizobium meliloti + Chlorantranilipurol,
SX + Sinorhizobium meliloti + cyantrani lip prol,
SX + Sinorhizobium meliloti + Tetraniriprole,
SX + Sinorhizobium meliloti + Tefluthrin,
SX + Sinorhizobium meliloti + Bifenthrin,
SX + Sinorhizobium meliloti + fipronil,
SX + Sinorhizobium meliloti + Brofuranilide,
SX + Rhizobium leguminosarum + clothianidin,
SX + Rhizobium leguminosarum + imidacloprid,
SX + Rhizobium leguminosarum + thiamethoxam,
SX + Rhizobium leguminosarum + Thiacloprid,
SX + Rhizobium leguminosarum + flupyrazine,
SX + Rhizobium leguminosarum + flupyrimine,
SX + Rhizobium leguminosarum + Triflumesopyrim,
SX + Rhizobium leguminosarum + Chlorantranilipurol,
SX + Rhizobium leguminosarum + cyantrani riprole,
SX + Rhizobium leguminosarum + tetraniriprole,
SX + Rhizobium leguminosarum + tefluthrin,
SX + Rhizobium leguminosarum + bifenthrin,
SX + Rhizobium leguminosarum + fipronil,
SX + Rhizobium leguminosarum + brofuranilide,
SX + Fluazaindolizine + Clothianidin,
SX + Fluazaindolizine + Imidacloprid,
SX + full aza indolysine + thiamethoxam,
SX + Fluazaindolizine + Thiacloprid,
SX + full azaindolizine + full pyrazine difuro,
SX + Fluazaindolizine + Flupyrimine,
SX + Fluazaindolizine + Triflumesopyrim,
SX + Fluazaindolizine + Chlorantranilipurol,
SX + Fluazaindolizine + Cyantraniriprole,
SX + Fluazaindolizine + Tetraniliprole,
SX + Fluazaindolizine + Tefluthrin,
SX + Fluazaindolizine + Bifenthrin,
SX + fluazaindolizine + fipronil,
SX + Fluazaindolizine + Brofuranilide,
SX + Thioxazaphene + Clothianidin,
SX + Thioxazaphen + Imidacloprid,
SX + Thioxazaphen + Thiamethoxam,
SX + Thioxazaphen + Thiacloprid,
SX + Thioxazaphene + Flupyra- diflon,
SX + Thioxazaphen + Flupyrimine,
SX + Thioxazaphen + Triflumesopyrim,
SX + Thioxazaphen + Chlorantraniliprole,
SX + Thioxazaphen + Cyantraniriprole,
SX + Thioxazaphen + Tetraniriprole,
SX + Thioxazaphene + Tefluthrin,
SX + Thioxazaphen + Bifenthrin,
SX + Thioxazaphen + Fipronil,
SX + Thioxazaphen + Brofuranilide,
SX + Fluene Sulfone + Clothianidin,
SX + Fluensulfone + Imidacloprid,
SX + Fuene Sulfone + Thiamethoxam,
SX + Fluensulfone + Thiacloprid,
SX + Fuenesulfone + Flupyladiflon,
SX + Fuenesulfone + Flupyrimine,
SX + Fuene Sulfone + Triflumesopyrim,
SX + Fluen Sulfone + Chlorantranilipurol,
SX + Fuene Sulfone + Cyan Traniriprole,
SX + Fluene Sulfone + Tetraniliprole,
SX + Fluensulfone + Tefluthrin,
SX + Fluensulfone + Bifenthrin,
SX + Fulenesulfone + Fipronil,
SX + fluene sulfone + brofuranilide,
SX + Abamectin + Clothianidin,
SX + Abamectin + Imidacloprid,
SX + Abamectin + Thiamethoxam,
SX + Abamectin + Thiacloprid,
SX + Abamectin + Flupyraziflon,
SX + Abamectin + Flupyrimine,
SX + Abamectin + Triflumesopilim,
SX + Abamectin + Chlorantranilipurol,
SX + Abamectin + Cyantrani Riprole,
SX + Abamectin + Tetraniriprole,
SX + Abamectin + Tefluthrin,
SX + Abamectin + Bifenthrin,
SX + Abamectin + Fipronil,
SX + Abamectin + Brofranilide,
SX + Fluopyram + Clothianidin,
SX + Fluopyram + Imidacloprid,
SX + Fluopyram + Thiamethoxam,
SX + Fluopyram + Thiacloprid,
SX + fluopyram + flupyrazifron,
SX + Fluopyram + Flupyrimine,
SX + Fluopyram + Triflumesopilim,
SX + Flu Opyram + Chlorantranilipurol,
SX + Flu Opium + Cyan Trani Liprol,
SX + Fluopyram + Tetraniriprole,
SX + Fluopyram + Tefluthrin,
SX + fluopyram + bifenthrin,
SX + Fluopyram + Fipronil,
SX + Fluopyram + Brofuranilide,
SX + Bacillus amyloliquefaciens + Trichoderma virens,
SX + Penicillium bilaiae + Bradyrhizobium japonicum,
SX + Penicillium bilaiae + Mesorhizobium ciceri,
SX + Bradyrhizobium japonicum + lipochitooligosaccharide,

  Group 13 is a combination of SX, main component 1 and main component 2 in any combination of the above “3 active ingredient list”, and 2 parts of SX, 0.5 part of main components 1 and 2 parts It comprises a composition A comprising this ingredient 2.

  Group 14 is a combination of SX, main component 1 and main component 2 in any combination of the above “3 active ingredient list”, and 2 parts of SX, 0.5 part of main components 1 and 4 parts It comprises a composition A comprising this ingredient 2.

  Group 15 is a combination of SX, main component 1 and main component 2 in any combination of the above “3 active ingredient list”, and 2 parts of SX, 0.5 part of main components 1 and 7 parts It comprises a composition A comprising this ingredient 2.

  Group 16 is a combination of SX, main component 1 and main component 2 in any combination of the above “3 active ingredient list”, and 2 parts of SX, 1.5 parts of main component 1 and 2 parts It comprises a composition A comprising this ingredient 2.

  Group 17 is a combination of SX, main component 1 and main component 2 in any combination of the above “3 active ingredient list”, and 2 parts of SX, 1.5 parts of main component 1 and 4 parts It comprises a composition A comprising this ingredient 2.

  Group 18 is a combination of SX, this component 1 and this component 2 is any combination of the above-mentioned "3 active ingredient list", and 2 parts SX, 1.5 parts of this component 1 and 7 parts It comprises a composition A comprising this ingredient 2.

  Group 19 is a combination of SX, main component 1 and main component 2 in any combination of the above "3 active ingredient list", and 2 parts of SX, 2 parts of main component 1 and 2.5 parts of It comprises a composition A comprising this ingredient 2.

  In group 20, the combination of SX, main component 1 and main component 2 is any combination of the above-mentioned "3 active ingredient list", and 1 part SX, 1 part main component 1 and 2 parts main component It consists of the composition A which consists of two.

  Group 21 is a combination of SX, this component 1 and this component 2 is any combination of the above-mentioned "3 active ingredient list", 0.1 part of SX, 0.5 parts of this component 1 and 1 Composition A comprising 5 parts of this ingredient 2

  In group 22, the combination of SX, main component 1 and main component 2 is any combination of the above-mentioned "3 active ingredient list", 0.1 part SX, 0.5 part main components 1 and 0 Composition A comprising 3 parts of this ingredient 2

  In group 23, the combination of SX, this component 1 and this component 2 is any combination of the above-mentioned "3 active ingredient list", and 0.1 part SX, 2 components of this component 1 and 1.5 It comprises a composition A consisting of the present component 2 of part.

  Group 24 is a combination of SX, main component 1 and main component 2 in any combination of the above "3 active ingredient list", and 5 parts of SX, 6.6 parts of main component 1 and 20 parts It comprises a composition A comprising this ingredient 2.

  Group 25 is a combination of SX, main component 1 and main component 2 in any combination of the above "3 active ingredient list", and 5 parts of SX, 6.6 parts of main components 1 and 5 parts It comprises a composition A comprising this ingredient 2.

  Group 26 is a combination of SX, main component 1 and main component 2 in any combination of the above-mentioned "3 active ingredient list", and 5 parts of SX, 6.6 parts of main components 1 and 8 parts It comprises a composition A comprising this ingredient 2.

  In group 27, the combination of SX, main component 1 and main component 2 is any combination of the above-mentioned "3 active ingredient list", and 1 part SX, 1 part main component 1 and 1 part main component It consists of the composition A which consists of two.

  Group 28 is a combination of SX, main component 1 and main component 2 in any combination of the above “3 active ingredient list”, and 1 part SX, 1 part main component 1 and 10 parts main component It consists of the composition A which consists of two.

  Group 29 is a combination of SX, this component 1 and this component 2 is any combination of the above-mentioned "3 active ingredient list", and 1 part SX, 10 parts of this component 1 and 1 part of this component It consists of the composition A which consists of two.

  In group 30, the combination of SX, main component 1 and main component 2 is any combination of the above-mentioned "3 active ingredient list", and 1 part SX, 10 parts of main component 1 and 10 parts of main component It consists of the composition A which consists of two.

  In group 31, the combination of SX, main component 1 and main component 2 is any combination of the above-mentioned "3 active ingredient list", 10 parts of SX, 1 part of main component 1 and 1 part of main components It consists of the composition A which consists of two.

  In group 32, the combination of SX, main component 1 and main component 2 is any combination of the above “3 active ingredient list”, and 10 parts of SX, 1 part of main component 1 and 10 parts of main component It consists of the composition A which consists of two.

  In group 33, the combination of SX, main component 1 and main component 2 is any combination of the above-mentioned “3 active ingredient list”, and 10 parts of SX, 10 parts of main component 1 and 1 part of main components It consists of the composition A which consists of two.

  In group 34, the combination of SX, main component 1, main component 2 and main component 3 is any combination of the following “4 active ingredient list”, and 2 parts of SX, 0.5 parts of main component 1 Composition A consisting of 1.5 parts of this ingredient 2 and 2 parts of this ingredient 3.

  In the "4 active ingredient list", for example, SX + spinetoram + clothianidin + isotianil means a combination of SX, spinetoram, clothianidin and isotianil, this component 1 is spinetoram, this component 2 is clothianidin, this component 3 is isotianil.

"4 active ingredient list":
SX + Spinetrum + Clothianidin + Isotianil,
SX + Spinetrum + Clothianidin + Flamethopyr,
SX + Spine Tram + Clothianidin + In Pillful Xam,
SX + Spinetrum + Isotianil + Flamethopyr,
SX + Spinetram + Isotianil + Impilfulxam,
SX + Clothianidin + Isotianil + Flamethopyr,
SX + Clothianidin + Isotianil + Impilfurxam,
SX + Clothianidin + Ferimson + Fusing
SX + clothianidin + fushalide + validamycin A,
SX + Ferimson + Husellide + Validamycin A,
SX + clothianidin + fushalide + validamycin A,
SX + clothianidin + fushalide + fermison.

  In group 35, the combination of SX, main component 1, main component 2 and main component 3 is any combination of the above “4 active ingredient list”, 2 parts of SX, 0.5 parts of main component 1 , Composition A consisting of 1.5 parts of this ingredient 2 and 4 parts of this ingredient 3.

  In group 36, the combination of SX, main component 1, main component 2 and main component 3 is any combination of the above “4 active ingredient list”, and 2 parts of SX, 0.5 parts of main component 1 , Composition A consisting of 2 parts of this ingredient 2 and 2 parts of this ingredient 3.

  In group 37, the combination of SX, main component 1, main component 2 and main component 3 is any combination of the above “4 active ingredient list”, and 2 parts of SX, 0.5 parts of main component 1 , Composition A consisting of 2 parts of this ingredient 2 and 4 parts of this ingredient 3.

  In group 38, the combination of SX, main component 1, main component 2 and main component 3 is any combination of the above “4 active ingredient list”, and 2 parts of SX, 1.5 parts of main component 1 , Composition A consisting of 2 parts of this ingredient 2 and 2 parts of this ingredient 3.

  In group 39, the combination of SX, main component 1, main component 2 and main component 3 is any combination of the above-mentioned "4 active ingredient list", and 2 parts of SX, 1.5 parts of main component 1 , Composition A consisting of 2 parts of this ingredient 2 and 4 parts of this ingredient 3.

  In group 40, the combination of SX, main component 1, main component 2 and main component 3 is any combination of the above-mentioned "4 active ingredient list", and 0.1 part SX, 0.5 part Component A Composition A consisting of 1 part of this ingredient 2 and 1.5 parts of this ingredient 3

  In group 41, the combination of SX, main component 1, main component 2 and main component 3 is any combination of the above-mentioned "4 active ingredient list", and 0.1 part SX, 0.5 part Composition 1 is composed of Composition A consisting of 1.5 parts of this ingredient 2 and 0.3 parts of this ingredient 3.

  In group 42, the combination of SX, main component 1, main component 2 and main component 3 is any combination of the above-mentioned "4 active ingredient list", 0.1 part of SX, 2 parts of main component 1 , Composition A consisting of 1.5 parts of this ingredient 2 and 0.3 parts of this ingredient 3.

  In group 43, the combination of SX, main component 1, main component 2 and main component 3 is any combination of the above “4 active ingredient list”, and 5 parts of SX, 6.6 parts of main component 1 , Composition A consisting of 15 parts of this ingredient 2 and 15 parts of this ingredient 3.

  In group 44, the combination of SX, main component 1, main component 2 and main component 3 is any combination of the above-mentioned “4 active ingredient list”, and 5 parts of SX, 6.6 parts of main component 1 , Composition A consisting of 20 parts of this ingredient 2 and 5 parts of this ingredient 3.

  Group 45 is a combination of SX, main component 1, main component 2, main component 3 and main component 4 which is any combination of the following "5 active ingredient list", 2 parts of SX, 0.5 parts The present component 1 is composed of a composition A comprising 1.5 parts of the component 2, 2 parts of the component 3 and 4 parts of the component 4.

  In the "5 active ingredient list", for example, SX + spinetoram + clothianidin + isotianil + flamethopyr means a combination of SX, spinetoram, clothianidin, isotianil and flamethopyr, this component 1 is spinetoram and this component 2 is clothianidin Yes, this ingredient 3 is isotianil and this ingredient 4 is framethopyr.

"5 active ingredient list":
SX + Spinetrum + Clothianidin + Isotianil + Flamethopyr,
SX + Spinetrum + Clothianidin + Isotianil + Impilfulxam,
SX + Clothianidin + Ferimzone + Fushalide + Validamycin A,
SX + Clothianidin + Fushalide + Ferimzone + Validamycin A,

  In group 46, the combination of SX, main component 1, main component 2, main component 3 and main component 4 is any combination of the above-mentioned "5 active ingredient list", and 2 parts of SX, 0.5 parts The present component 1 is composed of a composition A comprising 1.5 parts of the component 2, 2 parts of the component 3 and 2 parts of the component 4.

  Group 47 is a combination of SX, present component 1, present component 2, present component 3 and present component 4 is any combination of the above-mentioned "5 active ingredient list", 0.1 part of SX, 0. Composition A comprising 5 parts of the present component 1, 2 parts of the present component 2, 1.5 parts of the present component 3 and 0.3 parts of the present component 4

  In group 48, the combination of SX, main component 1, main component 2, main component 3 and main component 4 is any combination of the above-mentioned "5 active ingredient list", and 5 parts of SX, 6.6 parts Composition A consisting of 15 parts of the present component 2, 15 parts of the present component 3 and 5 parts of the present component 4.

  Group 1 'is a combination of SX, this component 1, this component 2, this component 3, this component 4, this component 4 and this component 5 in any one of the following "6 active ingredient list", and 1000 parts of SX Composition A comprising 1 part of the component 1, 1 part of the component 2, 1 part of the component 3, 1 part of the component 4 and 1 part of the component 5

  In the "6 active ingredient list", for example, SX + metconazole + mandestorobin + fluopyram + fludioxonil + metalaxyl M means a combination of SX, metconazole, mandestorobin, fluopyram, fludioxonil and metalaxyl M, and this component 1 is It is metconazole, this component 2 is mandestrobin, this component 3 is fluopyram, this component 4 is fludioxonil, and this component 5 is metalaxyl M.

"6 active ingredient list":
SX + Metconazole + Mandestrobin + Fluopyram + Fludioxonil + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluopyram + Fludioxonil + Picalbutrazox,
SX + metconazole + mandestorobin + fluopyram + thiophanate methyl + metalaxyl M,
SX + metconazole + mandestorobin + fluopyram + thiophanate methyl + picalbutrazox,
SX + Metconazole + Mandestrobin + Fluopyram + Thiabendazole + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluopyram + Thiabendazole + Picalbutrazox,
SX + Metconazole + Mandestrobin + Fluopyram + Thiuram + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluopyram + Thiuram + Picalbutrazox,
SX + Metconazole + Mandestrobin + Fluopyram + Torclophos Methyl + Metalaxyl M,
SX + metconazole + mandestrobin + fluopyram + tolclophos methyl + picalbutrazox,
SX + Metconazole + Mandestrobin + Fluopyram + Boscalid + Metalaxyl M,
SX + metconazole + mandestrobin + fluopyram + boscalid + picalbutrazox,
SX + Metconazole + Mandestrobin + Fluopyram + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluopyram + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Mandestrobin + Fluopyram + Mancozeb + Metalaxyl M,
SX + metconazole + mandestrobin + fluopyram + mancozeb + picalbutrazox,
SX + Metconazole + Mandestrobin + Fluopyram + Carbendazim + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluopyram + Carbendazim + Picalbutrazox,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Fludioxonil + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Fludioxonil + Picalbutrazox,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + mandestorobin + fluxapiroxide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Thiabendazole + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluxapiroxide + Thiabendazole + Picalbutrazox,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Thiuram + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluxapiroxide + Thiuram + Picalbutrazox,
SX + Metconazole + Mandestrobin + Fluxapiroxide + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Tolclophos Methyl + Picalbutrazox,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Boscalid + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Boscalid + Picalbutrazox,
SX + Metconazole + Mandestrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Mancozeb + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluxapiroxide + Mancozeb + Picalbutrazox,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Carbendazim + Metalaxyl M,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Carbendazim + Picalbutrazox,
SX + Metconazole + Mandestrobin + Boscalid + Fludioxonil + Metalaxyl M,
SX + Metconazole + Mandestrobin + Boscalid + Fludioxonil + Picalbutrazox,
SX + Metconazole + Mandestrobin + Boscalid + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + mandestrobin + boscalid + thiophanate methyl + picalbutrazox,
SX + Metconazole + Mandestrobin + Boscalid + Thiabendazole + Metalaxyl M,
SX + Metconazole + Mandestrobin + Boscalid + Thiabendazole + Picalbutrazox,
SX + Metconazole + Mandestrobin + Boscalid + Thiuram + Metalaxyl M,
SX + Metconazole + Mandestrobin + Boscalid + Thiuram + Picalbutrazox,
SX + Metconazole + Mandestrobin + Boscalid + Tolclophos Methyl + Metalaxyl M,
SX + metconazole + mandestrobin + boscalid + tolclophos methyl + picalbutrazox,
SX + Metconazole + Mandestrobin + Boscalid + Boscalid + Metalaxyl M,
SX + metconazole + mandestrobin + boscalid + boscalid + picalbutrazox,
SX + Metconazole + Mandestrobin + Boscalid + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Mandestrobin + Boscalid + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Mandestrobin + Boscalid + Mancozeb + Metalaxyl M,
SX + metconazole + mandestrobin + boscalid + mancozeb + picalbutrazox,
SX + Metconazole + Mandestrobin + Boscalid + Carbendazim + Metalaxyl M,
SX + Metconazole + Mandestrobin + Boscalid + Carbendazim + Picalbutrazox,
SX + Metconazole + Mandestrobin + Penflufen + Fludioxonil + Metalaxyl M,
SX + Metconazole + Mandestrobin + Penflufen + Fludioxonil + Picalbutrazox,
SX + Metconazole + Mandestrobin + Penflufen + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + mandestrobin + penflufen + thiophanate methyl + picalbutrazox,
SX + Metconazole + Mandestrobin + Penflufen + Thiabendazole + Metalaxyl M,
SX + Metconazole + Mandestrobin + Penflufen + Thiabendazole + Picalbutrazox,
SX + Metconazole + Mandestrobin + Penflufen + Thiuram + Metalaxyl M,
SX + Metconazole + Mandestrobin + Penflufen + Thiuram + Picalbutrazox,
SX + Metconazole + Mandestrobin + Penflufen + Tolclophos Methyl + Metalaxyl M,
SX + Metconazole + Mandestrobin + Penfulfen + Tolclophos Methyl + Picalbutrazox,
SX + Metconazole + Mandestrobin + Penfulfen + Boscalid + Metalaxyl M,
SX + Metconazole + Mandestrobin + Penfulfen + Boscalid + Picalbutrazox,
SX + Metconazole + Mandestrobin + Penflufen + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Mandestrobin + Penflufen + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Mandestrobin + Penflufen + Mancozeb + Metalaxyl M,
SX + Metconazole + Mandestrobin + Penflufen + Mancozeb + Picalbutrazox,
SX + Metconazole + Mandestrobin + Penflufen + Carbendazim + Metalaxyl M,
SX + Metconazole + Mandestrobin + Penflufen + Carbendazim + Picalbutrazox,
SX + Metconazole + Mandestrobin + Thifluzamide + Fludioxonil + Metalaxyl M,
SX + Metconazole + Mandestrobin + Thifluzamide + Fludioxonil + Picalbutrazox,
SX + metconazole + mandestorobin + thifluzamide + thiophanate methyl + metalaxyl M,
SX + metconazole + mandestorobin + thifluzamide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Mandestrobin + Thifluzamide + Thiabendazole + Metalaxyl M,
SX + Metconazole + Mandestrobin + Thifluzamide + Thiabendazole + Picalbutrazox,
SX + Metconazole + Mandestrobin + Tifluzamide + Thiuram + Metalaxyl M,
SX + Metconazole + Mandestrobin + Tifluzamide + Thiuram + Picalbutrazox,
SX + Metconazole + Mandestrobin + Tifluzamide + Torclophos Methyl + Metalaxyl M,
SX + metconazole + mandestorobin + thifluzamide + tolclophos methyl + picalbutrazox,
SX + Metconazole + Mandestrobin + Tifluzamide + Boscalid + Metalaxyl M,
SX + Metconazole + Mandestrobin + Tifluzamide + Boscalid + Picalbutrazox,
SX + Metconazole + Mandestrobin + Tifluzamide + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Mandestrobin + Tifluzamide + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Mandestrobin + Tifluzamide + Mancozeb + Metalaxyl M,
SX + Metconazole + Mandestrobin + Tifluzamide + Mancozeb + Picalbutrazox,
SX + Metconazole + Mandestrobin + Tifluzamide + Carbendazim + Metalaxyl M,
SX + Metconazole + Mandestrobin + Tifluzamide + Carbendazim + Picalbutrazox,
SX + Metconazole + Mandestrobin + Impilfurxam + Fludioxonil + Metalaxyl M,
SX + metconazole + mandestorobin + impilfurxam + fludioxonil + picalbutrazox,
SX + Metconazole + Mandestrobin + Impilfurxam + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + mandestorobin + impilfurxam + thiophanate methyl + picalbutrazox,
SX + Metconazole + Mandestrobin + Impilfurxam + Thiabendazole + Metalaxyl M,
SX + Metconazole + Mandestrobin + Impilfurxam + Thiabendazole + Picalbutrazox,
SX + Metconazole + Mandestrobin + Impilfurxam + Thiuram + Metalaxyl M,
SX + Metconazole + Mandestrobin + Impilfurxam + Thiuram + Picalbutrazox,
SX + Metconazole + Mandestrobin + Impilfurxam + Torclophos Methyl + Metalaxyl M,
SX + metconazole + mandestrobin + impilfurxam + tolclophos methyl + picalbutrazox,
SX + Metconazole + Mandestrobin + Impilfurxam + Boscalid + Metalaxyl M,
SX + metconazole + mandestrobin + impilfurxam + boscalid + picalbutrazox,
SX + Metconazole + Mandestrobin + Impilfurxam + Aminopyriphen + Metalaxyl M,
SX + metconazole + mandestrobin + impilfurxam + aminopyrifene + picalbutrazox,
SX + Metconazole + Mandestrobin + Impilfurxam + Mancozeb + Metalaxyl M,
SX + metconazole + mandestrobin + impilfurxam + mancozeb + picalbutrazox,
SX + Metconazole + Mandestrobin + Impilfurxam + Carbendazim + Metalaxyl M,
SX + metconazole + mandestrobin + impilfurxam + carbendazim + picalbutrazox,
SX + Metconazole + Mandestrobin + Sedaxane + Fludioxonil + Metalaxyl M,
SX + Metconazole + Mandestrobin + Sedaxane + Fludioxonil + Picalbutrazox,
SX + Metconazole + Mandestrobin + Sedaxane + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + mandestorobin + sedaxanthe + thiophanate methyl + picalbutrazox,
SX + Metconazole + Mandestrobin + Sedaxane + Thiabendazole + Metalaxyl M,
SX + Metconazole + Mandestrobin + Sedaxane + Thiabendazole + Picalbutrazox,
SX + Metconazole + Mandestrobin + Sedaxane + Thiuram + Metalaxyl M,
SX + Metconazole + Mandestrobin + Sedaxan + Thiuram + Picalbutrazox,
SX + Metconazole + Mandestrobin + Sedaxane + Tolclophos Methyl + Metalaxyl M,
SX + Metconazole + Mandestrobin + Sedaxane + Tolclophos Methyl + Picalbutrazox,
SX + Metconazole + Mandestrobin + Sedaxane + Boscalid + Metalaxyl M,
SX + metconazole + mandestrobin + sedaxanthe + boscalid + picalbutrazox,
SX + Metconazole + Mandestrobin + Sedaxane + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Mandestrobin + Sedaxane + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Mandestrobin + Sedaxane + Mancozeb + Metalaxyl M,
SX + Metconazole + Mandestrobin + Sedaxane + Mancozeb + Picalbutrazox,
SX + Metconazole + Mandestrobin + Sedaxane + Carbendazim + Metalaxyl M,
SX + Metconazole + Mandestrobin + Sedaxane + Carbendazim + Picalbutrazox,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Fludioxonil + Metalaxyl M,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Fludioxonil + Picalbutrazox,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiophane Methyl + Picalbutrazox,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiabendazole + Metalaxyl M,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiabendazole + Picalbutrazox,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiuram + Metalaxyl M,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiuram + Picalbutrazox,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Boscalid + Metalaxyl M,
SX + Metconazole + Mandestrobin + Pidiflumethofen + Boscalid + Picalbutrazox,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Mandestrobin + Pidiflumethofen + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Mandestrobin + Pidiflumethofen + Mancozeb + Metalaxyl M,
SX + Metconazole + Mandestrobin + Pidiflumethofen + Mancozeb + Picalbutrazox,
SX + Metconazole + Mandestrobin + Pidiflumethofen + Carbendazim + Metalaxyl M,
SX + Metconazole + Mandestrobin + Pidiflumethofen + Carbendazim + Picalbutrazox,
SX + Metconazole + Mandestrobin + Isoflusipram + Fludioxonil + Metalaxyl M,
SX + Metconazole + Mandestrobin + Isoflusipram + Fludioxonil + Picalbutrazox,
SX + Metconazole + Mandestrobin + Isoflusipram + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Mandestrobin + Isoflusipram + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Mandestrobin + Isoflusipram + Thiabendazole + Metalaxyl M,
SX + Metconazole + Mandestrobin + Isoflusipram + Thiabendazole + Picalbutrazox,
SX + Metconazole + Mandestrobin + Isoflusipram + Thiuram + Metalaxyl M,
SX + Metconazole + Mandestrobin + Isoflusipram + Thiuram + Picalbutrazox,
SX + metconazole + mandestorobin + isoflucypram + tolclophos methyl + metalaxyl M
SX + Metconazole + Mandestrobin + Isoflusipram + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Mandestrobin + Isoflusipram + Boscalid + Metalaxyl M,
SX + Metconazole + Mandestrobin + Isoflusipram + Boscalid + Picalbutrazox,
SX + Metconazole + Mandestrobin + Isoflusipram + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Mandestrobin + Isoflusipram + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Mandestrobin + Isoflusipram + Mancozeb + Metalaxyl M,
SX + Metconazole + Mandestrobin + Isoflusipram + Mancozeb + Picalbutrazox,
SX + Metconazole + Mandestrobin + Isoflusipram + Carbendazim + Metalaxyl M,
SX + Metconazole + Mandestrobin + Isoflusipram + Carbendazim + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluopyram + Fludioxonil + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Fluopyram + Fludioxonil + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluopyram + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + azoxystrobin + fluopyram + thiophanate methyl + picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluopyram + Thiabendazole + Metalaxyl M,
SX + metconazole + azoxystrobin + fluopyram + thiabendazole + picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluopyram + Thiuram + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Fluopyram + Thiuram + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluopyram + Torclophos Methyl + Metalaxyl M,
SX + metconazole + azoxystrobin + fluopyram + tolclophos methyl + picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluopyram + Boscalid + Metalaxyl M,
SX + metconazole + azoxystrobin + fluopyram + boscalid + picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluopyram + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Fluopyram + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluopyram + Mancozeb + Metalaxyl M,
SX + metconazole + azoxystrobin + fluopyram + mancozeb + picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluopyram + Carbendazim + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Fluopyram + Carbendazim + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Fludioxonil + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Fludioxonil + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + azoxystrobin + fluxapiroxide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Thiabendazole + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Fluxapiroxad + Thiabendazole + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Thiuram + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Thiuram + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Fluxapiroxad + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Boscalid + Metalaxyl M,
SX + metconazole + azoxystrobin + fluxapiroxide + boscalid + picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl M,
SX + metconazole + azoxystrobin + fluxapiroxide + aminopyrifene + picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Mancozeb + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Mancozeb + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Fluxapiroxad + Carbendazim + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Fluxapiroxad + Carbendazim + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Boscalid + Fludioxonil + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Boscalid + Fludioxonil + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Boscalid + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + azoxystrobin + boscalid + thiophanate methyl + picalbutrazox,
SX + Metconazole + Azoxystrobin + Boscalid + Thiabendazole + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Boscalid + Thiabendazole + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Boscalid + Thiuram + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Boscalid + Thiuram + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Boscalid + Tolclophos Methyl + Metalaxyl M,
SX + metconazole + azoxystrobin + boscalid + tolclophos methyl + picalbutrazox,
SX + Metconazole + Azoxystrobin + Boscalid + Boscalid + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Boscalid + Boscalid + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Boscalid + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Boscalid + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Boscalid + Mancozeb + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Boscalid + Mancozeb + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Boscalid + Carbendazim + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Boscalid + Carbendazim + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Penflufen + Fludioxonil + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Penflufen + Fludioxonil + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Penflufen + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + azoxystrobin + penflufen + thiophanate methyl + picalbutrazox,
SX + Metconazole + Azoxystrobin + Penflufen + Thiabendazole + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Penflufen + Thiabendazole + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Penflufen + Thiuram + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Penflufen + Thiuram + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Penflufen + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Penflufen + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Penflufen + Boscalid + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Penfulfen + Boscalid + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Penflufen + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Penflufen + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Penflufen + Mancozeb + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Penflufen + Mancozeb + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Penflufen + Carbendazim + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Penflufen + Carbendazim + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Thifluzamide + Fludioxonil + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Thifluzamide + Fludioxonil + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Thifluzamide + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Thifluzamide + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Thifluzamide + Thiabendazole + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Thifluzamide + Thiabendazole + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Thifluzamide + Thiuram + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Tifluzamide + Thiuram + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Thifluzamide + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Tifluzamide + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Thifluzamide + Boscalid + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Tifluzamide + Boscalid + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Tifluzamide + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Tifluzamide + Aminopyrifene + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Tifluzamide + Mancozeb + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Thifluzamide + Mancozeb + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Tifluzamide + Carbendazim + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Tifluzamide + Carbendazim + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Impilfurxam + Fludioxonil + Metalaxyl M,
SX + metconazole + azoxystrobin + impilfurxam + fludioxonil + picalbutrazox,
SX + Metconazole + Azoxystrobin + Impilfurxam + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + azoxystrobin + impilfurxam + thiophanate methyl + picalbutrazox,
SX + Metconazole + Azoxystrobin + Impilfurxam + Thiabendazole + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Impilfurxam + Thiabendazole + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Impilfurxam + Thiuram + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Impilfurxam + Thiuram + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Impilfurxam + Torclophos Methyl + Metalaxyl M,
SX + metconazole + azoxystrobin + impilfurxam + tolclophos methyl + picalbutrazox,
SX + Metconazole + Azoxystrobin + Impilfurxam + Boscalid + Metalaxyl M,
SX + metconazole + azoxystrobin + impilfurxam + boscalid + picalbutrazox,
SX + metconazole + azoxystrobin + impilfurxam + aminopyriphen + metalaxyl M,
SX + metconazole + azoxystrobin + impilfurxam + aminopyrifene + picalbutrazox,
SX + Metconazole + Azoxystrobin + Impilfurxam + Mancozeb + Metalaxyl M,
SX + metconazole + azoxystrobin + impilfurxam + mancozeb + picalbutrazox,
SX + Metconazole + Azoxystrobin + Impilfurxam + Carbendazim + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Impilfurxam + Carbendazim + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Sedaxane + Fludioxonil + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Sedaxane + Fludioxonil + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiabendazole + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiabendazole + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiuram + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiuram + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Sedaxane + Tolclophos Methyl + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Sedaxane + Tolclophos Methyl + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Sedaxane + Boscalid + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Sedaxane + Boscalid + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Sedaxane + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Sedaxane + Aminopyrifene + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Sedaxane + Mancozeb + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Sedaxane + Mancozeb + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Sedaxane + Carbendazim + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Sedaxane + Carbendazim + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Fludioxonil + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Fludioxonil + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiabendazole + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiabendazole + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiuram + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiuram + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Boscalid + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Boscalid + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Mancozeb + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Pidiflumethofen + Mancozeb + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Carbendazim + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Carbendazim + Picalbutrazox,
SX + metconazole + azoxystrobin + isoflucipal + fludioxonil + metalaxyl M,
SX + Metconazole + Azoxystrobin + Isoflusipram + Fludioxonil + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Isoflusipram + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Isoflusipram + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Isoflucipram + Thiabendazole + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Isoflucipram + Thiabendazole + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Isoflusipram + Thiuram + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Isoflusipram + Thiuram + Picalbutrazox,
SX + metconazole + azoxystrobin + isoflucypram + tolclophos methyl + metalaxyl M,
SX + metconazole + azoxystrobin + isoflucipram + tolclophos methyl + picalbutrazox,
SX + Metoconazole + Azoxystrobin + Isoflusipram + Boscalid + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Isoflusipram + Boscalid + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Isoflusipram + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Isoflusipram + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Isoflusipram + Mancozeb + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Isoflusipram + Mancozeb + Picalbutrazox,
SX + Metconazole + Azoxystrobin + Isoflusipram + Carbendazim + Metalaxyl M,
SX + Metconazole + Azoxystrobin + Isoflusipram + Carbendazim + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluopyram + Fludioxonil + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Fluopyram + Fludioxonil + Picalbutrazox,
SX + metconazole + fluoxastrobin + fluopyram + thiophanate methyl + metalaxyl M,
SX + metconazole + fluoxastrobin + fluopyram + thiophanate methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluopyram + Thiabendazole + Metalaxyl M,
SX + metconazole + fluoxastrobin + fluopyram + thiabendazole + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluopyram + Thiuram + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Fluopyram + Thiuram + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluopyram + Torclophos Methyl + Metalaxyl M,
SX + metconazole + fluoxastrobin + fluopyram + tolclophos methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluopyram + Boscalid + Metalaxyl M,
SX + metconazole + fluoxastrobin + fluopyram + boscalid + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluopyram + Aminopyriphen + Metalaxyl M,
SX + metconazole + fluoxastrobin + fluopyram + aminopyrifene + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluopyram + Mancozeb + Metalaxyl M,
SX + metconazole + fluoxastrobin + fluopyram + mancozeb + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluopyram + Carbendazim + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Fluopyram + Carbendazim + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Fludioxonil + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Fludioxonil + Picalbutrazox,
SX + metconazole + fluoxastrobin + fluxapiroxide + thiophanate methyl + metalaxyl M,
SX + metconazole + fluoxastrobin + fluxapiroxide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Thiabendazole + Metalaxyl M,
SX + metconazole + fluoxastrobin + fluxapiroxide + thiabendazole + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Thiuram + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Thiuram + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Torclophos Methyl + Metalaxyl M,
SX + metconazole + fluoxastrobin + fluxapiroxide + tolclophos methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Boscalid + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Boscalid + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl M,
SX + metconazole + fluoxastrobin + fluxapiroxide + aminopyrifene + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Mancozeb + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Mancozeb + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Carbendazim + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Carbendazim + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Boscalid + Fludioxonil + Metalaxyl M,
SX + metconazole + fluoxastrobin + boscalid + fludioxonil + picalbutrazox,
SX + metconazole + fluoxastrobin + boscalid + thiophanate methyl + metalaxyl M,
SX + metconazole + fluoxastrobin + boscalid + thiophanate methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Boscalid + Thiabendazole + Metalaxyl M,
SX + metconazole + fluoxastrobin + boscalid + thiabendazole + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Boscalid + Thiuram + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Boscalid + Thiuram + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Boscalid + Tolclophos Methyl + Metalaxyl M,
SX + metconazole + fluoxastrobin + boscalid + tolclophos methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Boscalid + Boscalid + Metalaxyl M,
SX + metconazole + fluoxastrobin + boscalid + boscalid + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Boscalid + Aminopyriphen + Metalaxyl M,
SX + metconazole + fluoxastrobin + boscalid + aminopyrifene + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Boscalid + Mancozeb + Metalaxyl M,
SX + metconazole + fluoxastrobin + boscalid + mancozeb + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Boscalid + Carbendazim + Metalaxyl M,
SX + metconazole + fluoxastrobin + boscalid + carbendazim + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Penflufen + Fludioxonil + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Penflufen + Fludioxonil + Picalbutrazox,
SX + metconazole + fluoxastrobin + penflufen + thiophanate methyl + metalaxyl M,
SX + metconazole + fluoxastrobin + penflufen + thiophanate methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Penflufen + Thiabendazole + Metalaxyl M,
SX + metconazole + fluoxastrobin + penflufen + thiabendazole + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Penflufen + Thiuram + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Penflufen + Thiuram + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Penflufen + Tolclophos Methyl + Metalaxyl M,
SX + metconazole + fluoxastrobin + penflufen + tolclophos methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Penflufen + Boscalid + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Penfulfen + Boscalid + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Penflufen + Aminopyriphen + Metalaxyl M,
SX + metconazole + fluoxastrobin + penflufen + aminopyrifene + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Penflufen + Mancozeb + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Penflufen + Mancozeb + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Penflufen + Carbendazim + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Penflufen + Carbendazim + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Fludioxonil + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Fludioxonil + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + fluoxastrobin + thifluzamide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Thiabendazole + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Thiabendazole + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Thiuram + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Thiuram + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Torclophos Methyl + Metalaxyl M,
SX + metconazole + fluoxastrobin + thifluzamide + tolclophos methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Boscalid + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Boscalid + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Aminopyriphen + Metalaxyl M,
SX + metconazole + fluoxastrobin + thifluzamide + aminopyrifene + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Mancozeb + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Mancozeb + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Carbendazim + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Carbendazim + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Fludioxonil + Metalaxyl M,
SX + metconazole + fluoxastrobin + impilfurxam + fludioxonil + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + fluoxastrobin + impilfurxam + thiophanate methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Thiabendazole + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Thiabendazole + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Thiuram + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Thiuram + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Torclophos Methyl + Metalaxyl M,
SX + metconazole + fluoxastrobin + impilfurxam + tolclophos methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Boscalid + Metalaxyl M,
SX + metconazole + fluoxastrobin + impilfurxam + boscalid + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Aminopyriphen + Metalaxyl M,
SX + metconazole + fluoxastrobin + impilfurxam + aminopyrifene + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Mancozeb + Metalaxyl M,
SX + metconazole + fluoxastrobin + impilfurxam + mancozeb + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Carbendazim + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Carbendazim + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Sedaxane + Fludioxonil + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Sedaxane + Fludioxonil + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Sedaxane + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + fluoxastrobin + sedaxanthe + thiophanate methyl + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Sedaxane + Thiabendazole + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Sedaxane + Thiabendazole + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Sedaxane + Thiuram + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Sedaxane + Thiuram + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Sedaxane + Tolclophos Methyl + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Sedaxane + Tolclophos Methyl + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Sedaxane + Boscalid + Metalaxyl M,
SX + metconazole + fluoxastrobin + sedaxanthe + boscalid + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Sedaxane + Aminopyriphen + Metalaxyl M,
SX + metconazole + fluoxastrobin + sedaxane + aminopyrifene + picalbutrazox,
SX + Metconazole + Fluoxastrobin + Sedaxane + Mancozeb + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Sedaxane + Mancozeb + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Sedaxane + Carbendazim + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Sedaxane + Carbendazim + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Fludioxonil + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Fludioxonil + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiabendazole + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiabendazole + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiuram + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiuram + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Boscalid + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Boscalid + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Mancozeb + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Mancozeb + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Carbendazim + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Carbendazim + Picalbutrazox,
SX + metconazole + fluoxastrobin + isoflucypram + fludioxonil + metalaxyl M,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Fludioxonil + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Isoflucipram + Thiabendazole + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Thiabendazole + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Thiuram + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Thiuram + Picalbutrazox,
SX + Metoconazole + Fluoxastrobin + Isoflusipam + Torclophos Methyl + Metalaxyl M,
SX + metconazole + fluoxastrobin + isoflucypram + tolclophos methyl + picalbutrazox,
SX + Metoconazole + Fluoxastrobin + Isoflusipram + Boscalid + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Boscalid + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Aminopyrifene + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Mancozeb + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Mancozeb + Picalbutrazox,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Carbendazim + Metalaxyl M,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Carbendazim + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluopyram + Fludioxonil + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluopyram + Fludioxonil + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluopirum + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluopyram + Methyl Thiophane + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluopyram + Thiabendazole + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluopyram + Thiabendazole + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluopyram + Thiuram + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluopyram + Thiuram + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluopyram + Torclophos Methyl + Metalaxyl M,
SX + metconazole + trifloxystrobin + fluopyram + tolclophos methyl + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluopyram + Boscalid + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluopyram + Boscalid + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluopyram + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluopyram + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluopyram + Mancozeb + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluopyram + Mancozeb + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluopyram + Carbendazim + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluopyram + Carbendazim + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Fludioxonil + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Fludioxonil + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + trifloxystrobin + fluxapiroxide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Thiabendazole + Metalaxyl M,
SX + metconazole + trifloxystrobin + fluxapiroxide + thiabendazole + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Thiuram + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Thiuram + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Torclophos Methyl + Metalaxyl M,
SX + metconazole + trifloxystrobin + fluxapiroxide + tolclophos methyl + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Boscalid + Metalaxyl M,
SX + Metoconazole + Trifloxystrobin + Fluxapiroxide + Boscalid + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Aminopyriphen + Picalbutrazox,
SX + Metoconazole + Trifloxystrobin + Fluxapiroxad + Mancozeb + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Mancozeb + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Carbendazim + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Carbendazim + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Boscalid + Fludioxonil + Metalaxyl M,
SX + metconazole + trifloxystrobin + boscalid + fludioxonil + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Boscalid + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + trifloxystrobin + boscalid + thiophanate methyl + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Boscalid + Thiabendazole + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Boscalid + Thiabendazole + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Boscalid + Thiuram + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Boscalid + Thiuram + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Boscalid + Tolclophos Methyl + Metalaxyl M,
SX + metconazole + trifloxystrobin + boscalid + tolclophos methyl + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Boscalid + Boscalid + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Boscalid + Boscalid + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Boscalid + Aminopyriphen + Metalaxyl M,
SX + metconazole + trifloxystrobin + boscalid + aminopyriphen + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Boscalid + Mancozeb + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Boscalid + Mancozeb + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Boscalid + Carbendazim + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Boscalid + Carbendazim + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Penflufen + Fludioxonil + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Penflufen + Fludioxonil + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Penflufen + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + trifloxystrobin + penflufen + thiophanate methyl + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Penflufen + Thiabendazole + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Penflufen + Thiabendazole + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Penflufen + Thiuram + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Penflufen + Thiuram + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Penflufen + Torclophos Methyl + Metalaxyl M,
SX + metconazole + trifloxystrobin + penflufen + tolclophos methyl + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Penflufen + Boscalid + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Penfulfen + Boscalid + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Penflufen + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Penflufen + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Penflufen + Mancozeb + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Penflufen + Mancozeb + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Penflufen + Carbendazim + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Penflufen + Carbendazim + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Fludioxonil + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Fludioxonil + Picalbutrazox,
SX + metconazole + trifloxystrobin + thifluzamide + thiophanate methyl + metalaxyl M,
SX + metconazole + trifloxystrobin + thifluzamide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Thiabendazole + Metalaxyl M,
SX + metconazole + trifloxystrobin + thifluzamide + thiabendazole + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Tifluzamide + Thiuram + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Thiuram + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Torclophos Methyl + Metalaxyl M,
SX + metconazole + trifloxystrobin + thifluzamide + tolclophos methyl + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Tifluzamide + Boscalid + Metalaxyl M,
SX + metconazole + trifloxystrobin + thifluzamide + boscalid + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Tifluzamide + Aminopyriphen + Metalaxyl M,
SX + metconazole + trifloxystrobin + tifluzamide + aminopyrifene + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Tifluzamide + Mancozeb + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Tifluzamide + Mancozeb + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Tifluzamide + Carbendazim + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Tifluzamide + Carbendazim + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Fludioxonil + Metalaxyl M,
SX + metconazole + trifloxystrobin + impilfurxam + fludioxonil + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + trifloxystrobin + impilfurxam + thiophanate methyl + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Thiabendazole + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Thiabendazole + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Thiuram + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Thiuram + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Torclophos Methyl + Metalaxyl M,
SX + metconazole + trifloxystrobin + impilfurxam + tolclofos methyl + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Boscalid + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Boscalid + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Aminopyriphen + Metalaxyl M,
SX + metconazole + trifloxystrobin + impilfurxam + aminopyrifene + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Mancozeb + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Mancozeb + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Carbendazim + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Carbendazim + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Sedaxane + Fludioxonil + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Sedaxane + Fludioxonil + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Sedaxane + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + trifloxystrobin + sedaxanthin + thiophanate methyl + picalbutrazox,
SX + Metconazole + Trifloxystrobin + Sedaxane + Thiabendazole + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Sedaxane + Thiabendazole + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Sedaxane + Thiuram + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Sedaxane + Thiuram + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Sedaxane + Tolclophos Methyl + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Sedaxane + Tolclophos Methyl + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Sedaxane + Boscalid + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Sedaxane + Boscalid + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Sedaxane + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Sedaxane + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Sedaxane + Mancozeb + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Sedaxane + Mancozeb + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Sedaxane + Carbendazim + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Sedaxane + Carbendazim + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Fludioxonil + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Fludioxonil + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiabendazole + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiabendazole + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiuram + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiuram + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Boscalid + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Boscalid + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Mancozeb + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Mancozeb + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Carbendazim + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Carbendazim + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Fludioxonil + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Fludioxonil + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Thiabendazole + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Thiabendazole + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Thiuram + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Thiuram + Picalbutrazox,
SX + Metoconazole + Trifloxystrobin + Isoflusipram + Torclophos Methyl + Metalaxyl M
SX + Metconazole + Trifloxystrobin + Isoflusipram + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Boscalid + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Boscalid + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Mancozeb + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Mancozeb + Picalbutrazox,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Carbendazim + Metalaxyl M,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Carbendazim + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluopyram + Fludioxonil + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Fluopyram + Fludioxonil + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluopyram + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + pyraclostrobin + fluopyram + thiophanate methyl + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluopyram + Thiabendazole + Metalaxyl M,
SX + metconazole + pyraclostrobin + fluopyram + thiabendazole + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluopyram + Thiuram + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Fluopyram + Thiuram + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluopyram + Torclophos Methyl + Metalaxyl M,
SX + metconazole + pyraclostrobin + fluopyram + tolclophos methyl + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluopyram + Boscalid + Metalaxyl M,
SX + metconazole + pyraclostrobin + fluopyram + boscalid + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluopyram + Aminopyriphen + Metalaxyl M,
SX + metconazole + pyraclostrobin + fluopyram + aminopyrifene + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluopyram + Mancozeb + Metalaxyl M,
SX + metconazole + pyraclostrobin + fluopyram + mancozeb + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluopyram + Carbendazim + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Fluopyram + Carbendazim + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Fludioxonil + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Fludioxonil + Picalbutrazox,
SX + metconazole + pyraclostrobin + fluxapiroxide + thiophanate methyl + metalaxyl M,
SX + metconazole + pyraclostrobin + fluxapiroxide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Thiabendazole + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Thiabendazole + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Thiuram + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Thiuram + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Torclophos Methyl + Metalaxyl M,
SX + metconazole + pyraclostrobin + fluxapiroxide + tolclophos methyl + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Boscalid + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Boscalid + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Mancozeb + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Mancozeb + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Carbendazim + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Carbendazim + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Boscalid + Fludioxonil + Metalaxyl M,
SX + metconazole + pyraclostrobin + boscalid + fludioxonil + picalbutrazox,
SX + metconazole + pyraclostrobin + boscalid + thiophanate methyl + metalaxyl M,
SX + metconazole + pyraclostrobin + boscalid + thiophanate methyl + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Boscalid + Thiabendazole + Metalaxyl M,
SX + metconazole + pyraclostrobin + boscalid + thiabendazole + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Boscalid + Thiuram + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Boscalid + Thiuram + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Boscalid + Tolclophos Methyl + Metalaxyl M,
SX + metconazole + pyraclostrobin + boscalid + tolclophos methyl + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Boscalid + Boscalid + Metalaxyl M,
SX + metconazole + pyraclostrobin + boscalid + boscalid + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Boscalid + Aminopyriphen + Metalaxyl M,
SX + metconazole + pyraclostrobin + boscalid + aminopyriphen + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Boscalid + Mancozeb + Metalaxyl M,
SX + metconazole + pyraclostrobin + boscalid + mancozeb + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Boscalid + Carbendazim + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Boscalid + Carbendazim + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Penflufen + Fludioxonil + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Penflufen + Fludioxonil + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Penflufen + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + pyraclostrobin + penflufen + thiophanate methyl + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Penflufen + Thiabendazole + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Penflufen + Thiabendazole + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Penflufen + Thiuram + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Penflufen + Thiuram + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Penflufen + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Penflufen + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Penfulfen + Boscalid + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Penfulfen + Boscalid + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Penflufen + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Penflufen + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Penflufen + Mancozeb + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Penflufen + Mancozeb + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Penflufen + Carbendazim + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Penflufen + Carbendazim + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Thifluzamide + Fludioxonil + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Thifluzamide + Fludioxonil + Picalbutrazox,
SX + metconazole + pyraclostrobin + thifluzamide + thiophanate methyl + metalaxyl M,
SX + metconazole + pyraclostrobin + thifluzamide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Thifluzamide + Thiabendazole + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Thifluzamide + Thiabendazole + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Thiuram + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Thiuram + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Boscalid + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Boscalid + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Mancozeb + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Mancozeb + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Carbendazim + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Carbendazim + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Fludioxonil + Metalaxyl M,
SX + metconazole + pyraclostrobin + impilfurxam + fludioxonil + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + pyraclostrobin + impilfurxam + thiophanate methyl + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Thiabendazole + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Thiabendazole + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Thiuram + Metalaxyl M,
SX + metconazole + pyraclostrobin + impilfurxam + thiuram + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Torclophos Methyl + Metalaxyl M,
SX + metconazole + pyraclostrobin + impilfurxam + tolclofos methyl + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Boscalid + Metalaxyl M,
SX + metconazole + pyraclostrobin + impilfurxam + boscalid + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Aminopyriphen + Metalaxyl M,
SX + metconazole + pyraclostrobin + impilfurxam + aminopyrifene + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Mancozeb + Metalaxyl M,
SX + metconazole + pyraclostrobin + impilfurxam + mancozeb + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Carbendazim + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Carbendazim + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Sedaxane + Fludioxonil + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Sedaxane + Fludioxonil + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Sedaxane + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + pyraclostrobin + sedaxane + thiophanate methyl + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Sedaxane + Thiabendazole + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Sedaxane + Thiabendazole + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Sedaxane + Thiuram + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Sedaxan + Thiuram + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Sedaxane + Tolclophos Methyl + Metalaxyl M,
SX + metconazole + pyraclostrobin + sedaxanthe + tolclophos methyl + picalbutrazox,
SX + Metconazole + Pyraclostrobin + Sedaxane + Boscalid + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Sedaxane + Boscalid + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Sedaxane + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Sedaxane + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Sedaxane + Mancozeb + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Sedaxan + Mancozeb + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Sedaxane + Carbendazim + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Sedaxane + Carbendazim + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Fludioxonil + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Fludioxonil + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiabendazole + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiabendazole + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiuram + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiuram + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Boscalid + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Boscalid + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Mancozeb + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Pidiflumethofen + Mancozeb + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Carbendazim + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Carbendazim + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Fludioxonil + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Fludioxonil + Picalbutrazox,
SX + Metoconazole + Pyraclostrobin + Isoflusipram + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Methyl Thiophane + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Thiabendazole + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Thiabendazole + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Thiuram + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Thiuram + Picalbutrazox,
SX + Metoconazole + Pyraclostrobin + Isoflusipram + Torclophos Methyl + Metalaxyl M,
SX + metconazole + pyraclostrobin + isoflucypram + tolclophos methyl + picalbutrazox
SX + Metconazole + Pyraclostrobin + Isoflusipram + Boscalid + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Boscalid + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Mancozeb + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Mancozeb + Picalbutrazox,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Carbendazim + Metalaxyl M,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Carbendazim + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluopyram + Fludioxonil + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Fluopyram + Fludioxonil + Picalbutrazox,
SX + metconazole + picoxystrobin + fluopyram + thiophanate methyl + metalaxyl M,
SX + metconazole + picoxystrobin + fluopyram + thiophanate methyl + picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluopyram + Thiabendazole + Metalaxyl M,
SX + metconazole + picoxystrobin + fluopyram + thiabendazole + picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluopyram + Thiuram + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Fluopyram + Thiuram + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluopyram + Torclophos Methyl + Metalaxyl M,
SX + metconazole + picoxystrobin + fluopyram + tolclophos methyl + picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluopyram + Boscalid + Metalaxyl M,
SX + metconazole + picoxystrobin + fluopyram + boscalid + picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluopyram + Aminopyriphen + Metalaxyl M,
SX + metconazole + picoxystrobin + fluopyram + aminopyrifene + picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluopyram + Mancozeb + Metalaxyl M,
SX + metconazole + picoxystrobin + fluopyram + mancozeb + picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluopyram + Carbendazim + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Fluopyram + Carbendazim + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Fludioxonil + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Fludioxonil + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + picoxystrobin + fluxapiroxide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Thiabendazole + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Thiabendazole + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Thiuram + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Thiuram + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Tolclophos Methyl + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Boscalid + Metalaxyl M,
SX + metconazole + picoxystrobin + fluxapiroxide + boscalid + picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Mancozeb + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Mancozeb + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Carbendazim + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Carbendazim + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Boscalid + Fludioxonil + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Boscalid + Fludioxonil + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Boscalid + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + picoxystrobin + boscalid + thiophanate methyl + picalbutrazox,
SX + Metconazole + Picoxystrobin + Boscalid + Thiabendazole + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Boscalid + Thiabendazole + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Boscalid + Thiuram + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Boscalid + Thiuram + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Boscalid + Tolclophos Methyl + Metalaxyl M,
SX + metconazole + picoxystrobin + boscalid + tolclophos methyl + picalbutrazox,
SX + Metconazole + Picoxystrobin + Boscalid + Boscalid + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Boscalid + Boscalid + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Boscalid + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Boscalid + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Boscalid + Mancozeb + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Boscalid + Mancozeb + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Boscalid + Carbendazim + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Boscalid + Carbendazim + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Penflufen + Fludioxonil + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Penflufen + Fludioxonil + Picalbutrazox,
SX + metconazole + picoxystrobin + penflufen + thiophanate methyl + metalaxyl M,
SX + metconazole + picoxystrobin + penflufen + thiophanate methyl + picalbutrazox,
SX + Metconazole + Picoxystrobin + Penflufen + Thiabendazole + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Penflufen + Thiabendazole + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Penflufen + Thiuram + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Penflufen + Thiuram + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Penflufen + Torclophos Methyl + Metalaxyl M,
SX + metconazole + picoxystrobin + penflufen + tolclophos methyl + picalbutrazox,
SX + Metconazole + Picoxystrobin + Penfulfen + Boscalid + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Penfulfen + Boscalid + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Penflufen + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Penflufen + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Penflufen + Mancozeb + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Penflufen + Mancozeb + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Penflufen + Carbendazim + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Penflufen + Carbendazim + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Thifluzamide + Fludioxonil + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Thifluzamide + Fludioxonil + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Thifluzamide + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + picoxystrobin + thifluzamide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Picoxystrobin + Thifluzamide + Thiabendazole + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Thifluzamide + Thiabendazole + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Thifluzamide + Thiuram + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Thifluzamide + Thiuram + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Thifluzamide + Torclophos Methyl + Metalaxyl M,
SX + metconazole + picoxystrobin + thifluzamide + tolclophos methyl + picalbutrazox,
SX + Metconazole + Picoxystrobin + Thifluzamide + Boscalid + Metalaxyl M,
SX + metconazole + picoxystrobin + thifluzamide + boscalid + picalbutrazox,
SX + Metconazole + Picoxystrobin + Tifluzamide + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Tifluzamide + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Tifluzamide + Mancozeb + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Tifluzamide + Mancozeb + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Tifluzamide + Carbendazim + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Thifluzamide + Carbendazim + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Impilfurxam + Fludioxonil + Metalaxyl M,
SX + metconazole + picoxystrobin + impilfurxam + fludioxonil + picalbutrazox,
SX + Metconazole + Picoxystrobin + Impilfurxam + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + picoxystrobin + impilfurxam + thiophanate methyl + picalbutrazox,
SX + Metconazole + Picoxystrobin + Impilfurxam + Thiabendazole + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Impilfurxam + Thiabendazole + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Impilfurxam + Thiuram + Metalaxyl M,
SX + metconazole + picoxystrobin + impilfurxam + thiuram + picalbutrazox,
SX + Metconazole + Picoxystrobin + Impilfurxam + Torclophos Methyl + Metalaxyl M,
SX + metconazole + picoxystrobin + impilfurxam + tolclofos methyl + picalbutrazox,
SX + Metconazole + Picoxystrobin + Impilfurxam + Boscalid + Metalaxyl M,
SX + metconazole + picoxystrobin + impilfurxam + boscalid + picalbutrazox,
SX + Metconazole + Picoxystrobin + Impilfurxam + Aminopyriphen + Metalaxyl M,
SX + metconazole + picoxystrobin + impilfurxam + aminopyrifene + picalbutrazox,
SX + Metconazole + Picoxystrobin + Impilfurxam + Mancozeb + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Impilfurxam + Mancozeb + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Impilfurxam + Carbendazim + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Impilfurxam + Carbendazim + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Sedaxane + Fludioxonil + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Sedaxane + Fludioxonil + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Sedaxane + Thiophanate Methyl + Metalaxyl M,
SX + metconazole + picoxystrobin + sedaxanthe + thiophanate methyl + picalbutrazox,
SX + Metconazole + Picoxystrobin + Sedaxane + Thiabendazole + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Sedaxane + Thiabendazole + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Sedaxane + Thiuram + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Sedaxane + Thiuram + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Sedaxane + Tolclophos Methyl + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Sedaxane + Tolclophos Methyl + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Sedaxane + Boscalid + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Sedaxane + Boscalid + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Sedaxane + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Sedaxane + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Sedaxane + Mancozeb + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Sedaxane + Mancozeb + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Sedaxane + Carbendazim + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Sedaxane + Carbendazim + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Fludioxonil + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Fludioxonil + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiabendazole + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Pidiflumethofen + Thiabendazole + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiuram + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiuram + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Boscalid + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Boscalid + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Pidiflumethofen + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Mancozeb + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Pidiflumethofen + Mancozeb + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Carbendazim + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Pidiflumethofen + Carbendazim + Picalbutrazox,
SX + Metoconazole + Picoxystrobin + Isoflusipram + Fludioxonil + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Isoflusipram + Fludioxonil + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Isoflusipram + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Isoflusipram + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Isoflucipram + Thiabendazole + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Isoflusipram + Thiabendazole + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Isoflusipram + Thiuram + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Isoflusipram + Thiuram + Picalbutrazox,
SX + metconazole + picoxystrobin + isoflucypram + tolclophos methyl + metalaxyl M,
SX + metconazole + picoxystrobin + isoflucypram + tolclophos methyl + picalbutrazox,
SX + Metoconazole + Picoxystrobin + Isoflusipram + Boscalid + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Isoflusipram + Boscalid + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Isoflusipram + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Isoflusipram + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Isoflusipram + Mancozeb + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Isoflusipram + Mancozeb + Picalbutrazox,
SX + Metconazole + Picoxystrobin + Isoflusipram + Carbendazim + Metalaxyl M,
SX + Metconazole + Picoxystrobin + Isoflusipram + Carbendazim + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Fluopyram + Fludioxonil + Metalaxyl M,
SX + metconazole + methyl tetraprole + fluopyram + fludioxonil + picalbutrazox,
SX + metconazole + methyl tetraprole + fluopyram + thiophanate methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + fluopyram + thiophanate methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Fluopyram + Thiabendazole + Metalaxyl M,
SX + metconazole + methyl tetraprole + fluopyram + thiabendazole + picalbutrazox,
SX + Metconazole + Methyltetraprole + Fluopyram + Thiuram + Metalaxyl M,
SX + metconazole + methyl tetraprole + fluopyram + thiuram + picalbutrazox,
SX + metconazole + methyl tetraprole + fluopyram + tolclophos methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + fluopyram + tolclophos methyl + picalbutrazox,
SX + metconazole + methyl tetraprole + fluopyram + boscalid + metalaxyl M,
SX + metconazole + methyl tetraprole + fluopyram + boscalid + picalbutrazox,
SX + Metconazole + Methyltetraprole + Fluopyram + Aminopyriphen + Metalaxyl M,
SX + metconazole + methyltetraprole + fluopyram + aminopyrifene + picalbutrazox,
SX + metconazole + methyl tetraprole + fluopyram + mancozeb + metalaxyl M,
SX + metconazole + methyl tetraprole + fluopyram + mancozeb + picalbutrazox,
SX + Metconazole + Methyltetraprole + Fluopyram + Carbendazim + Metalaxyl M,
SX + metconazole + methyl tetraprole + fluopyram + carbendazim + picalbutrazox,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Fludioxonil + Metalaxyl M,
SX + metconazole + methyltetraprole + fluxapiroxide + fludioxonil + picalbutrazox,
SX + metconazole + methyl tetraprole + fluxapiroxide + thiophanate methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + fluxapiroxide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Thiabendazole + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Thiabendazole + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Thiuram + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Thiuram + Picalbutrazox,
SX + metconazole + methyltetraprole + fluxapiroxide + tolclophos methyl + metalaxyl M,
SX + metconazole + methyltetraprole + fluxapiroxide + tolclophos methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Boscalid + Metalaxyl M,
SX + metconazole + methyl tetraprole + fluxapiroxide + boscalid + picalbutrazox,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Mancozeb + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Mancozeb + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Fluxapiroxad + Carbendazim + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Carbendazim + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Boscalid + Fludioxonil + Metalaxyl M,
SX + metconazole + methyl tetraprole + boscalid + fludioxonil + picalbutrazox,
SX + metconazole + methyl tetraprole + boscalid + thiophanate methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + boscalid + thiophanate methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Boscalid + Thiabendazole + Metalaxyl M,
SX + metconazole + methyl tetraprole + boscalid + thiabendazole + picalbutrazox,
SX + Metconazole + Methyltetraprole + Boscalid + Thiuram + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Boscalid + Thiuram + Picalbutrazox,
SX + metconazole + methyl tetraprole + boscalid + tolclophos methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + boscalid + tolclophos methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Boscalid + Boscalid + Metalaxyl M,
SX + metconazole + methyl tetraprole + boscalid + boscalid + picalbutrazox,
SX + Metconazole + Methyltetraprole + Boscalid + Aminopyriphen + Metalaxyl M,
SX + metconazole + methyltetraprole + boscalid + aminopyriphen + picalbutrazox,
SX + metconazole + methyl tetraprole + boscalid + mancozeb + metalaxyl M,
SX + metconazole + methyl tetraprole + boscalid + mancozeb + picalbutrazox
SX + Metconazole + Methyltetraprole + Boscalid + Carbendazim + Metalaxyl M,
SX + metconazole + methyl tetraprole + boscalid + carbendazim + picalbutrazox,
SX + Metconazole + Methyltetraprole + Penflufen + Fludioxonil + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Penflufen + Fludioxonil + Picalbutrazox,
SX + metconazole + methyl tetraprole + penflufen + thiophanate methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + penflufen + thiophanate methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Penflufen + Thiabendazole + Metalaxyl M,
SX + metconazole + methyltetraprole + penflufen + thiabendazole + picalbutrazox,
SX + Metconazole + Methyltetraprole + Penflufen + Thiuram + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Penflufen + Thiuram + Picalbutrazox,
SX + metconazole + methyl tetraprole + penflufen + tolclophos methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + penflufen + tolclophos methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Penflufen + Boscalid + Metalaxyl M,
SX + metconazole + methyl tetraprole + penflufen + boscalid + picalbutrazox,
SX + Metconazole + Methyltetraprole + Penflufen + Aminopyriphen + Metalaxyl M,
SX + metconazole + methyl tetraprole + penflufen + aminopyrifene + picalbutrazox,
SX + metconazole + methyl tetraprole + penflufen + mancozeb + metalaxyl M,
SX + metconazole + methyl tetraprole + penflufen + mancozeb + picalbutrazox,
SX + Metconazole + Methyltetraprole + Penflufen + Carbendazim + Metalaxyl M,
SX + metconazole + methyl tetraprole + penflufen + carbendazim + picalbutrazox,
SX + Metconazole + Methyltetraprole + Thifluzamide + Fludioxonil + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Thifluzamide + Fludioxonil + Picalbutrazox,
SX + metconazole + methyltetraprole + thifluzamide + thiophanate methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + thifluzamide + thiophanate methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Thifluzamide + Thiabendazole + Metalaxyl M,
SX + metconazole + methyltetraprole + thifluzamide + thiabendazole + picalbutrazox,
SX + Metconazole + Methyltetraprole + Thifluzamide + Thiuram + Metalaxyl M,
SX + metconazole + methyl tetraprole + thifluzamide + thiuram + picalbutrazox,
SX + metconazole + methyltetraprole + thifluzamide + tolclophos methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + thifluzamide + tolclophos methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Thifluzamide + Boscalid + Metalaxyl M,
SX + metconazole + methyl tetraprole + thifluzamide + boscalid + picalbutrazox,
SX + Metconazole + Methyltetraprole + Thifluzamide + Aminopyriphen + Metalaxyl M,
SX + metconazole + methyltetraprole + thifluzamide + aminopyrifene + picalbutrazox,
SX + Metconazole + Methyltetraprole + Thifluzamide + Mancozeb + Metalaxyl M,
SX + metconazole + methyl tetraprole + thifluzamide + mancozeb + picalbutrazox,
SX + Metconazole + Methyltetraprole + Thifluzamide + Carbendazim + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Thifluzamide + Carbendazim + Picalbutrazox,
SX + metconazole + methyl tetraprole + impilfurxam + fludioxonil + metalaxyl M,
SX + metconazole + methyl tetraprole + impilfurxam + fludioxonil + picalbutrazox,
SX + metconazole + methyl tetraprole + impilfurxam + thiophanate methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + impilfurxam + thiophanate methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Impilfurxam + Thiabendazole + Metalaxyl M,
SX + metconazole + methyl tetraprole + impilfurxam + thiabendazole + picalbutrazox,
SX + metconazole + methyl tetraprole + impilfurxam + thiuram + metalaxyl M,
SX + metconazole + methyl tetraprole + impilfurxam + thiuram + picalbutrazox,
SX + metconazole + methyl tetraprole + impilfurxam + tolclophos methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + impilfurxam + tolclophos methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Impilfurxam + Boscalid + Metalaxyl M,
SX + metconazole + methyl tetraprole + impilfurxam + boscalid + picalbutrazox,
SX + metconazole + methyl tetraprole + impilfurxam + aminopyriphen + metalaxyl M,
SX + metconazole + methyltetraprole + impilfurxam + aminopyrifene + picalbutrazox,
SX + metconazole + methyl tetraprole + impilfurxam + mancozeb + metalaxyl M,
SX + metconazole + methyl tetraprole + impilfurxam + mancozeb + picalbutrazox,
SX + Metconazole + Methyltetraprole + Impilfurxam + Carbendazim + Metalaxyl M,
SX + metconazole + methyl tetraprole + impilfurxam + carbendazim + picalbutrazox,
SX + Metconazole + Methyltetraprole + Sedaxane + Fludioxonil + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Sedaxane + Fludioxonil + Picalbutrazox,
SX + metconazole + methyl tetraprole + sedaxanthe + thiophanate methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + sedaxane + thiophanate methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Sedaxane + Thiabendazole + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Sedaxane + Thiabendazole + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Sedaxane + Thiuram + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Sedaxane + Thiuram + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Sedaxane + Tolclophos Methyl + Metalaxyl M,
SX + metconazole + methyl tetraprole + sedaxanthe + tolclophos methyl + picalbutrazox,
SX + Metconazole + Methyltetraprole + Sedaxane + Boscalid + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Sedaxane + Boscalid + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Sedaxane + Aminopyriphen + Metalaxyl M,
SX + metconazole + methyltetraprole + sedaxane + aminopyrifene + picalbutrazox,
SX + Metconazole + Methyltetraprole + Sedaxane + Mancozeb + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Sedaxane + Mancozeb + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Sedaxane + Carbendazim + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Sedaxane + Carbendazim + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Fludioxonil + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Fludioxonil + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiophanate Methyl + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiabendazole + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiabendazole + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiuram + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiuram + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Torclophos Methyl + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Torclophos Methyl + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Boscalid + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Boscalid + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Mancozeb + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Mancozeb + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Carbendazim + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Carbendazim + Picalbutrazox,
SX + metconazole + methyl tetraprole + isoflucypram + fludioxonil + metalaxyl M,
SX + metconazole + methyltetraprole + isoflucypram + fludioxonil + picalbutrazox,
SX + Metconazole + Methyltetraprole + Isoflusipram + Thiophanate Methyl + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Isoflusipram + Thiophanate Methyl + Picalbutrazox,
SX + metconazole + methyltetraprole + isoflucypram + thiabendazole + metalaxyl M,
SX + Metconazole + Methyltetraprole + Isoflucipram + Thiabendazole + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Isoflusipram + Thiuram + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Isoflusipram + Thiuram + Picalbutrazox,
SX + metconazole + methyl tetraprole + isoflucypram + tolclophos methyl + metalaxyl M,
SX + metconazole + methyl tetraprole + isoflucypram + tolclophos methyl + picalbutrazox
SX + metconazole + methyl tetraprole + isoflucypram + boscalid + metalaxyl M,
SX + Metconazole + Methyltetraprole + Isoflusipram + Boscalid + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Isoflusipram + Aminopyriphen + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Isoflusipram + Aminopyriphen + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Isoflusipram + Mancozeb + Metalaxyl M,
SX + Metconazole + Methyltetraprole + Isoflusipram + Mancozeb + Picalbutrazox,
SX + Metconazole + Methyltetraprole + Isoflusipram + Carbendazim + Metalaxyl M,
SX + metconazole + methyl tetraprole + isoflucypram + carbendazim + picalbutrazox.

  Group 2 'consists of composition A comprising 1 part tebuconazole instead of 1 part metconazole contained in each composition of group 1'.

  Group 3 'consists of composition A comprising 1 part difenoconazole instead of 1 part metconazole contained in each composition of group 1'.

  Group 4 'consists of composition A comprising 1 part triticonazole instead of 1 part metconazole contained in each composition of group 1'.

  Group 5 'consists of composition A comprising 1 part prothioconazole instead of 1 part metconazole contained in each composition of group 1'.

  Group 6 'consists of composition A comprising 1 part diniconazole in place of 1 part metconazole contained in each composition of group 1'.

  Group 7 'consists of composition A comprising 1 part diniconazole M instead of 1 part metconazole contained in each composition of group 1'.

  Group 8 'consists of composition A which comprises 1 part ipconazole instead of 1 part metconazole contained in each composition of group 1'.

  Group 9 'consists of composition A comprising 1 part prochloraz in place of 1 part metconazole contained in each composition of group 1'.

  Group 10 'consists of composition A comprising 1 part fluquinconazole instead of 1 part metconazole contained in each composition of group 1'.

  Group 11 'consists of composition A comprising 1 part bromconazole instead of 1 part metconazole contained in each composition of group 1'.

  Group 12 'consists of composition A which comprises 1 part mephentrifluconazole instead of 1 part metconazole contained in each composition of group 1'.

  Group 13 'is a combination of SX, main component 1, main component 2, main component 3, main component 4 and main component 5 described above in any of the above-mentioned "6 active ingredient list", and 1 part of SX Composition A comprising 1 part of the component 1, 1 part of the component 2, 1 part of the component 3, 1 part of the component 4 and 1 part of the component 5

  Group 14 'consists of composition A which comprises 1 part tebuconazole in place of 1 part metconazole contained in each composition of group 13'.

  Group 15 'consists of composition A comprising 1 part difenoconazole in place of 1 part metconazole contained in each composition of group 13'.

  Group 16 'consists of composition A comprising 1 part triticonazole instead of 1 part metconazole contained in each composition of group 13'.

  Group 17 'consists of composition A comprising 1 part prothioconazole in place of 1 part metconazole contained in each composition of group 13'.

  Group 18 'consists of composition A comprising 1 part diniconazole in place of 1 part metconazole contained in each composition of group 13'.

  Group 19 'consists of composition A comprising 1 part diniconazole M instead of 1 part metconazole contained in each composition of group 13'.

  Group 20 'consists of composition A comprising 1 part ipconazole instead of 1 part metconazole contained in each composition of group 13'.

  Group 21 'is composed of composition A comprising 1 part prochloraz in place of 1 part metconazole contained in each composition of group 13'.

  Group 22 'consists of composition A comprising 1 part fluquinconazole instead of 1 part metconazole contained in each composition of group 13'.

  Group 23 'consists of composition A comprising 1 part bromconazole instead of 1 part metconazole contained in each composition of group 13'.

  Group 24 'consists of composition A comprising 1 part mephentrifluconazole instead of 1 part metconazole contained in each composition of group 13'.

  Group 25 ′ is a composition A prepared by adding 1000 parts of clothianidin, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of groups 1 ′ to 12 ′. Configured

  Group 26 'is a composition A prepared by adding 1000 parts of clothianidin, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofranilide to each of the compositions of groups 1' to 12 '. Configured

  Group 27 'is a composition A prepared by adding 1000 parts of clothianidin, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of groups 1' to 12 '. Configured

  Group 28 ′ is a composition A prepared by adding 1000 parts of clothianidin, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide to each of the compositions of groups 1 ′ to 12 ′. Configured

  Group 29 'is composed of Composition A in which 1000 parts of clothianidin, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of Groups 1' to 12 '. Be done.

  Group 30 'is composed of composition A in which 1000 parts of clothianidin, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 31 'is composed of composition A in which 1000 parts of clothianidin, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 32 'is composed of Composition A in which 1000 parts of clothianidin, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of brofuranilide are further added to the compositions of Groups 1' to 12 '. Be done.

  Group 33 'is composed of composition A in which 1000 parts of clothianidin, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 1' to 12 '. Ru.

  Group 34 'is composed of composition A in which 1000 parts of clothianidin, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide are further added to the compositions of groups 1' to 12 '. Ru.

  Group 35 'is composed of composition A in which 1000 parts of clothianidin, 1000 parts of tetraniliprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 1' to 12 '. Ru.

  Group 36 'is composed of composition A in which 1000 parts of clothianidin, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of brofuranilide are further added to the compositions of groups 1' to 12 '. Ru.

  Group 37 ′ is a composition A prepared by adding 1000 parts of imidacloprid, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of groups 1 ′ to 12 ′. Configured

  Group 38 ′ is a composition A prepared by adding 1000 parts of imidacloprid, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofranilide to the compositions of each of groups 1 ′ to 12 ′. Configured

  Group 39 'is a composition A prepared by adding 1000 parts of imidacloprid, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of groups 1' to 12 '. Configured

  Group 40 'is a composition A prepared by adding 1000 parts of imidacloprid, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide to the compositions of each of groups 1' to 12 '. Configured

  Group 41 'is composed of composition A in which 1000 parts of imidacloprid, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 42 'is composed of composition A in which 1000 parts of imidacloprid, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 43 'is composed of Composition A in which 1000 parts of imidacloprid, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of Groups 1' to 12 '. Be done.

  Group 44 'is composed of composition A in which 1000 parts of imidacloprid, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 45 'is composed of composition A in which 1000 parts of imidacloprid, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 1' to 12 '. Ru.

  Group 46 'is composed of Composition A in which 1000 parts of imidacloprid, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of Groups 1' to 12 '. Ru.

  Group 47 'is composed of Composition A in which 1000 parts of imidacloprid, 1000 parts of tetraniliprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of Groups 1' to 12 '. Ru.

  Group 48 'is composed of composition A in which 1000 parts of imidacloprid, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 1' to 12 '. Ru.

  Group 49 ′ is a composition A prepared by adding 1000 parts of thiamethoxam, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of groups 1 ′ to 12 ′. Configured

  Group 50 'is a composition A obtained by further adding 1000 parts of thiamethoxam, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide to the compositions of each of groups 1' to 12 '. Configured

  Group 51 ′ is a composition A prepared by adding 1000 parts of thiamethoxam, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of groups 1 ′ to 12 ′. Configured

  Group 52 'is a composition A prepared by adding 1000 parts of thiamethoxam, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide to the compositions of each of groups 1' to 12 '. Configured

  Group 53 'is composed of composition A in which 1000 parts of thiamethoxam, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 54 'is composed of composition A in which 1000 parts of thiamethoxam, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 55 'is composed of composition A in which 1000 parts of thiamethoxam, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 56 'is composed of Composition A in which 1000 parts of thiamethoxam, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of Groups 1' to 12 '. Be done.

  Group 57 'is composed of Composition A in which 1000 parts of thiamethoxam, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of Groups 1' to 12 '. Ru.

  Group 58 'is composed of composition A in which 1000 parts of thiamethoxam, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 1' to 12 '. Ru.

  Group 59 'is composed of Composition A in which 1000 parts of thiamethoxam, 1000 parts of tetraniliprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of Groups 1' to 12 '. Ru.

  Group 60 'is composed of composition A in which 1000 parts of thiamethoxam, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 1' to 12 '. Ru.

  Group 61 'is a composition A prepared by adding 1000 parts of thiacloprid, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of groups 1' to 12 '. Configured

  Group 62 'is a composition A prepared by adding 1000 parts of thiacloprid, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofranilide to the compositions of each of groups 1' to 12 '. Configured

  The group 63 'is a composition A obtained by adding 1000 parts of thiacloprid, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of the groups 1' to 12 '. Configured

  Group 64 'is a composition A prepared by adding 1000 parts of thiacloprid, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofuranilide to the compositions of each of groups 1' to 12 '. Configured

  Group 65 'is composed of Composition A in which 1000 parts of thiacloprid, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of Groups 1' to 12 '. Be done.

  Group 66 'is composed of composition A in which 1000 parts of thiacloprid, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of brofuranilide are added to the compositions of each of groups 1' to 12 '. Be done.

  Group 67 'is composed of composition A in which 1000 parts of thiacloprid, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 68 'is composed of Composition A in which 1000 parts of thiacloprid, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of brofranilide are added to the compositions of each of Groups 1' to 12 '. Be done.

  Group 69 'is composed of Composition A in which 1000 parts of thiacloprid, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of Groups 1' to 12 '. Ru.

  Group 70 'is composed of composition A in which 1000 parts of thiacloprid, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 1' to 12 '. Ru.

  Group 71 'is composed of Composition A, in which 1000 parts of thiacloprid, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of Groups 1' to 12 '. Ru.

  Group 72 'is composed of composition A in which 1000 parts of thiacloprid, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 1' to 12 '. Ru.

  Group 73 ′ is a composition A prepared by adding 1000 parts of flupyradifluro, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of groups 1 ′ to 12 ′. Configured

  Group 74 'is a composition A prepared by adding 1000 parts of flupyradifluro, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide to the compositions of each of groups 1' to 12 '. Configured

  Group 75 'is a composition A prepared by adding 1000 parts of flupyradifluro, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of groups 1' to 12 '. Configured

  The group 76 'is a composition A prepared by adding 1000 parts of flupyradifluro, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofuranilide to the compositions of each of the groups 1' to 12 '. Configured

  Group 77 'is composed of Composition A in which 1000 parts of flupyradifluro, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of Groups 1' to 12 '. Be done.

  Group 78 'is composed of composition A in which 1000 parts of flupyradifluro, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of brofuranilide are added to the compositions of each of groups 1' to 12 '. Be done.

  Group 79 'is composed of composition A in which 1000 parts of flupyradifluro, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 80 'is composed of composition A in which 1000 parts of flupyradifluro, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 81 'is composed of Composition A in which 1000 parts of flupyradifluro, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of Groups 1' to 12 '. Ru.

  Group 82 'is composed of composition A in which 1000 parts of flupyradifluro, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 1' to 12 '. Ru.

  Group 83 'is composed of Composition A of each of Groups 1' to 12 'plus 1000 parts of flupyradifluro, 1000 parts of tetraniliprol, 1000 parts of bifenthrin and 1000 parts of fipronil. Ru.

  Group 84 'is composed of Composition A in which 1000 parts of flupyradifluro, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of brofuranilide are further added to the compositions of each of Groups 1' to 12 '. Ru.

  Group 85 ′ is a composition A prepared by adding 1000 parts of flupyrimine, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of groups 1 ′ to 12 ′. Configured

  Group 86 'is a composition A prepared by further adding 1000 parts of flupyrimine, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide to each composition of groups 1' to 12 '. Configured

  Group 87 'is a composition A prepared by adding 1000 parts of flupyrimine, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of groups 1' to 12 '. Configured

  Group 88 'is the composition A in which 1000 parts of flupyrimine, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 1' to 12 '. Configured

  Group 89 'is composed of Composition A of each of Groups 1' to 12 'plus 1000 parts of flupyrimine, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of fipronil. Be done.

  Group 90 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 91 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of cyantranililiprole, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 1' to 12 '. Be done.

  Group 92 'is composed of composition A obtained by adding 1000 parts of flupyrimine, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of brofuranilide to the compositions of each of groups 1' to 12 '. Be done.

  Group 93 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 1' to 12 '. Ru.

  Group 94 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 1' to 12 '. Ru.

  Group 95 'is composed of Composition A in which 1000 parts of flupyrimine, 1000 parts of tetraniliprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of Groups 1' to 12 '. Ru.

  Group 96 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 1' to 12 '. Ru.

  Group 97 'is a composition obtained by adding 1000 parts of triflumesopyrim, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of groups 1' to 12 '. It consists of A.

  Group 98 'is a composition obtained by further adding 1000 parts of triflumesopyrim, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide to the compositions of each of groups 1' to 12 '. It consists of A.

  Group 99 'is a composition obtained by further adding 1000 parts of triflumesopyrim, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of groups 1' to 12 '. It consists of A.

  Group 100 'is a composition in which 1000 parts of triflumesopyrim, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 1' to 12 '. It consists of A.

  The group 101 ′ is a composition A in which 1000 parts of triflumesopyrim, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of the groups 1 ′ to 12 ′. It consists of

  The group 102 ′ is a composition A in which 1000 parts of triflumesopyrim, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of the groups 1 ′ to 12 ′. It consists of

  The group 103 ′ is a composition A in which 1000 parts of triflumesopyrim, 1000 parts of cyantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of the groups 1 ′ to 12 ′. It consists of

  The group 104 ′ is a composition A in which 1000 parts of triflumesopyrim, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of the groups 1 ′ to 12 ′. It consists of

  Group 105 ′ is a composition A prepared by adding 1000 parts of triflumesopyrim, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of groups 1 ′ to 12 ′. Configured

  Group 106 'is a composition A prepared by adding 1000 parts of triflumesopyrim, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of brofranilide to the compositions of each of groups 1' to 12 '. Configured

  Group 107 ′ is a composition A prepared by adding 1000 parts of triflumesopyrim, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of groups 1 ′ to 12 ′. Configured

  Group 108 ′ is a composition A prepared by adding 1000 parts of triflumesopyrim, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of brofuranilide to each of the compositions of groups 1 ′ to 12 ′. Configured

  The group 109 'is a composition A prepared by adding 1 part of clothianidin, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of fipronil to each composition of groups 13' to 24 '. Configured

  The group 110 'is prepared by adding the composition of each of the groups 13' to 24 'to the composition A in which 1 part of clothianidin, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of brofuranilide are further added. Configured

  The group 111 'is a composition A prepared by adding 1 part of clothianidin, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of fipronil to each composition of groups 13' to 24 '. Configured

  The group 112 'is prepared by adding the composition of each of the groups 13' to 24 'to the composition A in which 1 part of clothianidin, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of brofuranilide are further added. Configured

  Group 113 'is composed of composition A in which 1 part of clothianidin, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 114 'is composed of Composition A in which 1 part of clothianidin, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 115 'is composed of composition A in which 1 part of clothianidin, 1 part of cyantranililiprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 116 'is composed of Composition A in which 1 part of clothianidin, 1 part of cyantrani riprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 117 'is composed of Composition A in which 1 part of clothianidin, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 118 'is composed of Composition A in which 1 part of clothianidin, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of brofuranilide are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 119 'is composed of composition A in which 1 part of clothianidin, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 120 'is composed of composition A in which 1 part of clothianidin, 1 part of tetraniliprole, 1 part of bifenthrin and 1 part of brofuranilide are further added to the composition of each of groups 13' to 24 '. Ru.

  The group 121 ′ is a composition A prepared by adding 1 part of imidacloprid, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of fipronil to each of the compositions of the groups 13 ′ to 24 ′. Configured

  The group 122 ′ is prepared by adding a portion of imidacloprid, a portion of chlorantraniliprole, a portion of tefluthrin and a portion of brofranilide to each composition of the groups 13 ′ to 24 ′. Configured

  The group 123 ′ is a composition A prepared by adding 1 part of imidacloprid, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of fipronil to each of the compositions of groups 13 ′ to 24 ′. Configured

  The group 124 'is prepared by adding a portion of imidacloprid, a portion of chlorantraniliprole, a portion of bifenthrin and a portion of brofranilide to each composition of the groups 13' to 24 '. Configured

  Group 125 'is composed of composition A in which 1 part of imidacloprid, 1 part of cyantraniliprole, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Be done.

  The group 126 'is composed of the composition A in which 1 part of imidacloprid, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of brofranilide are added to the composition of each of the groups 13' to 24 '. Be done.

  Group 127 'is composed of composition A in which 1 part of imidacloprid, 1 part of cyantraniliprole, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 128 'is composed of composition A in which 1 part of imidacloprid, 1 part of cyantrani riprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 129 'is composed of composition A in which 1 part of imidacloprid, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 130 'is composed of composition A in which 1 part of imidacloprid, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 131 'is composed of composition A in which 1 part of imidacloprid, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 132 'is composed of composition A in which 1 part of imidacloprid, 1 part of tetraniliprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Ru.

  The group 133 'is a composition A prepared by adding 1 part of thiamethoxam, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of fipronil to each of the groups 13' to 24 '. Configured

  The group 134 'is prepared by adding the composition of each of the groups 13' to 24 'together with 1 part of thiamethoxam, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of brofranilide. Configured

  The group 135 'is a composition A prepared by adding 1 part of thiamethoxam, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of fipronil to each of the groups 13' to 24 '. Configured

  The group 136 'is prepared by adding the composition of each of the groups 13' to 24 'to the composition A in which 1 part of thiamethoxam, 1 part of chlorantranilipurol, 1 part of bifenthrin and 1 part of brofranilide are further added. Configured

  Group 137 'is composed of composition A in which 1 part of thiamethoxam, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 138 'is composed of composition A in which 1 part of thiamethoxam, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 139 'is composed of composition A in which 1 part of thiamethoxam, 1 part of cyantranililiprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 140 'is composed of composition A in which 1 part of thiamethoxam, 1 part of cyantranililiprol, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 141 'is composed of composition A in which 1 part of thiamethoxam, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 142 'is composed of Composition A in which 1 part of thiamethoxam, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 143 'is composed of composition A in which 1 part of thiamethoxam, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Ru.

  The group 144 'is composed of a composition A in which 1 part of thiamethoxam, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of the groups 13' to 24 '. Ru.

  The group 145 'is a composition from the composition A in which 1 part of thiacloprid, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of the groups 13' to 24 '. Configured

  The group 146 'is prepared by adding the composition of each of the groups 13' to 24 'to the composition A in which 1 part of thiacloprid, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of brofranilide are further added. Configured

  The group 147 'is a composition from the composition A in which 1 part of thiacloprid, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of the groups 13' to 24 '. Configured

  A group 148 'is prepared by adding a portion of thiacloprid, a portion of chlorantraniliprole, a portion of bifenthrin and a portion of brofuranilide to each of the groups 13' to 24 '. Configured

  Group 149 'is composed of composition A in which 1 part of thiacloprid, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 150 'is composed of composition A in which 1 part of thiacloprid, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Be done.

  The group 151 'is composed of a composition A in which 1 part of thiacloprid, 1 part of cyantranililiprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of the groups 13' to 24 '. Be done.

  Group 152 'is composed of composition A in which 1 part of thiacloprid, 1 part of cyantranililiprol, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 153 'is composed of composition A in which 1 part of thiacloprid, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 154 'is composed of composition A in which 1 part of thiacloprid, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 155 'is composed of composition A in which 1 part of thiacloprid, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 156 'is composed of Composition A in which 1 part of thiacloprid, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Ru.

  The group 157 'is a composition from the composition A in which 1 part of flupyradifluro, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of fipronil are added to the composition of each of the groups 13' to 24 ' Configured

  The group 158 'is prepared by adding the composition of each of the groups 13' to 24 'to the composition A in which 1 part of flupyradifluro, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of brofranilide are further added. Configured

  The group 159 ′ is a composition A prepared by adding 1 part of flupyradifluro, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of fipronil to each composition of groups 13 ′ to 24 ′. Configured

  The group 160 'is prepared by adding the composition of each of the groups 13' to 24 'to the composition A in which 1 part of flupyradifluro, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of brofranilide are further added. Configured

  Group 161 'is composed of composition A in which 1 part of flupyradifluro, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Be done.

  The group 162 'is composed of composition A in which 1 part of flupyradifluro, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of brofuranilide are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 163 'is composed of composition A in which 1 part of flupyradifluro, 1 part of cyantranililiprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 164 'is composed of composition A in which 1 part of flupyradifluro, 1 part of cyantranililiprol, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 165 'is composed of composition A in which 1 part of flupyradifluro, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 166 'is composed of composition A in which 1 part of flupyradifluro, 1 part of tetraniliprole, 1 part of tefluthrin and 1 part of brofuranilide are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 167 'is composed of composition A in which 1 part of flupyradifluro, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Ru.

  The group 168 'is composed of composition A in which 1 part of flupyradifluro, 1 part of tetraniliprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 13' to 24 '. Ru.

  A group 169 'is a composition from the composition A in which 1 part flupyrimine, 1 part chlorantraniliprole, 1 part tefluthrin and 1 part fipronil are further added to the composition of each of the groups 13' to 24 '. Configured

  The group 170 ′ is prepared by adding the composition of each of the groups 13 ′ to 24 ′ to the composition A in which 1 part of flupyrimine, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of brofuranilide are further added. Configured

  The group 171 ′ is a composition A prepared by adding 1 part of flupyrimine, 1 part of chlorantranilipurol, 1 part of bifenthrin and 1 part of fipronil to each composition of groups 13 ′ to 24 ′. Configured

  The group 172 'is prepared by adding the composition of each of the groups 13' to 24 'to the composition A in which 1 part flupyrimine, 1 part chlorantraniliprole, 1 part bifenthrin and 1 part brofranilide are further added. Configured

  Group 173 'is composed of composition A in which 1 part of flupyrimine, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 174 'is composed of composition A in which 1 part of flupyrimine, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of brofuranilide are further added to the composition of each of groups 13' to 24 '. Be done.

  Group 175 'is composed of composition A in which 1 part of flupyrimine, 1 part of cyantranililiprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Be done.

  The group 176 'is composed of a composition A in which 1 part of flupyrimine, 1 part of cyantranililiprol, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of the groups 13' to 24 '. Be done.

  Group 177 ′ is composed of Composition A in which 1 part of flupyrimine, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13 ′ to 24 ′. Ru.

  Group 178 'is composed of composition A in which 1 part of flupyrimine, 1 part of tetraniliprole, 1 part of tefluthrin and 1 part of brofuranilide are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 179 'is composed of Composition A in which 1 part of flupyrimine, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 180 'is composed of composition A in which 1 part of flupyrimine, 1 part of tetraniliprole, 1 part of bifenthrin and 1 part of brofuranilide are further added to the composition of each of groups 13' to 24 '. Ru.

  Group 181 'is a composition in which 1 part of triflumesopyrim, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 13' to 24 '. It consists of A.

  The group 182 'is a composition in which 1 part of triflumesopyrim, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of the groups 13' to 24 '. It consists of A.

  Group 183 ′ is a composition in which 1 part of triflumesopyrim, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 13 ′ to 24 ′. It consists of A.

  The group 184 'is a composition in which 1 part of triflumesopyrim, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of the groups 13' to 24 '. It consists of A.

  The group 185 ′ is a composition A in which 1 part of triflumesopyrim, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of the groups 13 ′ to 24 ′. It consists of

  The group 186 ′ is a composition A in which 1 part of triflumesopyrim, 1 part of cyantrani riprole, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of the groups 13 ′ to 24 ′. It consists of

  The group 187 ′ is a composition A in which 1 part of triflumesopyrim, 1 part of cyantrani riprole, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of the groups 13 ′ to 24 ′. It consists of

  The group 188 ′ is a composition A in which 1 part of triflumesopyrim, 1 part of cyantrani riprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of the groups 13 ′ to 24 ′. It consists of

  Group 189 ′ is a composition A prepared by adding 1 part of triflumesopyrim, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil to each of the compositions of groups 13 ′ to 24 ′. Configured

  The group 190 ′ is prepared by adding the composition of each of the groups 13 ′ to 24 ′ to the composition A in which 1 part of triflumesopyrim, 1 part of tetraniriprole, 1 part of tefluthrin and 1 part of brofranilide are further added. Configured

  The group 191 ′ is a composition A prepared by adding 1 part of triflumesopyrim, 1 part of tetraniriprole, 1 part of bifenthrin and 1 part of fipronil to each of the compositions of groups 13 ′ to 24 ′. Configured

  The group 192 'is a composition from the composition A in which 1 part of triflumesopyrim, 1 part of tetraniriprole, 1 part of bifenthrin and 1 part of brofranilide are added to the composition of each of the groups 13' to 24 '. Configured

  Group 193 'is composed of composition A in which 1000 parts of Bacillus subutilis strain QST 713 is further added to the composition of each of groups 25' to 108 '.

  The group 194 'is composed of the composition A in which 1000 parts of Agrobacterium radiobacter strain K84 is further added to the composition of each of the groups 25' to 108 '.

  The group 195 'is composed of the composition A obtained by adding 1000 parts of Bacillus amyloliquefaciens strain MBI 600 to the composition of each of the groups 25' to 108 '.

  Group 196 'is composed of composition A in which 1000 parts of Bacillus pumilus strain QST 2808 is further added to the composition of each of groups 25' to 108 '.

  Group 197 'is composed of composition A obtained by adding 1000 parts of Burkholderia cepacia to the composition of each of groups 25' to 108 '.

  The group 198 'is composed of the composition A obtained by adding 1000 parts of Gliocladium catenulatum strain J1446 to the composition of each of the groups 25' to 108 '.

  The group 199 'is composed of the composition A in which 1000 parts of Pseudomonas chlororaphis strain MA 342 is further added to the composition of each of the groups 25' to 108 '.

  Group 200 'is composed of composition A in which 1000 parts of Pseudomonas fluorescens is further added to the composition of each of groups 25' to 108 '.

  Group 201 'is composed of composition A obtained by adding 1000 parts of Pythium oligandrum strain DV74 to each composition of groups 25' to 108 '.

  The group 202 'is composed of the composition A in which 1000 parts of Streptomyces griseoviridis strain K61 is further added to the composition of each of the groups 25' to 108 '.

  Group 203 'is composed of composition A in which 1000 parts of Trichoderma gamsii is further added to the composition of each of groups 25' to 108 '.

  The group 204 'is composed of the composition A in which 1000 parts of Trichoderma asperellum is further added to the composition of each of the groups 25' to 108 '.

  The group 205 'is composed of the composition A in which 1000 parts of Trichoderma harzianum strain T-22 is further added to the composition of each of the groups 25' to 108 '.

  The group 206 'is composed of composition A in which 1000 parts of Trichoderma virens strain GL-21 is further added to the composition of each of the groups 25' to 108 '.

  The group 207 'is composed of the composition A in which 1000 parts of Streptomyces lydicus strain WYEC 108 is further added to the composition of each of the groups 25' to 108 '.

  Group 208 'is composed of composition A obtained by adding 1000 parts of Bacillus thuringiensis subsp. Kurstraki strain ABTS-351 to the composition of each of groups 25' to 108 '.

  Group 209 'is composed of composition A obtained by adding 1000 parts of Bacillus thuringiensis subs. Kurstraki strain MBP 123 to each composition of groups 25' to 108 '.

  The group 210 'is composed of the composition A obtained by adding 1000 parts of Bacillus thuringiensis subs. Aizawai strain ABTS-1857 to the composition of each of the groups 25' to 108 '.

  Group 211 'is composed of composition A in which 1000 parts of Bacillus thuringiensis strain EX297512 is further added to the composition of each of groups 25' to 108 '.

  The group 212 'is composed of the composition A in which 1000 parts of the Metarhizium anisopliae strain F52 is further added to the composition of each of the groups 25' to 108 '.

  The group 213 'is composed of the composition A obtained by adding 1000 parts of Bacillus firmus strain 1-1582 to the composition of each of the groups 25' to 108 '.

  The group 214 'is composed of the composition A in which 1000 parts of Pasteuria nishizawae strain Pn1 is further added to the composition of each of the groups 25' to 108 '.

  The group 215 'is composed of the composition A in which 10000 parts of Bradyrhizobium japonicum strain TA-11 is further added to the composition of each of the groups 25' to 108 '.

  The group 216 'is composed of composition A in which 10000 parts of Sinorhizobium meliloti is further added to the composition of each of the groups 25' to 108 '.

  Group 217 'is composed of composition A in which 10000 parts of Rhizobium leguminosarum is further added to the composition of each of groups 25' to 108 '.

  The group 218 'is composed of the composition A in which 10000 parts of Rhizophagus intraradices strain RTI-801 is further added to the composition of each of the groups 25' to 108 '.

  Group 219 'is composed of composition A in which 10000 parts of Bacillus amyloliquefaciens and 10000 parts of Trichoderma virens are further added to the compositions of each of groups 25' to 108 '.

  The group 220 'is composed of the composition A in which 10000 parts of Penicillium bilaiae and 10000 parts of Bradyrhizobium japonicum are further added to the composition of each of the groups 25' to 108 '.

  The group 221 'is composed of composition A in which 10000 parts of Penicillium bilaiae and 10000 parts of Mesorhizobium ciceri are further added to the compositions of each of the groups 25' to 108 '.

  The group 222 'is composed of the composition A in which 10000 parts of Bradyrhizobium japonicum and 10000 parts of lipochitooligosaccharide are further added to the compositions of each of the groups 25' to 108 '.

  Group 223 'is composed of composition A in which 1 part of Bacillus subutilis strain QST 713 is further added to the composition of each of groups 109' to 192 '.

  The group 224 'is composed of the composition A in which 1 part of Agrobacterium radiobacter strain K84 is further added to the composition of each of the groups 109' to 192 '.

  The group 225 'is composed of the composition A in which 1 part of Bacillus amyloliquefaciens strain MBI 600 is further added to the composition of each of the groups 109' to 192 '.

  The group 226 'is composed of the composition A in which 1 part of Bacillus pumilus strain QST 2808 is further added to the composition of each of the groups 109' to 192 '.

  Group 227 'is composed of composition A obtained by adding 1 part of Burkholderia cepacia to the composition of each of groups 109' to 192 '.

  The group 228 'is composed of the composition A in which 1 part of Gliocladium catenulatum strain J1446 is further added to the composition of each of the groups 109' to 192 '.

  Group 229 'is composed of Composition A in which 1 part of Pseudomonas chlororaphis strain MA 342 is further added to the composition of each of Groups 109' to 192 '.

  Group 230 'is composed of composition A in which 1 part of Pseudomonas fluorescens is further added to the composition of each of groups 109' to 192 '.

  Group 231 'is composed of composition A obtained by adding 1 part of Pythium oligandrum strain DV74 to each composition of groups 109' to 192 '.

  Group 232 'is composed of composition A in which 1 part of Streptomyces griseoviridis strain K61 is further added to the composition of each of groups 109' to 192 '.

  Group 233 'is composed of composition A in which 1 part of Trichoderma gamsii is further added to the composition of each of groups 109' to 192 '.

  The group 234 'is composed of composition A in which 1 part of Trichoderma asperellum is further added to the composition of each of the groups 109' to 192 '.

  The group 235 'is composed of the composition A in which 1 part of Trichoderma harzianum strain T-22 is further added to the composition of each of the groups 109' to 192 '.

  Group 236 'is composed of composition A in which 1 part of Trichoderma virens strain GL-21 is further added to the composition of each of groups 109' to 192 '.

  Group 237 'is composed of composition A in which 1 part of Streptomyces lydicus strain WYEC 108 is further added to the composition of each of groups 109' to 192 '.

The group 238 'is composed of the composition A in which 1 part of Bacillus thuringiensis subsp. Kurstraki strain ABTS-351 is further added to the composition of each of the groups 109' to 192 '.

  The group 239 'is composed of the composition A in which 1 part of Bacillus thuringiensis subs. Kurstraki strain MBP 123 is further added to the composition of each of the groups 109' to 192 '.

  The group 240 'is composed of the composition A obtained by adding 1 part of Bacillus thuringiensis subs. Aizawai strain ABTS-1857 to the composition of each of the groups 109' to 192 '.

  The group 241 'is composed of the composition A in which 1 part of Bacillus thuringiensis strain EX297512 is further added to the composition of each of the groups 109' to 192 '.

  The group 242 'is composed of the composition A in which 1 part of the Metarhizium anisopliae strain F52 is further added to the composition of each of the groups 109' to 192 '.

  Group 243 'is composed of composition A obtained by adding 1 part of Bacillus firmus strain 1-1582 to the composition of each of groups 109' to 192 '.

  The group 244 'is composed of the composition A in which 1 part of Pasteuria nishizawae strain Pn1 is further added to the composition of each of the groups 109' to 192 '.

  The group 245 'is composed of the composition A in which 1 part of Bradyrhizobium japonicum strain TA-11 is further added to the composition of each of the groups 109' to 192 '.

  The group 246 'is composed of the composition A in which 1 part of Sinorhizobium meliloti is further added to the composition of each of the groups 109' to 192 '.

  The group 247 'is composed of the composition A in which 1 part of Rhizobium leguminosarum is further added to the composition of each of the groups 109' to 192 '.

  The group 248 'is composed of composition A in which 1 part of Rhizophagus intraradices strain RTI-801 is further added to the composition of each of the groups 109' to 192 '.

  The group 249 'is composed of the composition A obtained by adding 1 part of Bacillus amyloliquefaciens and 1 part of Trichoderma virens to the composition of each of the groups 109' to 192 '.

  Group 250 'is composed of composition A in which 1 part Penicillium bilaiae and 1 part Bradyrhizobium japonicum are further added to the composition of each of groups 109' to 192 '.

  Group 251 'is composed of composition A in which 1 part Penicillium bilaiae and 1 part Mesorhizobium ciceri are further added to the composition of each of groups 109' to 192 '.

  The group 252 'is composed of a composition A obtained by adding 1 part of Bradyrhizobium japonicum and 1 part of lipochitooligosaccharide to each of the compositions of the groups 109' to 192 '.

  Group 253 'is composed of composition A in which 1000 parts of fluazaindolizine is further added to the composition of each of groups 193' to 222 '.

  Group 254 'is composed of composition A obtained by adding 1000 parts of thioxazaphen to each composition of groups 193' to 222 '.

  Group 255 'is composed of composition A, in which 1000 parts of fluene sulfone is further added to the composition of each of groups 193' to 222 '.

  Group 256 'is composed of composition A in which 1000 parts of abamectin are further added to the composition of each of groups 193' to 222 '.

  Group 257 'is composed of composition A obtained by adding 1000 parts of fluopyram to each composition of groups 193' to 222 '.

  Group 258 'is composed of composition A in which 1 part of fluazaindolizine is further added to the composition of each of groups 223' to 252 '.

  The group 259 'is composed of the composition A in which 1 part of thioxazaphen is further added to the composition of each of the groups 223' to 252 '.

  Group 260 'is composed of composition A in which 1 part of fluene sulfone is further added to the composition of each of groups 223'-252'.

  Group 261 'is composed of composition A in which 1 part of abamectin is further added to the composition of each of groups 223' to 252 '.

  The group 262 'is composed of composition A in which 1 part of fluopyram is further added to the composition of each of the groups 223' to 252 '.

  In group 263 ', the combination of SX, main component 1, main component 2, main component 3, main component 4, main component 5 and main component 6 is any combination of the following "7 active ingredient list", Composition comprising 1000 parts of SX, 1 part of the component 1, 1 part of the component 2, 1 part of the component 3, 1 part of the component 4, 1 part of the component 5 and 1 part of the component 6 It consists of A.

  In the "7 list of active ingredients", for example, SX + metconazole + mandestrobin + fluopyram + fludioxonil + metalaxyl + ethaboxam means a combination of SX, metconazole, mandestrobin, fluopyram, fludioxonil, metalaxyl and etaboxam, this ingredient 1 is metconazole, this component 2 is mandestorobin, this component 3 is fluopyram, this component 4 is fludioxonil, this component 5 is metalaxyl, and this component 6 is etaboxam.

"7 active ingredient list":
SX + Metconazole + Mandestrobin + Fluopyram + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + fluopyram + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + mandestorobin + fluopyram + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + mandestorobin + fluopyram + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + mandestorobin + fluopyram + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + fluopyram + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + fluopyram + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + fluopyram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Boscalid + Metalaxyl + Etavoxam,
SX + metconazole + mandestorobin + fluopyram + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + fluopyram + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + mandestorobin + fluopyram + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + fluopyram + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + mandestrobin + fluopyram + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluopyram + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Thiophane Methyl + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + fluxapiroxide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + mandestorobin + fluxapiroxide + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxide + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + fluxapiroxide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxide + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxide + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Fluxapiroxide + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxide + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + boscalid + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + mandestrobin + boscalid + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + mandestorobin + boscalid + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + mandestorobin + boscalid + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Boscalid + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Boscalid + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + boscalid + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Boscalid + Metalaxyl + Etavoxam,
SX + metconazole + mandestrobin + boscalid + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + boscalid + aminopyrifene + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + mandestrobin + boscalid + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + mandestrobin + boscalid + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Boscalid + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + penflufen + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + mandestorobin + penflufen + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + mandestorobin + penflufen + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + mandestorobin + penflufen + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + penflufen + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Penflufen + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Penfulfen + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + mandestrobin + penflufen + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Penfulfen + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + mandestrobin + penflufen + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + penflufen + aminopyrifene + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + mandestrobin + penflufen + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + mandestrobin + penflufen + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Penflufen + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Thifluzamide + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + thifluzamide + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Thifluzamide + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Thifluzamide + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + thifluzamide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + mandestorobin + thifluzamide + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Thifluzamide + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + thifluzamide + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Thifluzamide + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Tifluzamide + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + thifluzamide + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Tifluzamide + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Tifluzamide + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + thifluzamide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + mandestorobin + thifluzamide + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Tifluzamide + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Tifluzamide + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Tifluzamide + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Tifluzamide + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + thifluzamide + aminopyrifene + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Tifluzamide + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Tifluzamide + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + thifluzamide + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Tifluzamide + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Tifluzamide + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + thifluzamide + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Tifluzamide + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Impilfurxam + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + impilfurxam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + mandestorobin + impilfurxam + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Impilfurxam + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + mandestrobin + impilfurxam + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + impilfurxam + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Torclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + mandestrobin + impilfurxam + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Impilfurxam + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + metconazole + mandestorobin + impilfurxam + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Impilfurxam + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Impilfulxam + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + mandestrobin + impilfurxam + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Mandestrobin + Impilfurxam + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Sedaxane + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Thiophane Methyl + Metalaxyl + Etaboxam,
SX + metconazole + mandestorobin + sedaxanthe + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + mandestorobin + sedaxanthe + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Sedaxane + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Sedaxane + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Sedaxane + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Sedaxane + Aminopyriphene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Aminopyriphene + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Sedaxane + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Sedaxane + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Sedaxane + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiophane Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiophane Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiophane Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Pidifulmethofen + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + metconazole + mandestorobin + isoflucypram + fludioxonil + metalaxyl + etaboxam,
SX + Metconazole + Mandestrobin + Isoflucipram + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Isoflucipram + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Isoflusipram + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Isoflucipram + Thiophanate Methyl + Metalaxyl + Oxathiapiproline,
SX + metconazole + mandestorobin + isoflucipam + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Isoflucipram + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Isoflucipram + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Isoflucipram + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Mandestrobin + Isoflusipram + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Isoflusipram + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Isoflusipram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + metconazole + mandestorobin + isoflucypram + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + mandestorobin + isoflucypram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + mandestorobin + isoflucypram + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + metconazole + mandestrobin + isoflucypram + boscalid + metalaxyl + etaboxam,
SX + metconazole + mandestorobin + isoflucypram + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + mandestorobin + isoflucypram + boscalid + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Isoflusipram + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Isoflusipram + Aminopyriphene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Isoflusipram + Aminopyrifene + Metalaxyl + Fluoxapiproline,
SX + metconazole + mandestrobin + isoflucypram + mancozeb + metalaxyl + etaboxam,
SX + metconazole + mandestorobin + isoflucypram + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + mandestrobin + isoflucypram + mancozeb + metalaxyl + fluoxapiproline,
SX + Metconazole + Mandestrobin + Isoflusipram + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Mandestrobin + Isoflusipram + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Mandestrobin + Isoflusipram + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Fludioxonil + Metalaxyl + Etaboxam,
SX + methconazole + azoxystrobin + fluopyram + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + azoxystrobin + fluopyram + thiophanate methyl + metalaxyl + etaboxam,
SX + methconazole + azoxystrobin + fluopyram + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + methconazole + azoxystrobin + fluopyram + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + fluopyram + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Thiuram + Metalaxyl + Etaboxam,
SX + methconazole + azoxystrobin + fluopyram + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluopiram + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + methconazole + azoxystrobin + fluopyram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + methconazole + azoxystrobin + fluopyram + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Fluopyram + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + fluopyram + aminopyrifene + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Aminopyrifene + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + fluopyram + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + fluopyram + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluopyram + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Thiophanate Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Thiophanate Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + fluxapiroxide + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + fluxapiroxide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxad + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + fluxapiroxide + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + fluxapiroxide + aminopyrifene + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxad + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxide + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + fluxapiroxad + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + boscalid + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + boscalid + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + boscalid + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + boscalid + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + boscalid + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + methconazole + azoxystrobin + boscalid + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + boscalid + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + boscalid + aminopyriphen + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + boscalid + aminopyriphen + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + boscalid + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + boscalid + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Boscalid + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + penflufen + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + penflufen + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + penflufen + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Penflufen + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + penflufen + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Penfulfen + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + penflufen + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + penflufen + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + penflufen + aminopyriphen + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + penflufen + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + penflufen + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Penflufen + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Thifluzamide + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + thifluzamide + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Thifluzamide + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Thifluzamide + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + thifluzamide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + thifluzamide + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Thifluzamide + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + thifluzamide + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Thifluzamide + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Tifluzamide + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + thifluzamide + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Thifluzamide + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Thifluzamide + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + thifluzamide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + thifluzamide + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Thifluzamide + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Tifluzamide + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Tifluzamide + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Tifluzamide + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + thifluzamide + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + thifluzamide + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Tifluzamide + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + thifluzamide + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Thifluzamide + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Thifluzamide + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + thifluzamide + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Tifluzamide + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Impilfurxam + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + impilfurxam + fludioxonil + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + impilfulxamm + fludioxonil + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Impilfurxam + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + impilfurxam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + impilfurxam + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Impilfurxam + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + impilfulxamm + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Impilfurxam + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Impilfurxam + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + impilfurxam + thiuram + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + impilfurxam + thiuram + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Impilfurxam + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + impilfurxam + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + impilfurxam + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Impilfurxam + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + impilfurxam + boscalid + metalaxyl + oxathiapiproline,
SX + Metoconazole + Azoxystrobin + Impilfurxam + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Impilfurxam + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + impilfurxam + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + impilfulxamm + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Impilfurxam + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + impilfurxam + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + impilfurxam + mancozeb + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Impilfurxam + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + impilfurxam + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Impilfurxam + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Sedaxane + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + sedaxanthe + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + sedaxanthe + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + sedaxanthe + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Sedaxane + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Sedaxane + Aminopyriphene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Aminopyriphene + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + sedaxanthe + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Sedaxane + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Sedaxane + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiophane Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Tolclophos Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + metconazole + azoxystrobin + isoflucipram + fludioxonil + metalaxyl + etaboxam,
SX + metconazole + azoxystrobin + isoflucypram + fludioxonil + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + isoflucypram + fludioxonil + metalaxyl + fluoxapiproline,
SX + Metoconazole + Azoxystrobin + Isoflucipram + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + isoflucipam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Isoflucipram + Thiophanate Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Azoxystrobin + Isoflucipram + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Isoflucipram + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Isoflucipram + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + metconazole + azoxystrobin + isoflucipram + thiuram + metalaxyl + etaboxam,
SX + Metconazole + Azoxystrobin + Isoflusipram + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Isoflusipram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + metconazole + azoxystrobin + isoflucipram + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + azoxystrobin + isoflucypram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + isoflucypram + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metoconazole + Azoxystrobin + Isoflucipram + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + azoxystrobin + isoflucypram + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + isoflucypram + boscalid + metalaxyl + fluoxapiproline,
SX + Metconazole + Azoxystrobin + Isoflusipram + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Azoxystrobin + Isoflusipram + Aminopyriphene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Azoxystrobin + Isoflusipram + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + metconazole + azoxystrobin + isoflucipram + mancozeb + metalaxyl + etaboxam,
SX + metconazole + azoxystrobin + isoflucypram + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + azoxystrobin + isoflucypram + mancozeb + metalaxyl + fluoxapiproline,
SX + metconazole + azoxystrobin + isoflucipram + carbendazim + metalaxyl + etaboxam,
SX + metconazole + azoxystrobin + isoflucypram + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Azoxystrobin + Isoflucipram + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluopyram + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + fluopyram + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluopyram + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + fluoxastrobin + fluopyram + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + fluopyram + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + fluopyram + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluopyram + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + fluopyram + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluopyram + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluopyram + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + fluopyram + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluopyram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluopyram + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + fluopyram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + fluopyram + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + metconazole + fluoxastrobin + fluopyram + boscalid + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + fluopyram + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluopyram + Boscalid + Metalaxyl + Fluoxapiproline,
SX + metconazole + fluoxastrobin + fluopyram + aminopyrifene + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + fluopyram + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + fluopyram + aminopyrifene + metalaxyl + fluoxapiproline,
SX + metconazole + fluoxastrobin + fluopyram + mancozeb + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + fluopyram + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + fluopyram + mancozeb + metalaxyl + fluoxapiproline,
SX + metconazole + fluoxastrobin + fluopyram + carbendazim + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + fluopyram + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluopyram + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + fluxapiroxide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Thiophane Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + fluxapiroxide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + fluxapiroxad + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxide + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Boscalid + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + boscalid + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Boscalid + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + fluoxastrobin + boscalid + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + boscalid + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + boscalid + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Boscalid + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + boscalid + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Boscalid + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Boscalid + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + boscalid + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Boscalid + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Boscalid + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + boscalid + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + boscalid + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Boscalid + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + boscalid + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Boscalid + Boscalid + Metalaxyl + Fluoxapiproline,
SX + metconazole + fluoxastrobin + boscalid + aminopyriphen + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + boscalid + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + boscalid + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Boscalid + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + boscalid + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + boscalid + mancozeb + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Boscalid + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + boscalid + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Boscalid + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + penflufen + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + fluoxastrobin + penflufen + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + penflufen + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + penflufen + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + penflufen + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + penflufen + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + penflufen + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + penflufen + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + penflufen + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + penflufen + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + penflufen + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + penflufen + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + penflufen + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Penflufen + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + fluoxastrobin + thifluzamide + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + thifluzamide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + thifluzamide + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + thifluzamide + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + thifluzamide + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + thifluzamide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Thifluzamide + Torclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + thifluzamide + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + thifluzamide + aminopyrifene + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + thifluzamide + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Tifluzamide + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + impilfurxam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Thiophanate Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Thiuram + Metalaxyl + Oxathiapiproline,
SX + metconazole + fluoxastrobin + impilfurxam + thiuram + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + impilfurxam + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + impilfurxam + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + impilfurxam + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + impilfulxamm + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + impilfurxam + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Impilfurxam + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Sedaxane + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Thiophane Methyl + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + sedaxane + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + sedaxanthin + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Sedaxane + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Sedaxane + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + sedaxanthe + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Sedaxane + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Sedaxane + Aminopyriphene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Sedaxane + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Sedaxane + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Sedaxane + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiophanato Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + metconazole + fluoxastrobin + isoflucypram + fludioxonil + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + isoflucypram + fludioxonil + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + isoflucypram + fludioxonil + metalaxyl + fluoxapiproline,
SX + metconazole + fluoxastrobin + isoflucypram + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + isoflucipam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + isoflucipam + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metoconazole + Fluoxastrobin + Isoflucipram + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Isoflucipram + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Isoflucipram + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + fluoxastrobin + isoflucypram + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + metconazole + fluoxastrobin + isoflucypram + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + isoflucypram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + isoflucypram + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + metconazole + fluoxastrobin + isoflucypram + boscalid + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + isoflucypram + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + isoflucypram + boscalid + metalaxyl + fluoxapiproline,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Aminopyrifene + Metalaxyl + Etaboxam,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Aminopyriphene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Fluoxastrobin + Isoflusipram + Aminopyrifene + Metalaxyl + Fluoxapiproline,
SX + metconazole + fluoxastrobin + isoflucypram + mancozeb + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + isoflucypram + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + isoflucypram + mancozeb + metalaxyl + fluoxapiproline,
SX + metconazole + fluoxastrobin + isoflucypram + carbendazim + metalaxyl + etaboxam,
SX + metconazole + fluoxastrobin + isoflucypram + carbendazim + metalaxyl + oxathiapiproline,
SX + metconazole + fluoxastrobin + isoflucypram + carbendazim + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluopiram + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + fluopyram + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Fluopyram + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluopiram + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + fluopyram + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Fluopyram + Thiophane Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluopyram + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Fluopyram + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Fluopyram + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluopyram + Thiuram + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Fluopyram + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Fluopyram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluopiram + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + fluopyram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Fluopyram + Torclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluopyram + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Fluopyram + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Fluopyram + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluopyram + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + fluopyram + aminopyrifene + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Fluopyram + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluopyram + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Fluopyram + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Fluopyram + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluopyram + Carbendazim + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Fluopyram + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Fluopyram + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + fluxapiroxide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + fluxapiroxide + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + fluxapiroxide + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + fluxapiroxide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metoconazole + Trifloxystrobin + Fluxapiroxide + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Fluxapiroxide + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Mancozeb + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Fluxapiroxide + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxide + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + fluxapiroxad + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Boscalid + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + boscalid + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Boscalid + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Boscalid + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + boscalid + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + boscalid + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Boscalid + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Boscalid + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Boscalid + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Boscalid + Thiuram + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Boscalid + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Boscalid + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Boscalid + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + boscalid + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + boscalid + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Boscalid + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + trifroxistorobin + boscalid + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + trifroxistorobin + boscalid + boscalid + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Boscalid + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + boscalid + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + boscalid + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Boscalid + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + boscalid + mancozeb + metalaxyl + oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Boscalid + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Boscalid + Carbendazim + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Boscalid + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Boscalid + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + penflufen + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + penflufen + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + penflufen + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + penflufen + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + penflufen + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Penfulfen + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + penflufen + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + penflufen + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Penfulfen + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Penflufen + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + penflufen + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + penflufen + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Penflufen + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + penflufen + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Penflufen + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + thifluzamide + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + trifloxystrobin + thifluzamide + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + trifloxystrobin + thifluzamide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + thifluzamide + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + thifluzamide + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + thifluzamide + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + thifluzamide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + thifluzamide + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Tifluzamide + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + thifluzamide + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Tifluzamide + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + thifluzamide + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + thifluzamide + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Tifluzamide + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + thifluzamide + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Tifluzamide + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + thifluzamide + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Thifluzamide + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + impilfurxam + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + trifloxystrobin + impilfurxam + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + trifloxystrobin + impilfurxam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + impilfurxam + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + impilfulxamm + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Tiuram + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + impilfurxam + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + impilfurxam + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + impilfurxam + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + impilfurxam + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + impilfulxamm + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + impilfurxam + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Impilfurxam + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Sedaxane + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Sedaxane + Thiophane Methyl + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Thiophanate Methyl + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Thiophane Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifroxistorobin + Sedaxane + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Sedaxane + Thiuram + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Sedoxane + Tolclophos Methyl + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Sedaxane + Boscalid + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Sedaxane + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Aminopyriphene + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Aminopyriphene + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Sedaxane + Mancozeb + Metalaxyl + Etaboxam,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Sedaxane + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + trifroxistorobin + sedaxanthe + carbendazim + metalaxyl + oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Sedaxane + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Methyl Thiophanato + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Tolclophos Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Pidiflumethofen + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metoconazole + Trifloxystrobin + Isoflusipram + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + isoflucypram + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Isoflusipram + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + isoflucipam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + isoflucipam + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + isoflucypram + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Isoflusipram + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + metconazole + trifloxystrobin + isoflucypram + thiuram + metalaxyl + etaboxam,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + metconazole + trifloxystrobin + isoflucypram + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + trifloxystrobin + isoflucypram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + trifloxystrobin + isoflucypram + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metoconazole + Trifloxystrobin + Isoflusipram + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + isoflucypram + boscalid + metalaxyl + oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Isoflusipram + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Trifloxystrobin + Isoflusipram + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metoconazole + Trifloxystrobin + Isoflusipram + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + isoflucypram + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + trifloxystrobin + isoflucypram + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Trifloxystrobin + Isoflusipram + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluopyram + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + fluopyram + fludioxonil + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + fluopyram + fludioxonil + metalaxyl + fluoxapiproline,
SX + metconazole + pyraclostrobin + fluopyram + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + pyraclostrobin + fluopyram + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + fluopyram + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluopyram + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + fluopyram + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Fluopyram + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluopyram + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + fluopyram + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Fluopyram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluopiram + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + fluopyram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + fluopyram + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + metconazole + pyraclostrobin + fluopyram + boscalid + metalaxyl + etaboxam,
SX + metconazole + pyraclostrobin + fluopyram + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Fluopyram + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluopirum + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + fluopyram + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + fluopyram + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluopyram + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + fluopyram + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + fluopyram + mancozeb + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluopyram + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + fluopyram + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Fluopyram + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Thiophane Methyl + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + fluxapiroxide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Thiophanato Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + fluxapiroxide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metoconazole + Pyraclostrobin + Fluxapiroxide + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxide + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + fluxapiroxad + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + boscalid + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + pyraclostrobin + boscalid + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + pyraclostrobin + boscalid + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + boscalid + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + boscalid + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + boscalid + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + boscalid + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + boscalid + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + boscalid + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + boscalid + aminopyriphen + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + boscalid + aminopyriphen + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + boscalid + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + boscalid + mancozeb + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + boscalid + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Boscalid + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + penflufen + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + pyraclostrobin + penflufen + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + pyraclostrobin + penflufen + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + penflufen + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + penflufen + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Penflufen + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Penfulfen + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + penflufen + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Penfulfen + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + penflufen + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + penflufen + aminopyrifene + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + penflufen + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + penflufen + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Penflufen + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Thifluzamide + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Thifluzamide + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Thifluzamide + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + pyraclostrobin + thifluzamide + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + pyraclostrobin + thifluzamide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + thifluzamide + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Thifluzamide + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + thifluzamide + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Thifluzamide + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + thifluzamide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Torclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + tifluzamide + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + tifluzamide + aminopyrifene + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + tifluzamide + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + tifluzamide + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Tifluzamide + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metoconazole + Pyraclostrobin + Impilfurxam + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + impilfurxam + fludioxonil + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + impilfurxam + fludioxonil + metalaxyl + fluoxapiproline,
SX + metconazole + pyraclostrobin + impilfurxam + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + pyraclostrobin + impilfurxam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + impilfurxam + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + impilfurxam + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + impilfurxam + thiuram + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + impilfurxam + thiuram + metalaxyl + fluoxapiproline,
SX + metconazole + pyraclostrobin + impilfurxam + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + pyraclostrobin + impilfurxam + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + impilfurxam + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + impilfurxam + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + impilfurxam + boscalid + metalaxyl + fluoxapiproline,
SX + metconazole + pyraclostrobin + impilfurxam + aminopyrifene + metalaxyl + etaboxam,
SX + metconazole + pyraclostrobin + impilfurxam + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + impilfurxam + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + impilfurxam + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + impilfurxam + mancozeb + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + impilfurxam + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Impilfurxam + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Sedaxane + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + pyraclostrobin + sedaxanthe + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + pyraclostrobin + sedaxanthe + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + sedaxanthe + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Sedaxane + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Sedaxane + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + sedaxanthe + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Sedaxane + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Sedaxane + Aminopyriphene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Sedaxane + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Sedaxane + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Sedaxane + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiophane Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiophanato Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiophanato Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Tolclophos Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Aminopyrifene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metoconazole + Pyraclostrobin + Isoflusipam + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + isoflucypram + fludioxonil + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + isoflucypram + fludioxonil + metalaxyl + fluoxapiproline,
SX + Metoconazole + Pyraclostrobin + Isoflusipram + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + isoflucipam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + isoflucipam + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metoconazole + Pyraclostrobin + Isoflusipram + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + isoflucypram + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metoconazole + Pyraclostrobin + Isoflusipram + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Thiuram + Metalaxyl + Etaboxam,
SX + Metoconazole + Pyraclostrobin + Isoflusipram + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metoconazole + Pyraclostrobin + Isoflusipam + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + isoflucipam + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + isoflucypram + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metoconazole + Pyraclostrobin + Isoflusipram + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + isoflucypram + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + isoflucypram + boscalid + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Aminopyriphene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metoconazole + Pyraclostrobin + Isoflusipram + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + isoflucypram + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + pyraclostrobin + isoflucypram + mancozeb + metalaxyl + fluoxapiproline,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + pyraclostrobin + isoflucypram + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Pyraclostrobin + Isoflusipram + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluopyram + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + fluopyram + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluopyram + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + picoxystrobin + fluopyram + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + picoxystrobin + fluopyram + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + fluopyram + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluopyram + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + fluopyram + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluopyram + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluopyram + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + fluopyram + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluopyram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + metconazole + picoxystrobin + fluopyram + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + picoxystrobin + fluopyram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + fluopyram + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + metconazole + picoxystrobin + fluopyram + boscalid + metalaxyl + etaboxam,
SX + metconazole + picoxystrobin + fluopyram + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + fluopyram + boscalid + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluopyram + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + fluopyram + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + fluopyram + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluopyram + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + fluopyram + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluopyram + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluopyram + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + fluopyram + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluopyram + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Thiophanato Methyl + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + fluxapiroxide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + fluxapiroxide + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Tolclophos Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Fluxapiroxide + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Fluxapiroxad + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + boscalid + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + boscalid + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + boscalid + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + boscalid + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + boscalid + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + boscalid + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + boscalid + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + boscalid + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + boscalid + aminopyriphen + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + boscalid + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + boscalid + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Boscalid + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + penflufen + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + penflufen + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + penflufen + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + penflufen + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + penflufen + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Penfulfen + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + penflufen + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Penfulfen + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + penflufen + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + penflufen + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + penflufen + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + penflufen + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + penflufen + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Penflufen + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Thifluzamide + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Thifluzamide + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Thifluzamide + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Thifluzamide + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + thifluzamide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + thifluzamide + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Thifluzamide + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + thifluzamide + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Thifluzamide + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Thifluzamide + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + thifluzamide + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Thifluzamide + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Thifluzamide + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + thifluzamide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + thifluzamide + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Thifluzamide + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + thifluzamide + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Tifluzamide + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Tifluzamide + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + thifluzamide + aminopyrifene + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Tifluzamide + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Tifluzamide + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + thifluzamide + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Tifluzamide + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Thifluzamide + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + thifluzamide + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Thifluzamide + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Impilfurxam + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + impilfurxam + fludioxonil + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + impilfurxam + fludioxonil + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Impilfurxam + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + impilfurxam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + impilfurxam + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Impilfurxam + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + impilfurxam + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Impilfurxam + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Impilfurxam + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + impilfurxam + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Impilfurxam + Thiuram + Metalaxyl + Fluoxapiproline,
SX + metconazole + picoxystrobin + impilfurxam + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + picoxystrobin + impilfurxam + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + impilfurxam + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Impilfurxam + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + impilfurxam + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Impilfurxam + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Impilfurxam + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + impilfurxam + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + impilfurxam + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Impilfurxam + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + impilfurxam + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Impilfurxam + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Impilfurxam + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + impilfurxam + carbendazim + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + impilfurxam + carbendazim + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Sedaxane + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Thiophane Methyl + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + sedaxanthe + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + sedaxanthe + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Sedaxane + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Sedaxane + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + sedaxanthe + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Sedaxane + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Sedaxane + Aminopyriphene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + sedaxanthe + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Sedaxane + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Sedaxane + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiophanate Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiophanato Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Tolclophos Methyl + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Torclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethofen + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethophene + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Pidiflumethofen + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Pidiflumethofen + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + metconazole + picoxystrobin + isoflucypram + fludioxonil + metalaxyl + etaboxam,
SX + metconazole + picoxystrobin + isoflucypram + fludioxonil + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + isoflucypram + fludioxonil + metalaxyl + fluoxapiproline,
SX + metconazole + picoxystrobin + isoflucypram + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + picoxystrobin + isoflucipam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + isoflucipam + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Isoflucipram + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Isoflucipram + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Isoflucipram + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metoconazole + Picoxystrobin + Isoflusipram + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + isoflucypram + thiuram + metalaxyl + oxathiapiproline,
SX + Metoconazole + Picoxystrobin + Isoflusipram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + metconazole + picoxystrobin + isoflucypram + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + picoxystrobin + isoflucypram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + isoflucypram + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metoconazole + Picoxystrobin + Isoflusipram + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + isoflucypram + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + isoflucypram + boscalid + metalaxyl + fluoxapiproline,
SX + Metconazole + Picoxystrobin + Isoflusipram + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Picoxystrobin + Isoflusipram + Aminopyriphen + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Picoxystrobin + Isoflusipram + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + metconazole + picoxystrobin + isoflucypram + mancozeb + metalaxyl + ethaboxam,
SX + metconazole + picoxystrobin + isoflucypram + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + isoflucypram + mancozeb + metalaxyl + fluoxapiproline,
SX + Metoconazole + Picoxystrobin + Isoflusipram + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + picoxystrobin + isoflucypram + carbendazim + metalaxyl + oxathiapiproline,
SX + metconazole + picoxystrobin + isoflucypram + carbendazim + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Fluopyram + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + fluopyram + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Fluopyram + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + methyl tetraprole + fluopyram + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + fluopyram + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + fluopyram + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Fluopyram + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + fluopyram + thiabendazole + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + fluopyram + thiabendazole + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Fluopyram + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + fluopyram + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Fluopyram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + metconazole + methyl tetraprole + fluopyram + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + fluopyram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + fluopyram + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + fluopyram + boscalid + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + fluopyram + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + fluopyram + boscalid + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + fluopyram + aminopyrifene + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + fluopyram + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + fluopyram + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Fluopyram + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + fluopyram + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + fluopyram + mancozeb + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + fluopyram + carbendazim + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + fluopyram + carbendazim + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + fluopyram + carbendazim + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Fluxapiroxad + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + fluxapiroxad + fludioxonil + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + fluxapiroxad + fludioxonil + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + fluxapiroxide + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + methyltetraprole + fluxapiroxide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + fluxapiroxide + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Fluxapiroxad + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + methyltetraprole + fluxapiroxide + thiabendazole + metalaxyl + oxathiapiproline,
SX + metconazole + methyltetraprole + fluxapiroxide + thiabendazole + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + fluxapiroxide + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Thiuram + Metalaxyl + Fluoxapiproline,
SX + metconazole + methyl tetraprole + fluxapiroxide + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + methyltetraprole + fluxapiroxide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + fluxapiroxide + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + fluxapiroxide + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + fluxapiroxide + boscalid + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Fluxapiroxad + Aminopyriphen + Metalaxyl + Etaboxam,
SX + metconazole + methyltetraprole + fluxapiroxide + aminopyrifene + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + fluxapiroxide + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Fluxapiroxide + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Fluxapiroxad + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + fluxapiroxide + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Fluxapiroxad + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Boscalid + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + boscalid + fludioxonil + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + boscalid + fludioxonil + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + boscalid + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + boscalid + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + boscalid + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Boscalid + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + boscalid + thiabendazole + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + boscalid + thiabendazole + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Boscalid + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + boscalid + thiuram + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + boscalid + thiuram + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Boscalid + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + boscalid + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + boscalid + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + boscalid + boscalid + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + boscalid + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + boscalid + boscalid + metalaxyl + fluoxapiproline,
SX + metconazole + methyltetraprole + boscalid + aminopyriphen + metalaxyl + etaboxam,
SX + metconazole + methyltetraprole + boscalid + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + methyltetraprole + boscalid + aminopyriphen + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Boscalid + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + boscalid + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + boscalid + mancozeb + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + boscalid + carbendazim + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + boscalid + carbendazim + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + boscalid + carbendazim + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Penflufen + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + penflufen + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Penflufen + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + methyl tetraprole + penflufen + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + penflufen + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + penflufen + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + metconazole + methyltetraprole + penflufen + thiabendazole + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + penflufen + thiabendazole + metalaxyl + oxathiapiproline,
SX + metconazole + methyltetraprole + penflufen + thiabendazole + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Penflufen + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + penflufen + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Penflufen + Thiuram + Metalaxyl + Fluoxapiproline,
SX + metconazole + methyl tetraprole + penflufen + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + penflufen + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + penflufen + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + penflufen + boscalid + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + penflufen + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + penflufen + boscalid + metalaxyl + fluoxapiproline,
SX + metconazole + methyltetraprole + penflufen + aminopyrifene + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + penflufen + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + methyltetraprole + penflufen + aminopyrifene + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + penflufen + mancozeb + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + penflufen + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + penflufen + mancozeb + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Penflufen + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + penflufen + carbendazim + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + penflufen + carbendazim + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Thifluzamide + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + thifluzamide + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Thifluzamide + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + methyl tetraprole + thifluzamide + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + thifluzamide + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + thifluzamide + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Thifluzamide + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + thifluzamide + thiabendazole + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Thifluzamide + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Thifluzamide + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + thifluzamide + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Thifluzamide + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Thifluzamide + Torclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + thifluzamide + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + thifluzamide + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Thifluzamide + Boscalid + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + thifluzamide + boscalid + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Thifluzamide + Boscalid + Metalaxyl + Fluoxapiproline,
SX + metconazole + methyltetraprole + thifluzamide + aminopyrifene + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + thifluzamide + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + methyltetraprole + thifluzamide + aminopyrifene + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Thifluzamide + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + thifluzamide + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + thifluzamide + mancozeb + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Thifluzamide + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + thifluzamide + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Thifluzamide + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + metconazole + methyl tetraprole + impilfurxam + fludioxonil + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + impilfurxam + fludioxonil + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + impilfurxam + fludioxonil + metalaxyl + fluoxapiproline,
SX + metconazole + methyltetraprole + impilfurxam + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + impilfurxam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + impilfurxam + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Impilfurxam + Thiabendazole + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + impilfulxamm + thiabendazole + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + impilfulxamm + thiabendazole + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + impilfurxam + thiuram + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + impilfurxam + thiuram + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + impilfulxamm + thiuram + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + impilfurxam + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + impilfurxam + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + impilfurxam + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + impilfurxam + boscalid + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + impilfurxam + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + methyltetraprole + impilfurxam + boscalid + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + impilfurxam + aminopyrifene + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + impilfurxam + aminopyrifene + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + impilfluxam + aminopyrifene + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + impilfurxam + mancozeb + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + impilfurxam + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + impilfurxam + mancozeb + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + impilfurxam + carbendazim + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + impilfurxam + carbendazim + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + impilfurxam + carbendazim + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Fludioxonil + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + sedaxanthe + fludioxonil + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + metconazole + methyl tetraprole + sedaxanthe + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + sedaxanthe + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + sedaxanthe + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Sedaxane + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Sedaxane + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + sedaxanthe + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Sedaxane + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Aminopyriphene + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Sedaxane + Aminopyriphene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Aminopyriphene + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Mancozeb + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + sedaxanthe + mancozeb + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + sedaxanthe + carbendazim + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Sedaxane + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Fludioxonil + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Fludioxonil + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Fludioxonil + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiophanate Methyl + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Methyl Thiophane + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiophanato Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiabendazole + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiabendazole + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiabendazole + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiuram + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiuram + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Thiuram + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Tolclophos Methyl + Metalaxyl + Etaboxam,
SX + metconazole + methyltetraprole + pidiflumethophene + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Tolclophos Methyl + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Boscalid + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Boscalid + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Boscalid + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Aminopyrifene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Mancozeb + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Mancozeb + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Mancozeb + Metalaxyl + Fluoxapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Carbendazim + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Carbendazim + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Pidiflumethophene + Carbendazim + Metalaxyl + Fluoxapiproline,
SX + metconazole + methyl tetraprole + isoflucypram + fludioxonil + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + isoflucipal + fludioxonil + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + isoflucypram + fludioxonil + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + isoflucypram + thiophanate methyl + metalaxyl + etaboxam,
SX + metconazole + methyltetraprole + isoflucipam + thiophanate methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + isoflucipam + thiophanate methyl + metalaxyl + fluoxapiproline,
SX + metconazole + methyltetraprole + isoflucypram + thiabendazole + metalaxyl + etaboxam,
SX + metconazole + methyltetraprole + isoflucypram + thiabendazole + metalaxyl + oxathiapiproline,
SX + metconazole + methyltetraprole + isoflucypram + thiabendazole + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Isoflusipram + Thiuram + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + isoflucipam + thiuram + metalaxyl + oxathiapiproline,
SX + Metconazole + Methyltetraprole + Isoflusipram + Thiuram + Metalaxyl + Fluoxapiproline,
SX + metconazole + methyl tetraprole + isoflucypram + tolclophos methyl + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + isoflucypram + tolclophos methyl + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + isoflucypram + tolclophos methyl + metalaxyl + fluoxapiproline,
SX + metconazole + methyl tetraprole + isoflucypram + boscalid + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + isoflucypram + boscalid + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + isoflucypram + boscalid + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Isoflusipram + Aminopyriphen + Metalaxyl + Etaboxam,
SX + Metconazole + Methyltetraprole + Isoflusipram + Aminopyriphene + Metalaxyl + Oxathiapiproline,
SX + Metconazole + Methyltetraprole + Isoflusipram + Aminopyriphen + Metalaxyl + Fluoxapiproline,
SX + metconazole + methyl tetraprole + isoflucypram + mancozeb + metalaxyl + etaboxam,
SX + metconazole + methyl tetraprole + isoflucypram + mancozeb + metalaxyl + oxathiapiproline,
SX + metconazole + methyltetraprole + isoflucipal + mancozeb + metalaxyl + fluoxapiproline,
SX + Metconazole + Methyltetraprole + Isoflucipram + Carbendazim + Metalaxyl + Etaboxam,
SX + metconazole + methyl tetraprole + isoflucypram + carbendazim + metalaxyl + oxathiapiproline,
SX + metconazole + methyl tetraprole + isoflucypram + carbendazim + metalaxyl + fluoxapiproline.

  Group 264 'consists of composition A comprising 1 part tebuconazole instead of 1 part metconazole contained in each composition of group 263'.

  Group 265 'consists of composition A comprising 1 part difenoconazole instead of 1 part metconazole contained in each composition of group 263'.

  Group 266 'is composed of composition A comprising 1 part triticonazole instead of 1 part metconazole contained in each composition of group 263'.

  Group 267 'consists of composition A comprising 1 part prothioconazole in place of 1 part metconazole contained in each composition of group 263'.

  Group 268 'consists of composition A comprising 1 part diniconazole in place of 1 part metconazole contained in each composition of group 263'.

  Group 269 'consists of composition A comprising 1 part diniconazole M instead of 1 part metconazole contained in each composition of group 263'.

  Group 270 'consists of composition A comprising 1 part ipconazole instead of 1 part metconazole contained in each composition of group 263'.

  Group 271 'is composed of composition A containing 1 part prochloraz instead of 1 part metconazole contained in each composition of group 263'.

  Group 272 'consists of composition A comprising 1 part fluquinconazole in place of 1 part metconazole contained in each composition of group 263'.

  Group 273 'consists of composition A comprising 1 part bromconazole in place of 1 part metconazole contained in each composition of group 263'.

  Group 274 'consists of composition A comprising 1 part mephentrifluconazole instead of 1 part metconazole contained in each composition of group 263'.

  Group 275 'is a combination of SX, main component 1, main component 2, main component 3, main component 4, main component 5 and main component 6 from any of the above-mentioned "7 active ingredient list", Composition comprising 1 part SX, 1 part present component 1, 1 part present component 2, 1 part present component 3, 1 part present component 4, 1 part present component 5 and 1 part present component 6 It consists of A.

  Group 276 'consists of composition A comprising 1 part tebuconazole instead of 1 part metconazole contained in each composition of group 275'.

  Group 277 'consists of composition A comprising 1 part difenoconazole in place of 1 part metconazole contained in each composition of group 275'.

  Group 278 'consists of composition A comprising 1 part triticonazole instead of 1 part metconazole contained in each composition of group 275'.

  Group 279 'consists of composition A comprising 1 part prothioconazole in place of 1 part metconazole contained in each composition of group 275'.

  Group 280 'consists of composition A comprising 1 part diniconazole in place of 1 part metconazole contained in each composition of group 275'.

  Group 281 'is composed of composition A comprising 1 part diniconazole M instead of 1 part metconazole contained in each composition of group 275'.

  Group 282 'consists of composition A comprising 1 part ipconazole instead of 1 part metconazole contained in each composition of group 275'.

  Group 283 'is composed of composition A comprising 1 part prochloraz in place of 1 part metconazole contained in each composition of group 275'.

  Group 284 'consists of composition A comprising 1 part fluquinconazole instead of 1 part metconazole contained in each composition of group 275'.

  Group 285 'consists of composition A comprising 1 part bromconazole in place of 1 part metconazole contained in each composition of group 275'.

  Group 286 'consists of composition A comprising 1 part mephentrifluconazole in place of 1 part metconazole contained in each composition of group 275'.

  Group 287 'is a composition A prepared by adding 1000 parts of clothianidin, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to each composition of groups 263' to 274 '. Configured

  A group 288 'is a composition A prepared by adding 1000 parts of clothianidin, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofranilide to each of the groups 263' to 274 '. Configured

  A group 289 'is a composition A prepared by adding 1000 parts of clothianidin, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to each composition of groups 263' to 274 '. Configured

  Group 290 ′ is a composition A prepared by adding 1000 parts of clothianidin, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide to the compositions of each of groups 263 ′ to 274 ′. Configured

  Group 291 'is composed of composition A in which 1000 parts of clothianidin, 1000 parts of cyantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 292 'is composed of composition A in which 1000 parts of clothianidin, 1000 parts of cyantrani riprole, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 293 'is composed of composition A in which 1000 parts of clothianidin, 1000 parts of cyantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 294 'is composed of composition A in which 1000 parts of clothianidin, 1000 parts of cyantrani riprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 295 'is composed of composition A in which 1000 parts of clothianidin, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 296 'is composed of composition A in which 1000 parts of clothianidin, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 297 'is composed of Composition A in which 1000 parts of clothianidin, 1000 parts of tetraniliprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 298 'is composed of Composition A in which 1000 parts of clothianidin, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 263' to 274 '. Ru.

  The group 299 'is a composition A prepared by adding 1000 parts of imidacloprid, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of the groups 263' to 274 '. Configured

  A group 300 'is a composition A prepared by adding 1000 parts of imidacloprid, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofranilide to the compositions of each of the groups 263' to 274 '. Configured

  The group 301 ′ is a composition A prepared by adding 1000 parts of imidacloprid, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of the groups 263 ′ to 274 ′. Configured

  The group 302 ′ is a composition A prepared by adding 1000 parts of imidacloprid, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide to each composition of the groups 263 ′ to 274 ′. Configured

  Group 303 'is composed of composition A in which 1000 parts of imidacloprid, 1000 parts of cyantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Be done.

  The group 304 'is composed of the composition A in which 1000 parts of imidacloprid, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of the groups 263' to 274 '. Be done.

  Group 305 'is composed of composition A in which 1000 parts of imidacloprid, 1000 parts of cyantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Be done.

  The group 306 'is composed of the composition A in which 1000 parts of imidacloprid, 1000 parts of cyantrani riprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of the groups 263' to 274 '. Be done.

  Group 307 'is composed of Composition A in which 1000 parts of imidacloprid, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 308 'is composed of composition A in which 1000 parts of imidacloprid, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 309 'is composed of composition A in which 1000 parts of imidacloprid, 1000 parts of tetraniliprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 310 'is composed of Composition A in which 1000 parts of imidacloprid, 1000 parts of tetraniriprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 311 ′ is a composition A prepared by adding 1000 parts of thiamethoxam, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of groups 263 ′ to 274 ′. Configured

  The group 312 ′ includes the composition A in which 1000 parts of thiamethoxam, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of the groups 263 ′ to 274 ′. Configured

  The group 313 ′ is a composition A prepared by adding 1000 parts of thiamethoxam, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of the groups 263 ′ to 274 ′. Configured

  A group 314 'is a composition A prepared by adding 1000 parts of thiamethoxam, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide to the compositions of each of the groups 263' to 274 '. Configured

  Group 315 'is composed of composition A in which 1000 parts of thiamethoxam, 1000 parts of cyantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 316 'is composed of composition A in which 1000 parts of thiamethoxam, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of brofranilide are added to the compositions of each of groups 263' to 274 '. Be done.

  Group 317 'is composed of composition A in which 1000 parts of thiamethoxam, 1000 parts of cyantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 318 'is composed of composition A in which 1000 parts of thiamethoxam, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 319 'is composed of Composition A in which 1000 parts of thiamethoxam, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 320 'is composed of composition A in which 1000 parts of thiamethoxam, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 321 'is composed of composition A in which 1000 parts of thiamethoxam, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 322 'is composed of composition A in which 1000 parts of thiamethoxam, 1000 parts of tetraniliprol, 1000 parts of bifenthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 263' to 274 '. Ru.

  A group 323 'is a composition A prepared by adding 1000 parts of thiacloprid, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of the groups 263' to 274 '. Configured

  The group 324 'is a composition A prepared by adding 1000 parts of thiacloprid, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide to the compositions of each of the groups 263' to 274 '. Configured

  The group 325 'is a composition A prepared by adding 1000 parts of thiacloprid, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of the groups 263' to 274 '. Configured

  The group 326 'is a composition A prepared by adding 1000 parts of thiacloprid, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide to the compositions of each of the groups 263' to 274 '. Configured

  Group 327 'is composed of composition A in which 1000 parts of thiacloprid, 1000 parts of cyantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 328 'is composed of composition A in which 1000 parts of thiacloprid, 1000 parts of cyantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 329 'is composed of composition A in which 1000 parts of thiacloprid, 1000 parts of cyantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 330 'is composed of composition A in which 1000 parts of thiacloprid, 1000 parts of cyantrani liprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 331 'is composed of composition A in which 1000 parts of thiacloprid, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 332 'is composed of composition A in which 1000 parts of thiacloprid, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 333 'is composed of composition A in which 1000 parts of thiacloprid, 1000 parts of tetraniliprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 334 'is composed of composition A in which 1000 parts of thiacloprid, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 263' to 274 '. Ru.

  A group 335 'is a composition A prepared by adding 1000 parts of flupyradifluro, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of the groups 263' to 274 '. Configured

  A group 336 'is a composition A prepared by adding 1000 parts of flupyradifluro, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofranilide to the compositions of each of the groups 263' to 274 '. Configured

  A group 337 'is a composition A prepared by adding 1000 parts of flupyradifluro, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to each composition of groups 263' to 274 '. Configured

  A group 338 'is a composition A prepared by adding 1000 parts of flupyradifluro, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide to the compositions of each of the groups 263' to 274 '. Configured

  Group 339 'is composed of composition A in which 1000 parts of flupyradifluro, 1000 parts of cyantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 340 'is composed of composition A in which 1000 parts of flupyradifluro, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 341 'is composed of composition A in which 1000 parts of flupyradifluro, 1000 parts of cyantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 342 'is composed of composition A in which 1000 parts of flupyradifluro, 1000 parts of cyantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 343 'is composed of composition A in which 1000 parts of flupyradifluro, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 344 'is composed of composition A in which 1000 parts of flupyradifrone, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 345 'is composed of composition A in which 1000 parts of flupyradifluro, 1000 parts of tetraniliprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 346 'is composed of composition A in which 1000 parts of flupyradifluro, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 347 'is a composition A prepared by adding 1000 parts of flupyrimine, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of groups 263' to 274 '. Configured

  The group 348 'is a composition A prepared by adding 1000 parts of flupyrimine, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide to the compositions of each of the groups 263' to 274 '. Configured

  Group 349 'is a composition A prepared by adding 1000 parts of flupyrimine, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to each composition of groups 263' to 274 '. Configured

  Group 350 ′ is a composition A from composition A in which 1000 parts of flupyrimine, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 263 ′ to 274 ′. Configured

  Group 351 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 352 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 353 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 354 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of cyantranililiprol, 1000 parts of bifenthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 263' to 274 '. Be done.

  Group 355 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 356 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of tetraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 357 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 358 'is composed of composition A in which 1000 parts of flupyrimine, 1000 parts of tetraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of groups 263' to 274 '. Ru.

  Group 359 'is a composition of each of groups 263' to 274 'plus 1000 parts of triflumesopyrim, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of fipronil. It consists of A.

  A group 360 'is a composition obtained by adding 1000 parts of triflumesopyrim, 1000 parts of chlorantraniliprole, 1000 parts of tefluthrin and 1000 parts of brofuranilide to the compositions of each of the groups 263' to 274 '. It consists of A.

  A group 361 'is a composition obtained by adding 1000 parts of triflumesopyrim, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of the groups 263' to 274 '. It consists of A.

  A group 362 'is a composition obtained by adding 1000 parts of triflumesopyrim, 1000 parts of chlorantraniliprole, 1000 parts of bifenthrin and 1000 parts of brofranilide to each of the groups 263' to 274 '. It consists of A.

  A group 363 'is a composition A in which 1000 parts of triflumesopyrim, 1000 parts of cyantranililiprol, 1000 parts of tefluthrin and 1000 parts of fipronil are further added to the compositions of each of the groups 263' to 274 '. It consists of

  A group 364 'is a composition A in which 1000 parts of triflumesopyrim, 1000 parts of cyantrani riprole, 1000 parts of tefluthrin and 1000 parts of brofranilide are further added to the compositions of each of the groups 263' to 274 '. It consists of

  The group 365 'is a composition A in which 1000 parts of triflumesopyrim, 1000 parts of cyantraniliprole, 1000 parts of bifenthrin and 1000 parts of fipronil are further added to the compositions of each of the groups 263' to 274 '. It consists of

  A group 366 'is a composition A in which 1000 parts of triflumesopyrim, 1000 parts of cyantrani riprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of the groups 263' to 274 '. It consists of

  Group 367 'is a composition A prepared by adding 1000 parts of triflumesopyrim, 1000 parts of tetraniliprol, 1000 parts of tefluthrin and 1000 parts of fipronil to the compositions of each of groups 263' to 274 '. Configured

  A group 368 'is a composition A prepared by adding 1000 parts of triflumesopyrim, 1000 parts of tetraniriprole, 1000 parts of tefluthrin and 1000 parts of brofranilide to the compositions of each of the groups 263' to 274 '. Configured

  Group 369 'is a composition A prepared by adding 1000 parts of triflumesopyrim, 1000 parts of tetraniliprol, 1000 parts of bifenthrin and 1000 parts of fipronil to the compositions of each of groups 263' to 274 '. Configured

  A group 370 'is a composition from the composition A in which 1000 parts of triflumesopyrim, 1000 parts of tetraniriprole, 1000 parts of bifenthrin and 1000 parts of brofranilide are further added to the compositions of each of the groups 263' to 274 '. Configured

  A group 371 'is a composition A in which 1 part of clothianidin, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. It consists of

  The group 372 'is a composition A prepared by adding 1 part of clothianidin, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of brofranilide to each of the groups 275' to 286 'of composition. Configured

  The group 373 'is a composition A prepared by adding 1 part of clothianidin, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of fipronil to each composition of groups 275' to 286 '. Configured

  A group 374 'is a composition A prepared by adding 1 part of clothianidin, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of brofranilide to each of the compositions of groups 275' to 286 '. Configured

  Group 375 'is composed of composition A in which 1 part of clothianidin, 1 part of cyantraniliprole, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 376 'is composed of composition A in which 1 part of clothianidin, 1 part of cyantrani riprole, 1 part of tefluthrin and 1 part of brofuranilide are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 377 'is composed of composition A in which 1 part of clothianidin, 1 part of cyantrani riprole, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 378 'is composed of composition A in which 1 part of clothianidin, 1 part of cyantrani riprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 379 'is composed of composition A in which 1 part of clothianidin, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Ru.

  The group 380 'is composed of the composition A in which 1 part of clothianidin, 1 part of tetraniliprole, 1 part of tefluthrin and 1 part of brofuranilide are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 381 'is composed of composition A in which 1 part of clothianidin, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 382 'is composed of composition A in which 1 part of clothianidin, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Ru.

  The group 383 'is a composition A prepared by adding 1 part of imidacloprid, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of fipronil to each of the groups 275' to 286 '. Configured

  The group 384 'is the composition A in which 1 part of imidacloprid, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of brofranilide are added to the composition of each of the groups 275' to 286 '. Configured

  The group 385 'is a composition A prepared by adding 1 part of imidacloprid, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of fipronil to each composition of groups 275' to 286 '. Configured

  A group 386 'is a composition A prepared by adding 1 part of imidacloprid, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of brofranilide to each of the compositions of groups 275' to 286 '. Configured

  Group 387 'is composed of composition A in which 1 part of imidacloprid, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 388 'is composed of composition A in which 1 part of imidacloprid, 1 part of cyantrani riprole, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 389 'is composed of composition A in which 1 part of imidacloprid, 1 part of cyantraniliprole, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 390 'is composed of composition A in which 1 part of imidacloprid, 1 part of cyantrani riprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 391 'is composed of composition A in which 1 part of imidacloprid, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 392 'is composed of composition A in which 1 part of imidacloprid, 1 part of tetraniriprole, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 393 'is composed of composition A in which 1 part of imidacloprid, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 394 'is composed of composition A in which 1 part of imidacloprid, 1 part of tetraniriprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Ru.

  A group 395 'is a composition A prepared by adding 1 part of thiamethoxam, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of fipronil to each composition of groups 275' to 286 '. Configured

  The group 396 'is a composition A prepared by adding 1 part of thiamethoxam, 1 part of chlorantranilipurol, 1 part of tefluthrin and 1 part of brofranilide to each of the groups 275' to 286 '. Configured

  The group 397 'is a composition A prepared by adding 1 part of thiamethoxam, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of fipronil to each composition of groups 275' to 286 '. Configured

  The group 398 'is a composition A prepared by adding 1 part of thiamethoxam, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of brofranilide to each of the groups 275' to 286 '. Configured

  Group 399 'is composed of composition A in which 1 part of thiamethoxam, 1 part of cyantraniliprole, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 400 'is composed of composition A in which 1 part of thiamethoxam, 1 part of cyantrani riprole, 1 part of tefluthrin and 1 part of brofranilide are added to the composition of each of groups 275' to 286 '. Be done.

  Group 401 'is composed of composition A in which 1 part of thiamethoxam, 1 part of cyantraniliprole, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Be done.

  The group 402 'is composed of a composition A in which 1 part of thiamethoxam, 1 part of cyantrani riprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of the groups 275' to 286 '. Be done.

  Group 403 'is composed of composition A in which 1 part of thiamethoxam, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 404 'is composed of composition A in which 1 part of thiamethoxam, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 405 'is composed of composition A in which 1 part of thiamethoxam, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 406 'is composed of composition A in which 1 part of thiamethoxam, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Ru.

  A group 407 ′ is a composition A prepared by adding 1 part of thiacloprid, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of fipronil to each of the groups 275 ′ to 286 ′. Configured

  The group 408 'is a composition from the composition A in which 1 part of thiacloprid, 1 part of chlorantranilipurol, 1 part of tefluthrin and 1 part of brofranilide is further added to the composition of each of the groups 275' to 286 '. Configured

  A group 409 ′ is a composition A prepared by adding 1 part of thiacloprid, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of fipronil to each composition of groups 275 ′ to 286 ′. Configured

  The group 410 'is a composition from the composition A in which 1 part of thiacloprid, 1 part of chlorantranilipurol, 1 part of bifenthrin and 1 part of brofranilide is added to the composition of each of the groups 275' to 286 '. Configured

  Group 411 'is composed of composition A in which 1 part of thiacloprid, 1 part of cyantraniliprole, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Be done.

  The group 412 'is composed of composition A in which 1 part of thiacloprid, 1 part of cyantrani riprole, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Be done.

  A group 413 'is composed of composition A in which 1 part of thiacloprid, 1 part of cyantraniliprole, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Be done.

  The group 414 'is composed of the composition A in which 1 part of thiacloprid, 1 part of cyantrani riprole, 1 part of bifenthrin and 1 part of brofranilide are added to the composition of each of groups 275' to 286 '. Be done.

  Group 415 'is composed of composition A in which 1 part of thiacloprid, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 416 'is composed of composition A in which 1 part of thiacloprid, 1 part of tetraniliprole, 1 part of tefluthrin and 1 part of brofuranilide are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 417 'is composed of composition A in which 1 part of thiacloprid, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 418 'is composed of composition A in which 1 part of thiacloprid, 1 part of tetraniliprole, 1 part of bifenthrin and 1 part of brofuranilide are further added to the composition of each of groups 275' to 286 '. Ru.

  The group 419 'is a composition from the composition A in which 1 part flupyradifluro, 1 part chlorantraniliprole, 1 part tefluthrin and 1 part fipronil are further added to the composition of each of the groups 275' to 286 '. Configured

  The group 420 ′ is prepared by adding the composition of each of the groups 275 ′ to 286 ′ to the composition A in which 1 part of flupyradifluro, 1 part of chlorantranilipurol, 1 part of tefluthrin and 1 part of brofranilide are further added. Configured

  The group 421 'is a composition from the composition A in which 1 part of flupyradifluro, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of the groups 275' to 286 '. Configured

  The group 422 'is a composition from the composition A in which 1 part flupyradifluro, 1 part chlorantraniliprole, 1 part bifenthrin and 1 part brofranilide are further added to the composition of each of the groups 275' to 286 '. Configured

  The group 423 'is composed of composition A in which 1 part of flupyradifluro, 1 part of cyantraniliprole, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Be done.

  The group 424 'is composed of composition A in which 1 part of flupyradifluro, 1 part of cyantrani riprole, 1 part of tefluthrin and 1 part of brofuranilide are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 425 'is composed of composition A in which 1 part of flupyradifluro, 1 part of cyantraniliprole, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 426 'is composed of composition A in which 1 part of flupyradifluro, 1 part of cyantrani riprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 427 'is composed of composition A in which 1 part of flupyradifluro, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 428 'is composed of composition A in which 1 part of flupyradifluro, 1 part of tetraniliprole, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 429 'is composed of composition A in which 1 part of flupyradifluro, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Ru.

  The group 430 'is composed of composition A in which 1 part of flupyradifluro, 1 part of tetraniliprole, 1 part of bifenthrin and 1 part of brofuranilide are further added to the composition of each of groups 275' to 286 '. Ru.

  The group 431 'is a composition from the composition A in which 1 part flupyrimine, 1 part chlorantraniliprole, 1 part tefluthrin and 1 part fipronil are further added to the composition of each of the groups 275' to 286 '. Configured

  The group 432 ′ is a composition from the composition A in which 1 part of flupyrimine, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of the groups 275 ′ to 286 ′. Configured

  The group 433 ′ is a composition A prepared by adding 1 part flupyrimine, 1 part chlorantraniliprole, 1 part bifenthrin and 1 part fipronil to each of the groups 275 ′ to 286 ′. Configured

  The group 434 'is a composition A prepared by adding 1 part of flupyrimine, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of brofranilide to each composition of groups 275' to 286 '. Configured

  Group 435 'is composed of composition A in which 1 part of flupyrimine, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 436 'is composed of composition A in which 1 part of flupyrimine, 1 part of cyantranililiprol, 1 part of tefluthrin and 1 part of brofuranilide are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 437 'is composed of composition A in which 1 part of flupyrimine, 1 part of cyantranililiprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 438 'is composed of composition A in which 1 part of flupyrimine, 1 part of cyantranililiprol, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Be done.

  Group 439 'is composed of composition A in which 1 part of flupyrimine, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 440 'is composed of composition A in which 1 part of flupyrimine, 1 part of tetraniliprole, 1 part of tefluthrin and 1 part of brofuranilide are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 441 'is composed of composition A in which 1 part of flupyrimine, 1 part of tetraniliprol, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. Ru.

  Group 442 'is composed of composition A in which 1 part of flupyrimine, 1 part of tetraniliprole, 1 part of bifenthrin and 1 part of brofuranilide are further added to the composition of each of groups 275' to 286 '. Ru.

  A group 443 'is a composition in which 1 part of triflumesopyrim, 1 part of chlorantraniliprole, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. It consists of A.

  Group 444 'is a composition of each of groups 275' to 286 'plus 1 part triflumesopyrim, 1 part chlorantraniliprole, 1 part tefluthrin and 1 part brofranilide. It consists of A.

  The group 445 'is a composition of each of the groups 275' to 286 'plus 1 part triflumesopyrim, 1 part chlorantraniliprole, 1 part bifenthrin and 1 part fipronil. It consists of A.

  A group 446 'is a composition in which 1 part of triflumesopyrim, 1 part of chlorantraniliprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. It consists of A.

  A group 447 'is a composition A in which 1 part of triflumesopyrim, 1 part of cyantrani riprole, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. It consists of

  The group 448 'is a composition A in which 1 part of triflumesopyrim, 1 part of cyantrani riprole, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. It consists of

  The group 449 'is a composition A in which 1 part of triflumesopyrim, 1 part of cyantrani riprole, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 '. It consists of

  The group 450 ′ is a composition A in which 1 part of triflumesopyrim, 1 part of cyantrani riprole, 1 part of bifenthrin and 1 part of brofranilide are further added to the composition of each of groups 275 ′ to 286 ′. It consists of

  The group 451 'is a composition from the composition A in which 1 part of triflumesopyrim, 1 part of tetraniliprol, 1 part of tefluthrin and 1 part of fipronil are further added to the composition of each of the groups 275' to 286 '. Configured

  The group 452 'is a composition from the composition A in which 1 part of triflumesopyrim, 1 part of tetraniriprole, 1 part of tefluthrin and 1 part of brofranilide are further added to the composition of each of groups 275' to 286 '. Configured

  The group 453 'is a composition from the composition A in which 1 part of triflumesopyrim, 1 part of tetraniriprole, 1 part of bifenthrin and 1 part of fipronil are further added to the composition of each of groups 275' to 286 ' Configured

  The group 454 'is a composition from the composition A in which 1 part of triflumesopyrim, 1 part of tetraniriprole, 1 part of bifenthrin and 1 part of brofranilide are added to the composition of each of the groups 275' to 286 '. Configured

  The group 455 'is composed of the composition A obtained by adding 1000 parts of Bacillus subutilis strain QST 713 to the composition of each of the groups 287' to 370 '.

  The group 456 'is composed of the composition A obtained by adding 1000 parts of Agrobacterium radiobacter strain K84 to the composition of each of the groups 287' to 370 '.

  The group 457 'is composed of the composition A obtained by adding 1000 parts of Bacillus amyloliquefaciens strain MBI 600 to the composition of each of the groups 287' to 370 '.

  The group 458 'is composed of the composition A obtained by adding 1000 parts of Bacillus pumilus strain QST 2808 to the composition of each of the groups 287' to 370 '.

  Group 459 'is composed of composition A obtained by adding 1000 parts of Burkholderia cepacia to the composition of each of groups 287' to 370 '.

  The group 460 'is composed of the composition A obtained by adding 1000 parts of Gliocladium catenulatum strain J1446 to the composition of each of the groups 287' to 370 '.

  The group 461 'is composed of the composition A obtained by adding 1000 parts of Pseudomonas chlororaphis strain MA 342 to each composition of the groups 287' to 370 '.

  Group 462 'is composed of composition A in which 1000 parts of Pseudomonas fluorescens is further added to the composition of each of groups 287' to 370 '.

  The group 463 'is composed of composition A obtained by adding 1000 parts of Pythium oligandrum strain DV74 to each composition of groups 287' to 370 '.

  The group 464 'is composed of the composition A obtained by adding 1000 parts of Streptomyces griseoviridis strain K61 to the composition of each of the groups 287' to 370 '.

  The group 465 'is composed of the composition A in which 1000 parts of Trichoderma gamsii is further added to the composition of each of the groups 287' to 370 '.

  The group 466 'is composed of the composition A in which 1000 parts of Trichoderma asperellum is further added to the composition of each of the groups 287' to 370 '.

  Group 467 'is composed of composition A in which 1000 parts of Trichoderma harzianum strain T-22 is further added to the composition of each of groups 287' to 370 '.

  The group 468 'is composed of the composition A obtained by adding 1000 parts of Trichoderma virens strain GL-21 to each composition of the groups 287' to 370 '.

  The group 469 'is composed of the composition A in which 1000 parts of Streptomyces lydicus strain WYEC 108 is further added to the composition of each of the groups 287' to 370 '.

  Group 470 'is composed of composition A obtained by adding 1000 parts of Bacillus thuringiensis subsp. Kurstraki strain ABTS-351 to the composition of each of groups 287' to 370 '.

  The group 471 'is composed of the composition A obtained by adding 1000 parts of Bacillus thuringiensis subs. Kurstraki strain MBP 123 to the composition of each of the groups 287' to 370 '.

  Group 472 'is composed of composition A obtained by adding 1000 parts of Bacillus thuringiensis subs. Aizawai strain ABTS-1857 to each composition of groups 287' to 370 '.

  Group 473 'is composed of composition A in which 1000 parts of Bacillus thuringiensis strain EX297512 is further added to the composition of each of groups 287' to 370 '.

  The group 474 'is composed of the composition A obtained by adding 1000 parts of the Metarhizium anisopliae strain F52 to the composition of each of the groups 287' to 370 '.

  The group 475 'is composed of the composition A obtained by adding 1000 parts of Bacillus firmus strain 1-1582 to the composition of each of the groups 287' to 370 '.

  Group 476 'is composed of composition A obtained by adding 1000 parts of Pasteuria nishizawae strain Pn1 to the composition of each of groups 287' to 370 '.

  Group 477 'is composed of composition A in which 10000 parts of Bradyrhizobium japonicum strain TA-11 are further added to the compositions of each of groups 287' to 370 '.

  Group 478 'is composed of composition A in which 10000 parts of Sinorhizobium meliloti is further added to the composition of each of groups 287' to 370 '.

  The group 479 'is composed of the composition A in which 10000 parts of Rhizobium leguminosarum is further added to the composition of each of the groups 287' to 370 '.

  The group 480 'is composed of the composition A in which 10000 parts of Rhizophagus intraradices strain RTI-801 is further added to the composition of each of the groups 287' to 370 '.

  Group 481 'is composed of composition A in which 10000 parts of Bacillus amyloliquefaciens and 10000 parts of Trichoderma virens are further added to the compositions of each of groups 287' to 370 '.

  Group 482 'is composed of composition A in which 10000 parts of Penicillium bilaiae and 10000 parts of Bradyrhizobium japonicum are further added to the compositions of each of groups 287' to 370 '.

  Group 483 'is composed of composition A obtained by adding 10000 parts of Penicillium bilaiae and 10000 parts of Mesorhizobium ciceri to the compositions of each of groups 287' to 370 '.

  Group 484 'is composed of composition A in which 10000 parts of Bradyrhizobium japonicum and 10000 parts of lipochitooligosaccharide are further added to the compositions of each of groups 287' to 370 '.

  Group 485 'is composed of composition A in which 1 part of Bacillus subutilis strain QST 713 is further added to the composition of each of groups 371' to 454 '.

  The group 486 'is composed of the composition A in which 1 part of Agrobacterium radiobacter strain K84 is further added to the composition of each of the groups 371' to 454 '.

  The group 487 'is composed of the composition A in which 1 part of the Bacillus amyloliquefaciens strain MBI 600 is further added to the composition of each of the groups 371' to 454 '.

  Group 488 'is composed of composition A in which 1 part of Bacillus pumilus strain QST 2808 is further added to the composition of each of groups 371' to 454 '.

  Group 489 'is composed of composition A in which 1 part of Burkholderia cepacia is further added to the composition of each of groups 371' to 454 '.

  The group 490 'is composed of the composition A in which 1 part of Gliocladium catenulatum strain J1446 is further added to the composition of each of the groups 371' to 454 '.

  The group 491 'is composed of the composition A in which 1 part of Pseudomonas chlororaphis strain MA 342 is further added to the composition of each of the groups 371' to 454 '.

  Group 492 'is composed of composition A in which 1 part of Pseudomonas fluorescens is further added to the composition of each of groups 371' to 454 '.

  The group 493 'is composed of the composition A in which 1 part of Pythium oligandrum strain DV74 is further added to the composition of each of the groups 371' to 454 '.

  The group 494 'is composed of composition A in which 1 part of Streptomyces griseoviridis strain K61 is further added to the composition of each of the groups 371' to 454 '.

  Group 495 'is composed of composition A in which 1 part of Trichoderma gamsii is further added to the composition of each of groups 371' to 454 '.

  Group 496 'is composed of composition A in which 1 part of Trichoderma asperellum is further added to the composition of each of groups 371' to 454 '.

  The group 497 'is composed of the composition A in which 1 part of Trichoderma harzianum strain T-22 is further added to the composition of each of the groups 371' to 454 '.

  The group 498 'is composed of the composition A in which 1 part of Trichoderma virens strain GL-21 is further added to the composition of each of the groups 371' to 454 '.

  The group 499 'is composed of the composition A in which 1 part of Streptomyces lydicus strain WYEC 108 is further added to the composition of each of the groups 371' to 454 '.

  Group 500 'is composed of composition A in which 1 part of Bacillus thuringiensis subsp. Kurstraki strain ABTS-351 is further added to the composition of each of groups 371' to 454 '.

  The group 501 'is composed of the composition A in which 1 part of Bacillus thuringiensis subs. Kurstraki strain MBP 123 is further added to the composition of each of the groups 371' to 454 '.

  Group 502 'is composed of composition A obtained by adding 1 part of Bacillus thuringiensis subs. Aizawai strain ABTS-1857 to each composition of groups 371' to 454 '.

  The group 503 'is composed of the composition A in which 1 part of Bacillus thuringiensis strain EX297512 is further added to the composition of each of the groups 371' to 454 '.

  The group 504 'is composed of the composition A in which 1 part of the Metarhizium anisopliae strain F52 is further added to the composition of each of the groups 371' to 454 '.

  The group 505 'is composed of the composition A in which 1 part of Bacillus firmus strain 1-1582 is further added to the composition of each of the groups 371' to 454 '.

  The group 506 'is composed of the composition A in which 1 part of the Pasteuria nishizawae strain Pn1 is further added to the composition of each of the groups 371' to 454 '.

  The group 507 'is composed of the composition A in which 1 part of the Bradyrhizobium japonicum strain TA-11 is further added to the composition of each of the groups 371' to 454 '.

  The group 508 'is composed of the composition A in which 1 part of Sinorhizobium meliloti is further added to the composition of each of the groups 371' to 454 '.

  The group 509 'is composed of the composition A in which 1 part of Rhizobium leguminosarum is further added to the composition of each of the groups 371' to 454 '.

  Group 510 'is composed of composition A in which 1 part of Rhizophagus intraradices strain RTI-801 is further added to the composition of each of groups 371' to 454 '.

  Group 511 'is composed of composition A in which 1 part of Bacillus amyloliquefaciens and 1 part of Trichoderma virens are further added to the composition of each of groups 371' to 454 '.

  The group 512 'is composed of the composition A in which 1 part Penicillium bilaiae and 1 part Bradyrhizobium japonicum are further added to the composition of each of the groups 371' to 454 '.

  Group 513 'is composed of composition A in which 1 part Penicillium bilaiae and 1 part Mesorhizobium ciceri are further added to the composition of each of groups 371' to 454 '.

  The group 514 'is composed of the composition A in which 1 part of Bradyrhizobium japonicum and 1 part of lipochitooligosaccharide are further added to the composition of each of the groups 371' to 454 '.

  Group 515 'is composed of composition A obtained by adding 1000 parts of fluazaindolizine to each composition of groups 455' to 484 '.

  Group 515 'is composed of composition A obtained by adding 1000 parts of fluazaindolizine to each composition of groups 455' to 484 '.

  Group 516 'is composed of composition A obtained by adding 1000 parts of thioxazaphen to each composition of groups 455' to 484 '.

  Group 517 'is composed of composition A in which 1000 parts of fluene sulfone is further added to the composition of each of groups 455' to 484 '.

  Group 518 'is composed of composition A obtained by adding 1000 parts of abamectin to each composition of groups 455' to 484 '.

  Group 519 'is composed of composition A obtained by adding 1000 parts of fluopyram to the composition of each of groups 455' to 484 '.

  The group 520 'is composed of the composition A in which 1 part of fluazaindolizine is further added to the composition of each of the groups 485' to 514 '.

  The group 521 'is composed of the composition A in which 1 part of thioxazaphen is further added to the composition of each of the groups 485' to 514 '.

  Group 522 'is composed of composition A in which 1 part of fluene sulfone is further added to the composition of each of groups 485' to 514 '.

  Group 523 'is composed of composition A in which 1 part of abamectin is further added to the composition of each of groups 485' to 514 '.

  The group 524 'is composed of the composition A in which 1 part of fluopyram is further added to the composition of each of the groups 485' to 514 '.

Next, formulation examples are shown.
The abbreviation SX means any one of the present compounds selected from the compound groups SX1 to SX1298. The abbreviation of MX means any one composition A selected from groups 1 to 48 and groups 1 'to 524'.

Formulation example 1
In 40 parts of SX or 40 parts of MX, 35 parts of a mixture of wet silica and polyoxyethylene alkyl ether sulfate ammonium salt (weight ratio 1: 1) and 25 parts of water are thoroughly mixed to obtain a preparation.

Formulation example 2
Each formulation is obtained by adding 3 parts of calcium lignin sulfonate, 2 parts of sodium lauryl sulfate and 55 parts of wet silica to 40 parts of SX or 40 parts of MX and mixing them.

Formulation example 3
To 40 parts of SX or 40 parts of MX, 15 parts of a mixture of wet silica and polyoxyethylene alkyl ether sulfate ammonium salt (weight ratio 1: 1) and 45 parts of water are added and thoroughly mixed to obtain a preparation.

Formulation example 4
35 parts of a mixture of wet silica and polyoxyethylene alkyl ether sulfate ammonium salt (weight ratio 1: 1) and 45 parts of water are added to 20 parts of SX or 20 parts of MX and thoroughly mixed to obtain a preparation.

Formulation example 5
20 parts of SX or 20 parts of MX and 1.5 parts of sorbitan trioleate are mixed with 28.5 parts of an aqueous solution containing 2 parts of polyvinyl alcohol and finely ground by a wet grinding method, and then 0.05 parts of xanthan gum and 90 parts of an aqueous solution containing 0.1 part of aluminum magnesium silicate is added, and 10 parts of propylene glycol is further added and mixed by stirring to obtain a preparation.

Formulation Example 6
A formulation is obtained by thoroughly grinding and mixing 3 parts of calcium lignin sulfonate, 2 parts of sodium lauryl sulfate and a wet silica part with 20 parts of SX or 20 parts of MX.

Formulation example 7
Add 3 parts of SX or 3 parts of MX, 1 part of wet silica, 2 parts of calcium lignin sulfonate, 30 parts of bentonite and the balance of kaolin clay to make the total amount 100 parts and mix. Then, an appropriate amount of water is added to the mixture, and the mixture is further stirred, granulated with a granulator, and blow-dried to obtain granules.

Formulation Example 8
A powder is obtained by adding 0.5 parts of SX or 1 part of MX, 10 parts of talc and the remaining part of kaolin clay to make the total amount 100 parts and mixing.

  Next, an application example of the composition B to plant seeds is shown.

Application example 1 (application to sorghum seeds)
By applying 200 mL of any one of the preparations obtained by the method described in Preparation Example 3 to 100 kg of dried sorghum seeds using a rotary seed processor (Seed Dresser, manufactured by Hans-Ulrich Hege GmbH) , Get treated seeds.

Application example 2 (application to sorghum seeds)
200 mL of any one of the formulations obtained by the method described in Formulation Example 1 is mixed with 180 g of Concep® II (comprising 136 g of oxabetrinyl (from Syngenta)). The resulting mixture is smeared onto 100 kg of dried sorghum seeds using a rotary seed processor (Seed Dresser, manufactured by Hans-Ulrich Hege GmbH) to obtain treated seeds. g

Application example 3 (application to sorghum seeds)
Formulation 200 mL of any one of the formulations obtained by the method described in Formulation Example 5 and 2.1 L of Concep (registered trademark) III (containing 40 g of fluxophenim (manufactured by Syngenta)) are mixed. The resulting mixture is smeared onto 100 kg of sorghum dried seeds using a rotary seed processor (Seed Dresser, manufactured by Hans-Ulrich Hege GmbH) to obtain treated seeds.

Application example 4 (application to corn seed)
Preparation Example 1 1 10 mL of any one of the preparations obtained by the method described in Preparation Example 1 using a rotary seed processor (Seed Dresser, manufactured by Hans-Ulrich Hege GmbH) to obtain corn “SR corn” (acetyl CoA carboxylase inhibitor) The treated seeds are obtained by smearing on 10 kg of dried seeds of maize (tolerant maize).

Application example 5 (application to corn seed)
Formulation 40 mL of any one of the formulations obtained by the method described in Formulation Example 4 using a rotary seed processor (Seed Dresser, manufactured by Hans-Ulrich Hege GmbH), corn “MaveraTM YieldGardTM Maize” The treated seeds are obtained by smearing 10 kg of dried seeds (corn with increased lysine production and resistance to lepidopteran pests).

Application example 6 (application to corn seed)
Formulation 100 mL of any one of the formulations obtained by the method described in Formulation Example 5 with a rotary seed processor (Seed Dresser, manufactured by Hans-Ulrich Hege GmbH) to obtain corn "Herculex Xtra" (glufosinate resistant, Lepidoptera) The treated seeds are obtained by smearing on 10 kg of dried seeds of pest resistant and coleopteran pest resistant maize).

Application example 7 (application to corn seed)
By treating 50 g of any one of the preparations obtained by the method described in Preparation Example 2 into 10 kg of dried seeds of corn "ZFN-12 maize" (corn with reduced phytic acid content), treated seeds are treated obtain.

Application Example 8 (Application to soybean seed)
Formulation 20 One of the formulation obtained by the method described in Formulation Example 15 is subjected to soybean "Plenish (trademark)" (oleic acid content) using a rotary seed processor (Seed Dresser, manufactured by Hans-Ulrich Hege GmbH) The treated seeds are obtained by smearing on 10 kg of dried seeds of soybeans that are increased in the resistance to sulfonylurea-type ALS-inhibiting herbicide and having an increase in

Application example 9 (application to soybean seeds)
Using a rotary seed processor (Seed Dresser, manufactured by Hans-Ulrich Hege GmbH), 100 mL of any one of the formulations obtained by the method described in Formulation Example 5 was subjected to soybean "IntactaTM Roundup ReadyTM". The treated seeds are obtained by smearing 10 kg of dried seeds of “2 Pro” (glyphosate resistant and resistant to lepidopterous pests) 10 kg.

Application example 10 (application to cotton seed)
Using a rotary seed processor (Seed Dresser, manufactured by Hans-Ulrich Hege GmbH), 50 mL of any one of the preparations obtained by the method described in Preparation Example 5 was cotton "Bollgard.RTM. 3 XtendFlex (registered) The treated seeds are obtained by smearing 10 kg of dried seeds of "Trademark" (Dicamba resistant, glyphosate resistant, glyphosate resistant and cotton resistant to lepidopteran) 10 kg.

Application example 11 (application to canola seeds)
Formulation 50 mL of any one of the formulations obtained by the method described in Formulation Example 5 was treated with a rotary seed processor (Seed Dresser, manufactured by Hans-Ulrich Hege GmbH) to a canola “Clearfield® canola” (imidazo). Each treated seed is obtained by smearing 10 kg of dried seeds of a linon-based ALS inhibitory herbicide-resistant canola).

Application example 12 (application to rape seed)
By applying 10 mL of any one of the formulations obtained by the method described in Formulation Example 4 to 10 kg of dried rapeseed seeds using a rotary seed processor (Seed Dresser, manufactured by Hans-Ulrich Hege GmbH) , Get treated seeds.

Application example 13 (application to wheat seeds)
By applying 50 ml of any one of the preparations obtained by the method described in Preparation Example 5 to 10 kg of dried wheat seeds using a rotary seed processor (Seed Dresser, manufactured by Hans-Ulrich Hege GmbH) , Get treated seeds.

Application example 14 (application to potato seed paste)
6 mL of any one of the formulations obtained by the method described in Formulation Example 3 is smeared so as to be uniform to 10 kg of potato seeds to obtain treated seeds.

Application Example 15
10 kg of dried rice seeds (dry rice cake) are put in a net bag and soaked for 10 minutes in a 50-fold water dilution solution of Benlate® wettable powder (Benomil wettable, manufactured by Sumitomo Chemical Co., Ltd.) Soak in water for 3 days. 5 kg of reduced iron powder 5 kg, 600 g of calcined gypsum, and 100 g of any one of the preparations obtained by the method described in Preparation Example 5 while rotating drained rice seeds into a rotary pan type rice seed coating machine After adding the water dilution liquid and powdering, 300 g of plaster is further coated. Thereafter, the rice seeds are taken out of the coating machine, dispersed on a vinyl sheet so as to have a thickness of 1 cm or less, and allowed to stand and dried to obtain treated seeds.

Application Example 16
After 10 kg of dried rice seeds (dried koji) are put in a mesh bag and soaked in a 20-fold water dilution solution of STANA® wettable powder (Oxolinic acid wettable powder, manufactured by Sumitomo Chemical Co., Ltd.) for 10 minutes, Soak in tap water for 3 days. Described in Formulation Example 2 20 kg of Carper® Granule 16 (Calcium Peroxide Granule, Hodogaya UPL Co., Ltd.) while rotating drained rice seed in a rotary pan-type rice seed coating machine and rotating it. Add 100g of any one of the preparations obtained by the method of 1. and coat. Thereafter, the rice seeds are taken out of the coating machine, dispersed on a vinyl sheet so as to have a thickness of 1 cm or less, and allowed to stand and dried to obtain treated seeds.

Application Example 17
Put 10 kg of dried rice seed (dried persimmon) in a net bag and disinfect it by soaking it in a 1500-fold water dilution solution of Padang SG water solvent (Kartap hydrochloric acid salt water solvent, Sumitomo Chemical Co., Ltd.) for 24 hours. Soak for 3 days and sprout. While rotating the drained rice seeds into a rotary pan-type rice seed coating machine and rotating them, 200 g of appropriate amount of zoji-indicator wash paste (polyvinyl alcohol, Sanwa Yushi Kogyo Co., Ltd.) and molybdenum trioxide (Japan Inorganic Chemical Industry Co., Ltd.) A 100 g 2-fold diluted water solution of any one of the preparations obtained by the method described in Preparation Example 5 is added, and the mixture is treated on the surface of rice seeds. Thereafter, the rice seeds are taken out of the coating machine, dispersed on a vinyl sheet so as to have a thickness of 1 cm or less, and allowed to stand and dried to obtain treated seeds.

  Hereinafter, the effects of the present invention will be shown in test examples.

Test Example 1
The treated corn seeds obtained by the method described in Application Example 4 are sown at a distance of 15 cm to a depth of 5 cm using a sowing machine.
As a result, corn treated with SX or MX can be confirmed to have an effect on harmful arthropods that damage the seedling blight fungus (Rhizoctonia solani and Pythium spp.), Negus galliceum nematode, and corn.

Test example 2
Treated seeds of soybean obtained by the method described in Application Example 8 are sown and cultivated.
As a result, soybeans treated with SX or MX can be confirmed to be effective against harmful arthropods which may damage soybean wilt (Fusarium oxysporum), rhizoctonia root rot (Rhizoctonia solani), soybean cyst nematode, and soybean.

Test Example 3
Treated seeds of canola obtained by the method described in Application Example 11 are sown and cultivated.
As a result, soybeans treated with SX or MX can be confirmed to have an effect on harmful arthropods that can damage seedling blight (Rhizoctonia solani), negus salent nematode, and canola.

Test Example 4
The rice seeds obtained in Application Example 15 are sown in a paddy field and cultivated.
As a result, the rice treated with SX or MX can be confirmed to have an effect on the rice weevil, the indreck beetle, the yellow leaf beetle, the white-tailed deer, the yellow-footed loin, the green leafhopper, the red leafhopper, the red leafhopper, the red leafhopper, the red leaf beetle, the green leafhopper. Furthermore, rice treated with SX or MX controls rice planthoppers and leafhoppers to control these insect-mediated rice dwarf diseases, tungose disease, rice grassy stunt disease, rice ragged stunt disease, rice streaks and leaves. It is possible to confirm the effects on diseases, black streak atrophy, rice south black streak atrophy, yellow dwarf disease, rice yellow leaf disease, transient yellowing disease and rice dwarf disease.

Test Example 5
Put 24 kg of rice seeds in a cloth bag and soak the whole bag in water for 24 hours. The rice seeds after immersion are placed on the concrete ground together with the above-mentioned bags, and allowed to stand for 36 hours with appropriate water so as not to dry. After standing, rice seeds taken out of the cloth bag are spread on a sheet, and an aqueous dilution of the preparation obtained by the method described in Preparation Example 6 is spread here and thoroughly stirred on the sheet. The rice seeds are sown by direct direct manual application to the paddy fields maintained at a flood depth of about 2 cm by performing cultivation, pouring water, puddling, etc. in advance and performing drainage treatment, Grow.
As a result, the rice treated with SX or MX can be confirmed to be effective against the rice weevil, the ground beetle, the ground beetle, the yellow-tailed deer, the ground beetle, the green leafhopper, the green leafhopper, the green leafhopper, the green leafhopper and the green leafhopper. The effect can also be confirmed on a rice weevil, a rice dung beetle, a brown dwarf beetle, a brown dwarf beetle, a tree dwarf beetle, a white dwarf tree, a white-leafed deer, a black-leafed tree dwarf, a black-nosed leafhopper, a red-winged dwarf, a red-winged dwarf, a red-handed dwarf, a red clover, a red clover, and a red clover. In particular, the effect can be confirmed on a rice weevil, a rice dander beetle, a ground louse beetle, a tree loin beetle, a white-tailed loin mosquito, a green leafhopper and a black leafhopper with reduced sensitivity to one or more compounds selected from group a4. In addition, by controlling harmful insects belonging to the planthopper family and leafhopper family, these insect-mediated rice dwarf diseases, tungose disease, rice grassy stunt disease, rice ragid stunt disease, rice streak leaf blight, black streak atrophy It is possible to protect rice from disease, rice south black rot disease, yellow dwarf disease, rice yellow leaf disease, transient yellowing disease, rice dwarf disease.

Test Example 6
After carrying out the scraping, the rice seeds obtained in Application Example 16 are sown streaky and cultivated in a paddy field which has been subjected to drainage control for several days with a passenger sowing machine. At this time, the seeding amount per 10 ares is 4 kg in dry weight.
As a result, the rice treated with SX or MX can be confirmed to be effective against the rice weevil, the indreck beetle, the yellow leafhopper, the white-tailed deer, the green-leafed leafhopper, the green-leafed green leafhopper, the green-leafed leafhopper, the green-leafed leafhopper, and the green-spotted moth. Furthermore, the effect on a rice weevil, a rice dung beetle, a brown dwarf beetle, a brown dwarf beetle, a white dwarf beetle, a white dwarf deer, a white loaf deer or a black flea leaf rower, a green leafhopper, a green leafhopper, a red flea leaf lice, a red flea leaf lice, or a red flea leaf lice, is detected. In particular, it is possible to confirm the effect on the rice water weevil, the locust locust, the tree planthopper, the locust locust, the locust tree planthopper, the black leafhopper, with reduced sensitivity to one or more compounds selected from group a4.

Test Example 7
The corn seeds obtained in Application Example 7 are sown at a distance of 15 cm to a depth of 5 cm using a sowing machine and cultivated.
As a result, corn treated with SX or MX can be confirmed to be effective against larvae of the genus Diabrotica such as Western corn rootworm, and click beetles (generally referred to as wire worms) represented by the genus Agriotes and genus Melanotus. The effect can also be confirmed on the larvae of the click beetle family having reduced sensitivity to one or more compounds selected from group a1 to group a18.

Test Example 8
The soybean seed obtained in Application Example 9 is sown and cultivated.
As a result, soybeans treated with SX or MX can confirm the effect on seed fly larvae. The effect can also be confirmed on seed fly larvae having reduced sensitivity to one or more compounds selected from group a1 to group a18.

Test Example 9
The canola seeds obtained in Application Example 11 are sown and cultivated.
As a result, the canola treated with SX or MX can be confirmed to have an effect on larvae of the beetle. In addition, the effect can be confirmed also on the larvae of the leaf beetle which has reduced sensitivity to one or more compounds selected from group a1 to group a18.

Test Example 10
The wheat seeds obtained in Application Example 13 are sown and cultivated.
As a result, wheat treated with SX or MX can be confirmed to be effective against clickworm larvae. The effect can also be confirmed on click beetles with reduced sensitivity to one or more compounds selected from group a1 to group a18.

Test Example 11
The potato seed pod obtained in Application Example 14 is planted in the soil and cultivated.
As a result, potatoes treated with SX or MX can be confirmed to be effective against larvae of the family Hamidaceae. In addition, the effect can be confirmed also on the larvae of the leaf beetle which has decreased sensitivity to one or more compounds selected from group a1 to group a18.

Test Example 12
The granules obtained in Formulation Example 7 are mixed with soil, and sugar cane stalk fragments are planted there and cultivated.
As a result, sugarcane treated with SX or MX can be confirmed to be effective against clickworm larvae. In addition, the effect can be confirmed on the click beetle family which has reduced sensitivity to one or more compounds selected from group a1 to group a18.

Test Example 13
A diluted solution of the preparation obtained by the method described in Preparation Example 5 is sprayed on a planting ditch for planting sugar cane stalk fragments before covering the soil, and the soil is covered and cultivated.
As a result, sugarcane treated with SX or MX can be confirmed to be effective against clickworm larvae. In addition, the effect can be confirmed on the click beetle family which has reduced sensitivity to one or more compounds selected from group a1 to group a18.

Test Example 14
Rice seeds (150 g in dry weight) are disinfected with a mixture of ipconazole and cupric hydroxide. Bed soil is laid in a nursery box (about 60 cm wide and about 30 cm long), and the seed-sterilized rice seeds are sown uniformly thereon. Subsequently, 50 g of the granule obtained by the method described in Preparation Example 7 is uniformly dispersed, covered with soil, and grown. Rice seedlings grown in the 2.5 leaf stage are transplanted to a paddy field using a rice transplanter and cultivated.
As a result, the rice treated with SX or MX can be confirmed to be effective against the rice weevil, the indigo plant beetle, the indigo planthopper, the indigo planthopper, the indible planthopper, the indigo planthopper, the indigo planthopper, the indopian planted catfish, the indigo plant indica, the indible plant indica, the indible plant bug, the indible plant bug, and the indible planthopper. In addition, the rice water weevil, the ground beetle, the ground beetle, the tree planter, the winged deer, the ground beetle, the green leafhopper, the green leafhopper, the green leafhopper, the green leaf beetle, the green leafhopper, the black spider beetle, the red leaf beetle You can see the effect. In particular, the effect can be confirmed on a rice weevil, a rice dander beetle, a yellow-spotted beetle, a yellow-spotted planthopper, a white-tailed locust, a brown-leafed locust, or a green leafhopper with reduced sensitivity to one or more compounds selected from group a4. In addition, by controlling harmful insects belonging to the planthopper family and leafhopper family, these insect-mediated rice dwarf diseases, tungose disease, rice grassy stunt disease, rice ragid stunt disease, rice streak leaf blight, black streak atrophy It is possible to protect rice from disease, rice south black rot disease, yellow dwarf disease, rice yellow leaf disease, transient yellowing disease, rice dwarf disease.

Test Example 15
The formulation obtained by the method described in Formulation Example 4 is diluted 400 times with water. 500 mL of the resulting diluted solution is subjected to irrigation using a watering apparatus on 3.5 leaf stage rice seedlings grown in a nursery box (about 60 cm wide and about 30 cm long). The treated rice seedlings are transplanted to a paddy field with a rice transplanter and cultivated.
As a result, the rice treated with SX or MX can be confirmed to be effective against the rice weevil, the indigo plant beetle, the indigo planthopper, the indigo planthopper, the indible planthopper, the indigo planthopper, the indigo planthopper, the indopian planted catfish, the indigo plant indica, the indible plant indica, the indible plant bug, the indible plant bug, and the indible planthopper. In addition, the rice water weevil, the ground beetle, the ground beetle, the tree planter, the winged deer, the ground beetle, the green leafhopper, the green leafhopper, the green leafhopper, the green leaf beetle, the green leafhopper, the black spider beetle, the red leaf beetle You can see the effect. In particular, the effect can be confirmed on a rice weevil, a rice dander beetle, a yellow-spotted beetle, a yellow-spotted planthopper, a white-tailed locust, a brown-leafed locust, or a green leafhopper with reduced sensitivity to one or more compounds selected from group a4. In addition, by controlling harmful insects belonging to the planthopper family and leafhopper family, these insect-mediated rice dwarf diseases, tungose disease, rice grassy stunt disease, rice ragid stunt disease, rice streak leaf blight, black streak atrophy It is possible to protect rice from disease, rice south black rot disease, yellow dwarf disease, rice yellow leaf disease, transient yellowing disease, rice dwarf disease.

Test Example 16
The formulation obtained by the method described in Formulation Example 5 is diluted 200 times with water. The resulting diluted solution (500 mL) is irrigated with 2.5 wt. Stage rice seedlings grown in a nursery box (about 60 cm wide and about 30 cm long) using jouro. The treated rice seedlings are transplanted to a paddy field with a rice transplanter and cultivated.
As a result, the rice treated with SX or MX can be confirmed to be effective against the rice weevil, the indigo plant beetle, the indigo planthopper, the indigo planthopper, the indible planthopper, the indigo planthopper, the indigo planthopper, the indopian planted catfish, the indigo plant indica, the indible plant indica, the indible plant bug, the indible plant bug, and the indible planthopper. In addition, the rice water weevil, the ground beetle, the ground beetle, the tree planter, the winged deer, the ground beetle, the green leafhopper, the green leafhopper, the green leafhopper, the green leaf beetle, the green leafhopper, the black spider beetle, the red leaf beetle You can see the effect. In particular, the effect can be confirmed on a rice weevil, a rice dander beetle, a yellow-spotted beetle, a yellow-spotted planthopper, a white-tailed locust, a brown-leafed locust, or a green leafhopper with reduced sensitivity to one or more compounds selected from group a4. In addition, by controlling harmful insects belonging to the planthopper family and leafhopper family, these insect-mediated rice dwarf diseases, tungose disease, rice grassy stunt disease, rice ragid stunt disease, rice streak leaf blight, black streak atrophy It is possible to protect rice from disease, rice south black rot disease, yellow dwarf disease, rice yellow leaf disease, transient yellowing disease, rice dwarf disease.

Test Example 17
SX or MX is formulated according to the method described in Formulation Example 4. Similarly, triflumesopyrim, flupyradiflone or flupyrimine are formulated into preparations according to the method described in Preparation Example 4, respectively. Spreader (trade name: Shindyne (registered trademark)) so that the above-mentioned preparation has an active ingredient concentration of 0.05 ppm, 0.2 ppm, 0.8 ppm, 3.1 ppm, 12.5 ppm, 50 ppm or 200 ppm, respectively. Dilute with water containing 0.05% by volume to obtain each dilution. Commercially available Admeier's wettable powder (active ingredient: imidacloprid, manufactured by Bayer CropScience Co., Ltd.) and Actara granular water-dispersible powder (active ingredient: thiamethoxam, manufactured by Syngenta Japan Co., Ltd.) have an active ingredient concentration of 0.05 ppm, Dilute with water containing 0.05% by volume of spreading agent (trade name: Syndyne (registered trademark)) to 0.2 ppm, 0.8 ppm, 3.1 ppm, 12.5 ppm, 50 ppm or 200 ppm, respectively Obtain a dilution of Susceptible strains (strains reared in the Sumitomo Chemical Co., Ltd. Health Agriculture and Related Business Research Institute) or reduced sensitivity strains (in Miyazaki Prefecture in 2016) for cucumber seedlings (the second true leaf development stage) planted in containers After collection, 30 cotton aphids (including all stages of growth) are inoculated in an inbred, breeding series. One day later, the resulting dilutions are sprayed onto the seedlings at a rate of 10 mL / seedling. On the other hand, cucumber is grown in the same manner as in the treated area except that the dilution containing SX or MX is not dispersed (this is referred to as an untreated area). Six days after the application, the number of surviving insects is observed, and the control value is determined by the formula 1).
Formula 1); Control value (%) = {1- (Cb × Tai) / (Cai × Tb)} × 100
The letters in the formula have the following meanings.
Cb: The number of test insects in the untreated area Cai: The number of living insects in the untreated area Tb: The number of insects in the treated area Tai: The number of living insects in the treated area As a result, the nicotinicity of the group a4 It is confirmed that all of the treated sections of acetylcholine receptor competitive modulators triflumesopyrim, flupyradiflone, flupirimin, imidacloprid or thiamethoxam have a lower effect on the desensitized line than the effect on the sensitive line. This confirms that the reduced sensitivity strain used in this test is a strain with reduced sensitivity to nicotinic acetylcholine receptor competitive modulators. On the other hand, the treated sections of SX or MX can confirm the same effect on susceptible lines as to sensitive lines.

Test Example 18
SX or MX is formulated according to the method described in Formulation Example 4. Similarly, flupyradifluro and flupyrimine are formulated into preparations according to the method described in Preparation Example 4, respectively. Spreader (trade name: Syndyne (registered trademark)) so that the above-mentioned preparation has an active ingredient concentration of 0.05 ppm, 0.2 ppm, 0.8 ppm, 3.1 ppm, 12.5 ppm, 50 ppm or 200 ppm, respectively. Dilute with water containing 0.05% by volume. Commercially available Ad Meyer's water-dispersible powder (active ingredient: imidacloprid, manufactured by Bayer CropScience Co., Ltd.), the active ingredient concentration is 0.05 ppm, 0.2 ppm, 0.8 ppm, 3.1 ppm, 3.1 ppm, 12.5 ppm, 50 ppm or It is diluted with water containing 0.05% by volume of a spreading agent (trade name: Shindyne (registered trademark)) to a concentration of 200 ppm. The diluted solution obtained for rice seedlings (Oryza sativa) planted (the 2.5th leaf stage) planted in a container is sprayed at a rate of 10 mL / seedling. After that, after being collected in Nagasaki Prefecture in 2016, the susceptible line Tobiirounka (the line which is reared in generations within the Sumitomo Chemical Co., Ltd. Health Agriculture and Related Business Research Institute) or the susceptible line Tobihirounka (in 2016) Release 20 third instar larvae. Six days later, the number of surviving insects is investigated, and the mortality is calculated by the equation 2). On the other hand, rice is grown in the same manner as in the treated area except that the dilution containing SX or MX is not dispersed (this is referred to as an untreated area).
Formula 2) Mortality rate (%) = {1-number of surviving insects / 20} x 100
As a result, it is confirmed that all of the treated sections of flupyradiflure, flupyrimine or imidacloprid, which are nicotinic acetylcholine receptor competitive modulators of group a4, have a lower effect on the desensitized line than the effects on the sensitive line. This confirms that the reduced sensitivity strain used in this test is a strain with reduced sensitivity to nicotinic acetylcholine receptor competitive modulators. On the other hand, the treated sections of SX or MX can confirm the same effect on susceptible lines as to sensitive lines.

Test Example 19
SX or MX is formulated according to the method described in Formulation Example 4. Spreader (trade name: Syndyne (registered trademark)) so that the above-mentioned preparation has an active ingredient concentration of 0.05 ppm, 0.2 ppm, 0.8 ppm, 3.1 ppm, 12.5 ppm, 50 ppm or 200 ppm, respectively. Dilute with water containing 0.05% by volume. The commercially available product is Phoenix Granule water-dispersible powder (active ingredient: flubendiamide, manufactured by Japan Pesticide Co., Ltd.), Prevathon Flable 5 (active ingredient: chlorantranilipurol, manufactured by Nissan Chemical Co., Ltd.), and Benedia OD (active ingredient: Spreading agent (Cyantrani lipol, manufactured by Kumiai Chemical Industries, Ltd.) to an active ingredient concentration of 0.05 ppm, 0.2 ppm, 0.8 ppm, 3.1 ppm, 3.1 ppm, 12.5 ppm, 50 ppm or 200 ppm, respectively Trade name: Dilute with water containing 0.05% by volume of Syndyne®. The diluted solution obtained is sprayed on cabbage (Brassicae oleracea) seedlings (third to fourth leaf development stage) planted in a container at a rate of 20 mL / seedling. After that, after being collected in Kumamoto prefecture in susceptible strain lineage (line which is reared in generations in Sumitomo Chemical Co., Ltd. health agriculture and related business research institute) or sensitivity decreasing lineage konaga (in 2016 in Kumamoto Prefecture) Release 10 3rd instar larvae of the strain). After 5 days, the number of living insects is counted, and the mortality is calculated from equation 3). On the other hand, cabbage is grown in the same manner as in the treated area except that the dilution containing SX or MX is not dispersed (this is referred to as an untreated area).
Formula 3) Mortality rate (%) = (1-number of surviving insects / 10) x 100
As a result, it is found that the group treated with ryanodine receptor modulator agent flubendiamide, chlorantranilipurol or cyantraniriprole, which is a group a17, has less effect on the desensitized line than the effect on the susceptible line. It is confirmed. This confirms that the reduced sensitivity strain used in this test is a strain with reduced sensitivity to ryanodine receptor modulator agents. On the other hand, the treated sections of SX or MX can confirm the same effect on susceptible lines as to sensitive lines.

Test Example 20
SX or MX is formulated according to the method described in Formulation Example 4. Similarly, flupyradifluro and flupyrimine are formulated into preparations according to the method described in Preparation Example 4, respectively. Spreader (trade name: Syndyne (registered trademark)) so that the above-mentioned preparation has an active ingredient concentration of 0.05 ppm, 0.2 ppm, 0.8 ppm, 3.1 ppm, 12.5 ppm, 50 ppm or 200 ppm, respectively. Dilute with water containing 0.05% by volume. Commercially available Admyer water dispersible granules (active ingredient: imidacloprid, manufactured by Bayer CropScience Co., Ltd.), Trebon emulsion (active ingredient: etofenprox, manufactured by Mitsui Chemicals Agro Co., Ltd.), Prince flowable (active ingredient: fipronil, BASF Japan Ltd.), Kirap floorable (Active ingredient: Ethiprole, Bayer CropScience Co., Ltd.), and upload floorable (Active ingredient: Buprofezin, Nippon Pesticide Co., Ltd.), respectively, the active ingredient concentration is 0.05 ppm, 0 2. Dilute with water containing 0.05% by volume of spreading agent (trade name: Syndyne®) to a concentration of 2 ppm, 0.8 ppm, 3.1 ppm, 12.5 ppm, 50 ppm or 200 ppm. The diluted solution obtained for rice seedlings (Oryza sativa) planted (the 2.5th leaf stage) planted in a container is sprayed at a rate of 10 mL / seedling. After that, after being collected in Nagasaki Prefecture in 2016, susceptible strains Himetobiunka (strains reared in generations within the Sumitomo Chemical Co., Ltd. Health Agriculture and Related Business Research Institute) or susceptible hypophysics are reared without breeding. Release 20 third instar larvae. Six days later, the number of surviving insects is investigated, and the mortality is calculated by the equation 2). On the other hand, rice is grown in the same manner as in the treated area except that the dilution containing SX or MX is not dispersed (this is referred to as an untreated area).
Formula 2) Mortality rate (%) = {1-number of surviving insects / 20} x 100
As a result, flupyra- diflone, flupirimine or imidacloprid, which is a nicotinic acetylcholine receptor competitive modulator of group a4, fipronil or ethiprole which is a GABAergic chloride channel antagonist of group a2, etofenprox which is a sodium channel modulator of group a3 or It is confirmed that the treated sections of buprofezin, which is a chitin biosynthesis inhibitor of group a12, are all less effective against the susceptible line than the effects against the susceptible line. From this, it is confirmed that the reduced sensitivity strain used in this test is a strain having reduced sensitivity to these compounds. On the other hand, the treated sections of SX or MX can confirm the same effect on susceptible lines as to sensitive lines.

Test Example 21
SX or MX is formulated according to the method described in Formulation Example 4. Spreader (trade name: Syndyne (registered trademark)) so that the above-mentioned preparation has an active ingredient concentration of 0.05 ppm, 0.2 ppm, 0.8 ppm, 3.1 ppm, 12.5 ppm, 50 ppm or 200 ppm, respectively. Dilute with water containing 0.05% by volume. Commercially available products, Prince Fleuble (active ingredient: fipronil, manufactured by BASF Japan Ltd.) and Kilaploafable (active ingredient: ethiprole, manufactured by Bayer CropScience Co., Ltd.) have active ingredient concentrations of 0.05 ppm and 0.2 ppm, respectively. Dilute with water containing 0.05% by volume of spreading agent (trade name: Syndyne.RTM.) To 0.8 ppm, 3.1 ppm, 12.5 ppm, 50 ppm or 200 ppm. The diluted solution obtained for the rice seedlings (the 2.5th leaf stage) planted in a container is sprayed at a rate of 10 mL / seedling. After that, after being collected in Nagasaki Prefecture in the susceptible line Sejironka (line that is reared in successive generations in Sumitomo Chemical Co., Ltd. Health Agriculture and Related Business Research Institute) or susceptible line pedigree (in 2016 in Nagasaki Prefecture) Release 20 third instar larvae. Six days later, the number of surviving insects is investigated, and the mortality is calculated by the equation 2). On the other hand, rice is grown in the same manner as in the treated area except that the dilution containing SX or MX is not dispersed (this is referred to as an untreated area).
Formula 2) Mortality rate (%) = {1-number of surviving insects / 20} x 100
As a result, it is confirmed that all of the treated sections of fipronil or ethiprole, which are GABAergic chloride channel antagonists of group a2, have a lower effect on the desensitized line than the effects on the sensitive line. From this, it is confirmed that the reduced sensitivity strain used in this test is a strain having reduced sensitivity to these compounds. On the other hand, the treated area of the present SX or MX can confirm the same effect on the susceptible line as to the susceptible line.

Test Example 22
SX or MX is formulated according to the method described in Formulation Example 4.
The above formulation is diluted 100 fold with water. The resulting diluted solution is subjected to 500 mL irrigation treatment in a cell-shaped nursery tray (about 60 cm wide and about 30 cm long) of cabbage one day before planting, and planted and cultivated in a field.
As a result, the cabbage treated with SX or MX can be confirmed to be effective against harmful insects belonging to Psyllidae, Noctilidae and Pterididae. The effect can also be confirmed on harmful insects belonging to the family Noga, Yaga, and White butterfly, whose sensitivity to one or more compounds selected from the groups a1 to a18 is reduced. In particular, the effect can be confirmed on diamondback moth having a reduced sensitivity to one or more compounds selected from group a17.

Test Example 23
SX or MX is formulated according to the method described in Formulation Example 7. After carrying out scraping, while the rice seed coated with iron oxide is sown several grains with a passenger planter in a paddy field that has been managed for several days with running water, the above formulation is 1 kg / 10 a in the seeding position Apply immediately below, 1 cm deep. After that, grow rice.
As a result, the rice treated with SX or MX can be confirmed to be effective against the rice weevil, the indigo plant bug, the indigo planthopper, the indigo planthopper, the indigo planthopper, the indigo planthopper, the indigo planthopper, the indopian planted catfish, the indigo plant indica, the indible plant indica, the indible plant bug, the indigo plant bug, and the indible plant bug. Also effective against one or more compounds selected from group a1 to group a18 against rice weevil, rice ground weevil, tree ground beetle, white-tailed deer, ground beetle, green leafhopper, green leafhopper, green leafhopper, black leaf beetle, red leaf beetle, red leafhopper, red-tailed leafhopper It can confirm. In particular, the effect can be confirmed on a rice weevil, a rice dander beetle, a ground louse beetle, a tree loin beetle, a white-tailed loin deer, a green leafhopper and a black leafhopper, which have reduced sensitivity to one or more compounds selected from group a4. In addition, by controlling harmful insects belonging to the planthopper family and leafhopper family, these insect-mediated rice dwarf diseases, tungose disease, rice grassy stunt disease, rice ragid stunt disease, rice streak leaf blight, black streak atrophy It is possible to protect rice from disease, rice south black streak atrophy, yellow dwarf disease, rice yellow leaf disease, transient yellowing disease and rice dwarf disease.

Test Example 24
SX or MX is formulated according to the method described in Formulation Example 7. After scraping, rice fields coated with Kalper (registered trademark) powder / granule 16 (calcium peroxide powder / granule, Hodogaya UPL Co., Ltd.) are treated with a caring seeder in a paddy field that has been flooded for several days. While sowing several seeds, the above-mentioned preparation is applied at a rate of 1 kg / 10a to a position 3 cm lateral and 3 cm deep at the seeding position. After that, grow rice.
As a result, the rice treated with SX or MX can be confirmed to be effective against the rice weevil, the indigo plant bug, the indigo planthopper, the indigo planthopper, the indigo planthopper, the indigo planthopper, the indigo planthopper, the indopian planted catfish, the indigo plant indica, the indible plant indica, the indible plant bug, the indigo plant bug, and the indible plant bug. Also effective against one or more compounds selected from group a1 to group a18 against rice weevil, rice ground weevil, tree ground beetle, white-tailed deer, ground beetle, green leafhopper, green leafhopper, green leafhopper, black leaf beetle, red leaf beetle, red leafhopper, red-tailed leafhopper It can confirm. In particular, the effect can be confirmed on a rice weevil, a rice dander beetle, a ground louse beetle, a tree loin beetle, a white-tailed loin deer, a green leafhopper and a black leafhopper, which have reduced sensitivity to one or more compounds selected from group a4. In addition, by controlling harmful insects belonging to the planthopper family and leafhopper family, these insect-mediated rice dwarf diseases, tungose disease, rice grassy stunt disease, rice ragid stunt disease, rice streak leaf blight, black streak atrophy It is possible to protect rice from disease, rice south black streak atrophy, yellow dwarf disease, rice yellow leaf disease, transient yellowing disease and rice dwarf disease.

  According to the present invention, harmful arthropods can be controlled.

Claims (4)

Formula (I)

[In the formula,
R ² represents a C 1 -C 6 alkyl group, a cyclopropyl group, or a cyclopropylmethyl group which may be substituted by one or more halogen atoms,
n represents 0, 1 or 2;
R ³ is a C 1 -C 6 chain hydrocarbon group optionally having one or more substituents selected from group B, and C ³ -C 7 optionally having one or more substituents selected from group E A cycloalkyl group, a C3-C7 cycloalkenyl group optionally having one or more substituents selected from group J, a phenyl group optionally having one or more substituents selected from group H, group H 5 or 6-membered aromatic heterocyclic group optionally having one or more substituents selected from OR ¹² , NR ¹¹ R ¹² , NR ^11a R ^12a , NR ²⁴ NR ¹¹ R ¹² , NR ²⁴ OR ¹¹ , NR ¹¹ C (O) R ¹³ , NR ²⁴ NR ¹¹ C (O) R ¹³ , NR ¹¹ C (O) OR ¹⁴ , NR ²⁴ NR ¹¹ C (O) OR ¹⁴ , NR ¹¹ C (O) NR ¹⁵ R ^{16 , NR 24 NR 11 C (O} ) NR 15 R 16, N = CHNR 15 R 16, N = S (O) x R 15 R 16, C (O) ^{17, C (O) OR 17} , C (O) NR 15 R 16, CR 24 = NOR 17, NR 11 CR 24 = NOR 17, represents a cyano group, a nitro group, or a halogen atom,
q represents 0, 1, 2, or 3, and when q is 2 or 3, plural R ^{3 s} may be the same or different,
When two R ^{3 s} are adjacent, two R ^{3 s} together with the carbon atom to which they are attached form a benzene ring, a pyrrole ring, a furan ring, a thiophene ring, a pyrazole ring, an imidazole ring, a triazole ring, an oxazole ring , Isoxazole ring, thiazole ring, oxadiazole ring, thiadiazole ring, pyridine ring, pyridazine ring, pyrimidine ring, or pyrazine ring {the benzene ring, the pyrrole ring, the furan ring, the thiophene ring, the pyrazole ring, The imidazole ring, the triazole ring, the oxazole ring, the isoxazole ring, the thiazole ring, the pyridine ring, the pyridazine ring, the pyrimidine ring, and the pyrazine ring are each independently one or more selected from group H Which may have a substituent of
Het represents a group represented by the following formula Het1 or a group represented by the following formula Het2,

A ¹ represents a nitrogen atom or CR ⁶ ,
A ² represents a nitrogen atom or CR ^4a ,
A ³ represents a nitrogen atom or CR ^{4 b} ,
A ⁴ represents a nitrogen atom or CR ^4c ,
Q ¹ represents an oxygen atom or a sulfur atom,
Q ² represents an oxygen atom, N—CN, N—NO ₂ , NR ²⁰ , N—C (O) R ²⁰ or N—C (O) OR ^15, and when n is 2, two Q ² May be the same or different,
R ²⁰ represents a C1-C6 alkyl group optionally having one or more halogen atoms or a hydrogen atom,
R ⁵ is a C 1 -C 6 chain hydrocarbon group which may have one or more substituents selected from group F, and C 3 -C 6 which may have one or more substituents selected from group J 5- or 6-membered aromatic heterocycle optionally having a cycloalkyl group, a phenyl group optionally having one or more substituents selected from group H, or one or more substituents selected from group H Represents a group,
R ^4a , R ^4b , and R ^4c are the same or different, and each independently represent a C1-C6 chain hydrocarbon group optionally having one or more halogen atoms, a nitro group, OR ¹⁸ , NR ¹⁸ R ^{19 represents} a cyano group, an amino group, a halogen atom or a hydrogen atom,
R ⁶ represents a hydrogen atom or a halogen atom,
T is a C1-C10 chain hydrocarbon group, (C1-C5 alkoxy) C2-C5 alkyl group, (C1-C5 alkylsulfanyl) C2-C5 alkyl group, (C1-C5 alkylsulfinyl) C2-C5 alkyl group, (C1-C5 alkylsulfonyl) C2-C5 alkyl group {C1-C10 chain hydrocarbon group, (C1-C5 alkoxy) C2-C5 alkyl group, (C1-C5 alkyl sulfanyl) C2-C5 alkyl group, The (C1-C5 alkylsulfinyl) C2-C5 alkyl group and the (C1-C5 alkylsulfonyl) C2-C5 alkyl group are each independently at least one selected from the group consisting of a cyano group and a halogen atom Having a group}, (C3-C7 cycloalkyl) C1-C3 alkyl group, C3-C7 cycloalkyl group { The (C 3 -C 7 cycloalkyl) C 1 -C 3 alkyl group and the C 3 -C 7 cycloalkyl group are each independently at least one substituent selected from the group consisting of a cyano group, a halogen atom and a C 1 -C 6 haloalkyl group. ^{a}, OR 1, S (O} ) v R 1, OS (O) 2 R 1, CH 2 OR 1, NR 1 R 29, C (O) R 1, C (O) NR 1 R 29, NR 29 C (O) R ¹ , N = CR ¹ R ³⁰ , a group represented by the following formula T-1, a group represented by the following formula T-2, a group represented by the following formula T-3, a group represented by the following formula T-4 A group represented by the group represented by the formula T-5, a group represented by the formula T-6, a group represented by the formula T-7, a group represented by the formula T-8, a group represented by the formula T-9 Or a group represented by the following formula T-10, a group represented by the following formula T-11, or a group represented by the following formula T-12,

X ¹ represents a nitrogen atom or CR ^1a ,
X ² represents a nitrogen atom or CR ^1b ,
X ³ represents a nitrogen atom or CR ^1c ,
X ⁴ represents a nitrogen atom or CR ^{1 d} ,
X ⁵ represents a nitrogen atom or CR ^1e ,
R ^1x is a C1-C5 chain hydrocarbon group having one or more halogen atoms, OR ⁷ , OS (O) ₂ R ⁷ , S (O) _m R ⁷ , NR ⁸ S (O) ₂ R ⁷ , or Represents a halogen atom,
R ^1a , R ^1b , R ^1c , R ^1d , and R ^1e are the same or different and each independently a C1-C6 chain hydrocarbon group which may have one or more halogen atoms, one or more A C3-C6 cycloalkyl group optionally having one or more halogen atoms, a halogen atom, or a hydrogen atom,
Y ¹ represents NR ²⁵ , an oxygen atom or a sulfur atom,
Y ² represents a nitrogen atom or CR ²⁶ ,
Y ³ represents a nitrogen atom or CR ²⁷ ;
Y ⁴ represents a nitrogen atom or CR ²⁸ ,
R ²⁵ , R ²⁶ , R ²⁷ and R ²⁸ are the same or different and each independently represents a C1-C6 chain hydrocarbon group optionally having one or more halogen atoms, one or more halogen atoms Represents a C3-C6 cycloalkyl group which may have a halogen atom or a hydrogen atom,
R ^1y is a C1-C5 chain hydrocarbon group having one or more halogen atoms, OR ⁷ , OS (O) ₂ R ⁷ , S (O) _m R ⁷ , NR ⁸ S (O) ₂ R ⁷ , cyano Represents a group or a halogen atom,
R ^1ay and R ⁷ are the same or different and each independently represents a C1-C6 chain hydrocarbon group having one or more halogen atoms,
m and v are the same or different and each independently represents 0, 1 or 2;
R ¹ represents a C1-C10 chain hydrocarbon group, a (C1-C5 alkoxy) C2-C5 alkyl group, a (C1-C5 alkylsulfanyl) C2-C5 alkyl group, a (C1-C5 alkylsulfinyl) C2-C5 alkyl group , (C1-C5 alkylsulfonyl) C2-C5 alkyl group {C1-C10 chain hydrocarbon group, (C1-C5 alkoxy) C2-C5 alkyl group, (C1-C5 alkyl sulfanyl) C2-C5 alkyl group And the (C1-C5 alkylsulfinyl) C2-C5 alkyl group and the (C1-C5 alkylsulfonyl) C2-C5 alkyl group are each independently one or more selected from the group consisting of a cyano group and a halogen atom. With a substituent}, (C3-C7 cycloalkyl) C1-C3 alkyl group, or C3-C7 cycloalkyl Group {wherein the (C 3 -C 7 cycloalkyl) C 1 -C 3 alkyl group and the C 3 -C 7 cycloalkyl group are each independently at least one selected from the group consisting of a cyano group, a halogen atom and a C 1 -C 6 haloalkyl group Represents a substituted group},
R ³⁰ represents a C1-C6 chain hydrocarbon group which may have one or more halogen atoms, a halogen atom, OR ³⁵ , NR ³⁶ R ³⁷ , or a hydrogen atom,
R ¹⁸ and R ³⁵ are the same or different and each independently represents a C1-C6 chain hydrocarbon group which may have one or more halogen atoms,
R ¹⁷ represents a C1-C6 chain hydrocarbon group optionally having one or more halogen atoms, a phenyl group optionally having one or more substituents selected from Group D, or a hydrogen atom ,
R ⁸ , R ¹¹ , R ¹⁹ , R ²⁴ , R ²⁹ , R ³⁶ , and R ³⁷ are the same or different, and each independently C1 to C6 chain formula optionally having one or more halogen atoms Represents a hydrocarbon group or a hydrogen atom,
R ¹² is a C 1 -C 6 chain hydrocarbon group optionally having one or more substituents selected from group F, and C 3 -C 7 optionally having one or more substituents selected from group J A cycloalkyl group, a C3-C7 cycloalkenyl group optionally having one or more substituents selected from group J, a phenyl group, a six-membered aromatic heterocyclic group {the phenyl group, and the six-membered aromatic complex Each of the ring groups may independently have one or more substituents selected from Group D}, a hydrogen atom, or S (O) ₂ R ²³ ,
R ²³ represents a C1-C6 chain hydrocarbon group which may have one or more halogen atoms, or a phenyl group which may have one or more substituents selected from Group D,
R ^11a and R ^12a together with the nitrogen atom to which they are attached represent a 3-7 membered non-aromatic heterocyclic group which may have one or more substituents selected from group E,
R ¹³ is a hydrogen atom, a C 1 -C 6 chain hydrocarbon group which may have one or more halogen atoms, a C 3 -C 7 cycloalkyl group which may have one or more halogen atoms, one or more (C3-C6 cycloalkyl) C1-C3 alkyl group optionally having a halogen atom, phenyl group optionally having one or more substituents selected from group D, or 1 selected from group D Represents a 5- or 6-membered aromatic heterocyclic group which may have the above substituents,
R ¹⁴ is a C1-C6 chain hydrocarbon group which may have one or more halogen atoms, a C3-C7 cycloalkyl group which may have one or more halogen atoms, one or more halogen atoms (C3-C6 cycloalkyl) C1-C3 alkyl group which may have, or phenyl C1-C3 alkyl group {phenyl moiety in the phenyl C1-C3 alkyl group is one or more substituents selected from group D May be included. Represents},
R ¹⁵ is 1 or more halogen atoms optionally may C1-C6 alkyl group optionally having, or represents a hydrogen atom,
R ¹⁶ is a C 1 -C 6 chain hydrocarbon group optionally having one or more substituents selected from group F, and C 3 -C 7 optionally having one or more substituents selected from group J Represents a cycloalkyl group, S (O) ₂ R ²³ or a hydrogen atom,
x represents 0 or 1;
Group B: C1-C6 alkoxy group optionally having one or more halogen atoms, C3-C6 alkenyloxy group optionally having one or more halogen atoms, one or more halogen atoms A C3-C6 alkynyloxy group, a C1-C6 alkylsulfanyl group optionally having one or more halogen atoms, a C1-C6 alkylsulfinyl group optionally having one or more halogen atoms, one or more A group consisting of a C1 to C6 alkylsulfonyl group which may have a halogen atom, a C3 to C6 cycloalkyl group which may have one or more halogen atoms, a cyano group, a hydroxy group, and a halogen atom.
Group D: C1-C6 chain hydrocarbon group optionally having one or more halogen atoms, hydroxy group, C1-C6 alkoxy group optionally having one or more halogen atoms, one or more halogen atoms A C3-C6 alkenyloxy group which may have one or more groups, a C3-C6 alkynyloxy group which may have one or more halogen atoms, a sulfanyl group, C1-which may have one or more halogen atoms C6 alkylsulfanyl group, C1 to C6 alkylsulfinyl group optionally having one or more halogen atoms, C1 to C6 alkylsulfonyl group optionally having one or more halogen atoms, amino group, NR ⁹ R ¹⁰ , C (O) R ¹⁰ , OC (O) R ⁹ , C (O) OR ⁹ , a cyano group, a nitro group, and a halogen atom.
R ⁹ represents a C 1 -C 6 alkyl group which may have one or more halogen atoms, or a C 3 -C 6 cycloalkyl group which may have one or more halogen atoms,
R ¹⁰ represents a C 1 -C 6 alkyl group which may have one or more halogen atoms, a C 3 -C 6 cycloalkyl group which may have one or more halogen atoms, or a hydrogen atom.
Group E: C1-C6 chain hydrocarbon group optionally having one or more halogen atoms, C1-C6 alkoxy group optionally having one or more halogen atoms, one or more halogen atoms A group consisting of an optionally substituted C3-C6 alkenyloxy group, an optionally substituted C3-C6 alkynyloxy group, a halogen atom, an oxo group, a hydroxy group, a cyano group, and a nitro group.
Group F: C3-C6 cycloalkyl group optionally having halogen atom or more, phenyl group, 6-membered aromatic heterocyclic group {The phenyl group and the 6-membered aromatic heterocyclic group are each independently Group which may have one or more substituents selected from group D}, OR ¹⁰ , amino group, NR ⁹ R ¹⁰ , a halogen atom, a nitro group, and a cyano group.
Group H: 5- or 6-membered aromatic heterocyclic group, C1-C6 alkyl group optionally having one or more halogen atoms, C3-C6 cycloalkyl group optionally having one or more halogen atoms, OR ¹⁰ , amino group, NR ⁹ R ¹⁰ , C (O) R ¹⁰ , C (O) NR ⁹ R ¹⁰ , OC (O) R ⁹ , OC (O) OR ⁹ , NR ¹⁰ C (O) R ⁹ , A group consisting of NR ¹⁰ C (O) OR ⁹ , C (O) OR ¹⁰ , a halogen atom, a nitro group, and a cyano group.
Group J: 1 or more halogen atoms optionally may C1-C6 alkyl group optionally having a halogen atom, a cyano group, triazolyl group, and NR ¹⁰ C (O) group consisting of R ^9. ]
A method for controlling noxious arthropods, which comprises applying an effective amount of a compound represented by the formula or its N-oxide to a harmful arthropod, a place where the noxious arthropod is located, a plant or a soil. The compound represented by formula (I) according to claim 1, group (a), group (b), group (c), group (d), group (e), group (f), group (g), A composition comprising one or more components selected from the group consisting of group (h), group (i) and group (j):
Group (a): a group consisting of an insecticidal active ingredient, an acaricidal active ingredient and a nematode active ingredient;
Group (b): bactericidal active ingredient;
Group (c): plant growth regulating component;
Group (d): drug damage reducing component;
Group (e): synergist;
Group (f): repellent component;
Group (g): mollusc component;
Group (h): Insect pheromone;
Group (i): herbicidal active ingredient;
Group (j): Microbial material.   A method for controlling noxious arthropods, which comprises applying an effective amount of the composition according to claim 2 to noxious arthropods, habitat of noxious arthropods, plants or soil.   A seed or vegetative organ that holds an effective amount of the compound of claim 1 or the composition of claim 2.